sentence,label,drug1,drug2
"CYP3A4 Inhibitors: DRUG1, an inhibitor of the drug metabolizing enzyme CYP3A4, significantly increased plasma concentrations of DRUG2 when coadministered to subjects who were poor metabolizers (see CLINICAL PHARMACOLOGY, Variability in Metabolism and Drug-Drug Interactions). ",mechanism,Ketoconazole,tolterodine
"For patients receiving DRUG1 or other potent CYP3A4 inhibitors such as other DRUG2 (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",negative,ketoconazole,azole antifungals
"For patients receiving DRUG1 or other potent CYP3A4 inhibitors such as other azole antifungals (eg, DRUG2, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",negative,ketoconazole,itraconazole
"For patients receiving DRUG1 or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, DRUG2) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",negative,ketoconazole,miconazole
"For patients receiving DRUG1 or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or DRUG2 (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",negative,ketoconazole,macrolide antibiotics
"For patients receiving DRUG1 or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, DRUG2, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",negative,ketoconazole,erythromycin
"For patients receiving DRUG1 or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, DRUG2) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",negative,ketoconazole,clarithromycin
"For patients receiving DRUG1 or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or DRUG2 or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",negative,ketoconazole,cyclosporine
"For patients receiving DRUG1 or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or DRUG2, the recommended dose of DETROL LA is 2 mg daily. ",negative,ketoconazole,vinblastine
"For patients receiving DRUG1 or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DRUG2 is 2 mg daily. ",advise,ketoconazole,DETROL LA
"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other DRUG1 (eg, DRUG2, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",negative,azole antifungals,itraconazole
"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other DRUG1 (eg, itraconazole, DRUG2) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",negative,azole antifungals,miconazole
"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other DRUG1 (eg, itraconazole, miconazole) or DRUG2 (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",negative,azole antifungals,macrolide antibiotics
"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other DRUG1 (eg, itraconazole, miconazole) or macrolide antibiotics (eg, DRUG2, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",negative,azole antifungals,erythromycin
"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other DRUG1 (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, DRUG2) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",negative,azole antifungals,clarithromycin
"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other DRUG1 (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or DRUG2 or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",negative,azole antifungals,cyclosporine
"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other DRUG1 (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or DRUG2, the recommended dose of DETROL LA is 2 mg daily. ",negative,azole antifungals,vinblastine
"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other DRUG1 (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DRUG2 is 2 mg daily. ",advise,azole antifungals,DETROL LA
"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, DRUG1, DRUG2) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",negative,itraconazole,miconazole
"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, DRUG1, miconazole) or DRUG2 (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",negative,itraconazole,macrolide antibiotics
"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, DRUG1, miconazole) or macrolide antibiotics (eg, DRUG2, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",negative,itraconazole,erythromycin
"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, DRUG1, miconazole) or macrolide antibiotics (eg, erythromycin, DRUG2) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",negative,itraconazole,clarithromycin
"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, DRUG1, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or DRUG2 or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",negative,itraconazole,cyclosporine
"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, DRUG1, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or DRUG2, the recommended dose of DETROL LA is 2 mg daily. ",negative,itraconazole,vinblastine
"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, DRUG1, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DRUG2 is 2 mg daily. ",advise,itraconazole,DETROL LA
"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, DRUG1) or DRUG2 (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",negative,miconazole,macrolide antibiotics
"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, DRUG1) or macrolide antibiotics (eg, DRUG2, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",negative,miconazole,erythromycin
"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, DRUG1) or macrolide antibiotics (eg, erythromycin, DRUG2) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",negative,miconazole,clarithromycin
"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, DRUG1) or macrolide antibiotics (eg, erythromycin, clarithromycin) or DRUG2 or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",negative,miconazole,cyclosporine
"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, DRUG1) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or DRUG2, the recommended dose of DETROL LA is 2 mg daily. ",negative,miconazole,vinblastine
"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, DRUG1) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DRUG2 is 2 mg daily. ",advise,miconazole,DETROL LA
"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or DRUG1 (eg, DRUG2, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",negative,macrolide antibiotics,erythromycin
"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or DRUG1 (eg, erythromycin, DRUG2) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",negative,macrolide antibiotics,clarithromycin
"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or DRUG1 (eg, erythromycin, clarithromycin) or DRUG2 or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",negative,macrolide antibiotics,cyclosporine
"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or DRUG1 (eg, erythromycin, clarithromycin) or cyclosporine or DRUG2, the recommended dose of DETROL LA is 2 mg daily. ",negative,macrolide antibiotics,vinblastine
"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or DRUG1 (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DRUG2 is 2 mg daily. ",advise,macrolide antibiotics,DETROL LA
"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, DRUG1, DRUG2) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",negative,erythromycin,clarithromycin
"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, DRUG1, clarithromycin) or DRUG2 or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",negative,erythromycin,cyclosporine
"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, DRUG1, clarithromycin) or cyclosporine or DRUG2, the recommended dose of DETROL LA is 2 mg daily. ",negative,erythromycin,vinblastine
"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, DRUG1, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DRUG2 is 2 mg daily. ",advise,erythromycin,DETROL LA
"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, DRUG1) or DRUG2 or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",negative,clarithromycin,cyclosporine
"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, DRUG1) or cyclosporine or DRUG2, the recommended dose of DETROL LA is 2 mg daily. ",negative,clarithromycin,vinblastine
"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, DRUG1) or cyclosporine or vinblastine, the recommended dose of DRUG2 is 2 mg daily. ",advise,clarithromycin,DETROL LA
"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or DRUG1 or DRUG2, the recommended dose of DETROL LA is 2 mg daily. ",negative,cyclosporine,vinblastine
"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or DRUG1 or vinblastine, the recommended dose of DRUG2 is 2 mg daily. ",advise,cyclosporine,DETROL LA
"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or DRUG1, the recommended dose of DRUG2 is 2 mg daily. ",advise,vinblastine,DETROL LA
Potential for DRUG1    to Affect Other Drugs DRUG2 is not expected to cause clinically important pharmacokinetic interactions with drugs that are metabolized by cytochrome P450 isozymes. ,negative,INVEGA,Paliperidone
"Given the primary CNS effects of DRUG1, DRUG2    should be used with caution in combination with other centrally acting drugs and alcohol. ",negative,paliperidone,INVEGA
"Given the primary CNS effects of DRUG1, INVEGA    should be used with caution in combination with other DRUG2 and alcohol. ",advise,paliperidone,centrally acting drugs
"Given the primary CNS effects of DRUG1, INVEGA    should be used with caution in combination with other centrally acting drugs and DRUG2. ",advise,paliperidone,alcohol
"Given the primary CNS effects of paliperidone, DRUG1    should be used with caution in combination with other DRUG2 and alcohol. ",advise,INVEGA,centrally acting drugs
"Given the primary CNS effects of paliperidone, DRUG1    should be used with caution in combination with other centrally acting drugs and DRUG2. ",advise,INVEGA,alcohol
"Given the primary CNS effects of paliperidone, INVEGA    should be used with caution in combination with other DRUG1 and DRUG2. ",negative,centrally acting drugs,alcohol
DRUG1 may antagonize the effect of DRUG2 and other dopamine agonists. ,effect,Paliperidone,levodopa
DRUG1 may antagonize the effect of levodopa and other DRUG2. ,effect,Paliperidone,dopamine agonists
Paliperidone may antagonize the effect of DRUG1 and other DRUG2. ,negative,levodopa,dopamine agonists
"Potential for Other Drugs to Affect DRUG1    DRUG2 is not a substrate of CYP1A2, CYP2A6, CYP2C9, and CYP2C19, so that an interaction with inhibitors or inducers of these isozymes is unlikely. ",negative,INVEGA,Paliperidone
"The concomitant use of DRUG1 with other DRUG2 or with other agents which produce dry mouth, constipation, somnolence (drowsiness), and/or other anticholinergic-like effects may increase the frequency and/or severity of such effects. ",effect,oxybutynin,anticholinergic drugs
"Mean DRUG1 plasma concentrations were approximately 2 fold higher when DRUG2 was administered with ketoconazole, a potent CYP3A4 inhibitor. ",negative,oxybutynin chloride,DITROPAN XL
"Mean DRUG1 plasma concentrations were approximately 2 fold higher when DITROPAN XL was administered with DRUG2, a potent CYP3A4 inhibitor. ",negative,oxybutynin chloride,ketoconazole
"Mean oxybutynin chloride plasma concentrations were approximately 2 fold higher when DRUG1 was administered with DRUG2, a potent CYP3A4 inhibitor. ",mechanism,DITROPAN XL,ketoconazole
"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as DRUG1 (e.g., DRUG2 and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). ",negative,antimycotic agents,itraconazole
"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as DRUG1 (e.g., itraconazole and DRUG2) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). ",negative,antimycotic agents,miconazole
"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as DRUG1 (e.g., itraconazole and miconazole) or DRUG2 (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). ",negative,antimycotic agents,macrolide antibiotics
"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as DRUG1 (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., DRUG2 and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). ",negative,antimycotic agents,erythromycin
"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as DRUG1 (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and DRUG2), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). ",negative,antimycotic agents,clarithromycin
"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as DRUG1 (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter DRUG2 mean pharmacokinetic parameters (i.e., Cmax and AUC). ",mechanism,antimycotic agents,oxybutynin
"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., DRUG1 and DRUG2) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). ",negative,itraconazole,miconazole
"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., DRUG1 and miconazole) or DRUG2 (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). ",negative,itraconazole,macrolide antibiotics
"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., DRUG1 and miconazole) or macrolide antibiotics (e.g., DRUG2 and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). ",negative,itraconazole,erythromycin
"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., DRUG1 and miconazole) or macrolide antibiotics (e.g., erythromycin and DRUG2), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). ",negative,itraconazole,clarithromycin
"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., DRUG1 and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter DRUG2 mean pharmacokinetic parameters (i.e., Cmax and AUC). ",mechanism,itraconazole,oxybutynin
"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and DRUG1) or DRUG2 (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). ",negative,miconazole,macrolide antibiotics
"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and DRUG1) or macrolide antibiotics (e.g., DRUG2 and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). ",negative,miconazole,erythromycin
"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and DRUG1) or macrolide antibiotics (e.g., erythromycin and DRUG2), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). ",negative,miconazole,clarithromycin
"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and DRUG1) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter DRUG2 mean pharmacokinetic parameters (i.e., Cmax and AUC). ",mechanism,miconazole,oxybutynin
"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or DRUG1 (e.g., DRUG2 and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). ",negative,macrolide antibiotics,erythromycin
"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or DRUG1 (e.g., erythromycin and DRUG2), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). ",negative,macrolide antibiotics,clarithromycin
"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or DRUG1 (e.g., erythromycin and clarithromycin), may alter DRUG2 mean pharmacokinetic parameters (i.e., Cmax and AUC). ",mechanism,macrolide antibiotics,oxybutynin
"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., DRUG1 and DRUG2), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). ",negative,erythromycin,clarithromycin
"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., DRUG1 and clarithromycin), may alter DRUG2 mean pharmacokinetic parameters (i.e., Cmax and AUC). ",mechanism,erythromycin,oxybutynin
"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and DRUG1), may alter DRUG2 mean pharmacokinetic parameters (i.e., Cmax and AUC). ",mechanism,clarithromycin,oxybutynin
"Concurrent ingestion of DRUG1 (20 mL of DRUG1 containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.    ",negative,antacid,antacid
"Concurrent ingestion of DRUG1 (20 mL of DRUG1 containing DRUG2, magnesium hydroxide, and simethicone) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.    ",negative,antacid,aluminum hydroxide
"Concurrent ingestion of DRUG1 (20 mL of DRUG1 containing aluminum hydroxide, DRUG2, and simethicone) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.    ",negative,antacid,magnesium hydroxide
"Concurrent ingestion of DRUG1 (20 mL of DRUG1 containing aluminum hydroxide, magnesium hydroxide, and DRUG2) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.    ",negative,antacid,simethicone
"Concurrent ingestion of DRUG1 (20 mL of DRUG1 containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly affect the exposure of DRUG2 or desethyloxybutynin.    ",negative,antacid,oxybutynin
"Concurrent ingestion of DRUG1 (20 mL of DRUG1 containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly affect the exposure of oxybutynin or DRUG2.    ",negative,antacid,desethyloxybutynin
"Concurrent ingestion of DRUG1 (20 mL of DRUG1 containing DRUG2, magnesium hydroxide, and simethicone) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.    ",negative,antacid,aluminum hydroxide
"Concurrent ingestion of DRUG1 (20 mL of DRUG1 containing aluminum hydroxide, DRUG2, and simethicone) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.    ",negative,antacid,magnesium hydroxide
"Concurrent ingestion of DRUG1 (20 mL of DRUG1 containing aluminum hydroxide, magnesium hydroxide, and DRUG2) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.    ",negative,antacid,simethicone
"Concurrent ingestion of DRUG1 (20 mL of DRUG1 containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly affect the exposure of DRUG2 or desethyloxybutynin.    ",negative,antacid,oxybutynin
"Concurrent ingestion of DRUG1 (20 mL of DRUG1 containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly affect the exposure of oxybutynin or DRUG2.    ",negative,antacid,desethyloxybutynin
"Concurrent ingestion of antacid (20 mL of antacid containing DRUG1, DRUG2, and simethicone) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.    ",negative,aluminum hydroxide,magnesium hydroxide
"Concurrent ingestion of antacid (20 mL of antacid containing DRUG1, magnesium hydroxide, and DRUG2) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.    ",negative,aluminum hydroxide,simethicone
"Concurrent ingestion of antacid (20 mL of antacid containing DRUG1, magnesium hydroxide, and simethicone) did not significantly affect the exposure of DRUG2 or desethyloxybutynin.    ",negative,aluminum hydroxide,oxybutynin
"Concurrent ingestion of antacid (20 mL of antacid containing DRUG1, magnesium hydroxide, and simethicone) did not significantly affect the exposure of oxybutynin or DRUG2.    ",negative,aluminum hydroxide,desethyloxybutynin
"Concurrent ingestion of antacid (20 mL of antacid containing aluminum hydroxide, DRUG1, and DRUG2) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.    ",negative,magnesium hydroxide,simethicone
"Concurrent ingestion of antacid (20 mL of antacid containing aluminum hydroxide, DRUG1, and simethicone) did not significantly affect the exposure of DRUG2 or desethyloxybutynin.    ",negative,magnesium hydroxide,oxybutynin
"Concurrent ingestion of antacid (20 mL of antacid containing aluminum hydroxide, DRUG1, and simethicone) did not significantly affect the exposure of oxybutynin or DRUG2.    ",negative,magnesium hydroxide,desethyloxybutynin
"Concurrent ingestion of antacid (20 mL of antacid containing aluminum hydroxide, magnesium hydroxide, and DRUG1) did not significantly affect the exposure of DRUG2 or desethyloxybutynin.    ",negative,simethicone,oxybutynin
"Concurrent ingestion of antacid (20 mL of antacid containing aluminum hydroxide, magnesium hydroxide, and DRUG1) did not significantly affect the exposure of oxybutynin or DRUG2.    ",negative,simethicone,desethyloxybutynin
"Concurrent ingestion of antacid (20 mL of antacid containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly affect the exposure of DRUG1 or DRUG2.    ",negative,oxybutynin,desethyloxybutynin
"DRUG1 has been reported to accelerate the metabolism of DRUG2 by the mechanism of hepatic microsomal enzyme induction, leading to an increase in dosage requirements for DRUG2. ",mechanism,Mitotane,warfarin
"DRUG1 has been reported to accelerate the metabolism of DRUG2 by the mechanism of hepatic microsomal enzyme induction, leading to an increase in dosage requirements for DRUG2. ",negative,Mitotane,warfarin
"Mitotane has been reported to accelerate the metabolism of DRUG1 by the mechanism of hepatic microsomal enzyme induction, leading to an increase in dosage requirements for DRUG1. ",negative,warfarin,warfarin
"Therefore, physicians should closely monitor patients for a change in DRUG1 dosage requirements when administering DRUG2 to patients on coumarin-type anticoagulants. ",negative,anticoagulant,Mitotane
"Therefore, physicians should closely monitor patients for a change in DRUG1 dosage requirements when administering Mitotane to patients on DRUG2. ",negative,anticoagulant,coumarin-type anticoagulants
"Therefore, physicians should closely monitor patients for a change in anticoagulant dosage requirements when administering DRUG1 to patients on DRUG2. ",advise,Mitotane,coumarin-type anticoagulants
Concomitant administration of DRUG1 and DRUG2 has been associated with erythema and histamine-like flushing and anaphylactoid reactions. ,effect,vancomycin,anesthetic agents
"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as DRUG1, DRUG2, bacitracin, polymyxin B, colistin, viomycin, or cisplatin, when indicated, requires careful monitoring.",negative,amphotericin B,aminoglycosides
"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as DRUG1, aminoglycosides, DRUG2, polymyxin B, colistin, viomycin, or cisplatin, when indicated, requires careful monitoring.",negative,amphotericin B,bacitracin
"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as DRUG1, aminoglycosides, bacitracin, DRUG2, colistin, viomycin, or cisplatin, when indicated, requires careful monitoring.",negative,amphotericin B,polymyxin B
"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as DRUG1, aminoglycosides, bacitracin, polymyxin B, DRUG2, viomycin, or cisplatin, when indicated, requires careful monitoring.",negative,amphotericin B,colistin
"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as DRUG1, aminoglycosides, bacitracin, polymyxin B, colistin, DRUG2, or cisplatin, when indicated, requires careful monitoring.",negative,amphotericin B,viomycin
"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as DRUG1, aminoglycosides, bacitracin, polymyxin B, colistin, viomycin, or DRUG2, when indicated, requires careful monitoring.",negative,amphotericin B,cisplatin
"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, DRUG1, DRUG2, polymyxin B, colistin, viomycin, or cisplatin, when indicated, requires careful monitoring.",negative,aminoglycosides,bacitracin
"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, DRUG1, bacitracin, DRUG2, colistin, viomycin, or cisplatin, when indicated, requires careful monitoring.",negative,aminoglycosides,polymyxin B
"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, DRUG1, bacitracin, polymyxin B, DRUG2, viomycin, or cisplatin, when indicated, requires careful monitoring.",negative,aminoglycosides,colistin
"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, DRUG1, bacitracin, polymyxin B, colistin, DRUG2, or cisplatin, when indicated, requires careful monitoring.",negative,aminoglycosides,viomycin
"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, DRUG1, bacitracin, polymyxin B, colistin, viomycin, or DRUG2, when indicated, requires careful monitoring.",negative,aminoglycosides,cisplatin
"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, DRUG1, DRUG2, colistin, viomycin, or cisplatin, when indicated, requires careful monitoring.",negative,bacitracin,polymyxin B
"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, DRUG1, polymyxin B, DRUG2, viomycin, or cisplatin, when indicated, requires careful monitoring.",negative,bacitracin,colistin
"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, DRUG1, polymyxin B, colistin, DRUG2, or cisplatin, when indicated, requires careful monitoring.",negative,bacitracin,viomycin
"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, DRUG1, polymyxin B, colistin, viomycin, or DRUG2, when indicated, requires careful monitoring.",negative,bacitracin,cisplatin
"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, bacitracin, DRUG1, DRUG2, viomycin, or cisplatin, when indicated, requires careful monitoring.",negative,polymyxin B,colistin
"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, bacitracin, DRUG1, colistin, DRUG2, or cisplatin, when indicated, requires careful monitoring.",negative,polymyxin B,viomycin
"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, bacitracin, DRUG1, colistin, viomycin, or DRUG2, when indicated, requires careful monitoring.",negative,polymyxin B,cisplatin
"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, bacitracin, polymyxin B, DRUG1, DRUG2, or cisplatin, when indicated, requires careful monitoring.",negative,colistin,viomycin
"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, bacitracin, polymyxin B, DRUG1, viomycin, or DRUG2, when indicated, requires careful monitoring.",negative,colistin,cisplatin
"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, bacitracin, polymyxin B, colistin, DRUG1, or DRUG2, when indicated, requires careful monitoring.",negative,viomycin,cisplatin
"Coadministration of DRUG1 with DRUG2 resulted in increased plasma ranitidine concentrations (57%), increased plasma bismuth trough concentrations (48%), and increased 14- hydroxy- DRUG2 plasma concentrations (31%). ",mechanism,TRITEC,clarithromycin
"Coadministration of DRUG1 with clarithromycin resulted in increased plasma DRUG2 concentrations (57%), increased plasma bismuth trough concentrations (48%), and increased 14- hydroxy- clarithromycin plasma concentrations (31%). ",negative,TRITEC,ranitidine
"Coadministration of DRUG1 with clarithromycin resulted in increased plasma ranitidine concentrations (57%), increased plasma bismuth trough concentrations (48%), and increased DRUG2 plasma concentrations (31%). ",negative,TRITEC,14- hydroxy- clarithromycin
"Coadministration of TRITEC with DRUG1 resulted in increased plasma DRUG2 concentrations (57%), increased plasma bismuth trough concentrations (48%), and increased 14- hydroxy- DRUG1 plasma concentrations (31%). ",negative,clarithromycin,ranitidine
"Coadministration of TRITEC with DRUG1 resulted in increased plasma ranitidine concentrations (57%), increased plasma bismuth trough concentrations (48%), and increased 14- hydroxy- DRUG1 plasma concentrations (31%). ",negative,clarithromycin,14- hydroxy- clarithromycin
"Coadministration of TRITEC with clarithromycin resulted in increased plasma DRUG1 concentrations (57%), increased plasma bismuth trough concentrations (48%), and increased DRUG2 plasma concentrations (31%). ",negative,ranitidine,14- hydroxy- clarithromycin
Coadministration with DRUG1 results in a slight decrease in the rate of DRUG2 absorption that is clinically unimportant. ,negative,aspirin,salicylate
Coadministration with a high dose of DRUG1 (170 mEq) results in a 28% decrease in plasma concentrations of DRUG2 and may decrease plasma concentrations of bismuth from TRITEC. ,mechanism,antacid,ranitidine
Coadministration with a high dose of DRUG1 (170 mEq) results in a 28% decrease in plasma concentrations of ranitidine and may decrease plasma concentrations of bismuth from DRUG2. ,mechanism,antacid,TRITEC
Coadministration with a high dose of antacid (170 mEq) results in a 28% decrease in plasma concentrations of DRUG1 and may decrease plasma concentrations of bismuth from DRUG2. ,negative,ranitidine,TRITEC
"For information on drug interactions associated with DRUG1, refer to the DRUG2     package insert.",negative,ranitidine,ZANTAC
"These include DRUG1, DRUG2, and oral and inhaled steroids. ",negative,sympathomimetic bronchodilators,methylxanthines
"These include DRUG1, methylxanthines, and oral and inhaled DRUG2. ",negative,sympathomimetic bronchodilators,steroids
"These include sympathomimetic bronchodilators, DRUG1, and oral and inhaled DRUG2. ",negative,methylxanthines,steroids
"However, the co   administration of DRUG1 with other DRUG2   containing drugs (e.g., ipratropium) has not been studied and is therefore not recommended.",advise,SPIRIVA,anticholinergic
"However, the co   administration of DRUG1 with other anticholinergic   containing drugs (e.g., DRUG2) has not been studied and is therefore not recommended.",advise,SPIRIVA,ipratropium
"However, the co   administration of SPIRIVA with other DRUG1   containing drugs (e.g., DRUG2) has not been studied and is therefore not recommended.",negative,anticholinergic,ipratropium
Prothrombin time or other suitable anticoagulation test should be monitored if DRUG1 is administered with DRUG2.   ,advise,tigecycline,warfarin
Concurrent use of DRUG1 with oral DRUG2 may render oral DRUG2 less effective.  ,effect,antibacterial drugs,contraceptives
Concurrent use of DRUG1 with oral DRUG2 may render oral DRUG2 less effective.  ,negative,antibacterial drugs,contraceptives
Concurrent use of antibacterial drugs with oral DRUG1 may render oral DRUG1 less effective.  ,negative,contraceptives,contraceptives
"DRUG1 may enhance the sedative effects of DRUG2 including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers. ",effect,Triprolidine,central nervous system depressants
"DRUG1 may enhance the sedative effects of central nervous system depressants including DRUG2, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers. ",effect,Triprolidine,alcohol
"DRUG1 may enhance the sedative effects of central nervous system depressants including alcohol, DRUG2, hypnotics, narcotic analgesics, sedatives, and tranquillisers. ",effect,Triprolidine,barbiturates
"DRUG1 may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, DRUG2, narcotic analgesics, sedatives, and tranquillisers. ",effect,Triprolidine,hypnotics
"DRUG1 may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, DRUG2, sedatives, and tranquillisers. ",effect,Triprolidine,narcotic analgesics
"DRUG1 may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, DRUG2, and tranquillisers. ",effect,Triprolidine,sedatives
"DRUG1 may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and DRUG2. ",effect,Triprolidine,tranquillisers
"Triprolidine may enhance the sedative effects of DRUG1 including DRUG2, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers. ",negative,central nervous system depressants,alcohol
"Triprolidine may enhance the sedative effects of DRUG1 including alcohol, DRUG2, hypnotics, narcotic analgesics, sedatives, and tranquillisers. ",negative,central nervous system depressants,barbiturates
"Triprolidine may enhance the sedative effects of DRUG1 including alcohol, barbiturates, DRUG2, narcotic analgesics, sedatives, and tranquillisers. ",negative,central nervous system depressants,hypnotics
"Triprolidine may enhance the sedative effects of DRUG1 including alcohol, barbiturates, hypnotics, DRUG2, sedatives, and tranquillisers. ",negative,central nervous system depressants,narcotic analgesics
"Triprolidine may enhance the sedative effects of DRUG1 including alcohol, barbiturates, hypnotics, narcotic analgesics, DRUG2, and tranquillisers. ",negative,central nervous system depressants,sedatives
"Triprolidine may enhance the sedative effects of DRUG1 including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and DRUG2. ",negative,central nervous system depressants,tranquillisers
"Triprolidine may enhance the sedative effects of central nervous system depressants including DRUG1, DRUG2, hypnotics, narcotic analgesics, sedatives, and tranquillisers. ",negative,alcohol,barbiturates
"Triprolidine may enhance the sedative effects of central nervous system depressants including DRUG1, barbiturates, DRUG2, narcotic analgesics, sedatives, and tranquillisers. ",negative,alcohol,hypnotics
"Triprolidine may enhance the sedative effects of central nervous system depressants including DRUG1, barbiturates, hypnotics, DRUG2, sedatives, and tranquillisers. ",negative,alcohol,narcotic analgesics
"Triprolidine may enhance the sedative effects of central nervous system depressants including DRUG1, barbiturates, hypnotics, narcotic analgesics, DRUG2, and tranquillisers. ",negative,alcohol,sedatives
"Triprolidine may enhance the sedative effects of central nervous system depressants including DRUG1, barbiturates, hypnotics, narcotic analgesics, sedatives, and DRUG2. ",negative,alcohol,tranquillisers
"Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, DRUG1, DRUG2, narcotic analgesics, sedatives, and tranquillisers. ",negative,barbiturates,hypnotics
"Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, DRUG1, hypnotics, DRUG2, sedatives, and tranquillisers. ",negative,barbiturates,narcotic analgesics
"Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, DRUG1, hypnotics, narcotic analgesics, DRUG2, and tranquillisers. ",negative,barbiturates,sedatives
"Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, DRUG1, hypnotics, narcotic analgesics, sedatives, and DRUG2. ",negative,barbiturates,tranquillisers
"Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, DRUG1, DRUG2, sedatives, and tranquillisers. ",negative,hypnotics,narcotic analgesics
"Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, DRUG1, narcotic analgesics, DRUG2, and tranquillisers. ",negative,hypnotics,sedatives
"Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, DRUG1, narcotic analgesics, sedatives, and DRUG2. ",negative,hypnotics,tranquillisers
"Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, DRUG1, DRUG2, and tranquillisers. ",negative,narcotic analgesics,sedatives
"Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, DRUG1, sedatives, and DRUG2. ",negative,narcotic analgesics,tranquillisers
"Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, DRUG1, and DRUG2. ",negative,sedatives,tranquillisers
"The effects of DRUG1, such as DRUG2 and tricyclic antidepressants may be enhanced by the concomitant administration of triprolidine. ",negative,anticholinergic drugs,atropine
"The effects of DRUG1, such as atropine and DRUG2 may be enhanced by the concomitant administration of triprolidine. ",negative,anticholinergic drugs,tricyclic antidepressants
"The effects of DRUG1, such as atropine and tricyclic antidepressants may be enhanced by the concomitant administration of DRUG2. ",effect,anticholinergic drugs,triprolidine
"The effects of anticholinergic drugs, such as DRUG1 and DRUG2 may be enhanced by the concomitant administration of triprolidine. ",negative,atropine,tricyclic antidepressants
"The effects of anticholinergic drugs, such as DRUG1 and tricyclic antidepressants may be enhanced by the concomitant administration of DRUG2. ",effect,atropine,triprolidine
"The effects of anticholinergic drugs, such as atropine and DRUG1 may be enhanced by the concomitant administration of DRUG2. ",effect,tricyclic antidepressants,triprolidine
"CYP 3A4 Inhibitors (e.g. DRUG1 and DRUG2) There have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs (e.g. dihydroergotamine and ergotamine) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities. ",negative,Macrolide Antibiotics,Protease Inhibitors
"CYP 3A4 Inhibitors (e.g. DRUG1 and Protease Inhibitors) There have been rare reports of serious adverse events in connection with the coadministration of certain DRUG2 (e.g. dihydroergotamine and ergotamine) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities. ",negative,Macrolide Antibiotics,ergot alkaloid drugs
"CYP 3A4 Inhibitors (e.g. DRUG1 and Protease Inhibitors) There have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs (e.g. DRUG2 and ergotamine) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities. ",negative,Macrolide Antibiotics,dihydroergotamine
"CYP 3A4 Inhibitors (e.g. DRUG1 and Protease Inhibitors) There have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs (e.g. dihydroergotamine and DRUG2) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities. ",negative,Macrolide Antibiotics,ergotamine
"CYP 3A4 Inhibitors (e.g. Macrolide Antibiotics and DRUG1) There have been rare reports of serious adverse events in connection with the coadministration of certain DRUG2 (e.g. dihydroergotamine and ergotamine) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities. ",negative,Protease Inhibitors,ergot alkaloid drugs
"CYP 3A4 Inhibitors (e.g. Macrolide Antibiotics and DRUG1) There have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs (e.g. DRUG2 and ergotamine) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities. ",negative,Protease Inhibitors,dihydroergotamine
"CYP 3A4 Inhibitors (e.g. Macrolide Antibiotics and DRUG1) There have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs (e.g. dihydroergotamine and DRUG2) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities. ",negative,Protease Inhibitors,ergotamine
"CYP 3A4 Inhibitors (e.g. Macrolide Antibiotics and Protease Inhibitors) There have been rare reports of serious adverse events in connection with the coadministration of certain DRUG1 (e.g. DRUG2 and ergotamine) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities. ",negative,ergot alkaloid drugs,dihydroergotamine
"CYP 3A4 Inhibitors (e.g. Macrolide Antibiotics and Protease Inhibitors) There have been rare reports of serious adverse events in connection with the coadministration of certain DRUG1 (e.g. dihydroergotamine and DRUG2) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities. ",negative,ergot alkaloid drugs,ergotamine
"CYP 3A4 Inhibitors (e.g. Macrolide Antibiotics and Protease Inhibitors) There have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs (e.g. DRUG1 and DRUG2) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities. ",negative,dihydroergotamine,ergotamine
"Examples of some of the more potent CYP 3A4 inhibitors include DRUG1 (e.g., DRUG2, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",negative,macrolide antibiotics,erythromycin
"Examples of some of the more potent CYP 3A4 inhibitors include DRUG1 (e.g., erythromycin, DRUG2, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",negative,macrolide antibiotics,troleandomycin
"Examples of some of the more potent CYP 3A4 inhibitors include DRUG1 (e.g., erythromycin, troleandomycin, DRUG2), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",negative,macrolide antibiotics,clarithromycin
"Examples of some of the more potent CYP 3A4 inhibitors include DRUG1 (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",negative,macrolide antibiotics,HIV protease inhibitors
"Examples of some of the more potent CYP 3A4 inhibitors include DRUG1 (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or DRUG2 (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",negative,macrolide antibiotics,reverse transcriptase inhibitors
"Examples of some of the more potent CYP 3A4 inhibitors include DRUG1 (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., DRUG2, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",negative,macrolide antibiotics,ritonavir
"Examples of some of the more potent CYP 3A4 inhibitors include DRUG1 (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, DRUG2, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",negative,macrolide antibiotics,indinavir
"Examples of some of the more potent CYP 3A4 inhibitors include DRUG1 (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, DRUG2, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",negative,macrolide antibiotics,nelfinavir
"Examples of some of the more potent CYP 3A4 inhibitors include DRUG1 (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, DRUG2) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",negative,macrolide antibiotics,delavirdine
"Examples of some of the more potent CYP 3A4 inhibitors include DRUG1 (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or DRUG2 (e.g., ketoconazole, itraconazole, voriconazole). ",negative,macrolide antibiotics,azole antifungals
"Examples of some of the more potent CYP 3A4 inhibitors include DRUG1 (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., DRUG2, itraconazole, voriconazole). ",negative,macrolide antibiotics,ketoconazole
"Examples of some of the more potent CYP 3A4 inhibitors include DRUG1 (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, DRUG2, voriconazole). ",negative,macrolide antibiotics,itraconazole
"Examples of some of the more potent CYP 3A4 inhibitors include DRUG1 (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, DRUG2). ",negative,macrolide antibiotics,voriconazole
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., DRUG1, DRUG2, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",negative,erythromycin,troleandomycin
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., DRUG1, troleandomycin, DRUG2), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",negative,erythromycin,clarithromycin
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., DRUG1, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",negative,erythromycin,HIV protease inhibitors
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., DRUG1, troleandomycin, clarithromycin), HIV protease or DRUG2 (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",negative,erythromycin,reverse transcriptase inhibitors
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., DRUG1, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., DRUG2, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",negative,erythromycin,ritonavir
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., DRUG1, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, DRUG2, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",negative,erythromycin,indinavir
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., DRUG1, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, DRUG2, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",negative,erythromycin,nelfinavir
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., DRUG1, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, DRUG2) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",negative,erythromycin,delavirdine
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., DRUG1, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or DRUG2 (e.g., ketoconazole, itraconazole, voriconazole). ",negative,erythromycin,azole antifungals
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., DRUG1, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., DRUG2, itraconazole, voriconazole). ",negative,erythromycin,ketoconazole
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., DRUG1, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, DRUG2, voriconazole). ",negative,erythromycin,itraconazole
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., DRUG1, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, DRUG2). ",negative,erythromycin,voriconazole
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, DRUG1, DRUG2), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",negative,troleandomycin,clarithromycin
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, DRUG1, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",negative,troleandomycin,HIV protease inhibitors
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, DRUG1, clarithromycin), HIV protease or DRUG2 (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",negative,troleandomycin,reverse transcriptase inhibitors
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, DRUG1, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., DRUG2, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",negative,troleandomycin,ritonavir
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, DRUG1, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, DRUG2, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",negative,troleandomycin,indinavir
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, DRUG1, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, DRUG2, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",negative,troleandomycin,nelfinavir
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, DRUG1, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, DRUG2) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",negative,troleandomycin,delavirdine
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, DRUG1, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or DRUG2 (e.g., ketoconazole, itraconazole, voriconazole). ",negative,troleandomycin,azole antifungals
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, DRUG1, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., DRUG2, itraconazole, voriconazole). ",negative,troleandomycin,ketoconazole
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, DRUG1, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, DRUG2, voriconazole). ",negative,troleandomycin,itraconazole
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, DRUG1, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, DRUG2). ",negative,troleandomycin,voriconazole
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, DRUG1), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",negative,clarithromycin,HIV protease inhibitors
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, DRUG1), HIV protease or DRUG2 (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",negative,clarithromycin,reverse transcriptase inhibitors
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, DRUG1), HIV protease or reverse transcriptase inhibitors (e.g., DRUG2, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",negative,clarithromycin,ritonavir
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, DRUG1), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, DRUG2, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",negative,clarithromycin,indinavir
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, DRUG1), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, DRUG2, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",negative,clarithromycin,nelfinavir
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, DRUG1), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, DRUG2) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",negative,clarithromycin,delavirdine
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, DRUG1), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or DRUG2 (e.g., ketoconazole, itraconazole, voriconazole). ",negative,clarithromycin,azole antifungals
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, DRUG1), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., DRUG2, itraconazole, voriconazole). ",negative,clarithromycin,ketoconazole
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, DRUG1), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, DRUG2, voriconazole). ",negative,clarithromycin,itraconazole
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, DRUG1), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, DRUG2). ",negative,clarithromycin,voriconazole
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or DRUG2 (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",negative,HIV protease inhibitors,reverse transcriptase inhibitors
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., DRUG2, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",negative,HIV protease inhibitors,ritonavir
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, DRUG2, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",negative,HIV protease inhibitors,indinavir
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, DRUG2, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",negative,HIV protease inhibitors,nelfinavir
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, DRUG2) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",negative,HIV protease inhibitors,delavirdine
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or DRUG2 (e.g., ketoconazole, itraconazole, voriconazole). ",negative,HIV protease inhibitors,azole antifungals
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., DRUG2, itraconazole, voriconazole). ",negative,HIV protease inhibitors,ketoconazole
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, DRUG2, voriconazole). ",negative,HIV protease inhibitors,itraconazole
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, DRUG2). ",negative,HIV protease inhibitors,voriconazole
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or DRUG1 (e.g., DRUG2, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",negative,reverse transcriptase inhibitors,ritonavir
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or DRUG1 (e.g., ritonavir, DRUG2, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",negative,reverse transcriptase inhibitors,indinavir
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or DRUG1 (e.g., ritonavir, indinavir, DRUG2, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",negative,reverse transcriptase inhibitors,nelfinavir
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or DRUG1 (e.g., ritonavir, indinavir, nelfinavir, DRUG2) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",negative,reverse transcriptase inhibitors,delavirdine
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or DRUG1 (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or DRUG2 (e.g., ketoconazole, itraconazole, voriconazole). ",negative,reverse transcriptase inhibitors,azole antifungals
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or DRUG1 (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., DRUG2, itraconazole, voriconazole). ",negative,reverse transcriptase inhibitors,ketoconazole
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or DRUG1 (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, DRUG2, voriconazole). ",negative,reverse transcriptase inhibitors,itraconazole
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or DRUG1 (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, DRUG2). ",negative,reverse transcriptase inhibitors,voriconazole
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., DRUG1, DRUG2, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",negative,ritonavir,indinavir
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., DRUG1, indinavir, DRUG2, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",negative,ritonavir,nelfinavir
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., DRUG1, indinavir, nelfinavir, DRUG2) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",negative,ritonavir,delavirdine
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., DRUG1, indinavir, nelfinavir, delavirdine) or DRUG2 (e.g., ketoconazole, itraconazole, voriconazole). ",negative,ritonavir,azole antifungals
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., DRUG1, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., DRUG2, itraconazole, voriconazole). ",negative,ritonavir,ketoconazole
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., DRUG1, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, DRUG2, voriconazole). ",negative,ritonavir,itraconazole
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., DRUG1, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, DRUG2). ",negative,ritonavir,voriconazole
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, DRUG1, DRUG2, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",negative,indinavir,nelfinavir
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, DRUG1, nelfinavir, DRUG2) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",negative,indinavir,delavirdine
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, DRUG1, nelfinavir, delavirdine) or DRUG2 (e.g., ketoconazole, itraconazole, voriconazole). ",negative,indinavir,azole antifungals
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, DRUG1, nelfinavir, delavirdine) or azole antifungals (e.g., DRUG2, itraconazole, voriconazole). ",negative,indinavir,ketoconazole
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, DRUG1, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, DRUG2, voriconazole). ",negative,indinavir,itraconazole
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, DRUG1, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, DRUG2). ",negative,indinavir,voriconazole
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, DRUG1, DRUG2) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",negative,nelfinavir,delavirdine
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, DRUG1, delavirdine) or DRUG2 (e.g., ketoconazole, itraconazole, voriconazole). ",negative,nelfinavir,azole antifungals
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, DRUG1, delavirdine) or azole antifungals (e.g., DRUG2, itraconazole, voriconazole). ",negative,nelfinavir,ketoconazole
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, DRUG1, delavirdine) or azole antifungals (e.g., ketoconazole, DRUG2, voriconazole). ",negative,nelfinavir,itraconazole
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, DRUG1, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, DRUG2). ",negative,nelfinavir,voriconazole
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, DRUG1) or DRUG2 (e.g., ketoconazole, itraconazole, voriconazole). ",negative,delavirdine,azole antifungals
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, DRUG1) or azole antifungals (e.g., DRUG2, itraconazole, voriconazole). ",negative,delavirdine,ketoconazole
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, DRUG1) or azole antifungals (e.g., ketoconazole, DRUG2, voriconazole). ",negative,delavirdine,itraconazole
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, DRUG1) or azole antifungals (e.g., ketoconazole, itraconazole, DRUG2). ",negative,delavirdine,voriconazole
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or DRUG1 (e.g., DRUG2, itraconazole, voriconazole). ",negative,azole antifungals,ketoconazole
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or DRUG1 (e.g., ketoconazole, DRUG2, voriconazole). ",negative,azole antifungals,itraconazole
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or DRUG1 (e.g., ketoconazole, itraconazole, DRUG2). ",negative,azole antifungals,voriconazole
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., DRUG1, DRUG2, voriconazole). ",negative,ketoconazole,itraconazole
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., DRUG1, itraconazole, DRUG2). ",negative,ketoconazole,voriconazole
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, DRUG1, DRUG2). ",negative,itraconazole,voriconazole
"Less potent inhibitors include DRUG1, DRUG2, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and clotrimazole. ",negative,saquinavir,nefazodone
"Less potent inhibitors include DRUG1, nefazodone, DRUG2, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and clotrimazole. ",negative,saquinavir,fluconazole
"Less potent inhibitors include DRUG1, nefazodone, fluconazole, grapefruit juice, DRUG2, fluvoxamine, zileuton, and clotrimazole. ",negative,saquinavir,fluoxetine
"Less potent inhibitors include DRUG1, nefazodone, fluconazole, grapefruit juice, fluoxetine, DRUG2, zileuton, and clotrimazole. ",negative,saquinavir,fluvoxamine
"Less potent inhibitors include DRUG1, nefazodone, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, DRUG2, and clotrimazole. ",negative,saquinavir,zileuton
"Less potent inhibitors include DRUG1, nefazodone, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and DRUG2. ",negative,saquinavir,clotrimazole
"Less potent inhibitors include saquinavir, DRUG1, DRUG2, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and clotrimazole. ",negative,nefazodone,fluconazole
"Less potent inhibitors include saquinavir, DRUG1, fluconazole, grapefruit juice, DRUG2, fluvoxamine, zileuton, and clotrimazole. ",negative,nefazodone,fluoxetine
"Less potent inhibitors include saquinavir, DRUG1, fluconazole, grapefruit juice, fluoxetine, DRUG2, zileuton, and clotrimazole. ",negative,nefazodone,fluvoxamine
"Less potent inhibitors include saquinavir, DRUG1, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, DRUG2, and clotrimazole. ",negative,nefazodone,zileuton
"Less potent inhibitors include saquinavir, DRUG1, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and DRUG2. ",negative,nefazodone,clotrimazole
"Less potent inhibitors include saquinavir, nefazodone, DRUG1, grapefruit juice, DRUG2, fluvoxamine, zileuton, and clotrimazole. ",negative,fluconazole,fluoxetine
"Less potent inhibitors include saquinavir, nefazodone, DRUG1, grapefruit juice, fluoxetine, DRUG2, zileuton, and clotrimazole. ",negative,fluconazole,fluvoxamine
"Less potent inhibitors include saquinavir, nefazodone, DRUG1, grapefruit juice, fluoxetine, fluvoxamine, DRUG2, and clotrimazole. ",negative,fluconazole,zileuton
"Less potent inhibitors include saquinavir, nefazodone, DRUG1, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and DRUG2. ",negative,fluconazole,clotrimazole
"Less potent inhibitors include saquinavir, nefazodone, fluconazole, grapefruit juice, DRUG1, DRUG2, zileuton, and clotrimazole. ",negative,fluoxetine,fluvoxamine
"Less potent inhibitors include saquinavir, nefazodone, fluconazole, grapefruit juice, DRUG1, fluvoxamine, DRUG2, and clotrimazole. ",negative,fluoxetine,zileuton
"Less potent inhibitors include saquinavir, nefazodone, fluconazole, grapefruit juice, DRUG1, fluvoxamine, zileuton, and DRUG2. ",negative,fluoxetine,clotrimazole
"Less potent inhibitors include saquinavir, nefazodone, fluconazole, grapefruit juice, fluoxetine, DRUG1, DRUG2, and clotrimazole. ",negative,fluvoxamine,zileuton
"Less potent inhibitors include saquinavir, nefazodone, fluconazole, grapefruit juice, fluoxetine, DRUG1, zileuton, and DRUG2. ",negative,fluvoxamine,clotrimazole
"Less potent inhibitors include saquinavir, nefazodone, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, DRUG1, and DRUG2. ",negative,zileuton,clotrimazole
Caution should be exercised when DRUG1    (DRUG2) is used concurrently with other vasoconstrictors or ergot alkaloids.,negative,Methergine,methylergonovine maleate
Caution should be exercised when DRUG1    (methylergonovine maleate) is used concurrently with other DRUG2 or ergot alkaloids.,advise,Methergine,vasoconstrictors
Caution should be exercised when DRUG1    (methylergonovine maleate) is used concurrently with other vasoconstrictors or DRUG2.,advise,Methergine,ergot alkaloids
Caution should be exercised when Methergine    (DRUG1) is used concurrently with other DRUG2 or ergot alkaloids.,advise,methylergonovine maleate,vasoconstrictors
Caution should be exercised when Methergine    (DRUG1) is used concurrently with other vasoconstrictors or DRUG2.,negative,methylergonovine maleate,ergot alkaloids
Caution should be exercised when Methergine    (methylergonovine maleate) is used concurrently with other DRUG1 or DRUG2.,negative,vasoconstrictors,ergot alkaloids
"Since DRUG1 is metabolized by a P450 enzyme system, drugs that induce or inhibit this drug metabolizing enzyme system may elicit important drug-drug interactions that may alter DRUG1 plasma concentrations. ",negative,trimetrexate,trimetrexate
"Agents that might be coadministered with DRUG1 in AIDS patients for other indications that could elicit this activity include DRUG2, rifampin, rifabutin, ketoconazole, and fluconazole. ",effect,trimetrexate,erythromycin
"Agents that might be coadministered with DRUG1 in AIDS patients for other indications that could elicit this activity include erythromycin, DRUG2, rifabutin, ketoconazole, and fluconazole. ",effect,trimetrexate,rifampin
"Agents that might be coadministered with DRUG1 in AIDS patients for other indications that could elicit this activity include erythromycin, rifampin, DRUG2, ketoconazole, and fluconazole. ",effect,trimetrexate,rifabutin
"Agents that might be coadministered with DRUG1 in AIDS patients for other indications that could elicit this activity include erythromycin, rifampin, rifabutin, DRUG2, and fluconazole. ",effect,trimetrexate,ketoconazole
"Agents that might be coadministered with DRUG1 in AIDS patients for other indications that could elicit this activity include erythromycin, rifampin, rifabutin, ketoconazole, and DRUG2. ",effect,trimetrexate,fluconazole
"Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include DRUG1, DRUG2, rifabutin, ketoconazole, and fluconazole. ",negative,erythromycin,rifampin
"Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include DRUG1, rifampin, DRUG2, ketoconazole, and fluconazole. ",negative,erythromycin,rifabutin
"Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include DRUG1, rifampin, rifabutin, DRUG2, and fluconazole. ",negative,erythromycin,ketoconazole
"Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include DRUG1, rifampin, rifabutin, ketoconazole, and DRUG2. ",negative,erythromycin,fluconazole
"Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include erythromycin, DRUG1, DRUG2, ketoconazole, and fluconazole. ",negative,rifampin,rifabutin
"Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include erythromycin, DRUG1, rifabutin, DRUG2, and fluconazole. ",negative,rifampin,ketoconazole
"Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include erythromycin, DRUG1, rifabutin, ketoconazole, and DRUG2. ",negative,rifampin,fluconazole
"Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include erythromycin, rifampin, DRUG1, DRUG2, and fluconazole. ",negative,rifabutin,ketoconazole
"Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include erythromycin, rifampin, DRUG1, ketoconazole, and DRUG2. ",negative,rifabutin,fluconazole
"Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include erythromycin, rifampin, rifabutin, DRUG1, and DRUG2. ",negative,ketoconazole,fluconazole
In vitro perfusion of isolated rat liver has shown that DRUG1 caused a significant reduction in DRUG2 metabolism and that acetaminophen altered the relative concentration of DRUG2 metabolites possibly by competing for sulfate metabolites. ,mechanism,cimetidine,trimetrexate
In vitro perfusion of isolated rat liver has shown that DRUG1 caused a significant reduction in trimetrexate metabolism and that DRUG2 altered the relative concentration of trimetrexate metabolites possibly by competing for sulfate metabolites. ,negative,cimetidine,acetaminophen
In vitro perfusion of isolated rat liver has shown that cimetidine caused a significant reduction in DRUG1 metabolism and that DRUG2 altered the relative concentration of DRUG1 metabolites possibly by competing for sulfate metabolites. ,negative,trimetrexate,acetaminophen
"Based on an in vitro rat liver model, nitrogen substituted DRUG1 (DRUG2, ketoconazole, miconazole) were potent, non-competitive inhibitors of trimetrexate metabolism. ",negative,imidazole drugs,clotrimazole
"Based on an in vitro rat liver model, nitrogen substituted DRUG1 (clotrimazole, DRUG2, miconazole) were potent, non-competitive inhibitors of trimetrexate metabolism. ",negative,imidazole drugs,ketoconazole
"Based on an in vitro rat liver model, nitrogen substituted DRUG1 (clotrimazole, ketoconazole, DRUG2) were potent, non-competitive inhibitors of trimetrexate metabolism. ",negative,imidazole drugs,miconazole
"Based on an in vitro rat liver model, nitrogen substituted DRUG1 (clotrimazole, ketoconazole, miconazole) were potent, non-competitive inhibitors of DRUG2 metabolism. ",mechanism,imidazole drugs,trimetrexate
"Based on an in vitro rat liver model, nitrogen substituted imidazole drugs (DRUG1, DRUG2, miconazole) were potent, non-competitive inhibitors of trimetrexate metabolism. ",negative,clotrimazole,ketoconazole
"Based on an in vitro rat liver model, nitrogen substituted imidazole drugs (DRUG1, ketoconazole, DRUG2) were potent, non-competitive inhibitors of trimetrexate metabolism. ",negative,clotrimazole,miconazole
"Based on an in vitro rat liver model, nitrogen substituted imidazole drugs (DRUG1, ketoconazole, miconazole) were potent, non-competitive inhibitors of DRUG2 metabolism. ",mechanism,clotrimazole,trimetrexate
"Based on an in vitro rat liver model, nitrogen substituted imidazole drugs (clotrimazole, DRUG1, DRUG2) were potent, non-competitive inhibitors of trimetrexate metabolism. ",negative,ketoconazole,miconazole
"Based on an in vitro rat liver model, nitrogen substituted imidazole drugs (clotrimazole, DRUG1, miconazole) were potent, non-competitive inhibitors of DRUG2 metabolism. ",mechanism,ketoconazole,trimetrexate
"Based on an in vitro rat liver model, nitrogen substituted imidazole drugs (clotrimazole, ketoconazole, DRUG1) were potent, non-competitive inhibitors of DRUG2 metabolism. ",mechanism,miconazole,trimetrexate
DRUG1 has been studied on a background of DRUG2 and heparin. ,negative,AGGRASTAT,aspirin
DRUG1 has been studied on a background of aspirin and DRUG2. ,negative,AGGRASTAT,heparin
AGGRASTAT has been studied on a background of DRUG1 and DRUG2. ,negative,aspirin,heparin
"The use of DRUG1, in combination with DRUG2 and aspirin, has been associated with an increase in bleeding compared to DRUG2 and aspirin alone (see",effect,AGGRASTAT,heparin
"The use of DRUG1, in combination with heparin and DRUG2, has been associated with an increase in bleeding compared to heparin and DRUG2 alone (see",effect,AGGRASTAT,aspirin
"The use of DRUG1, in combination with DRUG2 and aspirin, has been associated with an increase in bleeding compared to DRUG2 and aspirin alone (see",negative,AGGRASTAT,heparin
"The use of DRUG1, in combination with heparin and DRUG2, has been associated with an increase in bleeding compared to heparin and DRUG2 alone (see",negative,AGGRASTAT,aspirin
"The use of AGGRASTAT, in combination with DRUG1 and DRUG2, has been associated with an increase in bleeding compared to DRUG1 and DRUG2 alone (see",negative,heparin,aspirin
"The use of AGGRASTAT, in combination with DRUG1 and aspirin, has been associated with an increase in bleeding compared to DRUG1 and aspirin alone (see",negative,heparin,heparin
"The use of AGGRASTAT, in combination with DRUG1 and DRUG2, has been associated with an increase in bleeding compared to DRUG1 and DRUG2 alone (see",negative,heparin,aspirin
"The use of AGGRASTAT, in combination with DRUG2 and DRUG1, has been associated with an increase in bleeding compared to DRUG2 and DRUG1 alone (see",negative,aspirin,heparin
"The use of AGGRASTAT, in combination with heparin and DRUG1, has been associated with an increase in bleeding compared to heparin and DRUG1 alone (see",negative,aspirin,aspirin
"The use of AGGRASTAT, in combination with DRUG1 and DRUG2, has been associated with an increase in bleeding compared to DRUG1 and DRUG2 alone (see",negative,heparin,aspirin
"however, in patients with Paget's Disease prior DRUG1 use appears to reduce the anti-resorptive response to Calcitonin (salmon) nasal spray.",effect,diphosphonate,Calcitonin (salmon)
"To minimize CNS depression and possible potentiation, DRUG1, DRUG2, narcotics, hypotensive agents or phenothiazines should be used with caution. ",negative,barbiturates,antihistamines
"To minimize CNS depression and possible potentiation, DRUG1, antihistamines, DRUG2, hypotensive agents or phenothiazines should be used with caution. ",negative,barbiturates,narcotics
"To minimize CNS depression and possible potentiation, DRUG1, antihistamines, narcotics, DRUG2 or phenothiazines should be used with caution. ",negative,barbiturates,hypotensive agents
"To minimize CNS depression and possible potentiation, DRUG1, antihistamines, narcotics, hypotensive agents or DRUG2 should be used with caution. ",negative,barbiturates,phenothiazines
"To minimize CNS depression and possible potentiation, barbiturates, DRUG1, DRUG2, hypotensive agents or phenothiazines should be used with caution. ",negative,antihistamines,narcotics
"To minimize CNS depression and possible potentiation, barbiturates, DRUG1, narcotics, DRUG2 or phenothiazines should be used with caution. ",negative,antihistamines,hypotensive agents
"To minimize CNS depression and possible potentiation, barbiturates, DRUG1, narcotics, hypotensive agents or DRUG2 should be used with caution. ",negative,antihistamines,phenothiazines
"To minimize CNS depression and possible potentiation, barbiturates, antihistamines, DRUG1, DRUG2 or phenothiazines should be used with caution. ",negative,narcotics,hypotensive agents
"To minimize CNS depression and possible potentiation, barbiturates, antihistamines, DRUG1, hypotensive agents or DRUG2 should be used with caution. ",negative,narcotics,phenothiazines
"To minimize CNS depression and possible potentiation, barbiturates, antihistamines, narcotics, DRUG1 or DRUG2 should be used with caution. ",negative,hypotensive agents,phenothiazines
"Because DRUG1 exhibits some monoamine oxidase inhibitory activity, DRUG2, tricyclic antidepressant drugs (e.g., amitriptyline HCl, imipramine HCl) and other drugs and foods with known high tyramine content, such as wine, yogurt, ripe cheese and bananas, should be avoided. ",advise,Matulane,sympathomimetic drugs
"Because DRUG1 exhibits some monoamine oxidase inhibitory activity, sympathomimetic drugs, DRUG2 drugs (e.g., amitriptyline HCl, imipramine HCl) and other drugs and foods with known high tyramine content, such as wine, yogurt, ripe cheese and bananas, should be avoided. ",advise,Matulane,tricyclic antidepressant
"Because DRUG1 exhibits some monoamine oxidase inhibitory activity, sympathomimetic drugs, tricyclic antidepressant drugs (e.g., DRUG2, imipramine HCl) and other drugs and foods with known high tyramine content, such as wine, yogurt, ripe cheese and bananas, should be avoided. ",advise,Matulane,amitriptyline HCl
"Because DRUG1 exhibits some monoamine oxidase inhibitory activity, sympathomimetic drugs, tricyclic antidepressant drugs (e.g., amitriptyline HCl, DRUG2) and other drugs and foods with known high tyramine content, such as wine, yogurt, ripe cheese and bananas, should be avoided. ",advise,Matulane,imipramine HCl
"Because DRUG1 exhibits some monoamine oxidase inhibitory activity, sympathomimetic drugs, tricyclic antidepressant drugs (e.g., amitriptyline HCl, imipramine HCl) and other drugs and foods with known high DRUG2 content, such as wine, yogurt, ripe cheese and bananas, should be avoided. ",advise,Matulane,tyramine
"Because Matulane exhibits some monoamine oxidase inhibitory activity, DRUG1, DRUG2 drugs (e.g., amitriptyline HCl, imipramine HCl) and other drugs and foods with known high tyramine content, such as wine, yogurt, ripe cheese and bananas, should be avoided. ",negative,sympathomimetic drugs,tricyclic antidepressant
"Because Matulane exhibits some monoamine oxidase inhibitory activity, DRUG1, tricyclic antidepressant drugs (e.g., DRUG2, imipramine HCl) and other drugs and foods with known high tyramine content, such as wine, yogurt, ripe cheese and bananas, should be avoided. ",negative,sympathomimetic drugs,amitriptyline HCl
"Because Matulane exhibits some monoamine oxidase inhibitory activity, DRUG1, tricyclic antidepressant drugs (e.g., amitriptyline HCl, DRUG2) and other drugs and foods with known high tyramine content, such as wine, yogurt, ripe cheese and bananas, should be avoided. ",negative,sympathomimetic drugs,imipramine HCl
"Because Matulane exhibits some monoamine oxidase inhibitory activity, DRUG1, tricyclic antidepressant drugs (e.g., amitriptyline HCl, imipramine HCl) and other drugs and foods with known high DRUG2 content, such as wine, yogurt, ripe cheese and bananas, should be avoided. ",negative,sympathomimetic drugs,tyramine
"Because Matulane exhibits some monoamine oxidase inhibitory activity, sympathomimetic drugs, DRUG1 drugs (e.g., DRUG2, imipramine HCl) and other drugs and foods with known high tyramine content, such as wine, yogurt, ripe cheese and bananas, should be avoided. ",negative,tricyclic antidepressant,amitriptyline HCl
"Because Matulane exhibits some monoamine oxidase inhibitory activity, sympathomimetic drugs, DRUG1 drugs (e.g., amitriptyline HCl, DRUG2) and other drugs and foods with known high tyramine content, such as wine, yogurt, ripe cheese and bananas, should be avoided. ",negative,tricyclic antidepressant,imipramine HCl
"Because Matulane exhibits some monoamine oxidase inhibitory activity, sympathomimetic drugs, DRUG1 drugs (e.g., amitriptyline HCl, imipramine HCl) and other drugs and foods with known high DRUG2 content, such as wine, yogurt, ripe cheese and bananas, should be avoided. ",negative,tricyclic antidepressant,tyramine
"Because Matulane exhibits some monoamine oxidase inhibitory activity, sympathomimetic drugs, tricyclic antidepressant drugs (e.g., DRUG1, DRUG2) and other drugs and foods with known high tyramine content, such as wine, yogurt, ripe cheese and bananas, should be avoided. ",negative,amitriptyline HCl,imipramine HCl
"Because Matulane exhibits some monoamine oxidase inhibitory activity, sympathomimetic drugs, tricyclic antidepressant drugs (e.g., DRUG1, imipramine HCl) and other drugs and foods with known high DRUG2 content, such as wine, yogurt, ripe cheese and bananas, should be avoided. ",negative,amitriptyline HCl,tyramine
"Because Matulane exhibits some monoamine oxidase inhibitory activity, sympathomimetic drugs, tricyclic antidepressant drugs (e.g., amitriptyline HCl, DRUG1) and other drugs and foods with known high DRUG2 content, such as wine, yogurt, ripe cheese and bananas, should be avoided. ",negative,imipramine HCl,tyramine
"No cross-resistance with other DRUG1, radiotherapy or DRUG2 has been demonstrated.",negative,chemotherapeutic agents,steroids
patients receiving DRUG1 and DRUG2 should have more frequent monitoring of neutrophil counts.,advise,lithium,Neulasta
"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between DRUG1 and DRUG2, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. ",negative,MYCAMINE,mycophenolate mofetil
"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between DRUG1 and mycophenolate mofetil, DRUG2, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. ",negative,MYCAMINE,cyclosporine
"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between DRUG1 and mycophenolate mofetil, cyclosporine, DRUG2, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. ",negative,MYCAMINE,tacrolimus
"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between DRUG1 and mycophenolate mofetil, cyclosporine, tacrolimus, DRUG2, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. ",negative,MYCAMINE,prednisolone
"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between DRUG1 and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, DRUG2, nifedipine, fluconazole, ritonavir, and rifampin. ",negative,MYCAMINE,sirolimus
"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between DRUG1 and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, DRUG2, fluconazole, ritonavir, and rifampin. ",negative,MYCAMINE,nifedipine
"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between DRUG1 and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, DRUG2, ritonavir, and rifampin. ",negative,MYCAMINE,fluconazole
"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between DRUG1 and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, DRUG2, and rifampin. ",negative,MYCAMINE,ritonavir
"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between DRUG1 and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and DRUG2. ",negative,MYCAMINE,rifampin
"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and DRUG1, DRUG2, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. ",negative,mycophenolate mofetil,cyclosporine
"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and DRUG1, cyclosporine, DRUG2, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. ",negative,mycophenolate mofetil,tacrolimus
"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and DRUG1, cyclosporine, tacrolimus, DRUG2, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. ",negative,mycophenolate mofetil,prednisolone
"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and DRUG1, cyclosporine, tacrolimus, prednisolone, DRUG2, nifedipine, fluconazole, ritonavir, and rifampin. ",negative,mycophenolate mofetil,sirolimus
"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and DRUG1, cyclosporine, tacrolimus, prednisolone, sirolimus, DRUG2, fluconazole, ritonavir, and rifampin. ",negative,mycophenolate mofetil,nifedipine
"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and DRUG1, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, DRUG2, ritonavir, and rifampin. ",negative,mycophenolate mofetil,fluconazole
"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and DRUG1, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, DRUG2, and rifampin. ",negative,mycophenolate mofetil,ritonavir
"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and DRUG1, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and DRUG2. ",negative,mycophenolate mofetil,rifampin
"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, DRUG1, DRUG2, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. ",negative,cyclosporine,tacrolimus
"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, DRUG1, tacrolimus, DRUG2, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. ",negative,cyclosporine,prednisolone
"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, DRUG1, tacrolimus, prednisolone, DRUG2, nifedipine, fluconazole, ritonavir, and rifampin. ",negative,cyclosporine,sirolimus
"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, DRUG1, tacrolimus, prednisolone, sirolimus, DRUG2, fluconazole, ritonavir, and rifampin. ",negative,cyclosporine,nifedipine
"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, DRUG1, tacrolimus, prednisolone, sirolimus, nifedipine, DRUG2, ritonavir, and rifampin. ",negative,cyclosporine,fluconazole
"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, DRUG1, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, DRUG2, and rifampin. ",negative,cyclosporine,ritonavir
"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, DRUG1, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and DRUG2. ",negative,cyclosporine,rifampin
"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, DRUG1, DRUG2, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. ",negative,tacrolimus,prednisolone
"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, DRUG1, prednisolone, DRUG2, nifedipine, fluconazole, ritonavir, and rifampin. ",negative,tacrolimus,sirolimus
"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, DRUG1, prednisolone, sirolimus, DRUG2, fluconazole, ritonavir, and rifampin. ",negative,tacrolimus,nifedipine
"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, DRUG1, prednisolone, sirolimus, nifedipine, DRUG2, ritonavir, and rifampin. ",negative,tacrolimus,fluconazole
"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, DRUG1, prednisolone, sirolimus, nifedipine, fluconazole, DRUG2, and rifampin. ",negative,tacrolimus,ritonavir
"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, DRUG1, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and DRUG2. ",negative,tacrolimus,rifampin
"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, DRUG1, DRUG2, nifedipine, fluconazole, ritonavir, and rifampin. ",negative,prednisolone,sirolimus
"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, DRUG1, sirolimus, DRUG2, fluconazole, ritonavir, and rifampin. ",negative,prednisolone,nifedipine
"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, DRUG1, sirolimus, nifedipine, DRUG2, ritonavir, and rifampin. ",negative,prednisolone,fluconazole
"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, DRUG1, sirolimus, nifedipine, fluconazole, DRUG2, and rifampin. ",negative,prednisolone,ritonavir
"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, DRUG1, sirolimus, nifedipine, fluconazole, ritonavir, and DRUG2. ",negative,prednisolone,rifampin
"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, DRUG1, DRUG2, fluconazole, ritonavir, and rifampin. ",negative,sirolimus,nifedipine
"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, DRUG1, nifedipine, DRUG2, ritonavir, and rifampin. ",negative,sirolimus,fluconazole
"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, DRUG1, nifedipine, fluconazole, DRUG2, and rifampin. ",negative,sirolimus,ritonavir
"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, DRUG1, nifedipine, fluconazole, ritonavir, and DRUG2. ",negative,sirolimus,rifampin
"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, DRUG1, DRUG2, ritonavir, and rifampin. ",negative,nifedipine,fluconazole
"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, DRUG1, fluconazole, DRUG2, and rifampin. ",negative,nifedipine,ritonavir
"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, DRUG1, fluconazole, ritonavir, and DRUG2. ",negative,nifedipine,rifampin
"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, DRUG1, DRUG2, and rifampin. ",negative,fluconazole,ritonavir
"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, DRUG1, ritonavir, and DRUG2. ",negative,fluconazole,rifampin
"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, DRUG1, and DRUG2. ",negative,ritonavir,rifampin
"There was no effect of a single dose or multiple doses of DRUG1 on DRUG2, cyclosporine, tacrolimus, prednisolone, and fluconazole pharmacokinetics. ",negative,MYCAMINE,mycophenolate mofetil
"There was no effect of a single dose or multiple doses of DRUG1 on mycophenolate mofetil, DRUG2, tacrolimus, prednisolone, and fluconazole pharmacokinetics. ",negative,MYCAMINE,cyclosporine
"There was no effect of a single dose or multiple doses of DRUG1 on mycophenolate mofetil, cyclosporine, DRUG2, prednisolone, and fluconazole pharmacokinetics. ",negative,MYCAMINE,tacrolimus
"There was no effect of a single dose or multiple doses of DRUG1 on mycophenolate mofetil, cyclosporine, tacrolimus, DRUG2, and fluconazole pharmacokinetics. ",negative,MYCAMINE,prednisolone
"There was no effect of a single dose or multiple doses of DRUG1 on mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, and DRUG2 pharmacokinetics. ",negative,MYCAMINE,fluconazole
"There was no effect of a single dose or multiple doses of MYCAMINE on DRUG1, DRUG2, tacrolimus, prednisolone, and fluconazole pharmacokinetics. ",negative,mycophenolate mofetil,cyclosporine
"There was no effect of a single dose or multiple doses of MYCAMINE on DRUG1, cyclosporine, DRUG2, prednisolone, and fluconazole pharmacokinetics. ",negative,mycophenolate mofetil,tacrolimus
"There was no effect of a single dose or multiple doses of MYCAMINE on DRUG1, cyclosporine, tacrolimus, DRUG2, and fluconazole pharmacokinetics. ",negative,mycophenolate mofetil,prednisolone
"There was no effect of a single dose or multiple doses of MYCAMINE on DRUG1, cyclosporine, tacrolimus, prednisolone, and DRUG2 pharmacokinetics. ",negative,mycophenolate mofetil,fluconazole
"There was no effect of a single dose or multiple doses of MYCAMINE on mycophenolate mofetil, DRUG1, DRUG2, prednisolone, and fluconazole pharmacokinetics. ",negative,cyclosporine,tacrolimus
"There was no effect of a single dose or multiple doses of MYCAMINE on mycophenolate mofetil, DRUG1, tacrolimus, DRUG2, and fluconazole pharmacokinetics. ",negative,cyclosporine,prednisolone
"There was no effect of a single dose or multiple doses of MYCAMINE on mycophenolate mofetil, DRUG1, tacrolimus, prednisolone, and DRUG2 pharmacokinetics. ",negative,cyclosporine,fluconazole
"There was no effect of a single dose or multiple doses of MYCAMINE on mycophenolate mofetil, cyclosporine, DRUG1, DRUG2, and fluconazole pharmacokinetics. ",negative,tacrolimus,prednisolone
"There was no effect of a single dose or multiple doses of MYCAMINE on mycophenolate mofetil, cyclosporine, DRUG1, prednisolone, and DRUG2 pharmacokinetics. ",negative,tacrolimus,fluconazole
"There was no effect of a single dose or multiple doses of MYCAMINE on mycophenolate mofetil, cyclosporine, tacrolimus, DRUG1, and DRUG2 pharmacokinetics. ",negative,prednisolone,fluconazole
DRUG1 AUC was increased by 21% with no effect on Cmax in the presence of steady-state DRUG2 compared with DRUG1 alone. ,mechanism,Sirolimus,MYCAMINE
DRUG1 AUC was increased by 21% with no effect on Cmax in the presence of steady-state MYCAMINE compared with DRUG1 alone. ,negative,Sirolimus,sirolimus
DRUG2 AUC was increased by 21% with no effect on Cmax in the presence of steady-state DRUG1 compared with DRUG2 alone. ,negative,MYCAMINE,sirolimus
"DRUG1 AUC and Cmax were increased by 18% and 42%, respectively, in the presence of steady-state DRUG2 compared with DRUG1 alone. ",mechanism,Nifedipine,MYCAMINE
"DRUG1 AUC and Cmax were increased by 18% and 42%, respectively, in the presence of steady-state MYCAMINE compared with DRUG1 alone. ",negative,Nifedipine,nifedipine
"DRUG2 AUC and Cmax were increased by 18% and 42%, respectively, in the presence of steady-state DRUG1 compared with DRUG2 alone. ",negative,MYCAMINE,nifedipine
Patients receiving DRUG1 or DRUG2 in combination with MYCAMINE should be monitored for DRUG1 or DRUG2 toxicity and DRUG1 or DRUG2 dosage should be reduced if necessary. ,negative,sirolimus,nifedipine
Patients receiving DRUG1 or nifedipine in combination with DRUG2 should be monitored for DRUG1 or nifedipine toxicity and DRUG1 or nifedipine dosage should be reduced if necessary. ,advise,sirolimus,MYCAMINE
Patients receiving DRUG1 or nifedipine in combination with MYCAMINE should be monitored for DRUG1 or nifedipine toxicity and DRUG1 or nifedipine dosage should be reduced if necessary. ,negative,sirolimus,sirolimus
Patients receiving DRUG1 or DRUG2 in combination with MYCAMINE should be monitored for DRUG1 or DRUG2 toxicity and DRUG1 or DRUG2 dosage should be reduced if necessary. ,negative,sirolimus,nifedipine
Patients receiving DRUG1 or nifedipine in combination with MYCAMINE should be monitored for DRUG1 or nifedipine toxicity and DRUG1 or nifedipine dosage should be reduced if necessary. ,negative,sirolimus,sirolimus
Patients receiving DRUG1 or DRUG2 in combination with MYCAMINE should be monitored for DRUG1 or DRUG2 toxicity and DRUG1 or DRUG2 dosage should be reduced if necessary. ,negative,sirolimus,nifedipine
Patients receiving sirolimus or DRUG1 in combination with DRUG2 should be monitored for sirolimus or DRUG1 toxicity and sirolimus or DRUG1 dosage should be reduced if necessary. ,advise,nifedipine,MYCAMINE
Patients receiving DRUG2 or DRUG1 in combination with MYCAMINE should be monitored for DRUG2 or DRUG1 toxicity and DRUG2 or DRUG1 dosage should be reduced if necessary. ,negative,nifedipine,sirolimus
Patients receiving sirolimus or DRUG1 in combination with MYCAMINE should be monitored for sirolimus or DRUG1 toxicity and sirolimus or DRUG1 dosage should be reduced if necessary. ,negative,nifedipine,nifedipine
Patients receiving DRUG2 or DRUG1 in combination with MYCAMINE should be monitored for DRUG2 or DRUG1 toxicity and DRUG2 or DRUG1 dosage should be reduced if necessary. ,negative,nifedipine,sirolimus
Patients receiving sirolimus or DRUG1 in combination with MYCAMINE should be monitored for sirolimus or DRUG1 toxicity and sirolimus or DRUG1 dosage should be reduced if necessary. ,negative,nifedipine,nifedipine
Patients receiving DRUG2 or nifedipine in combination with DRUG1 should be monitored for DRUG2 or nifedipine toxicity and DRUG2 or nifedipine dosage should be reduced if necessary. ,negative,MYCAMINE,sirolimus
Patients receiving sirolimus or DRUG2 in combination with DRUG1 should be monitored for sirolimus or DRUG2 toxicity and sirolimus or DRUG2 dosage should be reduced if necessary. ,negative,MYCAMINE,nifedipine
Patients receiving DRUG2 or nifedipine in combination with DRUG1 should be monitored for DRUG2 or nifedipine toxicity and DRUG2 or nifedipine dosage should be reduced if necessary. ,negative,MYCAMINE,sirolimus
Patients receiving sirolimus or DRUG2 in combination with DRUG1 should be monitored for sirolimus or DRUG2 toxicity and sirolimus or DRUG2 dosage should be reduced if necessary. ,negative,MYCAMINE,nifedipine
Patients receiving DRUG1 or DRUG2 in combination with MYCAMINE should be monitored for DRUG1 or DRUG2 toxicity and DRUG1 or DRUG2 dosage should be reduced if necessary. ,negative,sirolimus,nifedipine
Patients receiving DRUG1 or nifedipine in combination with MYCAMINE should be monitored for DRUG1 or nifedipine toxicity and DRUG1 or nifedipine dosage should be reduced if necessary. ,negative,sirolimus,sirolimus
Patients receiving DRUG1 or DRUG2 in combination with MYCAMINE should be monitored for DRUG1 or DRUG2 toxicity and DRUG1 or DRUG2 dosage should be reduced if necessary. ,negative,sirolimus,nifedipine
Patients receiving DRUG2 or DRUG1 in combination with MYCAMINE should be monitored for DRUG2 or DRUG1 toxicity and DRUG2 or DRUG1 dosage should be reduced if necessary. ,negative,nifedipine,sirolimus
Patients receiving sirolimus or DRUG1 in combination with MYCAMINE should be monitored for sirolimus or DRUG1 toxicity and sirolimus or DRUG1 dosage should be reduced if necessary. ,negative,nifedipine,nifedipine
Patients receiving DRUG1 or DRUG2 in combination with MYCAMINE should be monitored for DRUG1 or DRUG2 toxicity and DRUG1 or DRUG2 dosage should be reduced if necessary. ,negative,sirolimus,nifedipine
"Dosages of concomitantly administered DRUG1 should be reduced by approximately half, because DRUG2 amplifies the therapeutic actions and side-effects of DRUG1. ",effect,opioids,levomepromazine
"Dosages of concomitantly administered DRUG1 should be reduced by approximately half, because levomepromazine amplifies the therapeutic actions and side-effects of DRUG1. ",negative,opioids,opioids
"Dosages of concomitantly administered DRUG2 should be reduced by approximately half, because DRUG1 amplifies the therapeutic actions and side-effects of DRUG2. ",effect,levomepromazine,opioids
Combination with DRUG1 (DRUG2) is associated with increased risk of seizures. ,negative,tramadol,Ultram
Additive sedative effects and confusional states may emerge if DRUG1 is given with DRUG2 or barbiturates. ,effect,levomepromazine,benzodiazepines
Additive sedative effects and confusional states may emerge if DRUG1 is given with benzodiazepines or DRUG2. ,effect,levomepromazine,barbiturates
Additive sedative effects and confusional states may emerge if levomepromazine is given with DRUG1 or DRUG2. ,negative,benzodiazepines,barbiturates
"Exert particular caution in combining DRUG1 with other DRUG2 (tricyclic antidepressants and antiparkinsonian-agents): Particularly the elderly may develop delirium, high fever, severe obstipation, even ileus and glaucoma. ",advise,levomepromazine,anticholinergic drugs
"Exert particular caution in combining DRUG1 with other anticholinergic drugs (DRUG2 and antiparkinsonian-agents): Particularly the elderly may develop delirium, high fever, severe obstipation, even ileus and glaucoma. ",advise,levomepromazine,tricyclic antidepressants
"Exert particular caution in combining DRUG1 with other anticholinergic drugs (tricyclic antidepressants and DRUG2): Particularly the elderly may develop delirium, high fever, severe obstipation, even ileus and glaucoma. ",advise,levomepromazine,antiparkinsonian-agents
"Exert particular caution in combining levomepromazine with other DRUG1 (DRUG2 and antiparkinsonian-agents): Particularly the elderly may develop delirium, high fever, severe obstipation, even ileus and glaucoma. ",negative,anticholinergic drugs,tricyclic antidepressants
"Exert particular caution in combining levomepromazine with other DRUG1 (tricyclic antidepressants and DRUG2): Particularly the elderly may develop delirium, high fever, severe obstipation, even ileus and glaucoma. ",negative,anticholinergic drugs,antiparkinsonian-agents
"Exert particular caution in combining levomepromazine with other anticholinergic drugs (DRUG1 and DRUG2): Particularly the elderly may develop delirium, high fever, severe obstipation, even ileus and glaucoma. ",negative,tricyclic antidepressants,antiparkinsonian-agents
DRUG1 and/or stimulantes of the DRUG2/amphetamine type may counteract the specific actions of levomepromazine. ,negative,Caffeine,ephedrine
DRUG1 and/or stimulantes of the ephedrine/DRUG2 type may counteract the specific actions of levomepromazine. ,negative,Caffeine,amphetamine
DRUG1 and/or stimulantes of the ephedrine/amphetamine type may counteract the specific actions of DRUG2. ,effect,Caffeine,levomepromazine
Caffeine and/or stimulantes of the DRUG1/DRUG2 type may counteract the specific actions of levomepromazine. ,negative,ephedrine,amphetamine
Caffeine and/or stimulantes of the DRUG1/amphetamine type may counteract the specific actions of DRUG2. ,effect,ephedrine,levomepromazine
Caffeine and/or stimulantes of the ephedrine/DRUG1 type may counteract the specific actions of DRUG2. ,effect,amphetamine,levomepromazine
"Although DRUG1 (a mixture of three stereoisomers) has been administered safely following succinylcholine-facilitated tracheal intubation, the interaction between DRUG1 and succinylcholine has not been systematically studied. ",negative,MIVACRON,MIVACRON
"Although DRUG1 (a mixture of three stereoisomers) has been administered safely following DRUG2-facilitated tracheal intubation, the interaction between DRUG1 and DRUG2 has not been systematically studied. ",negative,MIVACRON,succinylcholine
"Although DRUG1 (a mixture of three stereoisomers) has been administered safely following DRUG2-facilitated tracheal intubation, the interaction between DRUG1 and DRUG2 has not been systematically studied. ",negative,MIVACRON,succinylcholine
Prior administration of DRUG1 can potentiate the neuromuscular blocking effects of DRUG2. ,effect,succinylcholine,nondepolarizing agents
Evidence of spontaneous recovery from DRUG1 should be observed before the administration of DRUG2. ,advise,succinylcholine,MIVACRON
The use of DRUG1 before DRUG2 to attenuate some of the side effects of DRUG2 has not been studied. ,negative,MIVACRON,succinylcholine
The use of DRUG1 before DRUG2 to attenuate some of the side effects of DRUG2 has not been studied. ,negative,MIVACRON,succinylcholine
The use of MIVACRON before DRUG1 to attenuate some of the side effects of DRUG1 has not been studied. ,negative,succinylcholine,succinylcholine
There are no clinical data on the use of DRUG1 with other DRUG2. ,negative,MIVACRON,nondepolarizing neuromuscular blocking agents
DRUG1 and DRUG2 (administered with nitrous oxide/oxygen to achieve 1.25 M.C. ,negative,Isoflurane,enflurane
DRUG1 and enflurane (administered with DRUG2/oxygen to achieve 1.25 M.C. ,negative,Isoflurane,nitrous oxide
DRUG1 and enflurane (administered with nitrous oxide/DRUG2 to achieve 1.25 M.C. ,negative,Isoflurane,oxygen
Isoflurane and DRUG1 (administered with DRUG2/oxygen to achieve 1.25 M.C. ,negative,enflurane,nitrous oxide
Isoflurane and DRUG1 (administered with nitrous oxide/DRUG2 to achieve 1.25 M.C. ,negative,enflurane,oxygen
Isoflurane and enflurane (administered with DRUG1/DRUG2 to achieve 1.25 M.C. ,negative,nitrous oxide,oxygen
A greater potentiation of the neuromuscular blocking effects of DRUG1 may be expected with higher concentrations of DRUG2 or isoflurane. ,negative,MIVACRON,enflurane
A greater potentiation of the neuromuscular blocking effects of DRUG1 may be expected with higher concentrations of enflurane or DRUG2. ,negative,MIVACRON,isoflurane
A greater potentiation of the neuromuscular blocking effects of MIVACRON may be expected with higher concentrations of DRUG1 or DRUG2. ,negative,enflurane,isoflurane
"Other drugs which may enhance the neuromuscular blocking action of DRUG1 such as DRUG2 include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",negative,nondepolarizing agents,MIVACRON
"Other drugs which may enhance the neuromuscular blocking action of DRUG1 such as MIVACRON include certain DRUG2 (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",int,nondepolarizing agents,antibiotics
"Other drugs which may enhance the neuromuscular blocking action of DRUG1 such as MIVACRON include certain antibiotics (e.g., DRUG2, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",int,nondepolarizing agents,aminoglycosides
"Other drugs which may enhance the neuromuscular blocking action of DRUG1 such as MIVACRON include certain antibiotics (e.g., aminoglycosides, DRUG2, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",int,nondepolarizing agents,tetracyclines
"Other drugs which may enhance the neuromuscular blocking action of DRUG1 such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, DRUG2, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",int,nondepolarizing agents,bacitracin
"Other drugs which may enhance the neuromuscular blocking action of DRUG1 such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, DRUG2, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",int,nondepolarizing agents,polymyxins
"Other drugs which may enhance the neuromuscular blocking action of DRUG1 such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, DRUG2, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",int,nondepolarizing agents,lincomycin
"Other drugs which may enhance the neuromuscular blocking action of DRUG1 such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, DRUG2, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",int,nondepolarizing agents,clindamycin
"Other drugs which may enhance the neuromuscular blocking action of DRUG1 such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, DRUG2, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",int,nondepolarizing agents,colistin
"Other drugs which may enhance the neuromuscular blocking action of DRUG1 such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and DRUG2), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",int,nondepolarizing agents,sodium colistimethate
"Other drugs which may enhance the neuromuscular blocking action of DRUG1 such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), DRUG2 salts, lithium, local anesthetics, procainamide, and quinidine. ",int,nondepolarizing agents,magnesium
"Other drugs which may enhance the neuromuscular blocking action of DRUG1 such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, DRUG2, local anesthetics, procainamide, and quinidine. ",int,nondepolarizing agents,lithium
"Other drugs which may enhance the neuromuscular blocking action of DRUG1 such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local DRUG2, procainamide, and quinidine. ",int,nondepolarizing agents,anesthetics
"Other drugs which may enhance the neuromuscular blocking action of DRUG1 such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, DRUG2, and quinidine. ",int,nondepolarizing agents,procainamide
"Other drugs which may enhance the neuromuscular blocking action of DRUG1 such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and DRUG2. ",int,nondepolarizing agents,quinidine
"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as DRUG1 include certain DRUG2 (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",int,MIVACRON,antibiotics
"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as DRUG1 include certain antibiotics (e.g., DRUG2, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",int,MIVACRON,aminoglycosides
"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as DRUG1 include certain antibiotics (e.g., aminoglycosides, DRUG2, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",int,MIVACRON,tetracyclines
"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as DRUG1 include certain antibiotics (e.g., aminoglycosides, tetracyclines, DRUG2, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",int,MIVACRON,bacitracin
"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as DRUG1 include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, DRUG2, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",int,MIVACRON,polymyxins
"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as DRUG1 include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, DRUG2, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",int,MIVACRON,lincomycin
"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as DRUG1 include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, DRUG2, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",int,MIVACRON,clindamycin
"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as DRUG1 include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, DRUG2, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",int,MIVACRON,colistin
"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as DRUG1 include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and DRUG2), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",int,MIVACRON,sodium colistimethate
"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as DRUG1 include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), DRUG2 salts, lithium, local anesthetics, procainamide, and quinidine. ",int,MIVACRON,magnesium
"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as DRUG1 include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, DRUG2, local anesthetics, procainamide, and quinidine. ",int,MIVACRON,lithium
"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as DRUG1 include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local DRUG2, procainamide, and quinidine. ",int,MIVACRON,anesthetics
"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as DRUG1 include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, DRUG2, and quinidine. ",int,MIVACRON,procainamide
"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as DRUG1 include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and DRUG2. ",int,MIVACRON,quinidine
"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain DRUG1 (e.g., DRUG2, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",negative,antibiotics,aminoglycosides
"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain DRUG1 (e.g., aminoglycosides, DRUG2, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",negative,antibiotics,tetracyclines
"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain DRUG1 (e.g., aminoglycosides, tetracyclines, DRUG2, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",negative,antibiotics,bacitracin
"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain DRUG1 (e.g., aminoglycosides, tetracyclines, bacitracin, DRUG2, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",negative,antibiotics,polymyxins
"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain DRUG1 (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, DRUG2, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",negative,antibiotics,lincomycin
"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain DRUG1 (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, DRUG2, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",negative,antibiotics,clindamycin
"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain DRUG1 (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, DRUG2, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",negative,antibiotics,colistin
"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain DRUG1 (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and DRUG2), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",negative,antibiotics,sodium colistimethate
"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain DRUG1 (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), DRUG2 salts, lithium, local anesthetics, procainamide, and quinidine. ",negative,antibiotics,magnesium
"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain DRUG1 (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, DRUG2, local anesthetics, procainamide, and quinidine. ",negative,antibiotics,lithium
"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain DRUG1 (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local DRUG2, procainamide, and quinidine. ",negative,antibiotics,anesthetics
"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain DRUG1 (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, DRUG2, and quinidine. ",negative,antibiotics,procainamide
"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain DRUG1 (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and DRUG2. ",negative,antibiotics,quinidine
"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., DRUG1, DRUG2, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",negative,aminoglycosides,tetracyclines
"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., DRUG1, tetracyclines, DRUG2, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",negative,aminoglycosides,bacitracin
"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., DRUG1, tetracyclines, bacitracin, DRUG2, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",negative,aminoglycosides,polymyxins
"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., DRUG1, tetracyclines, bacitracin, polymyxins, DRUG2, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",negative,aminoglycosides,lincomycin
"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., DRUG1, tetracyclines, bacitracin, polymyxins, lincomycin, DRUG2, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",negative,aminoglycosides,clindamycin
"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., DRUG1, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, DRUG2, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",negative,aminoglycosides,colistin
"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., DRUG1, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and DRUG2), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",negative,aminoglycosides,sodium colistimethate
"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., DRUG1, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), DRUG2 salts, lithium, local anesthetics, procainamide, and quinidine. ",negative,aminoglycosides,magnesium
"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., DRUG1, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, DRUG2, local anesthetics, procainamide, and quinidine. ",negative,aminoglycosides,lithium
"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., DRUG1, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local DRUG2, procainamide, and quinidine. ",negative,aminoglycosides,anesthetics
"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., DRUG1, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, DRUG2, and quinidine. ",negative,aminoglycosides,procainamide
"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., DRUG1, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and DRUG2. ",negative,aminoglycosides,quinidine
"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, DRUG1, DRUG2, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",negative,tetracyclines,bacitracin
"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, DRUG1, bacitracin, DRUG2, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",negative,tetracyclines,polymyxins
"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, DRUG1, bacitracin, polymyxins, DRUG2, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",negative,tetracyclines,lincomycin
"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, DRUG1, bacitracin, polymyxins, lincomycin, DRUG2, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",negative,tetracyclines,clindamycin
"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, DRUG1, bacitracin, polymyxins, lincomycin, clindamycin, DRUG2, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",negative,tetracyclines,colistin
"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, DRUG1, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and DRUG2), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",negative,tetracyclines,sodium colistimethate
"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, DRUG1, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), DRUG2 salts, lithium, local anesthetics, procainamide, and quinidine. ",negative,tetracyclines,magnesium
"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, DRUG1, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, DRUG2, local anesthetics, procainamide, and quinidine. ",negative,tetracyclines,lithium
"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, DRUG1, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local DRUG2, procainamide, and quinidine. ",negative,tetracyclines,anesthetics
"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, DRUG1, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, DRUG2, and quinidine. ",negative,tetracyclines,procainamide
"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, DRUG1, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and DRUG2. ",negative,tetracyclines,quinidine
"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, DRUG1, DRUG2, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",negative,bacitracin,polymyxins
"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, DRUG1, polymyxins, DRUG2, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",negative,bacitracin,lincomycin
"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, DRUG1, polymyxins, lincomycin, DRUG2, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",negative,bacitracin,clindamycin
"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, DRUG1, polymyxins, lincomycin, clindamycin, DRUG2, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",negative,bacitracin,colistin
"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, DRUG1, polymyxins, lincomycin, clindamycin, colistin, and DRUG2), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",negative,bacitracin,sodium colistimethate
"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, DRUG1, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), DRUG2 salts, lithium, local anesthetics, procainamide, and quinidine. ",negative,bacitracin,magnesium
"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, DRUG1, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, DRUG2, local anesthetics, procainamide, and quinidine. ",negative,bacitracin,lithium
"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, DRUG1, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local DRUG2, procainamide, and quinidine. ",negative,bacitracin,anesthetics
"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, DRUG1, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, DRUG2, and quinidine. ",negative,bacitracin,procainamide
"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, DRUG1, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and DRUG2. ",negative,bacitracin,quinidine
"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, DRUG1, DRUG2, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",negative,polymyxins,lincomycin
"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, DRUG1, lincomycin, DRUG2, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",negative,polymyxins,clindamycin
"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, DRUG1, lincomycin, clindamycin, DRUG2, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",negative,polymyxins,colistin
"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, DRUG1, lincomycin, clindamycin, colistin, and DRUG2), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",negative,polymyxins,sodium colistimethate
"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, DRUG1, lincomycin, clindamycin, colistin, and sodium colistimethate), DRUG2 salts, lithium, local anesthetics, procainamide, and quinidine. ",negative,polymyxins,magnesium
"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, DRUG1, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, DRUG2, local anesthetics, procainamide, and quinidine. ",negative,polymyxins,lithium
"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, DRUG1, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local DRUG2, procainamide, and quinidine. ",negative,polymyxins,anesthetics
"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, DRUG1, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, DRUG2, and quinidine. ",negative,polymyxins,procainamide
"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, DRUG1, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and DRUG2. ",negative,polymyxins,quinidine
"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, DRUG1, DRUG2, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",negative,lincomycin,clindamycin
"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, DRUG1, clindamycin, DRUG2, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",negative,lincomycin,colistin
"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, DRUG1, clindamycin, colistin, and DRUG2), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",negative,lincomycin,sodium colistimethate
"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, DRUG1, clindamycin, colistin, and sodium colistimethate), DRUG2 salts, lithium, local anesthetics, procainamide, and quinidine. ",negative,lincomycin,magnesium
"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, DRUG1, clindamycin, colistin, and sodium colistimethate), magnesium salts, DRUG2, local anesthetics, procainamide, and quinidine. ",negative,lincomycin,lithium
"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, DRUG1, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local DRUG2, procainamide, and quinidine. ",negative,lincomycin,anesthetics
"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, DRUG1, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, DRUG2, and quinidine. ",negative,lincomycin,procainamide
"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, DRUG1, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and DRUG2. ",negative,lincomycin,quinidine
"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, DRUG1, DRUG2, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",negative,clindamycin,colistin
"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, DRUG1, colistin, and DRUG2), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",negative,clindamycin,sodium colistimethate
"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, DRUG1, colistin, and sodium colistimethate), DRUG2 salts, lithium, local anesthetics, procainamide, and quinidine. ",negative,clindamycin,magnesium
"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, DRUG1, colistin, and sodium colistimethate), magnesium salts, DRUG2, local anesthetics, procainamide, and quinidine. ",negative,clindamycin,lithium
"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, DRUG1, colistin, and sodium colistimethate), magnesium salts, lithium, local DRUG2, procainamide, and quinidine. ",negative,clindamycin,anesthetics
"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, DRUG1, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, DRUG2, and quinidine. ",negative,clindamycin,procainamide
"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, DRUG1, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and DRUG2. ",negative,clindamycin,quinidine
"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, DRUG1, and DRUG2), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",negative,colistin,sodium colistimethate
"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, DRUG1, and sodium colistimethate), DRUG2 salts, lithium, local anesthetics, procainamide, and quinidine. ",negative,colistin,magnesium
"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, DRUG1, and sodium colistimethate), magnesium salts, DRUG2, local anesthetics, procainamide, and quinidine. ",negative,colistin,lithium
"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, DRUG1, and sodium colistimethate), magnesium salts, lithium, local DRUG2, procainamide, and quinidine. ",negative,colistin,anesthetics
"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, DRUG1, and sodium colistimethate), magnesium salts, lithium, local anesthetics, DRUG2, and quinidine. ",negative,colistin,procainamide
"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, DRUG1, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and DRUG2. ",negative,colistin,quinidine
"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and DRUG1), DRUG2 salts, lithium, local anesthetics, procainamide, and quinidine. ",negative,sodium colistimethate,magnesium
"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and DRUG1), magnesium salts, DRUG2, local anesthetics, procainamide, and quinidine. ",negative,sodium colistimethate,lithium
"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and DRUG1), magnesium salts, lithium, local DRUG2, procainamide, and quinidine. ",negative,sodium colistimethate,anesthetics
"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and DRUG1), magnesium salts, lithium, local anesthetics, DRUG2, and quinidine. ",negative,sodium colistimethate,procainamide
"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and DRUG1), magnesium salts, lithium, local anesthetics, procainamide, and DRUG2. ",negative,sodium colistimethate,quinidine
"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), DRUG1 salts, DRUG2, local anesthetics, procainamide, and quinidine. ",negative,magnesium,lithium
"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), DRUG1 salts, lithium, local DRUG2, procainamide, and quinidine. ",negative,magnesium,anesthetics
"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), DRUG1 salts, lithium, local anesthetics, DRUG2, and quinidine. ",negative,magnesium,procainamide
"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), DRUG1 salts, lithium, local anesthetics, procainamide, and DRUG2. ",negative,magnesium,quinidine
"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, DRUG1, local DRUG2, procainamide, and quinidine. ",negative,lithium,anesthetics
"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, DRUG1, local anesthetics, DRUG2, and quinidine. ",negative,lithium,procainamide
"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, DRUG1, local anesthetics, procainamide, and DRUG2. ",negative,lithium,quinidine
"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local DRUG1, DRUG2, and quinidine. ",negative,anesthetics,procainamide
"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local DRUG1, procainamide, and DRUG2. ",negative,anesthetics,quinidine
"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, DRUG1, and DRUG2. ",negative,procainamide,quinidine
"The neuromuscular blocking effect of DRUG1 may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral DRUG2, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine. ",effect,MIVACRON,contraceptives
"The neuromuscular blocking effect of DRUG1 may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, DRUG2, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine. ",effect,MIVACRON,glucocorticoids
"The neuromuscular blocking effect of DRUG1 may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain DRUG2) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine. ",effect,MIVACRON,monoamine oxidase inhibitors
"The neuromuscular blocking effect of DRUG1 may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing DRUG2 has been demonstrated in patients chronically administered phenytoin or carbamazepine. ",negative,MIVACRON,neuromuscular blocking agents
"The neuromuscular blocking effect of DRUG1 may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered DRUG2 or carbamazepine. ",negative,MIVACRON,phenytoin
"The neuromuscular blocking effect of DRUG1 may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or DRUG2. ",negative,MIVACRON,carbamazepine
"The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral DRUG1, DRUG2, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine. ",negative,contraceptives,glucocorticoids
"The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral DRUG1, glucocorticoids, or certain DRUG2) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine. ",negative,contraceptives,monoamine oxidase inhibitors
"The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral DRUG1, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing DRUG2 has been demonstrated in patients chronically administered phenytoin or carbamazepine. ",negative,contraceptives,neuromuscular blocking agents
"The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral DRUG1, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered DRUG2 or carbamazepine. ",negative,contraceptives,phenytoin
"The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral DRUG1, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or DRUG2. ",negative,contraceptives,carbamazepine
"The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, DRUG1, or certain DRUG2) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine. ",negative,glucocorticoids,monoamine oxidase inhibitors
"The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, DRUG1, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing DRUG2 has been demonstrated in patients chronically administered phenytoin or carbamazepine. ",negative,glucocorticoids,neuromuscular blocking agents
"The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, DRUG1, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered DRUG2 or carbamazepine. ",negative,glucocorticoids,phenytoin
"The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, DRUG1, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or DRUG2. ",negative,glucocorticoids,carbamazepine
"The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain DRUG1) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing DRUG2 has been demonstrated in patients chronically administered phenytoin or carbamazepine. ",negative,monoamine oxidase inhibitors,neuromuscular blocking agents
"The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain DRUG1) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered DRUG2 or carbamazepine. ",negative,monoamine oxidase inhibitors,phenytoin
"The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain DRUG1) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or DRUG2. ",negative,monoamine oxidase inhibitors,carbamazepine
"The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing DRUG1 has been demonstrated in patients chronically administered DRUG2 or carbamazepine. ",effect,neuromuscular blocking agents,phenytoin
"The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing DRUG1 has been demonstrated in patients chronically administered phenytoin or DRUG2. ",effect,neuromuscular blocking agents,carbamazepine
"The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered DRUG1 or DRUG2. ",negative,phenytoin,carbamazepine
"While the effects of chronic DRUG1 or DRUG2 therapy on the action of MIVACRON are unknown, slightly shorter durations of neuromuscular block may be anticipated and infusion rate requirements may be higher. ",negative,phenytoin,carbamazepine
"While the effects of chronic DRUG1 or carbamazepine therapy on the action of DRUG2 are unknown, slightly shorter durations of neuromuscular block may be anticipated and infusion rate requirements may be higher. ",effect,phenytoin,MIVACRON
"While the effects of chronic phenytoin or DRUG1 therapy on the action of DRUG2 are unknown, slightly shorter durations of neuromuscular block may be anticipated and infusion rate requirements may be higher. ",effect,carbamazepine,MIVACRON
Some drug interactions are:  - birth control pills - DRUG1 - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUG2 or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,negative,corticosteroids,phenytoin
Some drug interactions are:  - birth control pills - DRUG1 - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or DRUG2 - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,negative,corticosteroids,carbamazepine
Some drug interactions are:  - birth control pills - DRUG1 - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain DRUG2 given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,negative,corticosteroids,antibiotics
Some drug interactions are:  - birth control pills - DRUG1 - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - DRUG2 - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,negative,corticosteroids,cisplatin
Some drug interactions are:  - birth control pills - DRUG1 - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - DRUG2 - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,negative,corticosteroids,edrophonium
Some drug interactions are:  - birth control pills - DRUG1 - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - DRUG2 - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,negative,corticosteroids,neostigmine
Some drug interactions are:  - birth control pills - DRUG1 - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - DRUG2 or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,negative,corticosteroids,polymyxin B
Some drug interactions are:  - birth control pills - DRUG1 - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or DRUG2 - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,negative,corticosteroids,bacitracin
Some drug interactions are:  - birth control pills - DRUG1 - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local DRUG2 such as procaine - general DRUG2 - succinylcholine or other muscle relaxants,negative,corticosteroids,anesthetics
Some drug interactions are:  - birth control pills - DRUG1 - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as DRUG2 - general anesthetics - succinylcholine or other muscle relaxants,negative,corticosteroids,procaine
Some drug interactions are:  - birth control pills - DRUG1 - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local DRUG2 such as procaine - general DRUG2 - succinylcholine or other muscle relaxants,negative,corticosteroids,anesthetics
Some drug interactions are:  - birth control pills - DRUG1 - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - DRUG2 or other muscle relaxants,negative,corticosteroids,succinylcholine
Some drug interactions are:  - birth control pills - DRUG1 - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other DRUG2,negative,corticosteroids,muscle relaxants
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUG1 or DRUG2 - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,negative,phenytoin,carbamazepine
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUG1 or carbamazepine - certain DRUG2 given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,negative,phenytoin,antibiotics
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUG1 or carbamazepine - certain antibiotics given by injection - DRUG2 - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,negative,phenytoin,cisplatin
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUG1 or carbamazepine - certain antibiotics given by injection - cisplatin - DRUG2 - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,negative,phenytoin,edrophonium
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUG1 or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - DRUG2 - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,negative,phenytoin,neostigmine
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUG1 or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - DRUG2 or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,negative,phenytoin,polymyxin B
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUG1 or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or DRUG2 - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,negative,phenytoin,bacitracin
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUG1 or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local DRUG2 such as procaine - general DRUG2 - succinylcholine or other muscle relaxants,negative,phenytoin,anesthetics
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUG1 or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as DRUG2 - general anesthetics - succinylcholine or other muscle relaxants,negative,phenytoin,procaine
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUG1 or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local DRUG2 such as procaine - general DRUG2 - succinylcholine or other muscle relaxants,negative,phenytoin,anesthetics
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUG1 or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - DRUG2 or other muscle relaxants,negative,phenytoin,succinylcholine
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUG1 or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other DRUG2,negative,phenytoin,muscle relaxants
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or DRUG1 - certain DRUG2 given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,negative,carbamazepine,antibiotics
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or DRUG1 - certain antibiotics given by injection - DRUG2 - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,negative,carbamazepine,cisplatin
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or DRUG1 - certain antibiotics given by injection - cisplatin - DRUG2 - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,negative,carbamazepine,edrophonium
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or DRUG1 - certain antibiotics given by injection - cisplatin - edrophonium - DRUG2 - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,negative,carbamazepine,neostigmine
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or DRUG1 - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - DRUG2 or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,negative,carbamazepine,polymyxin B
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or DRUG1 - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or DRUG2 - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,negative,carbamazepine,bacitracin
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or DRUG1 - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local DRUG2 such as procaine - general DRUG2 - succinylcholine or other muscle relaxants,negative,carbamazepine,anesthetics
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or DRUG1 - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as DRUG2 - general anesthetics - succinylcholine or other muscle relaxants,negative,carbamazepine,procaine
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or DRUG1 - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local DRUG2 such as procaine - general DRUG2 - succinylcholine or other muscle relaxants,negative,carbamazepine,anesthetics
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or DRUG1 - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - DRUG2 or other muscle relaxants,negative,carbamazepine,succinylcholine
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or DRUG1 - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other DRUG2,negative,carbamazepine,muscle relaxants
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain DRUG1 given by injection - DRUG2 - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,negative,antibiotics,cisplatin
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain DRUG1 given by injection - cisplatin - DRUG2 - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,negative,antibiotics,edrophonium
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain DRUG1 given by injection - cisplatin - edrophonium - DRUG2 - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,negative,antibiotics,neostigmine
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain DRUG1 given by injection - cisplatin - edrophonium - neostigmine - DRUG2 or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,negative,antibiotics,polymyxin B
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain DRUG1 given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or DRUG2 - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,negative,antibiotics,bacitracin
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain DRUG1 given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local DRUG2 such as procaine - general DRUG2 - succinylcholine or other muscle relaxants,negative,antibiotics,anesthetics
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain DRUG1 given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as DRUG2 - general anesthetics - succinylcholine or other muscle relaxants,negative,antibiotics,procaine
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain DRUG1 given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local DRUG2 such as procaine - general DRUG2 - succinylcholine or other muscle relaxants,negative,antibiotics,anesthetics
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain DRUG1 given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - DRUG2 or other muscle relaxants,negative,antibiotics,succinylcholine
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain DRUG1 given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other DRUG2,negative,antibiotics,muscle relaxants
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - DRUG1 - DRUG2 - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,negative,cisplatin,edrophonium
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - DRUG1 - edrophonium - DRUG2 - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,negative,cisplatin,neostigmine
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - DRUG1 - edrophonium - neostigmine - DRUG2 or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,negative,cisplatin,polymyxin B
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - DRUG1 - edrophonium - neostigmine - polymyxin B or DRUG2 - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,negative,cisplatin,bacitracin
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - DRUG1 - edrophonium - neostigmine - polymyxin B or bacitracin - local DRUG2 such as procaine - general DRUG2 - succinylcholine or other muscle relaxants,negative,cisplatin,anesthetics
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - DRUG1 - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as DRUG2 - general anesthetics - succinylcholine or other muscle relaxants,negative,cisplatin,procaine
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - DRUG1 - edrophonium - neostigmine - polymyxin B or bacitracin - local DRUG2 such as procaine - general DRUG2 - succinylcholine or other muscle relaxants,negative,cisplatin,anesthetics
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - DRUG1 - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - DRUG2 or other muscle relaxants,negative,cisplatin,succinylcholine
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - DRUG1 - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other DRUG2,negative,cisplatin,muscle relaxants
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - DRUG1 - DRUG2 - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,negative,edrophonium,neostigmine
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - DRUG1 - neostigmine - DRUG2 or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,negative,edrophonium,polymyxin B
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - DRUG1 - neostigmine - polymyxin B or DRUG2 - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,negative,edrophonium,bacitracin
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - DRUG1 - neostigmine - polymyxin B or bacitracin - local DRUG2 such as procaine - general DRUG2 - succinylcholine or other muscle relaxants,negative,edrophonium,anesthetics
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - DRUG1 - neostigmine - polymyxin B or bacitracin - local anesthetics such as DRUG2 - general anesthetics - succinylcholine or other muscle relaxants,negative,edrophonium,procaine
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - DRUG1 - neostigmine - polymyxin B or bacitracin - local DRUG2 such as procaine - general DRUG2 - succinylcholine or other muscle relaxants,negative,edrophonium,anesthetics
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - DRUG1 - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - DRUG2 or other muscle relaxants,negative,edrophonium,succinylcholine
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - DRUG1 - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other DRUG2,negative,edrophonium,muscle relaxants
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - DRUG1 - DRUG2 or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,negative,neostigmine,polymyxin B
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - DRUG1 - polymyxin B or DRUG2 - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,negative,neostigmine,bacitracin
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - DRUG1 - polymyxin B or bacitracin - local DRUG2 such as procaine - general DRUG2 - succinylcholine or other muscle relaxants,negative,neostigmine,anesthetics
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - DRUG1 - polymyxin B or bacitracin - local anesthetics such as DRUG2 - general anesthetics - succinylcholine or other muscle relaxants,negative,neostigmine,procaine
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - DRUG1 - polymyxin B or bacitracin - local DRUG2 such as procaine - general DRUG2 - succinylcholine or other muscle relaxants,negative,neostigmine,anesthetics
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - DRUG1 - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - DRUG2 or other muscle relaxants,negative,neostigmine,succinylcholine
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - DRUG1 - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other DRUG2,negative,neostigmine,muscle relaxants
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - DRUG1 or DRUG2 - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,negative,polymyxin B,bacitracin
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - DRUG1 or bacitracin - local DRUG2 such as procaine - general DRUG2 - succinylcholine or other muscle relaxants,negative,polymyxin B,anesthetics
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - DRUG1 or bacitracin - local anesthetics such as DRUG2 - general anesthetics - succinylcholine or other muscle relaxants,negative,polymyxin B,procaine
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - DRUG1 or bacitracin - local DRUG2 such as procaine - general DRUG2 - succinylcholine or other muscle relaxants,negative,polymyxin B,anesthetics
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - DRUG1 or bacitracin - local anesthetics such as procaine - general anesthetics - DRUG2 or other muscle relaxants,negative,polymyxin B,succinylcholine
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - DRUG1 or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other DRUG2,negative,polymyxin B,muscle relaxants
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or DRUG1 - local DRUG2 such as procaine - general DRUG2 - succinylcholine or other muscle relaxants,negative,bacitracin,anesthetics
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or DRUG1 - local anesthetics such as DRUG2 - general anesthetics - succinylcholine or other muscle relaxants,negative,bacitracin,procaine
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or DRUG1 - local DRUG2 such as procaine - general DRUG2 - succinylcholine or other muscle relaxants,negative,bacitracin,anesthetics
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or DRUG1 - local anesthetics such as procaine - general anesthetics - DRUG2 or other muscle relaxants,negative,bacitracin,succinylcholine
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or DRUG1 - local anesthetics such as procaine - general anesthetics - succinylcholine or other DRUG2,negative,bacitracin,muscle relaxants
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local DRUG1 such as DRUG2 - general DRUG1 - succinylcholine or other muscle relaxants,negative,anesthetics,procaine
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local DRUG1 such as procaine - general DRUG1 - succinylcholine or other muscle relaxants,negative,anesthetics,anesthetics
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local DRUG1 such as procaine - general DRUG1 - DRUG2 or other muscle relaxants,negative,anesthetics,succinylcholine
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local DRUG1 such as procaine - general DRUG1 - succinylcholine or other DRUG2,negative,anesthetics,muscle relaxants
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local DRUG2 such as DRUG1 - general DRUG2 - succinylcholine or other muscle relaxants,negative,procaine,anesthetics
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as DRUG1 - general anesthetics - DRUG2 or other muscle relaxants,negative,procaine,succinylcholine
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as DRUG1 - general anesthetics - succinylcholine or other DRUG2,negative,procaine,muscle relaxants
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local DRUG1 such as procaine - general DRUG1 - DRUG2 or other muscle relaxants,negative,anesthetics,succinylcholine
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local DRUG1 such as procaine - general DRUG1 - succinylcholine or other DRUG2,negative,anesthetics,muscle relaxants
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - DRUG1 or other DRUG2,negative,succinylcholine,muscle relaxants
Do not exceed a 5 mg daily dose of DRUG1 when administered with therapeutic doses of DRUG2 or other potent CYP3A4 inhibitors. ,advise,VESIcare,ketoconazole
"Patients with Congenital or Acquired QT Prolongation In a study of the effect of DRUG1 on the QT interval in 76 healthy women, the QT prolonging effect appeared less with DRUG1 10 mg than with 30 mg (three times the maximum recommended dose), and the effect of DRUG1 30 mg did not appear as large as that of the positive control moxifloxacin at its therapeutic dose. ",negative,solifenacin,solifenacin
"Patients with Congenital or Acquired QT Prolongation In a study of the effect of DRUG1 on the QT interval in 76 healthy women, the QT prolonging effect appeared less with DRUG1 10 mg than with 30 mg (three times the maximum recommended dose), and the effect of DRUG1 30 mg did not appear as large as that of the positive control moxifloxacin at its therapeutic dose. ",negative,solifenacin,solifenacin
"Patients with Congenital or Acquired QT Prolongation In a study of the effect of DRUG1 on the QT interval in 76 healthy women, the QT prolonging effect appeared less with DRUG1 10 mg than with 30 mg (three times the maximum recommended dose), and the effect of DRUG1 30 mg did not appear as large as that of the positive control DRUG2 at its therapeutic dose. ",negative,solifenacin,moxifloxacin
"Patients with Congenital or Acquired QT Prolongation In a study of the effect of DRUG1 on the QT interval in 76 healthy women, the QT prolonging effect appeared less with DRUG1 10 mg than with 30 mg (three times the maximum recommended dose), and the effect of DRUG1 30 mg did not appear as large as that of the positive control moxifloxacin at its therapeutic dose. ",negative,solifenacin,solifenacin
"Patients with Congenital or Acquired QT Prolongation In a study of the effect of DRUG1 on the QT interval in 76 healthy women, the QT prolonging effect appeared less with DRUG1 10 mg than with 30 mg (three times the maximum recommended dose), and the effect of DRUG1 30 mg did not appear as large as that of the positive control DRUG2 at its therapeutic dose. ",negative,solifenacin,moxifloxacin
"Patients with Congenital or Acquired QT Prolongation In a study of the effect of DRUG1 on the QT interval in 76 healthy women, the QT prolonging effect appeared less with DRUG1 10 mg than with 30 mg (three times the maximum recommended dose), and the effect of DRUG1 30 mg did not appear as large as that of the positive control DRUG2 at its therapeutic dose. ",negative,solifenacin,moxifloxacin
"Interaction with DRUG1: Although DRUG2 does not itself cause orthostatic hypotension, its administration to patients already receiving DRUG1 can result in profound orthostatic effects. ",negative,Guanethidine,minoxidil
"Interaction with DRUG1: Although minoxidil does not itself cause orthostatic hypotension, its administration to patients already receiving DRUG1 can result in profound orthostatic effects. ",negative,Guanethidine,guanethidine
"Interaction with DRUG2: Although DRUG1 does not itself cause orthostatic hypotension, its administration to patients already receiving DRUG2 can result in profound orthostatic effects. ",effect,minoxidil,guanethidine
If at all possible DRUG1 should be discontinued well before DRUG2 is begun. ,advise,guanethidine,minoxidil
"While co-administration of DRUG1    appeared to increase the clearance of DRUG2 by 70%, these results are not conclusive because of the small number of subjects studied and because patients took variable doses of DRUG2. ",mechanism,ZAVESCA,Cerezyme
"While co-administration of DRUG1    appeared to increase the clearance of DRUG2 by 70%, these results are not conclusive because of the small number of subjects studied and because patients took variable doses of DRUG2. ",negative,ZAVESCA,Cerezyme
"While co-administration of ZAVESCA    appeared to increase the clearance of DRUG1 by 70%, these results are not conclusive because of the small number of subjects studied and because patients took variable doses of DRUG1. ",negative,Cerezyme,Cerezyme
Combination therapy with DRUG1    (DRUG2) and ZAVESCA    is not indicated.,negative,Cerezyme,imiglucerase
Combination therapy with DRUG1    (imiglucerase) and DRUG2    is not indicated.,advise,Cerezyme,ZAVESCA
Combination therapy with Cerezyme    (DRUG1) and DRUG2    is not indicated.,advise,imiglucerase,ZAVESCA
DRUG1 administered concomitantly with DRUG2 may significantly decrease the serum concentrations of MPA. ,mechanism,Aminoglutethimide,depo-subQ provera 104
DRUG1 administered concomitantly with depo-subQ provera 104 may significantly decrease the serum concentrations of DRUG2. ,negative,Aminoglutethimide,MPA
Aminoglutethimide administered concomitantly with DRUG1 may significantly decrease the serum concentrations of DRUG2. ,negative,depo-subQ provera 104,MPA
Hypokalemia may develop during concomitant use of DRUG1 or DRUG2. ,negative,steroids,ACTH
DRUG1 may decrease arterial responsiveness to DRUG2. ,effect,Thiazides,norepinephrine
DRUG1 may increase the responsiveness of DRUG2. ,effect,Thiazide drugs,tubocurarine
"DRUG1 renal clearance is reduced by DRUG2, increasing the risk of DRUG1 toxicity. ",mechanism,Lithium,thiazides
"DRUG1 renal clearance is reduced by thiazides, increasing the risk of DRUG1 toxicity. ",negative,Lithium,lithium
"DRUG2 renal clearance is reduced by DRUG1, increasing the risk of DRUG2 toxicity. ",negative,thiazides,lithium
DRUG1 may add to or potentiate the action of other DRUG2. ,effect,Thiazides,antihypertensive drugs
Potentiation occurs with ganglionic or DRUG2.,negative,ganglionic adrenergic blocking drugs,peripheral adrenergic blocking drugs
"DRUG1: Patients on DRUG1, and especially those started recently, may occasionally experience an excessive reduction of blood pressure after initiation of ACEON    Tablets therapy. ",negative,Diuretics,diuretics
"DRUG1: Patients on DRUG1, and especially those started recently, may occasionally experience an excessive reduction of blood pressure after initiation of DRUG2    Tablets therapy. ",negative,Diuretics,ACEON
"DRUG1: Patients on DRUG1, and especially those started recently, may occasionally experience an excessive reduction of blood pressure after initiation of DRUG2    Tablets therapy. ",effect,diuretics,ACEON
The possibility of hypotensive effects can be minimized by either discontinuing the DRUG1 or increasing the salt intake prior to initiation of treatment with DRUG2. ,effect,diuretic,perindopril
"If DRUG1 cannot be interrupted, close medical supervision should be provided with the first dose of DRUG2    Tablets, for at least two hours and until blood pressure has stabilized for another hour. ",advise,diuretics,ACEON
The rate and extent of DRUG1 absorption and elimination are not affected by concomitant DRUG2. ,negative,perindopril,diuretics
"The bioavailability of DRUG1 was reduced by DRUG2, however, and this was associated with a decrease in plasma ACE inhibition. ",negative,perindoprilat,diuretics
DRUG1 Supplements and DRUG1-Sparing Diuretics: ACEON    Tablets may increase serum DRUG1 because of its potential to decrease aldosterone production. ,negative,Potassium,Potassium-Sparing Diuretics
DRUG1 Supplements and DRUG1-Sparing Diuretics: DRUG2    Tablets may increase serum DRUG1 because of its potential to decrease aldosterone production. ,negative,Potassium,ACEON
Potassium Supplements and DRUG1: DRUG2    Tablets may increase serum potassium because of its potential to decrease aldosterone production. ,negative,Potassium-Sparing Diuretics,ACEON
"Use of DRUG1 (DRUG2, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia. ",negative,potassium-sparing diuretics,spironolactone
"Use of DRUG1 (spironolactone, DRUG2, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia. ",negative,potassium-sparing diuretics,amiloride
"Use of DRUG1 (spironolactone, amiloride, DRUG2 and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia. ",negative,potassium-sparing diuretics,triamterene
"Use of DRUG1 (spironolactone, amiloride, triamterene and others), DRUG2 supplements or other drugs capable of increasing serum DRUG2 (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia. ",negative,potassium-sparing diuretics,potassium
"Use of DRUG1 (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (DRUG2, heparin, cyclosporine and others) can increase the risk of hyperkalemia. ",negative,potassium-sparing diuretics,indomethacin
"Use of DRUG1 (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, DRUG2, cyclosporine and others) can increase the risk of hyperkalemia. ",negative,potassium-sparing diuretics,heparin
"Use of DRUG1 (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, DRUG2 and others) can increase the risk of hyperkalemia. ",negative,potassium-sparing diuretics,cyclosporine
"Use of potassium-sparing diuretics (DRUG1, DRUG2, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia. ",negative,spironolactone,amiloride
"Use of potassium-sparing diuretics (DRUG1, amiloride, DRUG2 and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia. ",negative,spironolactone,triamterene
"Use of DRUG2-sparing diuretics (DRUG1, amiloride, triamterene and others), DRUG2 supplements or other drugs capable of increasing serum DRUG2 (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia. ",negative,spironolactone,potassium
"Use of potassium-sparing diuretics (DRUG1, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (DRUG2, heparin, cyclosporine and others) can increase the risk of hyperkalemia. ",negative,spironolactone,indomethacin
"Use of potassium-sparing diuretics (DRUG1, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, DRUG2, cyclosporine and others) can increase the risk of hyperkalemia. ",negative,spironolactone,heparin
"Use of potassium-sparing diuretics (DRUG1, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, DRUG2 and others) can increase the risk of hyperkalemia. ",negative,spironolactone,cyclosporine
"Use of potassium-sparing diuretics (spironolactone, DRUG1, DRUG2 and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia. ",negative,amiloride,triamterene
"Use of DRUG2-sparing diuretics (spironolactone, DRUG1, triamterene and others), DRUG2 supplements or other drugs capable of increasing serum DRUG2 (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia. ",negative,amiloride,potassium
"Use of potassium-sparing diuretics (spironolactone, DRUG1, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (DRUG2, heparin, cyclosporine and others) can increase the risk of hyperkalemia. ",negative,amiloride,indomethacin
"Use of potassium-sparing diuretics (spironolactone, DRUG1, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, DRUG2, cyclosporine and others) can increase the risk of hyperkalemia. ",negative,amiloride,heparin
"Use of potassium-sparing diuretics (spironolactone, DRUG1, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, DRUG2 and others) can increase the risk of hyperkalemia. ",negative,amiloride,cyclosporine
"Use of DRUG2-sparing diuretics (spironolactone, amiloride, DRUG1 and others), DRUG2 supplements or other drugs capable of increasing serum DRUG2 (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia. ",negative,triamterene,potassium
"Use of potassium-sparing diuretics (spironolactone, amiloride, DRUG1 and others), potassium supplements or other drugs capable of increasing serum potassium (DRUG2, heparin, cyclosporine and others) can increase the risk of hyperkalemia. ",negative,triamterene,indomethacin
"Use of potassium-sparing diuretics (spironolactone, amiloride, DRUG1 and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, DRUG2, cyclosporine and others) can increase the risk of hyperkalemia. ",negative,triamterene,heparin
"Use of potassium-sparing diuretics (spironolactone, amiloride, DRUG1 and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, DRUG2 and others) can increase the risk of hyperkalemia. ",negative,triamterene,cyclosporine
"Use of DRUG1-sparing diuretics (spironolactone, amiloride, triamterene and others), DRUG1 supplements or other drugs capable of increasing serum DRUG1 (DRUG2, heparin, cyclosporine and others) can increase the risk of hyperkalemia. ",negative,potassium,indomethacin
"Use of DRUG1-sparing diuretics (spironolactone, amiloride, triamterene and others), DRUG1 supplements or other drugs capable of increasing serum DRUG1 (indomethacin, DRUG2, cyclosporine and others) can increase the risk of hyperkalemia. ",negative,potassium,heparin
"Use of DRUG1-sparing diuretics (spironolactone, amiloride, triamterene and others), DRUG1 supplements or other drugs capable of increasing serum DRUG1 (indomethacin, heparin, DRUG2 and others) can increase the risk of hyperkalemia. ",negative,potassium,cyclosporine
"Use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (DRUG1, DRUG2, cyclosporine and others) can increase the risk of hyperkalemia. ",negative,indomethacin,heparin
"Use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (DRUG1, heparin, DRUG2 and others) can increase the risk of hyperkalemia. ",negative,indomethacin,cyclosporine
"Use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, DRUG1, DRUG2 and others) can increase the risk of hyperkalemia. ",negative,heparin,cyclosporine
DRUG1: Increased serum DRUG1 and symptoms of DRUG1 toxicity have been reported in patients receiving concomitant DRUG1 and ACE inhibitor therapy. ,negative,Lithium,lithium
DRUG1: Increased serum DRUG1 and symptoms of DRUG1 toxicity have been reported in patients receiving concomitant DRUG1 and ACE inhibitor therapy. ,negative,Lithium,lithium
DRUG1: Increased serum DRUG1 and symptoms of DRUG1 toxicity have been reported in patients receiving concomitant DRUG1 and ACE inhibitor therapy. ,negative,Lithium,lithium
DRUG1: Increased serum DRUG1 and symptoms of DRUG1 toxicity have been reported in patients receiving concomitant DRUG1 and ACE inhibitor therapy. ,negative,lithium,lithium
DRUG1: Increased serum DRUG1 and symptoms of DRUG1 toxicity have been reported in patients receiving concomitant DRUG1 and ACE inhibitor therapy. ,negative,lithium,lithium
DRUG1: Increased serum DRUG1 and symptoms of DRUG1 toxicity have been reported in patients receiving concomitant DRUG1 and ACE inhibitor therapy. ,negative,lithium,lithium
Use of a DRUG1 may further increase the risk of DRUG2 toxicity. ,negative,diuretic,lithium
"DRUG1: A controlled pharmacokinetic study has shown no effect on plasma DRUG1 concentrations when coadministered with ACEON    Tablets, but an effect of DRUG1 on the plasma concentration of perindopril/perindoprilat has not been excluded. ",negative,Digoxin,digoxin
"DRUG1: A controlled pharmacokinetic study has shown no effect on plasma DRUG1 concentrations when coadministered with DRUG2    Tablets, but an effect of DRUG1 on the plasma concentration of perindopril/perindoprilat has not been excluded. ",negative,Digoxin,ACEON
"DRUG1: A controlled pharmacokinetic study has shown no effect on plasma DRUG1 concentrations when coadministered with ACEON    Tablets, but an effect of DRUG1 on the plasma concentration of perindopril/perindoprilat has not been excluded. ",negative,Digoxin,digoxin
"DRUG1: A controlled pharmacokinetic study has shown no effect on plasma DRUG1 concentrations when coadministered with ACEON    Tablets, but an effect of DRUG1 on the plasma concentration of DRUG2/perindoprilat has not been excluded. ",negative,Digoxin,perindopril
"DRUG1: A controlled pharmacokinetic study has shown no effect on plasma DRUG1 concentrations when coadministered with ACEON    Tablets, but an effect of DRUG1 on the plasma concentration of perindopril/DRUG2 has not been excluded. ",negative,Digoxin,perindoprilat
"DRUG1: A controlled pharmacokinetic study has shown no effect on plasma DRUG1 concentrations when coadministered with DRUG2    Tablets, but an effect of DRUG1 on the plasma concentration of perindopril/perindoprilat has not been excluded. ",negative,digoxin,ACEON
"DRUG1: A controlled pharmacokinetic study has shown no effect on plasma DRUG1 concentrations when coadministered with ACEON    Tablets, but an effect of DRUG1 on the plasma concentration of perindopril/perindoprilat has not been excluded. ",negative,digoxin,digoxin
"DRUG1: A controlled pharmacokinetic study has shown no effect on plasma DRUG1 concentrations when coadministered with ACEON    Tablets, but an effect of DRUG1 on the plasma concentration of DRUG2/perindoprilat has not been excluded. ",negative,digoxin,perindopril
"DRUG1: A controlled pharmacokinetic study has shown no effect on plasma DRUG1 concentrations when coadministered with ACEON    Tablets, but an effect of DRUG1 on the plasma concentration of perindopril/DRUG2 has not been excluded. ",negative,digoxin,perindoprilat
"DRUG2: A controlled pharmacokinetic study has shown no effect on plasma DRUG2 concentrations when coadministered with DRUG1    Tablets, but an effect of DRUG2 on the plasma concentration of perindopril/perindoprilat has not been excluded. ",negative,ACEON,digoxin
"Digoxin: A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with DRUG1    Tablets, but an effect of digoxin on the plasma concentration of DRUG2/perindoprilat has not been excluded. ",negative,ACEON,perindopril
"Digoxin: A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with DRUG1    Tablets, but an effect of digoxin on the plasma concentration of perindopril/DRUG2 has not been excluded. ",negative,ACEON,perindoprilat
"DRUG1: A controlled pharmacokinetic study has shown no effect on plasma DRUG1 concentrations when coadministered with ACEON    Tablets, but an effect of DRUG1 on the plasma concentration of DRUG2/perindoprilat has not been excluded. ",mechanism,digoxin,perindopril
"DRUG1: A controlled pharmacokinetic study has shown no effect on plasma DRUG1 concentrations when coadministered with ACEON    Tablets, but an effect of DRUG1 on the plasma concentration of perindopril/DRUG2 has not been excluded. ",mechanism,digoxin,perindoprilat
"Digoxin: A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with ACEON    Tablets, but an effect of digoxin on the plasma concentration of DRUG1/DRUG2 has not been excluded. ",negative,perindopril,perindoprilat
DRUG1: Animal data have suggested the possibility of interaction between DRUG2 and DRUG1. ,negative,Gentamicin,perindopril
DRUG1: Animal data have suggested the possibility of interaction between perindopril and DRUG1. ,negative,Gentamicin,gentamicin
DRUG2: Animal data have suggested the possibility of interaction between DRUG1 and DRUG2. ,int,perindopril,gentamicin
Food Interaction: Oral administration of DRUG1    Tablets with food does not significantly lower the rate or extent of DRUG2 absorption relative to the fasted state. ,negative,ACEON,perindopril
"However, the extent of biotransformation of DRUG1 to the active metabolite, DRUG2, is reduced approximately 43%, resulting in a reduction in the plasma ACE inhibition curve of approximately 20%, probably clinically insignificant. ",negative,perindopril,perindoprilat
Concurrent use of DRUG1 and other DRUG2 may increase the CNS depressant effects of methyprylon or these other medications.,negative,alcohol,CNS depression-producing drugs
Concurrent use of DRUG1 and other CNS depression-producing drugs may increase the CNS depressant effects of DRUG2 or these other medications.,effect,alcohol,methyprylon
Concurrent use of alcohol and other DRUG1 may increase the CNS depressant effects of DRUG2 or these other medications.,effect,CNS depression-producing drugs,methyprylon
Administration of DRUG1 decreases oral clearance of DRUG2 by about 5%. ,mechanism,valproic acid,temozolomide
"In a study in which 34 different drugs were tested, therapeutically relevant concentrations of DRUG1, DRUG2 and sulfamethizole displaced protein-bound teniposide in fresh human serum to a small but significant extent. ",negative,tolbutamide,sodium salicylate
"In a study in which 34 different drugs were tested, therapeutically relevant concentrations of DRUG1, sodium salicylate and DRUG2 displaced protein-bound teniposide in fresh human serum to a small but significant extent. ",negative,tolbutamide,sulfamethizole
"In a study in which 34 different drugs were tested, therapeutically relevant concentrations of DRUG1, sodium salicylate and sulfamethizole displaced protein-bound DRUG2 in fresh human serum to a small but significant extent. ",mechanism,tolbutamide,teniposide
"In a study in which 34 different drugs were tested, therapeutically relevant concentrations of tolbutamide, DRUG1 and DRUG2 displaced protein-bound teniposide in fresh human serum to a small but significant extent. ",negative,sodium salicylate,sulfamethizole
"In a study in which 34 different drugs were tested, therapeutically relevant concentrations of tolbutamide, DRUG1 and sulfamethizole displaced protein-bound DRUG2 in fresh human serum to a small but significant extent. ",mechanism,sodium salicylate,teniposide
"In a study in which 34 different drugs were tested, therapeutically relevant concentrations of tolbutamide, sodium salicylate and DRUG1 displaced protein-bound DRUG2 in fresh human serum to a small but significant extent. ",mechanism,sulfamethizole,teniposide
"Therefore, caution should be used in administering DRUG1 (DRUG2 injection) to patients receiving these other agents. ",negative,VUMON,teniposide
There was no change in the plasma kinetics of DRUG1 when coadministered with DRUG2. ,negative,teniposide,methotrexate
An increase in intracellular levels of DRUG1 was observed in vitro in the presence of DRUG2.,mechanism,methotrexate,teniposide
DRUG1 (oral): The activity of oral DRUG1 may be potentiated by anti-vitamin-K activity attributed to methimazole.    ,negative,Anticoagulants,anticoagulants
DRUG1 (oral): The activity of oral DRUG1 may be potentiated by anti-vitamin-K activity attributed to DRUG2.    ,negative,Anticoagulants,methimazole
DRUG1 (oral): The activity of oral DRUG1 may be potentiated by anti-vitamin-K activity attributed to DRUG2.    ,effect,anticoagulants,methimazole
DRUG1: Serum digitalis levels may be increased when hyperthyroid patients on a stable DRUG2 regimen become euthyroid; ,negative,Digitalis glycosides,digitalis glycoside
DRUG1: DRUG1 clearance may decrease when hyperthyroid patients on a stable DRUG1 regimen become euthyroid; ,negative,Theophylline,Theophylline
DRUG1: DRUG1 clearance may decrease when hyperthyroid patients on a stable DRUG1 regimen become euthyroid; ,negative,Theophylline,theophylline
DRUG1: DRUG1 clearance may decrease when hyperthyroid patients on a stable DRUG1 regimen become euthyroid; ,negative,Theophylline,theophylline
The interaction of DRUG1 (DRUG2) with other drugs has not been studied in humans. ,negative,CYLERT,pemoline
Decreased seizure threshold has been reported in patients receiving DRUG1 concomitantly with DRUG2.,effect,CYLERT,antiepileptic medications
DRUG1: DRUG2 and probably other loop DRUG1 given concomitantly with metolazone can cause unusually large or prolonged losses of fluid and electrolytes. ,negative,Diuretics,Furosemide
DRUG1: Furosemide and probably other loop DRUG1 given concomitantly with metolazone can cause unusually large or prolonged losses of fluid and electrolytes. ,negative,Diuretics,loop diuretics
DRUG1: Furosemide and probably other loop DRUG1 given concomitantly with DRUG2 can cause unusually large or prolonged losses of fluid and electrolytes. ,negative,Diuretics,metolazone
Diuretics: DRUG1 and probably other DRUG2 given concomitantly with metolazone can cause unusually large or prolonged losses of fluid and electrolytes. ,negative,Furosemide,loop diuretics
Diuretics: DRUG1 and probably other loop diuretics given concomitantly with DRUG2 can cause unusually large or prolonged losses of fluid and electrolytes. ,effect,Furosemide,metolazone
Diuretics: Furosemide and probably other DRUG1 given concomitantly with DRUG2 can cause unusually large or prolonged losses of fluid and electrolytes. ,effect,loop diuretics,metolazone
"Other DRUG1: When DRUG2 Tablets are used with other antihypertensive drugs, care must be taken, especially during initial therapy. ",negative,Antihypertensives,MYKROX
"Other DRUG1: When MYKROX Tablets are used with other DRUG2, care must be taken, especially during initial therapy. ",negative,Antihypertensives,antihypertensive drugs
"Other Antihypertensives: When DRUG1 Tablets are used with other DRUG2, care must be taken, especially during initial therapy. ",advise,MYKROX,antihypertensive drugs
"DRUG1, DRUG2, and Narcotics: The hypotensive effects of these drugs may be potentiated by the volume contraction that may be associated with metolazone therapy. ",negative,Alcohol,Barbiturates
"DRUG1, Barbiturates, and DRUG2: The hypotensive effects of these drugs may be potentiated by the volume contraction that may be associated with metolazone therapy. ",negative,Alcohol,Narcotics
"DRUG1, Barbiturates, and Narcotics: The hypotensive effects of these drugs may be potentiated by the volume contraction that may be associated with DRUG2 therapy. ",negative,Alcohol,metolazone
"Alcohol, DRUG1, and DRUG2: The hypotensive effects of these drugs may be potentiated by the volume contraction that may be associated with metolazone therapy. ",negative,Barbiturates,Narcotics
"Alcohol, DRUG1, and Narcotics: The hypotensive effects of these drugs may be potentiated by the volume contraction that may be associated with DRUG2 therapy. ",negative,Barbiturates,metolazone
"Alcohol, Barbiturates, and DRUG1: The hypotensive effects of these drugs may be potentiated by the volume contraction that may be associated with DRUG2 therapy. ",negative,Narcotics,metolazone
DRUG1: DRUG2-induced hypokalemia can increase the sensitivity of the myocardium to digitalis. ,negative,Digitalis Glycosides,Diuretic
DRUG1: Diuretic-induced hypokalemia can increase the sensitivity of the myocardium to DRUG2. ,negative,Digitalis Glycosides,digitalis
DRUG2 Glycosides: DRUG1-induced hypokalemia can increase the sensitivity of the myocardium to DRUG2. ,effect,Diuretic,digitalis
DRUG1 or DRUG2: May increase the risk of hypokalemia and increase salt and water retention. ,negative,Corticosteroids,ACTH
DRUG1: Serum DRUG1 levels may increase. ,negative,Lithium,lithium
DRUG1: DRUG2-induced hypokalemia may enhance neuromuscular blocking effects of DRUG1 (such as tubocurarine) the most serious effect would be respiratory depression which could proceed to apnea. ,negative,Curariform Drugs,Diuretic
DRUG1: Diuretic-induced hypokalemia may enhance neuromuscular blocking effects of DRUG1 (such as tubocurarine) the most serious effect would be respiratory depression which could proceed to apnea. ,negative,Curariform Drugs,curariform drugs
DRUG1: Diuretic-induced hypokalemia may enhance neuromuscular blocking effects of DRUG1 (such as DRUG2) the most serious effect would be respiratory depression which could proceed to apnea. ,negative,Curariform Drugs,tubocurarine
DRUG2: DRUG1-induced hypokalemia may enhance neuromuscular blocking effects of DRUG2 (such as tubocurarine) the most serious effect would be respiratory depression which could proceed to apnea. ,effect,Diuretic,curariform drugs
Curariform Drugs: DRUG1-induced hypokalemia may enhance neuromuscular blocking effects of curariform drugs (such as DRUG2) the most serious effect would be respiratory depression which could proceed to apnea. ,effect,Diuretic,tubocurarine
DRUG1: Diuretic-induced hypokalemia may enhance neuromuscular blocking effects of DRUG1 (such as DRUG2) the most serious effect would be respiratory depression which could proceed to apnea. ,negative,curariform drugs,tubocurarine
DRUG1 and Other DRUG2: May decrease the antihypertensive effects of MYKROX Tablets. ,negative,Salicylates,Non-Steroidal Anti-Inflammatory Drugs
DRUG1 and Other Non-Steroidal Anti-Inflammatory Drugs: May decrease the antihypertensive effects of DRUG2 Tablets. ,effect,Salicylates,MYKROX
Salicylates and Other DRUG1: May decrease the antihypertensive effects of DRUG2 Tablets. ,effect,Non-Steroidal Anti-Inflammatory Drugs,MYKROX
"DRUG1: DRUG2 may decrease arterial responsiveness to norepinephrine, but this diminution is not sufficient to preclude effectiveness of the pressor agent for therapeutic use. ",negative,Sympathomimetics,Metolazone
"DRUG1: Metolazone may decrease arterial responsiveness to DRUG2, but this diminution is not sufficient to preclude effectiveness of the pressor agent for therapeutic use. ",negative,Sympathomimetics,norepinephrine
"Sympathomimetics: DRUG1 may decrease arterial responsiveness to DRUG2, but this diminution is not sufficient to preclude effectiveness of the pressor agent for therapeutic use. ",effect,Metolazone,norepinephrine
DRUG1: Efficacy may be decreased due to urinary alkalizing effect of DRUG2. ,effect,Methenamine,metolazone
"DRUG1: DRUG2, as well as other thiazide-like diuretics, may affect the hypoprothrombinemic response to DRUG1; ",negative,Anticoagulants,Metolazone
"DRUG1: Metolazone, as well as other DRUG2, may affect the hypoprothrombinemic response to DRUG1; ",negative,Anticoagulants,thiazide-like diuretics
"DRUG1: Metolazone, as well as other thiazide-like diuretics, may affect the hypoprothrombinemic response to DRUG1; ",negative,Anticoagulants,anticoagulants
"Anticoagulants: DRUG1, as well as other DRUG2, may affect the hypoprothrombinemic response to anticoagulants; ",negative,Metolazone,thiazide-like diuretics
"DRUG2: DRUG1, as well as other thiazide-like diuretics, may affect the hypoprothrombinemic response to DRUG2; ",effect,Metolazone,anticoagulants
"DRUG2: Metolazone, as well as other DRUG1, may affect the hypoprothrombinemic response to DRUG2; ",negative,thiazide-like diuretics,anticoagulants
"The following agents may increase certain actions or side effects of DRUG1: DRUG2, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",effect,anticholinergic drugs,amantadine
"The following agents may increase certain actions or side effects of DRUG1: amantadine, DRUG2 (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",effect,anticholinergic drugs,antiarrhythmic agents of class I
"The following agents may increase certain actions or side effects of DRUG1: amantadine, antiarrhythmic agents of class I (e.g., DRUG2), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",effect,anticholinergic drugs,quinidine
"The following agents may increase certain actions or side effects of DRUG1: amantadine, antiarrhythmic agents of class I (e.g., quinidine), DRUG2, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",effect,anticholinergic drugs,antihistamines
"The following agents may increase certain actions or side effects of DRUG1: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, DRUG2 (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",effect,anticholinergic drugs,antipsychotic agents
"The following agents may increase certain actions or side effects of DRUG1: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., DRUG2), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",effect,anticholinergic drugs,phenothiazines
"The following agents may increase certain actions or side effects of DRUG1: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), DRUG2, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",effect,anticholinergic drugs,benzodiazepines
"The following agents may increase certain actions or side effects of DRUG1: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, DRUG2, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",effect,anticholinergic drugs,MAO inhibitors
"The following agents may increase certain actions or side effects of DRUG1: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, DRUG2 (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",effect,anticholinergic drugs,narcotic analgesics
"The following agents may increase certain actions or side effects of DRUG1: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., DRUG2), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",effect,anticholinergic drugs,meperidine
"The following agents may increase certain actions or side effects of DRUG1: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), DRUG2 and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",effect,anticholinergic drugs,nitrates
"The following agents may increase certain actions or side effects of DRUG1: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and DRUG2, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",effect,anticholinergic drugs,nitrites
"The following agents may increase certain actions or side effects of DRUG1: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, DRUG2, tricyclic antidepressants, and other drugs having anticholinergic activity. ",effect,anticholinergic drugs,sympathomimetic agents
"The following agents may increase certain actions or side effects of DRUG1: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, DRUG2, and other drugs having anticholinergic activity. ",effect,anticholinergic drugs,tricyclic antidepressants
"The following agents may increase certain actions or side effects of anticholinergic drugs: DRUG1, DRUG2 (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",negative,amantadine,antiarrhythmic agents of class I
"The following agents may increase certain actions or side effects of anticholinergic drugs: DRUG1, antiarrhythmic agents of class I (e.g., DRUG2), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",negative,amantadine,quinidine
"The following agents may increase certain actions or side effects of anticholinergic drugs: DRUG1, antiarrhythmic agents of class I (e.g., quinidine), DRUG2, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",negative,amantadine,antihistamines
"The following agents may increase certain actions or side effects of anticholinergic drugs: DRUG1, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, DRUG2 (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",negative,amantadine,antipsychotic agents
"The following agents may increase certain actions or side effects of anticholinergic drugs: DRUG1, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., DRUG2), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",negative,amantadine,phenothiazines
"The following agents may increase certain actions or side effects of anticholinergic drugs: DRUG1, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), DRUG2, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",negative,amantadine,benzodiazepines
"The following agents may increase certain actions or side effects of anticholinergic drugs: DRUG1, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, DRUG2, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",negative,amantadine,MAO inhibitors
"The following agents may increase certain actions or side effects of anticholinergic drugs: DRUG1, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, DRUG2 (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",negative,amantadine,narcotic analgesics
"The following agents may increase certain actions or side effects of anticholinergic drugs: DRUG1, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., DRUG2), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",negative,amantadine,meperidine
"The following agents may increase certain actions or side effects of anticholinergic drugs: DRUG1, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), DRUG2 and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",negative,amantadine,nitrates
"The following agents may increase certain actions or side effects of anticholinergic drugs: DRUG1, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and DRUG2, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",negative,amantadine,nitrites
"The following agents may increase certain actions or side effects of anticholinergic drugs: DRUG1, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, DRUG2, tricyclic antidepressants, and other drugs having anticholinergic activity. ",negative,amantadine,sympathomimetic agents
"The following agents may increase certain actions or side effects of anticholinergic drugs: DRUG1, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, DRUG2, and other drugs having anticholinergic activity. ",negative,amantadine,tricyclic antidepressants
"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, DRUG1 (e.g., DRUG2), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",negative,antiarrhythmic agents of class I,quinidine
"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, DRUG1 (e.g., quinidine), DRUG2, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",negative,antiarrhythmic agents of class I,antihistamines
"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, DRUG1 (e.g., quinidine), antihistamines, DRUG2 (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",negative,antiarrhythmic agents of class I,antipsychotic agents
"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, DRUG1 (e.g., quinidine), antihistamines, antipsychotic agents (e.g., DRUG2), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",negative,antiarrhythmic agents of class I,phenothiazines
"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, DRUG1 (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), DRUG2, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",negative,antiarrhythmic agents of class I,benzodiazepines
"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, DRUG1 (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, DRUG2, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",negative,antiarrhythmic agents of class I,MAO inhibitors
"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, DRUG1 (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, DRUG2 (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",negative,antiarrhythmic agents of class I,narcotic analgesics
"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, DRUG1 (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., DRUG2), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",negative,antiarrhythmic agents of class I,meperidine
"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, DRUG1 (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), DRUG2 and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",negative,antiarrhythmic agents of class I,nitrates
"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, DRUG1 (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and DRUG2, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",negative,antiarrhythmic agents of class I,nitrites
"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, DRUG1 (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, DRUG2, tricyclic antidepressants, and other drugs having anticholinergic activity. ",negative,antiarrhythmic agents of class I,sympathomimetic agents
"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, DRUG1 (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, DRUG2, and other drugs having anticholinergic activity. ",negative,antiarrhythmic agents of class I,tricyclic antidepressants
"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., DRUG1), DRUG2, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",negative,quinidine,antihistamines
"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., DRUG1), antihistamines, DRUG2 (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",negative,quinidine,antipsychotic agents
"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., DRUG1), antihistamines, antipsychotic agents (e.g., DRUG2), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",negative,quinidine,phenothiazines
"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., DRUG1), antihistamines, antipsychotic agents (e.g., phenothiazines), DRUG2, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",negative,quinidine,benzodiazepines
"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., DRUG1), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, DRUG2, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",negative,quinidine,MAO inhibitors
"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., DRUG1), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, DRUG2 (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",negative,quinidine,narcotic analgesics
"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., DRUG1), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., DRUG2), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",negative,quinidine,meperidine
"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., DRUG1), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), DRUG2 and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",negative,quinidine,nitrates
"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., DRUG1), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and DRUG2, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",negative,quinidine,nitrites
"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., DRUG1), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, DRUG2, tricyclic antidepressants, and other drugs having anticholinergic activity. ",negative,quinidine,sympathomimetic agents
"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., DRUG1), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, DRUG2, and other drugs having anticholinergic activity. ",negative,quinidine,tricyclic antidepressants
"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), DRUG1, DRUG2 (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",negative,antihistamines,antipsychotic agents
"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), DRUG1, antipsychotic agents (e.g., DRUG2), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",negative,antihistamines,phenothiazines
"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), DRUG1, antipsychotic agents (e.g., phenothiazines), DRUG2, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",negative,antihistamines,benzodiazepines
"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), DRUG1, antipsychotic agents (e.g., phenothiazines), benzodiazepines, DRUG2, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",negative,antihistamines,MAO inhibitors
"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), DRUG1, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, DRUG2 (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",negative,antihistamines,narcotic analgesics
"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), DRUG1, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., DRUG2), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",negative,antihistamines,meperidine
"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), DRUG1, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), DRUG2 and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",negative,antihistamines,nitrates
"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), DRUG1, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and DRUG2, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",negative,antihistamines,nitrites
"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), DRUG1, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, DRUG2, tricyclic antidepressants, and other drugs having anticholinergic activity. ",negative,antihistamines,sympathomimetic agents
"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), DRUG1, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, DRUG2, and other drugs having anticholinergic activity. ",negative,antihistamines,tricyclic antidepressants
"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, DRUG1 (e.g., DRUG2), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",negative,antipsychotic agents,phenothiazines
"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, DRUG1 (e.g., phenothiazines), DRUG2, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",negative,antipsychotic agents,benzodiazepines
"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, DRUG1 (e.g., phenothiazines), benzodiazepines, DRUG2, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",negative,antipsychotic agents,MAO inhibitors
"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, DRUG1 (e.g., phenothiazines), benzodiazepines, MAO inhibitors, DRUG2 (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",negative,antipsychotic agents,narcotic analgesics
"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, DRUG1 (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., DRUG2), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",negative,antipsychotic agents,meperidine
"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, DRUG1 (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), DRUG2 and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",negative,antipsychotic agents,nitrates
"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, DRUG1 (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and DRUG2, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",negative,antipsychotic agents,nitrites
"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, DRUG1 (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, DRUG2, tricyclic antidepressants, and other drugs having anticholinergic activity. ",negative,antipsychotic agents,sympathomimetic agents
"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, DRUG1 (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, DRUG2, and other drugs having anticholinergic activity. ",negative,antipsychotic agents,tricyclic antidepressants
"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., DRUG1), DRUG2, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",negative,phenothiazines,benzodiazepines
"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., DRUG1), benzodiazepines, DRUG2, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",negative,phenothiazines,MAO inhibitors
"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., DRUG1), benzodiazepines, MAO inhibitors, DRUG2 (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",negative,phenothiazines,narcotic analgesics
"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., DRUG1), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., DRUG2), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",negative,phenothiazines,meperidine
"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., DRUG1), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), DRUG2 and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",negative,phenothiazines,nitrates
"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., DRUG1), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and DRUG2, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",negative,phenothiazines,nitrites
"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., DRUG1), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, DRUG2, tricyclic antidepressants, and other drugs having anticholinergic activity. ",negative,phenothiazines,sympathomimetic agents
"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., DRUG1), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, DRUG2, and other drugs having anticholinergic activity. ",negative,phenothiazines,tricyclic antidepressants
"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), DRUG1, DRUG2, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",negative,benzodiazepines,MAO inhibitors
"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), DRUG1, MAO inhibitors, DRUG2 (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",negative,benzodiazepines,narcotic analgesics
"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), DRUG1, MAO inhibitors, narcotic analgesics (e.g., DRUG2), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",negative,benzodiazepines,meperidine
"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), DRUG1, MAO inhibitors, narcotic analgesics (e.g., meperidine), DRUG2 and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",negative,benzodiazepines,nitrates
"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), DRUG1, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and DRUG2, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",negative,benzodiazepines,nitrites
"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), DRUG1, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, DRUG2, tricyclic antidepressants, and other drugs having anticholinergic activity. ",negative,benzodiazepines,sympathomimetic agents
"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), DRUG1, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, DRUG2, and other drugs having anticholinergic activity. ",negative,benzodiazepines,tricyclic antidepressants
"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, DRUG1, DRUG2 (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",negative,MAO inhibitors,narcotic analgesics
"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, DRUG1, narcotic analgesics (e.g., DRUG2), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",negative,MAO inhibitors,meperidine
"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, DRUG1, narcotic analgesics (e.g., meperidine), DRUG2 and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",negative,MAO inhibitors,nitrates
"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, DRUG1, narcotic analgesics (e.g., meperidine), nitrates and DRUG2, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",negative,MAO inhibitors,nitrites
"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, DRUG1, narcotic analgesics (e.g., meperidine), nitrates and nitrites, DRUG2, tricyclic antidepressants, and other drugs having anticholinergic activity. ",negative,MAO inhibitors,sympathomimetic agents
"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, DRUG1, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, DRUG2, and other drugs having anticholinergic activity. ",negative,MAO inhibitors,tricyclic antidepressants
"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, DRUG1 (e.g., DRUG2), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",negative,narcotic analgesics,meperidine
"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, DRUG1 (e.g., meperidine), DRUG2 and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",negative,narcotic analgesics,nitrates
"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, DRUG1 (e.g., meperidine), nitrates and DRUG2, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",negative,narcotic analgesics,nitrites
"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, DRUG1 (e.g., meperidine), nitrates and nitrites, DRUG2, tricyclic antidepressants, and other drugs having anticholinergic activity. ",negative,narcotic analgesics,sympathomimetic agents
"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, DRUG1 (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, DRUG2, and other drugs having anticholinergic activity. ",negative,narcotic analgesics,tricyclic antidepressants
"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., DRUG1), DRUG2 and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",negative,meperidine,nitrates
"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., DRUG1), nitrates and DRUG2, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",negative,meperidine,nitrites
"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., DRUG1), nitrates and nitrites, DRUG2, tricyclic antidepressants, and other drugs having anticholinergic activity. ",negative,meperidine,sympathomimetic agents
"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., DRUG1), nitrates and nitrites, sympathomimetic agents, DRUG2, and other drugs having anticholinergic activity. ",negative,meperidine,tricyclic antidepressants
"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), DRUG1 and DRUG2, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",negative,nitrates,nitrites
"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), DRUG1 and nitrites, DRUG2, tricyclic antidepressants, and other drugs having anticholinergic activity. ",negative,nitrates,sympathomimetic agents
"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), DRUG1 and nitrites, sympathomimetic agents, DRUG2, and other drugs having anticholinergic activity. ",negative,nitrates,tricyclic antidepressants
"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and DRUG1, DRUG2, tricyclic antidepressants, and other drugs having anticholinergic activity. ",negative,nitrites,sympathomimetic agents
"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and DRUG1, sympathomimetic agents, DRUG2, and other drugs having anticholinergic activity. ",negative,nitrites,tricyclic antidepressants
"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, DRUG1, DRUG2, and other drugs having anticholinergic activity. ",negative,sympathomimetic agents,tricyclic antidepressants
DRUG1 antagonize the effects of DRUG2. ,effect,Anticholinergics,antiglaucoma agents
DRUG1 in the presence of increased intraocular pressure may be hazardous when taken concurrently with agents such as DRUG2. ,effect,Anticholinergic drugs,corticosteroids
"DRUG1 may affect gastrointestinal absorption of various drugs, such as slowly dissolving dosage forms of DRUG2; ",mechanism,Anticholinergic agents,digoxin
"DRUG1 may antagonize the effects of drugs that alter gastrointestinal motility, such as DRUG2. ",effect,Anticholinergic drugs,metoclopramide
"Because DRUG1 may interfere with the absorption of DRUG2, simultaneous use of these drugs should be avoided. ",mechanism,antacids,anticholinergic agents
"DRUG1 should be used with caution in patients receiving other local DRUG2 or agents structurally related to amide-type local DRUG2, since the toxic effects of these drugs are additive. ",advise,Ropivacaine,anesthetics
"DRUG1 should be used with caution in patients receiving other local anesthetics or agents structurally related to DRUG2, since the toxic effects of these drugs are additive. ",negative,Ropivacaine,amide-type local anesthetics
"Ropivacaine should be used with caution in patients receiving other local DRUG1 or agents structurally related to amide-type local DRUG1, since the toxic effects of these drugs are additive. ",negative,anesthetics,amide-type local anesthetics
"In vivo, the plasma clearance of DRUG1 was reduced by 70% during coadministration of DRUG2 (25 mg bid for 2 days), a selective and potent CYP1A2 inhibitor. ",mechanism,ropivacaine,fluvoxamine
"Thus strong inhibitors of cytochrome P4501A2, such as DRUG1, given concomitantly during administration of DRUG2, can interact with DRUG2 leading to increased DRUG2 plasma levels. ",int,fluvoxamine,Ropivacaine
"Thus strong inhibitors of cytochrome P4501A2, such as DRUG1, given concomitantly during administration of DRUG2, can interact with DRUG2 leading to increased DRUG2 plasma levels. ",negative,fluvoxamine,Ropivacaine
"Thus strong inhibitors of cytochrome P4501A2, such as DRUG1, given concomitantly during administration of DRUG2, can interact with DRUG2 leading to increased DRUG2 plasma levels. ",negative,fluvoxamine,ropivacaine
"Thus strong inhibitors of cytochrome P4501A2, such as fluvoxamine, given concomitantly during administration of DRUG1, can interact with DRUG1 leading to increased DRUG1 plasma levels. ",negative,Ropivacaine,Ropivacaine
"Thus strong inhibitors of cytochrome P4501A2, such as fluvoxamine, given concomitantly during administration of DRUG1, can interact with DRUG1 leading to increased DRUG1 plasma levels. ",negative,Ropivacaine,ropivacaine
"Thus strong inhibitors of cytochrome P4501A2, such as fluvoxamine, given concomitantly during administration of DRUG1, can interact with DRUG1 leading to increased DRUG1 plasma levels. ",negative,Ropivacaine,ropivacaine
Possible interactions with drugs known to be metabolized by CYP1A2 via competitive inhibition such as DRUG1 and DRUG2 may also occur. ,negative,theophylline,imipramine
"Coadministration of a selective and potent inhibitor of CYP3A4, DRUG1 (100 mg bid for 2 days with DRUG2 infusion administered 1 hour after DRUG1) caused a 15% reduction in in-vivo plasma clearance of DRUG2.",negative,ketoconazole,ropivacaine
"Coadministration of a selective and potent inhibitor of CYP3A4, DRUG1 (100 mg bid for 2 days with ropivacaine infusion administered 1 hour after DRUG1) caused a 15% reduction in in-vivo plasma clearance of ropivacaine.",negative,ketoconazole,ketoconazole
"Coadministration of a selective and potent inhibitor of CYP3A4, DRUG1 (100 mg bid for 2 days with DRUG2 infusion administered 1 hour after DRUG1) caused a 15% reduction in in-vivo plasma clearance of DRUG2.",mechanism,ketoconazole,ropivacaine
"Coadministration of a selective and potent inhibitor of CYP3A4, DRUG2 (100 mg bid for 2 days with DRUG1 infusion administered 1 hour after DRUG2) caused a 15% reduction in in-vivo plasma clearance of DRUG1.",negative,ropivacaine,ketoconazole
"Coadministration of a selective and potent inhibitor of CYP3A4, ketoconazole (100 mg bid for 2 days with DRUG1 infusion administered 1 hour after ketoconazole) caused a 15% reduction in in-vivo plasma clearance of DRUG1.",negative,ropivacaine,ropivacaine
"Coadministration of a selective and potent inhibitor of CYP3A4, DRUG1 (100 mg bid for 2 days with DRUG2 infusion administered 1 hour after DRUG1) caused a 15% reduction in in-vivo plasma clearance of DRUG2.",negative,ketoconazole,ropivacaine
"In elderly patients concurrently receiving certain DRUG1, primarily DRUG2, an increased incidence of thrombopenia with purpura has been reported. ",negative,diuretics,thiazides
It has been reported that DRUG1 may prolong the prothrombin time in patients who are receiving the DRUG2 warfarin. ,negative,sulfamethoxazole,anticoagulant
It has been reported that DRUG1 may prolong the prothrombin time in patients who are receiving the anticoagulant DRUG2. ,effect,sulfamethoxazole,warfarin
It has been reported that sulfamethoxazole may prolong the prothrombin time in patients who are receiving the DRUG1 DRUG2. ,negative,anticoagulant,warfarin
DRUG1 may inhibit the hepatic metabolism of DRUG2. ,mechanism,Sulfamethoxazole,phenytoin
"At a 1.6-g dose, DRUG1 produced a slight but significant increase in the half-life of DRUG2 but did not produce a corresponding decrease in the metabolic clearance rate. ",mechanism,sulfamethoxazole,phenytoin
"DRUG1 can also displace DRUG2 from plasma protein-binding sites, thus increasing free DRUG2 concentrations. ",mechanism,Sulfonamides,methotrexate
"DRUG1 can also displace DRUG2 from plasma protein-binding sites, thus increasing free DRUG2 concentrations. ",negative,Sulfonamides,methotrexate
"Sulfonamides can also displace DRUG1 from plasma protein-binding sites, thus increasing free DRUG1 concentrations. ",negative,methotrexate,methotrexate
There is usually complete cross-resistance between DRUG1 (DRUG2) and TABLOID brand Thioguanine. ,negative,PURINETHOL,mercaptopurine
There is usually complete cross-resistance between DRUG1 (mercaptopurine) and DRUG2 brand Thioguanine. ,effect,PURINETHOL,TABLOID
There is usually complete cross-resistance between DRUG1 (mercaptopurine) and TABLOID brand DRUG2. ,effect,PURINETHOL,Thioguanine
There is usually complete cross-resistance between PURINETHOL (DRUG1) and DRUG2 brand Thioguanine. ,effect,mercaptopurine,TABLOID
There is usually complete cross-resistance between PURINETHOL (DRUG1) and TABLOID brand DRUG2. ,effect,mercaptopurine,Thioguanine
There is usually complete cross-resistance between PURINETHOL (mercaptopurine) and DRUG1 brand DRUG2. ,negative,TABLOID,Thioguanine
"As there is in vitro evidence that DRUG1 (e.g., DRUG2, mesalazine, or sulphasalazine) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent thioguanine therapy.    ",negative,aminosalicylate derivatives,olsalazine
"As there is in vitro evidence that DRUG1 (e.g., olsalazine, DRUG2, or sulphasalazine) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent thioguanine therapy.    ",negative,aminosalicylate derivatives,mesalazine
"As there is in vitro evidence that DRUG1 (e.g., olsalazine, mesalazine, or DRUG2) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent thioguanine therapy.    ",negative,aminosalicylate derivatives,sulphasalazine
"As there is in vitro evidence that DRUG1 (e.g., olsalazine, mesalazine, or sulphasalazine) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent DRUG2 therapy.    ",mechanism,aminosalicylate derivatives,thioguanine
"As there is in vitro evidence that aminosalicylate derivatives (e.g., DRUG1, DRUG2, or sulphasalazine) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent thioguanine therapy.    ",negative,olsalazine,mesalazine
"As there is in vitro evidence that aminosalicylate derivatives (e.g., DRUG1, mesalazine, or DRUG2) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent thioguanine therapy.    ",negative,olsalazine,sulphasalazine
"As there is in vitro evidence that aminosalicylate derivatives (e.g., DRUG1, mesalazine, or sulphasalazine) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent DRUG2 therapy.    ",mechanism,olsalazine,thioguanine
"As there is in vitro evidence that aminosalicylate derivatives (e.g., olsalazine, DRUG1, or DRUG2) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent thioguanine therapy.    ",negative,mesalazine,sulphasalazine
"As there is in vitro evidence that aminosalicylate derivatives (e.g., olsalazine, DRUG1, or sulphasalazine) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent DRUG2 therapy.    ",mechanism,mesalazine,thioguanine
"As there is in vitro evidence that aminosalicylate derivatives (e.g., olsalazine, mesalazine, or DRUG1) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent DRUG2 therapy.    ",mechanism,sulphasalazine,thioguanine
"DRUG1 has been reported to enhance the sedative activity of DRUG2, alcohol, chlorpromazine, and reserpine. ",effect,Thalidomide,barbiturates
"DRUG1 has been reported to enhance the sedative activity of barbiturates, DRUG2, chlorpromazine, and reserpine. ",negative,Thalidomide,alcohol
"DRUG1 has been reported to enhance the sedative activity of barbiturates, alcohol, DRUG2, and reserpine. ",negative,Thalidomide,chlorpromazine
"DRUG1 has been reported to enhance the sedative activity of barbiturates, alcohol, chlorpromazine, and DRUG2. ",negative,Thalidomide,reserpine
"Thalidomide has been reported to enhance the sedative activity of DRUG1, DRUG2, chlorpromazine, and reserpine. ",negative,barbiturates,alcohol
"Thalidomide has been reported to enhance the sedative activity of DRUG1, alcohol, DRUG2, and reserpine. ",negative,barbiturates,chlorpromazine
"Thalidomide has been reported to enhance the sedative activity of DRUG1, alcohol, chlorpromazine, and DRUG2. ",negative,barbiturates,reserpine
"Thalidomide has been reported to enhance the sedative activity of barbiturates, DRUG1, DRUG2, and reserpine. ",negative,alcohol,chlorpromazine
"Thalidomide has been reported to enhance the sedative activity of barbiturates, DRUG1, chlorpromazine, and DRUG2. ",negative,alcohol,reserpine
"Thalidomide has been reported to enhance the sedative activity of barbiturates, alcohol, DRUG1, and DRUG2. ",negative,chlorpromazine,reserpine
"Oral DRUG1: In 10 healthy women, the pharmacokinetic profiles of DRUG2 and ethinyl estradiol following administration of a single dose containing 1.0 mg of DRUG2 acetate and 75    g of ethinyl estradiol were studied. ",negative,Contraceptives,norethindrone
"Oral DRUG1: In 10 healthy women, the pharmacokinetic profiles of norethindrone and DRUG2 following administration of a single dose containing 1.0 mg of norethindrone acetate and 75    g of DRUG2 were studied. ",negative,Contraceptives,ethinyl estradiol
"Oral DRUG1: In 10 healthy women, the pharmacokinetic profiles of norethindrone and ethinyl estradiol following administration of a single dose containing 1.0 mg of DRUG2 and 75    g of ethinyl estradiol were studied. ",negative,Contraceptives,norethindrone acetate
"Oral DRUG1: In 10 healthy women, the pharmacokinetic profiles of norethindrone and DRUG2 following administration of a single dose containing 1.0 mg of norethindrone acetate and 75    g of DRUG2 were studied. ",negative,Contraceptives,ethinyl estradiol
"Oral Contraceptives: In 10 healthy women, the pharmacokinetic profiles of DRUG1 and DRUG2 following administration of a single dose containing 1.0 mg of DRUG1 acetate and 75    g of DRUG2 were studied. ",negative,norethindrone,ethinyl estradiol
"Oral Contraceptives: In 10 healthy women, the pharmacokinetic profiles of DRUG1 and ethinyl estradiol following administration of a single dose containing 1.0 mg of DRUG1 acetate and 75    g of ethinyl estradiol were studied. ",negative,norethindrone,norethindrone acetate
"Oral Contraceptives: In 10 healthy women, the pharmacokinetic profiles of DRUG1 and DRUG2 following administration of a single dose containing 1.0 mg of DRUG1 acetate and 75    g of DRUG2 were studied. ",negative,norethindrone,ethinyl estradiol
"Oral Contraceptives: In 10 healthy women, the pharmacokinetic profiles of norethindrone and DRUG1 following administration of a single dose containing 1.0 mg of DRUG2 and 75    g of DRUG1 were studied. ",negative,ethinyl estradiol,norethindrone acetate
"Oral Contraceptives: In 10 healthy women, the pharmacokinetic profiles of norethindrone and DRUG1 following administration of a single dose containing 1.0 mg of norethindrone acetate and 75    g of DRUG1 were studied. ",negative,ethinyl estradiol,ethinyl estradiol
"Oral Contraceptives: In 10 healthy women, the pharmacokinetic profiles of norethindrone and DRUG2 following administration of a single dose containing 1.0 mg of DRUG1 and 75    g of DRUG2 were studied. ",negative,norethindrone acetate,ethinyl estradiol
"Important Non-DRUG1 Drug Interactions Drugs That Interfere with DRUG2: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. ",negative,Thalidomide,Hormonal Contraceptives
"Important Non-DRUG1 Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of DRUG2, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. ",negative,Thalidomide,HIV-protease inhibitors
"Important Non-DRUG1 Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, DRUG2, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. ",negative,Thalidomide,griseofulvin
"Important Non-DRUG1 Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, DRUG2, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. ",negative,Thalidomide,modafinil
"Important Non-DRUG1 Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, DRUG2, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. ",negative,Thalidomide,penicillins
"Important Non-DRUG1 Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, DRUG2, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. ",negative,Thalidomide,rifampin
"Important Non-DRUG1 Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, DRUG2, phenytoin, carbamazepine, or certain herbal supplements such as St. ",negative,Thalidomide,rifabutin
"Important Non-DRUG1 Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, DRUG2, carbamazepine, or certain herbal supplements such as St. ",negative,Thalidomide,phenytoin
"Important Non-DRUG1 Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, DRUG2, or certain herbal supplements such as St. ",negative,Thalidomide,carbamazepine
"Important Non-Thalidomide Drug Interactions Drugs That Interfere with DRUG1: Concomitant use of DRUG2, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. ",negative,Hormonal Contraceptives,HIV-protease inhibitors
"Important Non-Thalidomide Drug Interactions Drugs That Interfere with DRUG1: Concomitant use of HIV-protease inhibitors, DRUG2, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. ",negative,Hormonal Contraceptives,griseofulvin
"Important Non-Thalidomide Drug Interactions Drugs That Interfere with DRUG1: Concomitant use of HIV-protease inhibitors, griseofulvin, DRUG2, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. ",negative,Hormonal Contraceptives,modafinil
"Important Non-Thalidomide Drug Interactions Drugs That Interfere with DRUG1: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, DRUG2, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. ",negative,Hormonal Contraceptives,penicillins
"Important Non-Thalidomide Drug Interactions Drugs That Interfere with DRUG1: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, DRUG2, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. ",negative,Hormonal Contraceptives,rifampin
"Important Non-Thalidomide Drug Interactions Drugs That Interfere with DRUG1: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, DRUG2, phenytoin, carbamazepine, or certain herbal supplements such as St. ",negative,Hormonal Contraceptives,rifabutin
"Important Non-Thalidomide Drug Interactions Drugs That Interfere with DRUG1: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, DRUG2, carbamazepine, or certain herbal supplements such as St. ",negative,Hormonal Contraceptives,phenytoin
"Important Non-Thalidomide Drug Interactions Drugs That Interfere with DRUG1: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, DRUG2, or certain herbal supplements such as St. ",negative,Hormonal Contraceptives,carbamazepine
"Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of DRUG1, DRUG2, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. ",negative,HIV-protease inhibitors,griseofulvin
"Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of DRUG1, griseofulvin, DRUG2, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. ",negative,HIV-protease inhibitors,modafinil
"Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of DRUG1, griseofulvin, modafinil, DRUG2, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. ",negative,HIV-protease inhibitors,penicillins
"Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of DRUG1, griseofulvin, modafinil, penicillins, DRUG2, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. ",negative,HIV-protease inhibitors,rifampin
"Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of DRUG1, griseofulvin, modafinil, penicillins, rifampin, DRUG2, phenytoin, carbamazepine, or certain herbal supplements such as St. ",negative,HIV-protease inhibitors,rifabutin
"Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of DRUG1, griseofulvin, modafinil, penicillins, rifampin, rifabutin, DRUG2, carbamazepine, or certain herbal supplements such as St. ",negative,HIV-protease inhibitors,phenytoin
"Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of DRUG1, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, DRUG2, or certain herbal supplements such as St. ",negative,HIV-protease inhibitors,carbamazepine
"Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, DRUG1, DRUG2, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. ",negative,griseofulvin,modafinil
"Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, DRUG1, modafinil, DRUG2, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. ",negative,griseofulvin,penicillins
"Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, DRUG1, modafinil, penicillins, DRUG2, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. ",negative,griseofulvin,rifampin
"Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, DRUG1, modafinil, penicillins, rifampin, DRUG2, phenytoin, carbamazepine, or certain herbal supplements such as St. ",negative,griseofulvin,rifabutin
"Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, DRUG1, modafinil, penicillins, rifampin, rifabutin, DRUG2, carbamazepine, or certain herbal supplements such as St. ",negative,griseofulvin,phenytoin
"Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, DRUG1, modafinil, penicillins, rifampin, rifabutin, phenytoin, DRUG2, or certain herbal supplements such as St. ",negative,griseofulvin,carbamazepine
"Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, DRUG1, DRUG2, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. ",negative,modafinil,penicillins
"Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, DRUG1, penicillins, DRUG2, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. ",negative,modafinil,rifampin
"Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, DRUG1, penicillins, rifampin, DRUG2, phenytoin, carbamazepine, or certain herbal supplements such as St. ",negative,modafinil,rifabutin
"Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, DRUG1, penicillins, rifampin, rifabutin, DRUG2, carbamazepine, or certain herbal supplements such as St. ",negative,modafinil,phenytoin
"Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, DRUG1, penicillins, rifampin, rifabutin, phenytoin, DRUG2, or certain herbal supplements such as St. ",negative,modafinil,carbamazepine
"Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, DRUG1, DRUG2, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. ",negative,penicillins,rifampin
"Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, DRUG1, rifampin, DRUG2, phenytoin, carbamazepine, or certain herbal supplements such as St. ",negative,penicillins,rifabutin
"Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, DRUG1, rifampin, rifabutin, DRUG2, carbamazepine, or certain herbal supplements such as St. ",negative,penicillins,phenytoin
"Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, DRUG1, rifampin, rifabutin, phenytoin, DRUG2, or certain herbal supplements such as St. ",negative,penicillins,carbamazepine
"Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, DRUG1, DRUG2, phenytoin, carbamazepine, or certain herbal supplements such as St. ",negative,rifampin,rifabutin
"Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, DRUG1, rifabutin, DRUG2, carbamazepine, or certain herbal supplements such as St. ",negative,rifampin,phenytoin
"Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, DRUG1, rifabutin, phenytoin, DRUG2, or certain herbal supplements such as St. ",negative,rifampin,carbamazepine
"Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, DRUG1, DRUG2, carbamazepine, or certain herbal supplements such as St. ",negative,rifabutin,phenytoin
"Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, DRUG1, phenytoin, DRUG2, or certain herbal supplements such as St. ",negative,rifabutin,carbamazepine
"Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, DRUG1, DRUG2, or certain herbal supplements such as St. ",negative,phenytoin,carbamazepine
DRUG1 with DRUG2 may reduce the effectiveness of the contraception and up to one month after discontinuation of these concomitant therapies. ,effect,John's Wort,hormonal contraceptive agents
"Catecholamine-depleting drugs (e.g., DRUG1) may have an additive effect when given with DRUG2. ",effect,reserpine,beta-blocking agents
"The CNS-depressant effect of DRUG1 is additive with that of other DRUG2, including alcohol. ",effect,propoxyphene,CNS depressants
"The CNS-depressant effect of DRUG1 is additive with that of other CNS depressants, including DRUG2. ",effect,propoxyphene,alcohol
"The CNS-depressant effect of propoxyphene is additive with that of other DRUG1, including DRUG2. ",negative,CNS depressants,alcohol
"Such occurrences have been reported when DRUG1 was administered to patients on DRUG2, anticonvulsants, or warfarin-like drugs. ",negative,propoxyphene,antidepressants
"Such occurrences have been reported when DRUG1 was administered to patients on antidepressants, DRUG2, or warfarin-like drugs. ",negative,propoxyphene,anticonvulsants
"Such occurrences have been reported when DRUG1 was administered to patients on antidepressants, anticonvulsants, or DRUG2-like drugs. ",negative,propoxyphene,warfarin
"Such occurrences have been reported when propoxyphene was administered to patients on DRUG1, DRUG2, or warfarin-like drugs. ",negative,antidepressants,anticonvulsants
"Such occurrences have been reported when propoxyphene was administered to patients on DRUG1, anticonvulsants, or DRUG2-like drugs. ",negative,antidepressants,warfarin
"Such occurrences have been reported when propoxyphene was administered to patients on antidepressants, DRUG1, or DRUG2-like drugs. ",negative,anticonvulsants,warfarin
DRUG1 at a Dose of 10 mg Once Daily Dosed to Pharmacokinetic Steady State  - did not cause clinically significant changes in the kinetics of a single intravenous dose of DRUG2 (predominantly a cytochrome P450 1A2 substrate). ,negative,Montelukast,theophylline
- did not change the pharmacokinetic profile of DRUG1 (a substrate of cytochromes P450 2A6 and 2C9) or influence the effect of a single 30-mg oral dose of DRUG1 on prothrombin time or the INR (International Normalized Ratio). ,negative,warfarin,warfarin
"- did not change the plasma concentration profile of DRUG1 (a substrate of cytochrome P450 3A4) or DRUG2, its carboxylated metabolite, and did not prolong the QTc interval following co-administration with DRUG1 60 mg twice daily. ",negative,terfenadine,fexofenadine
"- did not change the plasma concentration profile of DRUG1 (a substrate of cytochrome P450 3A4) or fexofenadine, its carboxylated metabolite, and did not prolong the QTc interval following co-administration with DRUG1 60 mg twice daily. ",negative,terfenadine,terfenadine
"- did not change the plasma concentration profile of DRUG2 (a substrate of cytochrome P450 3A4) or DRUG1, its carboxylated metabolite, and did not prolong the QTc interval following co-administration with DRUG2 60 mg twice daily. ",negative,fexofenadine,terfenadine
DRUG1 at Doses of    100 mg Daily Dosed to Pharmacokinetic Steady State:  - did not significantly alter the plasma concentrations of either component of an oral DRUG2 containing norethindrone 1 mg/ethinyl estradiol 35 mcg. ,negative,Montelukast,contraceptive
DRUG1 at Doses of    100 mg Daily Dosed to Pharmacokinetic Steady State:  - did not significantly alter the plasma concentrations of either component of an oral contraceptive containing DRUG2 1 mg/ethinyl estradiol 35 mcg. ,negative,Montelukast,norethindrone
DRUG1 at Doses of    100 mg Daily Dosed to Pharmacokinetic Steady State:  - did not significantly alter the plasma concentrations of either component of an oral contraceptive containing norethindrone 1 mg/ethinyl DRUG2 35 mcg. ,negative,Montelukast,estradiol
Montelukast at Doses of    100 mg Daily Dosed to Pharmacokinetic Steady State:  - did not significantly alter the plasma concentrations of either component of an oral DRUG1 containing DRUG2 1 mg/ethinyl estradiol 35 mcg. ,negative,contraceptive,norethindrone
Montelukast at Doses of    100 mg Daily Dosed to Pharmacokinetic Steady State:  - did not significantly alter the plasma concentrations of either component of an oral DRUG1 containing norethindrone 1 mg/ethinyl DRUG2 35 mcg. ,negative,contraceptive,estradiol
Montelukast at Doses of    100 mg Daily Dosed to Pharmacokinetic Steady State:  - did not significantly alter the plasma concentrations of either component of an oral contraceptive containing DRUG1 1 mg/ethinyl DRUG2 35 mcg. ,negative,norethindrone,estradiol
- did not cause any clinically significant change in plasma profiles of DRUG1 or DRUG2 following administration of either oral DRUG1 or intravenous DRUG2.  ,negative,prednisone,prednisolone
- did not cause any clinically significant change in plasma profiles of DRUG1 or prednisolone following administration of either oral DRUG1 or intravenous prednisolone.  ,negative,prednisone,prednisone
- did not cause any clinically significant change in plasma profiles of DRUG1 or DRUG2 following administration of either oral DRUG1 or intravenous DRUG2.  ,negative,prednisone,prednisolone
- did not cause any clinically significant change in plasma profiles of DRUG2 or DRUG1 following administration of either oral DRUG2 or intravenous DRUG1.  ,negative,prednisolone,prednisone
- did not cause any clinically significant change in plasma profiles of prednisone or DRUG1 following administration of either oral prednisone or intravenous DRUG1.  ,negative,prednisolone,prednisolone
- did not cause any clinically significant change in plasma profiles of DRUG1 or DRUG2 following administration of either oral DRUG1 or intravenous DRUG2.  ,negative,prednisone,prednisolone
"DRUG1, which induces hepatic metabolism, decreased the AUC of DRUG2 approximately 40% following a single 10-mg dose of DRUG2. ",negative,Phenobarbital,montelukast
"DRUG1, which induces hepatic metabolism, decreased the AUC of DRUG2 approximately 40% following a single 10-mg dose of DRUG2. ",negative,Phenobarbital,montelukast
"Phenobarbital, which induces hepatic metabolism, decreased the AUC of DRUG1 approximately 40% following a single 10-mg dose of DRUG1. ",negative,montelukast,montelukast
"It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers, such as DRUG1 or DRUG2, are co-administered with montelukast. ",negative,phenobarbital,rifampin
"It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers, such as DRUG1 or rifampin, are co-administered with DRUG2. ",advise,phenobarbital,montelukast
"It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers, such as phenobarbital or DRUG1, are co-administered with DRUG2. ",advise,rifampin,montelukast
"In drug-interaction studies, the recommended clinical dose of DRUG1 did not have clinically important effects on the pharmacokinetics of the following drugs: DRUG2, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. ",negative,montelukast,theophylline
"In drug-interaction studies, the recommended clinical dose of DRUG1 did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, DRUG2, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. ",negative,montelukast,prednisone
"In drug-interaction studies, the recommended clinical dose of DRUG1 did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, DRUG2, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. ",negative,montelukast,prednisolone
"In drug-interaction studies, the recommended clinical dose of DRUG1 did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral DRUG2 (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. ",negative,montelukast,contraceptives
"In drug-interaction studies, the recommended clinical dose of DRUG1 did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (DRUG2 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. ",negative,montelukast,norethindrone
"In drug-interaction studies, the recommended clinical dose of DRUG1 did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/DRUG2 35 mcg), terfenadine, digoxin, and warfarin. ",negative,montelukast,ethinyl estradiol
"In drug-interaction studies, the recommended clinical dose of DRUG1 did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), DRUG2, digoxin, and warfarin. ",negative,montelukast,terfenadine
"In drug-interaction studies, the recommended clinical dose of DRUG1 did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, DRUG2, and warfarin. ",negative,montelukast,digoxin
"In drug-interaction studies, the recommended clinical dose of DRUG1 did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and DRUG2. ",negative,montelukast,warfarin
"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: DRUG1, DRUG2, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. ",negative,theophylline,prednisone
"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: DRUG1, prednisone, DRUG2, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. ",negative,theophylline,prednisolone
"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: DRUG1, prednisone, prednisolone, oral DRUG2 (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. ",negative,theophylline,contraceptives
"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: DRUG1, prednisone, prednisolone, oral contraceptives (DRUG2 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. ",negative,theophylline,norethindrone
"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: DRUG1, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/DRUG2 35 mcg), terfenadine, digoxin, and warfarin. ",negative,theophylline,ethinyl estradiol
"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: DRUG1, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), DRUG2, digoxin, and warfarin. ",negative,theophylline,terfenadine
"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: DRUG1, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, DRUG2, and warfarin. ",negative,theophylline,digoxin
"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: DRUG1, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and DRUG2. ",negative,theophylline,warfarin
"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, DRUG1, DRUG2, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. ",negative,prednisone,prednisolone
"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, DRUG1, prednisolone, oral DRUG2 (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. ",negative,prednisone,contraceptives
"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, DRUG1, prednisolone, oral contraceptives (DRUG2 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. ",negative,prednisone,norethindrone
"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, DRUG1, prednisolone, oral contraceptives (norethindrone 1 mg/DRUG2 35 mcg), terfenadine, digoxin, and warfarin. ",negative,prednisone,ethinyl estradiol
"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, DRUG1, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), DRUG2, digoxin, and warfarin. ",negative,prednisone,terfenadine
"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, DRUG1, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, DRUG2, and warfarin. ",negative,prednisone,digoxin
"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, DRUG1, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and DRUG2. ",negative,prednisone,warfarin
"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, DRUG1, oral DRUG2 (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. ",negative,prednisolone,contraceptives
"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, DRUG1, oral contraceptives (DRUG2 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. ",negative,prednisolone,norethindrone
"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, DRUG1, oral contraceptives (norethindrone 1 mg/DRUG2 35 mcg), terfenadine, digoxin, and warfarin. ",negative,prednisolone,ethinyl estradiol
"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, DRUG1, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), DRUG2, digoxin, and warfarin. ",negative,prednisolone,terfenadine
"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, DRUG1, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, DRUG2, and warfarin. ",negative,prednisolone,digoxin
"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, DRUG1, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and DRUG2. ",negative,prednisolone,warfarin
"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral DRUG1 (DRUG2 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. ",negative,contraceptives,norethindrone
"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral DRUG1 (norethindrone 1 mg/DRUG2 35 mcg), terfenadine, digoxin, and warfarin. ",negative,contraceptives,ethinyl estradiol
"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral DRUG1 (norethindrone 1 mg/ethinyl estradiol 35 mcg), DRUG2, digoxin, and warfarin. ",negative,contraceptives,terfenadine
"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral DRUG1 (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, DRUG2, and warfarin. ",negative,contraceptives,digoxin
"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral DRUG1 (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and DRUG2. ",negative,contraceptives,warfarin
"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (DRUG1 1 mg/DRUG2 35 mcg), terfenadine, digoxin, and warfarin. ",negative,norethindrone,ethinyl estradiol
"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (DRUG1 1 mg/ethinyl estradiol 35 mcg), DRUG2, digoxin, and warfarin. ",negative,norethindrone,terfenadine
"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (DRUG1 1 mg/ethinyl estradiol 35 mcg), terfenadine, DRUG2, and warfarin. ",negative,norethindrone,digoxin
"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (DRUG1 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and DRUG2. ",negative,norethindrone,warfarin
"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/DRUG1 35 mcg), DRUG2, digoxin, and warfarin. ",negative,ethinyl estradiol,terfenadine
"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/DRUG1 35 mcg), terfenadine, DRUG2, and warfarin. ",negative,ethinyl estradiol,digoxin
"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/DRUG1 35 mcg), terfenadine, digoxin, and DRUG2. ",negative,ethinyl estradiol,warfarin
"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), DRUG1, DRUG2, and warfarin. ",negative,terfenadine,digoxin
"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), DRUG1, digoxin, and DRUG2. ",negative,terfenadine,warfarin
"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, DRUG1, and DRUG2. ",negative,digoxin,warfarin
"These medications included DRUG1, DRUG2, non-steroidal anti-inflammatory agents, benzodiazepines, and decongestants. ",negative,thyroid hormones,sedative hypnotics
"These medications included DRUG1, sedative hypnotics, DRUG2, benzodiazepines, and decongestants. ",negative,thyroid hormones,non-steroidal anti-inflammatory agents
"These medications included DRUG1, sedative hypnotics, non-steroidal anti-inflammatory agents, DRUG2, and decongestants. ",negative,thyroid hormones,benzodiazepines
"These medications included DRUG1, sedative hypnotics, non-steroidal anti-inflammatory agents, benzodiazepines, and DRUG2. ",negative,thyroid hormones,decongestants
"These medications included thyroid hormones, DRUG1, DRUG2, benzodiazepines, and decongestants. ",negative,sedative hypnotics,non-steroidal anti-inflammatory agents
"These medications included thyroid hormones, DRUG1, non-steroidal anti-inflammatory agents, DRUG2, and decongestants. ",negative,sedative hypnotics,benzodiazepines
"These medications included thyroid hormones, DRUG1, non-steroidal anti-inflammatory agents, benzodiazepines, and DRUG2. ",negative,sedative hypnotics,decongestants
"These medications included thyroid hormones, sedative hypnotics, DRUG1, DRUG2, and decongestants. ",negative,non-steroidal anti-inflammatory agents,benzodiazepines
"These medications included thyroid hormones, sedative hypnotics, DRUG1, benzodiazepines, and DRUG2. ",negative,non-steroidal anti-inflammatory agents,decongestants
"These medications included thyroid hormones, sedative hypnotics, non-steroidal anti-inflammatory agents, DRUG1, and DRUG2. ",negative,benzodiazepines,decongestants
"DRUG1, which induces hepatic metabolism, decreased the AUC of DRUG2 approximately 40% following a single 10-mg dose of DRUG2. ",negative,Phenobarbital,montelukast
"DRUG1, which induces hepatic metabolism, decreased the AUC of DRUG2 approximately 40% following a single 10-mg dose of DRUG2. ",negative,Phenobarbital,montelukast
"Phenobarbital, which induces hepatic metabolism, decreased the AUC of DRUG1 approximately 40% following a single 10-mg dose of DRUG1. ",negative,montelukast,montelukast
"It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers, such as DRUG1 or DRUG2, are co-administered with montelukast.",negative,phenobarbital,rifampin
"It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers, such as DRUG1 or rifampin, are co-administered with DRUG2.",advise,phenobarbital,montelukast
"It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers, such as phenobarbital or DRUG1, are co-administered with DRUG2.",advise,rifampin,montelukast
DRUG1/DRUG2: DRUG1/DRUG2 does not influence the pharmacokinetics of pramipexole in healthy volunteers (N= 10). ,negative,Carbidopa,Levodopa
DRUG1/Levodopa: DRUG1/Levodopa does not influence the pharmacokinetics of pramipexole in healthy volunteers (N= 10). ,negative,Carbidopa,Carbidopa
DRUG1/DRUG2: DRUG1/DRUG2 does not influence the pharmacokinetics of pramipexole in healthy volunteers (N= 10). ,negative,Carbidopa,Levodopa
DRUG1/Levodopa: DRUG1/Levodopa does not influence the pharmacokinetics of DRUG2 in healthy volunteers (N= 10). ,negative,Carbidopa,pramipexole
DRUG2/DRUG1: DRUG2/DRUG1 does not influence the pharmacokinetics of pramipexole in healthy volunteers (N= 10). ,negative,Levodopa,Carbidopa
Carbidopa/DRUG1: Carbidopa/DRUG1 does not influence the pharmacokinetics of pramipexole in healthy volunteers (N= 10). ,negative,Levodopa,Levodopa
Carbidopa/DRUG1: Carbidopa/DRUG1 does not influence the pharmacokinetics of DRUG2 in healthy volunteers (N= 10). ,negative,Levodopa,pramipexole
DRUG1/DRUG2: DRUG1/DRUG2 does not influence the pharmacokinetics of pramipexole in healthy volunteers (N= 10). ,negative,Carbidopa,Levodopa
DRUG1/Levodopa: DRUG1/Levodopa does not influence the pharmacokinetics of DRUG2 in healthy volunteers (N= 10). ,negative,Carbidopa,pramipexole
Carbidopa/DRUG1: Carbidopa/DRUG1 does not influence the pharmacokinetics of DRUG2 in healthy volunteers (N= 10). ,negative,Levodopa,pramipexole
"DRUG1: In healthy volunteers (N= 11), DRUG1 did not influence the pharmacokinetics of pramipexole. ",negative,Selegiline,selegiline
"DRUG1: In healthy volunteers (N= 11), DRUG1 did not influence the pharmacokinetics of DRUG2. ",negative,Selegiline,pramipexole
"DRUG1: In healthy volunteers (N= 11), DRUG1 did not influence the pharmacokinetics of DRUG2. ",negative,selegiline,pramipexole
DRUG1: Population pharmacokinetic analysis suggests that DRUG1 is unlikely to alter the oral clearance of pramipexole (N= 54). ,negative,Amantadine,amantadine
DRUG1: Population pharmacokinetic analysis suggests that DRUG1 is unlikely to alter the oral clearance of DRUG2 (N= 54). ,negative,Amantadine,pramipexole
DRUG1: Population pharmacokinetic analysis suggests that DRUG1 is unlikely to alter the oral clearance of DRUG2 (N= 54). ,negative,amantadine,pramipexole
"DRUG1: DRUG1, a known inhibitor of renal tubular secretion of organic bases via the cationic transport system, caused a 50% increase in pramipexole AUC and a 40% increase in half-life (N= 12). ",negative,Cimetidine,Cimetidine
"DRUG1: DRUG1, a known inhibitor of renal tubular secretion of organic bases via the cationic transport system, caused a 50% increase in DRUG2 AUC and a 40% increase in half-life (N= 12). ",negative,Cimetidine,pramipexole
"DRUG1: DRUG1, a known inhibitor of renal tubular secretion of organic bases via the cationic transport system, caused a 50% increase in DRUG2 AUC and a 40% increase in half-life (N= 12). ",mechanism,Cimetidine,pramipexole
"DRUG1: DRUG1, a known inhibitor of renal tubular secretion of organic acids via the aruonic transporter, did not noticeably influence pramipexole pharmacokinetics (N= 12). ",negative,Probenecid,Probenecid
"DRUG1: DRUG1, a known inhibitor of renal tubular secretion of organic acids via the aruonic transporter, did not noticeably influence DRUG2 pharmacokinetics (N= 12). ",negative,Probenecid,pramipexole
"DRUG1: DRUG1, a known inhibitor of renal tubular secretion of organic acids via the aruonic transporter, did not noticeably influence DRUG2 pharmacokinetics (N= 12). ",negative,Probenecid,pramipexole
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., DRUG1, DRUG2, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",negative,cimetidine,ranitidine
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., DRUG1, ranitidine, DRUG2, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",negative,cimetidine,diltiazem
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., DRUG1, ranitidine, diltiazem, DRUG2, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",negative,cimetidine,triamterene
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., DRUG1, ranitidine, diltiazem, triamterene, DRUG2, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",negative,cimetidine,verapamil
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., DRUG1, ranitidine, diltiazem, triamterene, verapamil, DRUG2, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",negative,cimetidine,quinidine
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., DRUG1, ranitidine, diltiazem, triamterene, verapamil, quinidine, and DRUG2) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",negative,cimetidine,quinine
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., DRUG1, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of DRUG2 by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of DRUG2. ",mechanism,cimetidine,pramipexole
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., DRUG1, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., DRUG2, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",negative,cimetidine,cephalosporins
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., DRUG1, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, DRUG2, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",negative,cimetidine,penicillins
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., DRUG1, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, DRUG2, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",negative,cimetidine,indomethacin
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., DRUG1, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, DRUG2, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",negative,cimetidine,hydrochlorothiazide
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., DRUG1, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and DRUG2) are likely to have little effect on the oral clearance of pramipexole. ",negative,cimetidine,chlorpropamide
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., DRUG1, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of DRUG2 by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of DRUG2. ",negative,cimetidine,pramipexole
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, DRUG1, DRUG2, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",negative,ranitidine,diltiazem
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, DRUG1, diltiazem, DRUG2, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",negative,ranitidine,triamterene
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, DRUG1, diltiazem, triamterene, DRUG2, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",negative,ranitidine,verapamil
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, DRUG1, diltiazem, triamterene, verapamil, DRUG2, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",negative,ranitidine,quinidine
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, DRUG1, diltiazem, triamterene, verapamil, quinidine, and DRUG2) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",negative,ranitidine,quinine
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, DRUG1, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of DRUG2 by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of DRUG2. ",mechanism,ranitidine,pramipexole
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, DRUG1, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., DRUG2, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",negative,ranitidine,cephalosporins
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, DRUG1, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, DRUG2, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",negative,ranitidine,penicillins
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, DRUG1, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, DRUG2, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",negative,ranitidine,indomethacin
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, DRUG1, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, DRUG2, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",negative,ranitidine,hydrochlorothiazide
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, DRUG1, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and DRUG2) are likely to have little effect on the oral clearance of pramipexole. ",negative,ranitidine,chlorpropamide
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, DRUG1, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of DRUG2 by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of DRUG2. ",negative,ranitidine,pramipexole
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, DRUG1, DRUG2, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",negative,diltiazem,triamterene
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, DRUG1, triamterene, DRUG2, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",negative,diltiazem,verapamil
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, DRUG1, triamterene, verapamil, DRUG2, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",negative,diltiazem,quinidine
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, DRUG1, triamterene, verapamil, quinidine, and DRUG2) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",negative,diltiazem,quinine
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, DRUG1, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of DRUG2 by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of DRUG2. ",mechanism,diltiazem,pramipexole
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, DRUG1, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., DRUG2, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",negative,diltiazem,cephalosporins
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, DRUG1, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, DRUG2, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",negative,diltiazem,penicillins
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, DRUG1, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, DRUG2, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",negative,diltiazem,indomethacin
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, DRUG1, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, DRUG2, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",negative,diltiazem,hydrochlorothiazide
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, DRUG1, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and DRUG2) are likely to have little effect on the oral clearance of pramipexole. ",negative,diltiazem,chlorpropamide
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, DRUG1, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of DRUG2 by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of DRUG2. ",negative,diltiazem,pramipexole
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, DRUG1, DRUG2, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",negative,triamterene,verapamil
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, DRUG1, verapamil, DRUG2, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",negative,triamterene,quinidine
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, DRUG1, verapamil, quinidine, and DRUG2) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",negative,triamterene,quinine
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, DRUG1, verapamil, quinidine, and quinine) decreases the oral clearance of DRUG2 by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of DRUG2. ",mechanism,triamterene,pramipexole
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, DRUG1, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., DRUG2, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",negative,triamterene,cephalosporins
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, DRUG1, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, DRUG2, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",negative,triamterene,penicillins
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, DRUG1, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, DRUG2, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",negative,triamterene,indomethacin
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, DRUG1, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, DRUG2, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",negative,triamterene,hydrochlorothiazide
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, DRUG1, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and DRUG2) are likely to have little effect on the oral clearance of pramipexole. ",negative,triamterene,chlorpropamide
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, DRUG1, verapamil, quinidine, and quinine) decreases the oral clearance of DRUG2 by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of DRUG2. ",negative,triamterene,pramipexole
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, DRUG1, DRUG2, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",negative,verapamil,quinidine
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, DRUG1, quinidine, and DRUG2) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",negative,verapamil,quinine
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, DRUG1, quinidine, and quinine) decreases the oral clearance of DRUG2 by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of DRUG2. ",mechanism,verapamil,pramipexole
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, DRUG1, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., DRUG2, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",negative,verapamil,cephalosporins
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, DRUG1, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, DRUG2, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",negative,verapamil,penicillins
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, DRUG1, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, DRUG2, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",negative,verapamil,indomethacin
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, DRUG1, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, DRUG2, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",negative,verapamil,hydrochlorothiazide
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, DRUG1, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and DRUG2) are likely to have little effect on the oral clearance of pramipexole. ",negative,verapamil,chlorpropamide
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, DRUG1, quinidine, and quinine) decreases the oral clearance of DRUG2 by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of DRUG2. ",negative,verapamil,pramipexole
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, DRUG1, and DRUG2) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",negative,quinidine,quinine
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, DRUG1, and quinine) decreases the oral clearance of DRUG2 by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of DRUG2. ",mechanism,quinidine,pramipexole
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, DRUG1, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., DRUG2, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",negative,quinidine,cephalosporins
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, DRUG1, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, DRUG2, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",negative,quinidine,penicillins
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, DRUG1, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, DRUG2, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",negative,quinidine,indomethacin
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, DRUG1, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, DRUG2, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",negative,quinidine,hydrochlorothiazide
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, DRUG1, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and DRUG2) are likely to have little effect on the oral clearance of pramipexole. ",negative,quinidine,chlorpropamide
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, DRUG1, and quinine) decreases the oral clearance of DRUG2 by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of DRUG2. ",negative,quinidine,pramipexole
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and DRUG1) decreases the oral clearance of DRUG2 by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of DRUG2. ",mechanism,quinine,pramipexole
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and DRUG1) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., DRUG2, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",negative,quinine,cephalosporins
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and DRUG1) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, DRUG2, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",negative,quinine,penicillins
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and DRUG1) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, DRUG2, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",negative,quinine,indomethacin
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and DRUG1) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, DRUG2, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",negative,quinine,hydrochlorothiazide
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and DRUG1) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and DRUG2) are likely to have little effect on the oral clearance of pramipexole. ",negative,quinine,chlorpropamide
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and DRUG1) decreases the oral clearance of DRUG2 by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of DRUG2. ",negative,quinine,pramipexole
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of DRUG1 by about 20%, while those secreted by the anionic transport system (e.g., DRUG2, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of DRUG1. ",negative,pramipexole,cephalosporins
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of DRUG1 by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, DRUG2, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of DRUG1. ",negative,pramipexole,penicillins
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of DRUG1 by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, DRUG2, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of DRUG1. ",negative,pramipexole,indomethacin
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of DRUG1 by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, DRUG2, and chlorpropamide) are likely to have little effect on the oral clearance of DRUG1. ",negative,pramipexole,hydrochlorothiazide
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of DRUG1 by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and DRUG2) are likely to have little effect on the oral clearance of DRUG1. ",negative,pramipexole,chlorpropamide
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of DRUG1 by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of DRUG1. ",negative,pramipexole,pramipexole
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., DRUG1, DRUG2, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",negative,cephalosporins,penicillins
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., DRUG1, penicillins, DRUG2, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",negative,cephalosporins,indomethacin
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., DRUG1, penicillins, indomethacin, DRUG2, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",negative,cephalosporins,hydrochlorothiazide
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., DRUG1, penicillins, indomethacin, hydrochlorothiazide, and DRUG2) are likely to have little effect on the oral clearance of pramipexole. ",negative,cephalosporins,chlorpropamide
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of DRUG2 by about 20%, while those secreted by the anionic transport system (e.g., DRUG1, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of DRUG2. ",mechanism,cephalosporins,pramipexole
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, DRUG1, DRUG2, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",negative,penicillins,indomethacin
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, DRUG1, indomethacin, DRUG2, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",negative,penicillins,hydrochlorothiazide
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, DRUG1, indomethacin, hydrochlorothiazide, and DRUG2) are likely to have little effect on the oral clearance of pramipexole. ",negative,penicillins,chlorpropamide
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of DRUG2 by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, DRUG1, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of DRUG2. ",mechanism,penicillins,pramipexole
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, DRUG1, DRUG2, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",negative,indomethacin,hydrochlorothiazide
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, DRUG1, hydrochlorothiazide, and DRUG2) are likely to have little effect on the oral clearance of pramipexole. ",negative,indomethacin,chlorpropamide
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of DRUG2 by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, DRUG1, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of DRUG2. ",mechanism,indomethacin,pramipexole
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, DRUG1, and DRUG2) are likely to have little effect on the oral clearance of pramipexole. ",negative,hydrochlorothiazide,chlorpropamide
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of DRUG2 by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, DRUG1, and chlorpropamide) are likely to have little effect on the oral clearance of DRUG2. ",mechanism,hydrochlorothiazide,pramipexole
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of DRUG2 by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and DRUG1) are likely to have little effect on the oral clearance of DRUG2. ",mechanism,chlorpropamide,pramipexole
CYP interactions: Inhibitors of cytochrome P450 enzymes would not be expected to affect DRUG1 elimination because DRUG1 is not appreciably metabolized by these enzymes in vivo or in vitro. ,negative,pramipexole,pramipexole
"DRUG1: Since DRUG2 is a dopamine agonist, it is possible that DRUG1, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",negative,Dopamine antagonists,pramipexole
"DRUG1: Since pramipexole is a DRUG2, it is possible that DRUG1, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",negative,Dopamine antagonists,dopamine agonist
"DRUG1: Since pramipexole is a dopamine agonist, it is possible that DRUG1, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",negative,Dopamine antagonists,dopamine antagonists
"DRUG1: Since pramipexole is a dopamine agonist, it is possible that DRUG1, such as the DRUG2 (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",negative,Dopamine antagonists,neuroleptics
"DRUG1: Since pramipexole is a dopamine agonist, it is possible that DRUG1, such as the neuroleptics (DRUG2, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",negative,Dopamine antagonists,phenothiazines
"DRUG1: Since pramipexole is a dopamine agonist, it is possible that DRUG1, such as the neuroleptics (phenothiazines, DRUG2, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",negative,Dopamine antagonists,butyrophenones
"DRUG1: Since pramipexole is a dopamine agonist, it is possible that DRUG1, such as the neuroleptics (phenothiazines, butyrophenones, DRUG2) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",negative,Dopamine antagonists,thioxanthenes
"DRUG1: Since pramipexole is a dopamine agonist, it is possible that DRUG1, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or DRUG2, may diminish the effectiveness of MIRAPEX. ",negative,Dopamine antagonists,metoclopramide
"DRUG1: Since pramipexole is a dopamine agonist, it is possible that DRUG1, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of DRUG2. ",negative,Dopamine antagonists,MIRAPEX
"Dopamine antagonists: Since DRUG1 is a DRUG2, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",negative,pramipexole,dopamine agonist
"DRUG2: Since DRUG1 is a dopamine agonist, it is possible that DRUG2, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",negative,pramipexole,dopamine antagonists
"Dopamine antagonists: Since DRUG1 is a dopamine agonist, it is possible that dopamine antagonists, such as the DRUG2 (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",negative,pramipexole,neuroleptics
"Dopamine antagonists: Since DRUG1 is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (DRUG2, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",negative,pramipexole,phenothiazines
"Dopamine antagonists: Since DRUG1 is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, DRUG2, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",negative,pramipexole,butyrophenones
"Dopamine antagonists: Since DRUG1 is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, DRUG2) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",negative,pramipexole,thioxanthenes
"Dopamine antagonists: Since DRUG1 is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or DRUG2, may diminish the effectiveness of MIRAPEX. ",negative,pramipexole,metoclopramide
"Dopamine antagonists: Since DRUG1 is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of DRUG2. ",negative,pramipexole,MIRAPEX
"DRUG2: Since pramipexole is a DRUG1, it is possible that DRUG2, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",negative,dopamine agonist,dopamine antagonists
"Dopamine antagonists: Since pramipexole is a DRUG1, it is possible that dopamine antagonists, such as the DRUG2 (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",negative,dopamine agonist,neuroleptics
"Dopamine antagonists: Since pramipexole is a DRUG1, it is possible that dopamine antagonists, such as the neuroleptics (DRUG2, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",negative,dopamine agonist,phenothiazines
"Dopamine antagonists: Since pramipexole is a DRUG1, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, DRUG2, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",negative,dopamine agonist,butyrophenones
"Dopamine antagonists: Since pramipexole is a DRUG1, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, DRUG2) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",negative,dopamine agonist,thioxanthenes
"Dopamine antagonists: Since pramipexole is a DRUG1, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or DRUG2, may diminish the effectiveness of MIRAPEX. ",negative,dopamine agonist,metoclopramide
"Dopamine antagonists: Since pramipexole is a DRUG1, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of DRUG2. ",negative,dopamine agonist,MIRAPEX
"DRUG1: Since pramipexole is a dopamine agonist, it is possible that DRUG1, such as the DRUG2 (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",negative,dopamine antagonists,neuroleptics
"DRUG1: Since pramipexole is a dopamine agonist, it is possible that DRUG1, such as the neuroleptics (DRUG2, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",negative,dopamine antagonists,phenothiazines
"DRUG1: Since pramipexole is a dopamine agonist, it is possible that DRUG1, such as the neuroleptics (phenothiazines, DRUG2, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",negative,dopamine antagonists,butyrophenones
"DRUG1: Since pramipexole is a dopamine agonist, it is possible that DRUG1, such as the neuroleptics (phenothiazines, butyrophenones, DRUG2) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",negative,dopamine antagonists,thioxanthenes
"DRUG1: Since pramipexole is a dopamine agonist, it is possible that DRUG1, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or DRUG2, may diminish the effectiveness of MIRAPEX. ",negative,dopamine antagonists,metoclopramide
"DRUG1: Since pramipexole is a dopamine agonist, it is possible that DRUG1, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of DRUG2. ",effect,dopamine antagonists,MIRAPEX
"Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the DRUG1 (DRUG2, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",negative,neuroleptics,phenothiazines
"Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the DRUG1 (phenothiazines, DRUG2, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",negative,neuroleptics,butyrophenones
"Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the DRUG1 (phenothiazines, butyrophenones, DRUG2) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",negative,neuroleptics,thioxanthenes
"Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the DRUG1 (phenothiazines, butyrophenones, thioxanthenes) or DRUG2, may diminish the effectiveness of MIRAPEX. ",negative,neuroleptics,metoclopramide
"Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the DRUG1 (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of DRUG2. ",effect,neuroleptics,MIRAPEX
"Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (DRUG1, DRUG2, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",negative,phenothiazines,butyrophenones
"Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (DRUG1, butyrophenones, DRUG2) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",negative,phenothiazines,thioxanthenes
"Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (DRUG1, butyrophenones, thioxanthenes) or DRUG2, may diminish the effectiveness of MIRAPEX. ",negative,phenothiazines,metoclopramide
"Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (DRUG1, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of DRUG2. ",effect,phenothiazines,MIRAPEX
"Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, DRUG1, DRUG2) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",negative,butyrophenones,thioxanthenes
"Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, DRUG1, thioxanthenes) or DRUG2, may diminish the effectiveness of MIRAPEX. ",negative,butyrophenones,metoclopramide
"Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, DRUG1, thioxanthenes) or metoclopramide, may diminish the effectiveness of DRUG2. ",effect,butyrophenones,MIRAPEX
"Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, DRUG1) or DRUG2, may diminish the effectiveness of MIRAPEX. ",negative,thioxanthenes,metoclopramide
"Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, DRUG1) or metoclopramide, may diminish the effectiveness of DRUG2. ",effect,thioxanthenes,MIRAPEX
"Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or DRUG1, may diminish the effectiveness of DRUG2. ",effect,metoclopramide,MIRAPEX
"Based on studies evaluating possible interactions of DRUG1 with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUG2, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,pantoprazole,theophylline
"Based on studies evaluating possible interactions of DRUG1 with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, DRUG2, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,pantoprazole,cisapride
"Based on studies evaluating possible interactions of DRUG1 with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, DRUG2, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,pantoprazole,antipyrine
"Based on studies evaluating possible interactions of DRUG1 with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, DRUG2, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,pantoprazole,caffeine
"Based on studies evaluating possible interactions of DRUG1 with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, DRUG2, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,pantoprazole,carbamazepine
"Based on studies evaluating possible interactions of DRUG1 with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, DRUG2 (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,pantoprazole,diazepam
"Based on studies evaluating possible interactions of DRUG1 with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, DRUG2), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,pantoprazole,desmethyldiazepam
"Based on studies evaluating possible interactions of DRUG1 with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), DRUG2, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,pantoprazole,diclofenac
"Based on studies evaluating possible interactions of DRUG1 with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, DRUG2, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,pantoprazole,naproxen
"Based on studies evaluating possible interactions of DRUG1 with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, DRUG2, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,pantoprazole,piroxicam
"Based on studies evaluating possible interactions of DRUG1 with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, DRUG2, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,pantoprazole,digoxin
"Based on studies evaluating possible interactions of DRUG1 with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, DRUG2, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,pantoprazole,ethanol
"Based on studies evaluating possible interactions of DRUG1 with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, DRUG2, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,pantoprazole,glyburide
"Based on studies evaluating possible interactions of DRUG1 with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral DRUG2 (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,pantoprazole,contraceptive
"Based on studies evaluating possible interactions of DRUG1 with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (DRUG2/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,pantoprazole,levonorgestrel
"Based on studies evaluating possible interactions of DRUG1 with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/DRUG2), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,pantoprazole,ethinyl estradiol
"Based on studies evaluating possible interactions of DRUG1 with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), DRUG2, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,pantoprazole,metoprolol
"Based on studies evaluating possible interactions of DRUG1 with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, DRUG2, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,pantoprazole,nifedipine
"Based on studies evaluating possible interactions of DRUG1 with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, DRUG2, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,pantoprazole,phenytoin
"Based on studies evaluating possible interactions of DRUG1 with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, DRUG2, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,pantoprazole,warfarin
"Based on studies evaluating possible interactions of DRUG1 with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, DRUG2, clarithromycin, metronidazole, or amoxicillin. ",negative,pantoprazole,midazolam
"Based on studies evaluating possible interactions of DRUG1 with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, DRUG2, metronidazole, or amoxicillin. ",negative,pantoprazole,clarithromycin
"Based on studies evaluating possible interactions of DRUG1 with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, DRUG2, or amoxicillin. ",negative,pantoprazole,metronidazole
"Based on studies evaluating possible interactions of DRUG1 with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or DRUG2. ",negative,pantoprazole,amoxicillin
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUG1, DRUG2, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,theophylline,cisapride
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUG1, cisapride, DRUG2, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,theophylline,antipyrine
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUG1, cisapride, antipyrine, DRUG2, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,theophylline,caffeine
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUG1, cisapride, antipyrine, caffeine, DRUG2, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,theophylline,carbamazepine
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUG1, cisapride, antipyrine, caffeine, carbamazepine, DRUG2 (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,theophylline,diazepam
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUG1, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, DRUG2), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,theophylline,desmethyldiazepam
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUG1, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), DRUG2, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,theophylline,diclofenac
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUG1, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, DRUG2, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,theophylline,naproxen
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUG1, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, DRUG2, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,theophylline,piroxicam
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUG1, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, DRUG2, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,theophylline,digoxin
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUG1, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, DRUG2, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,theophylline,ethanol
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUG1, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, DRUG2, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,theophylline,glyburide
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUG1, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral DRUG2 (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,theophylline,contraceptive
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUG1, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (DRUG2/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,theophylline,levonorgestrel
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUG1, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/DRUG2), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,theophylline,ethinyl estradiol
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUG1, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), DRUG2, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,theophylline,metoprolol
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUG1, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, DRUG2, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,theophylline,nifedipine
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUG1, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, DRUG2, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,theophylline,phenytoin
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUG1, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, DRUG2, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,theophylline,warfarin
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUG1, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, DRUG2, clarithromycin, metronidazole, or amoxicillin. ",negative,theophylline,midazolam
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUG1, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, DRUG2, metronidazole, or amoxicillin. ",negative,theophylline,clarithromycin
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUG1, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, DRUG2, or amoxicillin. ",negative,theophylline,metronidazole
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUG1, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or DRUG2. ",negative,theophylline,amoxicillin
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, DRUG1, DRUG2, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,cisapride,antipyrine
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, DRUG1, antipyrine, DRUG2, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,cisapride,caffeine
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, DRUG1, antipyrine, caffeine, DRUG2, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,cisapride,carbamazepine
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, DRUG1, antipyrine, caffeine, carbamazepine, DRUG2 (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,cisapride,diazepam
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, DRUG1, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, DRUG2), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,cisapride,desmethyldiazepam
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, DRUG1, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), DRUG2, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,cisapride,diclofenac
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, DRUG1, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, DRUG2, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,cisapride,naproxen
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, DRUG1, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, DRUG2, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,cisapride,piroxicam
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, DRUG1, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, DRUG2, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,cisapride,digoxin
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, DRUG1, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, DRUG2, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,cisapride,ethanol
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, DRUG1, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, DRUG2, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,cisapride,glyburide
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, DRUG1, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral DRUG2 (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,cisapride,contraceptive
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, DRUG1, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (DRUG2/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,cisapride,levonorgestrel
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, DRUG1, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/DRUG2), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,cisapride,ethinyl estradiol
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, DRUG1, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), DRUG2, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,cisapride,metoprolol
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, DRUG1, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, DRUG2, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,cisapride,nifedipine
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, DRUG1, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, DRUG2, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,cisapride,phenytoin
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, DRUG1, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, DRUG2, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,cisapride,warfarin
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, DRUG1, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, DRUG2, clarithromycin, metronidazole, or amoxicillin. ",negative,cisapride,midazolam
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, DRUG1, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, DRUG2, metronidazole, or amoxicillin. ",negative,cisapride,clarithromycin
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, DRUG1, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, DRUG2, or amoxicillin. ",negative,cisapride,metronidazole
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, DRUG1, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or DRUG2. ",negative,cisapride,amoxicillin
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, DRUG1, DRUG2, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,antipyrine,caffeine
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, DRUG1, caffeine, DRUG2, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,antipyrine,carbamazepine
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, DRUG1, caffeine, carbamazepine, DRUG2 (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,antipyrine,diazepam
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, DRUG1, caffeine, carbamazepine, diazepam (and its active metabolite, DRUG2), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,antipyrine,desmethyldiazepam
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, DRUG1, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), DRUG2, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,antipyrine,diclofenac
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, DRUG1, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, DRUG2, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,antipyrine,naproxen
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, DRUG1, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, DRUG2, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,antipyrine,piroxicam
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, DRUG1, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, DRUG2, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,antipyrine,digoxin
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, DRUG1, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, DRUG2, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,antipyrine,ethanol
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, DRUG1, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, DRUG2, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,antipyrine,glyburide
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, DRUG1, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral DRUG2 (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,antipyrine,contraceptive
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, DRUG1, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (DRUG2/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,antipyrine,levonorgestrel
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, DRUG1, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/DRUG2), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,antipyrine,ethinyl estradiol
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, DRUG1, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), DRUG2, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,antipyrine,metoprolol
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, DRUG1, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, DRUG2, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,antipyrine,nifedipine
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, DRUG1, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, DRUG2, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,antipyrine,phenytoin
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, DRUG1, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, DRUG2, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,antipyrine,warfarin
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, DRUG1, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, DRUG2, clarithromycin, metronidazole, or amoxicillin. ",negative,antipyrine,midazolam
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, DRUG1, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, DRUG2, metronidazole, or amoxicillin. ",negative,antipyrine,clarithromycin
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, DRUG1, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, DRUG2, or amoxicillin. ",negative,antipyrine,metronidazole
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, DRUG1, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or DRUG2. ",negative,antipyrine,amoxicillin
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, DRUG1, DRUG2, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,caffeine,carbamazepine
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, DRUG1, carbamazepine, DRUG2 (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,caffeine,diazepam
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, DRUG1, carbamazepine, diazepam (and its active metabolite, DRUG2), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,caffeine,desmethyldiazepam
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, DRUG1, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), DRUG2, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,caffeine,diclofenac
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, DRUG1, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, DRUG2, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,caffeine,naproxen
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, DRUG1, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, DRUG2, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,caffeine,piroxicam
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, DRUG1, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, DRUG2, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,caffeine,digoxin
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, DRUG1, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, DRUG2, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,caffeine,ethanol
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, DRUG1, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, DRUG2, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,caffeine,glyburide
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, DRUG1, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral DRUG2 (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,caffeine,contraceptive
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, DRUG1, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (DRUG2/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,caffeine,levonorgestrel
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, DRUG1, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/DRUG2), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,caffeine,ethinyl estradiol
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, DRUG1, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), DRUG2, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,caffeine,metoprolol
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, DRUG1, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, DRUG2, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,caffeine,nifedipine
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, DRUG1, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, DRUG2, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,caffeine,phenytoin
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, DRUG1, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, DRUG2, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,caffeine,warfarin
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, DRUG1, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, DRUG2, clarithromycin, metronidazole, or amoxicillin. ",negative,caffeine,midazolam
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, DRUG1, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, DRUG2, metronidazole, or amoxicillin. ",negative,caffeine,clarithromycin
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, DRUG1, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, DRUG2, or amoxicillin. ",negative,caffeine,metronidazole
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, DRUG1, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or DRUG2. ",negative,caffeine,amoxicillin
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, DRUG1, DRUG2 (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,carbamazepine,diazepam
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, DRUG1, diazepam (and its active metabolite, DRUG2), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,carbamazepine,desmethyldiazepam
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, DRUG1, diazepam (and its active metabolite, desmethyldiazepam), DRUG2, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,carbamazepine,diclofenac
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, DRUG1, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, DRUG2, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,carbamazepine,naproxen
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, DRUG1, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, DRUG2, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,carbamazepine,piroxicam
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, DRUG1, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, DRUG2, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,carbamazepine,digoxin
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, DRUG1, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, DRUG2, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,carbamazepine,ethanol
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, DRUG1, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, DRUG2, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,carbamazepine,glyburide
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, DRUG1, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral DRUG2 (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,carbamazepine,contraceptive
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, DRUG1, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (DRUG2/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,carbamazepine,levonorgestrel
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, DRUG1, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/DRUG2), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,carbamazepine,ethinyl estradiol
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, DRUG1, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), DRUG2, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,carbamazepine,metoprolol
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, DRUG1, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, DRUG2, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,carbamazepine,nifedipine
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, DRUG1, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, DRUG2, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,carbamazepine,phenytoin
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, DRUG1, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, DRUG2, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,carbamazepine,warfarin
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, DRUG1, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, DRUG2, clarithromycin, metronidazole, or amoxicillin. ",negative,carbamazepine,midazolam
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, DRUG1, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, DRUG2, metronidazole, or amoxicillin. ",negative,carbamazepine,clarithromycin
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, DRUG1, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, DRUG2, or amoxicillin. ",negative,carbamazepine,metronidazole
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, DRUG1, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or DRUG2. ",negative,carbamazepine,amoxicillin
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, DRUG1 (and its active metabolite, DRUG2), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,diazepam,desmethyldiazepam
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, DRUG1 (and its active metabolite, desmethyldiazepam), DRUG2, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,diazepam,diclofenac
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, DRUG1 (and its active metabolite, desmethyldiazepam), diclofenac, DRUG2, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,diazepam,naproxen
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, DRUG1 (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, DRUG2, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,diazepam,piroxicam
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, DRUG1 (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, DRUG2, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,diazepam,digoxin
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, DRUG1 (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, DRUG2, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,diazepam,ethanol
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, DRUG1 (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, DRUG2, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,diazepam,glyburide
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, DRUG1 (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral DRUG2 (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,diazepam,contraceptive
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, DRUG1 (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (DRUG2/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,diazepam,levonorgestrel
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, DRUG1 (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/DRUG2), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,diazepam,ethinyl estradiol
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, DRUG1 (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), DRUG2, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,diazepam,metoprolol
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, DRUG1 (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, DRUG2, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,diazepam,nifedipine
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, DRUG1 (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, DRUG2, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,diazepam,phenytoin
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, DRUG1 (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, DRUG2, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,diazepam,warfarin
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, DRUG1 (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, DRUG2, clarithromycin, metronidazole, or amoxicillin. ",negative,diazepam,midazolam
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, DRUG1 (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, DRUG2, metronidazole, or amoxicillin. ",negative,diazepam,clarithromycin
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, DRUG1 (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, DRUG2, or amoxicillin. ",negative,diazepam,metronidazole
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, DRUG1 (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or DRUG2. ",negative,diazepam,amoxicillin
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, DRUG1), DRUG2, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,desmethyldiazepam,diclofenac
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, DRUG1), diclofenac, DRUG2, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,desmethyldiazepam,naproxen
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, DRUG1), diclofenac, naproxen, DRUG2, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,desmethyldiazepam,piroxicam
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, DRUG1), diclofenac, naproxen, piroxicam, DRUG2, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,desmethyldiazepam,digoxin
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, DRUG1), diclofenac, naproxen, piroxicam, digoxin, DRUG2, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,desmethyldiazepam,ethanol
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, DRUG1), diclofenac, naproxen, piroxicam, digoxin, ethanol, DRUG2, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,desmethyldiazepam,glyburide
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, DRUG1), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral DRUG2 (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,desmethyldiazepam,contraceptive
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, DRUG1), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (DRUG2/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,desmethyldiazepam,levonorgestrel
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, DRUG1), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/DRUG2), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,desmethyldiazepam,ethinyl estradiol
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, DRUG1), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), DRUG2, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,desmethyldiazepam,metoprolol
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, DRUG1), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, DRUG2, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,desmethyldiazepam,nifedipine
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, DRUG1), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, DRUG2, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,desmethyldiazepam,phenytoin
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, DRUG1), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, DRUG2, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,desmethyldiazepam,warfarin
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, DRUG1), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, DRUG2, clarithromycin, metronidazole, or amoxicillin. ",negative,desmethyldiazepam,midazolam
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, DRUG1), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, DRUG2, metronidazole, or amoxicillin. ",negative,desmethyldiazepam,clarithromycin
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, DRUG1), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, DRUG2, or amoxicillin. ",negative,desmethyldiazepam,metronidazole
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, DRUG1), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or DRUG2. ",negative,desmethyldiazepam,amoxicillin
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), DRUG1, DRUG2, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,diclofenac,naproxen
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), DRUG1, naproxen, DRUG2, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,diclofenac,piroxicam
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), DRUG1, naproxen, piroxicam, DRUG2, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,diclofenac,digoxin
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), DRUG1, naproxen, piroxicam, digoxin, DRUG2, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,diclofenac,ethanol
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), DRUG1, naproxen, piroxicam, digoxin, ethanol, DRUG2, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,diclofenac,glyburide
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), DRUG1, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral DRUG2 (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,diclofenac,contraceptive
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), DRUG1, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (DRUG2/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,diclofenac,levonorgestrel
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), DRUG1, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/DRUG2), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,diclofenac,ethinyl estradiol
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), DRUG1, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), DRUG2, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,diclofenac,metoprolol
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), DRUG1, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, DRUG2, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,diclofenac,nifedipine
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), DRUG1, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, DRUG2, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,diclofenac,phenytoin
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), DRUG1, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, DRUG2, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,diclofenac,warfarin
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), DRUG1, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, DRUG2, clarithromycin, metronidazole, or amoxicillin. ",negative,diclofenac,midazolam
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), DRUG1, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, DRUG2, metronidazole, or amoxicillin. ",negative,diclofenac,clarithromycin
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), DRUG1, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, DRUG2, or amoxicillin. ",negative,diclofenac,metronidazole
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), DRUG1, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or DRUG2. ",negative,diclofenac,amoxicillin
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, DRUG1, DRUG2, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,naproxen,piroxicam
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, DRUG1, piroxicam, DRUG2, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,naproxen,digoxin
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, DRUG1, piroxicam, digoxin, DRUG2, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,naproxen,ethanol
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, DRUG1, piroxicam, digoxin, ethanol, DRUG2, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,naproxen,glyburide
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, DRUG1, piroxicam, digoxin, ethanol, glyburide, an oral DRUG2 (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,naproxen,contraceptive
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, DRUG1, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (DRUG2/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,naproxen,levonorgestrel
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, DRUG1, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/DRUG2), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,naproxen,ethinyl estradiol
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, DRUG1, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), DRUG2, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,naproxen,metoprolol
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, DRUG1, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, DRUG2, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,naproxen,nifedipine
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, DRUG1, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, DRUG2, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,naproxen,phenytoin
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, DRUG1, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, DRUG2, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,naproxen,warfarin
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, DRUG1, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, DRUG2, clarithromycin, metronidazole, or amoxicillin. ",negative,naproxen,midazolam
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, DRUG1, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, DRUG2, metronidazole, or amoxicillin. ",negative,naproxen,clarithromycin
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, DRUG1, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, DRUG2, or amoxicillin. ",negative,naproxen,metronidazole
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, DRUG1, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or DRUG2. ",negative,naproxen,amoxicillin
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, DRUG1, DRUG2, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,piroxicam,digoxin
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, DRUG1, digoxin, DRUG2, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,piroxicam,ethanol
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, DRUG1, digoxin, ethanol, DRUG2, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,piroxicam,glyburide
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, DRUG1, digoxin, ethanol, glyburide, an oral DRUG2 (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,piroxicam,contraceptive
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, DRUG1, digoxin, ethanol, glyburide, an oral contraceptive (DRUG2/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,piroxicam,levonorgestrel
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, DRUG1, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/DRUG2), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,piroxicam,ethinyl estradiol
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, DRUG1, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), DRUG2, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,piroxicam,metoprolol
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, DRUG1, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, DRUG2, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,piroxicam,nifedipine
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, DRUG1, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, DRUG2, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,piroxicam,phenytoin
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, DRUG1, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, DRUG2, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,piroxicam,warfarin
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, DRUG1, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, DRUG2, clarithromycin, metronidazole, or amoxicillin. ",negative,piroxicam,midazolam
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, DRUG1, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, DRUG2, metronidazole, or amoxicillin. ",negative,piroxicam,clarithromycin
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, DRUG1, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, DRUG2, or amoxicillin. ",negative,piroxicam,metronidazole
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, DRUG1, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or DRUG2. ",negative,piroxicam,amoxicillin
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, DRUG1, DRUG2, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,digoxin,ethanol
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, DRUG1, ethanol, DRUG2, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,digoxin,glyburide
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, DRUG1, ethanol, glyburide, an oral DRUG2 (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,digoxin,contraceptive
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, DRUG1, ethanol, glyburide, an oral contraceptive (DRUG2/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,digoxin,levonorgestrel
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, DRUG1, ethanol, glyburide, an oral contraceptive (levonorgestrel/DRUG2), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,digoxin,ethinyl estradiol
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, DRUG1, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), DRUG2, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,digoxin,metoprolol
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, DRUG1, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, DRUG2, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,digoxin,nifedipine
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, DRUG1, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, DRUG2, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,digoxin,phenytoin
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, DRUG1, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, DRUG2, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,digoxin,warfarin
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, DRUG1, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, DRUG2, clarithromycin, metronidazole, or amoxicillin. ",negative,digoxin,midazolam
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, DRUG1, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, DRUG2, metronidazole, or amoxicillin. ",negative,digoxin,clarithromycin
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, DRUG1, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, DRUG2, or amoxicillin. ",negative,digoxin,metronidazole
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, DRUG1, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or DRUG2. ",negative,digoxin,amoxicillin
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, DRUG1, DRUG2, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,ethanol,glyburide
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, DRUG1, glyburide, an oral DRUG2 (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,ethanol,contraceptive
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, DRUG1, glyburide, an oral contraceptive (DRUG2/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,ethanol,levonorgestrel
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, DRUG1, glyburide, an oral contraceptive (levonorgestrel/DRUG2), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,ethanol,ethinyl estradiol
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, DRUG1, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), DRUG2, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,ethanol,metoprolol
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, DRUG1, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, DRUG2, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,ethanol,nifedipine
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, DRUG1, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, DRUG2, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,ethanol,phenytoin
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, DRUG1, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, DRUG2, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,ethanol,warfarin
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, DRUG1, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, DRUG2, clarithromycin, metronidazole, or amoxicillin. ",negative,ethanol,midazolam
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, DRUG1, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, DRUG2, metronidazole, or amoxicillin. ",negative,ethanol,clarithromycin
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, DRUG1, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, DRUG2, or amoxicillin. ",negative,ethanol,metronidazole
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, DRUG1, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or DRUG2. ",negative,ethanol,amoxicillin
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, DRUG1, an oral DRUG2 (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,glyburide,contraceptive
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, DRUG1, an oral contraceptive (DRUG2/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,glyburide,levonorgestrel
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, DRUG1, an oral contraceptive (levonorgestrel/DRUG2), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,glyburide,ethinyl estradiol
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, DRUG1, an oral contraceptive (levonorgestrel/ethinyl estradiol), DRUG2, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,glyburide,metoprolol
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, DRUG1, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, DRUG2, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,glyburide,nifedipine
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, DRUG1, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, DRUG2, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,glyburide,phenytoin
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, DRUG1, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, DRUG2, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,glyburide,warfarin
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, DRUG1, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, DRUG2, clarithromycin, metronidazole, or amoxicillin. ",negative,glyburide,midazolam
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, DRUG1, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, DRUG2, metronidazole, or amoxicillin. ",negative,glyburide,clarithromycin
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, DRUG1, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, DRUG2, or amoxicillin. ",negative,glyburide,metronidazole
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, DRUG1, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or DRUG2. ",negative,glyburide,amoxicillin
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral DRUG1 (DRUG2/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,contraceptive,levonorgestrel
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral DRUG1 (levonorgestrel/DRUG2), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,contraceptive,ethinyl estradiol
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral DRUG1 (levonorgestrel/ethinyl estradiol), DRUG2, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,contraceptive,metoprolol
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral DRUG1 (levonorgestrel/ethinyl estradiol), metoprolol, DRUG2, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,contraceptive,nifedipine
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral DRUG1 (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, DRUG2, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,contraceptive,phenytoin
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral DRUG1 (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, DRUG2, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,contraceptive,warfarin
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral DRUG1 (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, DRUG2, clarithromycin, metronidazole, or amoxicillin. ",negative,contraceptive,midazolam
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral DRUG1 (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, DRUG2, metronidazole, or amoxicillin. ",negative,contraceptive,clarithromycin
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral DRUG1 (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, DRUG2, or amoxicillin. ",negative,contraceptive,metronidazole
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral DRUG1 (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or DRUG2. ",negative,contraceptive,amoxicillin
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (DRUG1/DRUG2), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,levonorgestrel,ethinyl estradiol
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (DRUG1/ethinyl estradiol), DRUG2, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,levonorgestrel,metoprolol
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (DRUG1/ethinyl estradiol), metoprolol, DRUG2, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,levonorgestrel,nifedipine
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (DRUG1/ethinyl estradiol), metoprolol, nifedipine, DRUG2, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,levonorgestrel,phenytoin
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (DRUG1/ethinyl estradiol), metoprolol, nifedipine, phenytoin, DRUG2, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,levonorgestrel,warfarin
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (DRUG1/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, DRUG2, clarithromycin, metronidazole, or amoxicillin. ",negative,levonorgestrel,midazolam
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (DRUG1/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, DRUG2, metronidazole, or amoxicillin. ",negative,levonorgestrel,clarithromycin
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (DRUG1/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, DRUG2, or amoxicillin. ",negative,levonorgestrel,metronidazole
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (DRUG1/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or DRUG2. ",negative,levonorgestrel,amoxicillin
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/DRUG1), DRUG2, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,ethinyl estradiol,metoprolol
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/DRUG1), metoprolol, DRUG2, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,ethinyl estradiol,nifedipine
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/DRUG1), metoprolol, nifedipine, DRUG2, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,ethinyl estradiol,phenytoin
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/DRUG1), metoprolol, nifedipine, phenytoin, DRUG2, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,ethinyl estradiol,warfarin
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/DRUG1), metoprolol, nifedipine, phenytoin, warfarin, DRUG2, clarithromycin, metronidazole, or amoxicillin. ",negative,ethinyl estradiol,midazolam
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/DRUG1), metoprolol, nifedipine, phenytoin, warfarin, midazolam, DRUG2, metronidazole, or amoxicillin. ",negative,ethinyl estradiol,clarithromycin
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/DRUG1), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, DRUG2, or amoxicillin. ",negative,ethinyl estradiol,metronidazole
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/DRUG1), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or DRUG2. ",negative,ethinyl estradiol,amoxicillin
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), DRUG1, DRUG2, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,metoprolol,nifedipine
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), DRUG1, nifedipine, DRUG2, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,metoprolol,phenytoin
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), DRUG1, nifedipine, phenytoin, DRUG2, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,metoprolol,warfarin
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), DRUG1, nifedipine, phenytoin, warfarin, DRUG2, clarithromycin, metronidazole, or amoxicillin. ",negative,metoprolol,midazolam
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), DRUG1, nifedipine, phenytoin, warfarin, midazolam, DRUG2, metronidazole, or amoxicillin. ",negative,metoprolol,clarithromycin
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), DRUG1, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, DRUG2, or amoxicillin. ",negative,metoprolol,metronidazole
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), DRUG1, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or DRUG2. ",negative,metoprolol,amoxicillin
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, DRUG1, DRUG2, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,nifedipine,phenytoin
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, DRUG1, phenytoin, DRUG2, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,nifedipine,warfarin
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, DRUG1, phenytoin, warfarin, DRUG2, clarithromycin, metronidazole, or amoxicillin. ",negative,nifedipine,midazolam
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, DRUG1, phenytoin, warfarin, midazolam, DRUG2, metronidazole, or amoxicillin. ",negative,nifedipine,clarithromycin
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, DRUG1, phenytoin, warfarin, midazolam, clarithromycin, DRUG2, or amoxicillin. ",negative,nifedipine,metronidazole
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, DRUG1, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or DRUG2. ",negative,nifedipine,amoxicillin
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, DRUG1, DRUG2, midazolam, clarithromycin, metronidazole, or amoxicillin. ",negative,phenytoin,warfarin
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, DRUG1, warfarin, DRUG2, clarithromycin, metronidazole, or amoxicillin. ",negative,phenytoin,midazolam
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, DRUG1, warfarin, midazolam, DRUG2, metronidazole, or amoxicillin. ",negative,phenytoin,clarithromycin
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, DRUG1, warfarin, midazolam, clarithromycin, DRUG2, or amoxicillin. ",negative,phenytoin,metronidazole
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, DRUG1, warfarin, midazolam, clarithromycin, metronidazole, or DRUG2. ",negative,phenytoin,amoxicillin
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, DRUG1, DRUG2, clarithromycin, metronidazole, or amoxicillin. ",negative,warfarin,midazolam
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, DRUG1, midazolam, DRUG2, metronidazole, or amoxicillin. ",negative,warfarin,clarithromycin
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, DRUG1, midazolam, clarithromycin, DRUG2, or amoxicillin. ",negative,warfarin,metronidazole
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, DRUG1, midazolam, clarithromycin, metronidazole, or DRUG2. ",negative,warfarin,amoxicillin
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, DRUG1, DRUG2, metronidazole, or amoxicillin. ",negative,midazolam,clarithromycin
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, DRUG1, clarithromycin, DRUG2, or amoxicillin. ",negative,midazolam,metronidazole
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, DRUG1, clarithromycin, metronidazole, or DRUG2. ",negative,midazolam,amoxicillin
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, DRUG1, DRUG2, or amoxicillin. ",negative,clarithromycin,metronidazole
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, DRUG1, metronidazole, or DRUG2. ",negative,clarithromycin,amoxicillin
"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, DRUG1, or DRUG2. ",negative,metronidazole,amoxicillin
"Therefore, when coadministered with DRUG1, adjustment of the dosage of DRUG1 or of such drugs may not be necessary. ",negative,pantoprazole,pantoprazole
"There have been postmarketing reports of increased INR and prothrombin time in patients receiving DRUG1, including DRUG2, and warfarin concomitantly. ",negative,proton pump inhibitors,pantoprazole
"There have been postmarketing reports of increased INR and prothrombin time in patients receiving DRUG1, including pantoprazole, and DRUG2 concomitantly. ",effect,proton pump inhibitors,warfarin
"There have been postmarketing reports of increased INR and prothrombin time in patients receiving proton pump inhibitors, including DRUG1, and DRUG2 concomitantly. ",effect,pantoprazole,warfarin
Patients treated with DRUG1 and DRUG2 concomitantly should be monitored for increases in INR and prothrombin time. ,advise,proton pump inhibitors,warfarin
"Because of profound and long lasting inhibition of gastric acid secretion, DRUG1 may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (eg, DRUG2, ampicillin esters, and iron salts). ",mechanism,pantoprazole,ketoconazole
"Because of profound and long lasting inhibition of gastric acid secretion, DRUG1 may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (eg, ketoconazole, DRUG2 esters, and iron salts). ",mechanism,pantoprazole,ampicillin
"Because of profound and long lasting inhibition of gastric acid secretion, DRUG1 may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (eg, ketoconazole, ampicillin esters, and DRUG2 salts). ",mechanism,pantoprazole,iron
"Because of profound and long lasting inhibition of gastric acid secretion, pantoprazole may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (eg, DRUG1, DRUG2 esters, and iron salts). ",negative,ketoconazole,ampicillin
"Because of profound and long lasting inhibition of gastric acid secretion, pantoprazole may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (eg, DRUG1, ampicillin esters, and DRUG2 salts). ",negative,ketoconazole,iron
"Because of profound and long lasting inhibition of gastric acid secretion, pantoprazole may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (eg, ketoconazole, DRUG1 esters, and DRUG2 salts). ",negative,ampicillin,iron
"Laboratory Tests There have been reports of false-positive urine screening tests for DRUG1 (DRUG2) in patients receiving most proton pump inhibitors, including pantoprazole. ",negative,tetrahydrocannabinol,THC
"Laboratory Tests There have been reports of false-positive urine screening tests for DRUG1 (THC) in patients receiving most DRUG2, including pantoprazole. ",negative,tetrahydrocannabinol,proton pump inhibitors
"Laboratory Tests There have been reports of false-positive urine screening tests for DRUG1 (THC) in patients receiving most proton pump inhibitors, including DRUG2. ",negative,tetrahydrocannabinol,pantoprazole
"Laboratory Tests There have been reports of false-positive urine screening tests for tetrahydrocannabinol (DRUG1) in patients receiving most DRUG2, including pantoprazole. ",negative,THC,proton pump inhibitors
"Laboratory Tests There have been reports of false-positive urine screening tests for tetrahydrocannabinol (DRUG1) in patients receiving most proton pump inhibitors, including DRUG2. ",negative,THC,pantoprazole
"Laboratory Tests There have been reports of false-positive urine screening tests for tetrahydrocannabinol (THC) in patients receiving most DRUG1, including DRUG2. ",negative,proton pump inhibitors,pantoprazole
"Other eye drops or medications such as DRUG1 (DRUG2) and carbachol (Carboptic, Isopto Carbachol) may decrease the effects of suprofen ophthalmic.",negative,acetylcholine chloride,Miochol
"Other eye drops or medications such as DRUG1 (Miochol) and DRUG2 (Carboptic, Isopto DRUG2) may decrease the effects of suprofen ophthalmic.",negative,acetylcholine chloride,carbachol
"Other eye drops or medications such as DRUG1 (Miochol) and carbachol (DRUG2, Isopto Carbachol) may decrease the effects of suprofen ophthalmic.",negative,acetylcholine chloride,Carboptic
"Other eye drops or medications such as DRUG1 (Miochol) and carbachol (Carboptic, DRUG2) may decrease the effects of suprofen ophthalmic.",negative,acetylcholine chloride,Isopto Carbachol
"Other eye drops or medications such as DRUG1 (Miochol) and carbachol (Carboptic, Isopto Carbachol) may decrease the effects of DRUG2 ophthalmic.",effect,acetylcholine chloride,suprofen
"Other eye drops or medications such as acetylcholine chloride (DRUG1) and DRUG2 (Carboptic, Isopto DRUG2) may decrease the effects of suprofen ophthalmic.",negative,Miochol,carbachol
"Other eye drops or medications such as acetylcholine chloride (DRUG1) and carbachol (DRUG2, Isopto Carbachol) may decrease the effects of suprofen ophthalmic.",negative,Miochol,Carboptic
"Other eye drops or medications such as acetylcholine chloride (DRUG1) and carbachol (Carboptic, DRUG2) may decrease the effects of suprofen ophthalmic.",negative,Miochol,Isopto Carbachol
"Other eye drops or medications such as acetylcholine chloride (DRUG1) and carbachol (Carboptic, Isopto Carbachol) may decrease the effects of DRUG2 ophthalmic.",effect,Miochol,suprofen
"Other eye drops or medications such as acetylcholine chloride (Miochol) and DRUG1 (DRUG2, Isopto DRUG1) may decrease the effects of suprofen ophthalmic.",negative,carbachol,Carboptic
"Other eye drops or medications such as acetylcholine chloride (Miochol) and DRUG1 (Carboptic, Isopto DRUG1) may decrease the effects of suprofen ophthalmic.",negative,carbachol,Isopto Carbachol
"Other eye drops or medications such as acetylcholine chloride (Miochol) and DRUG1 (Carboptic, Isopto DRUG1) may decrease the effects of DRUG2 ophthalmic.",effect,carbachol,suprofen
"Other eye drops or medications such as acetylcholine chloride (Miochol) and carbachol (DRUG1, DRUG2) may decrease the effects of suprofen ophthalmic.",negative,Carboptic,Isopto Carbachol
"Other eye drops or medications such as acetylcholine chloride (Miochol) and carbachol (DRUG1, Isopto Carbachol) may decrease the effects of DRUG2 ophthalmic.",effect,Carboptic,suprofen
"Other eye drops or medications such as acetylcholine chloride (Miochol) and carbachol (Carboptic, DRUG1) may decrease the effects of DRUG2 ophthalmic.",effect,Isopto Carbachol,suprofen
"You cannot take DRUG1 if you have taken a DRUG2 (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. ",advise,mazindol,monoamine oxidase inhibitor
"You cannot take DRUG1 if you have taken a monoamine oxidase inhibitor (DRUG2) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. ",advise,mazindol,MAOI
"You cannot take DRUG1 if you have taken a monoamine oxidase inhibitor (MAOI) such as DRUG2 (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. ",advise,mazindol,isocarboxazid
"You cannot take DRUG1 if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (DRUG2), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. ",advise,mazindol,Marplan
"You cannot take DRUG1 if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), DRUG2 (Parnate), or phenelzine (Nardil) in the last 14 days. ",advise,mazindol,tranylcypromine
"You cannot take DRUG1 if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (DRUG2), or phenelzine (Nardil) in the last 14 days. ",advise,mazindol,Parnate
"You cannot take DRUG1 if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or DRUG2 (Nardil) in the last 14 days. ",advise,mazindol,phenelzine
"You cannot take DRUG1 if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (DRUG2) in the last 14 days. ",advise,mazindol,Nardil
"You cannot take mazindol if you have taken a DRUG1 (DRUG2) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. ",negative,monoamine oxidase inhibitor,MAOI
"You cannot take mazindol if you have taken a DRUG1 (MAOI) such as DRUG2 (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. ",negative,monoamine oxidase inhibitor,isocarboxazid
"You cannot take mazindol if you have taken a DRUG1 (MAOI) such as isocarboxazid (DRUG2), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. ",negative,monoamine oxidase inhibitor,Marplan
"You cannot take mazindol if you have taken a DRUG1 (MAOI) such as isocarboxazid (Marplan), DRUG2 (Parnate), or phenelzine (Nardil) in the last 14 days. ",negative,monoamine oxidase inhibitor,tranylcypromine
"You cannot take mazindol if you have taken a DRUG1 (MAOI) such as isocarboxazid (Marplan), tranylcypromine (DRUG2), or phenelzine (Nardil) in the last 14 days. ",negative,monoamine oxidase inhibitor,Parnate
"You cannot take mazindol if you have taken a DRUG1 (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or DRUG2 (Nardil) in the last 14 days. ",negative,monoamine oxidase inhibitor,phenelzine
"You cannot take mazindol if you have taken a DRUG1 (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (DRUG2) in the last 14 days. ",negative,monoamine oxidase inhibitor,Nardil
"You cannot take mazindol if you have taken a monoamine oxidase inhibitor (DRUG1) such as DRUG2 (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. ",negative,MAOI,isocarboxazid
"You cannot take mazindol if you have taken a monoamine oxidase inhibitor (DRUG1) such as isocarboxazid (DRUG2), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. ",negative,MAOI,Marplan
"You cannot take mazindol if you have taken a monoamine oxidase inhibitor (DRUG1) such as isocarboxazid (Marplan), DRUG2 (Parnate), or phenelzine (Nardil) in the last 14 days. ",negative,MAOI,tranylcypromine
"You cannot take mazindol if you have taken a monoamine oxidase inhibitor (DRUG1) such as isocarboxazid (Marplan), tranylcypromine (DRUG2), or phenelzine (Nardil) in the last 14 days. ",negative,MAOI,Parnate
"You cannot take mazindol if you have taken a monoamine oxidase inhibitor (DRUG1) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or DRUG2 (Nardil) in the last 14 days. ",negative,MAOI,phenelzine
"You cannot take mazindol if you have taken a monoamine oxidase inhibitor (DRUG1) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (DRUG2) in the last 14 days. ",negative,MAOI,Nardil
"You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as DRUG1 (DRUG2), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. ",negative,isocarboxazid,Marplan
"You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as DRUG1 (Marplan), DRUG2 (Parnate), or phenelzine (Nardil) in the last 14 days. ",negative,isocarboxazid,tranylcypromine
"You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as DRUG1 (Marplan), tranylcypromine (DRUG2), or phenelzine (Nardil) in the last 14 days. ",negative,isocarboxazid,Parnate
"You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as DRUG1 (Marplan), tranylcypromine (Parnate), or DRUG2 (Nardil) in the last 14 days. ",negative,isocarboxazid,phenelzine
"You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as DRUG1 (Marplan), tranylcypromine (Parnate), or phenelzine (DRUG2) in the last 14 days. ",negative,isocarboxazid,Nardil
"You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (DRUG1), DRUG2 (Parnate), or phenelzine (Nardil) in the last 14 days. ",negative,Marplan,tranylcypromine
"You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (DRUG1), tranylcypromine (DRUG2), or phenelzine (Nardil) in the last 14 days. ",negative,Marplan,Parnate
"You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (DRUG1), tranylcypromine (Parnate), or DRUG2 (Nardil) in the last 14 days. ",negative,Marplan,phenelzine
"You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (DRUG1), tranylcypromine (Parnate), or phenelzine (DRUG2) in the last 14 days. ",negative,Marplan,Nardil
"You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), DRUG1 (DRUG2), or phenelzine (Nardil) in the last 14 days. ",negative,tranylcypromine,Parnate
"You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), DRUG1 (Parnate), or DRUG2 (Nardil) in the last 14 days. ",negative,tranylcypromine,phenelzine
"You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), DRUG1 (Parnate), or phenelzine (DRUG2) in the last 14 days. ",negative,tranylcypromine,Nardil
"You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (DRUG1), or DRUG2 (Nardil) in the last 14 days. ",negative,Parnate,phenelzine
"You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (DRUG1), or phenelzine (DRUG2) in the last 14 days. ",negative,Parnate,Nardil
"You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or DRUG1 (DRUG2) in the last 14 days. ",negative,phenelzine,Nardil
Changes in DRUG1 and other diabetes drug therapies may be necessary during treatment with DRUG2.,advise,insulin,mazindol
DRUG1 may reduce the effects of DRUG2 (Ismelin). ,effect,Mazindol,guanethidine
DRUG1 may reduce the effects of guanethidine (DRUG2). ,effect,Mazindol,Ismelin
Mazindol may reduce the effects of DRUG1 (DRUG2). ,negative,guanethidine,Ismelin
"Before taking this medication, tell your doctor if you are taking a DRUG1 such as DRUG2 (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",negative,tricyclic antidepressant,amitriptyline
"Before taking this medication, tell your doctor if you are taking a DRUG1 such as amitriptyline (DRUG2), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",negative,tricyclic antidepressant,Elavil
"Before taking this medication, tell your doctor if you are taking a DRUG1 such as amitriptyline (Elavil), DRUG2 (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",negative,tricyclic antidepressant,amoxapine
"Before taking this medication, tell your doctor if you are taking a DRUG1 such as amitriptyline (Elavil), amoxapine (DRUG2), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",negative,tricyclic antidepressant,Asendin
"Before taking this medication, tell your doctor if you are taking a DRUG1 such as amitriptyline (Elavil), amoxapine (Asendin), DRUG2 (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",negative,tricyclic antidepressant,doxepin
"Before taking this medication, tell your doctor if you are taking a DRUG1 such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (DRUG2), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",negative,tricyclic antidepressant,Sinequan
"Before taking this medication, tell your doctor if you are taking a DRUG1 such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), DRUG2 (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",negative,tricyclic antidepressant,nortriptyline
"Before taking this medication, tell your doctor if you are taking a DRUG1 such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (DRUG2), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",negative,tricyclic antidepressant,Pamelor
"Before taking this medication, tell your doctor if you are taking a DRUG1 such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), DRUG2 (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",negative,tricyclic antidepressant,imipramine
"Before taking this medication, tell your doctor if you are taking a DRUG1 such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (DRUG2), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",negative,tricyclic antidepressant,Tofranil
"Before taking this medication, tell your doctor if you are taking a DRUG1 such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), DRUG2 (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",negative,tricyclic antidepressant,clomipramine
"Before taking this medication, tell your doctor if you are taking a DRUG1 such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (DRUG2), protriptyline (Vivactil), or desipramine (Norpramin). ",negative,tricyclic antidepressant,Anafranil
"Before taking this medication, tell your doctor if you are taking a DRUG1 such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), DRUG2 (Vivactil), or desipramine (Norpramin). ",negative,tricyclic antidepressant,protriptyline
"Before taking this medication, tell your doctor if you are taking a DRUG1 such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (DRUG2), or desipramine (Norpramin). ",negative,tricyclic antidepressant,Vivactil
"Before taking this medication, tell your doctor if you are taking a DRUG1 such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or DRUG2 (Norpramin). ",negative,tricyclic antidepressant,desipramine
"Before taking this medication, tell your doctor if you are taking a DRUG1 such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (DRUG2). ",negative,tricyclic antidepressant,Norpramin
"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as DRUG1 (DRUG2), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",negative,amitriptyline,Elavil
"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as DRUG1 (Elavil), DRUG2 (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",negative,amitriptyline,amoxapine
"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as DRUG1 (Elavil), amoxapine (DRUG2), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",negative,amitriptyline,Asendin
"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as DRUG1 (Elavil), amoxapine (Asendin), DRUG2 (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",negative,amitriptyline,doxepin
"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as DRUG1 (Elavil), amoxapine (Asendin), doxepin (DRUG2), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",negative,amitriptyline,Sinequan
"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as DRUG1 (Elavil), amoxapine (Asendin), doxepin (Sinequan), DRUG2 (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",negative,amitriptyline,nortriptyline
"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as DRUG1 (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (DRUG2), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",negative,amitriptyline,Pamelor
"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as DRUG1 (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), DRUG2 (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",negative,amitriptyline,imipramine
"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as DRUG1 (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (DRUG2), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",negative,amitriptyline,Tofranil
"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as DRUG1 (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), DRUG2 (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",negative,amitriptyline,clomipramine
"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as DRUG1 (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (DRUG2), protriptyline (Vivactil), or desipramine (Norpramin). ",negative,amitriptyline,Anafranil
"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as DRUG1 (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), DRUG2 (Vivactil), or desipramine (Norpramin). ",negative,amitriptyline,protriptyline
"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as DRUG1 (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (DRUG2), or desipramine (Norpramin). ",negative,amitriptyline,Vivactil
"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as DRUG1 (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or DRUG2 (Norpramin). ",negative,amitriptyline,desipramine
"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as DRUG1 (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (DRUG2). ",negative,amitriptyline,Norpramin
"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (DRUG1), DRUG2 (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",negative,Elavil,amoxapine
"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (DRUG1), amoxapine (DRUG2), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",negative,Elavil,Asendin
"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (DRUG1), amoxapine (Asendin), DRUG2 (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",negative,Elavil,doxepin
"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (DRUG1), amoxapine (Asendin), doxepin (DRUG2), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",negative,Elavil,Sinequan
"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (DRUG1), amoxapine (Asendin), doxepin (Sinequan), DRUG2 (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",negative,Elavil,nortriptyline
"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (DRUG1), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (DRUG2), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",negative,Elavil,Pamelor
"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (DRUG1), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), DRUG2 (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",negative,Elavil,imipramine
"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (DRUG1), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (DRUG2), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",negative,Elavil,Tofranil
"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (DRUG1), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), DRUG2 (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",negative,Elavil,clomipramine
"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (DRUG1), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (DRUG2), protriptyline (Vivactil), or desipramine (Norpramin). ",negative,Elavil,Anafranil
"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (DRUG1), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), DRUG2 (Vivactil), or desipramine (Norpramin). ",negative,Elavil,protriptyline
"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (DRUG1), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (DRUG2), or desipramine (Norpramin). ",negative,Elavil,Vivactil
"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (DRUG1), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or DRUG2 (Norpramin). ",negative,Elavil,desipramine
"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (DRUG1), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (DRUG2). ",negative,Elavil,Norpramin
"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), DRUG1 (DRUG2), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",negative,amoxapine,Asendin
"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), DRUG1 (Asendin), DRUG2 (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",negative,amoxapine,doxepin
"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), DRUG1 (Asendin), doxepin (DRUG2), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",negative,amoxapine,Sinequan
"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), DRUG1 (Asendin), doxepin (Sinequan), DRUG2 (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",negative,amoxapine,nortriptyline
"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), DRUG1 (Asendin), doxepin (Sinequan), nortriptyline (DRUG2), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",negative,amoxapine,Pamelor
"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), DRUG1 (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), DRUG2 (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",negative,amoxapine,imipramine
"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), DRUG1 (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (DRUG2), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",negative,amoxapine,Tofranil
"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), DRUG1 (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), DRUG2 (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",negative,amoxapine,clomipramine
"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), DRUG1 (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (DRUG2), protriptyline (Vivactil), or desipramine (Norpramin). ",negative,amoxapine,Anafranil
"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), DRUG1 (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), DRUG2 (Vivactil), or desipramine (Norpramin). ",negative,amoxapine,protriptyline
"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), DRUG1 (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (DRUG2), or desipramine (Norpramin). ",negative,amoxapine,Vivactil
"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), DRUG1 (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or DRUG2 (Norpramin). ",negative,amoxapine,desipramine
"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), DRUG1 (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (DRUG2). ",negative,amoxapine,Norpramin
"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (DRUG1), DRUG2 (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",negative,Asendin,doxepin
"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (DRUG1), doxepin (DRUG2), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",negative,Asendin,Sinequan
"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (DRUG1), doxepin (Sinequan), DRUG2 (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",negative,Asendin,nortriptyline
"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (DRUG1), doxepin (Sinequan), nortriptyline (DRUG2), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",negative,Asendin,Pamelor
"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (DRUG1), doxepin (Sinequan), nortriptyline (Pamelor), DRUG2 (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",negative,Asendin,imipramine
"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (DRUG1), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (DRUG2), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",negative,Asendin,Tofranil
"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (DRUG1), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), DRUG2 (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",negative,Asendin,clomipramine
"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (DRUG1), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (DRUG2), protriptyline (Vivactil), or desipramine (Norpramin). ",negative,Asendin,Anafranil
"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (DRUG1), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), DRUG2 (Vivactil), or desipramine (Norpramin). ",negative,Asendin,protriptyline
"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (DRUG1), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (DRUG2), or desipramine (Norpramin). ",negative,Asendin,Vivactil
"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (DRUG1), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or DRUG2 (Norpramin). ",negative,Asendin,desipramine
"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (DRUG1), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (DRUG2). ",negative,Asendin,Norpramin
"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), DRUG1 (DRUG2), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",negative,doxepin,Sinequan
"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), DRUG1 (Sinequan), DRUG2 (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",negative,doxepin,nortriptyline
"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), DRUG1 (Sinequan), nortriptyline (DRUG2), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",negative,doxepin,Pamelor
"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), DRUG1 (Sinequan), nortriptyline (Pamelor), DRUG2 (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",negative,doxepin,imipramine
"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), DRUG1 (Sinequan), nortriptyline (Pamelor), imipramine (DRUG2), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",negative,doxepin,Tofranil
"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), DRUG1 (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), DRUG2 (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",negative,doxepin,clomipramine
"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), DRUG1 (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (DRUG2), protriptyline (Vivactil), or desipramine (Norpramin). ",negative,doxepin,Anafranil
"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), DRUG1 (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), DRUG2 (Vivactil), or desipramine (Norpramin). ",negative,doxepin,protriptyline
"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), DRUG1 (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (DRUG2), or desipramine (Norpramin). ",negative,doxepin,Vivactil
"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), DRUG1 (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or DRUG2 (Norpramin). ",negative,doxepin,desipramine
"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), DRUG1 (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (DRUG2). ",negative,doxepin,Norpramin
"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (DRUG1), DRUG2 (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",negative,Sinequan,nortriptyline
"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (DRUG1), nortriptyline (DRUG2), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",negative,Sinequan,Pamelor
"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (DRUG1), nortriptyline (Pamelor), DRUG2 (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",negative,Sinequan,imipramine
"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (DRUG1), nortriptyline (Pamelor), imipramine (DRUG2), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",negative,Sinequan,Tofranil
"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (DRUG1), nortriptyline (Pamelor), imipramine (Tofranil), DRUG2 (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",negative,Sinequan,clomipramine
"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (DRUG1), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (DRUG2), protriptyline (Vivactil), or desipramine (Norpramin). ",negative,Sinequan,Anafranil
"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (DRUG1), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), DRUG2 (Vivactil), or desipramine (Norpramin). ",negative,Sinequan,protriptyline
"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (DRUG1), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (DRUG2), or desipramine (Norpramin). ",negative,Sinequan,Vivactil
"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (DRUG1), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or DRUG2 (Norpramin). ",negative,Sinequan,desipramine
"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (DRUG1), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (DRUG2). ",negative,Sinequan,Norpramin
"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), DRUG1 (DRUG2), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",negative,nortriptyline,Pamelor
"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), DRUG1 (Pamelor), DRUG2 (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",negative,nortriptyline,imipramine
"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), DRUG1 (Pamelor), imipramine (DRUG2), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",negative,nortriptyline,Tofranil
"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), DRUG1 (Pamelor), imipramine (Tofranil), DRUG2 (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",negative,nortriptyline,clomipramine
"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), DRUG1 (Pamelor), imipramine (Tofranil), clomipramine (DRUG2), protriptyline (Vivactil), or desipramine (Norpramin). ",negative,nortriptyline,Anafranil
"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), DRUG1 (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), DRUG2 (Vivactil), or desipramine (Norpramin). ",negative,nortriptyline,protriptyline
"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), DRUG1 (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (DRUG2), or desipramine (Norpramin). ",negative,nortriptyline,Vivactil
"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), DRUG1 (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or DRUG2 (Norpramin). ",negative,nortriptyline,desipramine
"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), DRUG1 (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (DRUG2). ",negative,nortriptyline,Norpramin
"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (DRUG1), DRUG2 (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",negative,Pamelor,imipramine
"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (DRUG1), imipramine (DRUG2), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",negative,Pamelor,Tofranil
"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (DRUG1), imipramine (Tofranil), DRUG2 (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",negative,Pamelor,clomipramine
"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (DRUG1), imipramine (Tofranil), clomipramine (DRUG2), protriptyline (Vivactil), or desipramine (Norpramin). ",negative,Pamelor,Anafranil
"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (DRUG1), imipramine (Tofranil), clomipramine (Anafranil), DRUG2 (Vivactil), or desipramine (Norpramin). ",negative,Pamelor,protriptyline
"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (DRUG1), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (DRUG2), or desipramine (Norpramin). ",negative,Pamelor,Vivactil
"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (DRUG1), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or DRUG2 (Norpramin). ",negative,Pamelor,desipramine
"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (DRUG1), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (DRUG2). ",negative,Pamelor,Norpramin
"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), DRUG1 (DRUG2), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",negative,imipramine,Tofranil
"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), DRUG1 (Tofranil), DRUG2 (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",negative,imipramine,clomipramine
"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), DRUG1 (Tofranil), clomipramine (DRUG2), protriptyline (Vivactil), or desipramine (Norpramin). ",negative,imipramine,Anafranil
"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), DRUG1 (Tofranil), clomipramine (Anafranil), DRUG2 (Vivactil), or desipramine (Norpramin). ",negative,imipramine,protriptyline
"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), DRUG1 (Tofranil), clomipramine (Anafranil), protriptyline (DRUG2), or desipramine (Norpramin). ",negative,imipramine,Vivactil
"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), DRUG1 (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or DRUG2 (Norpramin). ",negative,imipramine,desipramine
"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), DRUG1 (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (DRUG2). ",negative,imipramine,Norpramin
"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (DRUG1), DRUG2 (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ",negative,Tofranil,clomipramine
"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (DRUG1), clomipramine (DRUG2), protriptyline (Vivactil), or desipramine (Norpramin). ",negative,Tofranil,Anafranil
"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (DRUG1), clomipramine (Anafranil), DRUG2 (Vivactil), or desipramine (Norpramin). ",negative,Tofranil,protriptyline
"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (DRUG1), clomipramine (Anafranil), protriptyline (DRUG2), or desipramine (Norpramin). ",negative,Tofranil,Vivactil
"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (DRUG1), clomipramine (Anafranil), protriptyline (Vivactil), or DRUG2 (Norpramin). ",negative,Tofranil,desipramine
"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (DRUG1), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (DRUG2). ",negative,Tofranil,Norpramin
"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), DRUG1 (DRUG2), protriptyline (Vivactil), or desipramine (Norpramin). ",negative,clomipramine,Anafranil
"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), DRUG1 (Anafranil), DRUG2 (Vivactil), or desipramine (Norpramin). ",negative,clomipramine,protriptyline
"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), DRUG1 (Anafranil), protriptyline (DRUG2), or desipramine (Norpramin). ",negative,clomipramine,Vivactil
"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), DRUG1 (Anafranil), protriptyline (Vivactil), or DRUG2 (Norpramin). ",negative,clomipramine,desipramine
"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), DRUG1 (Anafranil), protriptyline (Vivactil), or desipramine (DRUG2). ",negative,clomipramine,Norpramin
"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (DRUG1), DRUG2 (Vivactil), or desipramine (Norpramin). ",negative,Anafranil,protriptyline
"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (DRUG1), protriptyline (DRUG2), or desipramine (Norpramin). ",negative,Anafranil,Vivactil
"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (DRUG1), protriptyline (Vivactil), or DRUG2 (Norpramin). ",negative,Anafranil,desipramine
"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (DRUG1), protriptyline (Vivactil), or desipramine (DRUG2). ",negative,Anafranil,Norpramin
"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), DRUG1 (DRUG2), or desipramine (Norpramin). ",negative,protriptyline,Vivactil
"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), DRUG1 (Vivactil), or DRUG2 (Norpramin). ",negative,protriptyline,desipramine
"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), DRUG1 (Vivactil), or desipramine (DRUG2). ",negative,protriptyline,Norpramin
"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (DRUG1), or DRUG2 (Norpramin). ",negative,Vivactil,desipramine
"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (DRUG1), or desipramine (DRUG2). ",negative,Vivactil,Norpramin
"Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or DRUG1 (DRUG2). ",negative,desipramine,Norpramin
Pharmacokinetic properties of DRUG1 were not altered by the addition of either DRUG2 or zidovudine or the combination of DRUG2 and zidovudine. ,negative,abacavir,lamivudine
Pharmacokinetic properties of DRUG1 were not altered by the addition of either lamivudine or DRUG2 or the combination of lamivudine and DRUG2. ,negative,abacavir,zidovudine
Pharmacokinetic properties of DRUG1 were not altered by the addition of either DRUG2 or zidovudine or the combination of DRUG2 and zidovudine. ,negative,abacavir,lamivudine
Pharmacokinetic properties of DRUG1 were not altered by the addition of either lamivudine or DRUG2 or the combination of lamivudine and DRUG2. ,negative,abacavir,zidovudine
Pharmacokinetic properties of abacavir were not altered by the addition of either DRUG1 or DRUG2 or the combination of DRUG1 and DRUG2. ,negative,lamivudine,zidovudine
Pharmacokinetic properties of abacavir were not altered by the addition of either DRUG1 or zidovudine or the combination of DRUG1 and zidovudine. ,negative,lamivudine,lamivudine
Pharmacokinetic properties of abacavir were not altered by the addition of either DRUG1 or DRUG2 or the combination of DRUG1 and DRUG2. ,negative,lamivudine,zidovudine
Pharmacokinetic properties of abacavir were not altered by the addition of either DRUG2 or DRUG1 or the combination of DRUG2 and DRUG1. ,negative,zidovudine,lamivudine
Pharmacokinetic properties of abacavir were not altered by the addition of either lamivudine or DRUG1 or the combination of lamivudine and DRUG1. ,negative,zidovudine,zidovudine
Pharmacokinetic properties of abacavir were not altered by the addition of either DRUG1 or DRUG2 or the combination of DRUG1 and DRUG2. ,negative,lamivudine,zidovudine
No clinically significant changes to DRUG1 or DRUG2 pharmacokinetics were observed following concomitant administration of abacavir. ,negative,lamivudine,zidovudine
No clinically significant changes to DRUG1 or zidovudine pharmacokinetics were observed following concomitant administration of DRUG2. ,negative,lamivudine,abacavir
No clinically significant changes to lamivudine or DRUG1 pharmacokinetics were observed following concomitant administration of DRUG2. ,negative,zidovudine,abacavir
DRUG1 has no effect on the pharmacokinetic properties of DRUG2. ,negative,Abacavir,ethanol
DRUG1 decreases the elimination of DRUG2 causing an increase in overall exposure . The addition of methadone has no clinically significant effect on the pharmacokinetic properties of DRUG2. ,mechanism,Ethanol,abacavir
DRUG1 decreases the elimination of abacavir causing an increase in overall exposure . The addition of DRUG2 has no clinically significant effect on the pharmacokinetic properties of abacavir. ,negative,Ethanol,methadone
DRUG1 decreases the elimination of DRUG2 causing an increase in overall exposure . The addition of methadone has no clinically significant effect on the pharmacokinetic properties of DRUG2. ,negative,Ethanol,abacavir
Ethanol decreases the elimination of DRUG1 causing an increase in overall exposure . The addition of DRUG2 has no clinically significant effect on the pharmacokinetic properties of DRUG1. ,negative,abacavir,methadone
Ethanol decreases the elimination of DRUG1 causing an increase in overall exposure . The addition of methadone has no clinically significant effect on the pharmacokinetic properties of DRUG1. ,negative,abacavir,abacavir
Ethanol decreases the elimination of DRUG2 causing an increase in overall exposure . The addition of DRUG1 has no clinically significant effect on the pharmacokinetic properties of DRUG2. ,negative,methadone,abacavir
"In a study of 11 HIV-infected patients receiving DRUG1-maintenance therapy (40 mg and 90 mg daily) with 600 mg of DRUG2 twice daily (twice the currently recommended dose), oral DRUG1 clearance increased 22% (90% CI 6% to 42%). ",mechanism,methadone,ZIAGEN
"In a study of 11 HIV-infected patients receiving DRUG1-maintenance therapy (40 mg and 90 mg daily) with 600 mg of ZIAGEN twice daily (twice the currently recommended dose), oral DRUG1 clearance increased 22% (90% CI 6% to 42%). ",negative,methadone,methadone
"In a study of 11 HIV-infected patients receiving DRUG2-maintenance therapy (40 mg and 90 mg daily) with 600 mg of DRUG1 twice daily (twice the currently recommended dose), oral DRUG2 clearance increased 22% (90% CI 6% to 42%). ",negative,ZIAGEN,methadone
"DRUG1 may increase the effects of DRUG2, tolbutamide, and uricosurics. ",effect,Sulfoxone,barbiturates
"DRUG1 may increase the effects of barbiturates, DRUG2, and uricosurics. ",effect,Sulfoxone,tolbutamide
"DRUG1 may increase the effects of barbiturates, tolbutamide, and DRUG2. ",effect,Sulfoxone,uricosurics
"Sulfoxone may increase the effects of DRUG1, DRUG2, and uricosurics. ",negative,barbiturates,tolbutamide
"Sulfoxone may increase the effects of DRUG1, tolbutamide, and DRUG2. ",negative,barbiturates,uricosurics
"Sulfoxone may increase the effects of barbiturates, DRUG1, and DRUG2. ",negative,tolbutamide,uricosurics
"It may also interact with DRUG1 (increased thrombocytopenia), DRUG2 (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).",negative,thiazides,cyclosporine
"It may also interact with DRUG1 (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), DRUG2 (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).",negative,thiazides,sulfonylurea agents
"It may also interact with DRUG1 (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), DRUG2 (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).",negative,thiazides,warfarin
"It may also interact with DRUG1 (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), DRUG2 (decreased renal excretion of DRUG2), phenytoin (decreased hepatic clearance of phenytoin).",negative,thiazides,methotrexate
"It may also interact with DRUG1 (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), DRUG2 (decreased renal excretion of DRUG2), phenytoin (decreased hepatic clearance of phenytoin).",negative,thiazides,methotrexate
"It may also interact with DRUG1 (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), DRUG2 (decreased hepatic clearance of DRUG2).",negative,thiazides,phenytoin
"It may also interact with DRUG1 (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), DRUG2 (decreased hepatic clearance of DRUG2).",negative,thiazides,phenytoin
"It may also interact with thiazides (increased thrombocytopenia), DRUG1 (increased nephrotoxicity), DRUG2 (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).",negative,cyclosporine,sulfonylurea agents
"It may also interact with thiazides (increased thrombocytopenia), DRUG1 (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), DRUG2 (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).",negative,cyclosporine,warfarin
"It may also interact with thiazides (increased thrombocytopenia), DRUG1 (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), DRUG2 (decreased renal excretion of DRUG2), phenytoin (decreased hepatic clearance of phenytoin).",negative,cyclosporine,methotrexate
"It may also interact with thiazides (increased thrombocytopenia), DRUG1 (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), DRUG2 (decreased renal excretion of DRUG2), phenytoin (decreased hepatic clearance of phenytoin).",negative,cyclosporine,methotrexate
"It may also interact with thiazides (increased thrombocytopenia), DRUG1 (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), DRUG2 (decreased hepatic clearance of DRUG2).",negative,cyclosporine,phenytoin
"It may also interact with thiazides (increased thrombocytopenia), DRUG1 (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), DRUG2 (decreased hepatic clearance of DRUG2).",negative,cyclosporine,phenytoin
"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), DRUG1 (increased hypoglycemic response), DRUG2 (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).",negative,sulfonylurea agents,warfarin
"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), DRUG1 (increased hypoglycemic response), warfarin (increased anticoagulant effect), DRUG2 (decreased renal excretion of DRUG2), phenytoin (decreased hepatic clearance of phenytoin).",negative,sulfonylurea agents,methotrexate
"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), DRUG1 (increased hypoglycemic response), warfarin (increased anticoagulant effect), DRUG2 (decreased renal excretion of DRUG2), phenytoin (decreased hepatic clearance of phenytoin).",negative,sulfonylurea agents,methotrexate
"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), DRUG1 (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), DRUG2 (decreased hepatic clearance of DRUG2).",negative,sulfonylurea agents,phenytoin
"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), DRUG1 (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), DRUG2 (decreased hepatic clearance of DRUG2).",negative,sulfonylurea agents,phenytoin
"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), DRUG1 (increased anticoagulant effect), DRUG2 (decreased renal excretion of DRUG2), phenytoin (decreased hepatic clearance of phenytoin).",negative,warfarin,methotrexate
"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), DRUG1 (increased anticoagulant effect), DRUG2 (decreased renal excretion of DRUG2), phenytoin (decreased hepatic clearance of phenytoin).",negative,warfarin,methotrexate
"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), DRUG1 (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), DRUG2 (decreased hepatic clearance of DRUG2).",negative,warfarin,phenytoin
"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), DRUG1 (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), DRUG2 (decreased hepatic clearance of DRUG2).",negative,warfarin,phenytoin
"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), DRUG1 (decreased renal excretion of DRUG1), phenytoin (decreased hepatic clearance of phenytoin).",negative,methotrexate,methotrexate
"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), DRUG1 (decreased renal excretion of DRUG1), DRUG2 (decreased hepatic clearance of DRUG2).",negative,methotrexate,phenytoin
"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), DRUG1 (decreased renal excretion of DRUG1), DRUG2 (decreased hepatic clearance of DRUG2).",negative,methotrexate,phenytoin
"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), DRUG1 (decreased renal excretion of DRUG1), DRUG2 (decreased hepatic clearance of DRUG2).",negative,methotrexate,phenytoin
"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), DRUG1 (decreased renal excretion of DRUG1), DRUG2 (decreased hepatic clearance of DRUG2).",negative,methotrexate,phenytoin
"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), DRUG1 (decreased hepatic clearance of DRUG1).",negative,phenytoin,phenytoin
"DRUG1 are capable of potentiating DRUG2 (e.g., barbiturates, anesthetics, opiates, alcohol, etc.) ",effect,Phenothiazines,CNS depressants
"DRUG1 are capable of potentiating CNS depressants (e.g., DRUG2, anesthetics, opiates, alcohol, etc.) ",effect,Phenothiazines,barbiturates
"DRUG1 are capable of potentiating CNS depressants (e.g., barbiturates, DRUG2, opiates, alcohol, etc.) ",effect,Phenothiazines,anesthetics
"DRUG1 are capable of potentiating CNS depressants (e.g., barbiturates, anesthetics, DRUG2, alcohol, etc.) ",effect,Phenothiazines,opiates
"DRUG1 are capable of potentiating CNS depressants (e.g., barbiturates, anesthetics, opiates, DRUG2, etc.) ",effect,Phenothiazines,alcohol
"Phenothiazines are capable of potentiating DRUG1 (e.g., DRUG2, anesthetics, opiates, alcohol, etc.) ",negative,CNS depressants,barbiturates
"Phenothiazines are capable of potentiating DRUG1 (e.g., barbiturates, DRUG2, opiates, alcohol, etc.) ",negative,CNS depressants,anesthetics
"Phenothiazines are capable of potentiating DRUG1 (e.g., barbiturates, anesthetics, DRUG2, alcohol, etc.) ",negative,CNS depressants,opiates
"Phenothiazines are capable of potentiating DRUG1 (e.g., barbiturates, anesthetics, opiates, DRUG2, etc.) ",negative,CNS depressants,alcohol
"Phenothiazines are capable of potentiating CNS depressants (e.g., DRUG1, DRUG2, opiates, alcohol, etc.) ",negative,barbiturates,anesthetics
"Phenothiazines are capable of potentiating CNS depressants (e.g., DRUG1, anesthetics, DRUG2, alcohol, etc.) ",negative,barbiturates,opiates
"Phenothiazines are capable of potentiating CNS depressants (e.g., DRUG1, anesthetics, opiates, DRUG2, etc.) ",negative,barbiturates,alcohol
"Phenothiazines are capable of potentiating CNS depressants (e.g., barbiturates, DRUG1, DRUG2, alcohol, etc.) ",negative,anesthetics,opiates
"Phenothiazines are capable of potentiating CNS depressants (e.g., barbiturates, DRUG1, opiates, DRUG2, etc.) ",negative,anesthetics,alcohol
"Phenothiazines are capable of potentiating CNS depressants (e.g., barbiturates, anesthetics, DRUG1, DRUG2, etc.) ",negative,opiates,alcohol
as well as DRUG1 and DRUG2.,negative,atropine,phosphorous insecticides
Pharmacokinetic studies show that there are no significant alterations in pharmacokinetic parameters of DRUG1 or DRUG2 to warrant dosage adjustment when megestrol acetate is administered with these drugs. ,negative,zidovudine,rifabutin
Pharmacokinetic studies show that there are no significant alterations in pharmacokinetic parameters of DRUG1 or rifabutin to warrant dosage adjustment when DRUG2 is administered with these drugs. ,negative,zidovudine,megestrol acetate
Pharmacokinetic studies show that there are no significant alterations in pharmacokinetic parameters of zidovudine or DRUG1 to warrant dosage adjustment when DRUG2 is administered with these drugs. ,negative,rifabutin,megestrol acetate
A pharmacokinetic study demonstrated that coadministration of DRUG1 and DRUG2 results in a significant decrease in the pharmacokinetic parameters (~36% for Cmax and ~28% for AUC) of DRUG2. ,mechanism,megestrol acetate,indinavir
A pharmacokinetic study demonstrated that coadministration of DRUG1 and DRUG2 results in a significant decrease in the pharmacokinetic parameters (~36% for Cmax and ~28% for AUC) of DRUG2. ,negative,megestrol acetate,indinavir
A pharmacokinetic study demonstrated that coadministration of megestrol acetate and DRUG1 results in a significant decrease in the pharmacokinetic parameters (~36% for Cmax and ~28% for AUC) of DRUG1. ,negative,indinavir,indinavir
Administration of a higher dose of DRUG1 should be considered when coadministering with DRUG2. ,advise,indinavir,megestrol acetate
"The effects of DRUG1, DRUG2 or rifabutin on the pharmacokinetics of megestrol acetate were not studied.",negative,indinavir,zidovudine
"The effects of DRUG1, zidovudine or DRUG2 on the pharmacokinetics of megestrol acetate were not studied.",negative,indinavir,rifabutin
"The effects of DRUG1, zidovudine or rifabutin on the pharmacokinetics of DRUG2 were not studied.",negative,indinavir,megestrol acetate
"The effects of indinavir, DRUG1 or DRUG2 on the pharmacokinetics of megestrol acetate were not studied.",negative,zidovudine,rifabutin
"The effects of indinavir, DRUG1 or rifabutin on the pharmacokinetics of DRUG2 were not studied.",negative,zidovudine,megestrol acetate
"The effects of indinavir, zidovudine or DRUG1 on the pharmacokinetics of DRUG2 were not studied.",negative,rifabutin,megestrol acetate
DRUG1 has been reported to prolong the elimination half-life of DRUG2 and may lead to severe bone marrow suppression; ,mechanism,Streptozocin,doxorubicin
a reduction of the DRUG1 dosage should be considered in patients receiving DRUG2 concurrently. ,advise,doxorubicin,ZANOSAR
The concurrent use of DRUG1 and DRUG2 has been reported in one case to result in reduced DRUG1 cytotoxicity.    ,effect,streptozocin,phenytoin
The concurrent use of DRUG1 and phenytoin has been reported in one case to result in reduced DRUG1 cytotoxicity.    ,negative,streptozocin,streptozocin
The concurrent use of DRUG2 and DRUG1 has been reported in one case to result in reduced DRUG2 cytotoxicity.    ,negative,phenytoin,streptozocin
"DRUG1 should be used with caution in digitalized patients, since the combination of DRUG2 and sympathomimetic amines may cause ectopic arrhythmias. ",negative,ARAMINE,digitalis
"DRUG1 should be used with caution in digitalized patients, since the combination of digitalis and DRUG2 may cause ectopic arrhythmias. ",negative,ARAMINE,sympathomimetic amines
"ARAMINE should be used with caution in digitalized patients, since the combination of DRUG1 and DRUG2 may cause ectopic arrhythmias. ",effect,digitalis,sympathomimetic amines
DRUG1 or DRUG2 may potentiate the action of sympathomimetic amines. ,negative,Monoamine oxidase inhibitors,tricyclic antidepressants
DRUG1 or tricyclic antidepressants may potentiate the action of DRUG2. ,effect,Monoamine oxidase inhibitors,sympathomimetic amines
Monoamine oxidase inhibitors or DRUG1 may potentiate the action of DRUG2. ,effect,tricyclic antidepressants,sympathomimetic amines
"DRUG1 can interact with DRUG2, antichlolinergic, TCA, MAOIs, and alcohol.",int,Mequitazine,CNS depressant
"DRUG1 can interact with CNS depressant, DRUG2, TCA, MAOIs, and alcohol.",int,Mequitazine,antichlolinergic
"DRUG1 can interact with CNS depressant, antichlolinergic, DRUG2, MAOIs, and alcohol.",int,Mequitazine,TCA
"DRUG1 can interact with CNS depressant, antichlolinergic, TCA, DRUG2, and alcohol.",int,Mequitazine,MAOIs
"DRUG1 can interact with CNS depressant, antichlolinergic, TCA, MAOIs, and DRUG2.",int,Mequitazine,alcohol
"Mequitazine can interact with DRUG1, DRUG2, TCA, MAOIs, and alcohol.",negative,CNS depressant,antichlolinergic
"Mequitazine can interact with DRUG1, antichlolinergic, DRUG2, MAOIs, and alcohol.",negative,CNS depressant,TCA
"Mequitazine can interact with DRUG1, antichlolinergic, TCA, DRUG2, and alcohol.",negative,CNS depressant,MAOIs
"Mequitazine can interact with DRUG1, antichlolinergic, TCA, MAOIs, and DRUG2.",negative,CNS depressant,alcohol
"Mequitazine can interact with CNS depressant, DRUG1, DRUG2, MAOIs, and alcohol.",negative,antichlolinergic,TCA
"Mequitazine can interact with CNS depressant, DRUG1, TCA, DRUG2, and alcohol.",negative,antichlolinergic,MAOIs
"Mequitazine can interact with CNS depressant, DRUG1, TCA, MAOIs, and DRUG2.",negative,antichlolinergic,alcohol
"Mequitazine can interact with CNS depressant, antichlolinergic, DRUG1, DRUG2, and alcohol.",negative,TCA,MAOIs
"Mequitazine can interact with CNS depressant, antichlolinergic, DRUG1, MAOIs, and DRUG2.",negative,TCA,alcohol
"Mequitazine can interact with CNS depressant, antichlolinergic, TCA, DRUG1, and DRUG2.",negative,MAOIs,alcohol
"DRUG1 may decrease the effectiveness of oral DRUG2, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.",int,Barbiturates,contraceptives
"DRUG1 may decrease the effectiveness of oral contraceptives, certain DRUG2, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.",int,Barbiturates,antibiotics
"DRUG1 may decrease the effectiveness of oral contraceptives, certain antibiotics, DRUG2, theophylline, corticosteroids, anticoagulants, and beta blockers.",int,Barbiturates,quinidine
"DRUG1 may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, DRUG2, corticosteroids, anticoagulants, and beta blockers.",int,Barbiturates,theophylline
"DRUG1 may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, DRUG2, anticoagulants, and beta blockers.",int,Barbiturates,corticosteroids
"DRUG1 may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, DRUG2, and beta blockers.",int,Barbiturates,anticoagulants
"DRUG1 may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and DRUG2.",int,Barbiturates,beta blockers
"Barbiturates may decrease the effectiveness of oral DRUG1, certain DRUG2, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.",negative,contraceptives,antibiotics
"Barbiturates may decrease the effectiveness of oral DRUG1, certain antibiotics, DRUG2, theophylline, corticosteroids, anticoagulants, and beta blockers.",negative,contraceptives,quinidine
"Barbiturates may decrease the effectiveness of oral DRUG1, certain antibiotics, quinidine, DRUG2, corticosteroids, anticoagulants, and beta blockers.",negative,contraceptives,theophylline
"Barbiturates may decrease the effectiveness of oral DRUG1, certain antibiotics, quinidine, theophylline, DRUG2, anticoagulants, and beta blockers.",negative,contraceptives,corticosteroids
"Barbiturates may decrease the effectiveness of oral DRUG1, certain antibiotics, quinidine, theophylline, corticosteroids, DRUG2, and beta blockers.",negative,contraceptives,anticoagulants
"Barbiturates may decrease the effectiveness of oral DRUG1, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and DRUG2.",negative,contraceptives,beta blockers
"Barbiturates may decrease the effectiveness of oral contraceptives, certain DRUG1, DRUG2, theophylline, corticosteroids, anticoagulants, and beta blockers.",negative,antibiotics,quinidine
"Barbiturates may decrease the effectiveness of oral contraceptives, certain DRUG1, quinidine, DRUG2, corticosteroids, anticoagulants, and beta blockers.",negative,antibiotics,theophylline
"Barbiturates may decrease the effectiveness of oral contraceptives, certain DRUG1, quinidine, theophylline, DRUG2, anticoagulants, and beta blockers.",negative,antibiotics,corticosteroids
"Barbiturates may decrease the effectiveness of oral contraceptives, certain DRUG1, quinidine, theophylline, corticosteroids, DRUG2, and beta blockers.",negative,antibiotics,anticoagulants
"Barbiturates may decrease the effectiveness of oral contraceptives, certain DRUG1, quinidine, theophylline, corticosteroids, anticoagulants, and DRUG2.",negative,antibiotics,beta blockers
"Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, DRUG1, DRUG2, corticosteroids, anticoagulants, and beta blockers.",negative,quinidine,theophylline
"Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, DRUG1, theophylline, DRUG2, anticoagulants, and beta blockers.",negative,quinidine,corticosteroids
"Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, DRUG1, theophylline, corticosteroids, DRUG2, and beta blockers.",negative,quinidine,anticoagulants
"Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, DRUG1, theophylline, corticosteroids, anticoagulants, and DRUG2.",negative,quinidine,beta blockers
"Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, DRUG1, DRUG2, anticoagulants, and beta blockers.",negative,theophylline,corticosteroids
"Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, DRUG1, corticosteroids, DRUG2, and beta blockers.",negative,theophylline,anticoagulants
"Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, DRUG1, corticosteroids, anticoagulants, and DRUG2.",negative,theophylline,beta blockers
"Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, DRUG1, DRUG2, and beta blockers.",negative,corticosteroids,anticoagulants
"Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, DRUG1, anticoagulants, and DRUG2.",negative,corticosteroids,beta blockers
"Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, DRUG1, and DRUG2.",negative,anticoagulants,beta blockers
"DRUG1 may increase the effects of DRUG2, tolbutamide, and uricosurics. ",effect,Sulfamethizole,barbiturates
"DRUG1 may increase the effects of barbiturates, DRUG2, and uricosurics. ",effect,Sulfamethizole,tolbutamide
"DRUG1 may increase the effects of barbiturates, tolbutamide, and DRUG2. ",effect,Sulfamethizole,uricosurics
"Sulfamethizole may increase the effects of DRUG1, DRUG2, and uricosurics. ",negative,barbiturates,tolbutamide
"Sulfamethizole may increase the effects of DRUG1, tolbutamide, and DRUG2. ",negative,barbiturates,uricosurics
"Sulfamethizole may increase the effects of barbiturates, DRUG1, and DRUG2. ",negative,tolbutamide,uricosurics
"It may also interact with DRUG1 (increased thrombocytopenia), DRUG2 (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).",negative,thiazides,cyclosporine
"It may also interact with DRUG1 (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), DRUG2 (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).",negative,thiazides,sulfonylurea agents
"It may also interact with DRUG1 (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), DRUG2 (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).",negative,thiazides,warfarin
"It may also interact with DRUG1 (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), DRUG2 (decreased renal excretion of DRUG2), phenytoin (decreased hepatic clearance of phenytoin).",negative,thiazides,methotrexate
"It may also interact with DRUG1 (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), DRUG2 (decreased renal excretion of DRUG2), phenytoin (decreased hepatic clearance of phenytoin).",negative,thiazides,methotrexate
"It may also interact with DRUG1 (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), DRUG2 (decreased hepatic clearance of DRUG2).",negative,thiazides,phenytoin
"It may also interact with DRUG1 (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), DRUG2 (decreased hepatic clearance of DRUG2).",negative,thiazides,phenytoin
"It may also interact with thiazides (increased thrombocytopenia), DRUG1 (increased nephrotoxicity), DRUG2 (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).",negative,cyclosporine,sulfonylurea agents
"It may also interact with thiazides (increased thrombocytopenia), DRUG1 (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), DRUG2 (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).",negative,cyclosporine,warfarin
"It may also interact with thiazides (increased thrombocytopenia), DRUG1 (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), DRUG2 (decreased renal excretion of DRUG2), phenytoin (decreased hepatic clearance of phenytoin).",negative,cyclosporine,methotrexate
"It may also interact with thiazides (increased thrombocytopenia), DRUG1 (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), DRUG2 (decreased renal excretion of DRUG2), phenytoin (decreased hepatic clearance of phenytoin).",negative,cyclosporine,methotrexate
"It may also interact with thiazides (increased thrombocytopenia), DRUG1 (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), DRUG2 (decreased hepatic clearance of DRUG2).",negative,cyclosporine,phenytoin
"It may also interact with thiazides (increased thrombocytopenia), DRUG1 (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), DRUG2 (decreased hepatic clearance of DRUG2).",negative,cyclosporine,phenytoin
"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), DRUG1 (increased hypoglycemic response), DRUG2 (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).",negative,sulfonylurea agents,warfarin
"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), DRUG1 (increased hypoglycemic response), warfarin (increased anticoagulant effect), DRUG2 (decreased renal excretion of DRUG2), phenytoin (decreased hepatic clearance of phenytoin).",negative,sulfonylurea agents,methotrexate
"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), DRUG1 (increased hypoglycemic response), warfarin (increased anticoagulant effect), DRUG2 (decreased renal excretion of DRUG2), phenytoin (decreased hepatic clearance of phenytoin).",negative,sulfonylurea agents,methotrexate
"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), DRUG1 (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), DRUG2 (decreased hepatic clearance of DRUG2).",negative,sulfonylurea agents,phenytoin
"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), DRUG1 (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), DRUG2 (decreased hepatic clearance of DRUG2).",negative,sulfonylurea agents,phenytoin
"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), DRUG1 (increased anticoagulant effect), DRUG2 (decreased renal excretion of DRUG2), phenytoin (decreased hepatic clearance of phenytoin).",negative,warfarin,methotrexate
"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), DRUG1 (increased anticoagulant effect), DRUG2 (decreased renal excretion of DRUG2), phenytoin (decreased hepatic clearance of phenytoin).",negative,warfarin,methotrexate
"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), DRUG1 (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), DRUG2 (decreased hepatic clearance of DRUG2).",negative,warfarin,phenytoin
"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), DRUG1 (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), DRUG2 (decreased hepatic clearance of DRUG2).",negative,warfarin,phenytoin
"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), DRUG1 (decreased renal excretion of DRUG1), phenytoin (decreased hepatic clearance of phenytoin).",negative,methotrexate,methotrexate
"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), DRUG1 (decreased renal excretion of DRUG1), DRUG2 (decreased hepatic clearance of DRUG2).",negative,methotrexate,phenytoin
"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), DRUG1 (decreased renal excretion of DRUG1), DRUG2 (decreased hepatic clearance of DRUG2).",negative,methotrexate,phenytoin
"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), DRUG1 (decreased renal excretion of DRUG1), DRUG2 (decreased hepatic clearance of DRUG2).",negative,methotrexate,phenytoin
"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), DRUG1 (decreased renal excretion of DRUG1), DRUG2 (decreased hepatic clearance of DRUG2).",negative,methotrexate,phenytoin
"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), DRUG1 (decreased hepatic clearance of DRUG1).",negative,phenytoin,phenytoin
Patients studied in clinical trials of DRUG1 were routinely treated with DRUG2 and aspirin. ,negative,TNKase,heparin
Patients studied in clinical trials of DRUG1 were routinely treated with heparin and DRUG2. ,negative,TNKase,aspirin
Patients studied in clinical trials of TNKase were routinely treated with DRUG1 and DRUG2. ,negative,heparin,aspirin
"DRUG1 (such as DRUG2 and vitamin K antagonists) and drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy. ",negative,Anticoagulants,heparin
"DRUG1 (such as heparin and DRUG2) and drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy. ",negative,Anticoagulants,vitamin K antagonists
"DRUG1 (such as heparin and vitamin K antagonists) and drugs that alter platelet function (such as DRUG2, dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy. ",negative,Anticoagulants,acetylsalicylic acid
"DRUG1 (such as heparin and vitamin K antagonists) and drugs that alter platelet function (such as acetylsalicylic acid, DRUG2, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy. ",negative,Anticoagulants,dipyridamole
"DRUG1 (such as heparin and vitamin K antagonists) and drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after DRUG2 therapy. ",effect,Anticoagulants,TNKase
"Anticoagulants (such as DRUG1 and DRUG2) and drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy. ",negative,heparin,vitamin K antagonists
"Anticoagulants (such as DRUG1 and vitamin K antagonists) and drugs that alter platelet function (such as DRUG2, dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy. ",negative,heparin,acetylsalicylic acid
"Anticoagulants (such as DRUG1 and vitamin K antagonists) and drugs that alter platelet function (such as acetylsalicylic acid, DRUG2, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy. ",negative,heparin,dipyridamole
"Anticoagulants (such as DRUG1 and vitamin K antagonists) and drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after DRUG2 therapy. ",effect,heparin,TNKase
"Anticoagulants (such as heparin and DRUG1) and drugs that alter platelet function (such as DRUG2, dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy. ",negative,vitamin K antagonists,acetylsalicylic acid
"Anticoagulants (such as heparin and DRUG1) and drugs that alter platelet function (such as acetylsalicylic acid, DRUG2, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy. ",negative,vitamin K antagonists,dipyridamole
"Anticoagulants (such as heparin and DRUG1) and drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after DRUG2 therapy. ",effect,vitamin K antagonists,TNKase
"Anticoagulants (such as heparin and vitamin K antagonists) and drugs that alter platelet function (such as DRUG1, DRUG2, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy. ",negative,acetylsalicylic acid,dipyridamole
"Anticoagulants (such as heparin and vitamin K antagonists) and drugs that alter platelet function (such as DRUG1, dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after DRUG2 therapy. ",effect,acetylsalicylic acid,TNKase
"Anticoagulants (such as heparin and vitamin K antagonists) and drugs that alter platelet function (such as acetylsalicylic acid, DRUG1, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after DRUG2 therapy. ",effect,dipyridamole,TNKase
DRUG1: The effects of chronic DRUG1 use on the metabolism of rimantadine are not known. ,negative,Cimetidine,cimetidine
DRUG1: The effects of chronic DRUG1 use on the metabolism of DRUG2 are not known. ,negative,Cimetidine,rimantadine
DRUG1: The effects of chronic DRUG1 use on the metabolism of DRUG2 are not known. ,negative,cimetidine,rimantadine
"When a single 100 mg dose of DRUG1 was administered one hour after the initiation of DRUG2 (300 mg four times a day), the apparent total rimantadine clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total rimantadine clearance in the same subjects in the absence of DRUG2). ",mechanism,rimantadine HCl,Cimetidine
"When a single 100 mg dose of DRUG1 was administered one hour after the initiation of Cimetidine (300 mg four times a day), the apparent total DRUG2 clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total DRUG2 clearance in the same subjects in the absence of cimetidine). ",negative,rimantadine HCl,rimantadine
"When a single 100 mg dose of DRUG1 was administered one hour after the initiation of Cimetidine (300 mg four times a day), the apparent total DRUG2 clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total DRUG2 clearance in the same subjects in the absence of cimetidine). ",negative,rimantadine HCl,rimantadine
"When a single 100 mg dose of DRUG1 was administered one hour after the initiation of DRUG2 (300 mg four times a day), the apparent total rimantadine clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total rimantadine clearance in the same subjects in the absence of DRUG2). ",negative,rimantadine HCl,cimetidine
"When a single 100 mg dose of DRUG2 HCl was administered one hour after the initiation of DRUG1 (300 mg four times a day), the apparent total DRUG2 clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total DRUG2 clearance in the same subjects in the absence of DRUG1). ",negative,Cimetidine,rimantadine
"When a single 100 mg dose of DRUG2 HCl was administered one hour after the initiation of DRUG1 (300 mg four times a day), the apparent total DRUG2 clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total DRUG2 clearance in the same subjects in the absence of DRUG1). ",negative,Cimetidine,rimantadine
"When a single 100 mg dose of rimantadine HCl was administered one hour after the initiation of DRUG1 (300 mg four times a day), the apparent total rimantadine clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total rimantadine clearance in the same subjects in the absence of DRUG1). ",negative,Cimetidine,cimetidine
"When a single 100 mg dose of DRUG1 HCl was administered one hour after the initiation of Cimetidine (300 mg four times a day), the apparent total DRUG1 clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total DRUG1 clearance in the same subjects in the absence of cimetidine). ",negative,rimantadine,rimantadine
"When a single 100 mg dose of DRUG1 HCl was administered one hour after the initiation of DRUG2 (300 mg four times a day), the apparent total DRUG1 clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total DRUG1 clearance in the same subjects in the absence of DRUG2). ",negative,rimantadine,cimetidine
"When a single 100 mg dose of DRUG1 HCl was administered one hour after the initiation of DRUG2 (300 mg four times a day), the apparent total DRUG1 clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total DRUG1 clearance in the same subjects in the absence of DRUG2). ",negative,rimantadine,cimetidine
"DRUG1: DRUG2, 100 mg, was given twice daily for 13 days to 12 healthy volunteers. ",negative,Acetaminophen,Rimantadine HCl
Coadministration with DRUG1 reduced the peak concentration and AUC values for DRUG2 by approximately 11%. ,mechanism,acetaminophen,rimantadine
"DRUG1: DRUG2, 100 mg, was given twice daily fro 13 days to 12 healthy volunteers. ",negative,Aspirin,Rimantadine HCl
Peak plasma concentrations and AUC of DRUG1 were reduced approximately 10% in the presence of DRUG2.,mechanism,rimantadine,aspirin
DRUG1 may inhibit the hepatic metabolism of DRUG2. ,mechanism,Trimethoprim,phenytoin
"DRUG1, given at a common clinical dosage, increased the DRUG2 half-life by 51% and decreased the DRUG2 metabolic clearance rate by 30%. ",mechanism,Trimethoprim,phenytoin
"DRUG1, given at a common clinical dosage, increased the DRUG2 half-life by 51% and decreased the DRUG2 metabolic clearance rate by 30%. ",mechanism,Trimethoprim,phenytoin
"Trimethoprim, given at a common clinical dosage, increased the DRUG1 half-life by 51% and decreased the DRUG1 metabolic clearance rate by 30%. ",negative,phenytoin,phenytoin
DRUG1 should be administered with caution to patients taking DRUG2 because of the possibility of conduction disturbances. ,advise,Pilocarpine,beta adrenergic antagonists
"These effects should be considered when anticholinergic properties may be contributing to the therapeutic effect of concomitant medication (e.g., DRUG1, inhaled DRUG2). ",negative,atropine,ipratropium
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUG1, artificial tears, DRUG2, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",negative,acetylsalicylic acid,calcium
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUG1, artificial tears, calcium, DRUG2, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",negative,acetylsalicylic acid,conjugated estrogens
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUG1, artificial tears, calcium, conjugated estrogens, DRUG2, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",negative,acetylsalicylic acid,hydroxychloroquine sulfate
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUG1, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, DRUG2, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",negative,acetylsalicylic acid,ibuprofen
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUG1, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, DRUG2, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",negative,acetylsalicylic acid,levothyroxine sodium
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUG1, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, DRUG2, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",negative,acetylsalicylic acid,medroxyprogesterone acetate
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUG1, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, DRUG2, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",negative,acetylsalicylic acid,methotrexate
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUG1, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, DRUG2, naproxen, omeprazole, paracetamol, and prednisone.",negative,acetylsalicylic acid,multivitamins
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUG1, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, DRUG2, omeprazole, paracetamol, and prednisone.",negative,acetylsalicylic acid,naproxen
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUG1, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, DRUG2, paracetamol, and prednisone.",negative,acetylsalicylic acid,omeprazole
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUG1, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, DRUG2, and prednisone.",negative,acetylsalicylic acid,paracetamol
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUG1, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and DRUG2.",negative,acetylsalicylic acid,prednisone
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, DRUG1, DRUG2, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",negative,calcium,conjugated estrogens
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, DRUG1, conjugated estrogens, DRUG2, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",negative,calcium,hydroxychloroquine sulfate
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, DRUG1, conjugated estrogens, hydroxychloroquine sulfate, DRUG2, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",negative,calcium,ibuprofen
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, DRUG1, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, DRUG2, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",negative,calcium,levothyroxine sodium
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, DRUG1, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, DRUG2, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",negative,calcium,medroxyprogesterone acetate
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, DRUG1, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, DRUG2, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",negative,calcium,methotrexate
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, DRUG1, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, DRUG2, naproxen, omeprazole, paracetamol, and prednisone.",negative,calcium,multivitamins
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, DRUG1, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, DRUG2, omeprazole, paracetamol, and prednisone.",negative,calcium,naproxen
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, DRUG1, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, DRUG2, paracetamol, and prednisone.",negative,calcium,omeprazole
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, DRUG1, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, DRUG2, and prednisone.",negative,calcium,paracetamol
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, DRUG1, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and DRUG2.",negative,calcium,prednisone
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, DRUG1, DRUG2, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",negative,conjugated estrogens,hydroxychloroquine sulfate
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, DRUG1, hydroxychloroquine sulfate, DRUG2, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",negative,conjugated estrogens,ibuprofen
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, DRUG1, hydroxychloroquine sulfate, ibuprofen, DRUG2, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",negative,conjugated estrogens,levothyroxine sodium
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, DRUG1, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, DRUG2, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",negative,conjugated estrogens,medroxyprogesterone acetate
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, DRUG1, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, DRUG2, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",negative,conjugated estrogens,methotrexate
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, DRUG1, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, DRUG2, naproxen, omeprazole, paracetamol, and prednisone.",negative,conjugated estrogens,multivitamins
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, DRUG1, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, DRUG2, omeprazole, paracetamol, and prednisone.",negative,conjugated estrogens,naproxen
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, DRUG1, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, DRUG2, paracetamol, and prednisone.",negative,conjugated estrogens,omeprazole
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, DRUG1, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, DRUG2, and prednisone.",negative,conjugated estrogens,paracetamol
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, DRUG1, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and DRUG2.",negative,conjugated estrogens,prednisone
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, DRUG1, DRUG2, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",negative,hydroxychloroquine sulfate,ibuprofen
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, DRUG1, ibuprofen, DRUG2, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",negative,hydroxychloroquine sulfate,levothyroxine sodium
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, DRUG1, ibuprofen, levothyroxine sodium, DRUG2, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",negative,hydroxychloroquine sulfate,medroxyprogesterone acetate
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, DRUG1, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, DRUG2, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",negative,hydroxychloroquine sulfate,methotrexate
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, DRUG1, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, DRUG2, naproxen, omeprazole, paracetamol, and prednisone.",negative,hydroxychloroquine sulfate,multivitamins
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, DRUG1, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, DRUG2, omeprazole, paracetamol, and prednisone.",negative,hydroxychloroquine sulfate,naproxen
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, DRUG1, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, DRUG2, paracetamol, and prednisone.",negative,hydroxychloroquine sulfate,omeprazole
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, DRUG1, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, DRUG2, and prednisone.",negative,hydroxychloroquine sulfate,paracetamol
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, DRUG1, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and DRUG2.",negative,hydroxychloroquine sulfate,prednisone
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, DRUG1, DRUG2, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",negative,ibuprofen,levothyroxine sodium
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, DRUG1, levothyroxine sodium, DRUG2, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",negative,ibuprofen,medroxyprogesterone acetate
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, DRUG1, levothyroxine sodium, medroxyprogesterone acetate, DRUG2, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",negative,ibuprofen,methotrexate
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, DRUG1, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, DRUG2, naproxen, omeprazole, paracetamol, and prednisone.",negative,ibuprofen,multivitamins
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, DRUG1, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, DRUG2, omeprazole, paracetamol, and prednisone.",negative,ibuprofen,naproxen
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, DRUG1, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, DRUG2, paracetamol, and prednisone.",negative,ibuprofen,omeprazole
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, DRUG1, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, DRUG2, and prednisone.",negative,ibuprofen,paracetamol
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, DRUG1, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and DRUG2.",negative,ibuprofen,prednisone
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, DRUG1, DRUG2, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",negative,levothyroxine sodium,medroxyprogesterone acetate
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, DRUG1, medroxyprogesterone acetate, DRUG2, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",negative,levothyroxine sodium,methotrexate
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, DRUG1, medroxyprogesterone acetate, methotrexate, DRUG2, naproxen, omeprazole, paracetamol, and prednisone.",negative,levothyroxine sodium,multivitamins
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, DRUG1, medroxyprogesterone acetate, methotrexate, multivitamins, DRUG2, omeprazole, paracetamol, and prednisone.",negative,levothyroxine sodium,naproxen
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, DRUG1, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, DRUG2, paracetamol, and prednisone.",negative,levothyroxine sodium,omeprazole
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, DRUG1, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, DRUG2, and prednisone.",negative,levothyroxine sodium,paracetamol
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, DRUG1, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and DRUG2.",negative,levothyroxine sodium,prednisone
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, DRUG1, DRUG2, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",negative,medroxyprogesterone acetate,methotrexate
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, DRUG1, methotrexate, DRUG2, naproxen, omeprazole, paracetamol, and prednisone.",negative,medroxyprogesterone acetate,multivitamins
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, DRUG1, methotrexate, multivitamins, DRUG2, omeprazole, paracetamol, and prednisone.",negative,medroxyprogesterone acetate,naproxen
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, DRUG1, methotrexate, multivitamins, naproxen, DRUG2, paracetamol, and prednisone.",negative,medroxyprogesterone acetate,omeprazole
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, DRUG1, methotrexate, multivitamins, naproxen, omeprazole, DRUG2, and prednisone.",negative,medroxyprogesterone acetate,paracetamol
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, DRUG1, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and DRUG2.",negative,medroxyprogesterone acetate,prednisone
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, DRUG1, DRUG2, naproxen, omeprazole, paracetamol, and prednisone.",negative,methotrexate,multivitamins
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, DRUG1, multivitamins, DRUG2, omeprazole, paracetamol, and prednisone.",negative,methotrexate,naproxen
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, DRUG1, multivitamins, naproxen, DRUG2, paracetamol, and prednisone.",negative,methotrexate,omeprazole
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, DRUG1, multivitamins, naproxen, omeprazole, DRUG2, and prednisone.",negative,methotrexate,paracetamol
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, DRUG1, multivitamins, naproxen, omeprazole, paracetamol, and DRUG2.",negative,methotrexate,prednisone
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, DRUG1, DRUG2, omeprazole, paracetamol, and prednisone.",negative,multivitamins,naproxen
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, DRUG1, naproxen, DRUG2, paracetamol, and prednisone.",negative,multivitamins,omeprazole
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, DRUG1, naproxen, omeprazole, DRUG2, and prednisone.",negative,multivitamins,paracetamol
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, DRUG1, naproxen, omeprazole, paracetamol, and DRUG2.",negative,multivitamins,prednisone
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, DRUG1, DRUG2, paracetamol, and prednisone.",negative,naproxen,omeprazole
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, DRUG1, omeprazole, DRUG2, and prednisone.",negative,naproxen,paracetamol
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, DRUG1, omeprazole, paracetamol, and DRUG2.",negative,naproxen,prednisone
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, DRUG1, DRUG2, and prednisone.",negative,omeprazole,paracetamol
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, DRUG1, paracetamol, and DRUG2.",negative,omeprazole,prednisone
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, DRUG1, and DRUG2.",negative,paracetamol,prednisone
Mutual inhibition of metabolism occurs with concurrent use of DRUG1 and DRUG2; ,mechanism,cyclosporin,methylprednisolone
convulsions have been reported with concurrent use of DRUG1 and DRUG2. ,effect,methylprednisolone,cyclosporin
"Drugs that induce hepatic enzymes such as DRUG1, DRUG2, and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response. ",negative,phenobarbital,phenytoin
"Drugs that induce hepatic enzymes such as DRUG1, phenytoin, and DRUG2 may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response. ",negative,phenobarbital,rifampin
"Drugs that induce hepatic enzymes such as DRUG1, phenytoin, and rifampin may increase the clearance of DRUG2 and may require increased in DRUG2 dose to achieve the desired response. ",mechanism,phenobarbital,methylprednisolone
"Drugs that induce hepatic enzymes such as DRUG1, phenytoin, and rifampin may increase the clearance of DRUG2 and may require increased in DRUG2 dose to achieve the desired response. ",advise,phenobarbital,methylprednisolone
"Drugs that induce hepatic enzymes such as phenobarbital, DRUG1, and DRUG2 may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response. ",negative,phenytoin,rifampin
"Drugs that induce hepatic enzymes such as phenobarbital, DRUG1, and rifampin may increase the clearance of DRUG2 and may require increased in DRUG2 dose to achieve the desired response. ",mechanism,phenytoin,methylprednisolone
"Drugs that induce hepatic enzymes such as phenobarbital, DRUG1, and rifampin may increase the clearance of DRUG2 and may require increased in DRUG2 dose to achieve the desired response. ",advise,phenytoin,methylprednisolone
"Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and DRUG1 may increase the clearance of DRUG2 and may require increased in DRUG2 dose to achieve the desired response. ",mechanism,rifampin,methylprednisolone
"Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and DRUG1 may increase the clearance of DRUG2 and may require increased in DRUG2 dose to achieve the desired response. ",advise,rifampin,methylprednisolone
"Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of DRUG1 and may require increased in DRUG1 dose to achieve the desired response. ",negative,methylprednisolone,methylprednisolone
Drugs such as DRUG1 and DRUG2 may inhibit the metabolism of methylprednisolone and thus decrease its clearance. ,negative,troleandomycin,ketoconazole
Drugs such as DRUG1 and ketoconazole may inhibit the metabolism of DRUG2 and thus decrease its clearance. ,mechanism,troleandomycin,methylprednisolone
Drugs such as troleandomycin and DRUG1 may inhibit the metabolism of DRUG2 and thus decrease its clearance. ,mechanism,ketoconazole,methylprednisolone
DRUG1 may increase the clearance of chronic high dose DRUG2. ,mechanism,Methylprednisolone,aspirin
This could lead to decreased DRUG1 serum levels or increase the risk of DRUG1 toxicity when methylprednisolone is withdrawn. ,negative,salicylate,salicylate
This could lead to decreased DRUG1 serum levels or increase the risk of DRUG1 toxicity when DRUG2 is withdrawn. ,negative,salicylate,methylprednisolone
This could lead to decreased DRUG1 serum levels or increase the risk of DRUG1 toxicity when DRUG2 is withdrawn. ,effect,salicylate,methylprednisolone
DRUG1 should be used cautiously in conjunction with DRUG2 in patients suffering from hypoprothrombinemia. ,advise,Aspirin,corticosteroids
The effect of DRUG1 on oral DRUG2 is variable. ,negative,methylprednisolone,anticoagulants
There are reports of enhanced as well as diminished effects of DRUG1 when given concurrently with DRUG2. ,effect,anticoagulant,corticosteroids
The effects of DRUG1 on gastrointestinal motility are antagonized by DRUG2 and narcotic analgesics. ,effect,metoclopramide,anticholinergic drugs
The effects of DRUG1 on gastrointestinal motility are antagonized by anticholinergic drugs and DRUG2. ,effect,metoclopramide,narcotic analgesics
The effects of metoclopramide on gastrointestinal motility are antagonized by DRUG1 and DRUG2. ,negative,anticholinergic drugs,narcotic analgesics
"Additive sedative effects can occur when DRUG1 is given with DRUG2, sedatives, hypnotics, narcotics, or tranquilizers. ",effect,metoclopramide,alcohol
"Additive sedative effects can occur when DRUG1 is given with alcohol, DRUG2, hypnotics, narcotics, or tranquilizers. ",effect,metoclopramide,sedatives
"Additive sedative effects can occur when DRUG1 is given with alcohol, sedatives, DRUG2, narcotics, or tranquilizers. ",effect,metoclopramide,hypnotics
"Additive sedative effects can occur when DRUG1 is given with alcohol, sedatives, hypnotics, DRUG2, or tranquilizers. ",effect,metoclopramide,narcotics
"Additive sedative effects can occur when DRUG1 is given with alcohol, sedatives, hypnotics, narcotics, or DRUG2. ",effect,metoclopramide,tranquilizers
"Additive sedative effects can occur when metoclopramide is given with DRUG1, DRUG2, hypnotics, narcotics, or tranquilizers. ",negative,alcohol,sedatives
"Additive sedative effects can occur when metoclopramide is given with DRUG1, sedatives, DRUG2, narcotics, or tranquilizers. ",negative,alcohol,hypnotics
"Additive sedative effects can occur when metoclopramide is given with DRUG1, sedatives, hypnotics, DRUG2, or tranquilizers. ",negative,alcohol,narcotics
"Additive sedative effects can occur when metoclopramide is given with DRUG1, sedatives, hypnotics, narcotics, or DRUG2. ",negative,alcohol,tranquilizers
"Additive sedative effects can occur when metoclopramide is given with alcohol, DRUG1, DRUG2, narcotics, or tranquilizers. ",negative,sedatives,hypnotics
"Additive sedative effects can occur when metoclopramide is given with alcohol, DRUG1, hypnotics, DRUG2, or tranquilizers. ",negative,sedatives,narcotics
"Additive sedative effects can occur when metoclopramide is given with alcohol, DRUG1, hypnotics, narcotics, or DRUG2. ",negative,sedatives,tranquilizers
"Additive sedative effects can occur when metoclopramide is given with alcohol, sedatives, DRUG1, DRUG2, or tranquilizers. ",negative,hypnotics,narcotics
"Additive sedative effects can occur when metoclopramide is given with alcohol, sedatives, DRUG1, narcotics, or DRUG2. ",negative,hypnotics,tranquilizers
"Additive sedative effects can occur when metoclopramide is given with alcohol, sedatives, hypnotics, DRUG1, or DRUG2. ",negative,narcotics,tranquilizers
"The finding that DRUG1 releases catecholamines in patients with essential hypertension suggests that it should be used cautiously, if at all, in patients receiving DRUG2. ",advise,metoclopramide,monoamine oxi-dase inhibitors
"Absorption of drugs from the stomach may be diminished (e.g., DRUG1) by DRUG2, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, cyclosporine). ",mechanism,digoxin,metoclopramide
"Absorption of drugs from the stomach may be diminished (e.g., DRUG1) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., DRUG2, tetracycline, levodopa, ethanol, cyclosporine). ",negative,digoxin,acetaminophen
"Absorption of drugs from the stomach may be diminished (e.g., DRUG1) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, DRUG2, levodopa, ethanol, cyclosporine). ",negative,digoxin,tetracycline
"Absorption of drugs from the stomach may be diminished (e.g., DRUG1) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, DRUG2, ethanol, cyclosporine). ",negative,digoxin,levodopa
"Absorption of drugs from the stomach may be diminished (e.g., DRUG1) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, DRUG2, cyclosporine). ",negative,digoxin,ethanol
"Absorption of drugs from the stomach may be diminished (e.g., DRUG1) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, DRUG2). ",negative,digoxin,cyclosporine
"Absorption of drugs from the stomach may be diminished (e.g., digoxin) by DRUG1, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., DRUG2, tetracycline, levodopa, ethanol, cyclosporine). ",mechanism,metoclopramide,acetaminophen
"Absorption of drugs from the stomach may be diminished (e.g., digoxin) by DRUG1, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, DRUG2, levodopa, ethanol, cyclosporine). ",negative,metoclopramide,tetracycline
"Absorption of drugs from the stomach may be diminished (e.g., digoxin) by DRUG1, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, DRUG2, ethanol, cyclosporine). ",negative,metoclopramide,levodopa
"Absorption of drugs from the stomach may be diminished (e.g., digoxin) by DRUG1, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, DRUG2, cyclosporine). ",negative,metoclopramide,ethanol
"Absorption of drugs from the stomach may be diminished (e.g., digoxin) by DRUG1, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, DRUG2). ",negative,metoclopramide,cyclosporine
"Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., DRUG1, DRUG2, levodopa, ethanol, cyclosporine). ",negative,acetaminophen,tetracycline
"Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., DRUG1, tetracycline, DRUG2, ethanol, cyclosporine). ",negative,acetaminophen,levodopa
"Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., DRUG1, tetracycline, levodopa, DRUG2, cyclosporine). ",negative,acetaminophen,ethanol
"Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., DRUG1, tetracycline, levodopa, ethanol, DRUG2). ",negative,acetaminophen,cyclosporine
"Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, DRUG1, DRUG2, ethanol, cyclosporine). ",negative,tetracycline,levodopa
"Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, DRUG1, levodopa, DRUG2, cyclosporine). ",negative,tetracycline,ethanol
"Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, DRUG1, levodopa, ethanol, DRUG2). ",negative,tetracycline,cyclosporine
"Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, DRUG1, DRUG2, cyclosporine). ",negative,levodopa,ethanol
"Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, DRUG1, ethanol, DRUG2). ",negative,levodopa,cyclosporine
"Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, DRUG1, DRUG2). ",negative,ethanol,cyclosporine
"Because the action of DRUG1 will influence the delivery of food to the intestines and thus the rate of absorption, DRUG2 dosage or timing of dosage may require adjustment.",advise,metoclopramide,insulin
"DRUG1, particularly DRUG2, may cause serious cardiac arrhythmias during halothane anesthesia and therefore should be used only with great caution or not at all. ",negative,Vasopressors,metaraminol
"DRUG1, particularly metaraminol, may cause serious cardiac arrhythmias during DRUG2 anesthesia and therefore should be used only with great caution or not at all. ",effect,Vasopressors,halothane
"Vasopressors, particularly DRUG1, may cause serious cardiac arrhythmias during DRUG2 anesthesia and therefore should be used only with great caution or not at all. ",effect,metaraminol,halothane
DRUG1: The pressor effect of DRUG2 is markedly potentiated in patients receiving monoamine oxidase inhibitors (MAOI). ,negative,MAO Inhibitors,sympathomimetic pressor amines
DRUG1: The pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving DRUG2 (MAOI). ,negative,MAO Inhibitors,monoamine oxidase inhibitors
DRUG1: The pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving monoamine oxidase inhibitors (DRUG2). ,negative,MAO Inhibitors,MAOI
MAO Inhibitors: The pressor effect of DRUG1 is markedly potentiated in patients receiving DRUG2 (MAOI). ,effect,sympathomimetic pressor amines,monoamine oxidase inhibitors
MAO Inhibitors: The pressor effect of DRUG1 is markedly potentiated in patients receiving monoamine oxidase inhibitors (DRUG2). ,effect,sympathomimetic pressor amines,MAOI
MAO Inhibitors: The pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving DRUG1 (DRUG2). ,negative,monoamine oxidase inhibitors,MAOI
The pressor response of DRUG1 may also be potentiated by DRUG2.,effect,adrenergic agents,tricyclic antidepressants
"DRUG1 may interact with DRUG2 (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,Methscopolamine,antidepressants
"DRUG1 may interact with antidepressants (DRUG2 type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",int,Methscopolamine,tricyclic
"DRUG1 may interact with antidepressants (tricyclic type), DRUG2 (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",int,Methscopolamine,MAO inhibitors
"DRUG1 may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., DRUG2, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",int,Methscopolamine,phenelzine
"DRUG1 may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, DRUG2, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",int,Methscopolamine,linezolid
"DRUG1 may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, DRUG2, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",int,Methscopolamine,tranylcypromine
"DRUG1 may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, DRUG2, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",int,Methscopolamine,isocarboxazid
"DRUG1 may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, DRUG2, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",int,Methscopolamine,selegiline
"DRUG1 may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, DRUG2), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",int,Methscopolamine,furazolidone
"DRUG1 may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), DRUG2, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",int,Methscopolamine,quinidine
"DRUG1 may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, DRUG2, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",int,Methscopolamine,amantadine
"DRUG1 may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, DRUG2 (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",int,Methscopolamine,antihistamines
"DRUG1 may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., DRUG2), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",int,Methscopolamine,diphenhydramine
"DRUG1 may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other DRUG2, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",int,Methscopolamine,anticholinergics
"DRUG1 may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, DRUG2 supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",int,Methscopolamine,potassium chloride
"DRUG1 may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, DRUG2, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",int,Methscopolamine,antacids
"DRUG1 may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, DRUG2 (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",int,Methscopolamine,absorbent-type anti-diarrhea medicines
"DRUG1 may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., DRUG2-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",int,Methscopolamine,kaolin
"DRUG1 may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-DRUG2), phenothiazines (e.g., chlorpromazine, promethazine).",int,Methscopolamine,pectin
"DRUG1 may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), DRUG2 (e.g., chlorpromazine, promethazine).",int,Methscopolamine,phenothiazines
"DRUG1 may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., DRUG2, promethazine).",int,Methscopolamine,chlorpromazine
"DRUG1 may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, DRUG2).",int,Methscopolamine,promethazine
"Methscopolamine may interact with DRUG1 (DRUG2 type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,antidepressants,tricyclic
"Methscopolamine may interact with DRUG1 (tricyclic type), DRUG2 (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,antidepressants,MAO inhibitors
"Methscopolamine may interact with DRUG1 (tricyclic type), MAO inhibitors (e.g., DRUG2, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,antidepressants,phenelzine
"Methscopolamine may interact with DRUG1 (tricyclic type), MAO inhibitors (e.g., phenelzine, DRUG2, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,antidepressants,linezolid
"Methscopolamine may interact with DRUG1 (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, DRUG2, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,antidepressants,tranylcypromine
"Methscopolamine may interact with DRUG1 (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, DRUG2, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,antidepressants,isocarboxazid
"Methscopolamine may interact with DRUG1 (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, DRUG2, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,antidepressants,selegiline
"Methscopolamine may interact with DRUG1 (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, DRUG2), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,antidepressants,furazolidone
"Methscopolamine may interact with DRUG1 (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), DRUG2, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,antidepressants,quinidine
"Methscopolamine may interact with DRUG1 (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, DRUG2, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,antidepressants,amantadine
"Methscopolamine may interact with DRUG1 (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, DRUG2 (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,antidepressants,antihistamines
"Methscopolamine may interact with DRUG1 (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., DRUG2), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,antidepressants,diphenhydramine
"Methscopolamine may interact with DRUG1 (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other DRUG2, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,antidepressants,anticholinergics
"Methscopolamine may interact with DRUG1 (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, DRUG2 supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,antidepressants,potassium chloride
"Methscopolamine may interact with DRUG1 (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, DRUG2, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,antidepressants,antacids
"Methscopolamine may interact with DRUG1 (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, DRUG2 (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,antidepressants,absorbent-type anti-diarrhea medicines
"Methscopolamine may interact with DRUG1 (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., DRUG2-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,antidepressants,kaolin
"Methscopolamine may interact with DRUG1 (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-DRUG2), phenothiazines (e.g., chlorpromazine, promethazine).",negative,antidepressants,pectin
"Methscopolamine may interact with DRUG1 (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), DRUG2 (e.g., chlorpromazine, promethazine).",negative,antidepressants,phenothiazines
"Methscopolamine may interact with DRUG1 (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., DRUG2, promethazine).",negative,antidepressants,chlorpromazine
"Methscopolamine may interact with DRUG1 (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, DRUG2).",negative,antidepressants,promethazine
"Methscopolamine may interact with antidepressants (DRUG1 type), DRUG2 (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,tricyclic,MAO inhibitors
"Methscopolamine may interact with antidepressants (DRUG1 type), MAO inhibitors (e.g., DRUG2, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,tricyclic,phenelzine
"Methscopolamine may interact with antidepressants (DRUG1 type), MAO inhibitors (e.g., phenelzine, DRUG2, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,tricyclic,linezolid
"Methscopolamine may interact with antidepressants (DRUG1 type), MAO inhibitors (e.g., phenelzine, linezolid, DRUG2, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,tricyclic,tranylcypromine
"Methscopolamine may interact with antidepressants (DRUG1 type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, DRUG2, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,tricyclic,isocarboxazid
"Methscopolamine may interact with antidepressants (DRUG1 type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, DRUG2, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,tricyclic,selegiline
"Methscopolamine may interact with antidepressants (DRUG1 type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, DRUG2), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,tricyclic,furazolidone
"Methscopolamine may interact with antidepressants (DRUG1 type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), DRUG2, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,tricyclic,quinidine
"Methscopolamine may interact with antidepressants (DRUG1 type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, DRUG2, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,tricyclic,amantadine
"Methscopolamine may interact with antidepressants (DRUG1 type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, DRUG2 (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,tricyclic,antihistamines
"Methscopolamine may interact with antidepressants (DRUG1 type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., DRUG2), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,tricyclic,diphenhydramine
"Methscopolamine may interact with antidepressants (DRUG1 type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other DRUG2, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,tricyclic,anticholinergics
"Methscopolamine may interact with antidepressants (DRUG1 type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, DRUG2 supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,tricyclic,potassium chloride
"Methscopolamine may interact with antidepressants (DRUG1 type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, DRUG2, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,tricyclic,antacids
"Methscopolamine may interact with antidepressants (DRUG1 type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, DRUG2 (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,tricyclic,absorbent-type anti-diarrhea medicines
"Methscopolamine may interact with antidepressants (DRUG1 type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., DRUG2-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,tricyclic,kaolin
"Methscopolamine may interact with antidepressants (DRUG1 type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-DRUG2), phenothiazines (e.g., chlorpromazine, promethazine).",negative,tricyclic,pectin
"Methscopolamine may interact with antidepressants (DRUG1 type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), DRUG2 (e.g., chlorpromazine, promethazine).",negative,tricyclic,phenothiazines
"Methscopolamine may interact with antidepressants (DRUG1 type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., DRUG2, promethazine).",negative,tricyclic,chlorpromazine
"Methscopolamine may interact with antidepressants (DRUG1 type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, DRUG2).",negative,tricyclic,promethazine
"Methscopolamine may interact with antidepressants (tricyclic type), DRUG1 (e.g., DRUG2, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,MAO inhibitors,phenelzine
"Methscopolamine may interact with antidepressants (tricyclic type), DRUG1 (e.g., phenelzine, DRUG2, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,MAO inhibitors,linezolid
"Methscopolamine may interact with antidepressants (tricyclic type), DRUG1 (e.g., phenelzine, linezolid, DRUG2, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,MAO inhibitors,tranylcypromine
"Methscopolamine may interact with antidepressants (tricyclic type), DRUG1 (e.g., phenelzine, linezolid, tranylcypromine, DRUG2, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,MAO inhibitors,isocarboxazid
"Methscopolamine may interact with antidepressants (tricyclic type), DRUG1 (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, DRUG2, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,MAO inhibitors,selegiline
"Methscopolamine may interact with antidepressants (tricyclic type), DRUG1 (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, DRUG2), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,MAO inhibitors,furazolidone
"Methscopolamine may interact with antidepressants (tricyclic type), DRUG1 (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), DRUG2, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,MAO inhibitors,quinidine
"Methscopolamine may interact with antidepressants (tricyclic type), DRUG1 (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, DRUG2, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,MAO inhibitors,amantadine
"Methscopolamine may interact with antidepressants (tricyclic type), DRUG1 (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, DRUG2 (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,MAO inhibitors,antihistamines
"Methscopolamine may interact with antidepressants (tricyclic type), DRUG1 (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., DRUG2), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,MAO inhibitors,diphenhydramine
"Methscopolamine may interact with antidepressants (tricyclic type), DRUG1 (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other DRUG2, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,MAO inhibitors,anticholinergics
"Methscopolamine may interact with antidepressants (tricyclic type), DRUG1 (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, DRUG2 supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,MAO inhibitors,potassium chloride
"Methscopolamine may interact with antidepressants (tricyclic type), DRUG1 (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, DRUG2, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,MAO inhibitors,antacids
"Methscopolamine may interact with antidepressants (tricyclic type), DRUG1 (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, DRUG2 (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,MAO inhibitors,absorbent-type anti-diarrhea medicines
"Methscopolamine may interact with antidepressants (tricyclic type), DRUG1 (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., DRUG2-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,MAO inhibitors,kaolin
"Methscopolamine may interact with antidepressants (tricyclic type), DRUG1 (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-DRUG2), phenothiazines (e.g., chlorpromazine, promethazine).",negative,MAO inhibitors,pectin
"Methscopolamine may interact with antidepressants (tricyclic type), DRUG1 (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), DRUG2 (e.g., chlorpromazine, promethazine).",negative,MAO inhibitors,phenothiazines
"Methscopolamine may interact with antidepressants (tricyclic type), DRUG1 (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., DRUG2, promethazine).",negative,MAO inhibitors,chlorpromazine
"Methscopolamine may interact with antidepressants (tricyclic type), DRUG1 (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, DRUG2).",negative,MAO inhibitors,promethazine
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., DRUG1, DRUG2, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,phenelzine,linezolid
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., DRUG1, linezolid, DRUG2, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,phenelzine,tranylcypromine
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., DRUG1, linezolid, tranylcypromine, DRUG2, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,phenelzine,isocarboxazid
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., DRUG1, linezolid, tranylcypromine, isocarboxazid, DRUG2, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,phenelzine,selegiline
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., DRUG1, linezolid, tranylcypromine, isocarboxazid, selegiline, DRUG2), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,phenelzine,furazolidone
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., DRUG1, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), DRUG2, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,phenelzine,quinidine
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., DRUG1, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, DRUG2, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,phenelzine,amantadine
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., DRUG1, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, DRUG2 (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,phenelzine,antihistamines
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., DRUG1, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., DRUG2), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,phenelzine,diphenhydramine
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., DRUG1, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other DRUG2, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,phenelzine,anticholinergics
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., DRUG1, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, DRUG2 supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,phenelzine,potassium chloride
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., DRUG1, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, DRUG2, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,phenelzine,antacids
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., DRUG1, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, DRUG2 (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,phenelzine,absorbent-type anti-diarrhea medicines
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., DRUG1, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., DRUG2-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,phenelzine,kaolin
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., DRUG1, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-DRUG2), phenothiazines (e.g., chlorpromazine, promethazine).",negative,phenelzine,pectin
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., DRUG1, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), DRUG2 (e.g., chlorpromazine, promethazine).",negative,phenelzine,phenothiazines
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., DRUG1, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., DRUG2, promethazine).",negative,phenelzine,chlorpromazine
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., DRUG1, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, DRUG2).",negative,phenelzine,promethazine
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, DRUG1, DRUG2, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,linezolid,tranylcypromine
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, DRUG1, tranylcypromine, DRUG2, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,linezolid,isocarboxazid
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, DRUG1, tranylcypromine, isocarboxazid, DRUG2, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,linezolid,selegiline
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, DRUG1, tranylcypromine, isocarboxazid, selegiline, DRUG2), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,linezolid,furazolidone
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, DRUG1, tranylcypromine, isocarboxazid, selegiline, furazolidone), DRUG2, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,linezolid,quinidine
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, DRUG1, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, DRUG2, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,linezolid,amantadine
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, DRUG1, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, DRUG2 (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,linezolid,antihistamines
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, DRUG1, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., DRUG2), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,linezolid,diphenhydramine
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, DRUG1, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other DRUG2, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,linezolid,anticholinergics
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, DRUG1, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, DRUG2 supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,linezolid,potassium chloride
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, DRUG1, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, DRUG2, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,linezolid,antacids
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, DRUG1, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, DRUG2 (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,linezolid,absorbent-type anti-diarrhea medicines
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, DRUG1, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., DRUG2-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,linezolid,kaolin
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, DRUG1, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-DRUG2), phenothiazines (e.g., chlorpromazine, promethazine).",negative,linezolid,pectin
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, DRUG1, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), DRUG2 (e.g., chlorpromazine, promethazine).",negative,linezolid,phenothiazines
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, DRUG1, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., DRUG2, promethazine).",negative,linezolid,chlorpromazine
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, DRUG1, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, DRUG2).",negative,linezolid,promethazine
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, DRUG1, DRUG2, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,tranylcypromine,isocarboxazid
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, DRUG1, isocarboxazid, DRUG2, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,tranylcypromine,selegiline
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, DRUG1, isocarboxazid, selegiline, DRUG2), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,tranylcypromine,furazolidone
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, DRUG1, isocarboxazid, selegiline, furazolidone), DRUG2, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,tranylcypromine,quinidine
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, DRUG1, isocarboxazid, selegiline, furazolidone), quinidine, DRUG2, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,tranylcypromine,amantadine
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, DRUG1, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, DRUG2 (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,tranylcypromine,antihistamines
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, DRUG1, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., DRUG2), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,tranylcypromine,diphenhydramine
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, DRUG1, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other DRUG2, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,tranylcypromine,anticholinergics
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, DRUG1, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, DRUG2 supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,tranylcypromine,potassium chloride
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, DRUG1, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, DRUG2, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,tranylcypromine,antacids
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, DRUG1, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, DRUG2 (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,tranylcypromine,absorbent-type anti-diarrhea medicines
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, DRUG1, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., DRUG2-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,tranylcypromine,kaolin
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, DRUG1, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-DRUG2), phenothiazines (e.g., chlorpromazine, promethazine).",negative,tranylcypromine,pectin
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, DRUG1, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), DRUG2 (e.g., chlorpromazine, promethazine).",negative,tranylcypromine,phenothiazines
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, DRUG1, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., DRUG2, promethazine).",negative,tranylcypromine,chlorpromazine
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, DRUG1, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, DRUG2).",negative,tranylcypromine,promethazine
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, DRUG1, DRUG2, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,isocarboxazid,selegiline
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, DRUG1, selegiline, DRUG2), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,isocarboxazid,furazolidone
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, DRUG1, selegiline, furazolidone), DRUG2, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,isocarboxazid,quinidine
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, DRUG1, selegiline, furazolidone), quinidine, DRUG2, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,isocarboxazid,amantadine
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, DRUG1, selegiline, furazolidone), quinidine, amantadine, DRUG2 (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,isocarboxazid,antihistamines
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, DRUG1, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., DRUG2), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,isocarboxazid,diphenhydramine
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, DRUG1, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other DRUG2, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,isocarboxazid,anticholinergics
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, DRUG1, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, DRUG2 supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,isocarboxazid,potassium chloride
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, DRUG1, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, DRUG2, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,isocarboxazid,antacids
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, DRUG1, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, DRUG2 (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,isocarboxazid,absorbent-type anti-diarrhea medicines
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, DRUG1, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., DRUG2-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,isocarboxazid,kaolin
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, DRUG1, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-DRUG2), phenothiazines (e.g., chlorpromazine, promethazine).",negative,isocarboxazid,pectin
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, DRUG1, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), DRUG2 (e.g., chlorpromazine, promethazine).",negative,isocarboxazid,phenothiazines
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, DRUG1, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., DRUG2, promethazine).",negative,isocarboxazid,chlorpromazine
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, DRUG1, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, DRUG2).",negative,isocarboxazid,promethazine
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, DRUG1, DRUG2), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,selegiline,furazolidone
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, DRUG1, furazolidone), DRUG2, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,selegiline,quinidine
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, DRUG1, furazolidone), quinidine, DRUG2, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,selegiline,amantadine
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, DRUG1, furazolidone), quinidine, amantadine, DRUG2 (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,selegiline,antihistamines
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, DRUG1, furazolidone), quinidine, amantadine, antihistamines (e.g., DRUG2), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,selegiline,diphenhydramine
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, DRUG1, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other DRUG2, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,selegiline,anticholinergics
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, DRUG1, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, DRUG2 supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,selegiline,potassium chloride
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, DRUG1, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, DRUG2, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,selegiline,antacids
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, DRUG1, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, DRUG2 (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,selegiline,absorbent-type anti-diarrhea medicines
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, DRUG1, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., DRUG2-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,selegiline,kaolin
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, DRUG1, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-DRUG2), phenothiazines (e.g., chlorpromazine, promethazine).",negative,selegiline,pectin
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, DRUG1, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), DRUG2 (e.g., chlorpromazine, promethazine).",negative,selegiline,phenothiazines
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, DRUG1, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., DRUG2, promethazine).",negative,selegiline,chlorpromazine
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, DRUG1, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, DRUG2).",negative,selegiline,promethazine
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, DRUG1), DRUG2, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,furazolidone,quinidine
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, DRUG1), quinidine, DRUG2, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,furazolidone,amantadine
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, DRUG1), quinidine, amantadine, DRUG2 (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,furazolidone,antihistamines
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, DRUG1), quinidine, amantadine, antihistamines (e.g., DRUG2), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,furazolidone,diphenhydramine
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, DRUG1), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other DRUG2, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,furazolidone,anticholinergics
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, DRUG1), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, DRUG2 supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,furazolidone,potassium chloride
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, DRUG1), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, DRUG2, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,furazolidone,antacids
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, DRUG1), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, DRUG2 (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,furazolidone,absorbent-type anti-diarrhea medicines
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, DRUG1), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., DRUG2-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,furazolidone,kaolin
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, DRUG1), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-DRUG2), phenothiazines (e.g., chlorpromazine, promethazine).",negative,furazolidone,pectin
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, DRUG1), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), DRUG2 (e.g., chlorpromazine, promethazine).",negative,furazolidone,phenothiazines
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, DRUG1), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., DRUG2, promethazine).",negative,furazolidone,chlorpromazine
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, DRUG1), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, DRUG2).",negative,furazolidone,promethazine
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), DRUG1, DRUG2, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,quinidine,amantadine
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), DRUG1, amantadine, DRUG2 (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,quinidine,antihistamines
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), DRUG1, amantadine, antihistamines (e.g., DRUG2), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,quinidine,diphenhydramine
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), DRUG1, amantadine, antihistamines (e.g., diphenhydramine), other DRUG2, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,quinidine,anticholinergics
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), DRUG1, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, DRUG2 supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,quinidine,potassium chloride
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), DRUG1, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, DRUG2, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,quinidine,antacids
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), DRUG1, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, DRUG2 (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,quinidine,absorbent-type anti-diarrhea medicines
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), DRUG1, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., DRUG2-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,quinidine,kaolin
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), DRUG1, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-DRUG2), phenothiazines (e.g., chlorpromazine, promethazine).",negative,quinidine,pectin
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), DRUG1, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), DRUG2 (e.g., chlorpromazine, promethazine).",negative,quinidine,phenothiazines
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), DRUG1, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., DRUG2, promethazine).",negative,quinidine,chlorpromazine
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), DRUG1, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, DRUG2).",negative,quinidine,promethazine
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, DRUG1, DRUG2 (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,amantadine,antihistamines
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, DRUG1, antihistamines (e.g., DRUG2), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,amantadine,diphenhydramine
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, DRUG1, antihistamines (e.g., diphenhydramine), other DRUG2, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,amantadine,anticholinergics
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, DRUG1, antihistamines (e.g., diphenhydramine), other anticholinergics, DRUG2 supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,amantadine,potassium chloride
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, DRUG1, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, DRUG2, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,amantadine,antacids
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, DRUG1, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, DRUG2 (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,amantadine,absorbent-type anti-diarrhea medicines
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, DRUG1, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., DRUG2-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,amantadine,kaolin
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, DRUG1, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-DRUG2), phenothiazines (e.g., chlorpromazine, promethazine).",negative,amantadine,pectin
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, DRUG1, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), DRUG2 (e.g., chlorpromazine, promethazine).",negative,amantadine,phenothiazines
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, DRUG1, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., DRUG2, promethazine).",negative,amantadine,chlorpromazine
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, DRUG1, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, DRUG2).",negative,amantadine,promethazine
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, DRUG1 (e.g., DRUG2), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,antihistamines,diphenhydramine
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, DRUG1 (e.g., diphenhydramine), other DRUG2, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,antihistamines,anticholinergics
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, DRUG1 (e.g., diphenhydramine), other anticholinergics, DRUG2 supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,antihistamines,potassium chloride
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, DRUG1 (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, DRUG2, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,antihistamines,antacids
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, DRUG1 (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, DRUG2 (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,antihistamines,absorbent-type anti-diarrhea medicines
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, DRUG1 (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., DRUG2-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,antihistamines,kaolin
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, DRUG1 (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-DRUG2), phenothiazines (e.g., chlorpromazine, promethazine).",negative,antihistamines,pectin
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, DRUG1 (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), DRUG2 (e.g., chlorpromazine, promethazine).",negative,antihistamines,phenothiazines
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, DRUG1 (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., DRUG2, promethazine).",negative,antihistamines,chlorpromazine
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, DRUG1 (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, DRUG2).",negative,antihistamines,promethazine
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., DRUG1), other DRUG2, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,diphenhydramine,anticholinergics
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., DRUG1), other anticholinergics, DRUG2 supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,diphenhydramine,potassium chloride
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., DRUG1), other anticholinergics, potassium chloride supplements, DRUG2, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,diphenhydramine,antacids
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., DRUG1), other anticholinergics, potassium chloride supplements, antacids, DRUG2 (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,diphenhydramine,absorbent-type anti-diarrhea medicines
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., DRUG1), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., DRUG2-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,diphenhydramine,kaolin
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., DRUG1), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-DRUG2), phenothiazines (e.g., chlorpromazine, promethazine).",negative,diphenhydramine,pectin
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., DRUG1), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), DRUG2 (e.g., chlorpromazine, promethazine).",negative,diphenhydramine,phenothiazines
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., DRUG1), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., DRUG2, promethazine).",negative,diphenhydramine,chlorpromazine
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., DRUG1), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, DRUG2).",negative,diphenhydramine,promethazine
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other DRUG1, DRUG2 supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,anticholinergics,potassium chloride
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other DRUG1, potassium chloride supplements, DRUG2, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,anticholinergics,antacids
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other DRUG1, potassium chloride supplements, antacids, DRUG2 (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,anticholinergics,absorbent-type anti-diarrhea medicines
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other DRUG1, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., DRUG2-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,anticholinergics,kaolin
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other DRUG1, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-DRUG2), phenothiazines (e.g., chlorpromazine, promethazine).",negative,anticholinergics,pectin
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other DRUG1, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), DRUG2 (e.g., chlorpromazine, promethazine).",negative,anticholinergics,phenothiazines
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other DRUG1, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., DRUG2, promethazine).",negative,anticholinergics,chlorpromazine
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other DRUG1, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, DRUG2).",negative,anticholinergics,promethazine
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, DRUG1 supplements, DRUG2, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,potassium chloride,antacids
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, DRUG1 supplements, antacids, DRUG2 (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,potassium chloride,absorbent-type anti-diarrhea medicines
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, DRUG1 supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., DRUG2-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,potassium chloride,kaolin
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, DRUG1 supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-DRUG2), phenothiazines (e.g., chlorpromazine, promethazine).",negative,potassium chloride,pectin
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, DRUG1 supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), DRUG2 (e.g., chlorpromazine, promethazine).",negative,potassium chloride,phenothiazines
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, DRUG1 supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., DRUG2, promethazine).",negative,potassium chloride,chlorpromazine
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, DRUG1 supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, DRUG2).",negative,potassium chloride,promethazine
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, DRUG1, DRUG2 (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,antacids,absorbent-type anti-diarrhea medicines
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, DRUG1, absorbent-type anti-diarrhea medicines (e.g., DRUG2-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,antacids,kaolin
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, DRUG1, absorbent-type anti-diarrhea medicines (e.g., kaolin-DRUG2), phenothiazines (e.g., chlorpromazine, promethazine).",negative,antacids,pectin
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, DRUG1, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), DRUG2 (e.g., chlorpromazine, promethazine).",negative,antacids,phenothiazines
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, DRUG1, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., DRUG2, promethazine).",negative,antacids,chlorpromazine
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, DRUG1, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, DRUG2).",negative,antacids,promethazine
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, DRUG1 (e.g., DRUG2-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",negative,absorbent-type anti-diarrhea medicines,kaolin
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, DRUG1 (e.g., kaolin-DRUG2), phenothiazines (e.g., chlorpromazine, promethazine).",negative,absorbent-type anti-diarrhea medicines,pectin
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, DRUG1 (e.g., kaolin-pectin), DRUG2 (e.g., chlorpromazine, promethazine).",negative,absorbent-type anti-diarrhea medicines,phenothiazines
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, DRUG1 (e.g., kaolin-pectin), phenothiazines (e.g., DRUG2, promethazine).",negative,absorbent-type anti-diarrhea medicines,chlorpromazine
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, DRUG1 (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, DRUG2).",negative,absorbent-type anti-diarrhea medicines,promethazine
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., DRUG1-DRUG2), phenothiazines (e.g., chlorpromazine, promethazine).",negative,kaolin,pectin
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., DRUG1-pectin), DRUG2 (e.g., chlorpromazine, promethazine).",negative,kaolin,phenothiazines
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., DRUG1-pectin), phenothiazines (e.g., DRUG2, promethazine).",negative,kaolin,chlorpromazine
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., DRUG1-pectin), phenothiazines (e.g., chlorpromazine, DRUG2).",negative,kaolin,promethazine
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-DRUG1), DRUG2 (e.g., chlorpromazine, promethazine).",negative,pectin,phenothiazines
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-DRUG1), phenothiazines (e.g., DRUG2, promethazine).",negative,pectin,chlorpromazine
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-DRUG1), phenothiazines (e.g., chlorpromazine, DRUG2).",negative,pectin,promethazine
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), DRUG1 (e.g., DRUG2, promethazine).",negative,phenothiazines,chlorpromazine
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), DRUG1 (e.g., chlorpromazine, DRUG2).",negative,phenothiazines,promethazine
"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., DRUG1, DRUG2).",negative,chlorpromazine,promethazine
"Due to its effects on gastric emptying, DRUG1 therapy should not be considered for patients taking drugs that alter gastrointestinal motility (e.g., DRUG2 such as atropine) and agents that slow the intestinal absorption of nutrients (e.g., alpha glucosidase inhibitors). ",advise,SYMLIN,anticholinergic agents
"Due to its effects on gastric emptying, DRUG1 therapy should not be considered for patients taking drugs that alter gastrointestinal motility (e.g., anticholinergic agents such as DRUG2) and agents that slow the intestinal absorption of nutrients (e.g., alpha glucosidase inhibitors). ",advise,SYMLIN,atropine
"Due to its effects on gastric emptying, DRUG1 therapy should not be considered for patients taking drugs that alter gastrointestinal motility (e.g., anticholinergic agents such as atropine) and agents that slow the intestinal absorption of nutrients (e.g., DRUG2). ",advise,SYMLIN,alpha glucosidase inhibitors
"Due to its effects on gastric emptying, SYMLIN therapy should not be considered for patients taking drugs that alter gastrointestinal motility (e.g., DRUG1 such as DRUG2) and agents that slow the intestinal absorption of nutrients (e.g., alpha glucosidase inhibitors). ",negative,anticholinergic agents,atropine
"Due to its effects on gastric emptying, SYMLIN therapy should not be considered for patients taking drugs that alter gastrointestinal motility (e.g., DRUG1 such as atropine) and agents that slow the intestinal absorption of nutrients (e.g., DRUG2). ",negative,anticholinergic agents,alpha glucosidase inhibitors
"Due to its effects on gastric emptying, SYMLIN therapy should not be considered for patients taking drugs that alter gastrointestinal motility (e.g., anticholinergic agents such as DRUG1) and agents that slow the intestinal absorption of nutrients (e.g., DRUG2). ",negative,atropine,alpha glucosidase inhibitors
"When the rapid onset of a concomitant orally administered agent is a critical determinant of effectiveness (such as DRUG1), the agent should be administered at least 1 hour prior to or 2 hours after DRUG2 injection. ",advise,analgesics,SYMLIN
"In clinical trials, the concomitant use of DRUG1 or DRUG2 did not alter the adverse event profile of SYMLIN. ",negative,sulfonylureas,biguanides
"In clinical trials, the concomitant use of DRUG1 or biguanides did not alter the adverse event profile of DRUG2. ",negative,sulfonylureas,SYMLIN
"In clinical trials, the concomitant use of sulfonylureas or DRUG1 did not alter the adverse event profile of DRUG2. ",negative,biguanides,SYMLIN
No formal interaction studies have been performed to assess the effect of DRUG1 on the kinetics of oral DRUG2. ,negative,SYMLIN,antidiabetic agents
"Mixing DRUG1 and DRUG2 The pharmacokinetic parameters of DRUG1 were altered when mixed with regular, NPH, and 70/30 premixed formulations of recombinant human DRUG2 immediately prior to injection. ",negative,SYMLIN,Insulin
"Mixing DRUG1 and Insulin The pharmacokinetic parameters of DRUG1 were altered when mixed with regular, NPH, and 70/30 premixed formulations of recombinant human insulin immediately prior to injection. ",negative,SYMLIN,SYMLIN
"Mixing DRUG1 and Insulin The pharmacokinetic parameters of DRUG1 were altered when mixed with regular, NPH, and 70/30 premixed formulations of recombinant DRUG2 immediately prior to injection. ",negative,SYMLIN,human insulin
"Mixing DRUG2 and DRUG1 The pharmacokinetic parameters of DRUG2 were altered when mixed with regular, NPH, and 70/30 premixed formulations of recombinant human DRUG1 immediately prior to injection. ",negative,Insulin,SYMLIN
"Mixing SYMLIN and DRUG1 The pharmacokinetic parameters of SYMLIN were altered when mixed with regular, NPH, and 70/30 premixed formulations of recombinant human DRUG1 immediately prior to injection. ",negative,Insulin,human insulin
"Mixing DRUG1 and Insulin The pharmacokinetic parameters of DRUG1 were altered when mixed with regular, NPH, and 70/30 premixed formulations of recombinant DRUG2 immediately prior to injection. ",mechanism,SYMLIN,human insulin
"Thus, DRUG1 and DRUG2 should not be mixed and must be administered separately.",negative,SYMLIN,insulin
Patients receiving DRUG1 and DRUG2 generally should not be treated with ganglion blockers.  ,negative,antibiotics,sulfonamides
Patients receiving DRUG1 and sulfonamides generally should not be treated with DRUG2.  ,advise,antibiotics,ganglion blockers
Patients receiving antibiotics and DRUG1 generally should not be treated with DRUG2.  ,advise,sulfonamides,ganglion blockers
"The action of DRUG1 may be potentiated by anesthesia, other DRUG2 and alcohol.",effect,Mecamylamine,antihypertensive drugs
"The action of DRUG1 may be potentiated by anesthesia, other antihypertensive drugs and DRUG2.",effect,Mecamylamine,alcohol
"The action of Mecamylamine may be potentiated by anesthesia, other DRUG1 and DRUG2.",negative,antihypertensive drugs,alcohol
"Oral DRUG1 has been reported to potentiate the anticoagulant effect of DRUG2 and warfarin, resulting in a prolongation of prothrombin time. ",effect,metronidazole,coumarin
"Oral DRUG1 has been reported to potentiate the anticoagulant effect of coumarin and DRUG2, resulting in a prolongation of prothrombin time. ",effect,metronidazole,warfarin
"Oral metronidazole has been reported to potentiate the anticoagulant effect of DRUG1 and DRUG2, resulting in a prolongation of prothrombin time. ",negative,coumarin,warfarin
"Drug interactions should be kept in mind when DRUG1 (DRUG2 gel), 1% is prescribed for patients who are receiving anticoagulant treatment, although they are less likely to occur with topical DRUG2 administration because of low absorption.    ",negative,METROGEL,metronidazole
"Drug interactions should be kept in mind when DRUG1 (DRUG2 gel), 1% is prescribed for patients who are receiving anticoagulant treatment, although they are less likely to occur with topical DRUG2 administration because of low absorption.    ",negative,METROGEL,metronidazole
"Drug interactions should be kept in mind when METROGEL (DRUG1 gel), 1% is prescribed for patients who are receiving anticoagulant treatment, although they are less likely to occur with topical DRUG1 administration because of low absorption.    ",negative,metronidazole,metronidazole
Concomitant use of DRUG1 with DRUG2 may result in an adverse drug interaction.,int,alcohol,phentermine hydrochloride
Other DRUG1 should not be used concomitantly with DRUG2 because they may have additive effects.,advise,short-acting beta adrenergic aerosol bronchodilators,MAXAIR AUTOHALER
A study published in 2002 found that DRUG1 causes a statistically significant increase in plasma clearance of DRUG2. ,mechanism,vigabatrin,carbamazepine
"In 1984, Drs Rimmer and Richens at the University of Wales reported that administering DRUG1 with DRUG2 lowered the serum DRUG2 concentration in patients with treatment-resistant epilepsy. ",mechanism,vigabatrin,phenytoin
"In 1984, Drs Rimmer and Richens at the University of Wales reported that administering DRUG1 with DRUG2 lowered the serum DRUG2 concentration in patients with treatment-resistant epilepsy. ",negative,vigabatrin,phenytoin
"In 1984, Drs Rimmer and Richens at the University of Wales reported that administering vigabatrin with DRUG1 lowered the serum DRUG1 concentration in patients with treatment-resistant epilepsy. ",negative,phenytoin,phenytoin
DRUG1: Concurrent use of DRUG2 and anticholinesterase agents may result in increased systemic toxicity since DRUG1 inhibit the breakdown of DRUG2. ,negative,Anticholinesterases,procaine hydrochloride
DRUG1: Concurrent use of procaine hydrochloride and DRUG2 may result in increased systemic toxicity since DRUG1 inhibit the breakdown of procaine hydrochloride. ,negative,Anticholinesterases,anticholinesterase agents
DRUG1: Concurrent use of procaine hydrochloride and anticholinesterase agents may result in increased systemic toxicity since DRUG1 inhibit the breakdown of procaine hydrochloride. ,negative,Anticholinesterases,anticholinesterases
DRUG1: Concurrent use of DRUG2 and anticholinesterase agents may result in increased systemic toxicity since DRUG1 inhibit the breakdown of DRUG2. ,negative,Anticholinesterases,procaine hydrochloride
Anticholinesterases: Concurrent use of DRUG1 and DRUG2 may result in increased systemic toxicity since anticholinesterases inhibit the breakdown of DRUG1. ,effect,procaine hydrochloride,anticholinesterase agents
DRUG2: Concurrent use of DRUG1 and anticholinesterase agents may result in increased systemic toxicity since DRUG2 inhibit the breakdown of DRUG1. ,negative,procaine hydrochloride,anticholinesterases
Anticholinesterases: Concurrent use of DRUG1 and anticholinesterase agents may result in increased systemic toxicity since anticholinesterases inhibit the breakdown of DRUG1. ,negative,procaine hydrochloride,procaine hydrochloride
DRUG2: Concurrent use of procaine hydrochloride and DRUG1 may result in increased systemic toxicity since DRUG2 inhibit the breakdown of procaine hydrochloride. ,negative,anticholinesterase agents,anticholinesterases
Anticholinesterases: Concurrent use of DRUG2 and DRUG1 may result in increased systemic toxicity since anticholinesterases inhibit the breakdown of DRUG2. ,negative,anticholinesterase agents,procaine hydrochloride
DRUG1: Concurrent use of DRUG2 and anticholinesterase agents may result in increased systemic toxicity since DRUG1 inhibit the breakdown of DRUG2. ,mechanism,anticholinesterases,procaine hydrochloride
DRUG1 medications: Concurrent use of DRUG2 and DRUG1 medications may result in additive depressant effects. ,negative,CNS depressant,procaine hydrochloride
DRUG1 medications: Concurrent use of procaine hydrochloride and DRUG1 medications may result in additive depressant effects. ,negative,CNS depressant,CNS depressant medications
DRUG2: Concurrent use of DRUG1 and DRUG2 may result in additive depressant effects. ,effect,procaine hydrochloride,CNS depressant medications
"DRUG1: DRUG1 may increase the diffusion rate of procaine hydrochloride, resulting in a decreased time of onset, but an increase in systemic toxicity. ",negative,Hyaluronidase,Hyaluronidase
"DRUG1: DRUG1 may increase the diffusion rate of DRUG2, resulting in a decreased time of onset, but an increase in systemic toxicity. ",negative,Hyaluronidase,procaine hydrochloride
"DRUG1: DRUG1 may increase the diffusion rate of DRUG2, resulting in a decreased time of onset, but an increase in systemic toxicity. ",mechanism,Hyaluronidase,procaine hydrochloride
DRUG1 (such as DRUG2): Concurrent use of procaine hydrochloride and DRUG1 may result in prolongation or enhancement of the neuromuscular blockade. ,negative,Neuromuscular blocking agents,suxamethonium chloride
DRUG1 (such as suxamethonium chloride): Concurrent use of DRUG2 and DRUG1 may result in prolongation or enhancement of the neuromuscular blockade. ,negative,Neuromuscular blocking agents,procaine hydrochloride
DRUG1 (such as suxamethonium chloride): Concurrent use of procaine hydrochloride and DRUG1 may result in prolongation or enhancement of the neuromuscular blockade. ,negative,Neuromuscular blocking agents,neuromuscular blocking agents
Neuromuscular blocking agents (such as DRUG1): Concurrent use of DRUG2 and neuromuscular blocking agents may result in prolongation or enhancement of the neuromuscular blockade. ,negative,suxamethonium chloride,procaine hydrochloride
DRUG2 (such as DRUG1): Concurrent use of procaine hydrochloride and DRUG2 may result in prolongation or enhancement of the neuromuscular blockade. ,negative,suxamethonium chloride,neuromuscular blocking agents
DRUG2 (such as suxamethonium chloride): Concurrent use of DRUG1 and DRUG2 may result in prolongation or enhancement of the neuromuscular blockade. ,effect,procaine hydrochloride,neuromuscular blocking agents
DRUG1: Concurrent use of DRUG2 and DRUG1 may result in a reduction of the antibacterial action of the sulfonamide. ,negative,Sulfonamides,procaine hydrochloride
DRUG1: Concurrent use of procaine hydrochloride and DRUG1 may result in a reduction of the antibacterial action of the sulfonamide. ,negative,Sulfonamides,sulfonamides
DRUG1: Concurrent use of procaine hydrochloride and DRUG1 may result in a reduction of the antibacterial action of the DRUG2. ,negative,Sulfonamides,sulfonamide
DRUG2: Concurrent use of DRUG1 and DRUG2 may result in a reduction of the antibacterial action of the sulfonamide. ,effect,procaine hydrochloride,sulfonamides
Sulfonamides: Concurrent use of DRUG1 and sulfonamides may result in a reduction of the antibacterial action of the DRUG2. ,negative,procaine hydrochloride,sulfonamide
DRUG1: Concurrent use of procaine hydrochloride and DRUG1 may result in a reduction of the antibacterial action of the DRUG2. ,negative,sulfonamides,sulfonamide
DRUG1: Concurrent use of DRUG1 and procaine hydrochloride may extend the plasma half-life of procaine.,negative,Acetazolamide,acetazolamide
DRUG1: Concurrent use of DRUG1 and DRUG2 may extend the plasma half-life of procaine.,negative,Acetazolamide,procaine hydrochloride
DRUG1: Concurrent use of DRUG1 and DRUG2 hydrochloride may extend the plasma half-life of DRUG2.,negative,Acetazolamide,procaine
DRUG1: Concurrent use of DRUG1 and DRUG2 may extend the plasma half-life of procaine.,mechanism,acetazolamide,procaine hydrochloride
DRUG1: Concurrent use of DRUG1 and DRUG2 hydrochloride may extend the plasma half-life of DRUG2.,negative,acetazolamide,procaine
Acetazolamide: Concurrent use of acetazolamide and DRUG1 may extend the plasma half-life of DRUG2.,negative,procaine hydrochloride,procaine
"Co-administration of DRUG1 with strong inhibitors of the CYP3A4 family (e.g., DRUG2, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ",mechanism,SUTENT,ketoconazole
"Co-administration of DRUG1 with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, DRUG2, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ",mechanism,SUTENT,itraconazole
"Co-administration of DRUG1 with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, DRUG2, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ",mechanism,SUTENT,clarithromycin
"Co-administration of DRUG1 with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, DRUG2, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ",mechanism,SUTENT,atazanavir
"Co-administration of DRUG1 with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, DRUG2, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ",mechanism,SUTENT,indinavir
"Co-administration of DRUG1 with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, DRUG2, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ",mechanism,SUTENT,nefazodone
"Co-administration of DRUG1 with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, DRUG2, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ",mechanism,SUTENT,nelfinavir
"Co-administration of DRUG1 with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, DRUG2, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ",mechanism,SUTENT,ritonavir
"Co-administration of DRUG1 with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, DRUG2, telithromycin, voriconizole) may increases sunitinib concentrations. ",mechanism,SUTENT,saquinavir
"Co-administration of DRUG1 with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, DRUG2, voriconizole) may increases sunitinib concentrations. ",mechanism,SUTENT,telithromycin
"Co-administration of DRUG1 with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, DRUG2) may increases sunitinib concentrations. ",mechanism,SUTENT,voriconizole
"Co-administration of DRUG1 with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases DRUG2 concentrations. ",negative,SUTENT,sunitinib
"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., DRUG1, DRUG2, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ",negative,ketoconazole,itraconazole
"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., DRUG1, itraconazole, DRUG2, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ",negative,ketoconazole,clarithromycin
"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., DRUG1, itraconazole, clarithromycin, DRUG2, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ",negative,ketoconazole,atazanavir
"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., DRUG1, itraconazole, clarithromycin, atazanavir, DRUG2, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ",negative,ketoconazole,indinavir
"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., DRUG1, itraconazole, clarithromycin, atazanavir, indinavir, DRUG2, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ",negative,ketoconazole,nefazodone
"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., DRUG1, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, DRUG2, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ",negative,ketoconazole,nelfinavir
"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., DRUG1, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, DRUG2, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ",negative,ketoconazole,ritonavir
"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., DRUG1, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, DRUG2, telithromycin, voriconizole) may increases sunitinib concentrations. ",negative,ketoconazole,saquinavir
"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., DRUG1, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, DRUG2, voriconizole) may increases sunitinib concentrations. ",negative,ketoconazole,telithromycin
"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., DRUG1, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, DRUG2) may increases sunitinib concentrations. ",negative,ketoconazole,voriconizole
"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., DRUG1, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases DRUG2 concentrations. ",negative,ketoconazole,sunitinib
"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, DRUG1, DRUG2, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ",negative,itraconazole,clarithromycin
"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, DRUG1, clarithromycin, DRUG2, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ",negative,itraconazole,atazanavir
"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, DRUG1, clarithromycin, atazanavir, DRUG2, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ",negative,itraconazole,indinavir
"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, DRUG1, clarithromycin, atazanavir, indinavir, DRUG2, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ",negative,itraconazole,nefazodone
"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, DRUG1, clarithromycin, atazanavir, indinavir, nefazodone, DRUG2, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ",negative,itraconazole,nelfinavir
"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, DRUG1, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, DRUG2, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ",negative,itraconazole,ritonavir
"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, DRUG1, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, DRUG2, telithromycin, voriconizole) may increases sunitinib concentrations. ",negative,itraconazole,saquinavir
"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, DRUG1, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, DRUG2, voriconizole) may increases sunitinib concentrations. ",negative,itraconazole,telithromycin
"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, DRUG1, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, DRUG2) may increases sunitinib concentrations. ",negative,itraconazole,voriconizole
"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, DRUG1, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases DRUG2 concentrations. ",negative,itraconazole,sunitinib
"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, DRUG1, DRUG2, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ",negative,clarithromycin,atazanavir
"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, DRUG1, atazanavir, DRUG2, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ",negative,clarithromycin,indinavir
"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, DRUG1, atazanavir, indinavir, DRUG2, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ",negative,clarithromycin,nefazodone
"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, DRUG1, atazanavir, indinavir, nefazodone, DRUG2, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ",negative,clarithromycin,nelfinavir
"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, DRUG1, atazanavir, indinavir, nefazodone, nelfinavir, DRUG2, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ",negative,clarithromycin,ritonavir
"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, DRUG1, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, DRUG2, telithromycin, voriconizole) may increases sunitinib concentrations. ",negative,clarithromycin,saquinavir
"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, DRUG1, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, DRUG2, voriconizole) may increases sunitinib concentrations. ",negative,clarithromycin,telithromycin
"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, DRUG1, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, DRUG2) may increases sunitinib concentrations. ",negative,clarithromycin,voriconizole
"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, DRUG1, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases DRUG2 concentrations. ",negative,clarithromycin,sunitinib
"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, DRUG1, DRUG2, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ",negative,atazanavir,indinavir
"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, DRUG1, indinavir, DRUG2, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ",negative,atazanavir,nefazodone
"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, DRUG1, indinavir, nefazodone, DRUG2, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ",negative,atazanavir,nelfinavir
"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, DRUG1, indinavir, nefazodone, nelfinavir, DRUG2, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ",negative,atazanavir,ritonavir
"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, DRUG1, indinavir, nefazodone, nelfinavir, ritonavir, DRUG2, telithromycin, voriconizole) may increases sunitinib concentrations. ",negative,atazanavir,saquinavir
"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, DRUG1, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, DRUG2, voriconizole) may increases sunitinib concentrations. ",negative,atazanavir,telithromycin
"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, DRUG1, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, DRUG2) may increases sunitinib concentrations. ",negative,atazanavir,voriconizole
"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, DRUG1, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases DRUG2 concentrations. ",negative,atazanavir,sunitinib
"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, DRUG1, DRUG2, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ",negative,indinavir,nefazodone
"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, DRUG1, nefazodone, DRUG2, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ",negative,indinavir,nelfinavir
"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, DRUG1, nefazodone, nelfinavir, DRUG2, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ",negative,indinavir,ritonavir
"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, DRUG1, nefazodone, nelfinavir, ritonavir, DRUG2, telithromycin, voriconizole) may increases sunitinib concentrations. ",negative,indinavir,saquinavir
"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, DRUG1, nefazodone, nelfinavir, ritonavir, saquinavir, DRUG2, voriconizole) may increases sunitinib concentrations. ",negative,indinavir,telithromycin
"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, DRUG1, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, DRUG2) may increases sunitinib concentrations. ",negative,indinavir,voriconizole
"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, DRUG1, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases DRUG2 concentrations. ",negative,indinavir,sunitinib
"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, DRUG1, DRUG2, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ",negative,nefazodone,nelfinavir
"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, DRUG1, nelfinavir, DRUG2, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ",negative,nefazodone,ritonavir
"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, DRUG1, nelfinavir, ritonavir, DRUG2, telithromycin, voriconizole) may increases sunitinib concentrations. ",negative,nefazodone,saquinavir
"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, DRUG1, nelfinavir, ritonavir, saquinavir, DRUG2, voriconizole) may increases sunitinib concentrations. ",negative,nefazodone,telithromycin
"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, DRUG1, nelfinavir, ritonavir, saquinavir, telithromycin, DRUG2) may increases sunitinib concentrations. ",negative,nefazodone,voriconizole
"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, DRUG1, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases DRUG2 concentrations. ",negative,nefazodone,sunitinib
"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, DRUG1, DRUG2, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ",negative,nelfinavir,ritonavir
"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, DRUG1, ritonavir, DRUG2, telithromycin, voriconizole) may increases sunitinib concentrations. ",negative,nelfinavir,saquinavir
"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, DRUG1, ritonavir, saquinavir, DRUG2, voriconizole) may increases sunitinib concentrations. ",negative,nelfinavir,telithromycin
"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, DRUG1, ritonavir, saquinavir, telithromycin, DRUG2) may increases sunitinib concentrations. ",negative,nelfinavir,voriconizole
"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, DRUG1, ritonavir, saquinavir, telithromycin, voriconizole) may increases DRUG2 concentrations. ",negative,nelfinavir,sunitinib
"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, DRUG1, DRUG2, telithromycin, voriconizole) may increases sunitinib concentrations. ",negative,ritonavir,saquinavir
"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, DRUG1, saquinavir, DRUG2, voriconizole) may increases sunitinib concentrations. ",negative,ritonavir,telithromycin
"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, DRUG1, saquinavir, telithromycin, DRUG2) may increases sunitinib concentrations. ",negative,ritonavir,voriconizole
"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, DRUG1, saquinavir, telithromycin, voriconizole) may increases DRUG2 concentrations. ",negative,ritonavir,sunitinib
"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, DRUG1, DRUG2, voriconizole) may increases sunitinib concentrations. ",negative,saquinavir,telithromycin
"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, DRUG1, telithromycin, DRUG2) may increases sunitinib concentrations. ",negative,saquinavir,voriconizole
"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, DRUG1, telithromycin, voriconizole) may increases DRUG2 concentrations. ",negative,saquinavir,sunitinib
"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, DRUG1, DRUG2) may increases sunitinib concentrations. ",negative,telithromycin,voriconizole
"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, DRUG1, voriconizole) may increases DRUG2 concentrations. ",negative,telithromycin,sunitinib
"Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, DRUG1) may increases DRUG2 concentrations. ",negative,voriconizole,sunitinib
"Co-administration of DRUG1 with inducers of the CYP3A4 family (e.g., DRUG2, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. ",mechanism,SUTENT,dexamethasone
"Co-administration of DRUG1 with inducers of the CYP3A4 family (e.g., dexamethasone, DRUG2, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. ",mechanism,SUTENT,phenytoin
"Co-administration of DRUG1 with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, DRUG2, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. ",mechanism,SUTENT,carbamazepine
"Co-administration of DRUG1 with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, DRUG2, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. ",mechanism,SUTENT,rifampin
"Co-administration of DRUG1 with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, DRUG2, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. ",mechanism,SUTENT,rifabutin
"Co-administration of DRUG1 with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, DRUG2, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. ",mechanism,SUTENT,rifapentin
"Co-administration of DRUG1 with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, DRUG2, St. Johns Wort) may decrease sunitinib concentrations. ",mechanism,SUTENT,phenobarbital
"Co-administration of DRUG1 with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease DRUG2 concentrations. ",negative,SUTENT,sunitinib
"Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., DRUG1, DRUG2, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. ",negative,dexamethasone,phenytoin
"Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., DRUG1, phenytoin, DRUG2, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. ",negative,dexamethasone,carbamazepine
"Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., DRUG1, phenytoin, carbamazepine, DRUG2, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. ",negative,dexamethasone,rifampin
"Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., DRUG1, phenytoin, carbamazepine, rifampin, DRUG2, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. ",negative,dexamethasone,rifabutin
"Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., DRUG1, phenytoin, carbamazepine, rifampin, rifabutin, DRUG2, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. ",negative,dexamethasone,rifapentin
"Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., DRUG1, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, DRUG2, St. Johns Wort) may decrease sunitinib concentrations. ",negative,dexamethasone,phenobarbital
"Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., DRUG1, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease DRUG2 concentrations. ",negative,dexamethasone,sunitinib
"Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, DRUG1, DRUG2, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. ",negative,phenytoin,carbamazepine
"Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, DRUG1, carbamazepine, DRUG2, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. ",negative,phenytoin,rifampin
"Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, DRUG1, carbamazepine, rifampin, DRUG2, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. ",negative,phenytoin,rifabutin
"Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, DRUG1, carbamazepine, rifampin, rifabutin, DRUG2, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. ",negative,phenytoin,rifapentin
"Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, DRUG1, carbamazepine, rifampin, rifabutin, rifapentin, DRUG2, St. Johns Wort) may decrease sunitinib concentrations. ",negative,phenytoin,phenobarbital
"Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, DRUG1, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease DRUG2 concentrations. ",negative,phenytoin,sunitinib
"Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, DRUG1, DRUG2, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. ",negative,carbamazepine,rifampin
"Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, DRUG1, rifampin, DRUG2, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. ",negative,carbamazepine,rifabutin
"Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, DRUG1, rifampin, rifabutin, DRUG2, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. ",negative,carbamazepine,rifapentin
"Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, DRUG1, rifampin, rifabutin, rifapentin, DRUG2, St. Johns Wort) may decrease sunitinib concentrations. ",negative,carbamazepine,phenobarbital
"Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, DRUG1, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease DRUG2 concentrations. ",negative,carbamazepine,sunitinib
"Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, DRUG1, DRUG2, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. ",negative,rifampin,rifabutin
"Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, DRUG1, rifabutin, DRUG2, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. ",negative,rifampin,rifapentin
"Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, DRUG1, rifabutin, rifapentin, DRUG2, St. Johns Wort) may decrease sunitinib concentrations. ",negative,rifampin,phenobarbital
"Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, DRUG1, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease DRUG2 concentrations. ",negative,rifampin,sunitinib
"Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, DRUG1, DRUG2, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. ",negative,rifabutin,rifapentin
"Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, DRUG1, rifapentin, DRUG2, St. Johns Wort) may decrease sunitinib concentrations. ",negative,rifabutin,phenobarbital
"Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, DRUG1, rifapentin, phenobarbital, St. Johns Wort) may decrease DRUG2 concentrations. ",negative,rifabutin,sunitinib
"Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, DRUG1, DRUG2, St. Johns Wort) may decrease sunitinib concentrations. ",negative,rifapentin,phenobarbital
"Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, DRUG1, phenobarbital, St. Johns Wort) may decrease DRUG2 concentrations. ",negative,rifapentin,sunitinib
"Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, DRUG1, St. Johns Wort) may decrease DRUG2 concentrations. ",negative,phenobarbital,sunitinib
"Drugs that induce hepatic enzymes such as DRUG1, DRUG2 and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response. ",negative,phenobarbital,phenytoin
"Drugs that induce hepatic enzymes such as DRUG1, phenytoin and DRUG2 may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response. ",negative,phenobarbital,rifampin
"Drugs that induce hepatic enzymes such as DRUG1, phenytoin and rifampin may increase the clearance of DRUG2 and may require increases in corticosteroid dose to achieve the desired response. ",mechanism,phenobarbital,corticosteroids
"Drugs that induce hepatic enzymes such as DRUG1, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in DRUG2 dose to achieve the desired response. ",mechanism,phenobarbital,corticosteroid
"Drugs that induce hepatic enzymes such as phenobarbital, DRUG1 and DRUG2 may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response. ",negative,phenytoin,rifampin
"Drugs that induce hepatic enzymes such as phenobarbital, DRUG1 and rifampin may increase the clearance of DRUG2 and may require increases in corticosteroid dose to achieve the desired response. ",mechanism,phenytoin,corticosteroids
"Drugs that induce hepatic enzymes such as phenobarbital, DRUG1 and rifampin may increase the clearance of corticosteroids and may require increases in DRUG2 dose to achieve the desired response. ",mechanism,phenytoin,corticosteroid
"Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and DRUG1 may increase the clearance of DRUG2 and may require increases in corticosteroid dose to achieve the desired response. ",mechanism,rifampin,corticosteroids
"Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and DRUG1 may increase the clearance of corticosteroids and may require increases in DRUG2 dose to achieve the desired response. ",mechanism,rifampin,corticosteroid
"Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of DRUG1 and may require increases in DRUG2 dose to achieve the desired response. ",negative,corticosteroids,corticosteroid
Drugs such as DRUG1 and DRUG2 may inhibit the metabolism of corticosteroids and thus decrease their clearance. ,negative,troleandomycin,ketoconazole
Drugs such as DRUG1 and ketoconazole may inhibit the metabolism of DRUG2 and thus decrease their clearance. ,mechanism,troleandomycin,corticosteroids
Drugs such as troleandomycin and DRUG1 may inhibit the metabolism of DRUG2 and thus decrease their clearance. ,mechanism,ketoconazole,corticosteroids
DRUG1 may increase the clearance of chronic high dose DRUG2. ,mechanism,Corticosteroids,aspirin
This could lead to decreased DRUG1 serum levels or increase the risk of DRUG1 toxicity when corticosteroid is withdrawn. ,negative,salicylate,salicylate
This could lead to decreased DRUG1 serum levels or increase the risk of DRUG1 toxicity when DRUG2 is withdrawn. ,negative,salicylate,corticosteroid
This could lead to decreased DRUG1 serum levels or increase the risk of DRUG1 toxicity when DRUG2 is withdrawn. ,effect,salicylate,corticosteroid
DRUG1 should be used cautiously in conjunction with DRUG2 in patients suffering from hypoprothrombinemia. ,advise,Aspirin,corticosteroids
The effect of DRUG1 on oral DRUG2 is variable. ,effect,corticosteroids,anticoagulants
There are reports of enhanced as well as diminished effects of DRUG1 when given concurrently with DRUG2. ,effect,anticoagulants,corticosteroids
"Interactions for DRUG1 (DRUG2):  Loop Diuretics, Oral Contraceptives, Stavudine, Tricyclic Antidepressants",negative,Vitamin B1,Thiamine
"Interactions for DRUG1 (Thiamine):  DRUG2, Oral Contraceptives, Stavudine, Tricyclic Antidepressants",int,Vitamin B1,Loop Diuretics
"Interactions for DRUG1 (Thiamine):  Loop Diuretics, Oral DRUG2, Stavudine, Tricyclic Antidepressants",int,Vitamin B1,Contraceptives
"Interactions for DRUG1 (Thiamine):  Loop Diuretics, Oral Contraceptives, DRUG2, Tricyclic Antidepressants",int,Vitamin B1,Stavudine
"Interactions for DRUG1 (Thiamine):  Loop Diuretics, Oral Contraceptives, Stavudine, DRUG2",int,Vitamin B1,Tricyclic Antidepressants
"Interactions for Vitamin B1 (DRUG1):  DRUG2, Oral Contraceptives, Stavudine, Tricyclic Antidepressants",int,Thiamine,Loop Diuretics
"Interactions for Vitamin B1 (DRUG1):  Loop Diuretics, Oral DRUG2, Stavudine, Tricyclic Antidepressants",int,Thiamine,Contraceptives
"Interactions for Vitamin B1 (DRUG1):  Loop Diuretics, Oral Contraceptives, DRUG2, Tricyclic Antidepressants",int,Thiamine,Stavudine
"Interactions for Vitamin B1 (DRUG1):  Loop Diuretics, Oral Contraceptives, Stavudine, DRUG2",int,Thiamine,Tricyclic Antidepressants
"Interactions for Vitamin B1 (Thiamine):  DRUG1, Oral DRUG2, Stavudine, Tricyclic Antidepressants",negative,Loop Diuretics,Contraceptives
"Interactions for Vitamin B1 (Thiamine):  DRUG1, Oral Contraceptives, DRUG2, Tricyclic Antidepressants",negative,Loop Diuretics,Stavudine
"Interactions for Vitamin B1 (Thiamine):  DRUG1, Oral Contraceptives, Stavudine, DRUG2",negative,Loop Diuretics,Tricyclic Antidepressants
"Interactions for Vitamin B1 (Thiamine):  Loop Diuretics, Oral DRUG1, DRUG2, Tricyclic Antidepressants",negative,Contraceptives,Stavudine
"Interactions for Vitamin B1 (Thiamine):  Loop Diuretics, Oral DRUG1, Stavudine, DRUG2",negative,Contraceptives,Tricyclic Antidepressants
"Interactions for Vitamin B1 (Thiamine):  Loop Diuretics, Oral Contraceptives, DRUG1, DRUG2",negative,Stavudine,Tricyclic Antidepressants
Drug-Drug Interactions Effect of DRUG1    (DRUG2) on the Metabolism of Other Drugs: Rivastigmine is primarily metabolized through hydrolysis by esterases. ,negative,Exelon,rivastigmine tartrate
Drug-Drug Interactions Effect of DRUG1    (DRUG2 tartrate) on the Metabolism of Other Drugs: DRUG2 is primarily metabolized through hydrolysis by esterases. ,negative,Exelon,Rivastigmine
Drug-Drug Interactions Effect of Exelon    (DRUG1) on the Metabolism of Other Drugs: DRUG2 is primarily metabolized through hydrolysis by esterases. ,negative,rivastigmine tartrate,Rivastigmine
"No pharmacokinetic interaction was observed between DRUG1 and DRUG2, warfarin, diazepam, or fluoxetine in studies in healthy volunteers. ",negative,rivastigmine,digoxin
"No pharmacokinetic interaction was observed between DRUG1 and digoxin, DRUG2, diazepam, or fluoxetine in studies in healthy volunteers. ",negative,rivastigmine,warfarin
"No pharmacokinetic interaction was observed between DRUG1 and digoxin, warfarin, DRUG2, or fluoxetine in studies in healthy volunteers. ",negative,rivastigmine,diazepam
"No pharmacokinetic interaction was observed between DRUG1 and digoxin, warfarin, diazepam, or DRUG2 in studies in healthy volunteers. ",negative,rivastigmine,fluoxetine
"No pharmacokinetic interaction was observed between rivastigmine and DRUG1, DRUG2, diazepam, or fluoxetine in studies in healthy volunteers. ",negative,digoxin,warfarin
"No pharmacokinetic interaction was observed between rivastigmine and DRUG1, warfarin, DRUG2, or fluoxetine in studies in healthy volunteers. ",negative,digoxin,diazepam
"No pharmacokinetic interaction was observed between rivastigmine and DRUG1, warfarin, diazepam, or DRUG2 in studies in healthy volunteers. ",negative,digoxin,fluoxetine
"No pharmacokinetic interaction was observed between rivastigmine and digoxin, DRUG1, DRUG2, or fluoxetine in studies in healthy volunteers. ",negative,warfarin,diazepam
"No pharmacokinetic interaction was observed between rivastigmine and digoxin, DRUG1, diazepam, or DRUG2 in studies in healthy volunteers. ",negative,warfarin,fluoxetine
"No pharmacokinetic interaction was observed between rivastigmine and digoxin, warfarin, DRUG1, or DRUG2 in studies in healthy volunteers. ",negative,diazepam,fluoxetine
The elevation of prothrombin time induced by DRUG1 is not affected by administration of DRUG2. ,negative,warfarin,Exelon
Effect of Other Drugs on the Metabolism of DRUG1: Drugs that induce or inhibit CYP450 metabolism are not expected to alter the metabolism of DRUG2. ,negative,Exelon,rivastigmine
"Single dose pharmacokinetic studies demonstrated that the metabolism of DRUG1 is not significantly affected by concurrent administration of DRUG2, warfarin, diazepam, or fluoxetine. ",negative,rivastigmine,digoxin
"Single dose pharmacokinetic studies demonstrated that the metabolism of DRUG1 is not significantly affected by concurrent administration of digoxin, DRUG2, diazepam, or fluoxetine. ",negative,rivastigmine,warfarin
"Single dose pharmacokinetic studies demonstrated that the metabolism of DRUG1 is not significantly affected by concurrent administration of digoxin, warfarin, DRUG2, or fluoxetine. ",negative,rivastigmine,diazepam
"Single dose pharmacokinetic studies demonstrated that the metabolism of DRUG1 is not significantly affected by concurrent administration of digoxin, warfarin, diazepam, or DRUG2. ",negative,rivastigmine,fluoxetine
"Single dose pharmacokinetic studies demonstrated that the metabolism of rivastigmine is not significantly affected by concurrent administration of DRUG1, DRUG2, diazepam, or fluoxetine. ",negative,digoxin,warfarin
"Single dose pharmacokinetic studies demonstrated that the metabolism of rivastigmine is not significantly affected by concurrent administration of DRUG1, warfarin, DRUG2, or fluoxetine. ",negative,digoxin,diazepam
"Single dose pharmacokinetic studies demonstrated that the metabolism of rivastigmine is not significantly affected by concurrent administration of DRUG1, warfarin, diazepam, or DRUG2. ",negative,digoxin,fluoxetine
"Single dose pharmacokinetic studies demonstrated that the metabolism of rivastigmine is not significantly affected by concurrent administration of digoxin, DRUG1, DRUG2, or fluoxetine. ",negative,warfarin,diazepam
"Single dose pharmacokinetic studies demonstrated that the metabolism of rivastigmine is not significantly affected by concurrent administration of digoxin, DRUG1, diazepam, or DRUG2. ",negative,warfarin,fluoxetine
"Single dose pharmacokinetic studies demonstrated that the metabolism of rivastigmine is not significantly affected by concurrent administration of digoxin, warfarin, DRUG1, or DRUG2. ",negative,diazepam,fluoxetine
"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of DRUG1 were not influenced by commonly prescribed medications such as DRUG2 (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). ",negative,rivastigmine,antacids
"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of DRUG1 were not influenced by commonly prescribed medications such as antacids (n=77), DRUG2 (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). ",negative,rivastigmine,antihypertensives
"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of DRUG1 were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), DRUG2 (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). ",negative,rivastigmine,calcium channel blockers
"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of DRUG1 were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), DRUG2 (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). ",negative,rivastigmine,antidiabetics
"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of DRUG1 were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), DRUG2 (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). ",negative,rivastigmine,nonsteroidal anti-inflammatory drugs
"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of DRUG1 were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), DRUG2 (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). ",negative,rivastigmine,estrogens
"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of DRUG1 were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), DRUG2 (n=177), antianginals (n=35), and antihistamines (n=15). ",negative,rivastigmine,salicylate analgesics
"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of DRUG1 were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), DRUG2 (n=35), and antihistamines (n=15). ",negative,rivastigmine,antianginals
"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of DRUG1 were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and DRUG2 (n=15). ",negative,rivastigmine,antihistamines
"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as DRUG1 (n=77), DRUG2 (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). ",negative,antacids,antihypertensives
"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as DRUG1 (n=77), antihypertensives (n=72), DRUG2 (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). ",negative,antacids,calcium channel blockers
"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as DRUG1 (n=77), antihypertensives (n=72), calcium channel blockers (n=75), DRUG2 (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). ",negative,antacids,antidiabetics
"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as DRUG1 (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), DRUG2 (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). ",negative,antacids,nonsteroidal anti-inflammatory drugs
"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as DRUG1 (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), DRUG2 (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). ",negative,antacids,estrogens
"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as DRUG1 (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), DRUG2 (n=177), antianginals (n=35), and antihistamines (n=15). ",negative,antacids,salicylate analgesics
"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as DRUG1 (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), DRUG2 (n=35), and antihistamines (n=15). ",negative,antacids,antianginals
"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as DRUG1 (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and DRUG2 (n=15). ",negative,antacids,antihistamines
"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), DRUG1 (n=72), DRUG2 (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). ",negative,antihypertensives,calcium channel blockers
"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), DRUG1 (n=72), calcium channel blockers (n=75), DRUG2 (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). ",negative,antihypertensives,antidiabetics
"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), DRUG1 (n=72), calcium channel blockers (n=75), antidiabetics (n=21), DRUG2 (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). ",negative,antihypertensives,nonsteroidal anti-inflammatory drugs
"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), DRUG1 (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), DRUG2 (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). ",negative,antihypertensives,estrogens
"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), DRUG1 (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), DRUG2 (n=177), antianginals (n=35), and antihistamines (n=15). ",negative,antihypertensives,salicylate analgesics
"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), DRUG1 (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), DRUG2 (n=35), and antihistamines (n=15). ",negative,antihypertensives,antianginals
"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), DRUG1 (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and DRUG2 (n=15). ",negative,antihypertensives,antihistamines
"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), DRUG1 (n=75), DRUG2 (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). ",negative,calcium channel blockers,antidiabetics
"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), DRUG1 (n=75), antidiabetics (n=21), DRUG2 (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). ",negative,calcium channel blockers,nonsteroidal anti-inflammatory drugs
"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), DRUG1 (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), DRUG2 (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). ",negative,calcium channel blockers,estrogens
"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), DRUG1 (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), DRUG2 (n=177), antianginals (n=35), and antihistamines (n=15). ",negative,calcium channel blockers,salicylate analgesics
"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), DRUG1 (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), DRUG2 (n=35), and antihistamines (n=15). ",negative,calcium channel blockers,antianginals
"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), DRUG1 (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and DRUG2 (n=15). ",negative,calcium channel blockers,antihistamines
"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), DRUG1 (n=21), DRUG2 (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). ",negative,antidiabetics,nonsteroidal anti-inflammatory drugs
"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), DRUG1 (n=21), nonsteroidal anti-inflammatory drugs (n=79), DRUG2 (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). ",negative,antidiabetics,estrogens
"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), DRUG1 (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), DRUG2 (n=177), antianginals (n=35), and antihistamines (n=15). ",negative,antidiabetics,salicylate analgesics
"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), DRUG1 (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), DRUG2 (n=35), and antihistamines (n=15). ",negative,antidiabetics,antianginals
"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), DRUG1 (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and DRUG2 (n=15). ",negative,antidiabetics,antihistamines
"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), DRUG1 (n=79), DRUG2 (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). ",negative,nonsteroidal anti-inflammatory drugs,estrogens
"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), DRUG1 (n=79), estrogens (n=70), DRUG2 (n=177), antianginals (n=35), and antihistamines (n=15). ",negative,nonsteroidal anti-inflammatory drugs,salicylate analgesics
"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), DRUG1 (n=79), estrogens (n=70), salicylate analgesics (n=177), DRUG2 (n=35), and antihistamines (n=15). ",negative,nonsteroidal anti-inflammatory drugs,antianginals
"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), DRUG1 (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and DRUG2 (n=15). ",negative,nonsteroidal anti-inflammatory drugs,antihistamines
"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), DRUG1 (n=70), DRUG2 (n=177), antianginals (n=35), and antihistamines (n=15). ",negative,estrogens,salicylate analgesics
"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), DRUG1 (n=70), salicylate analgesics (n=177), DRUG2 (n=35), and antihistamines (n=15). ",negative,estrogens,antianginals
"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), DRUG1 (n=70), salicylate analgesics (n=177), antianginals (n=35), and DRUG2 (n=15). ",negative,estrogens,antihistamines
"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), DRUG1 (n=177), DRUG2 (n=35), and antihistamines (n=15). ",negative,salicylate analgesics,antianginals
"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), DRUG1 (n=177), antianginals (n=35), and DRUG2 (n=15). ",negative,salicylate analgesics,antihistamines
"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), DRUG1 (n=35), and DRUG2 (n=15). ",negative,antianginals,antihistamines
"Use with DRUG1: Because of their mechanism of action, DRUG2 have the potential to interfere with the activity of anticholinergic medications. ",negative,Anticholinergics,cholinesterase inhibitors
"Use with DRUG1: Because of their mechanism of action, cholinesterase inhibitors have the potential to interfere with the activity of DRUG2. ",negative,Anticholinergics,anticholinergic medications
"Use with Anticholinergics: Because of their mechanism of action, DRUG1 have the potential to interfere with the activity of DRUG2. ",int,cholinesterase inhibitors,anticholinergic medications
"Use with DRUG1 and Other DRUG2: A synergistic effect may be expected when DRUG2 are given concurrently with succinylcholine, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.",negative,Cholinomimetics,Cholinesterase Inhibitors
"Use with DRUG1 and Other DRUG2: A synergistic effect may be expected when DRUG2 are given concurrently with succinylcholine, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.",negative,Cholinomimetics,cholinesterase inhibitors
"Use with DRUG1 and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with DRUG2, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.",negative,Cholinomimetics,succinylcholine
"Use with DRUG1 and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar DRUG2 or cholinergic agonists such as bethanechol.",negative,Cholinomimetics,neuromuscular blocking agents
"Use with DRUG1 and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents or DRUG2 such as bethanechol.",negative,Cholinomimetics,cholinergic agonists
"Use with DRUG1 and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents or cholinergic agonists such as DRUG2.",negative,Cholinomimetics,bethanechol
"Use with Cholinomimetics and Other DRUG1: A synergistic effect may be expected when DRUG1 are given concurrently with succinylcholine, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.",negative,Cholinesterase Inhibitors,cholinesterase inhibitors
"Use with Cholinomimetics and Other DRUG1: A synergistic effect may be expected when DRUG1 are given concurrently with DRUG2, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.",negative,Cholinesterase Inhibitors,succinylcholine
"Use with Cholinomimetics and Other DRUG1: A synergistic effect may be expected when DRUG1 are given concurrently with succinylcholine, similar DRUG2 or cholinergic agonists such as bethanechol.",negative,Cholinesterase Inhibitors,neuromuscular blocking agents
"Use with Cholinomimetics and Other DRUG1: A synergistic effect may be expected when DRUG1 are given concurrently with succinylcholine, similar neuromuscular blocking agents or DRUG2 such as bethanechol.",negative,Cholinesterase Inhibitors,cholinergic agonists
"Use with Cholinomimetics and Other DRUG1: A synergistic effect may be expected when DRUG1 are given concurrently with succinylcholine, similar neuromuscular blocking agents or cholinergic agonists such as DRUG2.",negative,Cholinesterase Inhibitors,bethanechol
"Use with Cholinomimetics and Other DRUG1: A synergistic effect may be expected when DRUG1 are given concurrently with DRUG2, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.",effect,cholinesterase inhibitors,succinylcholine
"Use with Cholinomimetics and Other DRUG1: A synergistic effect may be expected when DRUG1 are given concurrently with succinylcholine, similar DRUG2 or cholinergic agonists such as bethanechol.",effect,cholinesterase inhibitors,neuromuscular blocking agents
"Use with Cholinomimetics and Other DRUG1: A synergistic effect may be expected when DRUG1 are given concurrently with succinylcholine, similar neuromuscular blocking agents or DRUG2 such as bethanechol.",effect,cholinesterase inhibitors,cholinergic agonists
"Use with Cholinomimetics and Other DRUG1: A synergistic effect may be expected when DRUG1 are given concurrently with succinylcholine, similar neuromuscular blocking agents or cholinergic agonists such as DRUG2.",effect,cholinesterase inhibitors,bethanechol
"Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with DRUG1, similar DRUG2 or cholinergic agonists such as bethanechol.",negative,succinylcholine,neuromuscular blocking agents
"Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with DRUG1, similar neuromuscular blocking agents or DRUG2 such as bethanechol.",negative,succinylcholine,cholinergic agonists
"Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with DRUG1, similar neuromuscular blocking agents or cholinergic agonists such as DRUG2.",negative,succinylcholine,bethanechol
"Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar DRUG1 or DRUG2 such as bethanechol.",negative,neuromuscular blocking agents,cholinergic agonists
"Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar DRUG1 or cholinergic agonists such as DRUG2.",negative,neuromuscular blocking agents,bethanechol
"Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents or DRUG1 such as DRUG2.",negative,cholinergic agonists,bethanechol
"DRUG1: Spontaneous adverse reaction reports of patients taking concomitant DRUG1 with recommended doses of terfenadine demonstrate QT interval prolongation and rare serious cardiac events, e.g. ",negative,Ketoconazole,ketoconazole
"DRUG1: Spontaneous adverse reaction reports of patients taking concomitant DRUG1 with recommended doses of DRUG2 demonstrate QT interval prolongation and rare serious cardiac events, e.g. ",negative,Ketoconazole,terfenadine
"DRUG1: Spontaneous adverse reaction reports of patients taking concomitant DRUG1 with recommended doses of DRUG2 demonstrate QT interval prolongation and rare serious cardiac events, e.g. ",effect,ketoconazole,terfenadine
"Pharmacokinetic data indicate that DRUG1 markedly inhibits the metabolism of DRUG2, resulting in elevated plasma DRUG2 levels. ",mechanism,ketoconazole,terfenadine
"Pharmacokinetic data indicate that DRUG1 markedly inhibits the metabolism of DRUG2, resulting in elevated plasma DRUG2 levels. ",negative,ketoconazole,terfenadine
"Pharmacokinetic data indicate that ketoconazole markedly inhibits the metabolism of DRUG1, resulting in elevated plasma DRUG1 levels. ",negative,terfenadine,terfenadine
Concomitant administration of DRUG1 and DRUG2 is contraindicated. ,advise,ketoconazole,terfenadine
DRUG1: Torsades de pointes and elevated parent DRUG2 levels have been reported during concomitant use of DRUG2 and DRUG1 in clinical trials of DRUG1 and from foreign post-marketing sources. ,negative,Itraconazole,terfenadine
DRUG1: Torsades de pointes and elevated parent DRUG2 levels have been reported during concomitant use of DRUG2 and DRUG1 in clinical trials of DRUG1 and from foreign post-marketing sources. ,negative,Itraconazole,terfenadine
DRUG1: Torsades de pointes and elevated parent terfenadine levels have been reported during concomitant use of terfenadine and DRUG1 in clinical trials of DRUG1 and from foreign post-marketing sources. ,negative,Itraconazole,itraconazole
DRUG1: Torsades de pointes and elevated parent terfenadine levels have been reported during concomitant use of terfenadine and DRUG1 in clinical trials of DRUG1 and from foreign post-marketing sources. ,negative,Itraconazole,itraconazole
Itraconazole: Torsades de pointes and elevated parent DRUG1 levels have been reported during concomitant use of DRUG1 and itraconazole in clinical trials of itraconazole and from foreign post-marketing sources. ,negative,terfenadine,terfenadine
DRUG2: Torsades de pointes and elevated parent DRUG1 levels have been reported during concomitant use of DRUG1 and DRUG2 in clinical trials of DRUG2 and from foreign post-marketing sources. ,negative,terfenadine,itraconazole
DRUG2: Torsades de pointes and elevated parent DRUG1 levels have been reported during concomitant use of DRUG1 and DRUG2 in clinical trials of DRUG2 and from foreign post-marketing sources. ,negative,terfenadine,itraconazole
DRUG2: Torsades de pointes and elevated parent DRUG1 levels have been reported during concomitant use of DRUG1 and DRUG2 in clinical trials of DRUG2 and from foreign post-marketing sources. ,mechanism,terfenadine,itraconazole
DRUG2: Torsades de pointes and elevated parent DRUG1 levels have been reported during concomitant use of DRUG1 and DRUG2 in clinical trials of DRUG2 and from foreign post-marketing sources. ,negative,terfenadine,itraconazole
DRUG1: Torsades de pointes and elevated parent terfenadine levels have been reported during concomitant use of terfenadine and DRUG1 in clinical trials of DRUG1 and from foreign post-marketing sources. ,negative,itraconazole,itraconazole
Concomitant administration of DRUG1 and DRUG2 is contraindicated. ,advise,itraconazole,terfenadine
"Due to the chemical similarity of other DRUG1 (including DRUG2, metronidazole, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions. ",negative,azole-type antifungal agents,fluconazole
"Due to the chemical similarity of other DRUG1 (including fluconazole, DRUG2, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions. ",negative,azole-type antifungal agents,metronidazole
"Due to the chemical similarity of other DRUG1 (including fluconazole, metronidazole, and DRUG2) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions. ",negative,azole-type antifungal agents,miconazole
"Due to the chemical similarity of other DRUG1 (including fluconazole, metronidazole, and miconazole) to DRUG2, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions. ",negative,azole-type antifungal agents,ketoconazole
"Due to the chemical similarity of other DRUG1 (including fluconazole, metronidazole, and miconazole) to ketoconazole, and DRUG2, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions. ",negative,azole-type antifungal agents,itraconazole
"Due to the chemical similarity of other DRUG1 (including fluconazole, metronidazole, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with DRUG2 is not recommended pending full examination of potential interactions. ",advise,azole-type antifungal agents,terfenadine
"Due to the chemical similarity of other azole-type antifungal agents (including DRUG1, DRUG2, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions. ",negative,fluconazole,metronidazole
"Due to the chemical similarity of other azole-type antifungal agents (including DRUG1, metronidazole, and DRUG2) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions. ",negative,fluconazole,miconazole
"Due to the chemical similarity of other azole-type antifungal agents (including DRUG1, metronidazole, and miconazole) to DRUG2, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions. ",negative,fluconazole,ketoconazole
"Due to the chemical similarity of other azole-type antifungal agents (including DRUG1, metronidazole, and miconazole) to ketoconazole, and DRUG2, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions. ",negative,fluconazole,itraconazole
"Due to the chemical similarity of other azole-type antifungal agents (including DRUG1, metronidazole, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with DRUG2 is not recommended pending full examination of potential interactions. ",advise,fluconazole,terfenadine
"Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, DRUG1, and DRUG2) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions. ",negative,metronidazole,miconazole
"Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, DRUG1, and miconazole) to DRUG2, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions. ",negative,metronidazole,ketoconazole
"Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, DRUG1, and miconazole) to ketoconazole, and DRUG2, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions. ",negative,metronidazole,itraconazole
"Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, DRUG1, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with DRUG2 is not recommended pending full examination of potential interactions. ",advise,metronidazole,terfenadine
"Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and DRUG1) to DRUG2, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions. ",negative,miconazole,ketoconazole
"Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and DRUG1) to ketoconazole, and DRUG2, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions. ",negative,miconazole,itraconazole
"Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and DRUG1) to ketoconazole, and itraconazole, concomitant use of these products with DRUG2 is not recommended pending full examination of potential interactions. ",advise,miconazole,terfenadine
"Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and miconazole) to DRUG1, and DRUG2, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions. ",negative,ketoconazole,itraconazole
"Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and miconazole) to DRUG1, and itraconazole, concomitant use of these products with DRUG2 is not recommended pending full examination of potential interactions. ",negative,ketoconazole,terfenadine
"Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and miconazole) to ketoconazole, and DRUG1, concomitant use of these products with DRUG2 is not recommended pending full examination of potential interactions. ",negative,itraconazole,terfenadine
"DRUG1: Clinical drug interaction studies indicate that DRUG2 and clarithromycin can exert an effect on terfenadine metabolism by a mechanism which may be similar to that of ketoconazole, but to a lesser extent. ",negative,Macrolides,erythromycin
"DRUG1: Clinical drug interaction studies indicate that erythromycin and DRUG2 can exert an effect on terfenadine metabolism by a mechanism which may be similar to that of ketoconazole, but to a lesser extent. ",negative,Macrolides,clarithromycin
"DRUG1: Clinical drug interaction studies indicate that erythromycin and clarithromycin can exert an effect on DRUG2 metabolism by a mechanism which may be similar to that of ketoconazole, but to a lesser extent. ",negative,Macrolides,terfenadine
"DRUG1: Clinical drug interaction studies indicate that erythromycin and clarithromycin can exert an effect on terfenadine metabolism by a mechanism which may be similar to that of DRUG2, but to a lesser extent. ",negative,Macrolides,ketoconazole
"Macrolides: Clinical drug interaction studies indicate that DRUG1 and DRUG2 can exert an effect on terfenadine metabolism by a mechanism which may be similar to that of ketoconazole, but to a lesser extent. ",negative,erythromycin,clarithromycin
"Macrolides: Clinical drug interaction studies indicate that DRUG1 and clarithromycin can exert an effect on DRUG2 metabolism by a mechanism which may be similar to that of ketoconazole, but to a lesser extent. ",mechanism,erythromycin,terfenadine
"Macrolides: Clinical drug interaction studies indicate that DRUG1 and clarithromycin can exert an effect on terfenadine metabolism by a mechanism which may be similar to that of DRUG2, but to a lesser extent. ",negative,erythromycin,ketoconazole
"Macrolides: Clinical drug interaction studies indicate that erythromycin and DRUG1 can exert an effect on DRUG2 metabolism by a mechanism which may be similar to that of ketoconazole, but to a lesser extent. ",mechanism,clarithromycin,terfenadine
"Macrolides: Clinical drug interaction studies indicate that erythromycin and DRUG1 can exert an effect on terfenadine metabolism by a mechanism which may be similar to that of DRUG2, but to a lesser extent. ",negative,clarithromycin,ketoconazole
"Macrolides: Clinical drug interaction studies indicate that erythromycin and clarithromycin can exert an effect on DRUG1 metabolism by a mechanism which may be similar to that of DRUG2, but to a lesser extent. ",negative,terfenadine,ketoconazole
"A few spontaneous accounts of QT interval prolongation with ventricular arrhythmia including torsades de pointes, have been reported in patients receiving DRUG1 or DRUG2. ",negative,erythromycin,troleandomycin
"Concomitant administration of DRUG1 with DRUG2, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of DRUG1 with other macrolide antibiotics, including azithromycin, is not recommended. ",advise,terfenadine,clarithromycin
"Concomitant administration of DRUG1 with clarithromycin, DRUG2, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of DRUG1 with other macrolide antibiotics, including azithromycin, is not recommended. ",advise,terfenadine,erythromycin
"Concomitant administration of DRUG1 with clarithromycin, erythromycin, or DRUG2 is contraindicated: Pending full characterization of potential interactions, concomitant administration of DRUG1 with other macrolide antibiotics, including azithromycin, is not recommended. ",advise,terfenadine,troleandomycin
"Concomitant administration of DRUG1 with clarithromycin, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of DRUG1 with other macrolide antibiotics, including azithromycin, is not recommended. ",negative,terfenadine,terfenadine
"Concomitant administration of DRUG1 with clarithromycin, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of DRUG1 with other DRUG2, including azithromycin, is not recommended. ",negative,terfenadine,macrolide antibiotics
"Concomitant administration of DRUG1 with clarithromycin, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of DRUG1 with other macrolide antibiotics, including DRUG2, is not recommended. ",negative,terfenadine,azithromycin
"Concomitant administration of terfenadine with DRUG1, DRUG2, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended. ",negative,clarithromycin,erythromycin
"Concomitant administration of terfenadine with DRUG1, erythromycin, or DRUG2 is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended. ",negative,clarithromycin,troleandomycin
"Concomitant administration of DRUG2 with DRUG1, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of DRUG2 with other macrolide antibiotics, including azithromycin, is not recommended. ",negative,clarithromycin,terfenadine
"Concomitant administration of terfenadine with DRUG1, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other DRUG2, including azithromycin, is not recommended. ",negative,clarithromycin,macrolide antibiotics
"Concomitant administration of terfenadine with DRUG1, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including DRUG2, is not recommended. ",negative,clarithromycin,azithromycin
"Concomitant administration of terfenadine with clarithromycin, DRUG1, or DRUG2 is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended. ",negative,erythromycin,troleandomycin
"Concomitant administration of DRUG2 with clarithromycin, DRUG1, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of DRUG2 with other macrolide antibiotics, including azithromycin, is not recommended. ",negative,erythromycin,terfenadine
"Concomitant administration of terfenadine with clarithromycin, DRUG1, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other DRUG2, including azithromycin, is not recommended. ",negative,erythromycin,macrolide antibiotics
"Concomitant administration of terfenadine with clarithromycin, DRUG1, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including DRUG2, is not recommended. ",negative,erythromycin,azithromycin
"Concomitant administration of DRUG2 with clarithromycin, erythromycin, or DRUG1 is contraindicated: Pending full characterization of potential interactions, concomitant administration of DRUG2 with other macrolide antibiotics, including azithromycin, is not recommended. ",negative,troleandomycin,terfenadine
"Concomitant administration of terfenadine with clarithromycin, erythromycin, or DRUG1 is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other DRUG2, including azithromycin, is not recommended. ",negative,troleandomycin,macrolide antibiotics
"Concomitant administration of terfenadine with clarithromycin, erythromycin, or DRUG1 is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including DRUG2, is not recommended. ",negative,troleandomycin,azithromycin
"Concomitant administration of DRUG1 with clarithromycin, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of DRUG1 with other DRUG2, including azithromycin, is not recommended. ",advise,terfenadine,macrolide antibiotics
"Concomitant administration of DRUG1 with clarithromycin, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of DRUG1 with other macrolide antibiotics, including DRUG2, is not recommended. ",advise,terfenadine,azithromycin
"Concomitant administration of terfenadine with clarithromycin, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other DRUG1, including DRUG2, is not recommended. ",negative,macrolide antibiotics,azithromycin
Studies to evaluate potential interactions of DRUG1 with DRUG2 are in progress.,negative,terfenadine,azithromycin
Caution is recommended when administering DRUG1 with compounds that are metabolized/eliminated predominantly by the UGT1A1 pathway (e.g. DRUG2). ,advise,NEXAVAR,irinotecan
Concomitant treatment with DRUG1 resulted in a 21% increase in the AUC of DRUG2. ,mechanism,NEXAVAR,doxorubicin
Caution is recommended when administering DRUG1 with DRUG2. ,advise,doxorubicin,NEXAVAR
"In a pharmacokinetic study of 18 chronic hepatitis C patients concomitantly receiving DRUG1, treatment with DRUG2 once weekly for 4 weeks was associated with a mean increase of 16% in DRUG1 AUC; ",mechanism,methadone,PEG-Intron
"In a pharmacokinetic study of 18 chronic hepatitis C patients concomitantly receiving DRUG1, treatment with PEG-Intron once weekly for 4 weeks was associated with a mean increase of 16% in DRUG1 AUC; ",negative,methadone,methadone
"In a pharmacokinetic study of 18 chronic hepatitis C patients concomitantly receiving DRUG2, treatment with DRUG1 once weekly for 4 weeks was associated with a mean increase of 16% in DRUG2 AUC; ",negative,PEG-Intron,methadone
"Since DRUG1 is a substrate for the metabolic pathways involving CYP2D6 and CYP1A2 enzymes, inhibition or induction of either of these enzymes would be expected to alter DRUG2 plasma concentrations. ",negative,MEXITIL,mexiletine
"In a formal, single-dose interaction study (n = 6 males) the clearance of DRUG1 was decreased by 38% following the coadministration of DRUG2, an inhibitor of CYP1A2. ",mechanism,mexiletine,fluvoxamine
"In another formal study (n = 8 extensive and n = 7 poor metabolizers of CYP2D6), coadministration of DRUG1 did not alter the kinetics of DRUG2 in the poor CYP2D6 metabolizer group. ",negative,propafenone,mexiletine
"In this crossover steady state study, the pharmacokinetics of DRUG1 were unaffected in either phenotype by the coadministration of DRUG2. ",negative,propafenone,mexiletine
"Addition of DRUG1 to DRUG2 did not lead to further electrocardiographic parameters changes of QRS, QTc, RR, and PR intervals than DRUG2 alone. ",negative,mexiletine,propafenone
"Addition of DRUG1 to DRUG2 did not lead to further electrocardiographic parameters changes of QRS, QTc, RR, and PR intervals than DRUG2 alone. ",negative,mexiletine,propafenone
"Addition of mexiletine to DRUG1 did not lead to further electrocardiographic parameters changes of QRS, QTc, RR, and PR intervals than DRUG1 alone. ",negative,propafenone,propafenone
"When concomitant administration of either of these two drugs with DRUG1 is initiated, the dose of DRUG1 should be slowly titrated to desired effect. ",negative,mexiletine,mexiletine
"In a large compassionate use program DRUG1    has been used concurrently with commonly employed antianginal, DRUG2, and anticoagulant drugs without observed interactions. ",negative,Mexitil,antihypertensive
"In a large compassionate use program DRUG1    has been used concurrently with commonly employed antianginal, antihypertensive, and DRUG2 without observed interactions. ",negative,Mexitil,anticoagulant drugs
"In a large compassionate use program Mexitil    has been used concurrently with commonly employed antianginal, DRUG1, and DRUG2 without observed interactions. ",negative,antihypertensive,anticoagulant drugs
"A variety of DRUG1 such as DRUG2 or propranolol were also added, sometimes with improved control of ventricular ectopy. ",negative,antiarrhythmics,quinidine
"A variety of DRUG1 such as quinidine or DRUG2 were also added, sometimes with improved control of ventricular ectopy. ",negative,antiarrhythmics,propranolol
"A variety of antiarrhythmics such as DRUG1 or DRUG2 were also added, sometimes with improved control of ventricular ectopy. ",negative,quinidine,propranolol
"When DRUG1 or other hepatic enzyme inducers such as DRUG2 and phenobarbital have been taken concurrently with Mexitil   , lowered Mexitil    plasma levels have been reported. ",negative,phenytoin,rifampin
"When DRUG1 or other hepatic enzyme inducers such as rifampin and DRUG2 have been taken concurrently with Mexitil   , lowered Mexitil    plasma levels have been reported. ",negative,phenytoin,phenobarbital
"When DRUG1 or other hepatic enzyme inducers such as rifampin and phenobarbital have been taken concurrently with DRUG2   , lowered DRUG2    plasma levels have been reported. ",mechanism,phenytoin,Mexitil
"When DRUG1 or other hepatic enzyme inducers such as rifampin and phenobarbital have been taken concurrently with DRUG2   , lowered DRUG2    plasma levels have been reported. ",negative,phenytoin,Mexitil
"When phenytoin or other hepatic enzyme inducers such as DRUG1 and DRUG2 have been taken concurrently with Mexitil   , lowered Mexitil    plasma levels have been reported. ",negative,rifampin,phenobarbital
"When phenytoin or other hepatic enzyme inducers such as DRUG1 and phenobarbital have been taken concurrently with DRUG2   , lowered DRUG2    plasma levels have been reported. ",mechanism,rifampin,Mexitil
"When phenytoin or other hepatic enzyme inducers such as DRUG1 and phenobarbital have been taken concurrently with DRUG2   , lowered DRUG2    plasma levels have been reported. ",negative,rifampin,Mexitil
"When phenytoin or other hepatic enzyme inducers such as rifampin and DRUG1 have been taken concurrently with DRUG2   , lowered DRUG2    plasma levels have been reported. ",mechanism,phenobarbital,Mexitil
"When phenytoin or other hepatic enzyme inducers such as rifampin and DRUG1 have been taken concurrently with DRUG2   , lowered DRUG2    plasma levels have been reported. ",negative,phenobarbital,Mexitil
"When phenytoin or other hepatic enzyme inducers such as rifampin and phenobarbital have been taken concurrently with DRUG1   , lowered DRUG1    plasma levels have been reported. ",negative,Mexitil,Mexitil
"In a formal study, DRUG1 were shown not to affect DRUG2    plasma concentrations. ",negative,benzodiazepines,Mexitil
"ECG intervals (PR, QRS, and QT) were not affected by concurrent DRUG1    and DRUG2, diuretics, or propranolol. ",negative,Mexitil,digoxin
"ECG intervals (PR, QRS, and QT) were not affected by concurrent DRUG1    and digoxin, DRUG2, or propranolol. ",negative,Mexitil,diuretics
"ECG intervals (PR, QRS, and QT) were not affected by concurrent DRUG1    and digoxin, diuretics, or DRUG2. ",negative,Mexitil,propranolol
"ECG intervals (PR, QRS, and QT) were not affected by concurrent Mexitil    and DRUG1, DRUG2, or propranolol. ",negative,digoxin,diuretics
"ECG intervals (PR, QRS, and QT) were not affected by concurrent Mexitil    and DRUG1, diuretics, or DRUG2. ",negative,digoxin,propranolol
"ECG intervals (PR, QRS, and QT) were not affected by concurrent Mexitil    and digoxin, DRUG1, or DRUG2. ",negative,diuretics,propranolol
"Concurrent administration of DRUG1 and DRUG2    has been reported to increase, decrease, or leave unchanged DRUG2    plasma levels; ",mechanism,cimetidine,Mexitil
"Concurrent administration of DRUG1 and DRUG2    has been reported to increase, decrease, or leave unchanged DRUG2    plasma levels; ",negative,cimetidine,Mexitil
"Concurrent administration of cimetidine and DRUG1    has been reported to increase, decrease, or leave unchanged DRUG1    plasma levels; ",negative,Mexitil,Mexitil
"DRUG1    does not alter serum DRUG2 levels but magnesium-aluminum hydroxide, when used to treat gastrointestinal symptoms due to DRUG1   , has been reported to lower serum DRUG2 levels. ",negative,Mexitil,digoxin
"DRUG1    does not alter serum digoxin levels but DRUG2, when used to treat gastrointestinal symptoms due to DRUG1   , has been reported to lower serum digoxin levels. ",negative,Mexitil,magnesium-aluminum hydroxide
"DRUG1    does not alter serum digoxin levels but magnesium-aluminum hydroxide, when used to treat gastrointestinal symptoms due to DRUG1   , has been reported to lower serum digoxin levels. ",negative,Mexitil,Mexitil
"DRUG1    does not alter serum DRUG2 levels but magnesium-aluminum hydroxide, when used to treat gastrointestinal symptoms due to DRUG1   , has been reported to lower serum DRUG2 levels. ",negative,Mexitil,digoxin
"Mexitil    does not alter serum DRUG1 levels but DRUG2, when used to treat gastrointestinal symptoms due to Mexitil   , has been reported to lower serum DRUG1 levels. ",negative,digoxin,magnesium-aluminum hydroxide
"DRUG2    does not alter serum DRUG1 levels but magnesium-aluminum hydroxide, when used to treat gastrointestinal symptoms due to DRUG2   , has been reported to lower serum DRUG1 levels. ",negative,digoxin,Mexitil
"Mexitil    does not alter serum DRUG1 levels but magnesium-aluminum hydroxide, when used to treat gastrointestinal symptoms due to Mexitil   , has been reported to lower serum DRUG1 levels. ",negative,digoxin,digoxin
"DRUG2    does not alter serum digoxin levels but DRUG1, when used to treat gastrointestinal symptoms due to DRUG2   , has been reported to lower serum digoxin levels. ",negative,magnesium-aluminum hydroxide,Mexitil
"Mexitil    does not alter serum DRUG2 levels but DRUG1, when used to treat gastrointestinal symptoms due to Mexitil   , has been reported to lower serum DRUG2 levels. ",mechanism,magnesium-aluminum hydroxide,digoxin
"DRUG1    does not alter serum DRUG2 levels but magnesium-aluminum hydroxide, when used to treat gastrointestinal symptoms due to DRUG1   , has been reported to lower serum DRUG2 levels. ",negative,Mexitil,digoxin
Concurrent use of DRUG1    and DRUG2 may lead to increased plasma DRUG2 levels. ,mechanism,Mexitil,theophylline
Concurrent use of DRUG1    and DRUG2 may lead to increased plasma DRUG2 levels. ,negative,Mexitil,theophylline
Concurrent use of Mexitil    and DRUG1 may lead to increased plasma DRUG1 levels. ,negative,theophylline,theophylline
"This increase was observed at the first test point which was the second day after starting DRUG1   . DRUG2 plasma levels returned to pre-DRUG1    values within 48 hours after discontinuing DRUG1   . If DRUG1 and DRUG2 are to be used concurrently, DRUG2 blood levels should be monitored, particularly when the DRUG1    dose is changed. ",negative,Mexitil,Theophylline
"This increase was observed at the first test point which was the second day after starting DRUG1   . Theophylline plasma levels returned to pre-DRUG1    values within 48 hours after discontinuing DRUG1   . If DRUG1 and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the DRUG1    dose is changed. ",negative,Mexitil,Mexitil
"This increase was observed at the first test point which was the second day after starting DRUG1   . Theophylline plasma levels returned to pre-DRUG1    values within 48 hours after discontinuing DRUG1   . If DRUG1 and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the DRUG1    dose is changed. ",negative,Mexitil,Mexitil
"This increase was observed at the first test point which was the second day after starting DRUG1   . Theophylline plasma levels returned to pre-DRUG1    values within 48 hours after discontinuing DRUG1   . If DRUG1 and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the DRUG1    dose is changed. ",negative,Mexitil,Mexitil
"This increase was observed at the first test point which was the second day after starting DRUG1   . DRUG2 plasma levels returned to pre-DRUG1    values within 48 hours after discontinuing DRUG1   . If DRUG1 and DRUG2 are to be used concurrently, DRUG2 blood levels should be monitored, particularly when the DRUG1    dose is changed. ",negative,Mexitil,theophylline
"This increase was observed at the first test point which was the second day after starting DRUG1   . DRUG2 plasma levels returned to pre-DRUG1    values within 48 hours after discontinuing DRUG1   . If DRUG1 and DRUG2 are to be used concurrently, DRUG2 blood levels should be monitored, particularly when the DRUG1    dose is changed. ",negative,Mexitil,theophylline
"This increase was observed at the first test point which was the second day after starting DRUG1   . Theophylline plasma levels returned to pre-DRUG1    values within 48 hours after discontinuing DRUG1   . If DRUG1 and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the DRUG1    dose is changed. ",negative,Mexitil,Mexitil
"This increase was observed at the first test point which was the second day after starting DRUG2   . DRUG1 plasma levels returned to pre-DRUG2    values within 48 hours after discontinuing DRUG2   . If DRUG2 and DRUG1 are to be used concurrently, DRUG1 blood levels should be monitored, particularly when the DRUG2    dose is changed. ",negative,Theophylline,Mexitil
"This increase was observed at the first test point which was the second day after starting DRUG2   . DRUG1 plasma levels returned to pre-DRUG2    values within 48 hours after discontinuing DRUG2   . If DRUG2 and DRUG1 are to be used concurrently, DRUG1 blood levels should be monitored, particularly when the DRUG2    dose is changed. ",mechanism,Theophylline,Mexitil
"This increase was observed at the first test point which was the second day after starting DRUG2   . DRUG1 plasma levels returned to pre-DRUG2    values within 48 hours after discontinuing DRUG2   . If DRUG2 and DRUG1 are to be used concurrently, DRUG1 blood levels should be monitored, particularly when the DRUG2    dose is changed. ",negative,Theophylline,Mexitil
"This increase was observed at the first test point which was the second day after starting Mexitil   . DRUG1 plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and DRUG1 are to be used concurrently, DRUG1 blood levels should be monitored, particularly when the Mexitil    dose is changed. ",negative,Theophylline,theophylline
"This increase was observed at the first test point which was the second day after starting Mexitil   . DRUG1 plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and DRUG1 are to be used concurrently, DRUG1 blood levels should be monitored, particularly when the Mexitil    dose is changed. ",negative,Theophylline,theophylline
"This increase was observed at the first test point which was the second day after starting DRUG2   . DRUG1 plasma levels returned to pre-DRUG2    values within 48 hours after discontinuing DRUG2   . If DRUG2 and DRUG1 are to be used concurrently, DRUG1 blood levels should be monitored, particularly when the DRUG2    dose is changed. ",negative,Theophylline,Mexitil
"This increase was observed at the first test point which was the second day after starting DRUG1   . Theophylline plasma levels returned to pre-DRUG1    values within 48 hours after discontinuing DRUG1   . If DRUG1 and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the DRUG1    dose is changed. ",negative,Mexitil,Mexitil
"This increase was observed at the first test point which was the second day after starting DRUG1   . Theophylline plasma levels returned to pre-DRUG1    values within 48 hours after discontinuing DRUG1   . If DRUG1 and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the DRUG1    dose is changed. ",negative,Mexitil,Mexitil
"This increase was observed at the first test point which was the second day after starting DRUG1   . DRUG2 plasma levels returned to pre-DRUG1    values within 48 hours after discontinuing DRUG1   . If DRUG1 and DRUG2 are to be used concurrently, DRUG2 blood levels should be monitored, particularly when the DRUG1    dose is changed. ",negative,Mexitil,theophylline
"This increase was observed at the first test point which was the second day after starting DRUG1   . DRUG2 plasma levels returned to pre-DRUG1    values within 48 hours after discontinuing DRUG1   . If DRUG1 and DRUG2 are to be used concurrently, DRUG2 blood levels should be monitored, particularly when the DRUG1    dose is changed. ",negative,Mexitil,theophylline
"This increase was observed at the first test point which was the second day after starting DRUG1   . Theophylline plasma levels returned to pre-DRUG1    values within 48 hours after discontinuing DRUG1   . If DRUG1 and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the DRUG1    dose is changed. ",negative,Mexitil,Mexitil
"This increase was observed at the first test point which was the second day after starting DRUG1   . Theophylline plasma levels returned to pre-DRUG1    values within 48 hours after discontinuing DRUG1   . If DRUG1 and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the DRUG1    dose is changed. ",negative,Mexitil,Mexitil
"This increase was observed at the first test point which was the second day after starting DRUG1   . DRUG2 plasma levels returned to pre-DRUG1    values within 48 hours after discontinuing DRUG1   . If DRUG1 and DRUG2 are to be used concurrently, DRUG2 blood levels should be monitored, particularly when the DRUG1    dose is changed. ",negative,Mexitil,theophylline
"This increase was observed at the first test point which was the second day after starting DRUG1   . DRUG2 plasma levels returned to pre-DRUG1    values within 48 hours after discontinuing DRUG1   . If DRUG1 and DRUG2 are to be used concurrently, DRUG2 blood levels should be monitored, particularly when the DRUG1    dose is changed. ",negative,Mexitil,theophylline
"This increase was observed at the first test point which was the second day after starting DRUG1   . Theophylline plasma levels returned to pre-DRUG1    values within 48 hours after discontinuing DRUG1   . If DRUG1 and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the DRUG1    dose is changed. ",negative,Mexitil,Mexitil
"This increase was observed at the first test point which was the second day after starting DRUG1   . DRUG2 plasma levels returned to pre-DRUG1    values within 48 hours after discontinuing DRUG1   . If DRUG1 and DRUG2 are to be used concurrently, DRUG2 blood levels should be monitored, particularly when the DRUG1    dose is changed. ",advise,Mexitil,theophylline
"This increase was observed at the first test point which was the second day after starting DRUG1   . DRUG2 plasma levels returned to pre-DRUG1    values within 48 hours after discontinuing DRUG1   . If DRUG1 and DRUG2 are to be used concurrently, DRUG2 blood levels should be monitored, particularly when the DRUG1    dose is changed. ",negative,Mexitil,theophylline
"This increase was observed at the first test point which was the second day after starting DRUG1   . Theophylline plasma levels returned to pre-DRUG1    values within 48 hours after discontinuing DRUG1   . If DRUG1 and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the DRUG1    dose is changed. ",negative,Mexitil,Mexitil
"This increase was observed at the first test point which was the second day after starting Mexitil   . DRUG1 plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and DRUG1 are to be used concurrently, DRUG1 blood levels should be monitored, particularly when the Mexitil    dose is changed. ",negative,theophylline,theophylline
"This increase was observed at the first test point which was the second day after starting DRUG2   . DRUG1 plasma levels returned to pre-DRUG2    values within 48 hours after discontinuing DRUG2   . If DRUG2 and DRUG1 are to be used concurrently, DRUG1 blood levels should be monitored, particularly when the DRUG2    dose is changed. ",negative,theophylline,Mexitil
"This increase was observed at the first test point which was the second day after starting DRUG2   . DRUG1 plasma levels returned to pre-DRUG2    values within 48 hours after discontinuing DRUG2   . If DRUG2 and DRUG1 are to be used concurrently, DRUG1 blood levels should be monitored, particularly when the DRUG2    dose is changed. ",negative,theophylline,Mexitil
"Additionally, in one controlled study in five normal subjects and seven patients, the clearance of DRUG1 was decreased 50% following the administration of DRUG2   .",mechanism,caffeine,Mexitil
"Usage with DRUG1: Due to the potential for increased CNS depressants effects, DRUG1 should be used with caution in patients who are currently receiving pentazocine.",negative,Alcohol,alcohol
"Usage with DRUG1: Due to the potential for increased CNS depressants effects, DRUG1 should be used with caution in patients who are currently receiving DRUG2.",negative,Alcohol,pentazocine
"Usage with DRUG1: Due to the potential for increased CNS depressants effects, DRUG1 should be used with caution in patients who are currently receiving DRUG2.",advise,alcohol,pentazocine
"DRUG1 may compete with other drugs, such as DRUG2, for sites of metabolism in the liver, thus elevating the serum levels of such compounds to potentially toxic levels. ",mechanism,Thiabendazole,theophylline
"Therefore, when concomitant use of DRUG1 and DRUG2 is anticipated, it may be necessary to monitor blood levels and/or reduce the dosage of such compounds. ",advise,thiabendazole,xanthine derivatives
"DRUG1 may be used with DRUG2, quinine and other antimalarials, and with other antibiotics. ",negative,Pyrimethamine,sulfonamides
"DRUG1 may be used with sulfonamides, DRUG2 and other antimalarials, and with other antibiotics. ",negative,Pyrimethamine,quinine
"DRUG1 may be used with sulfonamides, quinine and other DRUG2, and with other antibiotics. ",negative,Pyrimethamine,antimalarials
"DRUG1 may be used with sulfonamides, quinine and other antimalarials, and with other DRUG2. ",negative,Pyrimethamine,antibiotics
"Pyrimethamine may be used with DRUG1, DRUG2 and other antimalarials, and with other antibiotics. ",negative,sulfonamides,quinine
"Pyrimethamine may be used with DRUG1, quinine and other DRUG2, and with other antibiotics. ",negative,sulfonamides,antimalarials
"Pyrimethamine may be used with DRUG1, quinine and other antimalarials, and with other DRUG2. ",negative,sulfonamides,antibiotics
"Pyrimethamine may be used with sulfonamides, DRUG1 and other DRUG2, and with other antibiotics. ",negative,quinine,antimalarials
"Pyrimethamine may be used with sulfonamides, DRUG1 and other antimalarials, and with other DRUG2. ",negative,quinine,antibiotics
"Pyrimethamine may be used with sulfonamides, quinine and other DRUG1, and with other DRUG2. ",negative,antimalarials,antibiotics
DRUG1 (DRUG2) should be administered until normal hematopoiesis is restored. ,negative,Folinic acid,leucovorin
Mild hepatotoxicity has been reported in some patients when DRUG1 and DRUG2 were administered concomitantly.,effect,lorazepam,pyrimethamine
"DRUG1 inhibits some of the liver's ability to metabolize some other drugs - DRUG2, astemizole, cisapride, cyclosporine, and tricyclic antidepressants. ",mechanism,Posicor,terfenadine
"DRUG1 inhibits some of the liver's ability to metabolize some other drugs - terfenadine, DRUG2, cisapride, cyclosporine, and tricyclic antidepressants. ",mechanism,Posicor,astemizole
"DRUG1 inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, DRUG2, cyclosporine, and tricyclic antidepressants. ",mechanism,Posicor,cisapride
"DRUG1 inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, cisapride, DRUG2, and tricyclic antidepressants. ",mechanism,Posicor,cyclosporine
"DRUG1 inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, cisapride, cyclosporine, and DRUG2. ",mechanism,Posicor,tricyclic antidepressants
"Posicor inhibits some of the liver's ability to metabolize some other drugs - DRUG1, DRUG2, cisapride, cyclosporine, and tricyclic antidepressants. ",negative,terfenadine,astemizole
"Posicor inhibits some of the liver's ability to metabolize some other drugs - DRUG1, astemizole, DRUG2, cyclosporine, and tricyclic antidepressants. ",negative,terfenadine,cisapride
"Posicor inhibits some of the liver's ability to metabolize some other drugs - DRUG1, astemizole, cisapride, DRUG2, and tricyclic antidepressants. ",negative,terfenadine,cyclosporine
"Posicor inhibits some of the liver's ability to metabolize some other drugs - DRUG1, astemizole, cisapride, cyclosporine, and DRUG2. ",negative,terfenadine,tricyclic antidepressants
"Posicor inhibits some of the liver's ability to metabolize some other drugs - terfenadine, DRUG1, DRUG2, cyclosporine, and tricyclic antidepressants. ",negative,astemizole,cisapride
"Posicor inhibits some of the liver's ability to metabolize some other drugs - terfenadine, DRUG1, cisapride, DRUG2, and tricyclic antidepressants. ",negative,astemizole,cyclosporine
"Posicor inhibits some of the liver's ability to metabolize some other drugs - terfenadine, DRUG1, cisapride, cyclosporine, and DRUG2. ",negative,astemizole,tricyclic antidepressants
"Posicor inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, DRUG1, DRUG2, and tricyclic antidepressants. ",negative,cisapride,cyclosporine
"Posicor inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, DRUG1, cyclosporine, and DRUG2. ",negative,cisapride,tricyclic antidepressants
"Posicor inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, cisapride, DRUG1, and DRUG2. ",negative,cyclosporine,tricyclic antidepressants
DRUG1 may interact with DRUG2 or mitotane (causing too great a decrease in adrenal function).,int,Trilostane,aminoglutethimide
DRUG1 may interact with aminoglutethimide or DRUG2 (causing too great a decrease in adrenal function).,int,Trilostane,mitotane
Trilostane may interact with DRUG1 or DRUG2 (causing too great a decrease in adrenal function).,negative,aminoglutethimide,mitotane
"Concomitant administration of substances that are also tubularly secreted (e.g., DRUG1) could potentially result in delayed clearance of DRUG2. ",mechanism,probenecid,ALIMTA
"Although DRUG1 (400 mg qid) can be administered with DRUG2 in patients with normal renal function (creatinine clearance    80 mL/min), caution should be used when administering DRUG1 concurrently with DRUG2 to patients with mild to moderate renal insufficiency (creatinine clearance from 45 to 79 mL/min). ",negative,ibuprofen,ALIMTA
"Although DRUG1 (400 mg qid) can be administered with ALIMTA in patients with normal renal function (creatinine clearance    80 mL/min), caution should be used when administering DRUG1 concurrently with ALIMTA to patients with mild to moderate renal insufficiency (creatinine clearance from 45 to 79 mL/min). ",negative,ibuprofen,ibuprofen
"Although DRUG1 (400 mg qid) can be administered with DRUG2 in patients with normal renal function (creatinine clearance    80 mL/min), caution should be used when administering DRUG1 concurrently with DRUG2 to patients with mild to moderate renal insufficiency (creatinine clearance from 45 to 79 mL/min). ",negative,ibuprofen,ALIMTA
"Although DRUG2 (400 mg qid) can be administered with DRUG1 in patients with normal renal function (creatinine clearance    80 mL/min), caution should be used when administering DRUG2 concurrently with DRUG1 to patients with mild to moderate renal insufficiency (creatinine clearance from 45 to 79 mL/min). ",negative,ALIMTA,ibuprofen
"Although ibuprofen (400 mg qid) can be administered with DRUG1 in patients with normal renal function (creatinine clearance    80 mL/min), caution should be used when administering ibuprofen concurrently with DRUG1 to patients with mild to moderate renal insufficiency (creatinine clearance from 45 to 79 mL/min). ",negative,ALIMTA,ALIMTA
"Although DRUG1 (400 mg qid) can be administered with DRUG2 in patients with normal renal function (creatinine clearance    80 mL/min), caution should be used when administering DRUG1 concurrently with DRUG2 to patients with mild to moderate renal insufficiency (creatinine clearance from 45 to 79 mL/min). ",advise,ibuprofen,ALIMTA
"Patients with mild to moderate renal insufficiency should avoid taking DRUG1 with short elimination half-lives for a period of 2 days before, the day of, and 2 days following administration of DRUG2. ",advise,NSAIDs,ALIMTA
"In the absence of data regarding potential interaction between DRUG1 and DRUG2 with longer half-lives, all patients taking these DRUG2 should interrupt dosing for at least 5 days before, the day of, and 2 days following DRUG1 administration. ",negative,ALIMTA,NSAIDs
"In the absence of data regarding potential interaction between DRUG1 and DRUG2 with longer half-lives, all patients taking these DRUG2 should interrupt dosing for at least 5 days before, the day of, and 2 days following DRUG1 administration. ",negative,ALIMTA,NSAIDs
"In the absence of data regarding potential interaction between DRUG1 and NSAIDs with longer half-lives, all patients taking these NSAIDs should interrupt dosing for at least 5 days before, the day of, and 2 days following DRUG1 administration. ",negative,ALIMTA,ALIMTA
"In the absence of data regarding potential interaction between ALIMTA and DRUG1 with longer half-lives, all patients taking these DRUG1 should interrupt dosing for at least 5 days before, the day of, and 2 days following ALIMTA administration. ",negative,NSAIDs,NSAIDs
"In the absence of data regarding potential interaction between DRUG2 and DRUG1 with longer half-lives, all patients taking these DRUG1 should interrupt dosing for at least 5 days before, the day of, and 2 days following DRUG2 administration. ",negative,NSAIDs,ALIMTA
"In the absence of data regarding potential interaction between DRUG2 and DRUG1 with longer half-lives, all patients taking these DRUG1 should interrupt dosing for at least 5 days before, the day of, and 2 days following DRUG2 administration. ",advise,NSAIDs,ALIMTA
DRUG1 may decrease the hypotensive effect of DRUG2. ,effect,Ritalin,guanethidine
"Human pharmacologic studies have shown that DRUG1 may inhibit the metabolism of DRUG2, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",mechanism,Ritalin,coumarin anticoagulants
"Human pharmacologic studies have shown that DRUG1 may inhibit the metabolism of coumarin anticoagulants, DRUG2 (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",mechanism,Ritalin,anticonvulsants
"Human pharmacologic studies have shown that DRUG1 may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (DRUG2, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",mechanism,Ritalin,phenobarbital
"Human pharmacologic studies have shown that DRUG1 may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, DRUG2, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",mechanism,Ritalin,diphenylhydantoin
"Human pharmacologic studies have shown that DRUG1 may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, DRUG2), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",mechanism,Ritalin,primidone
"Human pharmacologic studies have shown that DRUG1 may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), DRUG2, and tricyclic drugs (imipramine, clomipramine, desipramine). ",mechanism,Ritalin,phenylbutazone
"Human pharmacologic studies have shown that DRUG1 may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and DRUG2 (imipramine, clomipramine, desipramine). ",mechanism,Ritalin,tricyclic drugs
"Human pharmacologic studies have shown that DRUG1 may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (DRUG2, clomipramine, desipramine). ",mechanism,Ritalin,imipramine
"Human pharmacologic studies have shown that DRUG1 may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, DRUG2, desipramine). ",mechanism,Ritalin,clomipramine
"Human pharmacologic studies have shown that DRUG1 may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, DRUG2). ",mechanism,Ritalin,desipramine
"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of DRUG1, DRUG2 (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",negative,coumarin anticoagulants,anticonvulsants
"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of DRUG1, anticonvulsants (DRUG2, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",negative,coumarin anticoagulants,phenobarbital
"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of DRUG1, anticonvulsants (phenobarbital, DRUG2, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",negative,coumarin anticoagulants,diphenylhydantoin
"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of DRUG1, anticonvulsants (phenobarbital, diphenylhydantoin, DRUG2), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",negative,coumarin anticoagulants,primidone
"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of DRUG1, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), DRUG2, and tricyclic drugs (imipramine, clomipramine, desipramine). ",negative,coumarin anticoagulants,phenylbutazone
"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of DRUG1, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and DRUG2 (imipramine, clomipramine, desipramine). ",negative,coumarin anticoagulants,tricyclic drugs
"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of DRUG1, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (DRUG2, clomipramine, desipramine). ",negative,coumarin anticoagulants,imipramine
"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of DRUG1, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, DRUG2, desipramine). ",negative,coumarin anticoagulants,clomipramine
"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of DRUG1, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, DRUG2). ",negative,coumarin anticoagulants,desipramine
"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, DRUG1 (DRUG2, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",negative,anticonvulsants,phenobarbital
"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, DRUG1 (phenobarbital, DRUG2, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",negative,anticonvulsants,diphenylhydantoin
"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, DRUG1 (phenobarbital, diphenylhydantoin, DRUG2), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",negative,anticonvulsants,primidone
"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, DRUG1 (phenobarbital, diphenylhydantoin, primidone), DRUG2, and tricyclic drugs (imipramine, clomipramine, desipramine). ",negative,anticonvulsants,phenylbutazone
"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, DRUG1 (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and DRUG2 (imipramine, clomipramine, desipramine). ",negative,anticonvulsants,tricyclic drugs
"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, DRUG1 (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (DRUG2, clomipramine, desipramine). ",negative,anticonvulsants,imipramine
"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, DRUG1 (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, DRUG2, desipramine). ",negative,anticonvulsants,clomipramine
"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, DRUG1 (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, DRUG2). ",negative,anticonvulsants,desipramine
"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (DRUG1, DRUG2, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",negative,phenobarbital,diphenylhydantoin
"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (DRUG1, diphenylhydantoin, DRUG2), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",negative,phenobarbital,primidone
"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (DRUG1, diphenylhydantoin, primidone), DRUG2, and tricyclic drugs (imipramine, clomipramine, desipramine). ",negative,phenobarbital,phenylbutazone
"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (DRUG1, diphenylhydantoin, primidone), phenylbutazone, and DRUG2 (imipramine, clomipramine, desipramine). ",negative,phenobarbital,tricyclic drugs
"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (DRUG1, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (DRUG2, clomipramine, desipramine). ",negative,phenobarbital,imipramine
"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (DRUG1, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, DRUG2, desipramine). ",negative,phenobarbital,clomipramine
"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (DRUG1, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, DRUG2). ",negative,phenobarbital,desipramine
"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, DRUG1, DRUG2), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",negative,diphenylhydantoin,primidone
"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, DRUG1, primidone), DRUG2, and tricyclic drugs (imipramine, clomipramine, desipramine). ",negative,diphenylhydantoin,phenylbutazone
"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, DRUG1, primidone), phenylbutazone, and DRUG2 (imipramine, clomipramine, desipramine). ",negative,diphenylhydantoin,tricyclic drugs
"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, DRUG1, primidone), phenylbutazone, and tricyclic drugs (DRUG2, clomipramine, desipramine). ",negative,diphenylhydantoin,imipramine
"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, DRUG1, primidone), phenylbutazone, and tricyclic drugs (imipramine, DRUG2, desipramine). ",negative,diphenylhydantoin,clomipramine
"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, DRUG1, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, DRUG2). ",negative,diphenylhydantoin,desipramine
"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, DRUG1), DRUG2, and tricyclic drugs (imipramine, clomipramine, desipramine). ",negative,primidone,phenylbutazone
"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, DRUG1), phenylbutazone, and DRUG2 (imipramine, clomipramine, desipramine). ",negative,primidone,tricyclic drugs
"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, DRUG1), phenylbutazone, and tricyclic drugs (DRUG2, clomipramine, desipramine). ",negative,primidone,imipramine
"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, DRUG1), phenylbutazone, and tricyclic drugs (imipramine, DRUG2, desipramine). ",negative,primidone,clomipramine
"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, DRUG1), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, DRUG2). ",negative,primidone,desipramine
"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), DRUG1, and DRUG2 (imipramine, clomipramine, desipramine). ",negative,phenylbutazone,tricyclic drugs
"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), DRUG1, and tricyclic drugs (DRUG2, clomipramine, desipramine). ",negative,phenylbutazone,imipramine
"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), DRUG1, and tricyclic drugs (imipramine, DRUG2, desipramine). ",negative,phenylbutazone,clomipramine
"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), DRUG1, and tricyclic drugs (imipramine, clomipramine, DRUG2). ",negative,phenylbutazone,desipramine
"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and DRUG1 (DRUG2, clomipramine, desipramine). ",negative,tricyclic drugs,imipramine
"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and DRUG1 (imipramine, DRUG2, desipramine). ",negative,tricyclic drugs,clomipramine
"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and DRUG1 (imipramine, clomipramine, DRUG2). ",negative,tricyclic drugs,desipramine
"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (DRUG1, DRUG2, desipramine). ",negative,imipramine,clomipramine
"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (DRUG1, clomipramine, DRUG2). ",negative,imipramine,desipramine
"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, DRUG1, DRUG2). ",negative,clomipramine,desipramine
The safety of using DRUG1 in combination with DRUG2 or other centrally acting alpha-2 agonists has not been systemically evaluated.    ,negative,methylphenidate,clonidine
The safety of using DRUG1 in combination with clonidine or other centrally acting DRUG2 has not been systemically evaluated.    ,negative,methylphenidate,alpha-2 agonists
The safety of using methylphenidate in combination with DRUG1 or other centrally acting DRUG2 has not been systemically evaluated.    ,negative,clonidine,alpha-2 agonists
DRUG1: Prolongation of prothrombin time (PT) and International Normalized Ratio (INR) were observed in patients receiving DRUG2 concomitantly with DRUG1. ,negative,Coumarin-Derivative Anticoagulants,ZOLINZA
DRUG1: Prolongation of prothrombin time (PT) and International Normalized Ratio (INR) were observed in patients receiving ZOLINZA concomitantly with DRUG1. ,negative,Coumarin-Derivative Anticoagulants,coumarin-derivative anticoagulants
DRUG2: Prolongation of prothrombin time (PT) and International Normalized Ratio (INR) were observed in patients receiving DRUG1 concomitantly with DRUG2. ,effect,ZOLINZA,coumarin-derivative anticoagulants
Physicians should carefully monitor PT and INR in patients concurrently administered DRUG1 and DRUG2. ,advise,ZOLINZA,coumarin derivatives
"Other DRUG1 Severe thrombocytopenia and gastrointestinal bleeding have been reported with concomitant use of DRUG2 and other DRUG1 (e.g., valproic acid). ",negative,HDAC Inhibitors,ZOLINZA
"Other DRUG1 Severe thrombocytopenia and gastrointestinal bleeding have been reported with concomitant use of ZOLINZA and other DRUG1 (e.g., valproic acid). ",negative,HDAC Inhibitors,HDAC inhibitors
"Other DRUG1 Severe thrombocytopenia and gastrointestinal bleeding have been reported with concomitant use of ZOLINZA and other DRUG1 (e.g., DRUG2). ",negative,HDAC Inhibitors,valproic acid
"Other DRUG2 Severe thrombocytopenia and gastrointestinal bleeding have been reported with concomitant use of DRUG1 and other DRUG2 (e.g., valproic acid). ",effect,ZOLINZA,HDAC inhibitors
"Other HDAC Inhibitors Severe thrombocytopenia and gastrointestinal bleeding have been reported with concomitant use of DRUG1 and other HDAC inhibitors (e.g., DRUG2). ",effect,ZOLINZA,valproic acid
"Other DRUG1 Severe thrombocytopenia and gastrointestinal bleeding have been reported with concomitant use of ZOLINZA and other DRUG1 (e.g., DRUG2). ",negative,HDAC inhibitors,valproic acid
No pharmacokinetic interaction between 85 mg/m2 DRUG1 and infusional DRUG2 has been observed in patients treated every 2 weeks. ,negative,ELOXATIN,5-FU
Increases of DRUG1 plasma concentrations by approximately 20% have been observed with doses of 130 mg/m2 DRUG2 dosed every 3 weeks. ,mechanism,5-FU,ELOXATIN
"DRUG1: In a multiple-dose study in 30 normal weight subjects, coadministration of DRUG2 and 40 grams of DRUG1 (e.g., approximately 3 glasses of wine) did not result in alteration of DRUG1 pharmacokinetics, orlistat pharmacodynamics (fecal fat excretion), or systemic exposure to orlistat. ",negative,Alcohol,XENICAL
"DRUG1: In a multiple-dose study in 30 normal weight subjects, coadministration of XENICAL and 40 grams of DRUG1 (e.g., approximately 3 glasses of wine) did not result in alteration of DRUG1 pharmacokinetics, orlistat pharmacodynamics (fecal fat excretion), or systemic exposure to orlistat. ",negative,Alcohol,alcohol
"DRUG1: In a multiple-dose study in 30 normal weight subjects, coadministration of XENICAL and 40 grams of DRUG1 (e.g., approximately 3 glasses of wine) did not result in alteration of DRUG1 pharmacokinetics, orlistat pharmacodynamics (fecal fat excretion), or systemic exposure to orlistat. ",negative,Alcohol,alcohol
"DRUG1: In a multiple-dose study in 30 normal weight subjects, coadministration of XENICAL and 40 grams of DRUG1 (e.g., approximately 3 glasses of wine) did not result in alteration of DRUG1 pharmacokinetics, DRUG2 pharmacodynamics (fecal fat excretion), or systemic exposure to DRUG2. ",negative,Alcohol,orlistat
"DRUG1: In a multiple-dose study in 30 normal weight subjects, coadministration of XENICAL and 40 grams of DRUG1 (e.g., approximately 3 glasses of wine) did not result in alteration of DRUG1 pharmacokinetics, DRUG2 pharmacodynamics (fecal fat excretion), or systemic exposure to DRUG2. ",negative,Alcohol,orlistat
"DRUG2: In a multiple-dose study in 30 normal weight subjects, coadministration of DRUG1 and 40 grams of DRUG2 (e.g., approximately 3 glasses of wine) did not result in alteration of DRUG2 pharmacokinetics, orlistat pharmacodynamics (fecal fat excretion), or systemic exposure to orlistat. ",negative,XENICAL,alcohol
"DRUG2: In a multiple-dose study in 30 normal weight subjects, coadministration of DRUG1 and 40 grams of DRUG2 (e.g., approximately 3 glasses of wine) did not result in alteration of DRUG2 pharmacokinetics, orlistat pharmacodynamics (fecal fat excretion), or systemic exposure to orlistat. ",negative,XENICAL,alcohol
"Alcohol: In a multiple-dose study in 30 normal weight subjects, coadministration of DRUG1 and 40 grams of alcohol (e.g., approximately 3 glasses of wine) did not result in alteration of alcohol pharmacokinetics, DRUG2 pharmacodynamics (fecal fat excretion), or systemic exposure to DRUG2. ",negative,XENICAL,orlistat
"Alcohol: In a multiple-dose study in 30 normal weight subjects, coadministration of DRUG1 and 40 grams of alcohol (e.g., approximately 3 glasses of wine) did not result in alteration of alcohol pharmacokinetics, DRUG2 pharmacodynamics (fecal fat excretion), or systemic exposure to DRUG2. ",negative,XENICAL,orlistat
"DRUG1: In a multiple-dose study in 30 normal weight subjects, coadministration of XENICAL and 40 grams of DRUG1 (e.g., approximately 3 glasses of wine) did not result in alteration of DRUG1 pharmacokinetics, orlistat pharmacodynamics (fecal fat excretion), or systemic exposure to orlistat. ",negative,alcohol,alcohol
"DRUG1: In a multiple-dose study in 30 normal weight subjects, coadministration of XENICAL and 40 grams of DRUG1 (e.g., approximately 3 glasses of wine) did not result in alteration of DRUG1 pharmacokinetics, DRUG2 pharmacodynamics (fecal fat excretion), or systemic exposure to DRUG2. ",negative,alcohol,orlistat
"DRUG1: In a multiple-dose study in 30 normal weight subjects, coadministration of XENICAL and 40 grams of DRUG1 (e.g., approximately 3 glasses of wine) did not result in alteration of DRUG1 pharmacokinetics, DRUG2 pharmacodynamics (fecal fat excretion), or systemic exposure to DRUG2. ",negative,alcohol,orlistat
"DRUG1: In a multiple-dose study in 30 normal weight subjects, coadministration of XENICAL and 40 grams of DRUG1 (e.g., approximately 3 glasses of wine) did not result in alteration of DRUG1 pharmacokinetics, DRUG2 pharmacodynamics (fecal fat excretion), or systemic exposure to DRUG2. ",negative,alcohol,orlistat
"DRUG1: In a multiple-dose study in 30 normal weight subjects, coadministration of XENICAL and 40 grams of DRUG1 (e.g., approximately 3 glasses of wine) did not result in alteration of DRUG1 pharmacokinetics, DRUG2 pharmacodynamics (fecal fat excretion), or systemic exposure to DRUG2. ",negative,alcohol,orlistat
"Alcohol: In a multiple-dose study in 30 normal weight subjects, coadministration of XENICAL and 40 grams of alcohol (e.g., approximately 3 glasses of wine) did not result in alteration of alcohol pharmacokinetics, DRUG1 pharmacodynamics (fecal fat excretion), or systemic exposure to DRUG1. ",negative,orlistat,orlistat
DRUG1: Preliminary data from a DRUG2 and DRUG1 drug interaction study indicate a reduction in DRUG1 plasma levels when DRUG2 was coadministered with DRUG1. ,negative,Cyclosporine,XENICAL
DRUG1: Preliminary data from a XENICAL and DRUG1 drug interaction study indicate a reduction in DRUG1 plasma levels when XENICAL was coadministered with DRUG1. ,negative,Cyclosporine,cyclosporine
DRUG1: Preliminary data from a XENICAL and DRUG1 drug interaction study indicate a reduction in DRUG1 plasma levels when XENICAL was coadministered with DRUG1. ,negative,Cyclosporine,cyclosporine
DRUG1: Preliminary data from a DRUG2 and DRUG1 drug interaction study indicate a reduction in DRUG1 plasma levels when DRUG2 was coadministered with DRUG1. ,negative,Cyclosporine,XENICAL
DRUG1: Preliminary data from a XENICAL and DRUG1 drug interaction study indicate a reduction in DRUG1 plasma levels when XENICAL was coadministered with DRUG1. ,negative,Cyclosporine,cyclosporine
DRUG2: Preliminary data from a DRUG1 and DRUG2 drug interaction study indicate a reduction in DRUG2 plasma levels when DRUG1 was coadministered with DRUG2. ,negative,XENICAL,cyclosporine
DRUG2: Preliminary data from a DRUG1 and DRUG2 drug interaction study indicate a reduction in DRUG2 plasma levels when DRUG1 was coadministered with DRUG2. ,negative,XENICAL,cyclosporine
Cyclosporine: Preliminary data from a DRUG1 and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when DRUG1 was coadministered with cyclosporine. ,negative,XENICAL,XENICAL
DRUG2: Preliminary data from a DRUG1 and DRUG2 drug interaction study indicate a reduction in DRUG2 plasma levels when DRUG1 was coadministered with DRUG2. ,negative,XENICAL,cyclosporine
DRUG1: Preliminary data from a XENICAL and DRUG1 drug interaction study indicate a reduction in DRUG1 plasma levels when XENICAL was coadministered with DRUG1. ,negative,cyclosporine,cyclosporine
DRUG1: Preliminary data from a DRUG2 and DRUG1 drug interaction study indicate a reduction in DRUG1 plasma levels when DRUG2 was coadministered with DRUG1. ,negative,cyclosporine,XENICAL
DRUG1: Preliminary data from a XENICAL and DRUG1 drug interaction study indicate a reduction in DRUG1 plasma levels when XENICAL was coadministered with DRUG1. ,negative,cyclosporine,cyclosporine
DRUG1: Preliminary data from a DRUG2 and DRUG1 drug interaction study indicate a reduction in DRUG1 plasma levels when DRUG2 was coadministered with DRUG1. ,negative,cyclosporine,XENICAL
DRUG1: Preliminary data from a XENICAL and DRUG1 drug interaction study indicate a reduction in DRUG1 plasma levels when XENICAL was coadministered with DRUG1. ,negative,cyclosporine,cyclosporine
DRUG2: Preliminary data from a DRUG1 and DRUG2 drug interaction study indicate a reduction in DRUG2 plasma levels when DRUG1 was coadministered with DRUG2. ,mechanism,XENICAL,cyclosporine
"DRUG1: In 12 normal-weight subjects receiving DRUG2 120 mg three times a day for 6 days, DRUG2 did not alter the pharmacokinetics of a single dose of DRUG1. ",negative,Digoxin,XENICAL
"DRUG1: In 12 normal-weight subjects receiving DRUG2 120 mg three times a day for 6 days, DRUG2 did not alter the pharmacokinetics of a single dose of DRUG1. ",negative,Digoxin,XENICAL
"DRUG1: In 12 normal-weight subjects receiving XENICAL 120 mg three times a day for 6 days, XENICAL did not alter the pharmacokinetics of a single dose of DRUG1. ",negative,Digoxin,digoxin
"Digoxin: In 12 normal-weight subjects receiving DRUG1 120 mg three times a day for 6 days, DRUG1 did not alter the pharmacokinetics of a single dose of digoxin. ",negative,XENICAL,XENICAL
"DRUG2: In 12 normal-weight subjects receiving DRUG1 120 mg three times a day for 6 days, DRUG1 did not alter the pharmacokinetics of a single dose of DRUG2. ",negative,XENICAL,digoxin
"DRUG2: In 12 normal-weight subjects receiving DRUG1 120 mg three times a day for 6 days, DRUG1 did not alter the pharmacokinetics of a single dose of DRUG2. ",negative,XENICAL,digoxin
DRUG1 and Analogues: A pharmacokinetic interaction study showed a 30% reduction in DRUG2 supplement absorption when concomitantly administered with XENICAL. ,negative,Fat-soluble Vitamin Supplements,beta-carotene
DRUG1 and Analogues: A pharmacokinetic interaction study showed a 30% reduction in beta-carotene supplement absorption when concomitantly administered with DRUG2. ,negative,Fat-soluble Vitamin Supplements,XENICAL
Fat-soluble Vitamin Supplements and Analogues: A pharmacokinetic interaction study showed a 30% reduction in DRUG1 supplement absorption when concomitantly administered with DRUG2. ,mechanism,beta-carotene,XENICAL
DRUG1 inhibited absorption of a DRUG2 supplement by approximately 60%. ,mechanism,XENICAL,vitamin E acetate
"The effect of DRUG1 on the absorption of supplemental DRUG2, vitamin A, and nutritionally-derived vitamin K is not known at this time. ",negative,orlistat,vitamin D
"The effect of DRUG1 on the absorption of supplemental vitamin D, DRUG2, and nutritionally-derived vitamin K is not known at this time. ",negative,orlistat,vitamin A
"The effect of DRUG1 on the absorption of supplemental vitamin D, vitamin A, and nutritionally-derived DRUG2 is not known at this time. ",negative,orlistat,vitamin K
"The effect of orlistat on the absorption of supplemental DRUG1, DRUG2, and nutritionally-derived vitamin K is not known at this time. ",negative,vitamin D,vitamin A
"The effect of orlistat on the absorption of supplemental DRUG1, vitamin A, and nutritionally-derived DRUG2 is not known at this time. ",negative,vitamin D,vitamin K
"The effect of orlistat on the absorption of supplemental vitamin D, DRUG1, and nutritionally-derived DRUG2 is not known at this time. ",negative,vitamin A,vitamin K
"DRUG1: In 12 normal-weight subjects receiving DRUG2 80 mg three times a day for 5 days, DRUG2 did not alter the pharmacokinetics or pharmacodynamics (blood glucose-lowering) of DRUG1. ",negative,Glyburide,orlistat
"DRUG1: In 12 normal-weight subjects receiving DRUG2 80 mg three times a day for 5 days, DRUG2 did not alter the pharmacokinetics or pharmacodynamics (blood glucose-lowering) of DRUG1. ",negative,Glyburide,orlistat
"DRUG1: In 12 normal-weight subjects receiving orlistat 80 mg three times a day for 5 days, orlistat did not alter the pharmacokinetics or pharmacodynamics (blood glucose-lowering) of DRUG1. ",negative,Glyburide,glyburide
"Glyburide: In 12 normal-weight subjects receiving DRUG1 80 mg three times a day for 5 days, DRUG1 did not alter the pharmacokinetics or pharmacodynamics (blood glucose-lowering) of glyburide. ",negative,orlistat,orlistat
"DRUG2: In 12 normal-weight subjects receiving DRUG1 80 mg three times a day for 5 days, DRUG1 did not alter the pharmacokinetics or pharmacodynamics (blood glucose-lowering) of DRUG2. ",negative,orlistat,glyburide
"DRUG2: In 12 normal-weight subjects receiving DRUG1 80 mg three times a day for 5 days, DRUG1 did not alter the pharmacokinetics or pharmacodynamics (blood glucose-lowering) of DRUG2. ",negative,orlistat,glyburide
"DRUG1 (extended-release tablets): In 17 normal-weight subjects receiving DRUG2 120 mg three times a day for 6 days, DRUG2 did not alter the bioavailability of DRUG1 (extended-release tablets). ",negative,Nifedipine,XENICAL
"DRUG1 (extended-release tablets): In 17 normal-weight subjects receiving DRUG2 120 mg three times a day for 6 days, DRUG2 did not alter the bioavailability of DRUG1 (extended-release tablets). ",negative,Nifedipine,XENICAL
"DRUG1 (extended-release tablets): In 17 normal-weight subjects receiving XENICAL 120 mg three times a day for 6 days, XENICAL did not alter the bioavailability of DRUG1 (extended-release tablets). ",negative,Nifedipine,nifedipine
"Nifedipine (extended-release tablets): In 17 normal-weight subjects receiving DRUG1 120 mg three times a day for 6 days, DRUG1 did not alter the bioavailability of nifedipine (extended-release tablets). ",negative,XENICAL,XENICAL
"DRUG2 (extended-release tablets): In 17 normal-weight subjects receiving DRUG1 120 mg three times a day for 6 days, DRUG1 did not alter the bioavailability of DRUG2 (extended-release tablets). ",negative,XENICAL,nifedipine
"DRUG2 (extended-release tablets): In 17 normal-weight subjects receiving DRUG1 120 mg three times a day for 6 days, DRUG1 did not alter the bioavailability of DRUG2 (extended-release tablets). ",negative,XENICAL,nifedipine
"Oral DRUG1: In 20 normal-weight female subjects, the treatment of DRUG2 120 mg three times a day for 23 days resulted in no changes in the ovulation-suppressing action of oral DRUG1. ",negative,Contraceptives,XENICAL
"Oral DRUG1: In 20 normal-weight female subjects, the treatment of XENICAL 120 mg three times a day for 23 days resulted in no changes in the ovulation-suppressing action of oral DRUG1. ",negative,Contraceptives,contraceptives
"Oral DRUG2: In 20 normal-weight female subjects, the treatment of DRUG1 120 mg three times a day for 23 days resulted in no changes in the ovulation-suppressing action of oral DRUG2. ",negative,XENICAL,contraceptives
"DRUG1: In 12 normal-weight subjects receiving DRUG2 120 mg three times a day for 7 days, DRUG2 did not alter the pharmacokinetics of a single 300-mg dose of DRUG1. ",negative,Phenytoin,XENICAL
"DRUG1: In 12 normal-weight subjects receiving DRUG2 120 mg three times a day for 7 days, DRUG2 did not alter the pharmacokinetics of a single 300-mg dose of DRUG1. ",negative,Phenytoin,XENICAL
"DRUG1: In 12 normal-weight subjects receiving XENICAL 120 mg three times a day for 7 days, XENICAL did not alter the pharmacokinetics of a single 300-mg dose of DRUG1. ",negative,Phenytoin,phenytoin
"Phenytoin: In 12 normal-weight subjects receiving DRUG1 120 mg three times a day for 7 days, DRUG1 did not alter the pharmacokinetics of a single 300-mg dose of phenytoin. ",negative,XENICAL,XENICAL
"DRUG2: In 12 normal-weight subjects receiving DRUG1 120 mg three times a day for 7 days, DRUG1 did not alter the pharmacokinetics of a single 300-mg dose of DRUG2. ",negative,XENICAL,phenytoin
"DRUG2: In 12 normal-weight subjects receiving DRUG1 120 mg three times a day for 7 days, DRUG1 did not alter the pharmacokinetics of a single 300-mg dose of DRUG2. ",negative,XENICAL,phenytoin
"DRUG1: In a 2-way crossover study of 24 normal-weight, mildly hypercholesterolemic patients receiving DRUG2 120 mg three times a day for 6 days, DRUG2 did not affect the pharmacokinetics of DRUG1. ",negative,Pravastatin,XENICAL
"DRUG1: In a 2-way crossover study of 24 normal-weight, mildly hypercholesterolemic patients receiving DRUG2 120 mg three times a day for 6 days, DRUG2 did not affect the pharmacokinetics of DRUG1. ",negative,Pravastatin,XENICAL
"DRUG1: In a 2-way crossover study of 24 normal-weight, mildly hypercholesterolemic patients receiving XENICAL 120 mg three times a day for 6 days, XENICAL did not affect the pharmacokinetics of DRUG1. ",negative,Pravastatin,pravastatin
"Pravastatin: In a 2-way crossover study of 24 normal-weight, mildly hypercholesterolemic patients receiving DRUG1 120 mg three times a day for 6 days, DRUG1 did not affect the pharmacokinetics of pravastatin. ",negative,XENICAL,XENICAL
"DRUG2: In a 2-way crossover study of 24 normal-weight, mildly hypercholesterolemic patients receiving DRUG1 120 mg three times a day for 6 days, DRUG1 did not affect the pharmacokinetics of DRUG2. ",negative,XENICAL,pravastatin
"DRUG2: In a 2-way crossover study of 24 normal-weight, mildly hypercholesterolemic patients receiving DRUG1 120 mg three times a day for 6 days, DRUG1 did not affect the pharmacokinetics of DRUG2. ",negative,XENICAL,pravastatin
"DRUG1: In 12 normal-weight subjects, administration of DRUG2 120 mg three times a day for 16 days did not result in any change in either DRUG1 pharmacokinetics (both R- and S-enantiomers) or pharmacodynamics (prothrombin time and serum Factor VII). ",negative,Warfarin,XENICAL
"DRUG1: In 12 normal-weight subjects, administration of XENICAL 120 mg three times a day for 16 days did not result in any change in either DRUG1 pharmacokinetics (both R- and S-enantiomers) or pharmacodynamics (prothrombin time and serum Factor VII). ",negative,Warfarin,warfarin
"DRUG2: In 12 normal-weight subjects, administration of DRUG1 120 mg three times a day for 16 days did not result in any change in either DRUG2 pharmacokinetics (both R- and S-enantiomers) or pharmacodynamics (prothrombin time and serum Factor VII). ",negative,XENICAL,warfarin
"Although undercarboxylated osteocalcin, a marker of vitamin K nutritional status, was unaltered with DRUG1 administration, vitamin K levels tended to decline in subjects taking DRUG1. ",negative,XENICAL,XENICAL
"Therefore, as DRUG1 absorption may be decreased with DRUG2, patients on chronic stable doses of warfarin who are prescribed DRUG2 should be monitored closely for changes in coagulation parameters.",mechanism,vitamin K,XENICAL
"Therefore, as DRUG1 absorption may be decreased with XENICAL, patients on chronic stable doses of DRUG2 who are prescribed XENICAL should be monitored closely for changes in coagulation parameters.",negative,vitamin K,warfarin
"Therefore, as DRUG1 absorption may be decreased with DRUG2, patients on chronic stable doses of warfarin who are prescribed DRUG2 should be monitored closely for changes in coagulation parameters.",negative,vitamin K,XENICAL
"Therefore, as vitamin K absorption may be decreased with DRUG1, patients on chronic stable doses of DRUG2 who are prescribed DRUG1 should be monitored closely for changes in coagulation parameters.",negative,XENICAL,warfarin
"Therefore, as vitamin K absorption may be decreased with DRUG1, patients on chronic stable doses of warfarin who are prescribed DRUG1 should be monitored closely for changes in coagulation parameters.",negative,XENICAL,XENICAL
"Therefore, as vitamin K absorption may be decreased with DRUG2, patients on chronic stable doses of DRUG1 who are prescribed DRUG2 should be monitored closely for changes in coagulation parameters.",advise,warfarin,XENICAL
"In vitro studies with human liver microsomes showed that DRUG1 does not inhibit the metabolism of DRUG2, ethinylestradiol, ethoxycoumarin, and cyclosporine. ",negative,terbinafine,tolbutamide
"In vitro studies with human liver microsomes showed that DRUG1 does not inhibit the metabolism of tolbutamide, DRUG2, ethoxycoumarin, and cyclosporine. ",negative,terbinafine,ethinylestradiol
"In vitro studies with human liver microsomes showed that DRUG1 does not inhibit the metabolism of tolbutamide, ethinylestradiol, DRUG2, and cyclosporine. ",negative,terbinafine,ethoxycoumarin
"In vitro studies with human liver microsomes showed that DRUG1 does not inhibit the metabolism of tolbutamide, ethinylestradiol, ethoxycoumarin, and DRUG2. ",negative,terbinafine,cyclosporine
"In vitro studies with human liver microsomes showed that terbinafine does not inhibit the metabolism of DRUG1, DRUG2, ethoxycoumarin, and cyclosporine. ",negative,tolbutamide,ethinylestradiol
"In vitro studies with human liver microsomes showed that terbinafine does not inhibit the metabolism of DRUG1, ethinylestradiol, DRUG2, and cyclosporine. ",negative,tolbutamide,ethoxycoumarin
"In vitro studies with human liver microsomes showed that terbinafine does not inhibit the metabolism of DRUG1, ethinylestradiol, ethoxycoumarin, and DRUG2. ",negative,tolbutamide,cyclosporine
"In vitro studies with human liver microsomes showed that terbinafine does not inhibit the metabolism of tolbutamide, DRUG1, DRUG2, and cyclosporine. ",negative,ethinylestradiol,ethoxycoumarin
"In vitro studies with human liver microsomes showed that terbinafine does not inhibit the metabolism of tolbutamide, DRUG1, ethoxycoumarin, and DRUG2. ",negative,ethinylestradiol,cyclosporine
"In vitro studies with human liver microsomes showed that terbinafine does not inhibit the metabolism of tolbutamide, ethinylestradiol, DRUG1, and DRUG2. ",negative,ethoxycoumarin,cyclosporine
"This may be of clinical relevance for compounds predominantly metabolized by this enzyme, such as DRUG1,    -blockers, DRUG2 (SSRIs), and monoamine oxidase inhibitors (MAO-Is) Type B, if they have a narrow therapeutic window. ",negative,tricyclic antidepressants,selective serotonin reuptake inhibitors
"This may be of clinical relevance for compounds predominantly metabolized by this enzyme, such as DRUG1,    -blockers, selective serotonin reuptake inhibitors (DRUG2), and monoamine oxidase inhibitors (MAO-Is) Type B, if they have a narrow therapeutic window. ",negative,tricyclic antidepressants,SSRIs
"This may be of clinical relevance for compounds predominantly metabolized by this enzyme, such as DRUG1,    -blockers, selective serotonin reuptake inhibitors (SSRIs), and DRUG2, if they have a narrow therapeutic window. ",negative,tricyclic antidepressants,monoamine oxidase inhibitors (MAO-Is) Type B
"This may be of clinical relevance for compounds predominantly metabolized by this enzyme, such as tricyclic antidepressants,    -blockers, DRUG1 (DRUG2), and monoamine oxidase inhibitors (MAO-Is) Type B, if they have a narrow therapeutic window. ",negative,selective serotonin reuptake inhibitors,SSRIs
"This may be of clinical relevance for compounds predominantly metabolized by this enzyme, such as tricyclic antidepressants,    -blockers, DRUG1 (SSRIs), and DRUG2, if they have a narrow therapeutic window. ",negative,selective serotonin reuptake inhibitors,monoamine oxidase inhibitors (MAO-Is) Type B
"This may be of clinical relevance for compounds predominantly metabolized by this enzyme, such as tricyclic antidepressants,    -blockers, selective serotonin reuptake inhibitors (DRUG1), and DRUG2, if they have a narrow therapeutic window. ",negative,SSRIs,monoamine oxidase inhibitors (MAO-Is) Type B
In vivo drug-drug interaction studies conducted in normal volunteer subjects showed that DRUG1 does not affect the clearance of DRUG2 or digoxin. ,negative,terbinafine,antipyrine
In vivo drug-drug interaction studies conducted in normal volunteer subjects showed that DRUG1 does not affect the clearance of antipyrine or DRUG2. ,negative,terbinafine,digoxin
In vivo drug-drug interaction studies conducted in normal volunteer subjects showed that terbinafine does not affect the clearance of DRUG1 or DRUG2. ,negative,antipyrine,digoxin
DRUG1 decreases the clearance of DRUG2 by 19%. ,mechanism,Terbinafine,caffeine
DRUG1 increases the clearance of DRUG2 by 15%. ,mechanism,Terbinafine,cyclosporine
"There have been spontaneous reports of increase or decrease in prothrombin times in patients concomitantly taking oral DRUG1 and DRUG2, however, a causal relationship between LAMISIL    Tablets and these changes has not been established. ",effect,terbinafine,warfarin
"There have been spontaneous reports of increase or decrease in prothrombin times in patients concomitantly taking oral DRUG1 and warfarin, however, a causal relationship between DRUG2    Tablets and these changes has not been established. ",negative,terbinafine,LAMISIL
"There have been spontaneous reports of increase or decrease in prothrombin times in patients concomitantly taking oral terbinafine and DRUG1, however, a causal relationship between DRUG2    Tablets and these changes has not been established. ",negative,warfarin,LAMISIL
"DRUG1 clearance is increased 100% by DRUG2, a CyP450 enzyme inducer, and decreased 33% by cimetidine, a CyP450 enzyme inhibitor. ",mechanism,Terbinafine,rifampin
"DRUG1 clearance is increased 100% by rifampin, a CyP450 enzyme inducer, and decreased 33% by DRUG2, a CyP450 enzyme inhibitor. ",mechanism,Terbinafine,cimetidine
"Terbinafine clearance is increased 100% by DRUG1, a CyP450 enzyme inducer, and decreased 33% by DRUG2, a CyP450 enzyme inhibitor. ",negative,rifampin,cimetidine
DRUG1 clearance is unaffected by DRUG2. ,negative,Terbinafine,cyclosporine
"There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral DRUG1, hormone replacement therapies, DRUG2, theophyllines, phenytoins, thiazide diuretics, beta blockers, and calcium channel blockers.",negative,contraceptives,hypoglycemics
"There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral DRUG1, hormone replacement therapies, hypoglycemics, DRUG2, phenytoins, thiazide diuretics, beta blockers, and calcium channel blockers.",negative,contraceptives,theophyllines
"There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral DRUG1, hormone replacement therapies, hypoglycemics, theophyllines, DRUG2, thiazide diuretics, beta blockers, and calcium channel blockers.",negative,contraceptives,phenytoins
"There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral DRUG1, hormone replacement therapies, hypoglycemics, theophyllines, phenytoins, DRUG2, beta blockers, and calcium channel blockers.",negative,contraceptives,thiazide diuretics
"There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral DRUG1, hormone replacement therapies, hypoglycemics, theophyllines, phenytoins, thiazide diuretics, DRUG2, and calcium channel blockers.",negative,contraceptives,beta blockers
"There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral DRUG1, hormone replacement therapies, hypoglycemics, theophyllines, phenytoins, thiazide diuretics, beta blockers, and DRUG2.",negative,contraceptives,calcium channel blockers
"There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, DRUG1, DRUG2, phenytoins, thiazide diuretics, beta blockers, and calcium channel blockers.",negative,hypoglycemics,theophyllines
"There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, DRUG1, theophyllines, DRUG2, thiazide diuretics, beta blockers, and calcium channel blockers.",negative,hypoglycemics,phenytoins
"There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, DRUG1, theophyllines, phenytoins, DRUG2, beta blockers, and calcium channel blockers.",negative,hypoglycemics,thiazide diuretics
"There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, DRUG1, theophyllines, phenytoins, thiazide diuretics, DRUG2, and calcium channel blockers.",negative,hypoglycemics,beta blockers
"There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, DRUG1, theophyllines, phenytoins, thiazide diuretics, beta blockers, and DRUG2.",negative,hypoglycemics,calcium channel blockers
"There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, DRUG1, DRUG2, thiazide diuretics, beta blockers, and calcium channel blockers.",negative,theophyllines,phenytoins
"There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, DRUG1, phenytoins, DRUG2, beta blockers, and calcium channel blockers.",negative,theophyllines,thiazide diuretics
"There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, DRUG1, phenytoins, thiazide diuretics, DRUG2, and calcium channel blockers.",negative,theophyllines,beta blockers
"There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, DRUG1, phenytoins, thiazide diuretics, beta blockers, and DRUG2.",negative,theophyllines,calcium channel blockers
"There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, theophyllines, DRUG1, DRUG2, beta blockers, and calcium channel blockers.",negative,phenytoins,thiazide diuretics
"There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, theophyllines, DRUG1, thiazide diuretics, DRUG2, and calcium channel blockers.",negative,phenytoins,beta blockers
"There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, theophyllines, DRUG1, thiazide diuretics, beta blockers, and DRUG2.",negative,phenytoins,calcium channel blockers
"There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, theophyllines, phenytoins, DRUG1, DRUG2, and calcium channel blockers.",negative,thiazide diuretics,beta blockers
"There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, theophyllines, phenytoins, DRUG1, beta blockers, and DRUG2.",negative,thiazide diuretics,calcium channel blockers
"There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, theophyllines, phenytoins, thiazide diuretics, DRUG1, and DRUG2.",negative,beta blockers,calcium channel blockers
DRUG1 AND OTHER DRUG2 WILL BE ADDITIVE TO DISALCID AND MAY INCREASE PLASMA CONCENTRATIONS OF SALICYLIC ACID TO TOXIC LEVELS. ,negative,ASPIRIN,SALICYLATE DRUGS
DRUG1 AND OTHER SALICYLATE DRUGS WILL BE ADDITIVE TO DRUG2 AND MAY INCREASE PLASMA CONCENTRATIONS OF SALICYLIC ACID TO TOXIC LEVELS. ,effect,ASPIRIN,DISALCID
DRUG1 AND OTHER SALICYLATE DRUGS WILL BE ADDITIVE TO DISALCID AND MAY INCREASE PLASMA CONCENTRATIONS OF DRUG2 TO TOXIC LEVELS. ,negative,ASPIRIN,SALICYLIC ACID
ASPIRIN AND OTHER DRUG1 WILL BE ADDITIVE TO DRUG2 AND MAY INCREASE PLASMA CONCENTRATIONS OF SALICYLIC ACID TO TOXIC LEVELS. ,effect,SALICYLATE DRUGS,DISALCID
ASPIRIN AND OTHER DRUG1 WILL BE ADDITIVE TO DISALCID AND MAY INCREASE PLASMA CONCENTRATIONS OF DRUG2 TO TOXIC LEVELS. ,negative,SALICYLATE DRUGS,SALICYLIC ACID
ASPIRIN AND OTHER SALICYLATE DRUGS WILL BE ADDITIVE TO DRUG1 AND MAY INCREASE PLASMA CONCENTRATIONS OF DRUG2 TO TOXIC LEVELS. ,negative,DISALCID,SALICYLIC ACID
DRUG1 given concomitantly with DRUG2 may predispose to systemic bleeding. ,effect,Salicylates,anticoagulant drugs
DRUG1 may enhance the hypoglycemic effect of oral DRUG2 of the sulfonylurea class. ,effect,Salicylates,antidiabetic drugs
"DRUG1 competes with a number of drugs for protein binding sites, notably DRUG2, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",mechanism,Salicylate,penicillin
"DRUG1 competes with a number of drugs for protein binding sites, notably penicillin, DRUG2, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",mechanism,Salicylate,thiopental
"DRUG1 competes with a number of drugs for protein binding sites, notably penicillin, thiopental, DRUG2, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",mechanism,Salicylate,thyroxine
"DRUG1 competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, DRUG2, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",mechanism,Salicylate,triiodothyronine
"DRUG1 competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, DRUG2, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",mechanism,Salicylate,phenytoin
"DRUG1 competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, DRUG2, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",mechanism,Salicylate,sulfinpyrazone
"DRUG1 competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, DRUG2, warfarin, methotrexate, and possibly corticosteroids. ",mechanism,Salicylate,naproxen
"DRUG1 competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, DRUG2, methotrexate, and possibly corticosteroids. ",mechanism,Salicylate,warfarin
"DRUG1 competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, DRUG2, and possibly corticosteroids. ",mechanism,Salicylate,methotrexate
"DRUG1 competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly DRUG2. ",mechanism,Salicylate,corticosteroids
"Salicylate competes with a number of drugs for protein binding sites, notably DRUG1, DRUG2, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",negative,penicillin,thiopental
"Salicylate competes with a number of drugs for protein binding sites, notably DRUG1, thiopental, DRUG2, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",negative,penicillin,thyroxine
"Salicylate competes with a number of drugs for protein binding sites, notably DRUG1, thiopental, thyroxine, DRUG2, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",negative,penicillin,triiodothyronine
"Salicylate competes with a number of drugs for protein binding sites, notably DRUG1, thiopental, thyroxine, triiodothyronine, DRUG2, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",negative,penicillin,phenytoin
"Salicylate competes with a number of drugs for protein binding sites, notably DRUG1, thiopental, thyroxine, triiodothyronine, phenytoin, DRUG2, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",negative,penicillin,sulfinpyrazone
"Salicylate competes with a number of drugs for protein binding sites, notably DRUG1, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, DRUG2, warfarin, methotrexate, and possibly corticosteroids. ",negative,penicillin,naproxen
"Salicylate competes with a number of drugs for protein binding sites, notably DRUG1, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, DRUG2, methotrexate, and possibly corticosteroids. ",negative,penicillin,warfarin
"Salicylate competes with a number of drugs for protein binding sites, notably DRUG1, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, DRUG2, and possibly corticosteroids. ",negative,penicillin,methotrexate
"Salicylate competes with a number of drugs for protein binding sites, notably DRUG1, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly DRUG2. ",negative,penicillin,corticosteroids
"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, DRUG1, DRUG2, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",negative,thiopental,thyroxine
"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, DRUG1, thyroxine, DRUG2, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",negative,thiopental,triiodothyronine
"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, DRUG1, thyroxine, triiodothyronine, DRUG2, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",negative,thiopental,phenytoin
"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, DRUG1, thyroxine, triiodothyronine, phenytoin, DRUG2, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",negative,thiopental,sulfinpyrazone
"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, DRUG1, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, DRUG2, warfarin, methotrexate, and possibly corticosteroids. ",negative,thiopental,naproxen
"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, DRUG1, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, DRUG2, methotrexate, and possibly corticosteroids. ",negative,thiopental,warfarin
"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, DRUG1, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, DRUG2, and possibly corticosteroids. ",negative,thiopental,methotrexate
"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, DRUG1, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly DRUG2. ",negative,thiopental,corticosteroids
"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, DRUG1, DRUG2, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",negative,thyroxine,triiodothyronine
"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, DRUG1, triiodothyronine, DRUG2, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",negative,thyroxine,phenytoin
"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, DRUG1, triiodothyronine, phenytoin, DRUG2, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",negative,thyroxine,sulfinpyrazone
"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, DRUG1, triiodothyronine, phenytoin, sulfinpyrazone, DRUG2, warfarin, methotrexate, and possibly corticosteroids. ",negative,thyroxine,naproxen
"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, DRUG1, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, DRUG2, methotrexate, and possibly corticosteroids. ",negative,thyroxine,warfarin
"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, DRUG1, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, DRUG2, and possibly corticosteroids. ",negative,thyroxine,methotrexate
"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, DRUG1, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly DRUG2. ",negative,thyroxine,corticosteroids
"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, DRUG1, DRUG2, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",negative,triiodothyronine,phenytoin
"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, DRUG1, phenytoin, DRUG2, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",negative,triiodothyronine,sulfinpyrazone
"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, DRUG1, phenytoin, sulfinpyrazone, DRUG2, warfarin, methotrexate, and possibly corticosteroids. ",negative,triiodothyronine,naproxen
"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, DRUG1, phenytoin, sulfinpyrazone, naproxen, DRUG2, methotrexate, and possibly corticosteroids. ",negative,triiodothyronine,warfarin
"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, DRUG1, phenytoin, sulfinpyrazone, naproxen, warfarin, DRUG2, and possibly corticosteroids. ",negative,triiodothyronine,methotrexate
"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, DRUG1, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly DRUG2. ",negative,triiodothyronine,corticosteroids
"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, DRUG1, DRUG2, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",negative,phenytoin,sulfinpyrazone
"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, DRUG1, sulfinpyrazone, DRUG2, warfarin, methotrexate, and possibly corticosteroids. ",negative,phenytoin,naproxen
"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, DRUG1, sulfinpyrazone, naproxen, DRUG2, methotrexate, and possibly corticosteroids. ",negative,phenytoin,warfarin
"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, DRUG1, sulfinpyrazone, naproxen, warfarin, DRUG2, and possibly corticosteroids. ",negative,phenytoin,methotrexate
"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, DRUG1, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly DRUG2. ",negative,phenytoin,corticosteroids
"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, DRUG1, DRUG2, warfarin, methotrexate, and possibly corticosteroids. ",negative,sulfinpyrazone,naproxen
"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, DRUG1, naproxen, DRUG2, methotrexate, and possibly corticosteroids. ",negative,sulfinpyrazone,warfarin
"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, DRUG1, naproxen, warfarin, DRUG2, and possibly corticosteroids. ",negative,sulfinpyrazone,methotrexate
"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, DRUG1, naproxen, warfarin, methotrexate, and possibly DRUG2. ",negative,sulfinpyrazone,corticosteroids
"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, DRUG1, DRUG2, methotrexate, and possibly corticosteroids. ",negative,naproxen,warfarin
"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, DRUG1, warfarin, DRUG2, and possibly corticosteroids. ",negative,naproxen,methotrexate
"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, DRUG1, warfarin, methotrexate, and possibly DRUG2. ",negative,naproxen,corticosteroids
"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, DRUG1, DRUG2, and possibly corticosteroids. ",negative,warfarin,methotrexate
"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, DRUG1, methotrexate, and possibly DRUG2. ",negative,warfarin,corticosteroids
"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, DRUG1, and possibly DRUG2. ",negative,methotrexate,corticosteroids
"Catecholamine-depleting drugs (e.g., DRUG1) may have an additive effect when given with DRUG2. ",effect,reserpine,beta-blocking agents
"DRUG1 has been used with a variety of DRUG2, including hydrochlorothiazide, hydralazine, and guanethidine without unexpected adverse interactions. ",negative,Pindolol,antihypertensive agents
"DRUG1 has been used with a variety of antihypertensive agents, including DRUG2, hydralazine, and guanethidine without unexpected adverse interactions. ",negative,Pindolol,hydrochlorothiazide
"DRUG1 has been used with a variety of antihypertensive agents, including hydrochlorothiazide, DRUG2, and guanethidine without unexpected adverse interactions. ",negative,Pindolol,hydralazine
"DRUG1 has been used with a variety of antihypertensive agents, including hydrochlorothiazide, hydralazine, and DRUG2 without unexpected adverse interactions. ",negative,Pindolol,guanethidine
"Pindolol has been used with a variety of DRUG1, including DRUG2, hydralazine, and guanethidine without unexpected adverse interactions. ",negative,antihypertensive agents,hydrochlorothiazide
"Pindolol has been used with a variety of DRUG1, including hydrochlorothiazide, DRUG2, and guanethidine without unexpected adverse interactions. ",negative,antihypertensive agents,hydralazine
"Pindolol has been used with a variety of DRUG1, including hydrochlorothiazide, hydralazine, and DRUG2 without unexpected adverse interactions. ",negative,antihypertensive agents,guanethidine
"Pindolol has been used with a variety of antihypertensive agents, including DRUG1, DRUG2, and guanethidine without unexpected adverse interactions. ",negative,hydrochlorothiazide,hydralazine
"Pindolol has been used with a variety of antihypertensive agents, including DRUG1, hydralazine, and DRUG2 without unexpected adverse interactions. ",negative,hydrochlorothiazide,guanethidine
"Pindolol has been used with a variety of antihypertensive agents, including hydrochlorothiazide, DRUG1, and DRUG2 without unexpected adverse interactions. ",negative,hydralazine,guanethidine
DRUG1 has been shown to increase serum DRUG2 levels when both drugs are co-administered. ,mechanism,Pindolol,thioridazine
"Although specific drug or food interactions with DRUG1 have not been studied, on the basis of this drug   s metabolism by CYP 3A4, it is possible that DRUG2, itraconazole, erythromycin, and grapefruit juice may inhibit its metabolism (increasing serum levels of DRUG1). ",negative,mifepristone,ketoconazole
"Although specific drug or food interactions with DRUG1 have not been studied, on the basis of this drug   s metabolism by CYP 3A4, it is possible that ketoconazole, DRUG2, erythromycin, and grapefruit juice may inhibit its metabolism (increasing serum levels of DRUG1). ",negative,mifepristone,itraconazole
"Although specific drug or food interactions with DRUG1 have not been studied, on the basis of this drug   s metabolism by CYP 3A4, it is possible that ketoconazole, itraconazole, DRUG2, and grapefruit juice may inhibit its metabolism (increasing serum levels of DRUG1). ",negative,mifepristone,erythromycin
"Although specific drug or food interactions with DRUG1 have not been studied, on the basis of this drug   s metabolism by CYP 3A4, it is possible that ketoconazole, itraconazole, erythromycin, and grapefruit juice may inhibit its metabolism (increasing serum levels of DRUG1). ",negative,mifepristone,mifepristone
"Although specific drug or food interactions with mifepristone have not been studied, on the basis of this drug   s metabolism by CYP 3A4, it is possible that DRUG1, DRUG2, erythromycin, and grapefruit juice may inhibit its metabolism (increasing serum levels of mifepristone). ",negative,ketoconazole,itraconazole
"Although specific drug or food interactions with mifepristone have not been studied, on the basis of this drug   s metabolism by CYP 3A4, it is possible that DRUG1, itraconazole, DRUG2, and grapefruit juice may inhibit its metabolism (increasing serum levels of mifepristone). ",negative,ketoconazole,erythromycin
"Although specific drug or food interactions with DRUG2 have not been studied, on the basis of this drug   s metabolism by CYP 3A4, it is possible that DRUG1, itraconazole, erythromycin, and grapefruit juice may inhibit its metabolism (increasing serum levels of DRUG2). ",mechanism,ketoconazole,mifepristone
"Although specific drug or food interactions with mifepristone have not been studied, on the basis of this drug   s metabolism by CYP 3A4, it is possible that ketoconazole, DRUG1, DRUG2, and grapefruit juice may inhibit its metabolism (increasing serum levels of mifepristone). ",negative,itraconazole,erythromycin
"Although specific drug or food interactions with DRUG2 have not been studied, on the basis of this drug   s metabolism by CYP 3A4, it is possible that ketoconazole, DRUG1, erythromycin, and grapefruit juice may inhibit its metabolism (increasing serum levels of DRUG2). ",mechanism,itraconazole,mifepristone
"Although specific drug or food interactions with DRUG2 have not been studied, on the basis of this drug   s metabolism by CYP 3A4, it is possible that ketoconazole, itraconazole, DRUG1, and grapefruit juice may inhibit its metabolism (increasing serum levels of DRUG2). ",mechanism,erythromycin,mifepristone
"Furthermore, DRUG1, DRUG2, St. ",negative,rifampin,dexamethasone
"John   s Wort, and certain DRUG1 (DRUG2, phenobarbital, carbamazepine) may induce mifepristone metabolism (lowering serum levels of mifepristone). ",negative,anticonvulsants,phenytoin
"John   s Wort, and certain DRUG1 (phenytoin, DRUG2, carbamazepine) may induce mifepristone metabolism (lowering serum levels of mifepristone). ",negative,anticonvulsants,phenobarbital
"John   s Wort, and certain DRUG1 (phenytoin, phenobarbital, DRUG2) may induce mifepristone metabolism (lowering serum levels of mifepristone). ",negative,anticonvulsants,carbamazepine
"John   s Wort, and certain DRUG1 (phenytoin, phenobarbital, carbamazepine) may induce DRUG2 metabolism (lowering serum levels of DRUG2). ",mechanism,anticonvulsants,mifepristone
"John   s Wort, and certain DRUG1 (phenytoin, phenobarbital, carbamazepine) may induce DRUG2 metabolism (lowering serum levels of DRUG2). ",negative,anticonvulsants,mifepristone
"John   s Wort, and certain anticonvulsants (DRUG1, DRUG2, carbamazepine) may induce mifepristone metabolism (lowering serum levels of mifepristone). ",negative,phenytoin,phenobarbital
"John   s Wort, and certain anticonvulsants (DRUG1, phenobarbital, DRUG2) may induce mifepristone metabolism (lowering serum levels of mifepristone). ",negative,phenytoin,carbamazepine
"John   s Wort, and certain anticonvulsants (DRUG1, phenobarbital, carbamazepine) may induce DRUG2 metabolism (lowering serum levels of DRUG2). ",mechanism,phenytoin,mifepristone
"John   s Wort, and certain anticonvulsants (DRUG1, phenobarbital, carbamazepine) may induce DRUG2 metabolism (lowering serum levels of DRUG2). ",negative,phenytoin,mifepristone
"John   s Wort, and certain anticonvulsants (phenytoin, DRUG1, DRUG2) may induce mifepristone metabolism (lowering serum levels of mifepristone). ",negative,phenobarbital,carbamazepine
"John   s Wort, and certain anticonvulsants (phenytoin, DRUG1, carbamazepine) may induce DRUG2 metabolism (lowering serum levels of DRUG2). ",mechanism,phenobarbital,mifepristone
"John   s Wort, and certain anticonvulsants (phenytoin, DRUG1, carbamazepine) may induce DRUG2 metabolism (lowering serum levels of DRUG2). ",negative,phenobarbital,mifepristone
"John   s Wort, and certain anticonvulsants (phenytoin, phenobarbital, DRUG1) may induce DRUG2 metabolism (lowering serum levels of DRUG2). ",mechanism,carbamazepine,mifepristone
"John   s Wort, and certain anticonvulsants (phenytoin, phenobarbital, DRUG1) may induce DRUG2 metabolism (lowering serum levels of DRUG2). ",negative,carbamazepine,mifepristone
"John   s Wort, and certain anticonvulsants (phenytoin, phenobarbital, carbamazepine) may induce DRUG1 metabolism (lowering serum levels of DRUG1). ",negative,mifepristone,mifepristone
"In addition to bleeding associated with DRUG1 and DRUG2, drugs that alter platelet function (such as aspirin, dipyridamole, and abciximab) may increase the risk of bleeding if administered prior to or after Retavase    therapy.",negative,heparin,vitamin K antagonists
"In addition to bleeding associated with DRUG1 and vitamin K antagonists, drugs that alter platelet function (such as DRUG2, dipyridamole, and abciximab) may increase the risk of bleeding if administered prior to or after Retavase    therapy.",negative,heparin,aspirin
"In addition to bleeding associated with DRUG1 and vitamin K antagonists, drugs that alter platelet function (such as aspirin, DRUG2, and abciximab) may increase the risk of bleeding if administered prior to or after Retavase    therapy.",negative,heparin,dipyridamole
"In addition to bleeding associated with DRUG1 and vitamin K antagonists, drugs that alter platelet function (such as aspirin, dipyridamole, and DRUG2) may increase the risk of bleeding if administered prior to or after Retavase    therapy.",negative,heparin,abciximab
"In addition to bleeding associated with DRUG1 and vitamin K antagonists, drugs that alter platelet function (such as aspirin, dipyridamole, and abciximab) may increase the risk of bleeding if administered prior to or after DRUG2    therapy.",effect,heparin,Retavase
"In addition to bleeding associated with heparin and DRUG1, drugs that alter platelet function (such as DRUG2, dipyridamole, and abciximab) may increase the risk of bleeding if administered prior to or after Retavase    therapy.",negative,vitamin K antagonists,aspirin
"In addition to bleeding associated with heparin and DRUG1, drugs that alter platelet function (such as aspirin, DRUG2, and abciximab) may increase the risk of bleeding if administered prior to or after Retavase    therapy.",negative,vitamin K antagonists,dipyridamole
"In addition to bleeding associated with heparin and DRUG1, drugs that alter platelet function (such as aspirin, dipyridamole, and DRUG2) may increase the risk of bleeding if administered prior to or after Retavase    therapy.",negative,vitamin K antagonists,abciximab
"In addition to bleeding associated with heparin and DRUG1, drugs that alter platelet function (such as aspirin, dipyridamole, and abciximab) may increase the risk of bleeding if administered prior to or after DRUG2    therapy.",effect,vitamin K antagonists,Retavase
"In addition to bleeding associated with heparin and vitamin K antagonists, drugs that alter platelet function (such as DRUG1, DRUG2, and abciximab) may increase the risk of bleeding if administered prior to or after Retavase    therapy.",negative,aspirin,dipyridamole
"In addition to bleeding associated with heparin and vitamin K antagonists, drugs that alter platelet function (such as DRUG1, dipyridamole, and DRUG2) may increase the risk of bleeding if administered prior to or after Retavase    therapy.",negative,aspirin,abciximab
"In addition to bleeding associated with heparin and vitamin K antagonists, drugs that alter platelet function (such as DRUG1, dipyridamole, and abciximab) may increase the risk of bleeding if administered prior to or after DRUG2    therapy.",effect,aspirin,Retavase
"In addition to bleeding associated with heparin and vitamin K antagonists, drugs that alter platelet function (such as aspirin, DRUG1, and DRUG2) may increase the risk of bleeding if administered prior to or after Retavase    therapy.",negative,dipyridamole,abciximab
"In addition to bleeding associated with heparin and vitamin K antagonists, drugs that alter platelet function (such as aspirin, DRUG1, and abciximab) may increase the risk of bleeding if administered prior to or after DRUG2    therapy.",effect,dipyridamole,Retavase
"In addition to bleeding associated with heparin and vitamin K antagonists, drugs that alter platelet function (such as aspirin, dipyridamole, and DRUG1) may increase the risk of bleeding if administered prior to or after DRUG2    therapy.",effect,abciximab,Retavase
"The occurrence of stupor, muscular rigidity, severe agitation, and elevated temperature has been reported in some patients receiving the combination of DRUG1 and DRUG2. ",effect,selegiline,meperidine
This is typical of the interaction of DRUG1 and DRUG2. ,int,meperidine,MAOIs
Severe toxicity has also been reported in patients receiving the combination of DRUG1 and DRUG2 and selective serotonin reuptake inhibitors and DRUG2. ,effect,tricyclic antidepressants,ELDEPRYL
Severe toxicity has also been reported in patients receiving the combination of DRUG1 and ELDEPRYL and DRUG2 and ELDEPRYL. ,negative,tricyclic antidepressants,selective serotonin reuptake inhibitors
Severe toxicity has also been reported in patients receiving the combination of DRUG1 and DRUG2 and selective serotonin reuptake inhibitors and DRUG2. ,negative,tricyclic antidepressants,ELDEPRYL
Severe toxicity has also been reported in patients receiving the combination of tricyclic antidepressants and DRUG1 and DRUG2 and DRUG1. ,negative,ELDEPRYL,selective serotonin reuptake inhibitors
Severe toxicity has also been reported in patients receiving the combination of tricyclic antidepressants and DRUG1 and selective serotonin reuptake inhibitors and DRUG1. ,negative,ELDEPRYL,ELDEPRYL
Severe toxicity has also been reported in patients receiving the combination of tricyclic antidepressants and DRUG2 and DRUG1 and DRUG2. ,effect,selective serotonin reuptake inhibitors,ELDEPRYL
One case of hypertensive crisis has been reported in a patient taking the recommended doses of DRUG1 and a DRUG2 (ephedrine).,effect,selegiline,sympathomimetic medication
One case of hypertensive crisis has been reported in a patient taking the recommended doses of DRUG1 and a sympathomimetic medication (DRUG2).,effect,selegiline,ephedrine
One case of hypertensive crisis has been reported in a patient taking the recommended doses of selegiline and a DRUG1 (DRUG2).,negative,sympathomimetic medication,ephedrine
Caution should be exercised when administering DRUG1 therapy in combination with other DRUG2. ,advise,ZADAXIN,immunomodulating drugs
Caution should be observed in administering DRUG1 to patients receiving DRUG2 or haloperidol because the extrapyramidal effects of these drugs can be expected to be potentiated by inhibition of catecholamine synthesis. ,advise,DEMSER,phenothiazines
Caution should be observed in administering DRUG1 to patients receiving phenothiazines or DRUG2 because the extrapyramidal effects of these drugs can be expected to be potentiated by inhibition of catecholamine synthesis. ,advise,DEMSER,haloperidol
Caution should be observed in administering DEMSER to patients receiving DRUG1 or DRUG2 because the extrapyramidal effects of these drugs can be expected to be potentiated by inhibition of catecholamine synthesis. ,negative,phenothiazines,haloperidol
Concurrent use of DRUG1 with DRUG2 or other CNS depressants can increase their sedative effects.,effect,DEMSER,alcohol
Concurrent use of DRUG1 with alcohol or other DRUG2 can increase their sedative effects.,effect,DEMSER,CNS depressants
Concurrent use of DEMSER with DRUG1 or other DRUG2 can increase their sedative effects.,negative,alcohol,CNS depressants
The metabolism of DRUG1 is accelerated by DRUG2; ,mechanism,Metopirone,phenytoin
DRUG1 inhibits the glucuronidation of DRUG2 and could possibly potentiate DRUG2 toxicity.,mechanism,Metopirone,acetaminophen
DRUG1 inhibits the glucuronidation of DRUG2 and could possibly potentiate DRUG2 toxicity.,effect,Metopirone,acetaminophen
Metopirone inhibits the glucuronidation of DRUG1 and could possibly potentiate DRUG1 toxicity.,negative,acetaminophen,acetaminophen
"DRUG1, such as the DRUG2 (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); ",negative,Dopamine antagonists,neuroleptics
"DRUG1, such as the neuroleptics (DRUG2, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); ",negative,Dopamine antagonists,phenothiazines
"DRUG1, such as the neuroleptics (phenothiazines, DRUG2, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); ",negative,Dopamine antagonists,butyrophenones
"DRUG1, such as the neuroleptics (phenothiazines, butyrophenones, DRUG2 ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); ",negative,Dopamine antagonists,thioxanthines
"DRUG1, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or DRUG2, ordinarily should not be administered concurrently with Permax (a dopamine agonist); ",negative,Dopamine antagonists,metoclopramide
"DRUG1, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with DRUG2 (a dopamine agonist); ",advise,Dopamine antagonists,Permax
"DRUG1, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a DRUG2); ",negative,Dopamine antagonists,dopamine agonist
"Dopamine antagonists, such as the DRUG1 (DRUG2, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); ",negative,neuroleptics,phenothiazines
"Dopamine antagonists, such as the DRUG1 (phenothiazines, DRUG2, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); ",negative,neuroleptics,butyrophenones
"Dopamine antagonists, such as the DRUG1 (phenothiazines, butyrophenones, DRUG2 ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); ",negative,neuroleptics,thioxanthines
"Dopamine antagonists, such as the DRUG1 (phenothiazines, butyrophenones, thioxanthines ) or DRUG2, ordinarily should not be administered concurrently with Permax (a dopamine agonist); ",negative,neuroleptics,metoclopramide
"Dopamine antagonists, such as the DRUG1 (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with DRUG2 (a dopamine agonist); ",advise,neuroleptics,Permax
"Dopamine antagonists, such as the DRUG1 (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a DRUG2); ",negative,neuroleptics,dopamine agonist
"Dopamine antagonists, such as the neuroleptics (DRUG1, DRUG2, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); ",negative,phenothiazines,butyrophenones
"Dopamine antagonists, such as the neuroleptics (DRUG1, butyrophenones, DRUG2 ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); ",negative,phenothiazines,thioxanthines
"Dopamine antagonists, such as the neuroleptics (DRUG1, butyrophenones, thioxanthines ) or DRUG2, ordinarily should not be administered concurrently with Permax (a dopamine agonist); ",negative,phenothiazines,metoclopramide
"Dopamine antagonists, such as the neuroleptics (DRUG1, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with DRUG2 (a dopamine agonist); ",advise,phenothiazines,Permax
"Dopamine antagonists, such as the neuroleptics (DRUG1, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a DRUG2); ",negative,phenothiazines,dopamine agonist
"Dopamine antagonists, such as the neuroleptics (phenothiazines, DRUG1, DRUG2 ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); ",negative,butyrophenones,thioxanthines
"Dopamine antagonists, such as the neuroleptics (phenothiazines, DRUG1, thioxanthines ) or DRUG2, ordinarily should not be administered concurrently with Permax (a dopamine agonist); ",negative,butyrophenones,metoclopramide
"Dopamine antagonists, such as the neuroleptics (phenothiazines, DRUG1, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with DRUG2 (a dopamine agonist); ",advise,butyrophenones,Permax
"Dopamine antagonists, such as the neuroleptics (phenothiazines, DRUG1, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a DRUG2); ",negative,butyrophenones,dopamine agonist
"Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, DRUG1 ) or DRUG2, ordinarily should not be administered concurrently with Permax (a dopamine agonist); ",negative,thioxanthines,metoclopramide
"Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, DRUG1 ) or metoclopramide, ordinarily should not be administered concurrently with DRUG2 (a dopamine agonist); ",advise,thioxanthines,Permax
"Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, DRUG1 ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a DRUG2); ",negative,thioxanthines,dopamine agonist
"Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or DRUG1, ordinarily should not be administered concurrently with DRUG2 (a dopamine agonist); ",advise,metoclopramide,Permax
"Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or DRUG1, ordinarily should not be administered concurrently with Permax (a DRUG2); ",negative,metoclopramide,dopamine agonist
"Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with DRUG1 (a DRUG2); ",negative,Permax,dopamine agonist
"Because DRUG1 is approximately 90% bound to plasma proteins, caution should be exercised if DRUG1 is coadministered with other drugs known to affect protein binding.",negative,pergolide mesylate,pergolide mesylate
"Co-administration of oral DRUG1 200 mg twice daily increased DRUG2 geometric mean AUC(0-24) and Cmax by 81% after topical application of DRUG2 ointment, 1% on the abraded skin of healthy adult males. ",negative,ketoconazole,retapamulin
"Co-administration of oral DRUG1 200 mg twice daily increased DRUG2 geometric mean AUC(0-24) and Cmax by 81% after topical application of DRUG2 ointment, 1% on the abraded skin of healthy adult males. ",mechanism,ketoconazole,retapamulin
"Co-administration of oral ketoconazole 200 mg twice daily increased DRUG1 geometric mean AUC(0-24) and Cmax by 81% after topical application of DRUG1 ointment, 1% on the abraded skin of healthy adult males. ",negative,retapamulin,retapamulin
"Due to low systemic exposure to DRUG1 following topical application in patients, dosage adjustments for DRUG1 are unnecessary when co-administered with CYP3A4 inhibitors, such as ketoconazole. ",negative,retapamulin,retapamulin
"Due to low systemic exposure to DRUG1 following topical application in patients, dosage adjustments for DRUG1 are unnecessary when co-administered with CYP3A4 inhibitors, such as DRUG2. ",negative,retapamulin,ketoconazole
"Due to low systemic exposure to DRUG1 following topical application in patients, dosage adjustments for DRUG1 are unnecessary when co-administered with CYP3A4 inhibitors, such as DRUG2. ",negative,retapamulin,ketoconazole
"Based on in vitro P450 inhibition studies and the low systemic exposure observed following topical application of DRUG1, DRUG2 is unlikely to affect the metabolism of other P450 substrates. ",negative,ALTABAX,retapamulin
"A multiple dose drug-drug interaction study demonstrated that DRUG1 approximately doubled DRUG2 AUC0-   . Since DRUG2 is partially metabolized by CYP3A and DRUG1 le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUG2 with DRUG1 and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",mechanism,ketoconazole,paricalcitol
"A multiple dose drug-drug interaction study demonstrated that DRUG1 approximately doubled DRUG2 AUC0-   . Since DRUG2 is partially metabolized by CYP3A and DRUG1 le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUG2 with DRUG1 and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",negative,ketoconazole,paricalcitol
"A multiple dose drug-drug interaction study demonstrated that DRUG1 approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and DRUG1 le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with DRUG1 and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",negative,ketoconazole,ketoconazole
"A multiple dose drug-drug interaction study demonstrated that DRUG1 approximately doubled DRUG2 AUC0-   . Since DRUG2 is partially metabolized by CYP3A and DRUG1 le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUG2 with DRUG1 and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",negative,ketoconazole,paricalcitol
"A multiple dose drug-drug interaction study demonstrated that DRUG1 approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and DRUG1 le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with DRUG1 and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",negative,ketoconazole,ketoconazole
"A multiple dose drug-drug interaction study demonstrated that DRUG1 approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and DRUG1 le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with DRUG1 and other strong P450 3A inhibitors including DRUG2, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",negative,ketoconazole,atazanavir
"A multiple dose drug-drug interaction study demonstrated that DRUG1 approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and DRUG1 le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with DRUG1 and other strong P450 3A inhibitors including atazanavir, DRUG2, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",negative,ketoconazole,clarithromycin
"A multiple dose drug-drug interaction study demonstrated that DRUG1 approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and DRUG1 le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with DRUG1 and other strong P450 3A inhibitors including atazanavir, clarithromycin, DRUG2, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",negative,ketoconazole,indinavir
"A multiple dose drug-drug interaction study demonstrated that DRUG1 approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and DRUG1 le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with DRUG1 and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, DRUG2, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",negative,ketoconazole,itraconazole
"A multiple dose drug-drug interaction study demonstrated that DRUG1 approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and DRUG1 le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with DRUG1 and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, DRUG2, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",negative,ketoconazole,nefazodone
"A multiple dose drug-drug interaction study demonstrated that DRUG1 approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and DRUG1 le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with DRUG1 and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, DRUG2, ritonavir, saquinavir, telithromycin or voriconazole. ",negative,ketoconazole,nelfinavir
"A multiple dose drug-drug interaction study demonstrated that DRUG1 approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and DRUG1 le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with DRUG1 and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, DRUG2, saquinavir, telithromycin or voriconazole. ",negative,ketoconazole,ritonavir
"A multiple dose drug-drug interaction study demonstrated that DRUG1 approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and DRUG1 le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with DRUG1 and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, DRUG2, telithromycin or voriconazole. ",negative,ketoconazole,saquinavir
"A multiple dose drug-drug interaction study demonstrated that DRUG1 approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and DRUG1 le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with DRUG1 and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, DRUG2 or voriconazole. ",negative,ketoconazole,telithromycin
"A multiple dose drug-drug interaction study demonstrated that DRUG1 approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and DRUG1 le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with DRUG1 and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or DRUG2. ",negative,ketoconazole,voriconazole
"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled DRUG1 AUC0-   . Since DRUG1 is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUG1 with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",negative,paricalcitol,paricalcitol
"A multiple dose drug-drug interaction study demonstrated that DRUG2 approximately doubled DRUG1 AUC0-   . Since DRUG1 is partially metabolized by CYP3A and DRUG2 le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUG1 with DRUG2 and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",negative,paricalcitol,ketoconazole
"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled DRUG1 AUC0-   . Since DRUG1 is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUG1 with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",negative,paricalcitol,paricalcitol
"A multiple dose drug-drug interaction study demonstrated that DRUG2 approximately doubled DRUG1 AUC0-   . Since DRUG1 is partially metabolized by CYP3A and DRUG2 le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUG1 with DRUG2 and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",negative,paricalcitol,ketoconazole
"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled DRUG1 AUC0-   . Since DRUG1 is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUG1 with ketoconazole and other strong P450 3A inhibitors including DRUG2, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",negative,paricalcitol,atazanavir
"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled DRUG1 AUC0-   . Since DRUG1 is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUG1 with ketoconazole and other strong P450 3A inhibitors including atazanavir, DRUG2, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",negative,paricalcitol,clarithromycin
"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled DRUG1 AUC0-   . Since DRUG1 is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUG1 with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, DRUG2, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",negative,paricalcitol,indinavir
"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled DRUG1 AUC0-   . Since DRUG1 is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUG1 with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, DRUG2, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",negative,paricalcitol,itraconazole
"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled DRUG1 AUC0-   . Since DRUG1 is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUG1 with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, DRUG2, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",negative,paricalcitol,nefazodone
"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled DRUG1 AUC0-   . Since DRUG1 is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUG1 with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, DRUG2, ritonavir, saquinavir, telithromycin or voriconazole. ",negative,paricalcitol,nelfinavir
"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled DRUG1 AUC0-   . Since DRUG1 is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUG1 with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, DRUG2, saquinavir, telithromycin or voriconazole. ",negative,paricalcitol,ritonavir
"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled DRUG1 AUC0-   . Since DRUG1 is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUG1 with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, DRUG2, telithromycin or voriconazole. ",negative,paricalcitol,saquinavir
"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled DRUG1 AUC0-   . Since DRUG1 is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUG1 with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, DRUG2 or voriconazole. ",negative,paricalcitol,telithromycin
"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled DRUG1 AUC0-   . Since DRUG1 is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUG1 with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or DRUG2. ",negative,paricalcitol,voriconazole
"A multiple dose drug-drug interaction study demonstrated that DRUG2 approximately doubled DRUG1 AUC0-   . Since DRUG1 is partially metabolized by CYP3A and DRUG2 le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUG1 with DRUG2 and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",negative,paricalcitol,ketoconazole
"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled DRUG1 AUC0-   . Since DRUG1 is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUG1 with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",negative,paricalcitol,paricalcitol
"A multiple dose drug-drug interaction study demonstrated that DRUG2 approximately doubled DRUG1 AUC0-   . Since DRUG1 is partially metabolized by CYP3A and DRUG2 le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUG1 with DRUG2 and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",negative,paricalcitol,ketoconazole
"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled DRUG1 AUC0-   . Since DRUG1 is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUG1 with ketoconazole and other strong P450 3A inhibitors including DRUG2, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",negative,paricalcitol,atazanavir
"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled DRUG1 AUC0-   . Since DRUG1 is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUG1 with ketoconazole and other strong P450 3A inhibitors including atazanavir, DRUG2, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",negative,paricalcitol,clarithromycin
"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled DRUG1 AUC0-   . Since DRUG1 is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUG1 with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, DRUG2, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",negative,paricalcitol,indinavir
"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled DRUG1 AUC0-   . Since DRUG1 is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUG1 with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, DRUG2, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",negative,paricalcitol,itraconazole
"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled DRUG1 AUC0-   . Since DRUG1 is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUG1 with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, DRUG2, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",negative,paricalcitol,nefazodone
"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled DRUG1 AUC0-   . Since DRUG1 is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUG1 with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, DRUG2, ritonavir, saquinavir, telithromycin or voriconazole. ",negative,paricalcitol,nelfinavir
"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled DRUG1 AUC0-   . Since DRUG1 is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUG1 with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, DRUG2, saquinavir, telithromycin or voriconazole. ",negative,paricalcitol,ritonavir
"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled DRUG1 AUC0-   . Since DRUG1 is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUG1 with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, DRUG2, telithromycin or voriconazole. ",negative,paricalcitol,saquinavir
"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled DRUG1 AUC0-   . Since DRUG1 is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUG1 with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, DRUG2 or voriconazole. ",negative,paricalcitol,telithromycin
"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled DRUG1 AUC0-   . Since DRUG1 is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUG1 with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or DRUG2. ",negative,paricalcitol,voriconazole
"A multiple dose drug-drug interaction study demonstrated that DRUG1 approximately doubled DRUG2 AUC0-   . Since DRUG2 is partially metabolized by CYP3A and DRUG1 le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUG2 with DRUG1 and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",negative,ketoconazole,paricalcitol
"A multiple dose drug-drug interaction study demonstrated that DRUG1 approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and DRUG1 le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with DRUG1 and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",negative,ketoconazole,ketoconazole
"A multiple dose drug-drug interaction study demonstrated that DRUG1 approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and DRUG1 le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with DRUG1 and other strong P450 3A inhibitors including DRUG2, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",negative,ketoconazole,atazanavir
"A multiple dose drug-drug interaction study demonstrated that DRUG1 approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and DRUG1 le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with DRUG1 and other strong P450 3A inhibitors including atazanavir, DRUG2, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",negative,ketoconazole,clarithromycin
"A multiple dose drug-drug interaction study demonstrated that DRUG1 approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and DRUG1 le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with DRUG1 and other strong P450 3A inhibitors including atazanavir, clarithromycin, DRUG2, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",negative,ketoconazole,indinavir
"A multiple dose drug-drug interaction study demonstrated that DRUG1 approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and DRUG1 le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with DRUG1 and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, DRUG2, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",negative,ketoconazole,itraconazole
"A multiple dose drug-drug interaction study demonstrated that DRUG1 approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and DRUG1 le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with DRUG1 and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, DRUG2, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",negative,ketoconazole,nefazodone
"A multiple dose drug-drug interaction study demonstrated that DRUG1 approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and DRUG1 le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with DRUG1 and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, DRUG2, ritonavir, saquinavir, telithromycin or voriconazole. ",negative,ketoconazole,nelfinavir
"A multiple dose drug-drug interaction study demonstrated that DRUG1 approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and DRUG1 le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with DRUG1 and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, DRUG2, saquinavir, telithromycin or voriconazole. ",negative,ketoconazole,ritonavir
"A multiple dose drug-drug interaction study demonstrated that DRUG1 approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and DRUG1 le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with DRUG1 and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, DRUG2, telithromycin or voriconazole. ",negative,ketoconazole,saquinavir
"A multiple dose drug-drug interaction study demonstrated that DRUG1 approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and DRUG1 le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with DRUG1 and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, DRUG2 or voriconazole. ",negative,ketoconazole,telithromycin
"A multiple dose drug-drug interaction study demonstrated that DRUG1 approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and DRUG1 le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with DRUG1 and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or DRUG2. ",negative,ketoconazole,voriconazole
"A multiple dose drug-drug interaction study demonstrated that DRUG2 approximately doubled DRUG1 AUC0-   . Since DRUG1 is partially metabolized by CYP3A and DRUG2 le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUG1 with DRUG2 and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",advise,paricalcitol,ketoconazole
"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled DRUG1 AUC0-   . Since DRUG1 is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUG1 with ketoconazole and other strong P450 3A inhibitors including DRUG2, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",advise,paricalcitol,atazanavir
"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled DRUG1 AUC0-   . Since DRUG1 is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUG1 with ketoconazole and other strong P450 3A inhibitors including atazanavir, DRUG2, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",advise,paricalcitol,clarithromycin
"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled DRUG1 AUC0-   . Since DRUG1 is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUG1 with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, DRUG2, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",advise,paricalcitol,indinavir
"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled DRUG1 AUC0-   . Since DRUG1 is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUG1 with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, DRUG2, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",advise,paricalcitol,itraconazole
"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled DRUG1 AUC0-   . Since DRUG1 is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUG1 with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, DRUG2, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",advise,paricalcitol,nefazodone
"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled DRUG1 AUC0-   . Since DRUG1 is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUG1 with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, DRUG2, ritonavir, saquinavir, telithromycin or voriconazole. ",advise,paricalcitol,nelfinavir
"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled DRUG1 AUC0-   . Since DRUG1 is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUG1 with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, DRUG2, saquinavir, telithromycin or voriconazole. ",advise,paricalcitol,ritonavir
"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled DRUG1 AUC0-   . Since DRUG1 is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUG1 with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, DRUG2, telithromycin or voriconazole. ",advise,paricalcitol,saquinavir
"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled DRUG1 AUC0-   . Since DRUG1 is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUG1 with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, DRUG2 or voriconazole. ",advise,paricalcitol,telithromycin
"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled DRUG1 AUC0-   . Since DRUG1 is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUG1 with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or DRUG2. ",advise,paricalcitol,voriconazole
"A multiple dose drug-drug interaction study demonstrated that DRUG1 approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and DRUG1 le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with DRUG1 and other strong P450 3A inhibitors including DRUG2, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",negative,ketoconazole,atazanavir
"A multiple dose drug-drug interaction study demonstrated that DRUG1 approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and DRUG1 le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with DRUG1 and other strong P450 3A inhibitors including atazanavir, DRUG2, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",negative,ketoconazole,clarithromycin
"A multiple dose drug-drug interaction study demonstrated that DRUG1 approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and DRUG1 le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with DRUG1 and other strong P450 3A inhibitors including atazanavir, clarithromycin, DRUG2, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",negative,ketoconazole,indinavir
"A multiple dose drug-drug interaction study demonstrated that DRUG1 approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and DRUG1 le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with DRUG1 and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, DRUG2, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",negative,ketoconazole,itraconazole
"A multiple dose drug-drug interaction study demonstrated that DRUG1 approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and DRUG1 le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with DRUG1 and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, DRUG2, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",negative,ketoconazole,nefazodone
"A multiple dose drug-drug interaction study demonstrated that DRUG1 approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and DRUG1 le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with DRUG1 and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, DRUG2, ritonavir, saquinavir, telithromycin or voriconazole. ",negative,ketoconazole,nelfinavir
"A multiple dose drug-drug interaction study demonstrated that DRUG1 approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and DRUG1 le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with DRUG1 and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, DRUG2, saquinavir, telithromycin or voriconazole. ",negative,ketoconazole,ritonavir
"A multiple dose drug-drug interaction study demonstrated that DRUG1 approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and DRUG1 le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with DRUG1 and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, DRUG2, telithromycin or voriconazole. ",negative,ketoconazole,saquinavir
"A multiple dose drug-drug interaction study demonstrated that DRUG1 approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and DRUG1 le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with DRUG1 and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, DRUG2 or voriconazole. ",negative,ketoconazole,telithromycin
"A multiple dose drug-drug interaction study demonstrated that DRUG1 approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and DRUG1 le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with DRUG1 and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or DRUG2. ",negative,ketoconazole,voriconazole
"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including DRUG1, DRUG2, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",negative,atazanavir,clarithromycin
"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including DRUG1, clarithromycin, DRUG2, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",negative,atazanavir,indinavir
"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including DRUG1, clarithromycin, indinavir, DRUG2, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",negative,atazanavir,itraconazole
"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including DRUG1, clarithromycin, indinavir, itraconazole, DRUG2, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",negative,atazanavir,nefazodone
"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including DRUG1, clarithromycin, indinavir, itraconazole, nefazodone, DRUG2, ritonavir, saquinavir, telithromycin or voriconazole. ",negative,atazanavir,nelfinavir
"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including DRUG1, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, DRUG2, saquinavir, telithromycin or voriconazole. ",negative,atazanavir,ritonavir
"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including DRUG1, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, DRUG2, telithromycin or voriconazole. ",negative,atazanavir,saquinavir
"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including DRUG1, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, DRUG2 or voriconazole. ",negative,atazanavir,telithromycin
"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including DRUG1, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or DRUG2. ",negative,atazanavir,voriconazole
"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, DRUG1, DRUG2, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",negative,clarithromycin,indinavir
"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, DRUG1, indinavir, DRUG2, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",negative,clarithromycin,itraconazole
"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, DRUG1, indinavir, itraconazole, DRUG2, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",negative,clarithromycin,nefazodone
"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, DRUG1, indinavir, itraconazole, nefazodone, DRUG2, ritonavir, saquinavir, telithromycin or voriconazole. ",negative,clarithromycin,nelfinavir
"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, DRUG1, indinavir, itraconazole, nefazodone, nelfinavir, DRUG2, saquinavir, telithromycin or voriconazole. ",negative,clarithromycin,ritonavir
"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, DRUG1, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, DRUG2, telithromycin or voriconazole. ",negative,clarithromycin,saquinavir
"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, DRUG1, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, DRUG2 or voriconazole. ",negative,clarithromycin,telithromycin
"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, DRUG1, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or DRUG2. ",negative,clarithromycin,voriconazole
"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, DRUG1, DRUG2, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",negative,indinavir,itraconazole
"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, DRUG1, itraconazole, DRUG2, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",negative,indinavir,nefazodone
"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, DRUG1, itraconazole, nefazodone, DRUG2, ritonavir, saquinavir, telithromycin or voriconazole. ",negative,indinavir,nelfinavir
"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, DRUG1, itraconazole, nefazodone, nelfinavir, DRUG2, saquinavir, telithromycin or voriconazole. ",negative,indinavir,ritonavir
"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, DRUG1, itraconazole, nefazodone, nelfinavir, ritonavir, DRUG2, telithromycin or voriconazole. ",negative,indinavir,saquinavir
"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, DRUG1, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, DRUG2 or voriconazole. ",negative,indinavir,telithromycin
"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, DRUG1, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or DRUG2. ",negative,indinavir,voriconazole
"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, DRUG1, DRUG2, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",negative,itraconazole,nefazodone
"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, DRUG1, nefazodone, DRUG2, ritonavir, saquinavir, telithromycin or voriconazole. ",negative,itraconazole,nelfinavir
"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, DRUG1, nefazodone, nelfinavir, DRUG2, saquinavir, telithromycin or voriconazole. ",negative,itraconazole,ritonavir
"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, DRUG1, nefazodone, nelfinavir, ritonavir, DRUG2, telithromycin or voriconazole. ",negative,itraconazole,saquinavir
"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, DRUG1, nefazodone, nelfinavir, ritonavir, saquinavir, DRUG2 or voriconazole. ",negative,itraconazole,telithromycin
"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, DRUG1, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or DRUG2. ",negative,itraconazole,voriconazole
"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, DRUG1, DRUG2, ritonavir, saquinavir, telithromycin or voriconazole. ",negative,nefazodone,nelfinavir
"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, DRUG1, nelfinavir, DRUG2, saquinavir, telithromycin or voriconazole. ",negative,nefazodone,ritonavir
"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, DRUG1, nelfinavir, ritonavir, DRUG2, telithromycin or voriconazole. ",negative,nefazodone,saquinavir
"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, DRUG1, nelfinavir, ritonavir, saquinavir, DRUG2 or voriconazole. ",negative,nefazodone,telithromycin
"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, DRUG1, nelfinavir, ritonavir, saquinavir, telithromycin or DRUG2. ",negative,nefazodone,voriconazole
"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, DRUG1, DRUG2, saquinavir, telithromycin or voriconazole. ",negative,nelfinavir,ritonavir
"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, DRUG1, ritonavir, DRUG2, telithromycin or voriconazole. ",negative,nelfinavir,saquinavir
"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, DRUG1, ritonavir, saquinavir, DRUG2 or voriconazole. ",negative,nelfinavir,telithromycin
"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, DRUG1, ritonavir, saquinavir, telithromycin or DRUG2. ",negative,nelfinavir,voriconazole
"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, DRUG1, DRUG2, telithromycin or voriconazole. ",negative,ritonavir,saquinavir
"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, DRUG1, saquinavir, DRUG2 or voriconazole. ",negative,ritonavir,telithromycin
"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, DRUG1, saquinavir, telithromycin or DRUG2. ",negative,ritonavir,voriconazole
"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, DRUG1, DRUG2 or voriconazole. ",negative,saquinavir,telithromycin
"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, DRUG1, telithromycin or DRUG2. ",negative,saquinavir,voriconazole
"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, DRUG1 or DRUG2. ",negative,telithromycin,voriconazole
"Dose adjustment of DRUG1 Capsules may be required, and iPTH and serum calcium concentrations should be closely monitored if a patient initiates or discontinues therapy with a strong CYP3A4 inhibitor such as DRUG2. ",advise,Zemplar,ketoconazole
"Drugs that impair intestinal absorption of DRUG1, such as DRUG2, may interfere with the absorption of Zemplar Capsules.",mechanism,fat-soluble vitamins,cholestyramine
"Drugs that impair intestinal absorption of DRUG1, such as cholestyramine, may interfere with the absorption of DRUG2 Capsules.",negative,fat-soluble vitamins,Zemplar
"Drugs that impair intestinal absorption of fat-soluble vitamins, such as DRUG1, may interfere with the absorption of DRUG2 Capsules.",mechanism,cholestyramine,Zemplar
"Caution is advised for patients receiving high-dose DRUG1 and DRUG2 concomitantly, as anorexia, tachypnea, lethargy, coma and death have been reported with concomitant use of high-dose DRUG1 and carbonic anhydrase inhibitors.",advise,aspirin,methazolamide
"Caution is advised for patients receiving high-dose DRUG1 and methazolamide concomitantly, as anorexia, tachypnea, lethargy, coma and death have been reported with concomitant use of high-dose DRUG1 and carbonic anhydrase inhibitors.",negative,aspirin,aspirin
"Caution is advised for patients receiving high-dose DRUG1 and methazolamide concomitantly, as anorexia, tachypnea, lethargy, coma and death have been reported with concomitant use of high-dose DRUG1 and DRUG2.",negative,aspirin,carbonic anhydrase inhibitors
"Caution is advised for patients receiving high-dose DRUG2 and DRUG1 concomitantly, as anorexia, tachypnea, lethargy, coma and death have been reported with concomitant use of high-dose DRUG2 and carbonic anhydrase inhibitors.",negative,methazolamide,aspirin
"Caution is advised for patients receiving high-dose aspirin and DRUG1 concomitantly, as anorexia, tachypnea, lethargy, coma and death have been reported with concomitant use of high-dose aspirin and DRUG2.",negative,methazolamide,carbonic anhydrase inhibitors
"Caution is advised for patients receiving high-dose DRUG1 and methazolamide concomitantly, as anorexia, tachypnea, lethargy, coma and death have been reported with concomitant use of high-dose DRUG1 and DRUG2.",effect,aspirin,carbonic anhydrase inhibitors
Drug-Drug Interactions: The pharmacokinetic and pharmacodynamic interactions between DRUG1 capsules and other DRUG2 have not been determined. ,negative,FLOMAX,alpha-adrenergic blocking agents
"However, interactions may be expected and DRUG1 capsules should NOT be used in combination with other DRUG2. ",advise,FLOMAX,alpha-adrenergic blocking agents
The pharmacokinetic interaction between DRUG1 and DRUG2 capsules was investigated. ,negative,cimetidine,FLOMAX
"Therefore, DRUG1 capsules should be used with caution in combination with DRUG2, particularly at doses higher than 0.4 mg. ",advise,FLOMAX,cimetidine
Results from limited in vitro and in vivo drug-drug interaction studies between DRUG1 and DRUG2 are inconclusive. ,negative,tamsulosin HCI,warfarin
"Therefore, caution should be exercised with concomitant administration of DRUG1 and DRUG2 capsules.        ",advise,warfarin,FLOMAX
"If DRUG1 replacement is required, the DRUG1 dose should be carefully adjusted. ",negative,glucocorticoid,glucocorticoid
Limited published data indicate that DRUG1 treatment increases cytochrome P450 (CP450) mediated DRUG2 clearance in man. ,mechanism,GH,antipyrine
"These data suggest that DRUG1 administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g., DRUG2, sex steroids, anticonvulsants, cyclosporin). ",mechanism,GH,corticosteroids
"These data suggest that DRUG1 administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g., corticosteroids, DRUG2, anticonvulsants, cyclosporin). ",mechanism,GH,sex steroids
"These data suggest that DRUG1 administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g., corticosteroids, sex steroids, DRUG2, cyclosporin). ",mechanism,GH,anticonvulsants
"These data suggest that DRUG1 administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, DRUG2). ",mechanism,GH,cyclosporin
"These data suggest that GH administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g., DRUG1, DRUG2, anticonvulsants, cyclosporin). ",negative,corticosteroids,sex steroids
"These data suggest that GH administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g., DRUG1, sex steroids, DRUG2, cyclosporin). ",negative,corticosteroids,anticonvulsants
"These data suggest that GH administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g., DRUG1, sex steroids, anticonvulsants, DRUG2). ",negative,corticosteroids,cyclosporin
"These data suggest that GH administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g., corticosteroids, DRUG1, DRUG2, cyclosporin). ",negative,sex steroids,anticonvulsants
"These data suggest that GH administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g., corticosteroids, DRUG1, anticonvulsants, DRUG2). ",negative,sex steroids,cyclosporin
"These data suggest that GH administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g., corticosteroids, sex steroids, DRUG1, DRUG2). ",negative,anticonvulsants,cyclosporin
The CNS depressant effects of DRUG1 may be additive with that of other DRUG2..,effect,oxycodone hydrochloride,CNS depressants
"Use with Other DRUG1: The depressant effects of DRUG2 are potentiated by the presence of other CNS depressants such as alcohol, sedatives, antihistaminics, or psychotropic drugs. ",negative,Central Nervous System Depressants,morphine
"Use with Other DRUG1: The depressant effects of morphine are potentiated by the presence of other DRUG2 such as alcohol, sedatives, antihistaminics, or psychotropic drugs. ",negative,Central Nervous System Depressants,CNS depressants
"Use with Other DRUG1: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as DRUG2, sedatives, antihistaminics, or psychotropic drugs. ",negative,Central Nervous System Depressants,alcohol
"Use with Other DRUG1: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol, DRUG2, antihistaminics, or psychotropic drugs. ",negative,Central Nervous System Depressants,sedatives
"Use with Other DRUG1: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol, sedatives, DRUG2, or psychotropic drugs. ",negative,Central Nervous System Depressants,antihistaminics
"Use with Other DRUG1: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol, sedatives, antihistaminics, or DRUG2. ",negative,Central Nervous System Depressants,psychotropic drugs
"Use with Other Central Nervous System Depressants: The depressant effects of DRUG1 are potentiated by the presence of other DRUG2 such as alcohol, sedatives, antihistaminics, or psychotropic drugs. ",effect,morphine,CNS depressants
"Use with Other Central Nervous System Depressants: The depressant effects of DRUG1 are potentiated by the presence of other CNS depressants such as DRUG2, sedatives, antihistaminics, or psychotropic drugs. ",effect,morphine,alcohol
"Use with Other Central Nervous System Depressants: The depressant effects of DRUG1 are potentiated by the presence of other CNS depressants such as alcohol, DRUG2, antihistaminics, or psychotropic drugs. ",effect,morphine,sedatives
"Use with Other Central Nervous System Depressants: The depressant effects of DRUG1 are potentiated by the presence of other CNS depressants such as alcohol, sedatives, DRUG2, or psychotropic drugs. ",effect,morphine,antihistaminics
"Use with Other Central Nervous System Depressants: The depressant effects of DRUG1 are potentiated by the presence of other CNS depressants such as alcohol, sedatives, antihistaminics, or DRUG2. ",effect,morphine,psychotropic drugs
"Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other DRUG1 such as DRUG2, sedatives, antihistaminics, or psychotropic drugs. ",negative,CNS depressants,alcohol
"Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other DRUG1 such as alcohol, DRUG2, antihistaminics, or psychotropic drugs. ",negative,CNS depressants,sedatives
"Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other DRUG1 such as alcohol, sedatives, DRUG2, or psychotropic drugs. ",negative,CNS depressants,antihistaminics
"Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other DRUG1 such as alcohol, sedatives, antihistaminics, or DRUG2. ",negative,CNS depressants,psychotropic drugs
"Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as DRUG1, DRUG2, antihistaminics, or psychotropic drugs. ",negative,alcohol,sedatives
"Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as DRUG1, sedatives, DRUG2, or psychotropic drugs. ",negative,alcohol,antihistaminics
"Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as DRUG1, sedatives, antihistaminics, or DRUG2. ",negative,alcohol,psychotropic drugs
"Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol, DRUG1, DRUG2, or psychotropic drugs. ",negative,sedatives,antihistaminics
"Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol, DRUG1, antihistaminics, or DRUG2. ",negative,sedatives,psychotropic drugs
"Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol, sedatives, DRUG1, or DRUG2. ",negative,antihistaminics,psychotropic drugs
"Use of DRUG1 in conjunction with oral DRUG2 may increase the risk of respiratory depression, hypotension and profound sedation or coma. ",effect,neuroleptics,morphine
"Interaction with DRUG1: DRUG2 (i.e., pentazocine, nalbuphine, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic. ",negative,Mixed Agonist/Antagonist Opioid Analgesics,Agonist/antagonist analgesics
"Interaction with DRUG1: Agonist/antagonist analgesics (i.e., DRUG2, nalbuphine, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic. ",negative,Mixed Agonist/Antagonist Opioid Analgesics,pentazocine
"Interaction with DRUG1: Agonist/antagonist analgesics (i.e., pentazocine, DRUG2, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic. ",negative,Mixed Agonist/Antagonist Opioid Analgesics,nalbuphine
"Interaction with DRUG1: Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, DRUG2, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic. ",negative,Mixed Agonist/Antagonist Opioid Analgesics,butorphanol
"Interaction with DRUG1: Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol, or DRUG2) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic. ",negative,Mixed Agonist/Antagonist Opioid Analgesics,buprenorphine
"Interaction with DRUG1: Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof DRUG2. ",negative,Mixed Agonist/Antagonist Opioid Analgesics,opioid agonist analgesic
"Interaction with Mixed Agonist/Antagonist Opioid Analgesics: DRUG1 (i.e., DRUG2, nalbuphine, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic. ",negative,Agonist/antagonist analgesics,pentazocine
"Interaction with Mixed Agonist/Antagonist Opioid Analgesics: DRUG1 (i.e., pentazocine, DRUG2, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic. ",negative,Agonist/antagonist analgesics,nalbuphine
"Interaction with Mixed Agonist/Antagonist Opioid Analgesics: DRUG1 (i.e., pentazocine, nalbuphine, DRUG2, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic. ",negative,Agonist/antagonist analgesics,butorphanol
"Interaction with Mixed Agonist/Antagonist Opioid Analgesics: DRUG1 (i.e., pentazocine, nalbuphine, butorphanol, or DRUG2) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic. ",negative,Agonist/antagonist analgesics,buprenorphine
"Interaction with Mixed Agonist/Antagonist Opioid Analgesics: DRUG1 (i.e., pentazocine, nalbuphine, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof DRUG2. ",advise,Agonist/antagonist analgesics,opioid agonist analgesic
"Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., DRUG1, DRUG2, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic. ",negative,pentazocine,nalbuphine
"Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., DRUG1, nalbuphine, DRUG2, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic. ",negative,pentazocine,butorphanol
"Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., DRUG1, nalbuphine, butorphanol, or DRUG2) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic. ",negative,pentazocine,buprenorphine
"Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., DRUG1, nalbuphine, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof DRUG2. ",advise,pentazocine,opioid agonist analgesic
"Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., pentazocine, DRUG1, DRUG2, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic. ",negative,nalbuphine,butorphanol
"Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., pentazocine, DRUG1, butorphanol, or DRUG2) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic. ",negative,nalbuphine,buprenorphine
"Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., pentazocine, DRUG1, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof DRUG2. ",advise,nalbuphine,opioid agonist analgesic
"Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, DRUG1, or DRUG2) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic. ",negative,butorphanol,buprenorphine
"Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, DRUG1, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof DRUG2. ",advise,butorphanol,opioid agonist analgesic
"Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol, or DRUG1) should NOT be administered to patients who have received or are receiving a course of therapy with a proof DRUG2. ",advise,buprenorphine,opioid agonist analgesic
"Because there is a theoretical basis that these effects may be additive, use of DRUG1-containing or DRUG2 (like dihydroergotamine or methysergide) and sumatriptan within 24 hours of each other should be avoided. ",negative,ergotamine,ergot-type medications
"Because there is a theoretical basis that these effects may be additive, use of DRUG1-containing or ergot-type medications (like DRUG2 or methysergide) and sumatriptan within 24 hours of each other should be avoided. ",negative,ergotamine,dihydroergotamine
"Because there is a theoretical basis that these effects may be additive, use of DRUG1-containing or ergot-type medications (like dihydroergotamine or DRUG2) and sumatriptan within 24 hours of each other should be avoided. ",negative,ergotamine,methysergide
"Because there is a theoretical basis that these effects may be additive, use of DRUG1-containing or ergot-type medications (like dihydroergotamine or methysergide) and DRUG2 within 24 hours of each other should be avoided. ",advise,ergotamine,sumatriptan
"Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or DRUG1 (like DRUG2 or methysergide) and sumatriptan within 24 hours of each other should be avoided. ",negative,ergot-type medications,dihydroergotamine
"Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or DRUG1 (like dihydroergotamine or DRUG2) and sumatriptan within 24 hours of each other should be avoided. ",negative,ergot-type medications,methysergide
"Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or DRUG1 (like dihydroergotamine or methysergide) and DRUG2 within 24 hours of each other should be avoided. ",advise,ergot-type medications,sumatriptan
"Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like DRUG1 or DRUG2) and sumatriptan within 24 hours of each other should be avoided. ",negative,dihydroergotamine,methysergide
"Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like DRUG1 or methysergide) and DRUG2 within 24 hours of each other should be avoided. ",advise,dihydroergotamine,sumatriptan
"Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or DRUG1) and DRUG2 within 24 hours of each other should be avoided. ",advise,methysergide,sumatriptan
"DRUG1 reduce DRUG2 clearance, significantly increasing systemic exposure. ",mechanism,MAO-A inhibitors,sumatriptan
"Therefore, the use of DRUG1 tablets in patients receiving DRUG2 is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. ",advise,sumatriptan succinate,MAO-A inhibitors
"Therefore, the use of DRUG1 tablets in patients receiving MAO-A inhibitors is contraindicated . DRUG2 (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. ",negative,sumatriptan succinate,Selective serotonin reuptake inhibitors
"Therefore, the use of DRUG1 tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (DRUG2) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. ",negative,sumatriptan succinate,SSRIs
"Therefore, the use of DRUG1 tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., DRUG2, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. ",negative,sumatriptan succinate,fluoxetine
"Therefore, the use of DRUG1 tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, DRUG2, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. ",negative,sumatriptan succinate,fluvoxamine
"Therefore, the use of DRUG1 tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, DRUG2, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. ",negative,sumatriptan succinate,paroxetine
"Therefore, the use of DRUG1 tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, DRUG2) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. ",negative,sumatriptan succinate,sertraline
"Therefore, the use of DRUG1 tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with DRUG2. ",negative,sumatriptan succinate,sumatriptan
"Therefore, the use of sumatriptan succinate tablets in patients receiving DRUG1 is contraindicated . DRUG2 (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. ",negative,MAO-A inhibitors,Selective serotonin reuptake inhibitors
"Therefore, the use of sumatriptan succinate tablets in patients receiving DRUG1 is contraindicated . Selective serotonin reuptake inhibitors (DRUG2) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. ",negative,MAO-A inhibitors,SSRIs
"Therefore, the use of sumatriptan succinate tablets in patients receiving DRUG1 is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., DRUG2, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. ",negative,MAO-A inhibitors,fluoxetine
"Therefore, the use of sumatriptan succinate tablets in patients receiving DRUG1 is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, DRUG2, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. ",negative,MAO-A inhibitors,fluvoxamine
"Therefore, the use of sumatriptan succinate tablets in patients receiving DRUG1 is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, DRUG2, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. ",negative,MAO-A inhibitors,paroxetine
"Therefore, the use of sumatriptan succinate tablets in patients receiving DRUG1 is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, DRUG2) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. ",negative,MAO-A inhibitors,sertraline
"Therefore, the use of DRUG2 succinate tablets in patients receiving DRUG1 is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with DRUG2. ",negative,MAO-A inhibitors,sumatriptan
"Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . DRUG1 (DRUG2) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. ",negative,Selective serotonin reuptake inhibitors,SSRIs
"Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . DRUG1 (SSRIs) (e.g., DRUG2, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. ",negative,Selective serotonin reuptake inhibitors,fluoxetine
"Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . DRUG1 (SSRIs) (e.g., fluoxetine, DRUG2, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. ",negative,Selective serotonin reuptake inhibitors,fluvoxamine
"Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . DRUG1 (SSRIs) (e.g., fluoxetine, fluvoxamine, DRUG2, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. ",negative,Selective serotonin reuptake inhibitors,paroxetine
"Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . DRUG1 (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, DRUG2) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. ",negative,Selective serotonin reuptake inhibitors,sertraline
"Therefore, the use of DRUG2 succinate tablets in patients receiving MAO-A inhibitors is contraindicated . DRUG1 (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with DRUG2. ",effect,Selective serotonin reuptake inhibitors,sumatriptan
"Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (DRUG1) (e.g., DRUG2, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. ",negative,SSRIs,fluoxetine
"Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (DRUG1) (e.g., fluoxetine, DRUG2, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. ",negative,SSRIs,fluvoxamine
"Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (DRUG1) (e.g., fluoxetine, fluvoxamine, DRUG2, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. ",negative,SSRIs,paroxetine
"Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (DRUG1) (e.g., fluoxetine, fluvoxamine, paroxetine, DRUG2) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. ",negative,SSRIs,sertraline
"Therefore, the use of DRUG2 succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (DRUG1) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with DRUG2. ",effect,SSRIs,sumatriptan
"Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., DRUG1, DRUG2, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. ",negative,fluoxetine,fluvoxamine
"Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., DRUG1, fluvoxamine, DRUG2, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. ",negative,fluoxetine,paroxetine
"Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., DRUG1, fluvoxamine, paroxetine, DRUG2) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. ",negative,fluoxetine,sertraline
"Therefore, the use of DRUG2 succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., DRUG1, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with DRUG2. ",effect,fluoxetine,sumatriptan
"Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, DRUG1, DRUG2, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. ",negative,fluvoxamine,paroxetine
"Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, DRUG1, paroxetine, DRUG2) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. ",negative,fluvoxamine,sertraline
"Therefore, the use of DRUG2 succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, DRUG1, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with DRUG2. ",effect,fluvoxamine,sumatriptan
"Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, DRUG1, DRUG2) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. ",negative,paroxetine,sertraline
"Therefore, the use of DRUG2 succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, DRUG1, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with DRUG2. ",effect,paroxetine,sumatriptan
"Therefore, the use of DRUG2 succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, DRUG1) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with DRUG2. ",effect,sertraline,sumatriptan
"If concomitant treatment with DRUG1 and an DRUG2 is clinically warranted, appropriate observation of the patient is advised.",advise,sumatriptan,SSRI
"DRUG1: Absorption of a single dose of DRUG2 was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing DRUG1 (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when DRUG2 was administered alone under fasting conditions. ",negative,Antacids,Myfortic
"DRUG1: Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking DRUG2-aluminum containing DRUG1 (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions. ",negative,Antacids,magnesium
"DRUG1: Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-DRUG2 containing DRUG1 (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions. ",negative,Antacids,aluminum
"DRUG1: Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing DRUG1 (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions. ",negative,Antacids,antacids
"DRUG1: Absorption of a single dose of DRUG2 was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing DRUG1 (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when DRUG2 was administered alone under fasting conditions. ",negative,Antacids,Myfortic
"Antacids: Absorption of a single dose of DRUG1 was decreased when administered to 12 stable renal transplant patients also taking DRUG2-aluminum containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when DRUG1 was administered alone under fasting conditions. ",mechanism,Myfortic,magnesium
"Antacids: Absorption of a single dose of DRUG1 was decreased when administered to 12 stable renal transplant patients also taking magnesium-DRUG2 containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when DRUG1 was administered alone under fasting conditions. ",mechanism,Myfortic,aluminum
"DRUG2: Absorption of a single dose of DRUG1 was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing DRUG2 (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when DRUG1 was administered alone under fasting conditions. ",negative,Myfortic,antacids
"Antacids: Absorption of a single dose of DRUG1 was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when DRUG1 was administered alone under fasting conditions. ",negative,Myfortic,Myfortic
"Antacids: Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking DRUG1-DRUG2 containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions. ",negative,magnesium,aluminum
"DRUG2: Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking DRUG1-aluminum containing DRUG2 (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions. ",negative,magnesium,antacids
"Antacids: Absorption of a single dose of DRUG2 was decreased when administered to 12 stable renal transplant patients also taking DRUG1-aluminum containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when DRUG2 was administered alone under fasting conditions. ",negative,magnesium,Myfortic
"DRUG2: Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-DRUG1 containing DRUG2 (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions. ",negative,aluminum,antacids
"Antacids: Absorption of a single dose of DRUG2 was decreased when administered to 12 stable renal transplant patients also taking magnesium-DRUG1 containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when DRUG2 was administered alone under fasting conditions. ",negative,aluminum,Myfortic
"DRUG1: Absorption of a single dose of DRUG2 was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing DRUG1 (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when DRUG2 was administered alone under fasting conditions. ",negative,antacids,Myfortic
It is recommended that DRUG1 and DRUG2 not be administered simultaneously. ,advise,Myfortic,antacids
"DRUG1: When studied in stable renal transplant patients, DRUG1, USP (MODIFIED) pharmacokinetics were unaffected by steady state dosing of Myfortic. ",negative,Cyclosporine,cyclosporine
"DRUG1: When studied in stable renal transplant patients, DRUG1, USP (MODIFIED) pharmacokinetics were unaffected by steady state dosing of DRUG2. ",negative,Cyclosporine,Myfortic
"DRUG1: When studied in stable renal transplant patients, DRUG1, USP (MODIFIED) pharmacokinetics were unaffected by steady state dosing of DRUG2. ",negative,cyclosporine,Myfortic
DRUG1/DRUG2: may be taken with Myfortic; ,negative,Acyclovir,Ganciclovir
DRUG1/Ganciclovir: may be taken with DRUG2; ,negative,Acyclovir,Myfortic
Acyclovir/DRUG1: may be taken with DRUG2; ,negative,Ganciclovir,Myfortic
"Both DRUG1/DRUG2 and MPAG concentrations are increased in the presence of renal impairment, their coexistence may compete for tubular secretion and further increase in the concentrations of the two. ",negative,acyclovir,ganciclovir
"Both DRUG1/ganciclovir and DRUG2 concentrations are increased in the presence of renal impairment, their coexistence may compete for tubular secretion and further increase in the concentrations of the two. ",negative,acyclovir,MPAG
"Both acyclovir/DRUG1 and DRUG2 concentrations are increased in the presence of renal impairment, their coexistence may compete for tubular secretion and further increase in the concentrations of the two. ",negative,ganciclovir,MPAG
"DRUG1/DRUG2: Given that DRUG1 and DRUG2 inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with DRUG1 or DRUG2. ",negative,Azathioprine,Mycophenolate Mofetil
"DRUG1/Mycophenolate Mofetil: Given that DRUG1 and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with DRUG1 or mycophenolate mofetil. ",negative,Azathioprine,azathioprine
"DRUG1/DRUG2: Given that DRUG1 and DRUG2 inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with DRUG1 or DRUG2. ",negative,Azathioprine,mycophenolate mofetil
"DRUG1/Mycophenolate Mofetil: Given that DRUG1 and mycophenolate mofetil inhibit purine metabolism, it is recommended that DRUG2 not be administered concomitantly with DRUG1 or mycophenolate mofetil. ",negative,Azathioprine,Myfortic
"DRUG1/Mycophenolate Mofetil: Given that DRUG1 and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with DRUG1 or mycophenolate mofetil. ",negative,Azathioprine,azathioprine
"DRUG1/DRUG2: Given that DRUG1 and DRUG2 inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with DRUG1 or DRUG2. ",negative,Azathioprine,mycophenolate mofetil
"DRUG2/DRUG1: Given that DRUG2 and DRUG1 inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with DRUG2 or DRUG1. ",negative,Mycophenolate Mofetil,azathioprine
"Azathioprine/DRUG1: Given that azathioprine and DRUG1 inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or DRUG1. ",negative,Mycophenolate Mofetil,mycophenolate mofetil
"Azathioprine/DRUG1: Given that azathioprine and DRUG1 inhibit purine metabolism, it is recommended that DRUG2 not be administered concomitantly with azathioprine or DRUG1. ",negative,Mycophenolate Mofetil,Myfortic
"DRUG2/DRUG1: Given that DRUG2 and DRUG1 inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with DRUG2 or DRUG1. ",negative,Mycophenolate Mofetil,azathioprine
"Azathioprine/DRUG1: Given that azathioprine and DRUG1 inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or DRUG1. ",negative,Mycophenolate Mofetil,mycophenolate mofetil
"DRUG1/DRUG2: Given that DRUG1 and DRUG2 inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with DRUG1 or DRUG2. ",negative,azathioprine,mycophenolate mofetil
"DRUG1/Mycophenolate Mofetil: Given that DRUG1 and mycophenolate mofetil inhibit purine metabolism, it is recommended that DRUG2 not be administered concomitantly with DRUG1 or mycophenolate mofetil. ",negative,azathioprine,Myfortic
"DRUG1/Mycophenolate Mofetil: Given that DRUG1 and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with DRUG1 or mycophenolate mofetil. ",negative,azathioprine,azathioprine
"DRUG1/DRUG2: Given that DRUG1 and DRUG2 inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with DRUG1 or DRUG2. ",negative,azathioprine,mycophenolate mofetil
"Azathioprine/DRUG1: Given that azathioprine and DRUG1 inhibit purine metabolism, it is recommended that DRUG2 not be administered concomitantly with azathioprine or DRUG1. ",negative,mycophenolate mofetil,Myfortic
"DRUG2/DRUG1: Given that DRUG2 and DRUG1 inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with DRUG2 or DRUG1. ",negative,mycophenolate mofetil,azathioprine
"Azathioprine/DRUG1: Given that azathioprine and DRUG1 inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or DRUG1. ",negative,mycophenolate mofetil,mycophenolate mofetil
"DRUG2/Mycophenolate Mofetil: Given that DRUG2 and mycophenolate mofetil inhibit purine metabolism, it is recommended that DRUG1 not be administered concomitantly with DRUG2 or mycophenolate mofetil. ",advise,Myfortic,azathioprine
"Azathioprine/DRUG2: Given that azathioprine and DRUG2 inhibit purine metabolism, it is recommended that DRUG1 not be administered concomitantly with azathioprine or DRUG2. ",advise,Myfortic,mycophenolate mofetil
"DRUG1/DRUG2: Given that DRUG1 and DRUG2 inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with DRUG1 or DRUG2. ",negative,azathioprine,mycophenolate mofetil
DRUG1 and Drugs that Bind Bile Acids: These drugs interrupt enterohepatic recirculation and reduce DRUG2 exposure when coadministered with mycophenolate mofetil. ,negative,Cholestyramine,MPA
DRUG1 and Drugs that Bind Bile Acids: These drugs interrupt enterohepatic recirculation and reduce MPA exposure when coadministered with DRUG2. ,negative,Cholestyramine,mycophenolate mofetil
Cholestyramine and Drugs that Bind Bile Acids: These drugs interrupt enterohepatic recirculation and reduce DRUG1 exposure when coadministered with DRUG2. ,negative,MPA,mycophenolate mofetil
"Therefore, do not administer DRUG1 with DRUG2 or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids, for example bile acid sequestrates or oral activated charcoal, because of the potential to reduce the efficacy of DRUG1. ",advise,Myfortic,cholestyramine
"Therefore, do not administer DRUG1 with cholestyramine or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids, for example bile acid sequestrates or oral DRUG2, because of the potential to reduce the efficacy of DRUG1. ",advise,Myfortic,activated charcoal
"Therefore, do not administer DRUG1 with cholestyramine or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids, for example bile acid sequestrates or oral activated charcoal, because of the potential to reduce the efficacy of DRUG1. ",negative,Myfortic,Myfortic
"Therefore, do not administer Myfortic with DRUG1 or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids, for example bile acid sequestrates or oral DRUG2, because of the potential to reduce the efficacy of Myfortic. ",negative,cholestyramine,activated charcoal
"Therefore, do not administer DRUG2 with DRUG1 or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids, for example bile acid sequestrates or oral activated charcoal, because of the potential to reduce the efficacy of DRUG2. ",negative,cholestyramine,Myfortic
"Therefore, do not administer DRUG2 with cholestyramine or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids, for example bile acid sequestrates or oral DRUG1, because of the potential to reduce the efficacy of DRUG2. ",negative,activated charcoal,Myfortic
"Oral DRUG1: Given the different metabolism of DRUG2 and oral DRUG1, no drug interaction between these two classes of drug is expected. ",negative,Contraceptives,Myfortic
"Oral DRUG1: Given the different metabolism of Myfortic and oral DRUG1, no drug interaction between these two classes of drug is expected. ",negative,Contraceptives,contraceptives
"Oral DRUG2: Given the different metabolism of DRUG1 and oral DRUG2, no drug interaction between these two classes of drug is expected. ",negative,Myfortic,contraceptives
"However, in a drug-drug interaction study, mean DRUG1 AUC was decreased by 15% when coadministered with DRUG2. ",mechanism,levonorgesterol,mycophenolate mofetil
"Therefore, it is recommended that oral DRUG1 are co- administered with DRUG2 with caution and additional birth control methods be considered. ",advise,contraceptives,Myfortic
"DRUG1: During treatment with DRUG2, the use of live attenuated vaccines should be avoided and patients should be advised that vaccinations may be less effective. ",negative,Live Vaccines,Myfortic
"DRUG1: During treatment with Myfortic, the use of DRUG2 should be avoided and patients should be advised that vaccinations may be less effective. ",negative,Live Vaccines,live attenuated vaccines
"Live Vaccines: During treatment with DRUG1, the use of DRUG2 should be avoided and patients should be advised that vaccinations may be less effective. ",advise,Myfortic,live attenuated vaccines
Interference of DRUG1 hydrolysis may lead to less DRUG2 available for absorption.,negative,MPAG,MPA
"Although this has not occurred in in vitro studies with DRUG1, interactions with DRUG1 have been reported with FELDENE since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering FELDENE to patients on DRUG1 and other highly protein-bound drugs. ",negative,coumarin-type anticoagulants,coumarin-type anticoagulants
"Although this has not occurred in in vitro studies with DRUG1, interactions with DRUG1 have been reported with DRUG2 since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering DRUG2 to patients on DRUG1 and other highly protein-bound drugs. ",negative,coumarin-type anticoagulants,FELDENE
"Although this has not occurred in in vitro studies with DRUG1, interactions with DRUG1 have been reported with DRUG2 since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering DRUG2 to patients on DRUG1 and other highly protein-bound drugs. ",negative,coumarin-type anticoagulants,FELDENE
"Although this has not occurred in in vitro studies with DRUG1, interactions with DRUG1 have been reported with FELDENE since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering FELDENE to patients on DRUG1 and other highly protein-bound drugs. ",negative,coumarin-type anticoagulants,coumarin-type anticoagulants
"Although this has not occurred in in vitro studies with DRUG1, interactions with DRUG1 have been reported with DRUG2 since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering DRUG2 to patients on DRUG1 and other highly protein-bound drugs. ",int,coumarin-type anticoagulants,FELDENE
"Although this has not occurred in in vitro studies with DRUG1, interactions with DRUG1 have been reported with DRUG2 since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering DRUG2 to patients on DRUG1 and other highly protein-bound drugs. ",negative,coumarin-type anticoagulants,FELDENE
"Although this has not occurred in in vitro studies with DRUG1, interactions with DRUG1 have been reported with FELDENE since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering FELDENE to patients on DRUG1 and other highly protein-bound drugs. ",negative,coumarin-type anticoagulants,coumarin-type anticoagulants
"Although this has not occurred in in vitro studies with coumarin-type anticoagulants, interactions with coumarin-type anticoagulants have been reported with DRUG1 since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering DRUG1 to patients on coumarin-type anticoagulants and other highly protein-bound drugs. ",negative,FELDENE,FELDENE
"Although this has not occurred in in vitro studies with DRUG2, interactions with DRUG2 have been reported with DRUG1 since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering DRUG1 to patients on DRUG2 and other highly protein-bound drugs. ",negative,FELDENE,coumarin-type anticoagulants
"Although this has not occurred in in vitro studies with DRUG2, interactions with DRUG2 have been reported with DRUG1 since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering DRUG1 to patients on DRUG2 and other highly protein-bound drugs. ",advise,FELDENE,coumarin-type anticoagulants
"Plasma levels of DRUG1 are depressed to approximately 80% of their normal values when DRUG2 is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on DRUG1 plasma levels . Nonsteroidal anti-inflammatory agents, including DRUG2, have been reported to increase steady state plasma lithium levels. ",negative,piroxicam,FELDENE
"Plasma levels of DRUG1 are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with DRUG2 (3900 mg/day), but concomitant administration of antacids has no effect on DRUG1 plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. ",negative,piroxicam,aspirin
"Plasma levels of DRUG1 are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of DRUG2 has no effect on DRUG1 plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. ",negative,piroxicam,antacids
"Plasma levels of DRUG1 are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on DRUG1 plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. ",negative,piroxicam,piroxicam
"Plasma levels of DRUG1 are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on DRUG1 plasma levels . DRUG2, including FELDENE, have been reported to increase steady state plasma lithium levels. ",negative,piroxicam,Nonsteroidal anti-inflammatory agents
"Plasma levels of DRUG1 are depressed to approximately 80% of their normal values when DRUG2 is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on DRUG1 plasma levels . Nonsteroidal anti-inflammatory agents, including DRUG2, have been reported to increase steady state plasma lithium levels. ",negative,piroxicam,FELDENE
"Plasma levels of DRUG1 are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on DRUG1 plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma DRUG2 levels. ",negative,piroxicam,lithium
"Plasma levels of piroxicam are depressed to approximately 80% of their normal values when DRUG1 is administered in conjunction with DRUG2 (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including DRUG1, have been reported to increase steady state plasma lithium levels. ",mechanism,FELDENE,aspirin
"Plasma levels of piroxicam are depressed to approximately 80% of their normal values when DRUG1 is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of DRUG2 has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including DRUG1, have been reported to increase steady state plasma lithium levels. ",negative,FELDENE,antacids
"Plasma levels of DRUG2 are depressed to approximately 80% of their normal values when DRUG1 is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on DRUG2 plasma levels . Nonsteroidal anti-inflammatory agents, including DRUG1, have been reported to increase steady state plasma lithium levels. ",negative,FELDENE,piroxicam
"Plasma levels of piroxicam are depressed to approximately 80% of their normal values when DRUG1 is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . DRUG2, including DRUG1, have been reported to increase steady state plasma lithium levels. ",negative,FELDENE,Nonsteroidal anti-inflammatory agents
"Plasma levels of piroxicam are depressed to approximately 80% of their normal values when DRUG1 is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including DRUG1, have been reported to increase steady state plasma lithium levels. ",negative,FELDENE,FELDENE
"Plasma levels of piroxicam are depressed to approximately 80% of their normal values when DRUG1 is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including DRUG1, have been reported to increase steady state plasma DRUG2 levels. ",negative,FELDENE,lithium
"Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with DRUG1 (3900 mg/day), but concomitant administration of DRUG2 has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. ",negative,aspirin,antacids
"Plasma levels of DRUG2 are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with DRUG1 (3900 mg/day), but concomitant administration of antacids has no effect on DRUG2 plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. ",negative,aspirin,piroxicam
"Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with DRUG1 (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . DRUG2, including FELDENE, have been reported to increase steady state plasma lithium levels. ",negative,aspirin,Nonsteroidal anti-inflammatory agents
"Plasma levels of piroxicam are depressed to approximately 80% of their normal values when DRUG2 is administered in conjunction with DRUG1 (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including DRUG2, have been reported to increase steady state plasma lithium levels. ",negative,aspirin,FELDENE
"Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with DRUG1 (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma DRUG2 levels. ",negative,aspirin,lithium
"Plasma levels of DRUG2 are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of DRUG1 has no effect on DRUG2 plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. ",negative,antacids,piroxicam
"Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of DRUG1 has no effect on piroxicam plasma levels . DRUG2, including FELDENE, have been reported to increase steady state plasma lithium levels. ",negative,antacids,Nonsteroidal anti-inflammatory agents
"Plasma levels of piroxicam are depressed to approximately 80% of their normal values when DRUG2 is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of DRUG1 has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including DRUG2, have been reported to increase steady state plasma lithium levels. ",negative,antacids,FELDENE
"Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of DRUG1 has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma DRUG2 levels. ",negative,antacids,lithium
"Plasma levels of DRUG1 are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on DRUG1 plasma levels . DRUG2, including FELDENE, have been reported to increase steady state plasma lithium levels. ",negative,piroxicam,Nonsteroidal anti-inflammatory agents
"Plasma levels of DRUG1 are depressed to approximately 80% of their normal values when DRUG2 is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on DRUG1 plasma levels . Nonsteroidal anti-inflammatory agents, including DRUG2, have been reported to increase steady state plasma lithium levels. ",negative,piroxicam,FELDENE
"Plasma levels of DRUG1 are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on DRUG1 plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma DRUG2 levels. ",negative,piroxicam,lithium
"Plasma levels of piroxicam are depressed to approximately 80% of their normal values when DRUG2 is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . DRUG1, including DRUG2, have been reported to increase steady state plasma lithium levels. ",negative,Nonsteroidal anti-inflammatory agents,FELDENE
"Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . DRUG1, including FELDENE, have been reported to increase steady state plasma DRUG2 levels. ",mechanism,Nonsteroidal anti-inflammatory agents,lithium
"Plasma levels of piroxicam are depressed to approximately 80% of their normal values when DRUG1 is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including DRUG1, have been reported to increase steady state plasma DRUG2 levels. ",mechanism,FELDENE,lithium
"It is recommended that plasma DRUG1 levels be monitored when initiating, adjusting and discontinuing DRUG2.",advise,lithium,FELDENE
"DRUG1, particularly DRUG2, may cause serious cardiac arrhythmias during halothane anesthesia and therefore should be used only with great caution or not at all. ",negative,Vasopressors,metaraminol
"DRUG1, particularly metaraminol, may cause serious cardiac arrhythmias during DRUG2 anesthesia and therefore should be used only with great caution or not at all. ",effect,Vasopressors,halothane
"Vasopressors, particularly DRUG1, may cause serious cardiac arrhythmias during DRUG2 anesthesia and therefore should be used only with great caution or not at all. ",effect,metaraminol,halothane
DRUG1 - The pressor effect of DRUG2 is markedly potentiated in patients receiving monoamine oxidase inhibitors (MAOI). ,negative,MAO Inhibitors,sympathomimetic pressor amines
DRUG1 - The pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving DRUG2 (MAOI). ,negative,MAO Inhibitors,monoamine oxidase inhibitors
DRUG1 - The pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving monoamine oxidase inhibitors (DRUG2). ,negative,MAO Inhibitors,MAOI
MAO Inhibitors - The pressor effect of DRUG1 is markedly potentiated in patients receiving DRUG2 (MAOI). ,effect,sympathomimetic pressor amines,monoamine oxidase inhibitors
MAO Inhibitors - The pressor effect of DRUG1 is markedly potentiated in patients receiving monoamine oxidase inhibitors (DRUG2). ,effect,sympathomimetic pressor amines,MAOI
MAO Inhibitors - The pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving DRUG1 (DRUG2). ,negative,monoamine oxidase inhibitors,MAOI
The pressor response of DRUG1 may also be potentiated by DRUG2.,effect,adrenergic agents,tricyclic antidepressants
Acromegalic patients with diabetes mellitus being treated with DRUG1 and/or oral DRUG2 agents may require dose reductions of these therapeutic agents after the initiation of therapy with SOMAVERT. ,negative,insulin,hypoglycemic
Acromegalic patients with diabetes mellitus being treated with DRUG1 and/or oral hypoglycemic agents may require dose reductions of these therapeutic agents after the initiation of therapy with DRUG2. ,advise,insulin,SOMAVERT
Acromegalic patients with diabetes mellitus being treated with insulin and/or oral DRUG1 agents may require dose reductions of these therapeutic agents after the initiation of therapy with DRUG2. ,advise,hypoglycemic,SOMAVERT
"In clinical studies, patients on DRUG1 often needed higher serum DRUG2 concentrations to achieve appropriate IGF-I suppression compared with patients not receiving DRUG1. ",mechanism,opioids,pegvisomant
"In clinical studies, patients on DRUG1 often needed higher serum pegvisomant concentrations to achieve appropriate IGF-I suppression compared with patients not receiving DRUG1. ",negative,opioids,opioids
"In clinical studies, patients on DRUG2 often needed higher serum DRUG1 concentrations to achieve appropriate IGF-I suppression compared with patients not receiving DRUG2. ",negative,pegvisomant,opioids
"DRUG1: There was a slight increase in the area under the curve (AUC, 11%) and mean peak drug concentration (Cmax, 18%) of DRUG1 with the co-administration of 100 mg sitagliptin for 10 days. ",negative,Digoxin,digoxin
"DRUG1: There was a slight increase in the area under the curve (AUC, 11%) and mean peak drug concentration (Cmax, 18%) of DRUG1 with the co-administration of 100 mg DRUG2 for 10 days. ",negative,Digoxin,sitagliptin
"DRUG1: There was a slight increase in the area under the curve (AUC, 11%) and mean peak drug concentration (Cmax, 18%) of DRUG1 with the co-administration of 100 mg DRUG2 for 10 days. ",mechanism,digoxin,sitagliptin
No dosage adjustment of DRUG1 or DRUG2 is recommended.,negative,digoxin,JANUVIA
Limited evidence suggests that DRUG1 may influence the intensity and duration of action of DRUG2.,mechanism,ascorbic acid,bishydroxycoumarin
"DRUG1 can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - DRUG2: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine",int,Vindesine,Phenytoin
"DRUG1 can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - DRUG2: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine",int,Vindesine,Live virus vaccines
"DRUG1 can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the DRUG2 virus, may increase the side effects of the vaccination, and decrease patient's response to the DRUG2 - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the DRUG2",negative,Vindesine,vaccine
"DRUG1 can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - DRUG2: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine",int,Vindesine,Mitomycin-C
"DRUG1 can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - DRUG2: may decrease patient's response to the vaccine",int,Vindesine,Killed virus vaccines
"DRUG1 can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the DRUG2 virus, may increase the side effects of the vaccination, and decrease patient's response to the DRUG2 - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the DRUG2",negative,Vindesine,vaccine
"Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - DRUG1: can increase seizure activity - DRUG2: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine",negative,Phenytoin,Live virus vaccines
"Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - DRUG1: can increase seizure activity - Live virus vaccines: may potentiate the replication of the DRUG2 virus, may increase the side effects of the vaccination, and decrease patient's response to the DRUG2 - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the DRUG2",negative,Phenytoin,vaccine
"Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - DRUG1: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - DRUG2: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine",negative,Phenytoin,Mitomycin-C
"Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - DRUG1: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - DRUG2: may decrease patient's response to the vaccine",negative,Phenytoin,Killed virus vaccines
"Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - DRUG1: can increase seizure activity - Live virus vaccines: may potentiate the replication of the DRUG2 virus, may increase the side effects of the vaccination, and decrease patient's response to the DRUG2 - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the DRUG2",negative,Phenytoin,vaccine
"Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - DRUG1: may potentiate the replication of the DRUG2 virus, may increase the side effects of the vaccination, and decrease patient's response to the DRUG2 - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the DRUG2",negative,Live virus vaccines,vaccine
"Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - DRUG1: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - DRUG2: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine",negative,Live virus vaccines,Mitomycin-C
"Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - DRUG1: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - DRUG2: may decrease patient's response to the vaccine",negative,Live virus vaccines,Killed virus vaccines
"Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - DRUG1: may potentiate the replication of the DRUG2 virus, may increase the side effects of the vaccination, and decrease patient's response to the DRUG2 - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the DRUG2",negative,Live virus vaccines,vaccine
"Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the DRUG1 virus, may increase the side effects of the vaccination, and decrease patient's response to the DRUG1 - DRUG2: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the DRUG1",negative,vaccine,Mitomycin-C
"Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the DRUG1 virus, may increase the side effects of the vaccination, and decrease patient's response to the DRUG1 - Mitomycin-C: may cause shortness of breath and bronchospasm - DRUG2: may decrease patient's response to the DRUG1",negative,vaccine,Killed virus vaccines
"Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the DRUG1 virus, may increase the side effects of the vaccination, and decrease patient's response to the DRUG1 - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the DRUG1",negative,vaccine,vaccine
"Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - DRUG1: may cause shortness of breath and bronchospasm - DRUG2: may decrease patient's response to the vaccine",negative,Mitomycin-C,Killed virus vaccines
"Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the DRUG2 virus, may increase the side effects of the vaccination, and decrease patient's response to the DRUG2 - DRUG1: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the DRUG2",negative,Mitomycin-C,vaccine
"Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the DRUG2 virus, may increase the side effects of the vaccination, and decrease patient's response to the DRUG2 - Mitomycin-C: may cause shortness of breath and bronchospasm - DRUG1: may decrease patient's response to the DRUG2",negative,Killed virus vaccines,vaccine
DRUG1: Excessive reductions in blood pressure may occur in patients on diuretic therapy when DRUG2 are started. ,negative,Diuretics,ACE inhibitors
"The possibility of hypotensive effects with DRUG1    can be minimized by discontinuing diuretic therapy for several days or cautiously increasing salt intake before initiation of treatment with DRUG1   . If this is not possible, the starting dose of moexpril should be reduced.. ",negative,UNIVASC,UNIVASC
"The possibility of hypotensive effects with DRUG1    can be minimized by discontinuing diuretic therapy for several days or cautiously increasing salt intake before initiation of treatment with DRUG1   . If this is not possible, the starting dose of DRUG2 should be reduced.. ",negative,UNIVASC,moexpril
"The possibility of hypotensive effects with DRUG1    can be minimized by discontinuing diuretic therapy for several days or cautiously increasing salt intake before initiation of treatment with DRUG1   . If this is not possible, the starting dose of DRUG2 should be reduced.. ",negative,UNIVASC,moexpril
DRUG1 Supplements and DRUG1-Sparing Diuretics: UNIVASC    can increase serum DRUG1 because it decreases aldosterone secretion. ,negative,Potassium,Potassium-Sparing Diuretics
DRUG1 Supplements and DRUG1-Sparing Diuretics: DRUG2    can increase serum DRUG1 because it decreases aldosterone secretion. ,negative,Potassium,UNIVASC
Potassium Supplements and DRUG1: DRUG2    can increase serum potassium because it decreases aldosterone secretion. ,negative,Potassium-Sparing Diuretics,UNIVASC
"Use of DRUG1 (DRUG2, triamterene, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. ",negative,potassium-sparing diuretics,spironolactone
"Use of DRUG1 (spironolactone, DRUG2, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. ",negative,potassium-sparing diuretics,triamterene
"Use of DRUG1 (spironolactone, triamterene, DRUG2) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. ",negative,potassium-sparing diuretics,amiloride
"Use of DRUG1 (spironolactone, triamterene, amiloride) or DRUG2 supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. ",negative,potassium-sparing diuretics,potassium
"Use of DRUG1 (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with DRUG2 can increase the risk of hyperkalemia. ",effect,potassium-sparing diuretics,ACE inhibitors
"Use of potassium-sparing diuretics (DRUG1, DRUG2, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. ",negative,spironolactone,triamterene
"Use of potassium-sparing diuretics (DRUG1, triamterene, DRUG2) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. ",negative,spironolactone,amiloride
"Use of DRUG2-sparing diuretics (DRUG1, triamterene, amiloride) or DRUG2 supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. ",negative,spironolactone,potassium
"Use of potassium-sparing diuretics (DRUG1, triamterene, amiloride) or potassium supplements concomitantly with DRUG2 can increase the risk of hyperkalemia. ",effect,spironolactone,ACE inhibitors
"Use of potassium-sparing diuretics (spironolactone, DRUG1, DRUG2) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. ",negative,triamterene,amiloride
"Use of DRUG2-sparing diuretics (spironolactone, DRUG1, amiloride) or DRUG2 supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. ",negative,triamterene,potassium
"Use of potassium-sparing diuretics (spironolactone, DRUG1, amiloride) or potassium supplements concomitantly with DRUG2 can increase the risk of hyperkalemia. ",effect,triamterene,ACE inhibitors
"Use of DRUG2-sparing diuretics (spironolactone, triamterene, DRUG1) or DRUG2 supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. ",negative,amiloride,potassium
"Use of potassium-sparing diuretics (spironolactone, triamterene, DRUG1) or potassium supplements concomitantly with DRUG2 can increase the risk of hyperkalemia. ",effect,amiloride,ACE inhibitors
"Use of DRUG1-sparing diuretics (spironolactone, triamterene, amiloride) or DRUG1 supplements concomitantly with DRUG2 can increase the risk of hyperkalemia. ",effect,potassium,ACE inhibitors
Oral DRUG1: Interaction studies with DRUG2 failed to identify any clinically important effect on the serum concentrations of the anticoagulant or on its anticoagulant effect. ,negative,Anticoagulants,warfarin
Oral DRUG1: Interaction studies with warfarin failed to identify any clinically important effect on the serum concentrations of the DRUG2 or on its DRUG2 effect. ,negative,Anticoagulants,anticoagulant
Oral Anticoagulants: Interaction studies with DRUG1 failed to identify any clinically important effect on the serum concentrations of the DRUG2 or on its DRUG2 effect. ,negative,warfarin,anticoagulant
DRUG1: Increased serum DRUG1 levels and symptoms of DRUG1 toxicity have been reported in patients receiving ACE inhibitors during therapy with DRUG1. ,negative,Lithium,lithium
DRUG1: Increased serum DRUG1 levels and symptoms of DRUG1 toxicity have been reported in patients receiving ACE inhibitors during therapy with DRUG1. ,negative,Lithium,lithium
DRUG1: Increased serum DRUG1 levels and symptoms of DRUG1 toxicity have been reported in patients receiving DRUG2 during therapy with DRUG1. ,negative,Lithium,ACE inhibitors
DRUG1: Increased serum DRUG1 levels and symptoms of DRUG1 toxicity have been reported in patients receiving ACE inhibitors during therapy with DRUG1. ,negative,Lithium,lithium
DRUG1: Increased serum DRUG1 levels and symptoms of DRUG1 toxicity have been reported in patients receiving ACE inhibitors during therapy with DRUG1. ,negative,lithium,lithium
DRUG1: Increased serum DRUG1 levels and symptoms of DRUG1 toxicity have been reported in patients receiving DRUG2 during therapy with DRUG1. ,negative,lithium,ACE inhibitors
DRUG1: Increased serum DRUG1 levels and symptoms of DRUG1 toxicity have been reported in patients receiving ACE inhibitors during therapy with DRUG1. ,negative,lithium,lithium
DRUG1: Increased serum DRUG1 levels and symptoms of DRUG1 toxicity have been reported in patients receiving DRUG2 during therapy with DRUG1. ,negative,lithium,ACE inhibitors
DRUG1: Increased serum DRUG1 levels and symptoms of DRUG1 toxicity have been reported in patients receiving ACE inhibitors during therapy with DRUG1. ,negative,lithium,lithium
DRUG2: Increased serum DRUG2 levels and symptoms of DRUG2 toxicity have been reported in patients receiving DRUG1 during therapy with DRUG2. ,effect,ACE inhibitors,lithium
"If a DRUG1 is also used, the risk of DRUG2 toxicity may be increased. ",effect,diuretic,lithium
"Other Agents: No clinically important pharmacokinetic interactions occurred when DRUG1    was administered concomitantly with DRUG2, digoxin, or cimetidine. ",negative,UNIVASC,hydrochlorothiazide
"Other Agents: No clinically important pharmacokinetic interactions occurred when DRUG1    was administered concomitantly with hydrochlorothiazide, DRUG2, or cimetidine. ",negative,UNIVASC,digoxin
"Other Agents: No clinically important pharmacokinetic interactions occurred when DRUG1    was administered concomitantly with hydrochlorothiazide, digoxin, or DRUG2. ",negative,UNIVASC,cimetidine
"Other Agents: No clinically important pharmacokinetic interactions occurred when UNIVASC    was administered concomitantly with DRUG1, DRUG2, or cimetidine. ",negative,hydrochlorothiazide,digoxin
"Other Agents: No clinically important pharmacokinetic interactions occurred when UNIVASC    was administered concomitantly with DRUG1, digoxin, or DRUG2. ",negative,hydrochlorothiazide,cimetidine
"Other Agents: No clinically important pharmacokinetic interactions occurred when UNIVASC    was administered concomitantly with hydrochlorothiazide, DRUG1, or DRUG2. ",negative,digoxin,cimetidine
"DRUG1    has been used in clinical trials concomitantly with DRUG2, diuretics, H2 blockers, digoxin, oral hypoglycemic agents, and cholesterol-lowering agents. ",negative,UNIVASC,calcium-channel-blocking agents
"DRUG1    has been used in clinical trials concomitantly with calcium-channel-blocking agents, DRUG2, H2 blockers, digoxin, oral hypoglycemic agents, and cholesterol-lowering agents. ",negative,UNIVASC,diuretics
"DRUG1    has been used in clinical trials concomitantly with calcium-channel-blocking agents, diuretics, DRUG2, digoxin, oral hypoglycemic agents, and cholesterol-lowering agents. ",negative,UNIVASC,H2 blockers
"DRUG1    has been used in clinical trials concomitantly with calcium-channel-blocking agents, diuretics, H2 blockers, DRUG2, oral hypoglycemic agents, and cholesterol-lowering agents. ",negative,UNIVASC,digoxin
"DRUG1    has been used in clinical trials concomitantly with calcium-channel-blocking agents, diuretics, H2 blockers, digoxin, oral DRUG2, and cholesterol-lowering agents. ",negative,UNIVASC,hypoglycemic agents
"UNIVASC    has been used in clinical trials concomitantly with DRUG1, DRUG2, H2 blockers, digoxin, oral hypoglycemic agents, and cholesterol-lowering agents. ",negative,calcium-channel-blocking agents,diuretics
"UNIVASC    has been used in clinical trials concomitantly with DRUG1, diuretics, DRUG2, digoxin, oral hypoglycemic agents, and cholesterol-lowering agents. ",negative,calcium-channel-blocking agents,H2 blockers
"UNIVASC    has been used in clinical trials concomitantly with DRUG1, diuretics, H2 blockers, DRUG2, oral hypoglycemic agents, and cholesterol-lowering agents. ",negative,calcium-channel-blocking agents,digoxin
"UNIVASC    has been used in clinical trials concomitantly with DRUG1, diuretics, H2 blockers, digoxin, oral DRUG2, and cholesterol-lowering agents. ",negative,calcium-channel-blocking agents,hypoglycemic agents
"UNIVASC    has been used in clinical trials concomitantly with calcium-channel-blocking agents, DRUG1, DRUG2, digoxin, oral hypoglycemic agents, and cholesterol-lowering agents. ",negative,diuretics,H2 blockers
"UNIVASC    has been used in clinical trials concomitantly with calcium-channel-blocking agents, DRUG1, H2 blockers, DRUG2, oral hypoglycemic agents, and cholesterol-lowering agents. ",negative,diuretics,digoxin
"UNIVASC    has been used in clinical trials concomitantly with calcium-channel-blocking agents, DRUG1, H2 blockers, digoxin, oral DRUG2, and cholesterol-lowering agents. ",negative,diuretics,hypoglycemic agents
"UNIVASC    has been used in clinical trials concomitantly with calcium-channel-blocking agents, diuretics, DRUG1, DRUG2, oral hypoglycemic agents, and cholesterol-lowering agents. ",negative,H2 blockers,digoxin
"UNIVASC    has been used in clinical trials concomitantly with calcium-channel-blocking agents, diuretics, DRUG1, digoxin, oral DRUG2, and cholesterol-lowering agents. ",negative,H2 blockers,hypoglycemic agents
"UNIVASC    has been used in clinical trials concomitantly with calcium-channel-blocking agents, diuretics, H2 blockers, DRUG1, oral DRUG2, and cholesterol-lowering agents. ",negative,digoxin,hypoglycemic agents
"DRUG1 may interact with the following drugs: DRUG2 and other NSAIDs (may lower DRUG1 levels), fluvoxamine (bioavailability of oral DRUG1 is increased with coadministration), beta blockers (may decrease DRUG1 levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of DRUG1 with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of DRUG1 and corticosteroids may interfere with the efficacy of the corticosteroids).",int,Melatonin,aspirin
"DRUG1 may interact with the following drugs: aspirin and other DRUG2 (may lower DRUG1 levels), fluvoxamine (bioavailability of oral DRUG1 is increased with coadministration), beta blockers (may decrease DRUG1 levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of DRUG1 with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of DRUG1 and corticosteroids may interfere with the efficacy of the corticosteroids).",int,Melatonin,NSAIDs
"DRUG1 may interact with the following drugs: aspirin and other NSAIDs (may lower DRUG1 levels), fluvoxamine (bioavailability of oral DRUG1 is increased with coadministration), beta blockers (may decrease DRUG1 levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of DRUG1 with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of DRUG1 and corticosteroids may interfere with the efficacy of the corticosteroids).",negative,Melatonin,melatonin
"DRUG1 may interact with the following drugs: aspirin and other NSAIDs (may lower DRUG1 levels), DRUG2 (bioavailability of oral DRUG1 is increased with coadministration), beta blockers (may decrease DRUG1 levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of DRUG1 with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of DRUG1 and corticosteroids may interfere with the efficacy of the corticosteroids).",int,Melatonin,fluvoxamine
"DRUG1 may interact with the following drugs: aspirin and other NSAIDs (may lower DRUG1 levels), fluvoxamine (bioavailability of oral DRUG1 is increased with coadministration), beta blockers (may decrease DRUG1 levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of DRUG1 with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of DRUG1 and corticosteroids may interfere with the efficacy of the corticosteroids).",negative,Melatonin,melatonin
"DRUG1 may interact with the following drugs: aspirin and other NSAIDs (may lower DRUG1 levels), fluvoxamine (bioavailability of oral DRUG1 is increased with coadministration), DRUG2 (may decrease DRUG1 levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of DRUG1 with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of DRUG1 and corticosteroids may interfere with the efficacy of the corticosteroids).",int,Melatonin,beta blockers
"DRUG1 may interact with the following drugs: aspirin and other NSAIDs (may lower DRUG1 levels), fluvoxamine (bioavailability of oral DRUG1 is increased with coadministration), beta blockers (may decrease DRUG1 levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of DRUG1 with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of DRUG1 and corticosteroids may interfere with the efficacy of the corticosteroids).",negative,Melatonin,melatonin
"DRUG1 may interact with the following drugs: aspirin and other NSAIDs (may lower DRUG1 levels), fluvoxamine (bioavailability of oral DRUG1 is increased with coadministration), beta blockers (may decrease DRUG1 levels), DRUG2 (reports of psychotic episodes when coadministered), progestin (coadministration of DRUG1 with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of DRUG1 and corticosteroids may interfere with the efficacy of the corticosteroids).",int,Melatonin,fluoxetine
"DRUG1 may interact with the following drugs: aspirin and other NSAIDs (may lower DRUG1 levels), fluvoxamine (bioavailability of oral DRUG1 is increased with coadministration), beta blockers (may decrease DRUG1 levels), fluoxetine (reports of psychotic episodes when coadministered), DRUG2 (coadministration of DRUG1 with DRUG2 can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of DRUG1 and corticosteroids may interfere with the efficacy of the corticosteroids).",int,Melatonin,progestin
"DRUG1 may interact with the following drugs: aspirin and other NSAIDs (may lower DRUG1 levels), fluvoxamine (bioavailability of oral DRUG1 is increased with coadministration), beta blockers (may decrease DRUG1 levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of DRUG1 with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of DRUG1 and corticosteroids may interfere with the efficacy of the corticosteroids).",negative,Melatonin,melatonin
"DRUG1 may interact with the following drugs: aspirin and other NSAIDs (may lower DRUG1 levels), fluvoxamine (bioavailability of oral DRUG1 is increased with coadministration), beta blockers (may decrease DRUG1 levels), fluoxetine (reports of psychotic episodes when coadministered), DRUG2 (coadministration of DRUG1 with DRUG2 can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of DRUG1 and corticosteroids may interfere with the efficacy of the corticosteroids).",negative,Melatonin,progestin
"DRUG1 may interact with the following drugs: aspirin and other NSAIDs (may lower DRUG1 levels), fluvoxamine (bioavailability of oral DRUG1 is increased with coadministration), beta blockers (may decrease DRUG1 levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of DRUG1 with progestin can inhibit ovarian function in women), DRUG2 and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of DRUG1 and corticosteroids may interfere with the efficacy of the corticosteroids).",int,Melatonin,benzodiazepenes
"DRUG1 may interact with the following drugs: aspirin and other NSAIDs (may lower DRUG1 levels), fluvoxamine (bioavailability of oral DRUG1 is increased with coadministration), beta blockers (may decrease DRUG1 levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of DRUG1 with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUG2 (coadministration of DRUG1 and DRUG2 may interfere with the efficacy of the DRUG2).",int,Melatonin,corticosteroids
"DRUG1 may interact with the following drugs: aspirin and other NSAIDs (may lower DRUG1 levels), fluvoxamine (bioavailability of oral DRUG1 is increased with coadministration), beta blockers (may decrease DRUG1 levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of DRUG1 with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of DRUG1 and corticosteroids may interfere with the efficacy of the corticosteroids).",negative,Melatonin,melatonin
"DRUG1 may interact with the following drugs: aspirin and other NSAIDs (may lower DRUG1 levels), fluvoxamine (bioavailability of oral DRUG1 is increased with coadministration), beta blockers (may decrease DRUG1 levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of DRUG1 with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUG2 (coadministration of DRUG1 and DRUG2 may interfere with the efficacy of the DRUG2).",negative,Melatonin,corticosteroids
"DRUG1 may interact with the following drugs: aspirin and other NSAIDs (may lower DRUG1 levels), fluvoxamine (bioavailability of oral DRUG1 is increased with coadministration), beta blockers (may decrease DRUG1 levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of DRUG1 with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUG2 (coadministration of DRUG1 and DRUG2 may interfere with the efficacy of the DRUG2).",negative,Melatonin,corticosteroids
"Melatonin may interact with the following drugs: DRUG1 and other DRUG2 (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",negative,aspirin,NSAIDs
"DRUG2 may interact with the following drugs: DRUG1 and other NSAIDs (may lower DRUG2 levels), fluvoxamine (bioavailability of oral DRUG2 is increased with coadministration), beta blockers (may decrease DRUG2 levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of DRUG2 with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of DRUG2 and corticosteroids may interfere with the efficacy of the corticosteroids).",negative,aspirin,melatonin
"Melatonin may interact with the following drugs: DRUG1 and other NSAIDs (may lower melatonin levels), DRUG2 (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",negative,aspirin,fluvoxamine
"DRUG2 may interact with the following drugs: DRUG1 and other NSAIDs (may lower DRUG2 levels), fluvoxamine (bioavailability of oral DRUG2 is increased with coadministration), beta blockers (may decrease DRUG2 levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of DRUG2 with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of DRUG2 and corticosteroids may interfere with the efficacy of the corticosteroids).",negative,aspirin,melatonin
"Melatonin may interact with the following drugs: DRUG1 and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), DRUG2 (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",negative,aspirin,beta blockers
"DRUG2 may interact with the following drugs: DRUG1 and other NSAIDs (may lower DRUG2 levels), fluvoxamine (bioavailability of oral DRUG2 is increased with coadministration), beta blockers (may decrease DRUG2 levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of DRUG2 with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of DRUG2 and corticosteroids may interfere with the efficacy of the corticosteroids).",negative,aspirin,melatonin
"Melatonin may interact with the following drugs: DRUG1 and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), DRUG2 (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",negative,aspirin,fluoxetine
"Melatonin may interact with the following drugs: DRUG1 and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), DRUG2 (coadministration of melatonin with DRUG2 can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",negative,aspirin,progestin
"DRUG2 may interact with the following drugs: DRUG1 and other NSAIDs (may lower DRUG2 levels), fluvoxamine (bioavailability of oral DRUG2 is increased with coadministration), beta blockers (may decrease DRUG2 levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of DRUG2 with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of DRUG2 and corticosteroids may interfere with the efficacy of the corticosteroids).",negative,aspirin,melatonin
"Melatonin may interact with the following drugs: DRUG1 and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), DRUG2 (coadministration of melatonin with DRUG2 can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",negative,aspirin,progestin
"Melatonin may interact with the following drugs: DRUG1 and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), DRUG2 and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",negative,aspirin,benzodiazepenes
"Melatonin may interact with the following drugs: DRUG1 and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUG2 (coadministration of melatonin and DRUG2 may interfere with the efficacy of the DRUG2).",negative,aspirin,corticosteroids
"DRUG2 may interact with the following drugs: DRUG1 and other NSAIDs (may lower DRUG2 levels), fluvoxamine (bioavailability of oral DRUG2 is increased with coadministration), beta blockers (may decrease DRUG2 levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of DRUG2 with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of DRUG2 and corticosteroids may interfere with the efficacy of the corticosteroids).",negative,aspirin,melatonin
"Melatonin may interact with the following drugs: DRUG1 and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUG2 (coadministration of melatonin and DRUG2 may interfere with the efficacy of the DRUG2).",negative,aspirin,corticosteroids
"Melatonin may interact with the following drugs: DRUG1 and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUG2 (coadministration of melatonin and DRUG2 may interfere with the efficacy of the DRUG2).",negative,aspirin,corticosteroids
"DRUG2 may interact with the following drugs: aspirin and other DRUG1 (may lower DRUG2 levels), fluvoxamine (bioavailability of oral DRUG2 is increased with coadministration), beta blockers (may decrease DRUG2 levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of DRUG2 with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of DRUG2 and corticosteroids may interfere with the efficacy of the corticosteroids).",negative,NSAIDs,melatonin
"Melatonin may interact with the following drugs: aspirin and other DRUG1 (may lower melatonin levels), DRUG2 (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",negative,NSAIDs,fluvoxamine
"DRUG2 may interact with the following drugs: aspirin and other DRUG1 (may lower DRUG2 levels), fluvoxamine (bioavailability of oral DRUG2 is increased with coadministration), beta blockers (may decrease DRUG2 levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of DRUG2 with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of DRUG2 and corticosteroids may interfere with the efficacy of the corticosteroids).",negative,NSAIDs,melatonin
"Melatonin may interact with the following drugs: aspirin and other DRUG1 (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), DRUG2 (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",negative,NSAIDs,beta blockers
"DRUG2 may interact with the following drugs: aspirin and other DRUG1 (may lower DRUG2 levels), fluvoxamine (bioavailability of oral DRUG2 is increased with coadministration), beta blockers (may decrease DRUG2 levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of DRUG2 with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of DRUG2 and corticosteroids may interfere with the efficacy of the corticosteroids).",negative,NSAIDs,melatonin
"Melatonin may interact with the following drugs: aspirin and other DRUG1 (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), DRUG2 (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",negative,NSAIDs,fluoxetine
"Melatonin may interact with the following drugs: aspirin and other DRUG1 (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), DRUG2 (coadministration of melatonin with DRUG2 can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",negative,NSAIDs,progestin
"DRUG2 may interact with the following drugs: aspirin and other DRUG1 (may lower DRUG2 levels), fluvoxamine (bioavailability of oral DRUG2 is increased with coadministration), beta blockers (may decrease DRUG2 levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of DRUG2 with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of DRUG2 and corticosteroids may interfere with the efficacy of the corticosteroids).",negative,NSAIDs,melatonin
"Melatonin may interact with the following drugs: aspirin and other DRUG1 (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), DRUG2 (coadministration of melatonin with DRUG2 can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",negative,NSAIDs,progestin
"Melatonin may interact with the following drugs: aspirin and other DRUG1 (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), DRUG2 and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",negative,NSAIDs,benzodiazepenes
"Melatonin may interact with the following drugs: aspirin and other DRUG1 (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUG2 (coadministration of melatonin and DRUG2 may interfere with the efficacy of the DRUG2).",negative,NSAIDs,corticosteroids
"DRUG2 may interact with the following drugs: aspirin and other DRUG1 (may lower DRUG2 levels), fluvoxamine (bioavailability of oral DRUG2 is increased with coadministration), beta blockers (may decrease DRUG2 levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of DRUG2 with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of DRUG2 and corticosteroids may interfere with the efficacy of the corticosteroids).",negative,NSAIDs,melatonin
"Melatonin may interact with the following drugs: aspirin and other DRUG1 (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUG2 (coadministration of melatonin and DRUG2 may interfere with the efficacy of the DRUG2).",negative,NSAIDs,corticosteroids
"Melatonin may interact with the following drugs: aspirin and other DRUG1 (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUG2 (coadministration of melatonin and DRUG2 may interfere with the efficacy of the DRUG2).",negative,NSAIDs,corticosteroids
"DRUG1 may interact with the following drugs: aspirin and other NSAIDs (may lower DRUG1 levels), DRUG2 (bioavailability of oral DRUG1 is increased with coadministration), beta blockers (may decrease DRUG1 levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of DRUG1 with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of DRUG1 and corticosteroids may interfere with the efficacy of the corticosteroids).",negative,melatonin,fluvoxamine
"DRUG1 may interact with the following drugs: aspirin and other NSAIDs (may lower DRUG1 levels), fluvoxamine (bioavailability of oral DRUG1 is increased with coadministration), beta blockers (may decrease DRUG1 levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of DRUG1 with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of DRUG1 and corticosteroids may interfere with the efficacy of the corticosteroids).",negative,melatonin,melatonin
"DRUG1 may interact with the following drugs: aspirin and other NSAIDs (may lower DRUG1 levels), fluvoxamine (bioavailability of oral DRUG1 is increased with coadministration), DRUG2 (may decrease DRUG1 levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of DRUG1 with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of DRUG1 and corticosteroids may interfere with the efficacy of the corticosteroids).",negative,melatonin,beta blockers
"DRUG1 may interact with the following drugs: aspirin and other NSAIDs (may lower DRUG1 levels), fluvoxamine (bioavailability of oral DRUG1 is increased with coadministration), beta blockers (may decrease DRUG1 levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of DRUG1 with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of DRUG1 and corticosteroids may interfere with the efficacy of the corticosteroids).",negative,melatonin,melatonin
"DRUG1 may interact with the following drugs: aspirin and other NSAIDs (may lower DRUG1 levels), fluvoxamine (bioavailability of oral DRUG1 is increased with coadministration), beta blockers (may decrease DRUG1 levels), DRUG2 (reports of psychotic episodes when coadministered), progestin (coadministration of DRUG1 with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of DRUG1 and corticosteroids may interfere with the efficacy of the corticosteroids).",negative,melatonin,fluoxetine
"DRUG1 may interact with the following drugs: aspirin and other NSAIDs (may lower DRUG1 levels), fluvoxamine (bioavailability of oral DRUG1 is increased with coadministration), beta blockers (may decrease DRUG1 levels), fluoxetine (reports of psychotic episodes when coadministered), DRUG2 (coadministration of DRUG1 with DRUG2 can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of DRUG1 and corticosteroids may interfere with the efficacy of the corticosteroids).",negative,melatonin,progestin
"DRUG1 may interact with the following drugs: aspirin and other NSAIDs (may lower DRUG1 levels), fluvoxamine (bioavailability of oral DRUG1 is increased with coadministration), beta blockers (may decrease DRUG1 levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of DRUG1 with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of DRUG1 and corticosteroids may interfere with the efficacy of the corticosteroids).",negative,melatonin,melatonin
"DRUG1 may interact with the following drugs: aspirin and other NSAIDs (may lower DRUG1 levels), fluvoxamine (bioavailability of oral DRUG1 is increased with coadministration), beta blockers (may decrease DRUG1 levels), fluoxetine (reports of psychotic episodes when coadministered), DRUG2 (coadministration of DRUG1 with DRUG2 can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of DRUG1 and corticosteroids may interfere with the efficacy of the corticosteroids).",negative,melatonin,progestin
"DRUG1 may interact with the following drugs: aspirin and other NSAIDs (may lower DRUG1 levels), fluvoxamine (bioavailability of oral DRUG1 is increased with coadministration), beta blockers (may decrease DRUG1 levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of DRUG1 with progestin can inhibit ovarian function in women), DRUG2 and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of DRUG1 and corticosteroids may interfere with the efficacy of the corticosteroids).",negative,melatonin,benzodiazepenes
"DRUG1 may interact with the following drugs: aspirin and other NSAIDs (may lower DRUG1 levels), fluvoxamine (bioavailability of oral DRUG1 is increased with coadministration), beta blockers (may decrease DRUG1 levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of DRUG1 with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUG2 (coadministration of DRUG1 and DRUG2 may interfere with the efficacy of the DRUG2).",negative,melatonin,corticosteroids
"DRUG1 may interact with the following drugs: aspirin and other NSAIDs (may lower DRUG1 levels), fluvoxamine (bioavailability of oral DRUG1 is increased with coadministration), beta blockers (may decrease DRUG1 levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of DRUG1 with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of DRUG1 and corticosteroids may interfere with the efficacy of the corticosteroids).",negative,melatonin,melatonin
"DRUG1 may interact with the following drugs: aspirin and other NSAIDs (may lower DRUG1 levels), fluvoxamine (bioavailability of oral DRUG1 is increased with coadministration), beta blockers (may decrease DRUG1 levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of DRUG1 with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUG2 (coadministration of DRUG1 and DRUG2 may interfere with the efficacy of the DRUG2).",negative,melatonin,corticosteroids
"DRUG1 may interact with the following drugs: aspirin and other NSAIDs (may lower DRUG1 levels), fluvoxamine (bioavailability of oral DRUG1 is increased with coadministration), beta blockers (may decrease DRUG1 levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of DRUG1 with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUG2 (coadministration of DRUG1 and DRUG2 may interfere with the efficacy of the DRUG2).",negative,melatonin,corticosteroids
"DRUG2 may interact with the following drugs: aspirin and other NSAIDs (may lower DRUG2 levels), DRUG1 (bioavailability of oral DRUG2 is increased with coadministration), beta blockers (may decrease DRUG2 levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of DRUG2 with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of DRUG2 and corticosteroids may interfere with the efficacy of the corticosteroids).",negative,fluvoxamine,melatonin
"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), DRUG1 (bioavailability of oral melatonin is increased with coadministration), DRUG2 (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",negative,fluvoxamine,beta blockers
"DRUG2 may interact with the following drugs: aspirin and other NSAIDs (may lower DRUG2 levels), DRUG1 (bioavailability of oral DRUG2 is increased with coadministration), beta blockers (may decrease DRUG2 levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of DRUG2 with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of DRUG2 and corticosteroids may interfere with the efficacy of the corticosteroids).",negative,fluvoxamine,melatonin
"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), DRUG1 (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), DRUG2 (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",negative,fluvoxamine,fluoxetine
"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), DRUG1 (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), DRUG2 (coadministration of melatonin with DRUG2 can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",negative,fluvoxamine,progestin
"DRUG2 may interact with the following drugs: aspirin and other NSAIDs (may lower DRUG2 levels), DRUG1 (bioavailability of oral DRUG2 is increased with coadministration), beta blockers (may decrease DRUG2 levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of DRUG2 with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of DRUG2 and corticosteroids may interfere with the efficacy of the corticosteroids).",negative,fluvoxamine,melatonin
"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), DRUG1 (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), DRUG2 (coadministration of melatonin with DRUG2 can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",negative,fluvoxamine,progestin
"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), DRUG1 (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), DRUG2 and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",negative,fluvoxamine,benzodiazepenes
"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), DRUG1 (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUG2 (coadministration of melatonin and DRUG2 may interfere with the efficacy of the DRUG2).",negative,fluvoxamine,corticosteroids
"DRUG2 may interact with the following drugs: aspirin and other NSAIDs (may lower DRUG2 levels), DRUG1 (bioavailability of oral DRUG2 is increased with coadministration), beta blockers (may decrease DRUG2 levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of DRUG2 with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of DRUG2 and corticosteroids may interfere with the efficacy of the corticosteroids).",negative,fluvoxamine,melatonin
"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), DRUG1 (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUG2 (coadministration of melatonin and DRUG2 may interfere with the efficacy of the DRUG2).",negative,fluvoxamine,corticosteroids
"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), DRUG1 (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUG2 (coadministration of melatonin and DRUG2 may interfere with the efficacy of the DRUG2).",negative,fluvoxamine,corticosteroids
"DRUG1 may interact with the following drugs: aspirin and other NSAIDs (may lower DRUG1 levels), fluvoxamine (bioavailability of oral DRUG1 is increased with coadministration), DRUG2 (may decrease DRUG1 levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of DRUG1 with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of DRUG1 and corticosteroids may interfere with the efficacy of the corticosteroids).",negative,melatonin,beta blockers
"DRUG1 may interact with the following drugs: aspirin and other NSAIDs (may lower DRUG1 levels), fluvoxamine (bioavailability of oral DRUG1 is increased with coadministration), beta blockers (may decrease DRUG1 levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of DRUG1 with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of DRUG1 and corticosteroids may interfere with the efficacy of the corticosteroids).",negative,melatonin,melatonin
"DRUG1 may interact with the following drugs: aspirin and other NSAIDs (may lower DRUG1 levels), fluvoxamine (bioavailability of oral DRUG1 is increased with coadministration), beta blockers (may decrease DRUG1 levels), DRUG2 (reports of psychotic episodes when coadministered), progestin (coadministration of DRUG1 with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of DRUG1 and corticosteroids may interfere with the efficacy of the corticosteroids).",negative,melatonin,fluoxetine
"DRUG1 may interact with the following drugs: aspirin and other NSAIDs (may lower DRUG1 levels), fluvoxamine (bioavailability of oral DRUG1 is increased with coadministration), beta blockers (may decrease DRUG1 levels), fluoxetine (reports of psychotic episodes when coadministered), DRUG2 (coadministration of DRUG1 with DRUG2 can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of DRUG1 and corticosteroids may interfere with the efficacy of the corticosteroids).",negative,melatonin,progestin
"DRUG1 may interact with the following drugs: aspirin and other NSAIDs (may lower DRUG1 levels), fluvoxamine (bioavailability of oral DRUG1 is increased with coadministration), beta blockers (may decrease DRUG1 levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of DRUG1 with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of DRUG1 and corticosteroids may interfere with the efficacy of the corticosteroids).",negative,melatonin,melatonin
"DRUG1 may interact with the following drugs: aspirin and other NSAIDs (may lower DRUG1 levels), fluvoxamine (bioavailability of oral DRUG1 is increased with coadministration), beta blockers (may decrease DRUG1 levels), fluoxetine (reports of psychotic episodes when coadministered), DRUG2 (coadministration of DRUG1 with DRUG2 can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of DRUG1 and corticosteroids may interfere with the efficacy of the corticosteroids).",negative,melatonin,progestin
"DRUG1 may interact with the following drugs: aspirin and other NSAIDs (may lower DRUG1 levels), fluvoxamine (bioavailability of oral DRUG1 is increased with coadministration), beta blockers (may decrease DRUG1 levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of DRUG1 with progestin can inhibit ovarian function in women), DRUG2 and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of DRUG1 and corticosteroids may interfere with the efficacy of the corticosteroids).",negative,melatonin,benzodiazepenes
"DRUG1 may interact with the following drugs: aspirin and other NSAIDs (may lower DRUG1 levels), fluvoxamine (bioavailability of oral DRUG1 is increased with coadministration), beta blockers (may decrease DRUG1 levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of DRUG1 with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUG2 (coadministration of DRUG1 and DRUG2 may interfere with the efficacy of the DRUG2).",negative,melatonin,corticosteroids
"DRUG1 may interact with the following drugs: aspirin and other NSAIDs (may lower DRUG1 levels), fluvoxamine (bioavailability of oral DRUG1 is increased with coadministration), beta blockers (may decrease DRUG1 levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of DRUG1 with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of DRUG1 and corticosteroids may interfere with the efficacy of the corticosteroids).",negative,melatonin,melatonin
"DRUG1 may interact with the following drugs: aspirin and other NSAIDs (may lower DRUG1 levels), fluvoxamine (bioavailability of oral DRUG1 is increased with coadministration), beta blockers (may decrease DRUG1 levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of DRUG1 with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUG2 (coadministration of DRUG1 and DRUG2 may interfere with the efficacy of the DRUG2).",negative,melatonin,corticosteroids
"DRUG1 may interact with the following drugs: aspirin and other NSAIDs (may lower DRUG1 levels), fluvoxamine (bioavailability of oral DRUG1 is increased with coadministration), beta blockers (may decrease DRUG1 levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of DRUG1 with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUG2 (coadministration of DRUG1 and DRUG2 may interfere with the efficacy of the DRUG2).",negative,melatonin,corticosteroids
"DRUG2 may interact with the following drugs: aspirin and other NSAIDs (may lower DRUG2 levels), fluvoxamine (bioavailability of oral DRUG2 is increased with coadministration), DRUG1 (may decrease DRUG2 levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of DRUG2 with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of DRUG2 and corticosteroids may interfere with the efficacy of the corticosteroids).",negative,beta blockers,melatonin
"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), DRUG1 (may decrease melatonin levels), DRUG2 (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",negative,beta blockers,fluoxetine
"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), DRUG1 (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), DRUG2 (coadministration of melatonin with DRUG2 can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",negative,beta blockers,progestin
"DRUG2 may interact with the following drugs: aspirin and other NSAIDs (may lower DRUG2 levels), fluvoxamine (bioavailability of oral DRUG2 is increased with coadministration), DRUG1 (may decrease DRUG2 levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of DRUG2 with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of DRUG2 and corticosteroids may interfere with the efficacy of the corticosteroids).",negative,beta blockers,melatonin
"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), DRUG1 (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), DRUG2 (coadministration of melatonin with DRUG2 can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",negative,beta blockers,progestin
"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), DRUG1 (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), DRUG2 and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",negative,beta blockers,benzodiazepenes
"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), DRUG1 (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUG2 (coadministration of melatonin and DRUG2 may interfere with the efficacy of the DRUG2).",negative,beta blockers,corticosteroids
"DRUG2 may interact with the following drugs: aspirin and other NSAIDs (may lower DRUG2 levels), fluvoxamine (bioavailability of oral DRUG2 is increased with coadministration), DRUG1 (may decrease DRUG2 levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of DRUG2 with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of DRUG2 and corticosteroids may interfere with the efficacy of the corticosteroids).",negative,beta blockers,melatonin
"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), DRUG1 (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUG2 (coadministration of melatonin and DRUG2 may interfere with the efficacy of the DRUG2).",negative,beta blockers,corticosteroids
"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), DRUG1 (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUG2 (coadministration of melatonin and DRUG2 may interfere with the efficacy of the DRUG2).",negative,beta blockers,corticosteroids
"DRUG1 may interact with the following drugs: aspirin and other NSAIDs (may lower DRUG1 levels), fluvoxamine (bioavailability of oral DRUG1 is increased with coadministration), beta blockers (may decrease DRUG1 levels), DRUG2 (reports of psychotic episodes when coadministered), progestin (coadministration of DRUG1 with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of DRUG1 and corticosteroids may interfere with the efficacy of the corticosteroids).",negative,melatonin,fluoxetine
"DRUG1 may interact with the following drugs: aspirin and other NSAIDs (may lower DRUG1 levels), fluvoxamine (bioavailability of oral DRUG1 is increased with coadministration), beta blockers (may decrease DRUG1 levels), fluoxetine (reports of psychotic episodes when coadministered), DRUG2 (coadministration of DRUG1 with DRUG2 can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of DRUG1 and corticosteroids may interfere with the efficacy of the corticosteroids).",negative,melatonin,progestin
"DRUG1 may interact with the following drugs: aspirin and other NSAIDs (may lower DRUG1 levels), fluvoxamine (bioavailability of oral DRUG1 is increased with coadministration), beta blockers (may decrease DRUG1 levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of DRUG1 with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of DRUG1 and corticosteroids may interfere with the efficacy of the corticosteroids).",negative,melatonin,melatonin
"DRUG1 may interact with the following drugs: aspirin and other NSAIDs (may lower DRUG1 levels), fluvoxamine (bioavailability of oral DRUG1 is increased with coadministration), beta blockers (may decrease DRUG1 levels), fluoxetine (reports of psychotic episodes when coadministered), DRUG2 (coadministration of DRUG1 with DRUG2 can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of DRUG1 and corticosteroids may interfere with the efficacy of the corticosteroids).",negative,melatonin,progestin
"DRUG1 may interact with the following drugs: aspirin and other NSAIDs (may lower DRUG1 levels), fluvoxamine (bioavailability of oral DRUG1 is increased with coadministration), beta blockers (may decrease DRUG1 levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of DRUG1 with progestin can inhibit ovarian function in women), DRUG2 and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of DRUG1 and corticosteroids may interfere with the efficacy of the corticosteroids).",negative,melatonin,benzodiazepenes
"DRUG1 may interact with the following drugs: aspirin and other NSAIDs (may lower DRUG1 levels), fluvoxamine (bioavailability of oral DRUG1 is increased with coadministration), beta blockers (may decrease DRUG1 levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of DRUG1 with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUG2 (coadministration of DRUG1 and DRUG2 may interfere with the efficacy of the DRUG2).",negative,melatonin,corticosteroids
"DRUG1 may interact with the following drugs: aspirin and other NSAIDs (may lower DRUG1 levels), fluvoxamine (bioavailability of oral DRUG1 is increased with coadministration), beta blockers (may decrease DRUG1 levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of DRUG1 with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of DRUG1 and corticosteroids may interfere with the efficacy of the corticosteroids).",negative,melatonin,melatonin
"DRUG1 may interact with the following drugs: aspirin and other NSAIDs (may lower DRUG1 levels), fluvoxamine (bioavailability of oral DRUG1 is increased with coadministration), beta blockers (may decrease DRUG1 levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of DRUG1 with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUG2 (coadministration of DRUG1 and DRUG2 may interfere with the efficacy of the DRUG2).",negative,melatonin,corticosteroids
"DRUG1 may interact with the following drugs: aspirin and other NSAIDs (may lower DRUG1 levels), fluvoxamine (bioavailability of oral DRUG1 is increased with coadministration), beta blockers (may decrease DRUG1 levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of DRUG1 with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUG2 (coadministration of DRUG1 and DRUG2 may interfere with the efficacy of the DRUG2).",negative,melatonin,corticosteroids
"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), DRUG1 (reports of psychotic episodes when coadministered), DRUG2 (coadministration of melatonin with DRUG2 can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",negative,fluoxetine,progestin
"DRUG2 may interact with the following drugs: aspirin and other NSAIDs (may lower DRUG2 levels), fluvoxamine (bioavailability of oral DRUG2 is increased with coadministration), beta blockers (may decrease DRUG2 levels), DRUG1 (reports of psychotic episodes when coadministered), progestin (coadministration of DRUG2 with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of DRUG2 and corticosteroids may interfere with the efficacy of the corticosteroids).",negative,fluoxetine,melatonin
"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), DRUG1 (reports of psychotic episodes when coadministered), DRUG2 (coadministration of melatonin with DRUG2 can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",negative,fluoxetine,progestin
"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), DRUG1 (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), DRUG2 and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",negative,fluoxetine,benzodiazepenes
"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), DRUG1 (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUG2 (coadministration of melatonin and DRUG2 may interfere with the efficacy of the DRUG2).",negative,fluoxetine,corticosteroids
"DRUG2 may interact with the following drugs: aspirin and other NSAIDs (may lower DRUG2 levels), fluvoxamine (bioavailability of oral DRUG2 is increased with coadministration), beta blockers (may decrease DRUG2 levels), DRUG1 (reports of psychotic episodes when coadministered), progestin (coadministration of DRUG2 with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of DRUG2 and corticosteroids may interfere with the efficacy of the corticosteroids).",negative,fluoxetine,melatonin
"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), DRUG1 (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUG2 (coadministration of melatonin and DRUG2 may interfere with the efficacy of the DRUG2).",negative,fluoxetine,corticosteroids
"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), DRUG1 (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUG2 (coadministration of melatonin and DRUG2 may interfere with the efficacy of the DRUG2).",negative,fluoxetine,corticosteroids
"DRUG2 may interact with the following drugs: aspirin and other NSAIDs (may lower DRUG2 levels), fluvoxamine (bioavailability of oral DRUG2 is increased with coadministration), beta blockers (may decrease DRUG2 levels), fluoxetine (reports of psychotic episodes when coadministered), DRUG1 (coadministration of DRUG2 with DRUG1 can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of DRUG2 and corticosteroids may interfere with the efficacy of the corticosteroids).",negative,progestin,melatonin
"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), DRUG1 (coadministration of melatonin with DRUG1 can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",negative,progestin,progestin
"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), DRUG1 (coadministration of melatonin with DRUG1 can inhibit ovarian function in women), DRUG2 and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",negative,progestin,benzodiazepenes
"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), DRUG1 (coadministration of melatonin with DRUG1 can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUG2 (coadministration of melatonin and DRUG2 may interfere with the efficacy of the DRUG2).",negative,progestin,corticosteroids
"DRUG2 may interact with the following drugs: aspirin and other NSAIDs (may lower DRUG2 levels), fluvoxamine (bioavailability of oral DRUG2 is increased with coadministration), beta blockers (may decrease DRUG2 levels), fluoxetine (reports of psychotic episodes when coadministered), DRUG1 (coadministration of DRUG2 with DRUG1 can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of DRUG2 and corticosteroids may interfere with the efficacy of the corticosteroids).",negative,progestin,melatonin
"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), DRUG1 (coadministration of melatonin with DRUG1 can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUG2 (coadministration of melatonin and DRUG2 may interfere with the efficacy of the DRUG2).",negative,progestin,corticosteroids
"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), DRUG1 (coadministration of melatonin with DRUG1 can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUG2 (coadministration of melatonin and DRUG2 may interfere with the efficacy of the DRUG2).",negative,progestin,corticosteroids
"DRUG1 may interact with the following drugs: aspirin and other NSAIDs (may lower DRUG1 levels), fluvoxamine (bioavailability of oral DRUG1 is increased with coadministration), beta blockers (may decrease DRUG1 levels), fluoxetine (reports of psychotic episodes when coadministered), DRUG2 (coadministration of DRUG1 with DRUG2 can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of DRUG1 and corticosteroids may interfere with the efficacy of the corticosteroids).",effect,melatonin,progestin
"DRUG1 may interact with the following drugs: aspirin and other NSAIDs (may lower DRUG1 levels), fluvoxamine (bioavailability of oral DRUG1 is increased with coadministration), beta blockers (may decrease DRUG1 levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of DRUG1 with progestin can inhibit ovarian function in women), DRUG2 and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of DRUG1 and corticosteroids may interfere with the efficacy of the corticosteroids).",negative,melatonin,benzodiazepenes
"DRUG1 may interact with the following drugs: aspirin and other NSAIDs (may lower DRUG1 levels), fluvoxamine (bioavailability of oral DRUG1 is increased with coadministration), beta blockers (may decrease DRUG1 levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of DRUG1 with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUG2 (coadministration of DRUG1 and DRUG2 may interfere with the efficacy of the DRUG2).",negative,melatonin,corticosteroids
"DRUG1 may interact with the following drugs: aspirin and other NSAIDs (may lower DRUG1 levels), fluvoxamine (bioavailability of oral DRUG1 is increased with coadministration), beta blockers (may decrease DRUG1 levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of DRUG1 with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of DRUG1 and corticosteroids may interfere with the efficacy of the corticosteroids).",negative,melatonin,melatonin
"DRUG1 may interact with the following drugs: aspirin and other NSAIDs (may lower DRUG1 levels), fluvoxamine (bioavailability of oral DRUG1 is increased with coadministration), beta blockers (may decrease DRUG1 levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of DRUG1 with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUG2 (coadministration of DRUG1 and DRUG2 may interfere with the efficacy of the DRUG2).",negative,melatonin,corticosteroids
"DRUG1 may interact with the following drugs: aspirin and other NSAIDs (may lower DRUG1 levels), fluvoxamine (bioavailability of oral DRUG1 is increased with coadministration), beta blockers (may decrease DRUG1 levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of DRUG1 with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUG2 (coadministration of DRUG1 and DRUG2 may interfere with the efficacy of the DRUG2).",negative,melatonin,corticosteroids
"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), DRUG1 (coadministration of melatonin with DRUG1 can inhibit ovarian function in women), DRUG2 and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",negative,progestin,benzodiazepenes
"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), DRUG1 (coadministration of melatonin with DRUG1 can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUG2 (coadministration of melatonin and DRUG2 may interfere with the efficacy of the DRUG2).",negative,progestin,corticosteroids
"DRUG2 may interact with the following drugs: aspirin and other NSAIDs (may lower DRUG2 levels), fluvoxamine (bioavailability of oral DRUG2 is increased with coadministration), beta blockers (may decrease DRUG2 levels), fluoxetine (reports of psychotic episodes when coadministered), DRUG1 (coadministration of DRUG2 with DRUG1 can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of DRUG2 and corticosteroids may interfere with the efficacy of the corticosteroids).",negative,progestin,melatonin
"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), DRUG1 (coadministration of melatonin with DRUG1 can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUG2 (coadministration of melatonin and DRUG2 may interfere with the efficacy of the DRUG2).",negative,progestin,corticosteroids
"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), DRUG1 (coadministration of melatonin with DRUG1 can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUG2 (coadministration of melatonin and DRUG2 may interfere with the efficacy of the DRUG2).",negative,progestin,corticosteroids
"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), DRUG1 and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUG2 (coadministration of melatonin and DRUG2 may interfere with the efficacy of the DRUG2).",negative,benzodiazepenes,corticosteroids
"DRUG2 may interact with the following drugs: aspirin and other NSAIDs (may lower DRUG2 levels), fluvoxamine (bioavailability of oral DRUG2 is increased with coadministration), beta blockers (may decrease DRUG2 levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of DRUG2 with progestin can inhibit ovarian function in women), DRUG1 and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of DRUG2 and corticosteroids may interfere with the efficacy of the corticosteroids).",negative,benzodiazepenes,melatonin
"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), DRUG1 and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUG2 (coadministration of melatonin and DRUG2 may interfere with the efficacy of the DRUG2).",negative,benzodiazepenes,corticosteroids
"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), DRUG1 and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUG2 (coadministration of melatonin and DRUG2 may interfere with the efficacy of the DRUG2).",negative,benzodiazepenes,corticosteroids
"DRUG2 may interact with the following drugs: aspirin and other NSAIDs (may lower DRUG2 levels), fluvoxamine (bioavailability of oral DRUG2 is increased with coadministration), beta blockers (may decrease DRUG2 levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of DRUG2 with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUG1 (coadministration of DRUG2 and DRUG1 may interfere with the efficacy of the DRUG1).",negative,corticosteroids,melatonin
"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUG1 (coadministration of melatonin and DRUG1 may interfere with the efficacy of the DRUG1).",negative,corticosteroids,corticosteroids
"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUG1 (coadministration of melatonin and DRUG1 may interfere with the efficacy of the DRUG1).",negative,corticosteroids,corticosteroids
"DRUG1 may interact with the following drugs: aspirin and other NSAIDs (may lower DRUG1 levels), fluvoxamine (bioavailability of oral DRUG1 is increased with coadministration), beta blockers (may decrease DRUG1 levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of DRUG1 with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUG2 (coadministration of DRUG1 and DRUG2 may interfere with the efficacy of the DRUG2).",effect,melatonin,corticosteroids
"DRUG1 may interact with the following drugs: aspirin and other NSAIDs (may lower DRUG1 levels), fluvoxamine (bioavailability of oral DRUG1 is increased with coadministration), beta blockers (may decrease DRUG1 levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of DRUG1 with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUG2 (coadministration of DRUG1 and DRUG2 may interfere with the efficacy of the DRUG2).",negative,melatonin,corticosteroids
"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUG1 (coadministration of melatonin and DRUG1 may interfere with the efficacy of the DRUG1).",negative,corticosteroids,corticosteroids
Drugs Affecting Hepatic Metabolism The metabolism and pharmacokinetics of DRUG1    (DRUG2) Orally Disintegrating Tablets may be affected by the induction or inhibition of drug-metab-olizing enzymes. ,negative,REMERON SolTab,mirtazapine
"While in vitro studies have shown that DRUG1 is not a potent inhibitor of any of these enzymes, an indication that DRUG1 is not likely to have a clinically significant inhibitory effect on the metabolism of other drugs that are substrates for these cytochrome P450 enzymes, the concomitant use of REMERON SolTab with most other drugs metabolized by these enzymes has not been formally studied. ",negative,mirtazapine,mirtazapine
"While in vitro studies have shown that DRUG1 is not a potent inhibitor of any of these enzymes, an indication that DRUG1 is not likely to have a clinically significant inhibitory effect on the metabolism of other drugs that are substrates for these cytochrome P450 enzymes, the concomitant use of DRUG2 with most other drugs metabolized by these enzymes has not been formally studied. ",negative,mirtazapine,REMERON SolTab
"While in vitro studies have shown that DRUG1 is not a potent inhibitor of any of these enzymes, an indication that DRUG1 is not likely to have a clinically significant inhibitory effect on the metabolism of other drugs that are substrates for these cytochrome P450 enzymes, the concomitant use of DRUG2 with most other drugs metabolized by these enzymes has not been formally studied. ",negative,mirtazapine,REMERON SolTab
DRUG1: Concomitant administration of DRUG1 (equivalent to 60 g) had a minimal effect on plasma levels of mirtazapine (15 mg) in 6 healthy male subjects. ,negative,Alcohol,alcohol
DRUG1: Concomitant administration of DRUG1 (equivalent to 60 g) had a minimal effect on plasma levels of DRUG2 (15 mg) in 6 healthy male subjects. ,negative,Alcohol,mirtazapine
DRUG1: Concomitant administration of DRUG1 (equivalent to 60 g) had a minimal effect on plasma levels of DRUG2 (15 mg) in 6 healthy male subjects. ,mechanism,alcohol,mirtazapine
"However, the impairment of cognitive and motor skills produced by DRUG1    were shown to be additive with those produced by DRUG2. ",effect,REMERON,alcohol
"Accordingly, patients should be advised to avoid DRUG1 while taking DRUG2. Diazepam: Concomitant administration of diazepam (15 mg) had a minimal effect on plasma levels of mirtazapine (15 mg) in 12 healthy subjects. ",advise,alcohol,REMERON SolTab
"Accordingly, patients should be advised to avoid DRUG1 while taking REMERON SolTab. DRUG2: Concomitant administration of DRUG2 (15 mg) had a minimal effect on plasma levels of mirtazapine (15 mg) in 12 healthy subjects. ",negative,alcohol,Diazepam
"Accordingly, patients should be advised to avoid DRUG1 while taking REMERON SolTab. DRUG2: Concomitant administration of DRUG2 (15 mg) had a minimal effect on plasma levels of mirtazapine (15 mg) in 12 healthy subjects. ",negative,alcohol,diazepam
"Accordingly, patients should be advised to avoid DRUG1 while taking REMERON SolTab. Diazepam: Concomitant administration of diazepam (15 mg) had a minimal effect on plasma levels of DRUG2 (15 mg) in 12 healthy subjects. ",negative,alcohol,mirtazapine
"Accordingly, patients should be advised to avoid alcohol while taking DRUG1. DRUG2: Concomitant administration of DRUG2 (15 mg) had a minimal effect on plasma levels of mirtazapine (15 mg) in 12 healthy subjects. ",negative,REMERON SolTab,Diazepam
"Accordingly, patients should be advised to avoid alcohol while taking DRUG1. DRUG2: Concomitant administration of DRUG2 (15 mg) had a minimal effect on plasma levels of mirtazapine (15 mg) in 12 healthy subjects. ",negative,REMERON SolTab,diazepam
"Accordingly, patients should be advised to avoid alcohol while taking DRUG1. Diazepam: Concomitant administration of diazepam (15 mg) had a minimal effect on plasma levels of DRUG2 (15 mg) in 12 healthy subjects. ",negative,REMERON SolTab,mirtazapine
"Accordingly, patients should be advised to avoid alcohol while taking REMERON SolTab. DRUG1: Concomitant administration of DRUG1 (15 mg) had a minimal effect on plasma levels of mirtazapine (15 mg) in 12 healthy subjects. ",negative,Diazepam,diazepam
"Accordingly, patients should be advised to avoid alcohol while taking REMERON SolTab. DRUG1: Concomitant administration of DRUG1 (15 mg) had a minimal effect on plasma levels of DRUG2 (15 mg) in 12 healthy subjects. ",negative,Diazepam,mirtazapine
"Accordingly, patients should be advised to avoid alcohol while taking REMERON SolTab. DRUG1: Concomitant administration of DRUG1 (15 mg) had a minimal effect on plasma levels of DRUG2 (15 mg) in 12 healthy subjects. ",mechanism,diazepam,mirtazapine
"However, the impairment of motor skills produced by DRUG1 has been shown to be additive with those caused by DRUG2. ",effect,REMERON,diazepam
"Accordingly, patients should be advised to avoid DRUG1 and other similar drugs while taking DRUG2.",advise,diazepam,REMERON SolTab
"Interaction with Other DRUG1: DRUG2 SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). ",negative,Central Nervous System Depressants,MEPERIDINE
"Interaction with Other DRUG1: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER DRUG2, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). ",negative,Central Nervous System Depressants,NARCOTIC ANALGESICS
"Interaction with Other DRUG1: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL DRUG2, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). ",negative,Central Nervous System Depressants,ANESTHETICS
"Interaction with Other DRUG1: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, DRUG2, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). ",negative,Central Nervous System Depressants,PHENOTHIAZINES
"Interaction with Other DRUG1: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER DRUG2, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). ",negative,Central Nervous System Depressants,TRANQUILIZERS
"Interaction with Other DRUG1: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, DRUG2 (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). ",negative,Central Nervous System Depressants,SEDATIVE-HYPNOTICS
"Interaction with Other DRUG1: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING DRUG2), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). ",negative,Central Nervous System Depressants,BARBITURATES
"Interaction with Other DRUG1: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), DRUG2 AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). ",negative,Central Nervous System Depressants,TRICYCLIC ANTIDEPRESSANTS
"Interaction with Other DRUG1: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER DRUG2 (INCLUDING ALCOHOL). ",negative,Central Nervous System Depressants,CNS DEPRESSANTS
"Interaction with Other DRUG1: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING DRUG2). ",negative,Central Nervous System Depressants,ALCOHOL
"Interaction with Other Central Nervous System Depressants: DRUG1 SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER DRUG2, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). ",advise,MEPERIDINE,NARCOTIC ANALGESICS
"Interaction with Other Central Nervous System Depressants: DRUG1 SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL DRUG2, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). ",advise,MEPERIDINE,ANESTHETICS
"Interaction with Other Central Nervous System Depressants: DRUG1 SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, DRUG2, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). ",advise,MEPERIDINE,PHENOTHIAZINES
"Interaction with Other Central Nervous System Depressants: DRUG1 SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER DRUG2, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). ",advise,MEPERIDINE,TRANQUILIZERS
"Interaction with Other Central Nervous System Depressants: DRUG1 SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, DRUG2 (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). ",advise,MEPERIDINE,SEDATIVE-HYPNOTICS
"Interaction with Other Central Nervous System Depressants: DRUG1 SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING DRUG2), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). ",advise,MEPERIDINE,BARBITURATES
"Interaction with Other Central Nervous System Depressants: DRUG1 SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), DRUG2 AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). ",advise,MEPERIDINE,TRICYCLIC ANTIDEPRESSANTS
"Interaction with Other Central Nervous System Depressants: DRUG1 SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER DRUG2 (INCLUDING ALCOHOL). ",advise,MEPERIDINE,CNS DEPRESSANTS
"Interaction with Other Central Nervous System Depressants: DRUG1 SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING DRUG2). ",advise,MEPERIDINE,ALCOHOL
"Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER DRUG1, GENERAL DRUG2, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). ",negative,NARCOTIC ANALGESICS,ANESTHETICS
"Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER DRUG1, GENERAL ANESTHETICS, DRUG2, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). ",negative,NARCOTIC ANALGESICS,PHENOTHIAZINES
"Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER DRUG1, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER DRUG2, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). ",negative,NARCOTIC ANALGESICS,TRANQUILIZERS
"Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER DRUG1, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, DRUG2 (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). ",negative,NARCOTIC ANALGESICS,SEDATIVE-HYPNOTICS
"Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER DRUG1, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING DRUG2), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). ",negative,NARCOTIC ANALGESICS,BARBITURATES
"Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER DRUG1, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), DRUG2 AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). ",negative,NARCOTIC ANALGESICS,TRICYCLIC ANTIDEPRESSANTS
"Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER DRUG1, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER DRUG2 (INCLUDING ALCOHOL). ",negative,NARCOTIC ANALGESICS,CNS DEPRESSANTS
"Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER DRUG1, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING DRUG2). ",negative,NARCOTIC ANALGESICS,ALCOHOL
"Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL DRUG1, DRUG2, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). ",negative,ANESTHETICS,PHENOTHIAZINES
"Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL DRUG1, PHENOTHIAZINES, OTHER DRUG2, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). ",negative,ANESTHETICS,TRANQUILIZERS
"Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL DRUG1, PHENOTHIAZINES, OTHER TRANQUILIZERS, DRUG2 (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). ",negative,ANESTHETICS,SEDATIVE-HYPNOTICS
"Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL DRUG1, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING DRUG2), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). ",negative,ANESTHETICS,BARBITURATES
"Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL DRUG1, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), DRUG2 AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). ",negative,ANESTHETICS,TRICYCLIC ANTIDEPRESSANTS
"Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL DRUG1, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER DRUG2 (INCLUDING ALCOHOL). ",negative,ANESTHETICS,CNS DEPRESSANTS
"Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL DRUG1, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING DRUG2). ",negative,ANESTHETICS,ALCOHOL
"Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, DRUG1, OTHER DRUG2, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). ",negative,PHENOTHIAZINES,TRANQUILIZERS
"Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, DRUG1, OTHER TRANQUILIZERS, DRUG2 (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). ",negative,PHENOTHIAZINES,SEDATIVE-HYPNOTICS
"Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, DRUG1, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING DRUG2), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). ",negative,PHENOTHIAZINES,BARBITURATES
"Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, DRUG1, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), DRUG2 AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). ",negative,PHENOTHIAZINES,TRICYCLIC ANTIDEPRESSANTS
"Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, DRUG1, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER DRUG2 (INCLUDING ALCOHOL). ",negative,PHENOTHIAZINES,CNS DEPRESSANTS
"Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, DRUG1, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING DRUG2). ",negative,PHENOTHIAZINES,ALCOHOL
"Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER DRUG1, DRUG2 (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). ",negative,TRANQUILIZERS,SEDATIVE-HYPNOTICS
"Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER DRUG1, SEDATIVE-HYPNOTICS (INCLUDING DRUG2), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). ",negative,TRANQUILIZERS,BARBITURATES
"Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER DRUG1, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), DRUG2 AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). ",negative,TRANQUILIZERS,TRICYCLIC ANTIDEPRESSANTS
"Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER DRUG1, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER DRUG2 (INCLUDING ALCOHOL). ",negative,TRANQUILIZERS,CNS DEPRESSANTS
"Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER DRUG1, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING DRUG2). ",negative,TRANQUILIZERS,ALCOHOL
"Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, DRUG1 (INCLUDING DRUG2), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). ",negative,SEDATIVE-HYPNOTICS,BARBITURATES
"Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, DRUG1 (INCLUDING BARBITURATES), DRUG2 AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). ",negative,SEDATIVE-HYPNOTICS,TRICYCLIC ANTIDEPRESSANTS
"Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, DRUG1 (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER DRUG2 (INCLUDING ALCOHOL). ",negative,SEDATIVE-HYPNOTICS,CNS DEPRESSANTS
"Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, DRUG1 (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING DRUG2). ",negative,SEDATIVE-HYPNOTICS,ALCOHOL
"Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING DRUG1), DRUG2 AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). ",negative,BARBITURATES,TRICYCLIC ANTIDEPRESSANTS
"Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING DRUG1), TRICYCLIC ANTIDEPRESSANTS AND OTHER DRUG2 (INCLUDING ALCOHOL). ",negative,BARBITURATES,CNS DEPRESSANTS
"Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING DRUG1), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING DRUG2). ",negative,BARBITURATES,ALCOHOL
"Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), DRUG1 AND OTHER DRUG2 (INCLUDING ALCOHOL). ",negative,TRICYCLIC ANTIDEPRESSANTS,CNS DEPRESSANTS
"Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), DRUG1 AND OTHER CNS DEPRESSANTS (INCLUDING DRUG2). ",negative,TRICYCLIC ANTIDEPRESSANTS,ALCOHOL
"Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER DRUG1 (INCLUDING DRUG2). ",negative,CNS DEPRESSANTS,ALCOHOL
"Concurrent administration of DRUG1 (e.g., DRUG2, tetracycline) may diminish the bactericidal effects of penicillins by slowing the rate of bacterial growth. ",negative,bacteriostatic antibiotics,erythromycin
"Concurrent administration of DRUG1 (e.g., erythromycin, DRUG2) may diminish the bactericidal effects of penicillins by slowing the rate of bacterial growth. ",negative,bacteriostatic antibiotics,tetracycline
"Concurrent administration of DRUG1 (e.g., erythromycin, tetracycline) may diminish the bactericidal effects of DRUG2 by slowing the rate of bacterial growth. ",effect,bacteriostatic antibiotics,penicillins
"Concurrent administration of bacteriostatic antibiotics (e.g., DRUG1, DRUG2) may diminish the bactericidal effects of penicillins by slowing the rate of bacterial growth. ",negative,erythromycin,tetracycline
"Concurrent administration of bacteriostatic antibiotics (e.g., DRUG1, tetracycline) may diminish the bactericidal effects of DRUG2 by slowing the rate of bacterial growth. ",effect,erythromycin,penicillins
"Concurrent administration of bacteriostatic antibiotics (e.g., erythromycin, DRUG1) may diminish the bactericidal effects of DRUG2 by slowing the rate of bacterial growth. ",effect,tetracycline,penicillins
DRUG1 blood levels may be prolonged by concurrent administration of DRUG2 which blocks the renal tubular secretion of penicillins. ,mechanism,Penicillin,probenecid
DRUG1 blood levels may be prolonged by concurrent administration of probenecid which blocks the renal tubular secretion of DRUG2. ,negative,Penicillin,penicillins
Penicillin blood levels may be prolonged by concurrent administration of DRUG1 which blocks the renal tubular secretion of DRUG2. ,negative,probenecid,penicillins
Displacement of DRUG1 from plasma protein binding sites will elevate the level of free DRUG1 in the serum.,negative,penicillin,penicillin
Drug Interactions: Women on oral DRUG1 have shown a significant increase in plasma DRUG2 levels.,mechanism,contraceptives,vitamin A
DRUG1 is not known to interact with other drugs including DRUG2 supplements; ,negative,CHEMET,iron
"Concomitant administration of DRUG1 with other chelation therapy, such as DRUG2 is not recommended. ",advise,CHEMET,CaNa 2 EDTA
"When DRUG1 is used with other DRUG2, potentiation of antihypertensive effect may occur. ",effect,methyldopa,antihypertensive drugs
Patients may require reduced doses of DRUG1 when on DRUG2. ,advise,anesthetics,methyldopa
When DRUG1 and DRUG2 are given concomitantly the patient should be carefully monitored for symptoms of DRUG2 toxicity. ,advise,methyldopa,lithium
When DRUG1 and DRUG2 are given concomitantly the patient should be carefully monitored for symptoms of DRUG2 toxicity. ,negative,methyldopa,lithium
When methyldopa and DRUG1 are given concomitantly the patient should be carefully monitored for symptoms of DRUG1 toxicity. ,negative,lithium,lithium
Several studies demonstrate a decrease in the bioavailability of DRUG1 when it is ingested with DRUG2 or ferrous gluconate. ,mechanism,methyldopa,ferrous sulfate
Several studies demonstrate a decrease in the bioavailability of DRUG1 when it is ingested with ferrous sulfate or DRUG2. ,mechanism,methyldopa,ferrous gluconate
Several studies demonstrate a decrease in the bioavailability of methyldopa when it is ingested with DRUG1 or DRUG2. ,negative,ferrous sulfate,ferrous gluconate
Coadministration of DRUG1 with DRUG2 or ferrous gluconate is not recommended. ,advise,methyldopa,ferrous sulfate
Coadministration of DRUG1 with ferrous sulfate or DRUG2 is not recommended. ,advise,methyldopa,ferrous gluconate
Coadministration of methyldopa with DRUG1 or DRUG2 is not recommended. ,negative,ferrous sulfate,ferrous gluconate
"DRUG1 does not interfere with measurement of DRUG2 (vanillylmandelic acid), a test for pheochromocytoma, by those methods which convert DRUG2 to vanillin. ",negative,Methyldopa,VMA
"DRUG1 does not interfere with measurement of VMA (DRUG2), a test for pheochromocytoma, by those methods which convert VMA to vanillin. ",negative,Methyldopa,vanillylmandelic acid
"DRUG1 does not interfere with measurement of DRUG2 (vanillylmandelic acid), a test for pheochromocytoma, by those methods which convert DRUG2 to vanillin. ",negative,Methyldopa,VMA
"DRUG1 does not interfere with measurement of VMA (vanillylmandelic acid), a test for pheochromocytoma, by those methods which convert VMA to DRUG2. ",negative,Methyldopa,vanillin
"Methyldopa does not interfere with measurement of DRUG1 (DRUG2), a test for pheochromocytoma, by those methods which convert DRUG1 to vanillin. ",negative,VMA,vanillylmandelic acid
"Methyldopa does not interfere with measurement of DRUG1 (vanillylmandelic acid), a test for pheochromocytoma, by those methods which convert DRUG1 to vanillin. ",negative,VMA,VMA
"Methyldopa does not interfere with measurement of DRUG1 (vanillylmandelic acid), a test for pheochromocytoma, by those methods which convert DRUG1 to DRUG2. ",negative,VMA,vanillin
"Methyldopa does not interfere with measurement of DRUG2 (DRUG1), a test for pheochromocytoma, by those methods which convert DRUG2 to vanillin. ",negative,vanillylmandelic acid,VMA
"Methyldopa does not interfere with measurement of VMA (DRUG1), a test for pheochromocytoma, by those methods which convert VMA to DRUG2. ",negative,vanillylmandelic acid,vanillin
"Methyldopa does not interfere with measurement of DRUG1 (vanillylmandelic acid), a test for pheochromocytoma, by those methods which convert DRUG1 to DRUG2. ",negative,VMA,vanillin
DRUG1 and DRUG2 are incompatible with sodium bicarbonate solution. ,negative,norepinephrine,dobutamine
DRUG1 and dobutamine are incompatible with DRUG2 solution. ,int,norepinephrine,sodium bicarbonate
norepinephrine and DRUG1 are incompatible with DRUG2 solution. ,int,dobutamine,sodium bicarbonate
"The addition of DRUG1 to parenteral solutions containing DRUG2 should be avoided, except where compatibility has been previously established. ",negative,sodium bicarbonate,calcium
"The bioavailability of DRUG1 is decreased 80% by DRUG2, when DRUG2 and DRUG1 are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before DRUG1. ",mechanism,SKELID,calcium
"The bioavailability of DRUG1 is decreased 80% by DRUG2, when DRUG2 and DRUG1 are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before DRUG1. ",negative,SKELID,calcium
"The bioavailability of DRUG1 is decreased 80% by calcium, when calcium and DRUG1 are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before DRUG1. ",negative,SKELID,SKELID
"The bioavailability of DRUG1 is decreased 80% by calcium, when calcium and DRUG1 are administered at the same time, and 60% by some DRUG2- or magnesium-containing antacids, when administered 1 hour before DRUG1. ",negative,SKELID,aluminum
"The bioavailability of DRUG1 is decreased 80% by calcium, when calcium and DRUG1 are administered at the same time, and 60% by some aluminum- or DRUG2-containing antacids, when administered 1 hour before DRUG1. ",negative,SKELID,magnesium
"The bioavailability of DRUG1 is decreased 80% by calcium, when calcium and DRUG1 are administered at the same time, and 60% by some aluminum- or magnesium-containing DRUG2, when administered 1 hour before DRUG1. ",negative,SKELID,antacids
"The bioavailability of DRUG1 is decreased 80% by calcium, when calcium and DRUG1 are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before DRUG1. ",negative,SKELID,SKELID
"The bioavailability of SKELID is decreased 80% by DRUG1, when DRUG1 and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID. ",negative,calcium,calcium
"The bioavailability of DRUG2 is decreased 80% by DRUG1, when DRUG1 and DRUG2 are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before DRUG2. ",negative,calcium,SKELID
"The bioavailability of SKELID is decreased 80% by DRUG1, when DRUG1 and SKELID are administered at the same time, and 60% by some DRUG2- or magnesium-containing antacids, when administered 1 hour before SKELID. ",negative,calcium,aluminum
"The bioavailability of SKELID is decreased 80% by DRUG1, when DRUG1 and SKELID are administered at the same time, and 60% by some aluminum- or DRUG2-containing antacids, when administered 1 hour before SKELID. ",negative,calcium,magnesium
"The bioavailability of SKELID is decreased 80% by DRUG1, when DRUG1 and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing DRUG2, when administered 1 hour before SKELID. ",negative,calcium,antacids
"The bioavailability of DRUG2 is decreased 80% by DRUG1, when DRUG1 and DRUG2 are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before DRUG2. ",negative,calcium,SKELID
"The bioavailability of DRUG2 is decreased 80% by DRUG1, when DRUG1 and DRUG2 are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before DRUG2. ",negative,calcium,SKELID
"The bioavailability of SKELID is decreased 80% by DRUG1, when DRUG1 and SKELID are administered at the same time, and 60% by some DRUG2- or magnesium-containing antacids, when administered 1 hour before SKELID. ",negative,calcium,aluminum
"The bioavailability of SKELID is decreased 80% by DRUG1, when DRUG1 and SKELID are administered at the same time, and 60% by some aluminum- or DRUG2-containing antacids, when administered 1 hour before SKELID. ",negative,calcium,magnesium
"The bioavailability of SKELID is decreased 80% by DRUG1, when DRUG1 and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing DRUG2, when administered 1 hour before SKELID. ",negative,calcium,antacids
"The bioavailability of DRUG2 is decreased 80% by DRUG1, when DRUG1 and DRUG2 are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before DRUG2. ",negative,calcium,SKELID
"The bioavailability of DRUG1 is decreased 80% by calcium, when calcium and DRUG1 are administered at the same time, and 60% by some DRUG2- or magnesium-containing antacids, when administered 1 hour before DRUG1. ",negative,SKELID,aluminum
"The bioavailability of DRUG1 is decreased 80% by calcium, when calcium and DRUG1 are administered at the same time, and 60% by some aluminum- or DRUG2-containing antacids, when administered 1 hour before DRUG1. ",negative,SKELID,magnesium
"The bioavailability of DRUG1 is decreased 80% by calcium, when calcium and DRUG1 are administered at the same time, and 60% by some aluminum- or magnesium-containing DRUG2, when administered 1 hour before DRUG1. ",negative,SKELID,antacids
"The bioavailability of DRUG1 is decreased 80% by calcium, when calcium and DRUG1 are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before DRUG1. ",negative,SKELID,SKELID
"The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some DRUG1- or DRUG2-containing antacids, when administered 1 hour before SKELID. ",negative,aluminum,magnesium
"The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some DRUG1- or magnesium-containing DRUG2, when administered 1 hour before SKELID. ",negative,aluminum,antacids
"The bioavailability of DRUG2 is decreased 80% by calcium, when calcium and DRUG2 are administered at the same time, and 60% by some DRUG1- or magnesium-containing antacids, when administered 1 hour before DRUG2. ",mechanism,aluminum,SKELID
"The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or DRUG1-containing DRUG2, when administered 1 hour before SKELID. ",negative,magnesium,antacids
"The bioavailability of DRUG2 is decreased 80% by calcium, when calcium and DRUG2 are administered at the same time, and 60% by some aluminum- or DRUG1-containing antacids, when administered 1 hour before DRUG2. ",mechanism,magnesium,SKELID
"The bioavailability of DRUG2 is decreased 80% by calcium, when calcium and DRUG2 are administered at the same time, and 60% by some aluminum- or magnesium-containing DRUG1, when administered 1 hour before DRUG2. ",negative,antacids,SKELID
DRUG1 may decrease bioavailability of DRUG2 by up to 50% when taken 2 hours after DRUG2. ,mechanism,Aspirin,SKELID
DRUG1 may decrease bioavailability of DRUG2 by up to 50% when taken 2 hours after DRUG2. ,negative,Aspirin,SKELID
Aspirin may decrease bioavailability of DRUG1 by up to 50% when taken 2 hours after DRUG1. ,negative,SKELID,SKELID
The bioavailability of DRUG1 is increased 2-4 fold by DRUG2 but is not significantly altered by coadministration of diclofenac. ,mechanism,SKELID,indomethacin
The bioavailability of DRUG1 is increased 2-4 fold by indomethacin but is not significantly altered by coadministration of DRUG2. ,negative,SKELID,diclofenac
The bioavailability of SKELID is increased 2-4 fold by DRUG1 but is not significantly altered by coadministration of DRUG2. ,negative,indomethacin,diclofenac
The pharmacokinetic parameters of DRUG1 are not significantly modified by DRUG2 coadministration. ,negative,digoxin,SKELID
In vitro studies show that DRUG1 does not displace DRUG2 from its binding site on protein.,negative,tiludronate,warfarin
"DRUG1, a bacteriostatic DRUG2, may antagonize the bactericidal effect of penicillin and concurrent use of these drugs should be avoided.",negative,Tetracycline,antibiotic
"DRUG1, a bacteriostatic antibiotic, may antagonize the bactericidal effect of DRUG2 and concurrent use of these drugs should be avoided.",effect,Tetracycline,penicillin
"Tetracycline, a bacteriostatic DRUG1, may antagonize the bactericidal effect of DRUG2 and concurrent use of these drugs should be avoided.",negative,antibiotic,penicillin
"DRUG1 should be used with care in patients taking other drugs that are capable of causing CNS effects such as DRUG2, tranquilizers, or alcohol. ",advise,Scopolamine,sedatives
"DRUG1 should be used with care in patients taking other drugs that are capable of causing CNS effects such as sedatives, DRUG2, or alcohol. ",advise,Scopolamine,tranquilizers
"DRUG1 should be used with care in patients taking other drugs that are capable of causing CNS effects such as sedatives, tranquilizers, or DRUG2. ",advise,Scopolamine,alcohol
"Scopolamine should be used with care in patients taking other drugs that are capable of causing CNS effects such as DRUG1, DRUG2, or alcohol. ",negative,sedatives,tranquilizers
"Scopolamine should be used with care in patients taking other drugs that are capable of causing CNS effects such as DRUG1, tranquilizers, or DRUG2. ",negative,sedatives,alcohol
"Scopolamine should be used with care in patients taking other drugs that are capable of causing CNS effects such as sedatives, DRUG1, or DRUG2. ",negative,tranquilizers,alcohol
"e.g., other DRUG1, DRUG2 (including meclizine), tricyclic antidepressants, and muscle relaxants. ",negative,belladonna alkaloids,antihistamines
"e.g., other DRUG1, antihistamines (including DRUG2), tricyclic antidepressants, and muscle relaxants. ",negative,belladonna alkaloids,meclizine
"e.g., other DRUG1, antihistamines (including meclizine), DRUG2, and muscle relaxants. ",negative,belladonna alkaloids,tricyclic antidepressants
"e.g., other DRUG1, antihistamines (including meclizine), tricyclic antidepressants, and DRUG2. ",negative,belladonna alkaloids,muscle relaxants
"e.g., other belladonna alkaloids, DRUG1 (including DRUG2), tricyclic antidepressants, and muscle relaxants. ",negative,antihistamines,meclizine
"e.g., other belladonna alkaloids, DRUG1 (including meclizine), DRUG2, and muscle relaxants. ",negative,antihistamines,tricyclic antidepressants
"e.g., other belladonna alkaloids, DRUG1 (including meclizine), tricyclic antidepressants, and DRUG2. ",negative,antihistamines,muscle relaxants
"e.g., other belladonna alkaloids, antihistamines (including DRUG1), DRUG2, and muscle relaxants. ",negative,meclizine,tricyclic antidepressants
"e.g., other belladonna alkaloids, antihistamines (including DRUG1), tricyclic antidepressants, and DRUG2. ",negative,meclizine,muscle relaxants
"e.g., other belladonna alkaloids, antihistamines (including meclizine), DRUG1, and DRUG2. ",negative,tricyclic antidepressants,muscle relaxants
"The induction dose requirements of DRUG1 Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with DRUG2 (eg, morphine, meperidine, and fentanyl, etc.) ",effect,DIPRIVAN,narcotics
"The induction dose requirements of DRUG1 Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with narcotics (eg, DRUG2, meperidine, and fentanyl, etc.) ",effect,DIPRIVAN,morphine
"The induction dose requirements of DRUG1 Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with narcotics (eg, morphine, DRUG2, and fentanyl, etc.) ",effect,DIPRIVAN,meperidine
"The induction dose requirements of DRUG1 Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with narcotics (eg, morphine, meperidine, and DRUG2, etc.) ",effect,DIPRIVAN,fentanyl
"The induction dose requirements of DIPRIVAN Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with DRUG1 (eg, DRUG2, meperidine, and fentanyl, etc.) ",negative,narcotics,morphine
"The induction dose requirements of DIPRIVAN Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with DRUG1 (eg, morphine, DRUG2, and fentanyl, etc.) ",negative,narcotics,meperidine
"The induction dose requirements of DIPRIVAN Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with DRUG1 (eg, morphine, meperidine, and DRUG2, etc.) ",negative,narcotics,fentanyl
"The induction dose requirements of DIPRIVAN Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with narcotics (eg, DRUG1, DRUG2, and fentanyl, etc.) ",negative,morphine,meperidine
"The induction dose requirements of DIPRIVAN Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with narcotics (eg, DRUG1, meperidine, and DRUG2, etc.) ",negative,morphine,fentanyl
"The induction dose requirements of DIPRIVAN Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with narcotics (eg, morphine, DRUG1, and DRUG2, etc.) ",negative,meperidine,fentanyl
"and combinations of DRUG1 and DRUG2 (eg, benzodiazepines, barbiturates, chloral hydrate, droperidol, etc.). ",negative,opioids,sedatives
"and combinations of DRUG1 and sedatives (eg, DRUG2, barbiturates, chloral hydrate, droperidol, etc.). ",negative,opioids,benzodiazepines
"and combinations of DRUG1 and sedatives (eg, benzodiazepines, DRUG2, chloral hydrate, droperidol, etc.). ",negative,opioids,barbiturates
"and combinations of DRUG1 and sedatives (eg, benzodiazepines, barbiturates, DRUG2, droperidol, etc.). ",negative,opioids,chloral hydrate
"and combinations of DRUG1 and sedatives (eg, benzodiazepines, barbiturates, chloral hydrate, DRUG2, etc.). ",negative,opioids,droperidol
"and combinations of opioids and DRUG1 (eg, DRUG2, barbiturates, chloral hydrate, droperidol, etc.). ",negative,sedatives,benzodiazepines
"and combinations of opioids and DRUG1 (eg, benzodiazepines, DRUG2, chloral hydrate, droperidol, etc.). ",negative,sedatives,barbiturates
"and combinations of opioids and DRUG1 (eg, benzodiazepines, barbiturates, DRUG2, droperidol, etc.). ",negative,sedatives,chloral hydrate
"and combinations of opioids and DRUG1 (eg, benzodiazepines, barbiturates, chloral hydrate, DRUG2, etc.). ",negative,sedatives,droperidol
"and combinations of opioids and sedatives (eg, DRUG1, DRUG2, chloral hydrate, droperidol, etc.). ",negative,benzodiazepines,barbiturates
"and combinations of opioids and sedatives (eg, DRUG1, barbiturates, DRUG2, droperidol, etc.). ",negative,benzodiazepines,chloral hydrate
"and combinations of opioids and sedatives (eg, DRUG1, barbiturates, chloral hydrate, DRUG2, etc.). ",negative,benzodiazepines,droperidol
"and combinations of opioids and sedatives (eg, benzodiazepines, DRUG1, DRUG2, droperidol, etc.). ",negative,barbiturates,chloral hydrate
"and combinations of opioids and sedatives (eg, benzodiazepines, DRUG1, chloral hydrate, DRUG2, etc.). ",negative,barbiturates,droperidol
"and combinations of opioids and sedatives (eg, benzodiazepines, barbiturates, DRUG1, DRUG2, etc.). ",negative,chloral hydrate,droperidol
"During maintenance of anesthesia or sedation, the rate of DRUG1 Injectable Emulsion administration should be adjusted according to the desired level of anesthesia or sedation and may be reduced in the presence of supplemental DRUG2 (eg, nitrous oxide or opioids). ",advise,DIPRIVAN,analgesic agents
"During maintenance of anesthesia or sedation, the rate of DRUG1 Injectable Emulsion administration should be adjusted according to the desired level of anesthesia or sedation and may be reduced in the presence of supplemental analgesic agents (eg, DRUG2 or opioids). ",advise,DIPRIVAN,nitrous oxide
"During maintenance of anesthesia or sedation, the rate of DRUG1 Injectable Emulsion administration should be adjusted according to the desired level of anesthesia or sedation and may be reduced in the presence of supplemental analgesic agents (eg, nitrous oxide or DRUG2). ",advise,DIPRIVAN,opioids
"During maintenance of anesthesia or sedation, the rate of DIPRIVAN Injectable Emulsion administration should be adjusted according to the desired level of anesthesia or sedation and may be reduced in the presence of supplemental DRUG1 (eg, DRUG2 or opioids). ",negative,analgesic agents,nitrous oxide
"During maintenance of anesthesia or sedation, the rate of DIPRIVAN Injectable Emulsion administration should be adjusted according to the desired level of anesthesia or sedation and may be reduced in the presence of supplemental DRUG1 (eg, nitrous oxide or DRUG2). ",negative,analgesic agents,opioids
"During maintenance of anesthesia or sedation, the rate of DIPRIVAN Injectable Emulsion administration should be adjusted according to the desired level of anesthesia or sedation and may be reduced in the presence of supplemental analgesic agents (eg, DRUG1 or DRUG2). ",negative,nitrous oxide,opioids
"The concurrent administration of potent inhalational agents (eg, DRUG1, DRUG2, and halothane) during maintenance with DIPRIVAN Injectable Emulsion has not been extensively evaluated. ",negative,isoflurane,enflurane
"The concurrent administration of potent inhalational agents (eg, DRUG1, enflurane, and DRUG2) during maintenance with DIPRIVAN Injectable Emulsion has not been extensively evaluated. ",negative,isoflurane,halothane
"The concurrent administration of potent inhalational agents (eg, DRUG1, enflurane, and halothane) during maintenance with DRUG2 Injectable Emulsion has not been extensively evaluated. ",negative,isoflurane,DIPRIVAN
"The concurrent administration of potent inhalational agents (eg, isoflurane, DRUG1, and DRUG2) during maintenance with DIPRIVAN Injectable Emulsion has not been extensively evaluated. ",negative,enflurane,halothane
"The concurrent administration of potent inhalational agents (eg, isoflurane, DRUG1, and halothane) during maintenance with DRUG2 Injectable Emulsion has not been extensively evaluated. ",negative,enflurane,DIPRIVAN
"The concurrent administration of potent inhalational agents (eg, isoflurane, enflurane, and DRUG1) during maintenance with DRUG2 Injectable Emulsion has not been extensively evaluated. ",negative,halothane,DIPRIVAN
"DRUG1 Injectable Emulsion does not cause a clinically significant change in onset, intensity, or duration of action of the commonly used DRUG2 (eg, succinylcholine and nondepolarizing muscle relaxants). ",negative,DIPRIVAN,neuromuscular blocking agents
"DRUG1 Injectable Emulsion does not cause a clinically significant change in onset, intensity, or duration of action of the commonly used neuromuscular blocking agents (eg, DRUG2 and nondepolarizing muscle relaxants). ",negative,DIPRIVAN,succinylcholine
"DRUG1 Injectable Emulsion does not cause a clinically significant change in onset, intensity, or duration of action of the commonly used neuromuscular blocking agents (eg, succinylcholine and DRUG2). ",negative,DIPRIVAN,nondepolarizing muscle relaxants
"DIPRIVAN Injectable Emulsion does not cause a clinically significant change in onset, intensity, or duration of action of the commonly used DRUG1 (eg, DRUG2 and nondepolarizing muscle relaxants). ",negative,neuromuscular blocking agents,succinylcholine
"DIPRIVAN Injectable Emulsion does not cause a clinically significant change in onset, intensity, or duration of action of the commonly used DRUG1 (eg, succinylcholine and DRUG2). ",negative,neuromuscular blocking agents,nondepolarizing muscle relaxants
"DIPRIVAN Injectable Emulsion does not cause a clinically significant change in onset, intensity, or duration of action of the commonly used neuromuscular blocking agents (eg, DRUG1 and DRUG2). ",negative,succinylcholine,nondepolarizing muscle relaxants
"No significant adverse interactions with commonly used premedications or drugs used during anesthesia or sedation (including a range of DRUG1, inhalational agents, DRUG2, and local anesthetic agents) have been observed.",negative,muscle relaxants,analgesic agents
"No significant adverse interactions with commonly used premedications or drugs used during anesthesia or sedation (including a range of DRUG1, inhalational agents, analgesic agents, and local DRUG2) have been observed.",negative,muscle relaxants,anesthetic agents
"No significant adverse interactions with commonly used premedications or drugs used during anesthesia or sedation (including a range of muscle relaxants, inhalational agents, DRUG1, and local DRUG2) have been observed.",negative,analgesic agents,anesthetic agents
"The in vitro binding of DRUG1 to human plasma proteins is unaffected by DRUG2, and DRUG2 does not alter the prothrombin time of normal volunteers. ",negative,warfarin,tolmetin
"The in vitro binding of DRUG1 to human plasma proteins is unaffected by DRUG2, and DRUG2 does not alter the prothrombin time of normal volunteers. ",negative,warfarin,tolmetin
"The in vitro binding of warfarin to human plasma proteins is unaffected by DRUG1, and DRUG1 does not alter the prothrombin time of normal volunteers. ",negative,tolmetin,tolmetin
"However, increased prothrombin time and bleeding have been reported in patients on concomitant DRUG1 and DRUG2 therapy. ",effect,TOLECTIN,warfarin
"Therefore, caution should be exercised when administering DRUG1 to patients on DRUG2. ",advise,TOLECTIN,anticoagulants
In adult diabetic patients under treatment with either DRUG1 or DRUG2 there is no change in the clinical effects of either TOLECTIN or the hypoglycemic agents. ,negative,sulfonylureas,insulin
In adult diabetic patients under treatment with either DRUG1 or insulin there is no change in the clinical effects of either DRUG2 or the hypoglycemic agents. ,negative,sulfonylureas,TOLECTIN
In adult diabetic patients under treatment with either DRUG1 or insulin there is no change in the clinical effects of either TOLECTIN or the DRUG2. ,negative,sulfonylureas,hypoglycemic agents
In adult diabetic patients under treatment with either sulfonylureas or DRUG1 there is no change in the clinical effects of either DRUG2 or the hypoglycemic agents. ,negative,insulin,TOLECTIN
In adult diabetic patients under treatment with either sulfonylureas or DRUG1 there is no change in the clinical effects of either TOLECTIN or the DRUG2. ,negative,insulin,hypoglycemic agents
In adult diabetic patients under treatment with either sulfonylureas or insulin there is no change in the clinical effects of either DRUG1 or the DRUG2. ,negative,TOLECTIN,hypoglycemic agents
Caution should be used if DRUG1 is administered concomitantly with DRUG2. ,advise,TOLECTIN,methotrexate
"DRUG1 and other DRUG2 have been reported to reduce the tubular secretion of methotrexate in an animal model, possibly enhancing the toxicity of methotrexate. ",negative,TOLECTIN,nonsteroidal anti-inflammatory drugs
"DRUG1 and other nonsteroidal anti-inflammatory drugs have been reported to reduce the tubular secretion of DRUG2 in an animal model, possibly enhancing the toxicity of DRUG2. ",mechanism,TOLECTIN,methotrexate
"DRUG1 and other nonsteroidal anti-inflammatory drugs have been reported to reduce the tubular secretion of DRUG2 in an animal model, possibly enhancing the toxicity of DRUG2. ",negative,TOLECTIN,methotrexate
"TOLECTIN and other DRUG1 have been reported to reduce the tubular secretion of DRUG2 in an animal model, possibly enhancing the toxicity of DRUG2. ",mechanism,nonsteroidal anti-inflammatory drugs,methotrexate
"TOLECTIN and other DRUG1 have been reported to reduce the tubular secretion of DRUG2 in an animal model, possibly enhancing the toxicity of DRUG2. ",negative,nonsteroidal anti-inflammatory drugs,methotrexate
"TOLECTIN and other nonsteroidal anti-inflammatory drugs have been reported to reduce the tubular secretion of DRUG1 in an animal model, possibly enhancing the toxicity of DRUG1. ",negative,methotrexate,methotrexate
DRUG1 may accentuate the orthostatic hypotension that may occur with DRUG2. ,effect,Thiazide diuretics,phenothiazines
Antihypertensive effects of DRUG1 and related compounds may be counteracted when DRUG2 are used concomitantly. ,effect,guanethidine,phenothiazines
Concomitant administration of DRUG1 with DRUG2 results in increased plasma levels of both drugs.,mechanism,propranolol,phenothiazines
"In clinical studies of DRUG1, patients taking DRUG1 concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. ",negative,TOBI,TOBI
"In clinical studies of DRUG1, patients taking DRUG1 concomitantly with DRUG2 (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. ",negative,TOBI,dornase alfa
"In clinical studies of DRUG1, patients taking DRUG1 concomitantly with dornase alfa (DRUG2   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. ",negative,TOBI,PULMOZYME
"In clinical studies of DRUG1, patients taking DRUG1 concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. ",negative,TOBI,(beta)-agonists
"In clinical studies of DRUG1, patients taking DRUG1 concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled DRUG2, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. ",negative,TOBI,corticosteroids
"In clinical studies of DRUG1, patients taking DRUG1 concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other DRUG2, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. ",negative,TOBI,anti-pseudomonal antibiotics
"In clinical studies of DRUG1, patients taking DRUG1 concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral DRUG2 demonstrated adverse experience profiles similar to the study population as a whole. ",negative,TOBI,aminoglycosides
"In clinical studies of DRUG1, patients taking DRUG1 concomitantly with DRUG2 (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. ",effect,TOBI,dornase alfa
"In clinical studies of DRUG1, patients taking DRUG1 concomitantly with dornase alfa (DRUG2   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. ",effect,TOBI,PULMOZYME
"In clinical studies of DRUG1, patients taking DRUG1 concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. ",effect,TOBI,(beta)-agonists
"In clinical studies of DRUG1, patients taking DRUG1 concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled DRUG2, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. ",effect,TOBI,corticosteroids
"In clinical studies of DRUG1, patients taking DRUG1 concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other DRUG2, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. ",effect,TOBI,anti-pseudomonal antibiotics
"In clinical studies of DRUG1, patients taking DRUG1 concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral DRUG2 demonstrated adverse experience profiles similar to the study population as a whole. ",effect,TOBI,aminoglycosides
"In clinical studies of TOBI, patients taking TOBI concomitantly with DRUG1 (DRUG2   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. ",negative,dornase alfa,PULMOZYME
"In clinical studies of TOBI, patients taking TOBI concomitantly with DRUG1 (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. ",negative,dornase alfa,(beta)-agonists
"In clinical studies of TOBI, patients taking TOBI concomitantly with DRUG1 (PULMOZYME   , Genentech), (beta)-agonists, inhaled DRUG2, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. ",negative,dornase alfa,corticosteroids
"In clinical studies of TOBI, patients taking TOBI concomitantly with DRUG1 (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other DRUG2, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. ",negative,dornase alfa,anti-pseudomonal antibiotics
"In clinical studies of TOBI, patients taking TOBI concomitantly with DRUG1 (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral DRUG2 demonstrated adverse experience profiles similar to the study population as a whole. ",negative,dornase alfa,aminoglycosides
"In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (DRUG1   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. ",negative,PULMOZYME,(beta)-agonists
"In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (DRUG1   , Genentech), (beta)-agonists, inhaled DRUG2, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. ",negative,PULMOZYME,corticosteroids
"In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (DRUG1   , Genentech), (beta)-agonists, inhaled corticosteroids, other DRUG2, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. ",negative,PULMOZYME,anti-pseudomonal antibiotics
"In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (DRUG1   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral DRUG2 demonstrated adverse experience profiles similar to the study population as a whole. ",negative,PULMOZYME,aminoglycosides
"In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled DRUG2, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. ",negative,(beta)-agonists,corticosteroids
"In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other DRUG2, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. ",negative,(beta)-agonists,anti-pseudomonal antibiotics
"In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral DRUG2 demonstrated adverse experience profiles similar to the study population as a whole. ",negative,(beta)-agonists,aminoglycosides
"In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled DRUG1, other DRUG2, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. ",negative,corticosteroids,anti-pseudomonal antibiotics
"In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled DRUG1, other anti-pseudomonal antibiotics, or parenteral DRUG2 demonstrated adverse experience profiles similar to the study population as a whole. ",negative,corticosteroids,aminoglycosides
"In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other DRUG1, or parenteral DRUG2 demonstrated adverse experience profiles similar to the study population as a whole. ",negative,anti-pseudomonal antibiotics,aminoglycosides
Some DRUG1 can enhance DRUG2 toxicity by altering antibiotic concentrations in serum and tissue. ,effect,diuretics,aminoglycoside
Some DRUG1 can enhance aminoglycoside toxicity by altering DRUG2 concentrations in serum and tissue. ,negative,diuretics,antibiotic
Some diuretics can enhance DRUG1 toxicity by altering DRUG2 concentrations in serum and tissue. ,negative,aminoglycoside,antibiotic
"DRUG1 should not be administered concomitantly with DRUG2, furosemide, urea, or mannitol.",advise,TOBI,ethacrynic acid
"DRUG1 should not be administered concomitantly with ethacrynic acid, DRUG2, urea, or mannitol.",advise,TOBI,furosemide
"DRUG1 should not be administered concomitantly with ethacrynic acid, furosemide, DRUG2, or mannitol.",advise,TOBI,urea
"DRUG1 should not be administered concomitantly with ethacrynic acid, furosemide, urea, or DRUG2.",advise,TOBI,mannitol
"TOBI should not be administered concomitantly with DRUG1, DRUG2, urea, or mannitol.",negative,ethacrynic acid,furosemide
"TOBI should not be administered concomitantly with DRUG1, furosemide, DRUG2, or mannitol.",negative,ethacrynic acid,urea
"TOBI should not be administered concomitantly with DRUG1, furosemide, urea, or DRUG2.",negative,ethacrynic acid,mannitol
"TOBI should not be administered concomitantly with ethacrynic acid, DRUG1, DRUG2, or mannitol.",negative,furosemide,urea
"TOBI should not be administered concomitantly with ethacrynic acid, DRUG1, urea, or DRUG2.",negative,furosemide,mannitol
"TOBI should not be administered concomitantly with ethacrynic acid, furosemide, DRUG1, or DRUG2.",negative,urea,mannitol
An inhibitor of CYP2C8 (such as DRUG1) may increase the AUC of DRUG2 and an inducer of CYP2C8 (such as rifampin) may decrease the AUC of DRUG2. ,mechanism,gemfibrozil,rosiglitazone
An inhibitor of CYP2C8 (such as DRUG1) may increase the AUC of rosiglitazone and an inducer of CYP2C8 (such as DRUG2) may decrease the AUC of rosiglitazone. ,negative,gemfibrozil,rifampin
An inhibitor of CYP2C8 (such as DRUG1) may increase the AUC of DRUG2 and an inducer of CYP2C8 (such as rifampin) may decrease the AUC of DRUG2. ,negative,gemfibrozil,rosiglitazone
An inhibitor of CYP2C8 (such as gemfibrozil) may increase the AUC of DRUG1 and an inducer of CYP2C8 (such as DRUG2) may decrease the AUC of DRUG1. ,negative,rosiglitazone,rifampin
An inhibitor of CYP2C8 (such as gemfibrozil) may increase the AUC of DRUG1 and an inducer of CYP2C8 (such as rifampin) may decrease the AUC of DRUG1. ,negative,rosiglitazone,rosiglitazone
An inhibitor of CYP2C8 (such as gemfibrozil) may increase the AUC of DRUG2 and an inducer of CYP2C8 (such as DRUG1) may decrease the AUC of DRUG2. ,mechanism,rifampin,rosiglitazone
DRUG1: DRUG1 causes a 60% reduction in the absorption and enterohepatic cycling of raloxifene and should not be coadministered with EVISTA. ,negative,Cholestyramine,Cholestyramine
DRUG1: DRUG1 causes a 60% reduction in the absorption and enterohepatic cycling of DRUG2 and should not be coadministered with EVISTA. ,negative,Cholestyramine,raloxifene
DRUG1: DRUG1 causes a 60% reduction in the absorption and enterohepatic cycling of raloxifene and should not be coadministered with DRUG2. ,negative,Cholestyramine,EVISTA
DRUG1: DRUG1 causes a 60% reduction in the absorption and enterohepatic cycling of DRUG2 and should not be coadministered with EVISTA. ,mechanism,Cholestyramine,raloxifene
DRUG1: DRUG1 causes a 60% reduction in the absorption and enterohepatic cycling of raloxifene and should not be coadministered with DRUG2. ,advise,Cholestyramine,EVISTA
Cholestyramine: Cholestyramine causes a 60% reduction in the absorption and enterohepatic cycling of DRUG1 and should not be coadministered with DRUG2. ,negative,raloxifene,EVISTA
DRUG1: The coadministration of DRUG2 and DRUG1 has not been assessed under chronic conditions. ,negative,Warfarin,EVISTA
DRUG1: The coadministration of EVISTA and DRUG1 has not been assessed under chronic conditions. ,negative,Warfarin,warfarin
DRUG2: The coadministration of DRUG1 and DRUG2 has not been assessed under chronic conditions. ,negative,EVISTA,warfarin
"If DRUG1 is given concurrently with DRUG2, prothrombin time should be monitored. ",advise,EVISTA,warfarin
"In vitro, DRUG1 did not affect the binding of DRUG2, phenytoin, or tamoxifen. ",negative,raloxifene,warfarin
"In vitro, DRUG1 did not affect the binding of warfarin, DRUG2, or tamoxifen. ",negative,raloxifene,phenytoin
"In vitro, DRUG1 did not affect the binding of warfarin, phenytoin, or DRUG2. ",negative,raloxifene,tamoxifen
"In vitro, raloxifene did not affect the binding of DRUG1, DRUG2, or tamoxifen. ",negative,warfarin,phenytoin
"In vitro, raloxifene did not affect the binding of DRUG1, phenytoin, or DRUG2. ",negative,warfarin,tamoxifen
"In vitro, raloxifene did not affect the binding of warfarin, DRUG1, or DRUG2. ",negative,phenytoin,tamoxifen
"Caution should be used when DRUG1 is coadministered with other highly protein-bound drugs, such as DRUG2, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide. ",advise,EVISTA,clofibrate
"Caution should be used when DRUG1 is coadministered with other highly protein-bound drugs, such as clofibrate, DRUG2, naproxen, ibuprofen, diazepam, and diazoxide. ",advise,EVISTA,indomethacin
"Caution should be used when DRUG1 is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, DRUG2, ibuprofen, diazepam, and diazoxide. ",advise,EVISTA,naproxen
"Caution should be used when DRUG1 is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, DRUG2, diazepam, and diazoxide. ",advise,EVISTA,ibuprofen
"Caution should be used when DRUG1 is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, DRUG2, and diazoxide. ",advise,EVISTA,diazepam
"Caution should be used when DRUG1 is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and DRUG2. ",advise,EVISTA,diazoxide
"Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as DRUG1, DRUG2, naproxen, ibuprofen, diazepam, and diazoxide. ",negative,clofibrate,indomethacin
"Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as DRUG1, indomethacin, DRUG2, ibuprofen, diazepam, and diazoxide. ",negative,clofibrate,naproxen
"Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as DRUG1, indomethacin, naproxen, DRUG2, diazepam, and diazoxide. ",negative,clofibrate,ibuprofen
"Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as DRUG1, indomethacin, naproxen, ibuprofen, DRUG2, and diazoxide. ",negative,clofibrate,diazepam
"Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as DRUG1, indomethacin, naproxen, ibuprofen, diazepam, and DRUG2. ",negative,clofibrate,diazoxide
"Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, DRUG1, DRUG2, ibuprofen, diazepam, and diazoxide. ",negative,indomethacin,naproxen
"Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, DRUG1, naproxen, DRUG2, diazepam, and diazoxide. ",negative,indomethacin,ibuprofen
"Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, DRUG1, naproxen, ibuprofen, DRUG2, and diazoxide. ",negative,indomethacin,diazepam
"Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, DRUG1, naproxen, ibuprofen, diazepam, and DRUG2. ",negative,indomethacin,diazoxide
"Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, DRUG1, DRUG2, diazepam, and diazoxide. ",negative,naproxen,ibuprofen
"Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, DRUG1, ibuprofen, DRUG2, and diazoxide. ",negative,naproxen,diazepam
"Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, DRUG1, ibuprofen, diazepam, and DRUG2. ",negative,naproxen,diazoxide
"Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, DRUG1, DRUG2, and diazoxide. ",negative,ibuprofen,diazepam
"Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, DRUG1, diazepam, and DRUG2. ",negative,ibuprofen,diazoxide
"Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, DRUG1, and DRUG2. ",negative,diazepam,diazoxide
DRUG1 competes with DRUG2 for active tubular secretion and thus inhibits the renal excretion of DRUG2. ,mechanism,Probenecid,meropenem
DRUG1 competes with DRUG2 for active tubular secretion and thus inhibits the renal excretion of DRUG2. ,negative,Probenecid,meropenem
Probenecid competes with DRUG1 for active tubular secretion and thus inhibits the renal excretion of DRUG1. ,negative,meropenem,meropenem
"Therefore, the coadministration of DRUG1 with DRUG2 is not recommended. ",advise,probenecid,meropenem
There is evidence that DRUG1 may reduce serum levels of DRUG2 to subtherapeutic levels (therapeutic range considered to be 50 to 100    g/mL total valproate).,mechanism,meropenem,valproic acid
There is evidence that DRUG1 may reduce serum levels of valproic acid to subtherapeutic levels (therapeutic range considered to be 50 to 100    g/mL total DRUG2).,negative,meropenem,valproate
There is evidence that meropenem may reduce serum levels of DRUG1 to subtherapeutic levels (therapeutic range considered to be 50 to 100    g/mL total DRUG2).,negative,valproic acid,valproate
Other DRUG1 should not be used concomitantly with DRUG2    (metaproterenol sulfate USP) because they may have additive effects. ,advise,beta adrenergic aerosol bronchodilators,Alupent
Other DRUG1 should not be used concomitantly with Alupent    (DRUG2 USP) because they may have additive effects. ,advise,beta adrenergic aerosol bronchodilators,metaproterenol sulfate
Other beta adrenergic aerosol bronchodilators should not be used concomitantly with DRUG1    (DRUG2 USP) because they may have additive effects. ,negative,Alupent,metaproterenol sulfate
"DRUG1 should be administered with caution to patients being treated with DRUG2 or tricyclic antidepressants, since the action of DRUG1 on the vascular system may be potentiated.",advise,Beta adrenergic agonists,monoamine oxidase inhibitors
"DRUG1 should be administered with caution to patients being treated with monoamine oxidase inhibitors or DRUG2, since the action of DRUG1 on the vascular system may be potentiated.",advise,Beta adrenergic agonists,tricyclic antidepressants
"DRUG1 should be administered with caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, since the action of DRUG1 on the vascular system may be potentiated.",negative,Beta adrenergic agonists,beta adrenergic agonists
"Beta adrenergic agonists should be administered with caution to patients being treated with DRUG1 or DRUG2, since the action of beta adrenergic agonists on the vascular system may be potentiated.",negative,monoamine oxidase inhibitors,tricyclic antidepressants
"DRUG2 should be administered with caution to patients being treated with DRUG1 or tricyclic antidepressants, since the action of DRUG2 on the vascular system may be potentiated.",negative,monoamine oxidase inhibitors,beta adrenergic agonists
"DRUG2 should be administered with caution to patients being treated with monoamine oxidase inhibitors or DRUG1, since the action of DRUG2 on the vascular system may be potentiated.",negative,tricyclic antidepressants,beta adrenergic agonists
"Drug Interactions: The use of DRUG1    (DRUG2) Injection before succinylcholine, for the purpose of attenuating some of the side effects of succinylcholine, has not been studied. ",negative,ZEMURON,rocuronium bromide
"Drug Interactions: The use of DRUG1    (rocuronium bromide) Injection before DRUG2, for the purpose of attenuating some of the side effects of DRUG2, has not been studied. ",negative,ZEMURON,succinylcholine
"Drug Interactions: The use of DRUG1    (rocuronium bromide) Injection before DRUG2, for the purpose of attenuating some of the side effects of DRUG2, has not been studied. ",negative,ZEMURON,succinylcholine
"Drug Interactions: The use of ZEMURON    (DRUG1) Injection before DRUG2, for the purpose of attenuating some of the side effects of DRUG2, has not been studied. ",negative,rocuronium bromide,succinylcholine
"Drug Interactions: The use of ZEMURON    (DRUG1) Injection before DRUG2, for the purpose of attenuating some of the side effects of DRUG2, has not been studied. ",negative,rocuronium bromide,succinylcholine
"Drug Interactions: The use of ZEMURON    (rocuronium bromide) Injection before DRUG1, for the purpose of attenuating some of the side effects of DRUG1, has not been studied. ",negative,succinylcholine,succinylcholine
"If DRUG1    is administered following administration of DRUG2, it should not be given until recovery from DRUG2 has been observed. ",advise,ZEMURON,succinylcholine
"If DRUG1    is administered following administration of DRUG2, it should not be given until recovery from DRUG2 has been observed. ",negative,ZEMURON,succinylcholine
"If ZEMURON    is administered following administration of DRUG1, it should not be given until recovery from DRUG1 has been observed. ",negative,succinylcholine,succinylcholine
"The median duration of action of DRUG1    0.6 mg/kg administered after a 1 mg/kg dose of DRUG2 when T 1 returned to 75% of control was 36 minutes (range 14-57, n=12) vs. ",negative,ZEMURON,succinylcholine
There are no controlled studies documenting the use of DRUG1    before or after other DRUG2. ,negative,ZEMURON,nondepolarizing muscle relaxants
"Because DRUG1 is metabolized by hepatic cytochrome P-450 drug-metabolizing enzymes (CYP3A4, CYP2D6, CYP1A2), inducers or inhibitors of these enzymes may change the clearance and, hence, the half-life of DRUG1. ",negative,ondansetron,ondansetron
"DRUG1, DRUG2, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., DRUG1, DRUG2, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. ",negative,Phenytoin,Carbamazepine
"DRUG1, Carbamazepine, and DRUG2: In patients treated with potent inducers of CYP3A4 (i.e., DRUG1, carbamazepine, and DRUG2), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. ",negative,Phenytoin,Rifampicin
"DRUG1, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., DRUG1, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. ",negative,Phenytoin,phenytoin
"DRUG1, DRUG2, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., DRUG1, DRUG2, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. ",negative,Phenytoin,carbamazepine
"DRUG1, Carbamazepine, and DRUG2: In patients treated with potent inducers of CYP3A4 (i.e., DRUG1, carbamazepine, and DRUG2), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. ",negative,Phenytoin,rifampicin
"DRUG1, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., DRUG1, carbamazepine, and rifampicin), the clearance of DRUG2 was significantly increased and DRUG2 blood concentrations were decreased. ",negative,Phenytoin,ondansetron
"DRUG1, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., DRUG1, carbamazepine, and rifampicin), the clearance of DRUG2 was significantly increased and DRUG2 blood concentrations were decreased. ",negative,Phenytoin,ondansetron
"Phenytoin, DRUG1, and DRUG2: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, DRUG1, and DRUG2), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. ",negative,Carbamazepine,Rifampicin
"DRUG2, DRUG1, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., DRUG2, DRUG1, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. ",negative,Carbamazepine,phenytoin
"Phenytoin, DRUG1, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, DRUG1, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. ",negative,Carbamazepine,carbamazepine
"Phenytoin, DRUG1, and DRUG2: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, DRUG1, and DRUG2), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. ",negative,Carbamazepine,rifampicin
"Phenytoin, DRUG1, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, DRUG1, and rifampicin), the clearance of DRUG2 was significantly increased and DRUG2 blood concentrations were decreased. ",negative,Carbamazepine,ondansetron
"Phenytoin, DRUG1, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, DRUG1, and rifampicin), the clearance of DRUG2 was significantly increased and DRUG2 blood concentrations were decreased. ",negative,Carbamazepine,ondansetron
"DRUG2, Carbamazepine, and DRUG1: In patients treated with potent inducers of CYP3A4 (i.e., DRUG2, carbamazepine, and DRUG1), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. ",negative,Rifampicin,phenytoin
"Phenytoin, DRUG2, and DRUG1: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, DRUG2, and DRUG1), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. ",negative,Rifampicin,carbamazepine
"Phenytoin, Carbamazepine, and DRUG1: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and DRUG1), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. ",negative,Rifampicin,rifampicin
"Phenytoin, Carbamazepine, and DRUG1: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and DRUG1), the clearance of DRUG2 was significantly increased and DRUG2 blood concentrations were decreased. ",negative,Rifampicin,ondansetron
"Phenytoin, Carbamazepine, and DRUG1: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and DRUG1), the clearance of DRUG2 was significantly increased and DRUG2 blood concentrations were decreased. ",negative,Rifampicin,ondansetron
"DRUG1, DRUG2, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., DRUG1, DRUG2, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. ",negative,phenytoin,carbamazepine
"DRUG1, Carbamazepine, and DRUG2: In patients treated with potent inducers of CYP3A4 (i.e., DRUG1, carbamazepine, and DRUG2), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. ",negative,phenytoin,rifampicin
"DRUG1, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., DRUG1, carbamazepine, and rifampicin), the clearance of DRUG2 was significantly increased and DRUG2 blood concentrations were decreased. ",mechanism,phenytoin,ondansetron
"DRUG1, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., DRUG1, carbamazepine, and rifampicin), the clearance of DRUG2 was significantly increased and DRUG2 blood concentrations were decreased. ",mechanism,phenytoin,ondansetron
"Phenytoin, DRUG1, and DRUG2: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, DRUG1, and DRUG2), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. ",negative,carbamazepine,rifampicin
"Phenytoin, DRUG1, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, DRUG1, and rifampicin), the clearance of DRUG2 was significantly increased and DRUG2 blood concentrations were decreased. ",mechanism,carbamazepine,ondansetron
"Phenytoin, DRUG1, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, DRUG1, and rifampicin), the clearance of DRUG2 was significantly increased and DRUG2 blood concentrations were decreased. ",mechanism,carbamazepine,ondansetron
"Phenytoin, Carbamazepine, and DRUG1: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and DRUG1), the clearance of DRUG2 was significantly increased and DRUG2 blood concentrations were decreased. ",mechanism,rifampicin,ondansetron
"Phenytoin, Carbamazepine, and DRUG1: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and DRUG1), the clearance of DRUG2 was significantly increased and DRUG2 blood concentrations were decreased. ",mechanism,rifampicin,ondansetron
"Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of DRUG1 was significantly increased and DRUG1 blood concentrations were decreased. ",negative,ondansetron,ondansetron
"However, on the basis of available data, no dosage adjustment for DRUG1 is recommended for patients on these drugs.1,3  DRUG2: Although no pharmacokinetic drug interaction between DRUG1 and DRUG2 has been observed, data from 2 small studies indicate that DRUG1 may be associated with an increase in patient controlled administration of DRUG2.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by DRUG1. ",negative,ondansetron,Tramadol
"However, on the basis of available data, no dosage adjustment for DRUG1 is recommended for patients on these drugs.1,3  Tramadol: Although no pharmacokinetic drug interaction between DRUG1 and tramadol has been observed, data from 2 small studies indicate that DRUG1 may be associated with an increase in patient controlled administration of tramadol.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by DRUG1. ",negative,ondansetron,ondansetron
"However, on the basis of available data, no dosage adjustment for DRUG1 is recommended for patients on these drugs.1,3  DRUG2: Although no pharmacokinetic drug interaction between DRUG1 and DRUG2 has been observed, data from 2 small studies indicate that DRUG1 may be associated with an increase in patient controlled administration of DRUG2.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by DRUG1. ",negative,ondansetron,tramadol
"However, on the basis of available data, no dosage adjustment for DRUG1 is recommended for patients on these drugs.1,3  Tramadol: Although no pharmacokinetic drug interaction between DRUG1 and tramadol has been observed, data from 2 small studies indicate that DRUG1 may be associated with an increase in patient controlled administration of tramadol.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by DRUG1. ",negative,ondansetron,ondansetron
"However, on the basis of available data, no dosage adjustment for DRUG1 is recommended for patients on these drugs.1,3  DRUG2: Although no pharmacokinetic drug interaction between DRUG1 and DRUG2 has been observed, data from 2 small studies indicate that DRUG1 may be associated with an increase in patient controlled administration of DRUG2.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by DRUG1. ",negative,ondansetron,tramadol
"However, on the basis of available data, no dosage adjustment for DRUG1 is recommended for patients on these drugs.1,3  Tramadol: Although no pharmacokinetic drug interaction between DRUG1 and tramadol has been observed, data from 2 small studies indicate that DRUG1 may be associated with an increase in patient controlled administration of tramadol.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by DRUG1. ",negative,ondansetron,ondansetron
"However, on the basis of available data, no dosage adjustment for DRUG2 is recommended for patients on these drugs.1,3  DRUG1: Although no pharmacokinetic drug interaction between DRUG2 and DRUG1 has been observed, data from 2 small studies indicate that DRUG2 may be associated with an increase in patient controlled administration of DRUG1.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by DRUG2. ",negative,Tramadol,ondansetron
"However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  DRUG1: Although no pharmacokinetic drug interaction between ondansetron and DRUG1 has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of DRUG1.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron. ",negative,Tramadol,tramadol
"However, on the basis of available data, no dosage adjustment for DRUG2 is recommended for patients on these drugs.1,3  DRUG1: Although no pharmacokinetic drug interaction between DRUG2 and DRUG1 has been observed, data from 2 small studies indicate that DRUG2 may be associated with an increase in patient controlled administration of DRUG1.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by DRUG2. ",negative,Tramadol,ondansetron
"However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  DRUG1: Although no pharmacokinetic drug interaction between ondansetron and DRUG1 has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of DRUG1.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron. ",negative,Tramadol,tramadol
"However, on the basis of available data, no dosage adjustment for DRUG2 is recommended for patients on these drugs.1,3  DRUG1: Although no pharmacokinetic drug interaction between DRUG2 and DRUG1 has been observed, data from 2 small studies indicate that DRUG2 may be associated with an increase in patient controlled administration of DRUG1.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by DRUG2. ",negative,Tramadol,ondansetron
"However, on the basis of available data, no dosage adjustment for DRUG1 is recommended for patients on these drugs.1,3  DRUG2: Although no pharmacokinetic drug interaction between DRUG1 and DRUG2 has been observed, data from 2 small studies indicate that DRUG1 may be associated with an increase in patient controlled administration of DRUG2.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by DRUG1. ",negative,ondansetron,tramadol
"However, on the basis of available data, no dosage adjustment for DRUG1 is recommended for patients on these drugs.1,3  Tramadol: Although no pharmacokinetic drug interaction between DRUG1 and tramadol has been observed, data from 2 small studies indicate that DRUG1 may be associated with an increase in patient controlled administration of tramadol.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by DRUG1. ",negative,ondansetron,ondansetron
"However, on the basis of available data, no dosage adjustment for DRUG1 is recommended for patients on these drugs.1,3  DRUG2: Although no pharmacokinetic drug interaction between DRUG1 and DRUG2 has been observed, data from 2 small studies indicate that DRUG1 may be associated with an increase in patient controlled administration of DRUG2.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by DRUG1. ",negative,ondansetron,tramadol
"However, on the basis of available data, no dosage adjustment for DRUG1 is recommended for patients on these drugs.1,3  Tramadol: Although no pharmacokinetic drug interaction between DRUG1 and tramadol has been observed, data from 2 small studies indicate that DRUG1 may be associated with an increase in patient controlled administration of tramadol.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by DRUG1. ",negative,ondansetron,ondansetron
"However, on the basis of available data, no dosage adjustment for DRUG2 is recommended for patients on these drugs.1,3  DRUG1: Although no pharmacokinetic drug interaction between DRUG2 and DRUG1 has been observed, data from 2 small studies indicate that DRUG2 may be associated with an increase in patient controlled administration of DRUG1.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by DRUG2. ",negative,tramadol,ondansetron
"However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  DRUG1: Although no pharmacokinetic drug interaction between ondansetron and DRUG1 has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of DRUG1.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron. ",negative,tramadol,tramadol
"However, on the basis of available data, no dosage adjustment for DRUG2 is recommended for patients on these drugs.1,3  DRUG1: Although no pharmacokinetic drug interaction between DRUG2 and DRUG1 has been observed, data from 2 small studies indicate that DRUG2 may be associated with an increase in patient controlled administration of DRUG1.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by DRUG2. ",negative,tramadol,ondansetron
"However, on the basis of available data, no dosage adjustment for DRUG1 is recommended for patients on these drugs.1,3  DRUG2: Although no pharmacokinetic drug interaction between DRUG1 and DRUG2 has been observed, data from 2 small studies indicate that DRUG1 may be associated with an increase in patient controlled administration of DRUG2.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by DRUG1. ",effect,ondansetron,tramadol
"However, on the basis of available data, no dosage adjustment for DRUG1 is recommended for patients on these drugs.1,3  Tramadol: Although no pharmacokinetic drug interaction between DRUG1 and tramadol has been observed, data from 2 small studies indicate that DRUG1 may be associated with an increase in patient controlled administration of tramadol.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by DRUG1. ",negative,ondansetron,ondansetron
"However, on the basis of available data, no dosage adjustment for DRUG2 is recommended for patients on these drugs.1,3  DRUG1: Although no pharmacokinetic drug interaction between DRUG2 and DRUG1 has been observed, data from 2 small studies indicate that DRUG2 may be associated with an increase in patient controlled administration of DRUG1.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by DRUG2. ",negative,tramadol,ondansetron
"In humans, DRUG1, DRUG2, and cisplatin do not affect the pharmacokinetics of ondansetron.  ",negative,carmustine,etoposide
"In humans, DRUG1, etoposide, and DRUG2 do not affect the pharmacokinetics of ondansetron.  ",negative,carmustine,cisplatin
"In humans, DRUG1, etoposide, and cisplatin do not affect the pharmacokinetics of DRUG2.  ",negative,carmustine,ondansetron
"In humans, carmustine, DRUG1, and DRUG2 do not affect the pharmacokinetics of ondansetron.  ",negative,etoposide,cisplatin
"In humans, carmustine, DRUG1, and cisplatin do not affect the pharmacokinetics of DRUG2.  ",negative,etoposide,ondansetron
"In humans, carmustine, etoposide, and DRUG1 do not affect the pharmacokinetics of DRUG2.  ",negative,cisplatin,ondansetron
DRUG1 did not increase blood levels of high-dose DRUG2.,negative,ondansetron,methotrexate
Administration of DRUG1 in combination with DRUG2 resulted in a two-fold decrease in DRUG2 clearance in a non-human primate study and in a 1.5-fold increase in DRUG2 serum levels in clinical studies.,mechanism,paclitaxel,HERCEPTIN
Administration of DRUG1 in combination with DRUG2 resulted in a two-fold decrease in DRUG2 clearance in a non-human primate study and in a 1.5-fold increase in DRUG2 serum levels in clinical studies.,negative,paclitaxel,HERCEPTIN
Administration of DRUG1 in combination with DRUG2 resulted in a two-fold decrease in DRUG2 clearance in a non-human primate study and in a 1.5-fold increase in DRUG2 serum levels in clinical studies.,negative,paclitaxel,HERCEPTIN
Administration of paclitaxel in combination with DRUG1 resulted in a two-fold decrease in DRUG1 clearance in a non-human primate study and in a 1.5-fold increase in DRUG1 serum levels in clinical studies.,negative,HERCEPTIN,HERCEPTIN
Administration of paclitaxel in combination with DRUG1 resulted in a two-fold decrease in DRUG1 clearance in a non-human primate study and in a 1.5-fold increase in DRUG1 serum levels in clinical studies.,negative,HERCEPTIN,HERCEPTIN
Administration of paclitaxel in combination with DRUG1 resulted in a two-fold decrease in DRUG1 clearance in a non-human primate study and in a 1.5-fold increase in DRUG1 serum levels in clinical studies.,negative,HERCEPTIN,HERCEPTIN
Concomitant administrations not recommended:  - DRUG1 and DRUG2: Certain macrolides interact with DRUG1 and DRUG2 leading to increased serum concentrations of the latter. ,negative,Terfenadine,astemizole
Concomitant administrations not recommended:  - DRUG1 and astemizole: Certain DRUG2 interact with DRUG1 and astemizole leading to increased serum concentrations of the latter. ,negative,Terfenadine,macrolides
Concomitant administrations not recommended:  - DRUG1 and astemizole: Certain macrolides interact with DRUG1 and astemizole leading to increased serum concentrations of the latter. ,negative,Terfenadine,terfenadine
Concomitant administrations not recommended:  - DRUG1 and DRUG2: Certain macrolides interact with DRUG1 and DRUG2 leading to increased serum concentrations of the latter. ,negative,Terfenadine,astemizole
Concomitant administrations not recommended:  - Terfenadine and DRUG1: Certain DRUG2 interact with terfenadine and DRUG1 leading to increased serum concentrations of the latter. ,negative,astemizole,macrolides
Concomitant administrations not recommended:  - DRUG2 and DRUG1: Certain macrolides interact with DRUG2 and DRUG1 leading to increased serum concentrations of the latter. ,negative,astemizole,terfenadine
Concomitant administrations not recommended:  - Terfenadine and DRUG1: Certain macrolides interact with terfenadine and DRUG1 leading to increased serum concentrations of the latter. ,negative,astemizole,astemizole
Concomitant administrations not recommended:  - DRUG2 and astemizole: Certain DRUG1 interact with DRUG2 and astemizole leading to increased serum concentrations of the latter. ,int,macrolides,terfenadine
Concomitant administrations not recommended:  - Terfenadine and DRUG2: Certain DRUG1 interact with terfenadine and DRUG2 leading to increased serum concentrations of the latter. ,int,macrolides,astemizole
Concomitant administrations not recommended:  - DRUG1 and DRUG2: Certain macrolides interact with DRUG1 and DRUG2 leading to increased serum concentrations of the latter. ,negative,terfenadine,astemizole
"Although such a reaction has not been demonstrated with DRUG1, concomitant administration of DRUG1 with terfenadine or astemizole is not recommended. ",negative,roxithromycin,roxithromycin
"Although such a reaction has not been demonstrated with DRUG1, concomitant administration of DRUG1 with DRUG2 or astemizole is not recommended. ",negative,roxithromycin,terfenadine
"Although such a reaction has not been demonstrated with DRUG1, concomitant administration of DRUG1 with terfenadine or DRUG2 is not recommended. ",negative,roxithromycin,astemizole
"Although such a reaction has not been demonstrated with DRUG1, concomitant administration of DRUG1 with DRUG2 or astemizole is not recommended. ",advise,roxithromycin,terfenadine
"Although such a reaction has not been demonstrated with DRUG1, concomitant administration of DRUG1 with terfenadine or DRUG2 is not recommended. ",advise,roxithromycin,astemizole
"Although such a reaction has not been demonstrated with roxithromycin, concomitant administration of roxithromycin with DRUG1 or DRUG2 is not recommended. ",negative,terfenadine,astemizole
"- DRUG1, DRUG2: Other drugs such as DRUG1 or DRUG2, which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme, including some macrolide antibacterials. ",negative,Cisapride,pimozide
"- DRUG1, pimozide: Other drugs such as DRUG1 or pimozide, which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme, including some macrolide antibacterials. ",negative,Cisapride,cisapride
"- DRUG1, DRUG2: Other drugs such as DRUG1 or DRUG2, which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme, including some macrolide antibacterials. ",negative,Cisapride,pimozide
"- DRUG1, pimozide: Other drugs such as DRUG1 or pimozide, which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme, including some DRUG2. ",negative,Cisapride,macrolide antibacterials
"- DRUG2, DRUG1: Other drugs such as DRUG2 or DRUG1, which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme, including some macrolide antibacterials. ",negative,pimozide,cisapride
"- Cisapride, DRUG1: Other drugs such as cisapride or DRUG1, which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme, including some macrolide antibacterials. ",negative,pimozide,pimozide
"- Cisapride, DRUG1: Other drugs such as cisapride or DRUG1, which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme, including some DRUG2. ",mechanism,pimozide,macrolide antibacterials
"- DRUG1, DRUG2: Other drugs such as DRUG1 or DRUG2, which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme, including some macrolide antibacterials. ",negative,cisapride,pimozide
"- DRUG1, pimozide: Other drugs such as DRUG1 or pimozide, which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme, including some DRUG2. ",mechanism,cisapride,macrolide antibacterials
"- Cisapride, DRUG1: Other drugs such as cisapride or DRUG1, which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme, including some DRUG2. ",negative,pimozide,macrolide antibacterials
"Although such a risk is not verified for DRUG1, combination of DRUG1 with such drugs is not recommended.",negative,roxithromycin,roxithromycin
Some DRUG1 may interact with DRUG2. ,int,anticonvulsants,Mephenytoin
"Those DRUG1 include DRUG2, valproic acid, and phenobarbital. ",negative,anticonvulsants,divalproex sodium
"Those DRUG1 include divalproex sodium, DRUG2, and phenobarbital. ",negative,anticonvulsants,valproic acid
"Those DRUG1 include divalproex sodium, valproic acid, and DRUG2. ",negative,anticonvulsants,phenobarbital
"Those anticonvulsants include DRUG1, DRUG2, and phenobarbital. ",negative,divalproex sodium,valproic acid
"Those anticonvulsants include DRUG1, valproic acid, and DRUG2. ",negative,divalproex sodium,phenobarbital
"Those anticonvulsants include divalproex sodium, DRUG1, and DRUG2. ",negative,valproic acid,phenobarbital
"DRUG1 may also affect the effects of other drugs, which include some DRUG2, warfarin, certain heart medicines, birth control pills, anti-infective medicines, furosemide and theophylline Please note that DRUG1 may interact with other drugs that are not listed here.",effect,Mephenytoin,steroid medications
"DRUG1 may also affect the effects of other drugs, which include some steroid medications, DRUG2, certain heart medicines, birth control pills, anti-infective medicines, furosemide and theophylline Please note that DRUG1 may interact with other drugs that are not listed here.",effect,Mephenytoin,warfarin
"DRUG1 may also affect the effects of other drugs, which include some steroid medications, warfarin, certain heart medicines, birth control pills, DRUG2, furosemide and theophylline Please note that DRUG1 may interact with other drugs that are not listed here.",effect,Mephenytoin,anti-infective medicines
"DRUG1 may also affect the effects of other drugs, which include some steroid medications, warfarin, certain heart medicines, birth control pills, anti-infective medicines, DRUG2 and theophylline Please note that DRUG1 may interact with other drugs that are not listed here.",effect,Mephenytoin,furosemide
"DRUG1 may also affect the effects of other drugs, which include some steroid medications, warfarin, certain heart medicines, birth control pills, anti-infective medicines, furosemide and DRUG2 Please note that DRUG1 may interact with other drugs that are not listed here.",effect,Mephenytoin,theophylline
"DRUG1 may also affect the effects of other drugs, which include some steroid medications, warfarin, certain heart medicines, birth control pills, anti-infective medicines, furosemide and theophylline Please note that DRUG1 may interact with other drugs that are not listed here.",negative,Mephenytoin,Mephenytoin
"Mephenytoin may also affect the effects of other drugs, which include some DRUG1, DRUG2, certain heart medicines, birth control pills, anti-infective medicines, furosemide and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here.",negative,steroid medications,warfarin
"Mephenytoin may also affect the effects of other drugs, which include some DRUG1, warfarin, certain heart medicines, birth control pills, DRUG2, furosemide and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here.",negative,steroid medications,anti-infective medicines
"Mephenytoin may also affect the effects of other drugs, which include some DRUG1, warfarin, certain heart medicines, birth control pills, anti-infective medicines, DRUG2 and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here.",negative,steroid medications,furosemide
"Mephenytoin may also affect the effects of other drugs, which include some DRUG1, warfarin, certain heart medicines, birth control pills, anti-infective medicines, furosemide and DRUG2 Please note that Mephenytoin may interact with other drugs that are not listed here.",negative,steroid medications,theophylline
"DRUG2 may also affect the effects of other drugs, which include some DRUG1, warfarin, certain heart medicines, birth control pills, anti-infective medicines, furosemide and theophylline Please note that DRUG2 may interact with other drugs that are not listed here.",negative,steroid medications,Mephenytoin
"Mephenytoin may also affect the effects of other drugs, which include some steroid medications, DRUG1, certain heart medicines, birth control pills, DRUG2, furosemide and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here.",negative,warfarin,anti-infective medicines
"Mephenytoin may also affect the effects of other drugs, which include some steroid medications, DRUG1, certain heart medicines, birth control pills, anti-infective medicines, DRUG2 and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here.",negative,warfarin,furosemide
"Mephenytoin may also affect the effects of other drugs, which include some steroid medications, DRUG1, certain heart medicines, birth control pills, anti-infective medicines, furosemide and DRUG2 Please note that Mephenytoin may interact with other drugs that are not listed here.",negative,warfarin,theophylline
"DRUG2 may also affect the effects of other drugs, which include some steroid medications, DRUG1, certain heart medicines, birth control pills, anti-infective medicines, furosemide and theophylline Please note that DRUG2 may interact with other drugs that are not listed here.",negative,warfarin,Mephenytoin
"Mephenytoin may also affect the effects of other drugs, which include some steroid medications, warfarin, certain heart medicines, birth control pills, DRUG1, DRUG2 and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here.",negative,anti-infective medicines,furosemide
"Mephenytoin may also affect the effects of other drugs, which include some steroid medications, warfarin, certain heart medicines, birth control pills, DRUG1, furosemide and DRUG2 Please note that Mephenytoin may interact with other drugs that are not listed here.",negative,anti-infective medicines,theophylline
"DRUG2 may also affect the effects of other drugs, which include some steroid medications, warfarin, certain heart medicines, birth control pills, DRUG1, furosemide and theophylline Please note that DRUG2 may interact with other drugs that are not listed here.",negative,anti-infective medicines,Mephenytoin
"Mephenytoin may also affect the effects of other drugs, which include some steroid medications, warfarin, certain heart medicines, birth control pills, anti-infective medicines, DRUG1 and DRUG2 Please note that Mephenytoin may interact with other drugs that are not listed here.",negative,furosemide,theophylline
"DRUG2 may also affect the effects of other drugs, which include some steroid medications, warfarin, certain heart medicines, birth control pills, anti-infective medicines, DRUG1 and theophylline Please note that DRUG2 may interact with other drugs that are not listed here.",negative,furosemide,Mephenytoin
"DRUG2 may also affect the effects of other drugs, which include some steroid medications, warfarin, certain heart medicines, birth control pills, anti-infective medicines, furosemide and DRUG1 Please note that DRUG2 may interact with other drugs that are not listed here.",negative,theophylline,Mephenytoin
"The interaction of DRUG1, DRUG2, with other drugs has not been well studied. ",negative,Streptase,Streptokinase
"Use of DRUG1 and DRUG2 -- Streptase, Streptokinase, alone or in combination with DRUG2 and DRUG1, may cause bleeding complications. ",negative,Anticoagulants,Antiplatelet Agents
"Use of DRUG1 and Antiplatelet Agents -- DRUG2, Streptokinase, alone or in combination with antiplatelet agents and DRUG1, may cause bleeding complications. ",negative,Anticoagulants,Streptase
"Use of DRUG1 and Antiplatelet Agents -- Streptase, DRUG2, alone or in combination with antiplatelet agents and DRUG1, may cause bleeding complications. ",negative,Anticoagulants,Streptokinase
"Use of DRUG1 and DRUG2 -- Streptase, Streptokinase, alone or in combination with DRUG2 and DRUG1, may cause bleeding complications. ",negative,Anticoagulants,antiplatelet agents
"Use of DRUG1 and Antiplatelet Agents -- Streptase, Streptokinase, alone or in combination with antiplatelet agents and DRUG1, may cause bleeding complications. ",negative,Anticoagulants,anticoagulants
"Use of Anticoagulants and DRUG1 -- DRUG2, Streptokinase, alone or in combination with DRUG1 and anticoagulants, may cause bleeding complications. ",negative,Antiplatelet Agents,Streptase
"Use of Anticoagulants and DRUG1 -- Streptase, DRUG2, alone or in combination with DRUG1 and anticoagulants, may cause bleeding complications. ",negative,Antiplatelet Agents,Streptokinase
"Use of Anticoagulants and DRUG1 -- Streptase, Streptokinase, alone or in combination with DRUG1 and anticoagulants, may cause bleeding complications. ",negative,Antiplatelet Agents,antiplatelet agents
"Use of DRUG2 and DRUG1 -- Streptase, Streptokinase, alone or in combination with DRUG1 and DRUG2, may cause bleeding complications. ",negative,Antiplatelet Agents,anticoagulants
"Use of Anticoagulants and Antiplatelet Agents -- DRUG1, DRUG2, alone or in combination with antiplatelet agents and anticoagulants, may cause bleeding complications. ",negative,Streptase,Streptokinase
"Use of Anticoagulants and DRUG2 -- DRUG1, Streptokinase, alone or in combination with DRUG2 and anticoagulants, may cause bleeding complications. ",effect,Streptase,antiplatelet agents
"Use of DRUG2 and Antiplatelet Agents -- DRUG1, Streptokinase, alone or in combination with antiplatelet agents and DRUG2, may cause bleeding complications. ",effect,Streptase,anticoagulants
"Use of Anticoagulants and DRUG2 -- Streptase, DRUG1, alone or in combination with DRUG2 and anticoagulants, may cause bleeding complications. ",effect,Streptokinase,antiplatelet agents
"Use of DRUG2 and Antiplatelet Agents -- Streptase, DRUG1, alone or in combination with antiplatelet agents and DRUG2, may cause bleeding complications. ",effect,Streptokinase,anticoagulants
"Use of DRUG2 and DRUG1 -- Streptase, Streptokinase, alone or in combination with DRUG1 and DRUG2, may cause bleeding complications. ",negative,antiplatelet agents,anticoagulants
"In the treatment of acute MI, DRUG1, when not otherwise contraindicated, should be administered with DRUG2 ( see below ). ",negative,aspirin,Streptokinase
"Anticoagulation and DRUG1 After Treatment for Myocardial Infarction -- In the treatment of acute myocardial infarction, the use of DRUG2 has been shown to reduce the incidence of reinfarction and stroke. ",negative,Antiplatelets,aspirin
"The addition of DRUG1 to DRUG2 causes a minimal increase in the risk of minor bleeding (3.9% vs. 3.1%), but does not appear to increase the incidence of major bleeding (see",effect,aspirin,Streptokinase
DRUG1 and DRUG2 increase the effects of pseudoephedrine. ,negative,MAO inhibitors,beta adrenergic blockers
DRUG1 and beta adrenergic blockers increase the effects of DRUG2. ,effect,MAO inhibitors,pseudoephedrine
MAO inhibitors and DRUG1 increase the effects of DRUG2. ,effect,beta adrenergic blockers,pseudoephedrine
"DRUG1 may reduce the antihypertensive effects of DRUG2, mecamylamine, reserpine and veratrum alkaloids.",effect,Sympathomimetics,methyldopa
"DRUG1 may reduce the antihypertensive effects of methyldopa, DRUG2, reserpine and veratrum alkaloids.",effect,Sympathomimetics,mecamylamine
"DRUG1 may reduce the antihypertensive effects of methyldopa, mecamylamine, DRUG2 and veratrum alkaloids.",effect,Sympathomimetics,reserpine
"DRUG1 may reduce the antihypertensive effects of methyldopa, mecamylamine, reserpine and DRUG2.",effect,Sympathomimetics,veratrum alkaloids
"Sympathomimetics may reduce the antihypertensive effects of DRUG1, DRUG2, reserpine and veratrum alkaloids.",negative,methyldopa,mecamylamine
"Sympathomimetics may reduce the antihypertensive effects of DRUG1, mecamylamine, DRUG2 and veratrum alkaloids.",negative,methyldopa,reserpine
"Sympathomimetics may reduce the antihypertensive effects of DRUG1, mecamylamine, reserpine and DRUG2.",negative,methyldopa,veratrum alkaloids
"Sympathomimetics may reduce the antihypertensive effects of methyldopa, DRUG1, DRUG2 and veratrum alkaloids.",negative,mecamylamine,reserpine
"Sympathomimetics may reduce the antihypertensive effects of methyldopa, DRUG1, reserpine and DRUG2.",negative,mecamylamine,veratrum alkaloids
"Sympathomimetics may reduce the antihypertensive effects of methyldopa, mecamylamine, DRUG1 and DRUG2.",negative,reserpine,veratrum alkaloids
"Because DRUG1 have been shown to depress plasma prothrombin activity, patients who are on DRUG2 therapy may require downward adjustment of their DRUG2 dosage. ",advise,tetracyclines,anticoagulant
"Because DRUG1 have been shown to depress plasma prothrombin activity, patients who are on DRUG2 therapy may require downward adjustment of their DRUG2 dosage. ",negative,tetracyclines,anticoagulant
"Because tetracyclines have been shown to depress plasma prothrombin activity, patients who are on DRUG1 therapy may require downward adjustment of their DRUG1 dosage. ",negative,anticoagulant,anticoagulant
"Since bacteriostatic drugs may interfere with the bactericidal action of DRUG1, it is advisable to avoid giving DRUG2 in conjunction with DRUG1. ",negative,penicillin,tetracycline class drugs
"Since bacteriostatic drugs may interfere with the bactericidal action of DRUG1, it is advisable to avoid giving tetracycline class drugs in conjunction with DRUG1. ",negative,penicillin,penicillin
"Since bacteriostatic drugs may interfere with the bactericidal action of DRUG2, it is advisable to avoid giving DRUG1 in conjunction with DRUG2. ",advise,tetracycline class drugs,penicillin
"Absorption of DRUG1 is impaired by DRUG2 containing aluminum, calcium or magnesium, and iron-containing preparations. ",negative,tetracyclines,antacids
"Absorption of DRUG1 is impaired by antacids containing DRUG2, calcium or magnesium, and iron-containing preparations. ",mechanism,tetracyclines,aluminum
"Absorption of DRUG1 is impaired by antacids containing aluminum, DRUG2 or magnesium, and iron-containing preparations. ",mechanism,tetracyclines,calcium
"Absorption of DRUG1 is impaired by antacids containing aluminum, calcium or DRUG2, and iron-containing preparations. ",mechanism,tetracyclines,magnesium
"Absorption of DRUG1 is impaired by antacids containing aluminum, calcium or magnesium, and DRUG2-containing preparations. ",mechanism,tetracyclines,iron
"Absorption of tetracyclines is impaired by DRUG1 containing DRUG2, calcium or magnesium, and iron-containing preparations. ",negative,antacids,aluminum
"Absorption of tetracyclines is impaired by DRUG1 containing aluminum, DRUG2 or magnesium, and iron-containing preparations. ",negative,antacids,calcium
"Absorption of tetracyclines is impaired by DRUG1 containing aluminum, calcium or DRUG2, and iron-containing preparations. ",negative,antacids,magnesium
"Absorption of tetracyclines is impaired by DRUG1 containing aluminum, calcium or magnesium, and DRUG2-containing preparations. ",negative,antacids,iron
"Absorption of tetracyclines is impaired by antacids containing DRUG1, DRUG2 or magnesium, and iron-containing preparations. ",negative,aluminum,calcium
"Absorption of tetracyclines is impaired by antacids containing DRUG1, calcium or DRUG2, and iron-containing preparations. ",negative,aluminum,magnesium
"Absorption of tetracyclines is impaired by antacids containing DRUG1, calcium or magnesium, and DRUG2-containing preparations. ",negative,aluminum,iron
"Absorption of tetracyclines is impaired by antacids containing aluminum, DRUG1 or DRUG2, and iron-containing preparations. ",negative,calcium,magnesium
"Absorption of tetracyclines is impaired by antacids containing aluminum, DRUG1 or magnesium, and DRUG2-containing preparations. ",negative,calcium,iron
"Absorption of tetracyclines is impaired by antacids containing aluminum, calcium or DRUG1, and DRUG2-containing preparations. ",negative,magnesium,iron
The concurrent use of DRUG1 and DRUG2 has been reported to result in fatal renal toxicity. ,effect,tetracycline,methoxyflurane
Concurrent use of DRUG1 with oral DRUG2 may render oral DRUG2 less effective.,effect,tetracyclines,contraceptives
Concurrent use of DRUG1 with oral DRUG2 may render oral DRUG2 less effective.,negative,tetracyclines,contraceptives
Concurrent use of tetracyclines with oral DRUG1 may render oral DRUG1 less effective.,negative,contraceptives,contraceptives
"The concomitant use of DRUG1 with other DRUG2 that produce dry mouth, constipation, and other anticholinergic pharmacological effects may increase the frequency and/or severity of such effects. ",effect,Sanctura,anticholinergic agents
"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with DRUG1 have not been conducted, DRUG1 has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). ",negative,Sanctura,Sanctura
"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with DRUG1 have not been conducted, DRUG1 has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. DRUG2, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). ",negative,Sanctura,digoxin
"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with DRUG1 have not been conducted, DRUG1 has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, DRUG2, pancuronium, morphine, vancomycin, metformin and tenofovir). ",negative,Sanctura,procainamide
"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with DRUG1 have not been conducted, DRUG1 has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, DRUG2, morphine, vancomycin, metformin and tenofovir). ",negative,Sanctura,pancuronium
"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with DRUG1 have not been conducted, DRUG1 has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, DRUG2, vancomycin, metformin and tenofovir). ",negative,Sanctura,morphine
"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with DRUG1 have not been conducted, DRUG1 has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, DRUG2, metformin and tenofovir). ",negative,Sanctura,vancomycin
"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with DRUG1 have not been conducted, DRUG1 has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, DRUG2 and tenofovir). ",negative,Sanctura,metformin
"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with DRUG1 have not been conducted, DRUG1 has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and DRUG2). ",negative,Sanctura,tenofovir
"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with DRUG1 have not been conducted, DRUG1 has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. DRUG2, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). ",mechanism,Sanctura,digoxin
"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with DRUG1 have not been conducted, DRUG1 has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, DRUG2, pancuronium, morphine, vancomycin, metformin and tenofovir). ",mechanism,Sanctura,procainamide
"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with DRUG1 have not been conducted, DRUG1 has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, DRUG2, morphine, vancomycin, metformin and tenofovir). ",mechanism,Sanctura,pancuronium
"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with DRUG1 have not been conducted, DRUG1 has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, DRUG2, vancomycin, metformin and tenofovir). ",mechanism,Sanctura,morphine
"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with DRUG1 have not been conducted, DRUG1 has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, DRUG2, metformin and tenofovir). ",mechanism,Sanctura,vancomycin
"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with DRUG1 have not been conducted, DRUG1 has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, DRUG2 and tenofovir). ",mechanism,Sanctura,metformin
"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with DRUG1 have not been conducted, DRUG1 has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and DRUG2). ",mechanism,Sanctura,tenofovir
"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. DRUG1, DRUG2, pancuronium, morphine, vancomycin, metformin and tenofovir). ",negative,digoxin,procainamide
"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. DRUG1, procainamide, DRUG2, morphine, vancomycin, metformin and tenofovir). ",negative,digoxin,pancuronium
"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. DRUG1, procainamide, pancuronium, DRUG2, vancomycin, metformin and tenofovir). ",negative,digoxin,morphine
"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. DRUG1, procainamide, pancuronium, morphine, DRUG2, metformin and tenofovir). ",negative,digoxin,vancomycin
"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. DRUG1, procainamide, pancuronium, morphine, vancomycin, DRUG2 and tenofovir). ",negative,digoxin,metformin
"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. DRUG1, procainamide, pancuronium, morphine, vancomycin, metformin and DRUG2). ",negative,digoxin,tenofovir
"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, DRUG1, DRUG2, morphine, vancomycin, metformin and tenofovir). ",negative,procainamide,pancuronium
"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, DRUG1, pancuronium, DRUG2, vancomycin, metformin and tenofovir). ",negative,procainamide,morphine
"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, DRUG1, pancuronium, morphine, DRUG2, metformin and tenofovir). ",negative,procainamide,vancomycin
"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, DRUG1, pancuronium, morphine, vancomycin, DRUG2 and tenofovir). ",negative,procainamide,metformin
"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, DRUG1, pancuronium, morphine, vancomycin, metformin and DRUG2). ",negative,procainamide,tenofovir
"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, DRUG1, DRUG2, vancomycin, metformin and tenofovir). ",negative,pancuronium,morphine
"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, DRUG1, morphine, DRUG2, metformin and tenofovir). ",negative,pancuronium,vancomycin
"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, DRUG1, morphine, vancomycin, DRUG2 and tenofovir). ",negative,pancuronium,metformin
"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, DRUG1, morphine, vancomycin, metformin and DRUG2). ",negative,pancuronium,tenofovir
"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, DRUG1, DRUG2, metformin and tenofovir). ",negative,morphine,vancomycin
"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, DRUG1, vancomycin, DRUG2 and tenofovir). ",negative,morphine,metformin
"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, DRUG1, vancomycin, metformin and DRUG2). ",negative,morphine,tenofovir
"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, DRUG1, DRUG2 and tenofovir). ",negative,vancomycin,metformin
"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, DRUG1, metformin and DRUG2). ",negative,vancomycin,tenofovir
"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, DRUG1 and DRUG2). ",negative,metformin,tenofovir
Coadministration of DRUG1 with drugs that are eliminated by active renal tubular secretion may increase the serum concentration of DRUG1 and/or the coadministered drug due to competition for this elimination pathway. ,negative,Sanctura,Sanctura
DRUG INTERACTIONS  There are no known drug/drug interactions with oral DRUG1  Vaccinations with DRUG2 are not recommended in immunocompromised individuals  Nalidixic acid together with high-dose intravenous melphalan has caused deaths in children due to haemorrhagic enterocolitis.  ,negative,ALKERAN,live organism vaccines
DRUG INTERACTIONS  There are no known drug/drug interactions with oral DRUG1  Vaccinations with live organism vaccines are not recommended in immunocompromised individuals  DRUG2 together with high-dose intravenous melphalan has caused deaths in children due to haemorrhagic enterocolitis.  ,negative,ALKERAN,Nalidixic acid
DRUG INTERACTIONS  There are no known drug/drug interactions with oral DRUG1  Vaccinations with live organism vaccines are not recommended in immunocompromised individuals  Nalidixic acid together with high-dose intravenous DRUG2 has caused deaths in children due to haemorrhagic enterocolitis.  ,negative,ALKERAN,melphalan
DRUG INTERACTIONS  There are no known drug/drug interactions with oral ALKERAN  Vaccinations with DRUG1 are not recommended in immunocompromised individuals  DRUG2 together with high-dose intravenous melphalan has caused deaths in children due to haemorrhagic enterocolitis.  ,negative,live organism vaccines,Nalidixic acid
DRUG INTERACTIONS  There are no known drug/drug interactions with oral ALKERAN  Vaccinations with DRUG1 are not recommended in immunocompromised individuals  Nalidixic acid together with high-dose intravenous DRUG2 has caused deaths in children due to haemorrhagic enterocolitis.  ,negative,live organism vaccines,melphalan
DRUG INTERACTIONS  There are no known drug/drug interactions with oral ALKERAN  Vaccinations with live organism vaccines are not recommended in immunocompromised individuals  DRUG1 together with high-dose intravenous DRUG2 has caused deaths in children due to haemorrhagic enterocolitis.  ,effect,Nalidixic acid,melphalan
Impaired renal function has been described in bone marrow transplant patients who were conditioned with high-dose intravenous DRUG1 and who subsequently received DRUG2 to prevent graft-versus-host disease,effect,melphalan,cyclosporin
"Drug Interactions: Inhibitors of CYP3A4 Isozymes: Caution is advised when DRUG1 is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some drugs in the drug classes of DRUG2, protease inhibitors, calcium channel antagonists, and macrolide antibiotics). ",advise,midazolam,azole antimycotics
"Drug Interactions: Inhibitors of CYP3A4 Isozymes: Caution is advised when DRUG1 is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some drugs in the drug classes of azole antimycotics, DRUG2, calcium channel antagonists, and macrolide antibiotics). ",advise,midazolam,protease inhibitors
"Drug Interactions: Inhibitors of CYP3A4 Isozymes: Caution is advised when DRUG1 is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some drugs in the drug classes of azole antimycotics, protease inhibitors, DRUG2, and macrolide antibiotics). ",advise,midazolam,calcium channel antagonists
"Drug Interactions: Inhibitors of CYP3A4 Isozymes: Caution is advised when DRUG1 is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some drugs in the drug classes of azole antimycotics, protease inhibitors, calcium channel antagonists, and DRUG2). ",advise,midazolam,macrolide antibiotics
"Drug Interactions: Inhibitors of CYP3A4 Isozymes: Caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some drugs in the drug classes of DRUG1, DRUG2, calcium channel antagonists, and macrolide antibiotics). ",negative,azole antimycotics,protease inhibitors
"Drug Interactions: Inhibitors of CYP3A4 Isozymes: Caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some drugs in the drug classes of DRUG1, protease inhibitors, DRUG2, and macrolide antibiotics). ",negative,azole antimycotics,calcium channel antagonists
"Drug Interactions: Inhibitors of CYP3A4 Isozymes: Caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some drugs in the drug classes of DRUG1, protease inhibitors, calcium channel antagonists, and DRUG2). ",negative,azole antimycotics,macrolide antibiotics
"Drug Interactions: Inhibitors of CYP3A4 Isozymes: Caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some drugs in the drug classes of azole antimycotics, DRUG1, DRUG2, and macrolide antibiotics). ",negative,protease inhibitors,calcium channel antagonists
"Drug Interactions: Inhibitors of CYP3A4 Isozymes: Caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some drugs in the drug classes of azole antimycotics, DRUG1, calcium channel antagonists, and DRUG2). ",negative,protease inhibitors,macrolide antibiotics
"Drug Interactions: Inhibitors of CYP3A4 Isozymes: Caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some drugs in the drug classes of azole antimycotics, protease inhibitors, DRUG1, and DRUG2). ",negative,calcium channel antagonists,macrolide antibiotics
"Drugs such as DRUG1, DRUG2, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. ",negative,erythromycin,diltiazem
"Drugs such as DRUG1, diltiazem, DRUG2, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. ",negative,erythromycin,verapamil
"Drugs such as DRUG1, diltiazem, verapamil, DRUG2, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. ",negative,erythromycin,ketoconazole
"Drugs such as DRUG1, diltiazem, verapamil, ketoconazole, DRUG2 and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. ",negative,erythromycin,fluconazole
"Drugs such as DRUG1, diltiazem, verapamil, ketoconazole, fluconazole and DRUG2 were shown to significantly increase the C max and AUC of orally administered midazolam. ",negative,erythromycin,itraconazole
"Drugs such as DRUG1, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered DRUG2. ",mechanism,erythromycin,midazolam
"Drugs such as erythromycin, DRUG1, DRUG2, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. ",negative,diltiazem,verapamil
"Drugs such as erythromycin, DRUG1, verapamil, DRUG2, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. ",negative,diltiazem,ketoconazole
"Drugs such as erythromycin, DRUG1, verapamil, ketoconazole, DRUG2 and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. ",negative,diltiazem,fluconazole
"Drugs such as erythromycin, DRUG1, verapamil, ketoconazole, fluconazole and DRUG2 were shown to significantly increase the C max and AUC of orally administered midazolam. ",negative,diltiazem,itraconazole
"Drugs such as erythromycin, DRUG1, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered DRUG2. ",mechanism,diltiazem,midazolam
"Drugs such as erythromycin, diltiazem, DRUG1, DRUG2, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. ",negative,verapamil,ketoconazole
"Drugs such as erythromycin, diltiazem, DRUG1, ketoconazole, DRUG2 and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. ",negative,verapamil,fluconazole
"Drugs such as erythromycin, diltiazem, DRUG1, ketoconazole, fluconazole and DRUG2 were shown to significantly increase the C max and AUC of orally administered midazolam. ",negative,verapamil,itraconazole
"Drugs such as erythromycin, diltiazem, DRUG1, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered DRUG2. ",mechanism,verapamil,midazolam
"Drugs such as erythromycin, diltiazem, verapamil, DRUG1, DRUG2 and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. ",negative,ketoconazole,fluconazole
"Drugs such as erythromycin, diltiazem, verapamil, DRUG1, fluconazole and DRUG2 were shown to significantly increase the C max and AUC of orally administered midazolam. ",negative,ketoconazole,itraconazole
"Drugs such as erythromycin, diltiazem, verapamil, DRUG1, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered DRUG2. ",mechanism,ketoconazole,midazolam
"Drugs such as erythromycin, diltiazem, verapamil, ketoconazole, DRUG1 and DRUG2 were shown to significantly increase the C max and AUC of orally administered midazolam. ",negative,fluconazole,itraconazole
"Drugs such as erythromycin, diltiazem, verapamil, ketoconazole, DRUG1 and itraconazole were shown to significantly increase the C max and AUC of orally administered DRUG2. ",mechanism,fluconazole,midazolam
"Drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and DRUG1 were shown to significantly increase the C max and AUC of orally administered DRUG2. ",mechanism,itraconazole,midazolam
"Although not studied, the potent cytochrome P450 3A4 inhibitors DRUG1 and DRUG2 may cause intense and prolonged sedation and respiratory depression due to a decrease in plasma clearance of midazolam. ",negative,ritonavir,nelfinavir
"Although not studied, the potent cytochrome P450 3A4 inhibitors DRUG1 and nelfinavir may cause intense and prolonged sedation and respiratory depression due to a decrease in plasma clearance of DRUG2. ",mechanism,ritonavir,midazolam
"Although not studied, the potent cytochrome P450 3A4 inhibitors ritonavir and DRUG1 may cause intense and prolonged sedation and respiratory depression due to a decrease in plasma clearance of DRUG2. ",mechanism,nelfinavir,midazolam
"Inducers of CYP3A4 Isozymes: Cytochrome P450 inducers, such as DRUG1, DRUG2, and phenytoin, induce metabolism and caused a markedly decreased C max and AUC of oral midazolam in adult studies. ",negative,rifampin,carbamazepine
"Inducers of CYP3A4 Isozymes: Cytochrome P450 inducers, such as DRUG1, carbamazepine, and DRUG2, induce metabolism and caused a markedly decreased C max and AUC of oral midazolam in adult studies. ",negative,rifampin,phenytoin
"Inducers of CYP3A4 Isozymes: Cytochrome P450 inducers, such as DRUG1, carbamazepine, and phenytoin, induce metabolism and caused a markedly decreased C max and AUC of oral DRUG2 in adult studies. ",mechanism,rifampin,midazolam
"Inducers of CYP3A4 Isozymes: Cytochrome P450 inducers, such as rifampin, DRUG1, and DRUG2, induce metabolism and caused a markedly decreased C max and AUC of oral midazolam in adult studies. ",negative,carbamazepine,phenytoin
"Inducers of CYP3A4 Isozymes: Cytochrome P450 inducers, such as rifampin, DRUG1, and phenytoin, induce metabolism and caused a markedly decreased C max and AUC of oral DRUG2 in adult studies. ",mechanism,carbamazepine,midazolam
"Inducers of CYP3A4 Isozymes: Cytochrome P450 inducers, such as rifampin, carbamazepine, and DRUG1, induce metabolism and caused a markedly decreased C max and AUC of oral DRUG2 in adult studies. ",mechanism,phenytoin,midazolam
The difficulty in achieving adequate sedation may have been the result of decreased absorption of the DRUG1 due to both the gastrointestinal effects and stimulant effects of DRUG2. ,negative,sedatives,methylphenidate
"The sedative effect of DRUG1 is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly DRUG2 (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ",effect,VERSED Syrup,narcotics
"The sedative effect of DRUG1 is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, DRUG2, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ",effect,VERSED Syrup,morphine
"The sedative effect of DRUG1 is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, DRUG2 and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ",effect,VERSED Syrup,meperidine
"The sedative effect of DRUG1 is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and DRUG2), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ",effect,VERSED Syrup,fentanyl
"The sedative effect of DRUG1 is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), DRUG2, ketamine, nitrous oxide, secobarbital and droperidol. ",effect,VERSED Syrup,propofol
"The sedative effect of DRUG1 is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, DRUG2, nitrous oxide, secobarbital and droperidol. ",effect,VERSED Syrup,ketamine
"The sedative effect of DRUG1 is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, DRUG2, secobarbital and droperidol. ",effect,VERSED Syrup,nitrous oxide
"The sedative effect of DRUG1 is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, DRUG2 and droperidol. ",effect,VERSED Syrup,secobarbital
"The sedative effect of DRUG1 is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and DRUG2. ",effect,VERSED Syrup,droperidol
"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly DRUG1 (eg, DRUG2, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ",negative,narcotics,morphine
"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly DRUG1 (eg, morphine, DRUG2 and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ",negative,narcotics,meperidine
"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly DRUG1 (eg, morphine, meperidine and DRUG2), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ",negative,narcotics,fentanyl
"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly DRUG1 (eg, morphine, meperidine and fentanyl), DRUG2, ketamine, nitrous oxide, secobarbital and droperidol. ",negative,narcotics,propofol
"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly DRUG1 (eg, morphine, meperidine and fentanyl), propofol, DRUG2, nitrous oxide, secobarbital and droperidol. ",negative,narcotics,ketamine
"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly DRUG1 (eg, morphine, meperidine and fentanyl), propofol, ketamine, DRUG2, secobarbital and droperidol. ",negative,narcotics,nitrous oxide
"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly DRUG1 (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, DRUG2 and droperidol. ",negative,narcotics,secobarbital
"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly DRUG1 (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and DRUG2. ",negative,narcotics,droperidol
"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, DRUG1, DRUG2 and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ",negative,morphine,meperidine
"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, DRUG1, meperidine and DRUG2), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ",negative,morphine,fentanyl
"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, DRUG1, meperidine and fentanyl), DRUG2, ketamine, nitrous oxide, secobarbital and droperidol. ",negative,morphine,propofol
"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, DRUG1, meperidine and fentanyl), propofol, DRUG2, nitrous oxide, secobarbital and droperidol. ",negative,morphine,ketamine
"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, DRUG1, meperidine and fentanyl), propofol, ketamine, DRUG2, secobarbital and droperidol. ",negative,morphine,nitrous oxide
"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, DRUG1, meperidine and fentanyl), propofol, ketamine, nitrous oxide, DRUG2 and droperidol. ",negative,morphine,secobarbital
"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, DRUG1, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and DRUG2. ",negative,morphine,droperidol
"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, DRUG1 and DRUG2), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ",negative,meperidine,fentanyl
"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, DRUG1 and fentanyl), DRUG2, ketamine, nitrous oxide, secobarbital and droperidol. ",negative,meperidine,propofol
"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, DRUG1 and fentanyl), propofol, DRUG2, nitrous oxide, secobarbital and droperidol. ",negative,meperidine,ketamine
"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, DRUG1 and fentanyl), propofol, ketamine, DRUG2, secobarbital and droperidol. ",negative,meperidine,nitrous oxide
"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, DRUG1 and fentanyl), propofol, ketamine, nitrous oxide, DRUG2 and droperidol. ",negative,meperidine,secobarbital
"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, DRUG1 and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and DRUG2. ",negative,meperidine,droperidol
"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and DRUG1), DRUG2, ketamine, nitrous oxide, secobarbital and droperidol. ",negative,fentanyl,propofol
"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and DRUG1), propofol, DRUG2, nitrous oxide, secobarbital and droperidol. ",negative,fentanyl,ketamine
"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and DRUG1), propofol, ketamine, DRUG2, secobarbital and droperidol. ",negative,fentanyl,nitrous oxide
"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and DRUG1), propofol, ketamine, nitrous oxide, DRUG2 and droperidol. ",negative,fentanyl,secobarbital
"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and DRUG1), propofol, ketamine, nitrous oxide, secobarbital and DRUG2. ",negative,fentanyl,droperidol
"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), DRUG1, DRUG2, nitrous oxide, secobarbital and droperidol. ",negative,propofol,ketamine
"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), DRUG1, ketamine, DRUG2, secobarbital and droperidol. ",negative,propofol,nitrous oxide
"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), DRUG1, ketamine, nitrous oxide, DRUG2 and droperidol. ",negative,propofol,secobarbital
"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), DRUG1, ketamine, nitrous oxide, secobarbital and DRUG2. ",negative,propofol,droperidol
"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, DRUG1, DRUG2, secobarbital and droperidol. ",negative,ketamine,nitrous oxide
"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, DRUG1, nitrous oxide, DRUG2 and droperidol. ",negative,ketamine,secobarbital
"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, DRUG1, nitrous oxide, secobarbital and DRUG2. ",negative,ketamine,droperidol
"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, DRUG1, DRUG2 and droperidol. ",negative,nitrous oxide,secobarbital
"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, DRUG1, secobarbital and DRUG2. ",negative,nitrous oxide,droperidol
"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, DRUG1 and DRUG2. ",negative,secobarbital,droperidol
"No significant adverse interactions with common premedications (such as DRUG1, DRUG2, glycopyrrolate, diazepam, hydroxyzine, and other muscle relaxants) or local anesthetics have been observed.",negative,atropine,scopolamine
"No significant adverse interactions with common premedications (such as DRUG1, scopolamine, DRUG2, diazepam, hydroxyzine, and other muscle relaxants) or local anesthetics have been observed.",negative,atropine,glycopyrrolate
"No significant adverse interactions with common premedications (such as DRUG1, scopolamine, glycopyrrolate, DRUG2, hydroxyzine, and other muscle relaxants) or local anesthetics have been observed.",negative,atropine,diazepam
"No significant adverse interactions with common premedications (such as DRUG1, scopolamine, glycopyrrolate, diazepam, DRUG2, and other muscle relaxants) or local anesthetics have been observed.",negative,atropine,hydroxyzine
"No significant adverse interactions with common premedications (such as DRUG1, scopolamine, glycopyrrolate, diazepam, hydroxyzine, and other DRUG2) or local anesthetics have been observed.",negative,atropine,muscle relaxants
"No significant adverse interactions with common premedications (such as DRUG1, scopolamine, glycopyrrolate, diazepam, hydroxyzine, and other muscle relaxants) or local DRUG2 have been observed.",negative,atropine,anesthetics
"No significant adverse interactions with common premedications (such as atropine, DRUG1, DRUG2, diazepam, hydroxyzine, and other muscle relaxants) or local anesthetics have been observed.",negative,scopolamine,glycopyrrolate
"No significant adverse interactions with common premedications (such as atropine, DRUG1, glycopyrrolate, DRUG2, hydroxyzine, and other muscle relaxants) or local anesthetics have been observed.",negative,scopolamine,diazepam
"No significant adverse interactions with common premedications (such as atropine, DRUG1, glycopyrrolate, diazepam, DRUG2, and other muscle relaxants) or local anesthetics have been observed.",negative,scopolamine,hydroxyzine
"No significant adverse interactions with common premedications (such as atropine, DRUG1, glycopyrrolate, diazepam, hydroxyzine, and other DRUG2) or local anesthetics have been observed.",negative,scopolamine,muscle relaxants
"No significant adverse interactions with common premedications (such as atropine, DRUG1, glycopyrrolate, diazepam, hydroxyzine, and other muscle relaxants) or local DRUG2 have been observed.",negative,scopolamine,anesthetics
"No significant adverse interactions with common premedications (such as atropine, scopolamine, DRUG1, DRUG2, hydroxyzine, and other muscle relaxants) or local anesthetics have been observed.",negative,glycopyrrolate,diazepam
"No significant adverse interactions with common premedications (such as atropine, scopolamine, DRUG1, diazepam, DRUG2, and other muscle relaxants) or local anesthetics have been observed.",negative,glycopyrrolate,hydroxyzine
"No significant adverse interactions with common premedications (such as atropine, scopolamine, DRUG1, diazepam, hydroxyzine, and other DRUG2) or local anesthetics have been observed.",negative,glycopyrrolate,muscle relaxants
"No significant adverse interactions with common premedications (such as atropine, scopolamine, DRUG1, diazepam, hydroxyzine, and other muscle relaxants) or local DRUG2 have been observed.",negative,glycopyrrolate,anesthetics
"No significant adverse interactions with common premedications (such as atropine, scopolamine, glycopyrrolate, DRUG1, DRUG2, and other muscle relaxants) or local anesthetics have been observed.",negative,diazepam,hydroxyzine
"No significant adverse interactions with common premedications (such as atropine, scopolamine, glycopyrrolate, DRUG1, hydroxyzine, and other DRUG2) or local anesthetics have been observed.",negative,diazepam,muscle relaxants
"No significant adverse interactions with common premedications (such as atropine, scopolamine, glycopyrrolate, DRUG1, hydroxyzine, and other muscle relaxants) or local DRUG2 have been observed.",negative,diazepam,anesthetics
"No significant adverse interactions with common premedications (such as atropine, scopolamine, glycopyrrolate, diazepam, DRUG1, and other DRUG2) or local anesthetics have been observed.",negative,hydroxyzine,muscle relaxants
"No significant adverse interactions with common premedications (such as atropine, scopolamine, glycopyrrolate, diazepam, DRUG1, and other muscle relaxants) or local DRUG2 have been observed.",negative,hydroxyzine,anesthetics
"No significant adverse interactions with common premedications (such as atropine, scopolamine, glycopyrrolate, diazepam, hydroxyzine, and other DRUG1) or local DRUG2 have been observed.",negative,muscle relaxants,anesthetics
"Drugs which may potentiate the myeloproliferative effects of DRUG1, such as DRUG2 and corticosteroids, should be used with caution.",effect,Leukine,lithium
"Drugs which may potentiate the myeloproliferative effects of DRUG1, such as lithium and DRUG2, should be used with caution.",effect,Leukine,corticosteroids
"Drugs which may potentiate the myeloproliferative effects of Leukine, such as DRUG1 and DRUG2, should be used with caution.",negative,lithium,corticosteroids
"These are described in greater detail below:  Oral DRUG1, DRUG2, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral DRUG1: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",negative,hypoglycemics,Coumarin-type anticoagulants
"These are described in greater detail below:  Oral DRUG1, Coumarin-type anticoagulants, DRUG2, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral DRUG1: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",negative,hypoglycemics,Phenytoin
"These are described in greater detail below:  Oral DRUG1, Coumarin-type anticoagulants, Phenytoin, DRUG2, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral DRUG1: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",negative,hypoglycemics,Cyclosporine
"These are described in greater detail below:  Oral DRUG1, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, DRUG2, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral DRUG1: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",negative,hypoglycemics,Rifampin
"These are described in greater detail below:  Oral DRUG1, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, DRUG2, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral DRUG1: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",negative,hypoglycemics,Theophylline
"These are described in greater detail below:  Oral DRUG1, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, DRUG2, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral DRUG1: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",negative,hypoglycemics,Terfenadine
"These are described in greater detail below:  Oral DRUG1, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, DRUG2, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral DRUG1: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",negative,hypoglycemics,Cisapride
"These are described in greater detail below:  Oral DRUG1, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, DRUG2, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral DRUG1: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",negative,hypoglycemics,Astemizole
"These are described in greater detail below:  Oral DRUG1, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, DRUG2, Tacrolimus, Short-acting benzodiazepines,  Oral DRUG1: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",negative,hypoglycemics,Rifabutin
"These are described in greater detail below:  Oral DRUG1, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, DRUG2, Short-acting benzodiazepines,  Oral DRUG1: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",negative,hypoglycemics,Tacrolimus
"These are described in greater detail below:  Oral DRUG1, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, DRUG2,  Oral DRUG1: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",negative,hypoglycemics,Short-acting benzodiazepines
"These are described in greater detail below:  Oral DRUG1, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral DRUG1: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",negative,hypoglycemics,hypoglycemics
"These are described in greater detail below:  Oral DRUG1, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral DRUG1: Clinically significant hypoglycemia may be precipitated by the use of DRUG2 with oral hypoglycemic agents; ",negative,hypoglycemics,DIFLUCAN
"These are described in greater detail below:  Oral DRUG1, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral DRUG1: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral DRUG2; ",negative,hypoglycemics,hypoglycemic agents
"These are described in greater detail below:  Oral hypoglycemics, DRUG1, DRUG2, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",negative,Coumarin-type anticoagulants,Phenytoin
"These are described in greater detail below:  Oral hypoglycemics, DRUG1, Phenytoin, DRUG2, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",negative,Coumarin-type anticoagulants,Cyclosporine
"These are described in greater detail below:  Oral hypoglycemics, DRUG1, Phenytoin, Cyclosporine, DRUG2, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",negative,Coumarin-type anticoagulants,Rifampin
"These are described in greater detail below:  Oral hypoglycemics, DRUG1, Phenytoin, Cyclosporine, Rifampin, DRUG2, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",negative,Coumarin-type anticoagulants,Theophylline
"These are described in greater detail below:  Oral hypoglycemics, DRUG1, Phenytoin, Cyclosporine, Rifampin, Theophylline, DRUG2, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",negative,Coumarin-type anticoagulants,Terfenadine
"These are described in greater detail below:  Oral hypoglycemics, DRUG1, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, DRUG2, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",negative,Coumarin-type anticoagulants,Cisapride
"These are described in greater detail below:  Oral hypoglycemics, DRUG1, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, DRUG2, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",negative,Coumarin-type anticoagulants,Astemizole
"These are described in greater detail below:  Oral hypoglycemics, DRUG1, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, DRUG2, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",negative,Coumarin-type anticoagulants,Rifabutin
"These are described in greater detail below:  Oral hypoglycemics, DRUG1, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, DRUG2, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",negative,Coumarin-type anticoagulants,Tacrolimus
"These are described in greater detail below:  Oral hypoglycemics, DRUG1, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, DRUG2,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",negative,Coumarin-type anticoagulants,Short-acting benzodiazepines
"These are described in greater detail below:  Oral DRUG2, DRUG1, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral DRUG2: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",negative,Coumarin-type anticoagulants,hypoglycemics
"These are described in greater detail below:  Oral hypoglycemics, DRUG1, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DRUG2 with oral hypoglycemic agents; ",negative,Coumarin-type anticoagulants,DIFLUCAN
"These are described in greater detail below:  Oral hypoglycemics, DRUG1, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral DRUG2; ",negative,Coumarin-type anticoagulants,hypoglycemic agents
"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, DRUG1, DRUG2, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",negative,Phenytoin,Cyclosporine
"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, DRUG1, Cyclosporine, DRUG2, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",negative,Phenytoin,Rifampin
"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, DRUG1, Cyclosporine, Rifampin, DRUG2, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",negative,Phenytoin,Theophylline
"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, DRUG1, Cyclosporine, Rifampin, Theophylline, DRUG2, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",negative,Phenytoin,Terfenadine
"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, DRUG1, Cyclosporine, Rifampin, Theophylline, Terfenadine, DRUG2, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",negative,Phenytoin,Cisapride
"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, DRUG1, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, DRUG2, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",negative,Phenytoin,Astemizole
"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, DRUG1, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, DRUG2, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",negative,Phenytoin,Rifabutin
"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, DRUG1, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, DRUG2, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",negative,Phenytoin,Tacrolimus
"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, DRUG1, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, DRUG2,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",negative,Phenytoin,Short-acting benzodiazepines
"These are described in greater detail below:  Oral DRUG2, Coumarin-type anticoagulants, DRUG1, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral DRUG2: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",negative,Phenytoin,hypoglycemics
"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, DRUG1, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DRUG2 with oral hypoglycemic agents; ",negative,Phenytoin,DIFLUCAN
"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, DRUG1, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral DRUG2; ",negative,Phenytoin,hypoglycemic agents
"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, DRUG1, DRUG2, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",negative,Cyclosporine,Rifampin
"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, DRUG1, Rifampin, DRUG2, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",negative,Cyclosporine,Theophylline
"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, DRUG1, Rifampin, Theophylline, DRUG2, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",negative,Cyclosporine,Terfenadine
"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, DRUG1, Rifampin, Theophylline, Terfenadine, DRUG2, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",negative,Cyclosporine,Cisapride
"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, DRUG1, Rifampin, Theophylline, Terfenadine, Cisapride, DRUG2, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",negative,Cyclosporine,Astemizole
"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, DRUG1, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, DRUG2, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",negative,Cyclosporine,Rifabutin
"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, DRUG1, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, DRUG2, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",negative,Cyclosporine,Tacrolimus
"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, DRUG1, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, DRUG2,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",negative,Cyclosporine,Short-acting benzodiazepines
"These are described in greater detail below:  Oral DRUG2, Coumarin-type anticoagulants, Phenytoin, DRUG1, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral DRUG2: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",negative,Cyclosporine,hypoglycemics
"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, DRUG1, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DRUG2 with oral hypoglycemic agents; ",negative,Cyclosporine,DIFLUCAN
"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, DRUG1, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral DRUG2; ",negative,Cyclosporine,hypoglycemic agents
"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, DRUG1, DRUG2, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",negative,Rifampin,Theophylline
"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, DRUG1, Theophylline, DRUG2, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",negative,Rifampin,Terfenadine
"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, DRUG1, Theophylline, Terfenadine, DRUG2, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",negative,Rifampin,Cisapride
"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, DRUG1, Theophylline, Terfenadine, Cisapride, DRUG2, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",negative,Rifampin,Astemizole
"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, DRUG1, Theophylline, Terfenadine, Cisapride, Astemizole, DRUG2, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",negative,Rifampin,Rifabutin
"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, DRUG1, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, DRUG2, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",negative,Rifampin,Tacrolimus
"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, DRUG1, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, DRUG2,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",negative,Rifampin,Short-acting benzodiazepines
"These are described in greater detail below:  Oral DRUG2, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, DRUG1, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral DRUG2: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",negative,Rifampin,hypoglycemics
"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, DRUG1, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DRUG2 with oral hypoglycemic agents; ",negative,Rifampin,DIFLUCAN
"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, DRUG1, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral DRUG2; ",negative,Rifampin,hypoglycemic agents
"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, DRUG1, DRUG2, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",negative,Theophylline,Terfenadine
"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, DRUG1, Terfenadine, DRUG2, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",negative,Theophylline,Cisapride
"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, DRUG1, Terfenadine, Cisapride, DRUG2, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",negative,Theophylline,Astemizole
"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, DRUG1, Terfenadine, Cisapride, Astemizole, DRUG2, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",negative,Theophylline,Rifabutin
"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, DRUG1, Terfenadine, Cisapride, Astemizole, Rifabutin, DRUG2, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",negative,Theophylline,Tacrolimus
"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, DRUG1, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, DRUG2,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",negative,Theophylline,Short-acting benzodiazepines
"These are described in greater detail below:  Oral DRUG2, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, DRUG1, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral DRUG2: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",negative,Theophylline,hypoglycemics
"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, DRUG1, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DRUG2 with oral hypoglycemic agents; ",negative,Theophylline,DIFLUCAN
"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, DRUG1, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral DRUG2; ",negative,Theophylline,hypoglycemic agents
"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, DRUG1, DRUG2, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",negative,Terfenadine,Cisapride
"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, DRUG1, Cisapride, DRUG2, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",negative,Terfenadine,Astemizole
"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, DRUG1, Cisapride, Astemizole, DRUG2, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",negative,Terfenadine,Rifabutin
"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, DRUG1, Cisapride, Astemizole, Rifabutin, DRUG2, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",negative,Terfenadine,Tacrolimus
"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, DRUG1, Cisapride, Astemizole, Rifabutin, Tacrolimus, DRUG2,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",negative,Terfenadine,Short-acting benzodiazepines
"These are described in greater detail below:  Oral DRUG2, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, DRUG1, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral DRUG2: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",negative,Terfenadine,hypoglycemics
"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, DRUG1, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DRUG2 with oral hypoglycemic agents; ",negative,Terfenadine,DIFLUCAN
"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, DRUG1, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral DRUG2; ",negative,Terfenadine,hypoglycemic agents
"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, DRUG1, DRUG2, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",negative,Cisapride,Astemizole
"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, DRUG1, Astemizole, DRUG2, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",negative,Cisapride,Rifabutin
"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, DRUG1, Astemizole, Rifabutin, DRUG2, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",negative,Cisapride,Tacrolimus
"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, DRUG1, Astemizole, Rifabutin, Tacrolimus, DRUG2,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",negative,Cisapride,Short-acting benzodiazepines
"These are described in greater detail below:  Oral DRUG2, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, DRUG1, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral DRUG2: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",negative,Cisapride,hypoglycemics
"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, DRUG1, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DRUG2 with oral hypoglycemic agents; ",negative,Cisapride,DIFLUCAN
"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, DRUG1, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral DRUG2; ",negative,Cisapride,hypoglycemic agents
"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, DRUG1, DRUG2, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",negative,Astemizole,Rifabutin
"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, DRUG1, Rifabutin, DRUG2, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",negative,Astemizole,Tacrolimus
"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, DRUG1, Rifabutin, Tacrolimus, DRUG2,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",negative,Astemizole,Short-acting benzodiazepines
"These are described in greater detail below:  Oral DRUG2, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, DRUG1, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral DRUG2: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",negative,Astemizole,hypoglycemics
"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, DRUG1, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DRUG2 with oral hypoglycemic agents; ",negative,Astemizole,DIFLUCAN
"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, DRUG1, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral DRUG2; ",negative,Astemizole,hypoglycemic agents
"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, DRUG1, DRUG2, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",negative,Rifabutin,Tacrolimus
"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, DRUG1, Tacrolimus, DRUG2,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",negative,Rifabutin,Short-acting benzodiazepines
"These are described in greater detail below:  Oral DRUG2, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, DRUG1, Tacrolimus, Short-acting benzodiazepines,  Oral DRUG2: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",negative,Rifabutin,hypoglycemics
"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, DRUG1, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DRUG2 with oral hypoglycemic agents; ",negative,Rifabutin,DIFLUCAN
"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, DRUG1, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral DRUG2; ",negative,Rifabutin,hypoglycemic agents
"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, DRUG1, DRUG2,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",negative,Tacrolimus,Short-acting benzodiazepines
"These are described in greater detail below:  Oral DRUG2, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, DRUG1, Short-acting benzodiazepines,  Oral DRUG2: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",negative,Tacrolimus,hypoglycemics
"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, DRUG1, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DRUG2 with oral hypoglycemic agents; ",negative,Tacrolimus,DIFLUCAN
"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, DRUG1, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral DRUG2; ",negative,Tacrolimus,hypoglycemic agents
"These are described in greater detail below:  Oral DRUG2, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, DRUG1,  Oral DRUG2: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ",negative,Short-acting benzodiazepines,hypoglycemics
"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, DRUG1,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DRUG2 with oral hypoglycemic agents; ",negative,Short-acting benzodiazepines,DIFLUCAN
"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, DRUG1,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral DRUG2; ",negative,Short-acting benzodiazepines,hypoglycemic agents
"These are described in greater detail below:  Oral DRUG1, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral DRUG1: Clinically significant hypoglycemia may be precipitated by the use of DRUG2 with oral hypoglycemic agents; ",negative,hypoglycemics,DIFLUCAN
"These are described in greater detail below:  Oral DRUG1, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral DRUG1: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral DRUG2; ",negative,hypoglycemics,hypoglycemic agents
"These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DRUG1 with oral DRUG2; ",effect,DIFLUCAN,hypoglycemic agents
one fatality has been reported from hypoglycemia in association with combined DRUG1 and DRUG2 use. ,effect,DIFLUCAN,glyburide
"DRUG1 reduces the metabolism of DRUG2, glyburide, and glipizide and increases the plasma concentration of these agents. ",mechanism,DIFLUCAN,tolbutamide
"DRUG1 reduces the metabolism of tolbutamide, DRUG2, and glipizide and increases the plasma concentration of these agents. ",mechanism,DIFLUCAN,glyburide
"DRUG1 reduces the metabolism of tolbutamide, glyburide, and DRUG2 and increases the plasma concentration of these agents. ",mechanism,DIFLUCAN,glipizide
"DIFLUCAN reduces the metabolism of DRUG1, DRUG2, and glipizide and increases the plasma concentration of these agents. ",negative,tolbutamide,glyburide
"DIFLUCAN reduces the metabolism of DRUG1, glyburide, and DRUG2 and increases the plasma concentration of these agents. ",negative,tolbutamide,glipizide
"DIFLUCAN reduces the metabolism of tolbutamide, DRUG1, and DRUG2 and increases the plasma concentration of these agents. ",negative,glyburide,glipizide
"When DRUG1 is used concomitantly with these or other DRUG2, blood glucose concentrations should be carefully monitored and the dose of the sulfonylurea should be adjusted as necessary. ",advise,DIFLUCAN,sulfonylurea oral hypoglycemic agents
"When DRUG1 is used concomitantly with these or other DRUG2 oral hypoglycemic agents, blood glucose concentrations should be carefully monitored and the dose of the DRUG2 should be adjusted as necessary. ",negative,DIFLUCAN,sulfonylurea
"When DIFLUCAN is used concomitantly with these or other DRUG1, blood glucose concentrations should be carefully monitored and the dose of the DRUG2 should be adjusted as necessary. ",negative,sulfonylurea oral hypoglycemic agents,sulfonylurea
DRUG1: Prothrombin time may be increased in patients receiving concomitant DRUG2 and DRUG1. ,negative,Coumarin-type anticoagulants,DIFLUCAN
DRUG1: Prothrombin time may be increased in patients receiving concomitant DIFLUCAN and DRUG1. ,negative,Coumarin-type anticoagulants,coumarin-type anticoagulants
DRUG2: Prothrombin time may be increased in patients receiving concomitant DRUG1 and DRUG2. ,effect,DIFLUCAN,coumarin-type anticoagulants
"In post-marketing experience, as with other DRUG1, bleeding events (bruising, epistaxis, gastrointestinal bleeding, hematuria, and melena) have been reported in association with increases in prothrombin time in patients receiving DRUG2 concurrently with warfarin. ",negative,azole antifungals,fluconazole
"In post-marketing experience, as with other DRUG1, bleeding events (bruising, epistaxis, gastrointestinal bleeding, hematuria, and melena) have been reported in association with increases in prothrombin time in patients receiving fluconazole concurrently with DRUG2. ",negative,azole antifungals,warfarin
"In post-marketing experience, as with other azole antifungals, bleeding events (bruising, epistaxis, gastrointestinal bleeding, hematuria, and melena) have been reported in association with increases in prothrombin time in patients receiving DRUG1 concurrently with DRUG2. ",effect,fluconazole,warfarin
Careful monitoring of prothrombin time in patients receiving DRUG1 and DRUG2 is recommended. ,advise,DIFLUCAN,coumarin-type anticoagulants
DRUG1: DRUG2 increases the plasma concentrations of DRUG1. ,negative,Phenytoin,DIFLUCAN
DRUG1: DIFLUCAN increases the plasma concentrations of DRUG1. ,negative,Phenytoin,phenytoin
DRUG2: DRUG1 increases the plasma concentrations of DRUG2. ,mechanism,DIFLUCAN,phenytoin
Careful monitoring of DRUG1 concentrations in patients receiving DRUG2 and DRUG1 is recommended. ,negative,phenytoin,DIFLUCAN
Careful monitoring of DRUG1 concentrations in patients receiving DIFLUCAN and DRUG1 is recommended. ,negative,phenytoin,phenytoin
Careful monitoring of DRUG2 concentrations in patients receiving DRUG1 and DRUG2 is recommended. ,advise,DIFLUCAN,phenytoin
DRUG1: DRUG2 may significantly increase DRUG1 levels in renal transplant patients with or without renal impairment. ,negative,Cyclosporine,DIFLUCAN
DRUG1: DIFLUCAN may significantly increase DRUG1 levels in renal transplant patients with or without renal impairment. ,negative,Cyclosporine,cyclosporine
DRUG2: DRUG1 may significantly increase DRUG2 levels in renal transplant patients with or without renal impairment. ,mechanism,DIFLUCAN,cyclosporine
Careful monitoring of DRUG1 concentrations and serum creatinine is recommended in patients receiving DRUG2 and DRUG1. ,negative,cyclosporine,DIFLUCAN
Careful monitoring of DRUG1 concentrations and serum creatinine is recommended in patients receiving DIFLUCAN and DRUG1. ,negative,cyclosporine,cyclosporine
Careful monitoring of DRUG2 concentrations and serum creatinine is recommended in patients receiving DRUG1 and DRUG2. ,advise,DIFLUCAN,cyclosporine
DRUG1: DRUG1 enhances the metabolism of concurrently administered DIFLUCAN. ,negative,Rifampin,Rifampin
DRUG1: DRUG1 enhances the metabolism of concurrently administered DRUG2. ,negative,Rifampin,DIFLUCAN
DRUG1: DRUG1 enhances the metabolism of concurrently administered DRUG2. ,mechanism,Rifampin,DIFLUCAN
"Depending on clinical circumstances, consideration should be given to increasing the dose of DRUG1 when it is administered with DRUG2. ",advise,DIFLUCAN,rifampin
DRUG1: DRUG2 increases the serum concentrations of DRUG1. ,negative,Theophylline,DIFLUCAN
DRUG1: DIFLUCAN increases the serum concentrations of DRUG1. ,negative,Theophylline,theophylline
DRUG2: DRUG1 increases the serum concentrations of DRUG2. ,mechanism,DIFLUCAN,theophylline
Careful monitoring of serum DRUG1 concentrations in patients receiving DRUG2 and DRUG1 is recommended. ,negative,theophylline,DIFLUCAN
Careful monitoring of serum DRUG1 concentrations in patients receiving DIFLUCAN and DRUG1 is recommended. ,negative,theophylline,theophylline
Careful monitoring of serum DRUG2 concentrations in patients receiving DRUG1 and DRUG2 is recommended. ,advise,DIFLUCAN,theophylline
"DRUG1: Because of the occurrence of serious cardiac dysrhythmias secondary to prolongation of the QTc interval in patients receiving DRUG2 in conjunction with DRUG1, interaction studies have been performed. ",negative,Terfenadine,azole antifungals
"DRUG1: Because of the occurrence of serious cardiac dysrhythmias secondary to prolongation of the QTc interval in patients receiving azole antifungals in conjunction with DRUG1, interaction studies have been performed. ",negative,Terfenadine,terfenadine
"DRUG2: Because of the occurrence of serious cardiac dysrhythmias secondary to prolongation of the QTc interval in patients receiving DRUG1 in conjunction with DRUG2, interaction studies have been performed. ",effect,azole antifungals,terfenadine
Another study at a 400-mg and 800-mg daily dose of DRUG1 demonstrated that DRUG2 taken in doses of 400 mg per day or greater significantly increases plasma levels of terfenadine when taken concomitantly. ,negative,fluconazole,DIFLUCAN
Another study at a 400-mg and 800-mg daily dose of DRUG1 demonstrated that DIFLUCAN taken in doses of 400 mg per day or greater significantly increases plasma levels of DRUG2 when taken concomitantly. ,negative,fluconazole,terfenadine
Another study at a 400-mg and 800-mg daily dose of fluconazole demonstrated that DRUG1 taken in doses of 400 mg per day or greater significantly increases plasma levels of DRUG2 when taken concomitantly. ,mechanism,DIFLUCAN,terfenadine
The combined use of DRUG1 at doses of 400 mg or greater with DRUG2 is contraindicated. ,advise,fluconazole,terfenadine
The coadministration of DRUG1 at doses lower than 400 mg/day with DRUG2 should be carefully monitored. ,advise,fluconazole,terfenadine
"DRUG1: There have been reports of cardiac events, including torsade de pointes in patients to whom DRUG2 and DRUG1 were coadministered. ",negative,Cisapride,fluconazole
"DRUG1: There have been reports of cardiac events, including torsade de pointes in patients to whom fluconazole and DRUG1 were coadministered. ",negative,Cisapride,cisapride
"DRUG2: There have been reports of cardiac events, including torsade de pointes in patients to whom DRUG1 and DRUG2 were coadministered. ",effect,fluconazole,cisapride
A controlled study found that concomitant DRUG1 200 mg once daily and DRUG2 20 mg four times a day yielded a significant increase in DRUG2 plasma levels and prolongation of QTc interval.,mechanism,fluconazole,cisapride
A controlled study found that concomitant DRUG1 200 mg once daily and DRUG2 20 mg four times a day yielded a significant increase in DRUG2 plasma levels and prolongation of QTc interval.,negative,fluconazole,cisapride
A controlled study found that concomitant fluconazole 200 mg once daily and DRUG1 20 mg four times a day yielded a significant increase in DRUG1 plasma levels and prolongation of QTc interval.,negative,cisapride,cisapride
The combined use of DRUG1 with DRUG2 is contraindicated. ,advise,fluconazole,cisapride
DRUG1: The use of DRUG2 in patients concurrently taking DRUG1 or other drugs metabolized by the cytochrome P450 system may be associated with elevations in serum levels of these drugs. ,negative,Astemizole,fluconazole
DRUG1: The use of fluconazole in patients concurrently taking DRUG1 or other drugs metabolized by the cytochrome P450 system may be associated with elevations in serum levels of these drugs. ,negative,Astemizole,astemizole
DRUG2: The use of DRUG1 in patients concurrently taking DRUG2 or other drugs metabolized by the cytochrome P450 system may be associated with elevations in serum levels of these drugs. ,mechanism,fluconazole,astemizole
DRUG1: There have been reports of uveitis in patients to whom DRUG2 and DRUG1 were coadministered. ,negative,Rifabutin,fluconazole
DRUG1: There have been reports of uveitis in patients to whom fluconazole and DRUG1 were coadministered. ,negative,Rifabutin,rifabutin
DRUG2: There have been reports of uveitis in patients to whom DRUG1 and DRUG2 were coadministered. ,effect,fluconazole,rifabutin
Patients receiving DRUG1 and DRUG2 concomitantly should be carefully monitored. ,advise,rifabutin,fluconazole
DRUG1: There have been reports of nephrotoxicity in patients to whom DRUG2 and DRUG1 were coadministered. ,negative,Tacrolimus,fluconazole
DRUG1: There have been reports of nephrotoxicity in patients to whom fluconazole and DRUG1 were coadministered. ,negative,Tacrolimus,tacrolimus
DRUG2: There have been reports of nephrotoxicity in patients to whom DRUG1 and DRUG2 were coadministered. ,effect,fluconazole,tacrolimus
Patients receiving DRUG1 and DRUG2 concomitantly should be carefully monitored. ,advise,tacrolimus,fluconazole
"DRUG1: Following oral administration of DRUG2, fluconazole resulted in substantial increases in DRUG2 concentrations and psychomotor effects. ",negative,Short-acting Benzodiazepines,midazolam
"DRUG1: Following oral administration of midazolam, DRUG2 resulted in substantial increases in midazolam concentrations and psychomotor effects. ",negative,Short-acting Benzodiazepines,fluconazole
"DRUG1: Following oral administration of DRUG2, fluconazole resulted in substantial increases in DRUG2 concentrations and psychomotor effects. ",negative,Short-acting Benzodiazepines,midazolam
"Short-acting Benzodiazepines: Following oral administration of DRUG1, DRUG2 resulted in substantial increases in DRUG1 concentrations and psychomotor effects. ",mechanism,midazolam,fluconazole
"Short-acting Benzodiazepines: Following oral administration of DRUG1, fluconazole resulted in substantial increases in DRUG1 concentrations and psychomotor effects. ",negative,midazolam,midazolam
"Short-acting Benzodiazepines: Following oral administration of DRUG2, DRUG1 resulted in substantial increases in DRUG2 concentrations and psychomotor effects. ",negative,fluconazole,midazolam
This effect on DRUG1 appears to be more pronounced following oral administration of DRUG2 than with DRUG2 administered intravenously. ,effect,midazolam,fluconazole
This effect on DRUG1 appears to be more pronounced following oral administration of DRUG2 than with DRUG2 administered intravenously. ,negative,midazolam,fluconazole
This effect on midazolam appears to be more pronounced following oral administration of DRUG1 than with DRUG1 administered intravenously. ,negative,fluconazole,fluconazole
"If DRUG1, which are metabolized by the cytochrome P450 system, are concomitantly administered with DRUG2, consideration should be given to decreasing the benzodiazepine dosage, and the patients should be appropriately monitored. ",advise,short-acting benzodiazepines,fluconazole
"If DRUG1, which are metabolized by the cytochrome P450 system, are concomitantly administered with fluconazole, consideration should be given to decreasing the DRUG2 dosage, and the patients should be appropriately monitored. ",negative,short-acting benzodiazepines,benzodiazepine
"If short-acting benzodiazepines, which are metabolized by the cytochrome P450 system, are concomitantly administered with DRUG1, consideration should be given to decreasing the DRUG2 dosage, and the patients should be appropriately monitored. ",negative,fluconazole,benzodiazepine
DRUG1 tablets coadministered with DRUG2- and levonorgestrel-containing oral contraceptives produced an overall mean increase in DRUG2 and levonorgestrel levels; ,mechanism,Fluconazole,ethinyl estradiol
DRUG1 tablets coadministered with ethinyl estradiol- and DRUG2-containing oral contraceptives produced an overall mean increase in ethinyl estradiol and DRUG2 levels; ,mechanism,Fluconazole,levonorgestrel
DRUG1 tablets coadministered with ethinyl estradiol- and levonorgestrel-containing oral DRUG2 produced an overall mean increase in ethinyl estradiol and levonorgestrel levels; ,negative,Fluconazole,contraceptives
DRUG1 tablets coadministered with DRUG2- and levonorgestrel-containing oral contraceptives produced an overall mean increase in DRUG2 and levonorgestrel levels; ,negative,Fluconazole,ethinyl estradiol
DRUG1 tablets coadministered with ethinyl estradiol- and DRUG2-containing oral contraceptives produced an overall mean increase in ethinyl estradiol and DRUG2 levels; ,negative,Fluconazole,levonorgestrel
Fluconazole tablets coadministered with DRUG1- and DRUG2-containing oral contraceptives produced an overall mean increase in DRUG1 and DRUG2 levels; ,negative,ethinyl estradiol,levonorgestrel
Fluconazole tablets coadministered with DRUG1- and levonorgestrel-containing oral DRUG2 produced an overall mean increase in DRUG1 and levonorgestrel levels; ,negative,ethinyl estradiol,contraceptives
Fluconazole tablets coadministered with DRUG1- and levonorgestrel-containing oral contraceptives produced an overall mean increase in DRUG1 and levonorgestrel levels; ,negative,ethinyl estradiol,ethinyl estradiol
Fluconazole tablets coadministered with DRUG1- and DRUG2-containing oral contraceptives produced an overall mean increase in DRUG1 and DRUG2 levels; ,negative,ethinyl estradiol,levonorgestrel
Fluconazole tablets coadministered with ethinyl estradiol- and DRUG1-containing oral DRUG2 produced an overall mean increase in ethinyl estradiol and DRUG1 levels; ,negative,levonorgestrel,contraceptives
Fluconazole tablets coadministered with DRUG2- and DRUG1-containing oral contraceptives produced an overall mean increase in DRUG2 and DRUG1 levels; ,negative,levonorgestrel,ethinyl estradiol
Fluconazole tablets coadministered with ethinyl estradiol- and DRUG1-containing oral contraceptives produced an overall mean increase in ethinyl estradiol and DRUG1 levels; ,negative,levonorgestrel,levonorgestrel
Fluconazole tablets coadministered with DRUG2- and levonorgestrel-containing oral DRUG1 produced an overall mean increase in DRUG2 and levonorgestrel levels; ,negative,contraceptives,ethinyl estradiol
Fluconazole tablets coadministered with ethinyl estradiol- and DRUG2-containing oral DRUG1 produced an overall mean increase in ethinyl estradiol and DRUG2 levels; ,negative,contraceptives,levonorgestrel
Fluconazole tablets coadministered with DRUG1- and DRUG2-containing oral contraceptives produced an overall mean increase in DRUG1 and DRUG2 levels; ,negative,ethinyl estradiol,levonorgestrel
"however, in some patients there were decreases up to 47% and 33% of DRUG1 and DRUG2 levels. ",negative,ethinyl estradiol,levonorgestrel
The data presently available indicate that the decreases in some individual DRUG1 and DRUG2 AUC values with fluconazole treatment are likely the result of random variation. ,negative,ethinyl estradiol,levonorgestrel
The data presently available indicate that the decreases in some individual DRUG1 and levonorgestrel AUC values with DRUG2 treatment are likely the result of random variation. ,negative,ethinyl estradiol,fluconazole
The data presently available indicate that the decreases in some individual ethinyl estradiol and DRUG1 AUC values with DRUG2 treatment are likely the result of random variation. ,negative,levonorgestrel,fluconazole
"While there is evidence that DRUG1 can inhibit the metabolism of DRUG2 and levonorgestrel, there is no evidence that DRUG1 is a net inducer of DRUG2 or levonorgestrel metabolism. ",mechanism,fluconazole,ethinyl estradiol
"While there is evidence that DRUG1 can inhibit the metabolism of ethinyl estradiol and DRUG2, there is no evidence that DRUG1 is a net inducer of ethinyl estradiol or DRUG2 metabolism. ",mechanism,fluconazole,levonorgestrel
"While there is evidence that DRUG1 can inhibit the metabolism of ethinyl estradiol and levonorgestrel, there is no evidence that DRUG1 is a net inducer of ethinyl estradiol or levonorgestrel metabolism. ",negative,fluconazole,fluconazole
"While there is evidence that DRUG1 can inhibit the metabolism of DRUG2 and levonorgestrel, there is no evidence that DRUG1 is a net inducer of DRUG2 or levonorgestrel metabolism. ",negative,fluconazole,ethinyl estradiol
"While there is evidence that DRUG1 can inhibit the metabolism of ethinyl estradiol and DRUG2, there is no evidence that DRUG1 is a net inducer of ethinyl estradiol or DRUG2 metabolism. ",negative,fluconazole,levonorgestrel
"While there is evidence that fluconazole can inhibit the metabolism of DRUG1 and DRUG2, there is no evidence that fluconazole is a net inducer of DRUG1 or DRUG2 metabolism. ",negative,ethinyl estradiol,levonorgestrel
"While there is evidence that DRUG2 can inhibit the metabolism of DRUG1 and levonorgestrel, there is no evidence that DRUG2 is a net inducer of DRUG1 or levonorgestrel metabolism. ",negative,ethinyl estradiol,fluconazole
"While there is evidence that fluconazole can inhibit the metabolism of DRUG1 and levonorgestrel, there is no evidence that fluconazole is a net inducer of DRUG1 or levonorgestrel metabolism. ",negative,ethinyl estradiol,ethinyl estradiol
"While there is evidence that fluconazole can inhibit the metabolism of DRUG1 and DRUG2, there is no evidence that fluconazole is a net inducer of DRUG1 or DRUG2 metabolism. ",negative,ethinyl estradiol,levonorgestrel
"While there is evidence that DRUG2 can inhibit the metabolism of ethinyl estradiol and DRUG1, there is no evidence that DRUG2 is a net inducer of ethinyl estradiol or DRUG1 metabolism. ",negative,levonorgestrel,fluconazole
"While there is evidence that fluconazole can inhibit the metabolism of DRUG2 and DRUG1, there is no evidence that fluconazole is a net inducer of DRUG2 or DRUG1 metabolism. ",negative,levonorgestrel,ethinyl estradiol
"While there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and DRUG1, there is no evidence that fluconazole is a net inducer of ethinyl estradiol or DRUG1 metabolism. ",negative,levonorgestrel,levonorgestrel
"While there is evidence that DRUG1 can inhibit the metabolism of DRUG2 and levonorgestrel, there is no evidence that DRUG1 is a net inducer of DRUG2 or levonorgestrel metabolism. ",negative,fluconazole,ethinyl estradiol
"While there is evidence that DRUG1 can inhibit the metabolism of ethinyl estradiol and DRUG2, there is no evidence that DRUG1 is a net inducer of ethinyl estradiol or DRUG2 metabolism. ",negative,fluconazole,levonorgestrel
"While there is evidence that fluconazole can inhibit the metabolism of DRUG1 and DRUG2, there is no evidence that fluconazole is a net inducer of DRUG1 or DRUG2 metabolism. ",negative,ethinyl estradiol,levonorgestrel
"Although a causal relationship has not been established, there have been reports of bleeding and/or prolonged prothrombin time in patients treated with DRUG1 with and without DRUG2 or platelet aggregation inhibitors. ",effect,TRENTAL,anticoagulants
"Although a causal relationship has not been established, there have been reports of bleeding and/or prolonged prothrombin time in patients treated with DRUG1 with and without anticoagulants or DRUG2. ",effect,TRENTAL,platelet aggregation inhibitors
"Although a causal relationship has not been established, there have been reports of bleeding and/or prolonged prothrombin time in patients treated with TRENTAL with and without DRUG1 or DRUG2. ",negative,anticoagulants,platelet aggregation inhibitors
Concomitant administration of DRUG1 and DRUG2-containing drugs leads to increased DRUG2 levels and DRUG2 toxicity in some individuals. ,mechanism,TRENTAL,theophylline
Concomitant administration of DRUG1 and DRUG2-containing drugs leads to increased DRUG2 levels and DRUG2 toxicity in some individuals. ,negative,TRENTAL,theophylline
Concomitant administration of DRUG1 and DRUG2-containing drugs leads to increased DRUG2 levels and DRUG2 toxicity in some individuals. ,negative,TRENTAL,theophylline
Concomitant administration of TRENTAL and DRUG1-containing drugs leads to increased DRUG1 levels and DRUG1 toxicity in some individuals. ,negative,theophylline,theophylline
Concomitant administration of TRENTAL and DRUG1-containing drugs leads to increased DRUG1 levels and DRUG1 toxicity in some individuals. ,negative,theophylline,theophylline
Concomitant administration of TRENTAL and DRUG1-containing drugs leads to increased DRUG1 levels and DRUG1 toxicity in some individuals. ,negative,theophylline,theophylline
"DRUG1 has been used concurrently with DRUG2, beta blockers, digitalis, diuretics, antidiabetic agents, and antiarrhythmics, without observed problems. ",negative,TRENTAL,antihypertensive drugs
"DRUG1 has been used concurrently with antihypertensive drugs, DRUG2, digitalis, diuretics, antidiabetic agents, and antiarrhythmics, without observed problems. ",negative,TRENTAL,beta blockers
"DRUG1 has been used concurrently with antihypertensive drugs, beta blockers, DRUG2, diuretics, antidiabetic agents, and antiarrhythmics, without observed problems. ",negative,TRENTAL,digitalis
"DRUG1 has been used concurrently with antihypertensive drugs, beta blockers, digitalis, DRUG2, antidiabetic agents, and antiarrhythmics, without observed problems. ",negative,TRENTAL,diuretics
"DRUG1 has been used concurrently with antihypertensive drugs, beta blockers, digitalis, diuretics, DRUG2, and antiarrhythmics, without observed problems. ",negative,TRENTAL,antidiabetic agents
"DRUG1 has been used concurrently with antihypertensive drugs, beta blockers, digitalis, diuretics, antidiabetic agents, and DRUG2, without observed problems. ",negative,TRENTAL,antiarrhythmics
"TRENTAL has been used concurrently with DRUG1, DRUG2, digitalis, diuretics, antidiabetic agents, and antiarrhythmics, without observed problems. ",negative,antihypertensive drugs,beta blockers
"TRENTAL has been used concurrently with DRUG1, beta blockers, DRUG2, diuretics, antidiabetic agents, and antiarrhythmics, without observed problems. ",negative,antihypertensive drugs,digitalis
"TRENTAL has been used concurrently with DRUG1, beta blockers, digitalis, DRUG2, antidiabetic agents, and antiarrhythmics, without observed problems. ",negative,antihypertensive drugs,diuretics
"TRENTAL has been used concurrently with DRUG1, beta blockers, digitalis, diuretics, DRUG2, and antiarrhythmics, without observed problems. ",negative,antihypertensive drugs,antidiabetic agents
"TRENTAL has been used concurrently with DRUG1, beta blockers, digitalis, diuretics, antidiabetic agents, and DRUG2, without observed problems. ",negative,antihypertensive drugs,antiarrhythmics
"TRENTAL has been used concurrently with antihypertensive drugs, DRUG1, DRUG2, diuretics, antidiabetic agents, and antiarrhythmics, without observed problems. ",negative,beta blockers,digitalis
"TRENTAL has been used concurrently with antihypertensive drugs, DRUG1, digitalis, DRUG2, antidiabetic agents, and antiarrhythmics, without observed problems. ",negative,beta blockers,diuretics
"TRENTAL has been used concurrently with antihypertensive drugs, DRUG1, digitalis, diuretics, DRUG2, and antiarrhythmics, without observed problems. ",negative,beta blockers,antidiabetic agents
"TRENTAL has been used concurrently with antihypertensive drugs, DRUG1, digitalis, diuretics, antidiabetic agents, and DRUG2, without observed problems. ",negative,beta blockers,antiarrhythmics
"TRENTAL has been used concurrently with antihypertensive drugs, beta blockers, DRUG1, DRUG2, antidiabetic agents, and antiarrhythmics, without observed problems. ",negative,digitalis,diuretics
"TRENTAL has been used concurrently with antihypertensive drugs, beta blockers, DRUG1, diuretics, DRUG2, and antiarrhythmics, without observed problems. ",negative,digitalis,antidiabetic agents
"TRENTAL has been used concurrently with antihypertensive drugs, beta blockers, DRUG1, diuretics, antidiabetic agents, and DRUG2, without observed problems. ",negative,digitalis,antiarrhythmics
"TRENTAL has been used concurrently with antihypertensive drugs, beta blockers, digitalis, DRUG1, DRUG2, and antiarrhythmics, without observed problems. ",negative,diuretics,antidiabetic agents
"TRENTAL has been used concurrently with antihypertensive drugs, beta blockers, digitalis, DRUG1, antidiabetic agents, and DRUG2, without observed problems. ",negative,diuretics,antiarrhythmics
"TRENTAL has been used concurrently with antihypertensive drugs, beta blockers, digitalis, diuretics, DRUG1, and DRUG2, without observed problems. ",negative,antidiabetic agents,antiarrhythmics
DRUG1 Reports suggest that DRUG2 may diminish the antihypertensive effect of angiotensin-converting enzyme (ACE) inhibitors. ,negative,ACE inhibitors,NSAIDs
DRUG1 Reports suggest that NSAIDs may diminish the antihypertensive effect of DRUG2. ,negative,ACE inhibitors,angiotensin-converting enzyme (ACE) inhibitors
ACE inhibitors Reports suggest that DRUG1 may diminish the antihypertensive effect of DRUG2. ,effect,NSAIDs,angiotensin-converting enzyme (ACE) inhibitors
This interaction should be given consideration in patients taking DRUG1 concomitantly with DRUG2. ,advise,NSAIDs,ACE inhibitors
DRUG1: Concomitant administration of DRUG1 (1000 mg TID) to healthy volunteers tended to increase the AUC (10%) and Cmax (24%) of meloxicam. ,negative,Aspirin,aspirin
DRUG1: Concomitant administration of DRUG1 (1000 mg TID) to healthy volunteers tended to increase the AUC (10%) and Cmax (24%) of DRUG2. ,negative,Aspirin,meloxicam
DRUG1: Concomitant administration of DRUG1 (1000 mg TID) to healthy volunteers tended to increase the AUC (10%) and Cmax (24%) of DRUG2. ,mechanism,aspirin,meloxicam
"however, as with other DRUG1, concomitant administration of DRUG2 and aspirin is not generally recommended because of the potential for increased adverse effects. ",negative,NSAIDs,meloxicam
"however, as with other DRUG1, concomitant administration of meloxicam and DRUG2 is not generally recommended because of the potential for increased adverse effects. ",advise,NSAIDs,aspirin
"however, as with other NSAIDs, concomitant administration of DRUG1 and DRUG2 is not generally recommended because of the potential for increased adverse effects. ",advise,meloxicam,aspirin
"Concomitant administration of low-dose DRUG1 with DRUG2 may result in an increased rate of GI ulceration or other complications, compared to use of DRUG2 alone. ",effect,aspirin,MOBIC
"Concomitant administration of low-dose DRUG1 with DRUG2 may result in an increased rate of GI ulceration or other complications, compared to use of DRUG2 alone. ",negative,aspirin,MOBIC
"Concomitant administration of low-dose aspirin with DRUG1 may result in an increased rate of GI ulceration or other complications, compared to use of DRUG1 alone. ",negative,MOBIC,MOBIC
DRUG1 is not a substitute for DRUG2 for cardiovascular prophylaxis. ,negative,MOBIC,aspirin
DRUG1: Pretreatment for four days with DRUG1 significantly increased the clearance of meloxicam by 50%. ,negative,Cholestyramine,cholestyramine
DRUG1: Pretreatment for four days with DRUG1 significantly increased the clearance of DRUG2 by 50%. ,negative,Cholestyramine,meloxicam
DRUG1: Pretreatment for four days with DRUG1 significantly increased the clearance of DRUG2 by 50%. ,mechanism,cholestyramine,meloxicam
DRUG1: Concomitant administration of 200 mg DRUG1 QID did not alter the single-dose pharmacokinetics of 30 mg meloxicam. ,negative,Cimetidine,cimetidine
DRUG1: Concomitant administration of 200 mg DRUG1 QID did not alter the single-dose pharmacokinetics of 30 mg DRUG2. ,negative,Cimetidine,meloxicam
DRUG1: Concomitant administration of 200 mg DRUG1 QID did not alter the single-dose pharmacokinetics of 30 mg DRUG2. ,negative,cimetidine,meloxicam
DRUG1: DRUG2 15 mg once daily for 7 days did not alter the plasma concentration profile of DRUG1 after b-acetyldigoxin administration for 7 days at clinical doses. ,negative,Digoxin,Meloxicam
DRUG1: Meloxicam 15 mg once daily for 7 days did not alter the plasma concentration profile of DRUG1 after b-acetyldigoxin administration for 7 days at clinical doses. ,negative,Digoxin,digoxin
DRUG2: DRUG1 15 mg once daily for 7 days did not alter the plasma concentration profile of DRUG2 after b-acetyldigoxin administration for 7 days at clinical doses. ,negative,Meloxicam,digoxin
In vitro testing found no protein binding drug interaction between DRUG1 and DRUG2. ,negative,digoxin,meloxicam
"DRUG1: Clinical studies, as well as post-marketing observations, have shown that DRUG2 can reduce the natriuretic effect of DRUG1 and thiazide diuretics in some patients. ",negative,Furosemide,NSAIDs
"DRUG1: Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of DRUG1 and thiazide diuretics in some patients. ",negative,Furosemide,furosemide
"DRUG1: Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of DRUG1 and DRUG2 in some patients. ",negative,Furosemide,thiazide diuretics
"DRUG2: Clinical studies, as well as post-marketing observations, have shown that DRUG1 can reduce the natriuretic effect of DRUG2 and thiazide diuretics in some patients. ",effect,NSAIDs,furosemide
"Furosemide: Clinical studies, as well as post-marketing observations, have shown that DRUG1 can reduce the natriuretic effect of furosemide and DRUG2 in some patients. ",effect,NSAIDs,thiazide diuretics
"DRUG1: Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of DRUG1 and DRUG2 in some patients. ",negative,furosemide,thiazide diuretics
Studies with DRUG1 agents and DRUG2 have not demonstrated a reduction in natriuretic effect. ,negative,furosemide,meloxicam
DRUG1: single and multiple dose pharmacodynamics and pharmacokinetics are not affected by multiple doses of DRUG2. ,negative,Furosemide,meloxicam
"Nevertheless, during concomitant therapy with DRUG1 and DRUG2, patients should be observed closely for signs of declining renal function, as well as to assure diuretic efficacy. ",advise,furosemide,MOBIC
"DRUG1: In clinical trials, DRUG2 have produced an elevation of plasma DRUG1 levels and a reduction in renal DRUG1 clearance. ",negative,Lithium,NSAIDs
"DRUG1: In clinical trials, NSAIDs have produced an elevation of plasma DRUG1 levels and a reduction in renal DRUG1 clearance. ",negative,Lithium,lithium
"DRUG1: In clinical trials, NSAIDs have produced an elevation of plasma DRUG1 levels and a reduction in renal DRUG1 clearance. ",negative,Lithium,lithium
"DRUG2: In clinical trials, DRUG1 have produced an elevation of plasma DRUG2 levels and a reduction in renal DRUG2 clearance. ",mechanism,NSAIDs,lithium
"DRUG2: In clinical trials, DRUG1 have produced an elevation of plasma DRUG2 levels and a reduction in renal DRUG2 clearance. ",negative,NSAIDs,lithium
"DRUG1: In clinical trials, NSAIDs have produced an elevation of plasma DRUG1 levels and a reduction in renal DRUG1 clearance. ",negative,lithium,lithium
"In a study conducted in healthy subjects, mean pre-dose DRUG1 concentration and AUC were increased by 21% in subjects receiving DRUG1 doses ranging from 804 to 1072 mg BID with meloxicam 15 mg QD as compared to subjects receiving DRUG1 alone. ",negative,lithium,lithium
"In a study conducted in healthy subjects, mean pre-dose DRUG1 concentration and AUC were increased by 21% in subjects receiving DRUG1 doses ranging from 804 to 1072 mg BID with DRUG2 15 mg QD as compared to subjects receiving DRUG1 alone. ",negative,lithium,meloxicam
"In a study conducted in healthy subjects, mean pre-dose DRUG1 concentration and AUC were increased by 21% in subjects receiving DRUG1 doses ranging from 804 to 1072 mg BID with meloxicam 15 mg QD as compared to subjects receiving DRUG1 alone. ",negative,lithium,lithium
"In a study conducted in healthy subjects, mean pre-dose DRUG1 concentration and AUC were increased by 21% in subjects receiving DRUG1 doses ranging from 804 to 1072 mg BID with DRUG2 15 mg QD as compared to subjects receiving DRUG1 alone. ",mechanism,lithium,meloxicam
"In a study conducted in healthy subjects, mean pre-dose DRUG1 concentration and AUC were increased by 21% in subjects receiving DRUG1 doses ranging from 804 to 1072 mg BID with meloxicam 15 mg QD as compared to subjects receiving DRUG1 alone. ",negative,lithium,lithium
"In a study conducted in healthy subjects, mean pre-dose DRUG2 concentration and AUC were increased by 21% in subjects receiving DRUG2 doses ranging from 804 to 1072 mg BID with DRUG1 15 mg QD as compared to subjects receiving DRUG2 alone. ",negative,meloxicam,lithium
Patients on DRUG1 treatment should be closely monitored when DRUG2 is introduced or withdrawn. ,advise,lithium,MOBIC
DRUG1: A study in 13 rheumatoid arthritis (RA) patients evaluated the effects of multiple doses of DRUG2 on the pharmacokinetics of DRUG1 taken once weekly. ,negative,Methotrexate,meloxicam
DRUG1: A study in 13 rheumatoid arthritis (RA) patients evaluated the effects of multiple doses of meloxicam on the pharmacokinetics of DRUG1 taken once weekly. ,negative,Methotrexate,methotrexate
DRUG2: A study in 13 rheumatoid arthritis (RA) patients evaluated the effects of multiple doses of DRUG1 on the pharmacokinetics of DRUG2 taken once weekly. ,negative,meloxicam,methotrexate
DRUG1 did not have a significant effect on the pharmacokinetics of single doses of DRUG2. ,negative,Meloxicam,methotrexate
"In vitro, DRUG1 did not displace DRUG2 from its human serum binding sites. ",negative,methotrexate,meloxicam
"DRUG1: Anticoagulant activity should be monitored, particularly in the first few days after initiating or changing DRUG2 therapy in patients receiving DRUG1 or similar agents, since these patients are at an increased risk of bleeding. ",negative,Warfarin,MOBIC
"DRUG1: Anticoagulant activity should be monitored, particularly in the first few days after initiating or changing MOBIC therapy in patients receiving DRUG1 or similar agents, since these patients are at an increased risk of bleeding. ",negative,Warfarin,warfarin
"DRUG2: Anticoagulant activity should be monitored, particularly in the first few days after initiating or changing DRUG1 therapy in patients receiving DRUG2 or similar agents, since these patients are at an increased risk of bleeding. ",advise,MOBIC,warfarin
The effect of DRUG1 on the anticoagulant effect of DRUG2 was studied in a group of healthy subjects receiving daily doses of DRUG2 that produced an INR (International Normalized Ratio) between 1.2 and 1.8. ,negative,meloxicam,warfarin
The effect of DRUG1 on the anticoagulant effect of DRUG2 was studied in a group of healthy subjects receiving daily doses of DRUG2 that produced an INR (International Normalized Ratio) between 1.2 and 1.8. ,negative,meloxicam,warfarin
The effect of meloxicam on the anticoagulant effect of DRUG1 was studied in a group of healthy subjects receiving daily doses of DRUG1 that produced an INR (International Normalized Ratio) between 1.2 and 1.8. ,negative,warfarin,warfarin
"In these subjects, DRUG1 did not alter DRUG2 pharmacokinetics and the average anticoagulant effect of DRUG2 as determined by prothrombin time. ",negative,meloxicam,warfarin
"In these subjects, DRUG1 did not alter DRUG2 pharmacokinetics and the average anticoagulant effect of DRUG2 as determined by prothrombin time. ",negative,meloxicam,warfarin
"In these subjects, meloxicam did not alter DRUG1 pharmacokinetics and the average anticoagulant effect of DRUG1 as determined by prothrombin time. ",negative,warfarin,warfarin
Caution should be used when administering DRUG1 with DRUG2 since patients on DRUG2 may experience changes in INR and an increased risk of bleeding complications when a new medication is introduced.,advise,MOBIC,warfarin
Caution should be used when administering DRUG1 with DRUG2 since patients on DRUG2 may experience changes in INR and an increased risk of bleeding complications when a new medication is introduced.,negative,MOBIC,warfarin
Caution should be used when administering MOBIC with DRUG1 since patients on DRUG1 may experience changes in INR and an increased risk of bleeding complications when a new medication is introduced.,negative,warfarin,warfarin
"When administered concomitantly with DRUG1   , DRUG2 may enhance or precipitate bradycardia, A.V. ",effect,ProAmatine,cardiac glycosides
"The use of drugs that stimulate alpha-adrenergic receptors (e.g., DRUG1, DRUG2, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. ",negative,phenylephrine,pseudoephedrine
"The use of drugs that stimulate alpha-adrenergic receptors (e.g., DRUG1, pseudoephedrine, DRUG2, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. ",negative,phenylephrine,ephedrine
"The use of drugs that stimulate alpha-adrenergic receptors (e.g., DRUG1, pseudoephedrine, ephedrine, DRUG2 or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. ",negative,phenylephrine,phenylpropanolamine
"The use of drugs that stimulate alpha-adrenergic receptors (e.g., DRUG1, pseudoephedrine, ephedrine, phenylpropanolamine or DRUG2) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. ",negative,phenylephrine,dihydroergotamine
"The use of drugs that stimulate alpha-adrenergic receptors (e.g., DRUG1, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of DRUG2   . Therefore, caution should be used when DRUG2    is administered concomitantly with agents that cause vasoconstriction. ",effect,phenylephrine,ProAmatine
"The use of drugs that stimulate alpha-adrenergic receptors (e.g., DRUG1, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of DRUG2   . Therefore, caution should be used when DRUG2    is administered concomitantly with agents that cause vasoconstriction. ",negative,phenylephrine,ProAmatine
"The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, DRUG1, DRUG2, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. ",negative,pseudoephedrine,ephedrine
"The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, DRUG1, ephedrine, DRUG2 or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. ",negative,pseudoephedrine,phenylpropanolamine
"The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, DRUG1, ephedrine, phenylpropanolamine or DRUG2) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. ",negative,pseudoephedrine,dihydroergotamine
"The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, DRUG1, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of DRUG2   . Therefore, caution should be used when DRUG2    is administered concomitantly with agents that cause vasoconstriction. ",effect,pseudoephedrine,ProAmatine
"The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, DRUG1, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of DRUG2   . Therefore, caution should be used when DRUG2    is administered concomitantly with agents that cause vasoconstriction. ",negative,pseudoephedrine,ProAmatine
"The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, DRUG1, DRUG2 or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. ",negative,ephedrine,phenylpropanolamine
"The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, DRUG1, phenylpropanolamine or DRUG2) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. ",negative,ephedrine,dihydroergotamine
"The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, DRUG1, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of DRUG2   . Therefore, caution should be used when DRUG2    is administered concomitantly with agents that cause vasoconstriction. ",effect,ephedrine,ProAmatine
"The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, DRUG1, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of DRUG2   . Therefore, caution should be used when DRUG2    is administered concomitantly with agents that cause vasoconstriction. ",negative,ephedrine,ProAmatine
"The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, DRUG1 or DRUG2) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. ",negative,phenylpropanolamine,dihydroergotamine
"The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, DRUG1 or dihydroergotamine) may enhance or potentiate the pressor effects of DRUG2   . Therefore, caution should be used when DRUG2    is administered concomitantly with agents that cause vasoconstriction. ",effect,phenylpropanolamine,ProAmatine
"The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, DRUG1 or dihydroergotamine) may enhance or potentiate the pressor effects of DRUG2   . Therefore, caution should be used when DRUG2    is administered concomitantly with agents that cause vasoconstriction. ",negative,phenylpropanolamine,ProAmatine
"The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or DRUG1) may enhance or potentiate the pressor effects of DRUG2   . Therefore, caution should be used when DRUG2    is administered concomitantly with agents that cause vasoconstriction. ",effect,dihydroergotamine,ProAmatine
"The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or DRUG1) may enhance or potentiate the pressor effects of DRUG2   . Therefore, caution should be used when DRUG2    is administered concomitantly with agents that cause vasoconstriction. ",negative,dihydroergotamine,ProAmatine
"The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of DRUG1   . Therefore, caution should be used when DRUG1    is administered concomitantly with agents that cause vasoconstriction. ",negative,ProAmatine,ProAmatine
"DRUG1    has been used in patients concomitantly treated with salt-retaining steroid therapy (i.e., DRUG2), with or without salt supplementation. ",negative,ProAmatine,fludrocortisone acetate
"DRUG1. DRUG2, such as prazosin, terazosin, and doxazosin, can antagonize the effects of DRUG1. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",negative,ProAmatine,Alpha-adrenergic blocking agents
"DRUG1. Alpha-adrenergic blocking agents, such as DRUG2, terazosin, and doxazosin, can antagonize the effects of DRUG1. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",negative,ProAmatine,prazosin
"DRUG1. Alpha-adrenergic blocking agents, such as prazosin, DRUG2, and doxazosin, can antagonize the effects of DRUG1. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",negative,ProAmatine,terazosin
"DRUG1. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and DRUG2, can antagonize the effects of DRUG1. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",negative,ProAmatine,doxazosin
"DRUG1. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of DRUG1. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",negative,ProAmatine,ProAmatine
"DRUG1. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of DRUG1. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUG2 (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",negative,ProAmatine,desglymidodrine
"DRUG1. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of DRUG1. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as DRUG2, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",negative,ProAmatine,metformin
"DRUG1. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of DRUG1. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, DRUG2, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",negative,ProAmatine,cimetidine
"DRUG1. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of DRUG1. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, DRUG2, procainamide, triamterene, flecainide, and quinidine. ",negative,ProAmatine,ranitidine
"DRUG1. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of DRUG1. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, DRUG2, triamterene, flecainide, and quinidine. ",negative,ProAmatine,procainamide
"DRUG1. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of DRUG1. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, DRUG2, flecainide, and quinidine. ",negative,ProAmatine,triamterene
"DRUG1. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of DRUG1. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, DRUG2, and quinidine. ",negative,ProAmatine,flecainide
"DRUG1. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of DRUG1. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and DRUG2. ",negative,ProAmatine,quinidine
"ProAmatine. DRUG1, such as DRUG2, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",negative,Alpha-adrenergic blocking agents,prazosin
"ProAmatine. DRUG1, such as prazosin, DRUG2, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",negative,Alpha-adrenergic blocking agents,terazosin
"ProAmatine. DRUG1, such as prazosin, terazosin, and DRUG2, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",negative,Alpha-adrenergic blocking agents,doxazosin
"DRUG2. DRUG1, such as prazosin, terazosin, and doxazosin, can antagonize the effects of DRUG2. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",effect,Alpha-adrenergic blocking agents,ProAmatine
"ProAmatine. DRUG1, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUG2 (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",negative,Alpha-adrenergic blocking agents,desglymidodrine
"ProAmatine. DRUG1, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as DRUG2, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",negative,Alpha-adrenergic blocking agents,metformin
"ProAmatine. DRUG1, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, DRUG2, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",negative,Alpha-adrenergic blocking agents,cimetidine
"ProAmatine. DRUG1, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, DRUG2, procainamide, triamterene, flecainide, and quinidine. ",negative,Alpha-adrenergic blocking agents,ranitidine
"ProAmatine. DRUG1, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, DRUG2, triamterene, flecainide, and quinidine. ",negative,Alpha-adrenergic blocking agents,procainamide
"ProAmatine. DRUG1, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, DRUG2, flecainide, and quinidine. ",negative,Alpha-adrenergic blocking agents,triamterene
"ProAmatine. DRUG1, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, DRUG2, and quinidine. ",negative,Alpha-adrenergic blocking agents,flecainide
"ProAmatine. DRUG1, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and DRUG2. ",negative,Alpha-adrenergic blocking agents,quinidine
"ProAmatine. Alpha-adrenergic blocking agents, such as DRUG1, DRUG2, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",negative,prazosin,terazosin
"ProAmatine. Alpha-adrenergic blocking agents, such as DRUG1, terazosin, and DRUG2, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",negative,prazosin,doxazosin
"DRUG2. Alpha-adrenergic blocking agents, such as DRUG1, terazosin, and doxazosin, can antagonize the effects of DRUG2. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",effect,prazosin,ProAmatine
"ProAmatine. Alpha-adrenergic blocking agents, such as DRUG1, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUG2 (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",negative,prazosin,desglymidodrine
"ProAmatine. Alpha-adrenergic blocking agents, such as DRUG1, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as DRUG2, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",negative,prazosin,metformin
"ProAmatine. Alpha-adrenergic blocking agents, such as DRUG1, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, DRUG2, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",negative,prazosin,cimetidine
"ProAmatine. Alpha-adrenergic blocking agents, such as DRUG1, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, DRUG2, procainamide, triamterene, flecainide, and quinidine. ",negative,prazosin,ranitidine
"ProAmatine. Alpha-adrenergic blocking agents, such as DRUG1, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, DRUG2, triamterene, flecainide, and quinidine. ",negative,prazosin,procainamide
"ProAmatine. Alpha-adrenergic blocking agents, such as DRUG1, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, DRUG2, flecainide, and quinidine. ",negative,prazosin,triamterene
"ProAmatine. Alpha-adrenergic blocking agents, such as DRUG1, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, DRUG2, and quinidine. ",negative,prazosin,flecainide
"ProAmatine. Alpha-adrenergic blocking agents, such as DRUG1, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and DRUG2. ",negative,prazosin,quinidine
"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, DRUG1, and DRUG2, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",negative,terazosin,doxazosin
"DRUG2. Alpha-adrenergic blocking agents, such as prazosin, DRUG1, and doxazosin, can antagonize the effects of DRUG2. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",effect,terazosin,ProAmatine
"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, DRUG1, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUG2 (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",negative,terazosin,desglymidodrine
"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, DRUG1, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as DRUG2, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",negative,terazosin,metformin
"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, DRUG1, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, DRUG2, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",negative,terazosin,cimetidine
"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, DRUG1, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, DRUG2, procainamide, triamterene, flecainide, and quinidine. ",negative,terazosin,ranitidine
"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, DRUG1, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, DRUG2, triamterene, flecainide, and quinidine. ",negative,terazosin,procainamide
"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, DRUG1, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, DRUG2, flecainide, and quinidine. ",negative,terazosin,triamterene
"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, DRUG1, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, DRUG2, and quinidine. ",negative,terazosin,flecainide
"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, DRUG1, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and DRUG2. ",negative,terazosin,quinidine
"DRUG2. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and DRUG1, can antagonize the effects of DRUG2. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",effect,doxazosin,ProAmatine
"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and DRUG1, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUG2 (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",negative,doxazosin,desglymidodrine
"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and DRUG1, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as DRUG2, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",negative,doxazosin,metformin
"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and DRUG1, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, DRUG2, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",negative,doxazosin,cimetidine
"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and DRUG1, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, DRUG2, procainamide, triamterene, flecainide, and quinidine. ",negative,doxazosin,ranitidine
"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and DRUG1, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, DRUG2, triamterene, flecainide, and quinidine. ",negative,doxazosin,procainamide
"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and DRUG1, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, DRUG2, flecainide, and quinidine. ",negative,doxazosin,triamterene
"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and DRUG1, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, DRUG2, and quinidine. ",negative,doxazosin,flecainide
"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and DRUG1, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and DRUG2. ",negative,doxazosin,quinidine
"DRUG1. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of DRUG1. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUG2 (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",negative,ProAmatine,desglymidodrine
"DRUG1. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of DRUG1. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as DRUG2, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",negative,ProAmatine,metformin
"DRUG1. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of DRUG1. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, DRUG2, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",negative,ProAmatine,cimetidine
"DRUG1. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of DRUG1. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, DRUG2, procainamide, triamterene, flecainide, and quinidine. ",negative,ProAmatine,ranitidine
"DRUG1. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of DRUG1. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, DRUG2, triamterene, flecainide, and quinidine. ",negative,ProAmatine,procainamide
"DRUG1. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of DRUG1. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, DRUG2, flecainide, and quinidine. ",negative,ProAmatine,triamterene
"DRUG1. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of DRUG1. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, DRUG2, and quinidine. ",negative,ProAmatine,flecainide
"DRUG1. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of DRUG1. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and DRUG2. ",negative,ProAmatine,quinidine
"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUG1 (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as DRUG2, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",mechanism,desglymidodrine,metformin
"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUG1 (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, DRUG2, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",mechanism,desglymidodrine,cimetidine
"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUG1 (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, DRUG2, procainamide, triamterene, flecainide, and quinidine. ",mechanism,desglymidodrine,ranitidine
"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUG1 (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, DRUG2, triamterene, flecainide, and quinidine. ",mechanism,desglymidodrine,procainamide
"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUG1 (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, DRUG2, flecainide, and quinidine. ",mechanism,desglymidodrine,triamterene
"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUG1 (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, DRUG2, and quinidine. ",mechanism,desglymidodrine,flecainide
"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUG1 (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and DRUG2. ",mechanism,desglymidodrine,quinidine
"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as DRUG1, DRUG2, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",negative,metformin,cimetidine
"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as DRUG1, cimetidine, DRUG2, procainamide, triamterene, flecainide, and quinidine. ",negative,metformin,ranitidine
"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as DRUG1, cimetidine, ranitidine, DRUG2, triamterene, flecainide, and quinidine. ",negative,metformin,procainamide
"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as DRUG1, cimetidine, ranitidine, procainamide, DRUG2, flecainide, and quinidine. ",negative,metformin,triamterene
"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as DRUG1, cimetidine, ranitidine, procainamide, triamterene, DRUG2, and quinidine. ",negative,metformin,flecainide
"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as DRUG1, cimetidine, ranitidine, procainamide, triamterene, flecainide, and DRUG2. ",negative,metformin,quinidine
"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, DRUG1, DRUG2, procainamide, triamterene, flecainide, and quinidine. ",negative,cimetidine,ranitidine
"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, DRUG1, ranitidine, DRUG2, triamterene, flecainide, and quinidine. ",negative,cimetidine,procainamide
"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, DRUG1, ranitidine, procainamide, DRUG2, flecainide, and quinidine. ",negative,cimetidine,triamterene
"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, DRUG1, ranitidine, procainamide, triamterene, DRUG2, and quinidine. ",negative,cimetidine,flecainide
"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, DRUG1, ranitidine, procainamide, triamterene, flecainide, and DRUG2. ",negative,cimetidine,quinidine
"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, DRUG1, DRUG2, triamterene, flecainide, and quinidine. ",negative,ranitidine,procainamide
"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, DRUG1, procainamide, DRUG2, flecainide, and quinidine. ",negative,ranitidine,triamterene
"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, DRUG1, procainamide, triamterene, DRUG2, and quinidine. ",negative,ranitidine,flecainide
"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, DRUG1, procainamide, triamterene, flecainide, and DRUG2. ",negative,ranitidine,quinidine
"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, DRUG1, DRUG2, flecainide, and quinidine. ",negative,procainamide,triamterene
"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, DRUG1, triamterene, DRUG2, and quinidine. ",negative,procainamide,flecainide
"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, DRUG1, triamterene, flecainide, and DRUG2. ",negative,procainamide,quinidine
"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, DRUG1, DRUG2, and quinidine. ",negative,triamterene,flecainide
"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, DRUG1, flecainide, and DRUG2. ",negative,triamterene,quinidine
"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, DRUG1, and DRUG2. ",negative,flecainide,quinidine
Preliminary evidence suggests that DRUG1 inhibits DRUG2 metabolism and may result in an increase in plasma concentrations of DRUG2.,mechanism,cimetidine,mebendazole
Preliminary evidence suggests that DRUG1 inhibits DRUG2 metabolism and may result in an increase in plasma concentrations of DRUG2.,negative,cimetidine,mebendazole
Preliminary evidence suggests that cimetidine inhibits DRUG1 metabolism and may result in an increase in plasma concentrations of DRUG1.,negative,mebendazole,mebendazole
Interactions for DRUG1 (DRUG2):  Alcohol - impairs the intestinal absorption of DRUG2,negative,Vitamin B2,Riboflavin
Interactions for DRUG1 (Riboflavin):  DRUG2 - impairs the intestinal absorption of riboflavin,negative,Vitamin B2,Alcohol
Interactions for DRUG1 (DRUG2):  Alcohol - impairs the intestinal absorption of DRUG2,negative,Vitamin B2,riboflavin
Interactions for Vitamin B2 (DRUG1):  DRUG2 - impairs the intestinal absorption of DRUG1,negative,Riboflavin,Alcohol
Interactions for Vitamin B2 (DRUG1):  Alcohol - impairs the intestinal absorption of DRUG1,negative,Riboflavin,riboflavin
Interactions for Vitamin B2 (DRUG2):  DRUG1 - impairs the intestinal absorption of DRUG2,mechanism,Alcohol,riboflavin
DRUG1 - concurrent use decreases gastrointestinal absorption of DRUG2; ,mechanism,Probenecid,riboflavin
requirements for DRUG1 may be increased in patients receiving DRUG2.,effect,riboflavin,probenecid
"The concomitant use of other DRUG1 including DRUG2, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. ",negative,CNS depressants,sedatives
"The concomitant use of other DRUG1 including sedatives, DRUG2, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. ",negative,CNS depressants,hypnotics
"The concomitant use of other DRUG1 including sedatives, hypnotics, DRUG2, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. ",negative,CNS depressants,tranquilizers
"The concomitant use of other DRUG1 including sedatives, hypnotics, tranquilizers, general DRUG2, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. ",negative,CNS depressants,anesthetics
"The concomitant use of other DRUG1 including sedatives, hypnotics, tranquilizers, general anesthetics, DRUG2, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. ",negative,CNS depressants,phenothiazines
"The concomitant use of other DRUG1 including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other DRUG2, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. ",negative,CNS depressants,opioids
"The concomitant use of other DRUG1 including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, DRUG2, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. ",negative,CNS depressants,tricyclic antidepressants
"The concomitant use of other DRUG1 including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, DRUG2, and alcohol may produce additive CNS depressant effects. ",negative,CNS depressants,monoamine oxidase (MAO) inhibitors
"The concomitant use of other DRUG1 including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and DRUG2 may produce additive CNS depressant effects. ",negative,CNS depressants,alcohol
"The concomitant use of other CNS depressants including DRUG1, DRUG2, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. ",negative,sedatives,hypnotics
"The concomitant use of other CNS depressants including DRUG1, hypnotics, DRUG2, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. ",negative,sedatives,tranquilizers
"The concomitant use of other CNS depressants including DRUG1, hypnotics, tranquilizers, general DRUG2, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. ",negative,sedatives,anesthetics
"The concomitant use of other CNS depressants including DRUG1, hypnotics, tranquilizers, general anesthetics, DRUG2, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. ",negative,sedatives,phenothiazines
"The concomitant use of other CNS depressants including DRUG1, hypnotics, tranquilizers, general anesthetics, phenothiazines, other DRUG2, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. ",negative,sedatives,opioids
"The concomitant use of other CNS depressants including DRUG1, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, DRUG2, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. ",negative,sedatives,tricyclic antidepressants
"The concomitant use of other CNS depressants including DRUG1, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, DRUG2, and alcohol may produce additive CNS depressant effects. ",negative,sedatives,monoamine oxidase (MAO) inhibitors
"The concomitant use of other CNS depressants including DRUG1, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and DRUG2 may produce additive CNS depressant effects. ",negative,sedatives,alcohol
"The concomitant use of other CNS depressants including sedatives, DRUG1, DRUG2, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. ",negative,hypnotics,tranquilizers
"The concomitant use of other CNS depressants including sedatives, DRUG1, tranquilizers, general DRUG2, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. ",negative,hypnotics,anesthetics
"The concomitant use of other CNS depressants including sedatives, DRUG1, tranquilizers, general anesthetics, DRUG2, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. ",negative,hypnotics,phenothiazines
"The concomitant use of other CNS depressants including sedatives, DRUG1, tranquilizers, general anesthetics, phenothiazines, other DRUG2, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. ",negative,hypnotics,opioids
"The concomitant use of other CNS depressants including sedatives, DRUG1, tranquilizers, general anesthetics, phenothiazines, other opioids, DRUG2, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. ",negative,hypnotics,tricyclic antidepressants
"The concomitant use of other CNS depressants including sedatives, DRUG1, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, DRUG2, and alcohol may produce additive CNS depressant effects. ",negative,hypnotics,monoamine oxidase (MAO) inhibitors
"The concomitant use of other CNS depressants including sedatives, DRUG1, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and DRUG2 may produce additive CNS depressant effects. ",negative,hypnotics,alcohol
"The concomitant use of other CNS depressants including sedatives, hypnotics, DRUG1, general DRUG2, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. ",negative,tranquilizers,anesthetics
"The concomitant use of other CNS depressants including sedatives, hypnotics, DRUG1, general anesthetics, DRUG2, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. ",negative,tranquilizers,phenothiazines
"The concomitant use of other CNS depressants including sedatives, hypnotics, DRUG1, general anesthetics, phenothiazines, other DRUG2, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. ",negative,tranquilizers,opioids
"The concomitant use of other CNS depressants including sedatives, hypnotics, DRUG1, general anesthetics, phenothiazines, other opioids, DRUG2, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. ",negative,tranquilizers,tricyclic antidepressants
"The concomitant use of other CNS depressants including sedatives, hypnotics, DRUG1, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, DRUG2, and alcohol may produce additive CNS depressant effects. ",negative,tranquilizers,monoamine oxidase (MAO) inhibitors
"The concomitant use of other CNS depressants including sedatives, hypnotics, DRUG1, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and DRUG2 may produce additive CNS depressant effects. ",negative,tranquilizers,alcohol
"The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general DRUG1, DRUG2, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. ",negative,anesthetics,phenothiazines
"The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general DRUG1, phenothiazines, other DRUG2, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. ",negative,anesthetics,opioids
"The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general DRUG1, phenothiazines, other opioids, DRUG2, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. ",negative,anesthetics,tricyclic antidepressants
"The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general DRUG1, phenothiazines, other opioids, tricyclic antidepressants, DRUG2, and alcohol may produce additive CNS depressant effects. ",negative,anesthetics,monoamine oxidase (MAO) inhibitors
"The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general DRUG1, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and DRUG2 may produce additive CNS depressant effects. ",negative,anesthetics,alcohol
"The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, DRUG1, other DRUG2, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. ",negative,phenothiazines,opioids
"The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, DRUG1, other opioids, DRUG2, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. ",negative,phenothiazines,tricyclic antidepressants
"The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, DRUG1, other opioids, tricyclic antidepressants, DRUG2, and alcohol may produce additive CNS depressant effects. ",negative,phenothiazines,monoamine oxidase (MAO) inhibitors
"The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, DRUG1, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and DRUG2 may produce additive CNS depressant effects. ",negative,phenothiazines,alcohol
"The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other DRUG1, DRUG2, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. ",negative,opioids,tricyclic antidepressants
"The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other DRUG1, tricyclic antidepressants, DRUG2, and alcohol may produce additive CNS depressant effects. ",negative,opioids,monoamine oxidase (MAO) inhibitors
"The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other DRUG1, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and DRUG2 may produce additive CNS depressant effects. ",negative,opioids,alcohol
"The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, DRUG1, DRUG2, and alcohol may produce additive CNS depressant effects. ",negative,tricyclic antidepressants,monoamine oxidase (MAO) inhibitors
"The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, DRUG1, monoamine oxidase (MAO) inhibitors, and DRUG2 may produce additive CNS depressant effects. ",negative,tricyclic antidepressants,alcohol
"The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, DRUG1, and DRUG2 may produce additive CNS depressant effects. ",negative,monoamine oxidase (MAO) inhibitors,alcohol
"DRUG1 or other medications with anticholinergic activity when used concurrently with DRUG2 may result in increased risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. ",effect,Anticholinergics,opioid analgesics
It has been reported that the incidence of bradycardia was increased when DRUG1 was combined with DRUG2 for induction of anesthesia. ,effect,oxymorphone,propofol
"In addition, CNS toxicity has been reported (confusion, disorientation, respiratory depression, apnea, seizures) following coadministration of DRUG1 with DRUG2; ",effect,cimetidine,opioid analgesics
"Since DRUG1 (DRUG2) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg DRUG2 may increase the plasma concentrations of phenytoin and phenobarbital).",negative,Celontin,methsuximide
"Since DRUG1 (methsuximide) may interact with concurrently administered DRUG2, periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital).",advise,Celontin,antiepileptic drugs
"Since DRUG1 (DRUG2) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg DRUG2 may increase the plasma concentrations of phenytoin and phenobarbital).",negative,Celontin,methsuximide
"Since DRUG1 (methsuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of DRUG2 and phenobarbital).",negative,Celontin,phenytoin
"Since DRUG1 (methsuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of phenytoin and DRUG2).",negative,Celontin,phenobarbital
"Since Celontin (DRUG1) may interact with concurrently administered DRUG2, periodic serum level determinations of these drugs may be necessary (eg DRUG1 may increase the plasma concentrations of phenytoin and phenobarbital).",advise,methsuximide,antiepileptic drugs
"Since Celontin (DRUG1) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg DRUG1 may increase the plasma concentrations of phenytoin and phenobarbital).",negative,methsuximide,methsuximide
"Since Celontin (DRUG1) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg DRUG1 may increase the plasma concentrations of DRUG2 and phenobarbital).",negative,methsuximide,phenytoin
"Since Celontin (DRUG1) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg DRUG1 may increase the plasma concentrations of phenytoin and DRUG2).",negative,methsuximide,phenobarbital
"Since Celontin (DRUG2) may interact with concurrently administered DRUG1, periodic serum level determinations of these drugs may be necessary (eg DRUG2 may increase the plasma concentrations of phenytoin and phenobarbital).",negative,antiepileptic drugs,methsuximide
"Since Celontin (methsuximide) may interact with concurrently administered DRUG1, periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of DRUG2 and phenobarbital).",negative,antiepileptic drugs,phenytoin
"Since Celontin (methsuximide) may interact with concurrently administered DRUG1, periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of phenytoin and DRUG2).",negative,antiepileptic drugs,phenobarbital
"Since Celontin (DRUG1) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg DRUG1 may increase the plasma concentrations of DRUG2 and phenobarbital).",mechanism,methsuximide,phenytoin
"Since Celontin (DRUG1) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg DRUG1 may increase the plasma concentrations of phenytoin and DRUG2).",mechanism,methsuximide,phenobarbital
"Since Celontin (methsuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of DRUG1 and DRUG2).",negative,phenytoin,phenobarbital
"When DRUG1 and DRUG2 are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected when DRUG1 is used alone. ",effect,atropine,pralidoxime
"When DRUG1 and pralidoxime are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected when DRUG1 is used alone. ",negative,atropine,atropine
"When DRUG2 and DRUG1 are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected when DRUG2 is used alone. ",negative,pralidoxime,atropine
This is especially true if the total dose of DRUG1 has been large and the administration of DRUG2 has been delayed. ,negative,atropine,pralidoxime
"2 - 4 The following precautions should be kept in mind in the treatment of anticholinesterase poisoning, although they do not bear directly on the use of DRUG1: since DRUG2 are potentiated by the anticholinesterases, they should be used cautiously in the treatment of convulsions; ",negative,pralidoxime,barbiturates
"2 - 4 The following precautions should be kept in mind in the treatment of anticholinesterase poisoning, although they do not bear directly on the use of DRUG1: since barbiturates are potentiated by the DRUG2, they should be used cautiously in the treatment of convulsions; ",negative,pralidoxime,anticholinesterases
"2 - 4 The following precautions should be kept in mind in the treatment of anticholinesterase poisoning, although they do not bear directly on the use of pralidoxime: since DRUG1 are potentiated by the DRUG2, they should be used cautiously in the treatment of convulsions; ",effect,barbiturates,anticholinesterases
"DRUG1, DRUG2, aminophylline, succinylcholine, reserpine, and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning.",negative,morphine,theophylline
"DRUG1, theophylline, DRUG2, succinylcholine, reserpine, and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning.",negative,morphine,aminophylline
"DRUG1, theophylline, aminophylline, DRUG2, reserpine, and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning.",negative,morphine,succinylcholine
"DRUG1, theophylline, aminophylline, succinylcholine, DRUG2, and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning.",negative,morphine,reserpine
"DRUG1, theophylline, aminophylline, succinylcholine, reserpine, and DRUG2 should be avoided in patients with organophosphate poisoning.",negative,morphine,phenothiazine-type tranquilizers
"morphine, DRUG1, DRUG2, succinylcholine, reserpine, and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning.",negative,theophylline,aminophylline
"morphine, DRUG1, aminophylline, DRUG2, reserpine, and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning.",negative,theophylline,succinylcholine
"morphine, DRUG1, aminophylline, succinylcholine, DRUG2, and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning.",negative,theophylline,reserpine
"morphine, DRUG1, aminophylline, succinylcholine, reserpine, and DRUG2 should be avoided in patients with organophosphate poisoning.",negative,theophylline,phenothiazine-type tranquilizers
"morphine, theophylline, DRUG1, DRUG2, reserpine, and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning.",negative,aminophylline,succinylcholine
"morphine, theophylline, DRUG1, succinylcholine, DRUG2, and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning.",negative,aminophylline,reserpine
"morphine, theophylline, DRUG1, succinylcholine, reserpine, and DRUG2 should be avoided in patients with organophosphate poisoning.",negative,aminophylline,phenothiazine-type tranquilizers
"morphine, theophylline, aminophylline, DRUG1, DRUG2, and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning.",negative,succinylcholine,reserpine
"morphine, theophylline, aminophylline, DRUG1, reserpine, and DRUG2 should be avoided in patients with organophosphate poisoning.",negative,succinylcholine,phenothiazine-type tranquilizers
"morphine, theophylline, aminophylline, succinylcholine, DRUG1, and DRUG2 should be avoided in patients with organophosphate poisoning.",negative,reserpine,phenothiazine-type tranquilizers
Reduced absorption of DRUG1 and DRUG2 have been reported when those agents were administered concomitantly with sulfasalazine. ,negative,folic acid,digoxin
Reduced absorption of DRUG1 and digoxin have been reported when those agents were administered concomitantly with DRUG2. ,mechanism,folic acid,sulfasalazine
Reduced absorption of folic acid and DRUG1 have been reported when those agents were administered concomitantly with DRUG2. ,mechanism,digoxin,sulfasalazine
"When daily doses of DRUG1 2 g and weekly doses of DRUG2 7.5 mg were coadministered to 15 rheumatoid arthritis patients in a drug-drug interaction study, the pharmacokinetic disposition of the drugs was not altered. ",negative,sulfasalazine,methotrexate
Daily doses of DRUG1 2 g (maximum 3 g) and weekly doses of DRUG2 7.5 mg (maximum 15 mg) were administered alone or in combination to 310 rheumatoid arthritis patients in two controlled 52-week clinical studies. ,negative,sulfasalazine,methotrexate
DRUG1 DRUG2 may increase sensitivity to oral DRUG1. ,negative,Anticoagulants,Anabolic steroids
DRUG1 Anabolic steroids may increase sensitivity to oral DRUG1. ,negative,Anticoagulants,anticoagulants
DRUG2 DRUG1 may increase sensitivity to oral DRUG2. ,effect,Anabolic steroids,anticoagulants
"DRUG1: A multidose study of DRUG2, given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with DRUG1, resulted in a mean increase in S-DRUG1 half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL: similar increases in R-DRUG1 half-life and AUC were also detected. ",negative,Warfarin,oxandrolone
"DRUG1: A multidose study of oxandrolone, given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with DRUG1, resulted in a mean increase in S-DRUG1 half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL: similar increases in R-DRUG1 half-life and AUC were also detected. ",negative,Warfarin,warfarin
"DRUG1: A multidose study of oxandrolone, given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with DRUG1, resulted in a mean increase in S-DRUG1 half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL: similar increases in R-DRUG1 half-life and AUC were also detected. ",negative,Warfarin,S-warfarin
"DRUG1: A multidose study of oxandrolone, given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with DRUG1, resulted in a mean increase in S-DRUG1 half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL: similar increases in R-DRUG1 half-life and AUC were also detected. ",negative,Warfarin,R-warfarin
"DRUG2: A multidose study of DRUG1, given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with DRUG2, resulted in a mean increase in S-DRUG2 half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL: similar increases in R-DRUG2 half-life and AUC were also detected. ",mechanism,oxandrolone,warfarin
"Warfarin: A multidose study of DRUG1, given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with warfarin, resulted in a mean increase in DRUG2 half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL: similar increases in R-warfarin half-life and AUC were also detected. ",negative,oxandrolone,S-warfarin
"Warfarin: A multidose study of DRUG1, given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with warfarin, resulted in a mean increase in S-warfarin half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL: similar increases in DRUG2 half-life and AUC were also detected. ",negative,oxandrolone,R-warfarin
"DRUG1: A multidose study of oxandrolone, given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with DRUG1, resulted in a mean increase in S-DRUG1 half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL: similar increases in R-DRUG1 half-life and AUC were also detected. ",negative,warfarin,S-warfarin
"DRUG1: A multidose study of oxandrolone, given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with DRUG1, resulted in a mean increase in S-DRUG1 half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL: similar increases in R-DRUG1 half-life and AUC were also detected. ",negative,warfarin,R-warfarin
"Warfarin: A multidose study of oxandrolone, given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with warfarin, resulted in a mean increase in DRUG1 half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL: similar increases in DRUG2 half-life and AUC were also detected. ",negative,S-warfarin,R-warfarin
"A 5.5-fold decrease in the mean DRUG1 dose from 6.13 mg/day to 1.13 mg/day (approximately 80-85% reduction of DRUG1 dose), was necessary to maintain a target INR of 1.5. ",negative,warfarin,warfarin
"When DRUG1 therapy is initiated in a patient already receiving treatment with DRUG2, the INR or prothrombin time (PT) should be monitored closely and the dose of DRUG2 adjusted as necessary until a stable target INR or PT has been achieved. ",advise,oxandrolone,warfarin
"When DRUG1 therapy is initiated in a patient already receiving treatment with DRUG2, the INR or prothrombin time (PT) should be monitored closely and the dose of DRUG2 adjusted as necessary until a stable target INR or PT has been achieved. ",negative,oxandrolone,warfarin
"When oxandrolone therapy is initiated in a patient already receiving treatment with DRUG1, the INR or prothrombin time (PT) should be monitored closely and the dose of DRUG1 adjusted as necessary until a stable target INR or PT has been achieved. ",negative,warfarin,warfarin
"Furthermore, in patients receiving both drugs, careful monitoring of the INR or PT, and adjustment of the DRUG1 dosage if indicated are recommended when the DRUG2 dose is changed or discontinued. ",advise,warfarin,oxandrolone
Oral DRUG1 DRUG2 may inhibit the metabolism of oral DRUG1. ,negative,hypoglycemic agents,Oxandrolone
Oral DRUG1 Oxandrolone may inhibit the metabolism of oral DRUG1. ,negative,hypoglycemic agents,hypoglycemic agents
Oral DRUG2 DRUG1 may inhibit the metabolism of oral DRUG2. ,mechanism,Oxandrolone,hypoglycemic agents
"DRUG1 or DRUG2 In patients with edema, concomitant administration with adrenal cortical steroids or DRUG2 may increase the edema. ",negative,Adrenal steroids,ACTH
"DRUG1 or ACTH In patients with edema, concomitant administration with DRUG2 or ACTH may increase the edema. ",negative,Adrenal steroids,adrenal cortical steroids
"DRUG1 or DRUG2 In patients with edema, concomitant administration with adrenal cortical steroids or DRUG2 may increase the edema. ",negative,Adrenal steroids,ACTH
"Adrenal steroids or DRUG1 In patients with edema, concomitant administration with DRUG2 or DRUG1 may increase the edema. ",negative,ACTH,adrenal cortical steroids
"Adrenal steroids or DRUG1 In patients with edema, concomitant administration with adrenal cortical steroids or DRUG1 may increase the edema. ",negative,ACTH,ACTH
"Adrenal steroids or DRUG2 In patients with edema, concomitant administration with DRUG1 or DRUG2 may increase the edema. ",negative,adrenal cortical steroids,ACTH
DRUG1 may reverse the analgesic activity of DRUG2. ,effect,Methysergide,narcotic analgesics
"Concurrent use with DRUG1 including DRUG2, sumatriptan, and nicotine (e.g. smoking) may result in enhanced vasoconstriction.",negative,vasoconstrictor agents,ergot alkaloids
"Concurrent use with DRUG1 including ergot alkaloids, DRUG2, and nicotine (e.g. smoking) may result in enhanced vasoconstriction.",negative,vasoconstrictor agents,sumatriptan
"Concurrent use with DRUG1 including ergot alkaloids, sumatriptan, and DRUG2 (e.g. smoking) may result in enhanced vasoconstriction.",negative,vasoconstrictor agents,nicotine
"Concurrent use with vasoconstrictor agents including DRUG1, DRUG2, and nicotine (e.g. smoking) may result in enhanced vasoconstriction.",negative,ergot alkaloids,sumatriptan
"Concurrent use with vasoconstrictor agents including DRUG1, sumatriptan, and DRUG2 (e.g. smoking) may result in enhanced vasoconstriction.",negative,ergot alkaloids,nicotine
"Concurrent use with vasoconstrictor agents including ergot alkaloids, DRUG1, and DRUG2 (e.g. smoking) may result in enhanced vasoconstriction.",negative,sumatriptan,nicotine
DRUG1 competitively inhibits the intracellular phosphorylation of DRUG2. ,effect,Zidovudine,stavudine
"Therefore, use of DRUG1 in combination with DRUG2 should be avoided. ",advise,zidovudine,ZERIT
In vitro data indicate that the phosphorylation of DRUG1 is also inhibited at relevant concentrations by DRUG2 and ribavirin. ,effect,stavudine,doxorubicin
In vitro data indicate that the phosphorylation of DRUG1 is also inhibited at relevant concentrations by doxorubicin and DRUG2. ,effect,stavudine,ribavirin
In vitro data indicate that the phosphorylation of stavudine is also inhibited at relevant concentrations by DRUG1 and DRUG2. ,negative,doxorubicin,ribavirin
"When administered concurrently, DRUG1 may increase the effects of oral DRUG2; ",effect,testolactone,anticoagulants
DRUG1: Concomitant DRUG1 administration decreased the mean AUC of total ezetimibe approximately 55%. ,negative,Cholestyramine,cholestyramine
DRUG1: Concomitant DRUG1 administration decreased the mean AUC of total DRUG2 approximately 55%. ,negative,Cholestyramine,ezetimibe
DRUG1: Concomitant DRUG1 administration decreased the mean AUC of total DRUG2 approximately 55%. ,mechanism,cholestyramine,ezetimibe
The incremental LDL-C reduction due to adding DRUG1 to DRUG2 may be reduced by this interaction. ,effect,ezetimibe,cholestyramine
DRUG1: The safety and effectiveness of DRUG2 administered with DRUG1 have not been established. ,negative,Fibrates,ezetimibe
DRUG1: The safety and effectiveness of ezetimibe administered with DRUG1 have not been established. ,negative,Fibrates,fibrates
DRUG2: The safety and effectiveness of DRUG1 administered with DRUG2 have not been established. ,negative,ezetimibe,fibrates
Co-administration of DRUG1 with DRUG2 is not recommended until use in patients is studied. ,advise,ZETIA,fibrates
"DRUG1: In a pharmacokinetic study, concomitant DRUG1 administration increased total ezetimibe concentrations approximately 1.5-fold. ",negative,Fenofibrate,fenofibrate
"DRUG1: In a pharmacokinetic study, concomitant DRUG1 administration increased total DRUG2 concentrations approximately 1.5-fold. ",negative,Fenofibrate,ezetimibe
"DRUG1: In a pharmacokinetic study, concomitant DRUG1 administration increased total DRUG2 concentrations approximately 1.5-fold. ",mechanism,fenofibrate,ezetimibe
"DRUG1: In a pharmacokinetic study, concomitant DRUG1 administration increased total ezetimibe concentrations approximately 1.7-fold. ",negative,Gemfibrozil,gemfibrozil
"DRUG1: In a pharmacokinetic study, concomitant DRUG1 administration increased total DRUG2 concentrations approximately 1.7-fold. ",negative,Gemfibrozil,ezetimibe
"DRUG1: In a pharmacokinetic study, concomitant DRUG1 administration increased total DRUG2 concentrations approximately 1.7-fold. ",negative,gemfibrozil,ezetimibe
"DRUG1: No clinically significant pharmacokinetic interactions were seen when DRUG2 was co-administered with atorvastatin, simvastatin, pravastatin, lovastatin, or fluvastatin. ",negative,HMG-CoA reductase inhibitors,ezetimibe
"DRUG1: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with DRUG2, simvastatin, pravastatin, lovastatin, or fluvastatin. ",negative,HMG-CoA reductase inhibitors,atorvastatin
"DRUG1: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, DRUG2, pravastatin, lovastatin, or fluvastatin. ",negative,HMG-CoA reductase inhibitors,simvastatin
"DRUG1: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, simvastatin, DRUG2, lovastatin, or fluvastatin. ",negative,HMG-CoA reductase inhibitors,pravastatin
"DRUG1: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, simvastatin, pravastatin, DRUG2, or fluvastatin. ",negative,HMG-CoA reductase inhibitors,lovastatin
"DRUG1: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, simvastatin, pravastatin, lovastatin, or DRUG2. ",negative,HMG-CoA reductase inhibitors,fluvastatin
"HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when DRUG1 was co-administered with DRUG2, simvastatin, pravastatin, lovastatin, or fluvastatin. ",negative,ezetimibe,atorvastatin
"HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when DRUG1 was co-administered with atorvastatin, DRUG2, pravastatin, lovastatin, or fluvastatin. ",negative,ezetimibe,simvastatin
"HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when DRUG1 was co-administered with atorvastatin, simvastatin, DRUG2, lovastatin, or fluvastatin. ",negative,ezetimibe,pravastatin
"HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when DRUG1 was co-administered with atorvastatin, simvastatin, pravastatin, DRUG2, or fluvastatin. ",negative,ezetimibe,lovastatin
"HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when DRUG1 was co-administered with atorvastatin, simvastatin, pravastatin, lovastatin, or DRUG2. ",negative,ezetimibe,fluvastatin
"HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with DRUG1, DRUG2, pravastatin, lovastatin, or fluvastatin. ",negative,atorvastatin,simvastatin
"HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with DRUG1, simvastatin, DRUG2, lovastatin, or fluvastatin. ",negative,atorvastatin,pravastatin
"HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with DRUG1, simvastatin, pravastatin, DRUG2, or fluvastatin. ",negative,atorvastatin,lovastatin
"HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with DRUG1, simvastatin, pravastatin, lovastatin, or DRUG2. ",negative,atorvastatin,fluvastatin
"HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, DRUG1, DRUG2, lovastatin, or fluvastatin. ",negative,simvastatin,pravastatin
"HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, DRUG1, pravastatin, DRUG2, or fluvastatin. ",negative,simvastatin,lovastatin
"HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, DRUG1, pravastatin, lovastatin, or DRUG2. ",negative,simvastatin,fluvastatin
"HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, simvastatin, DRUG1, DRUG2, or fluvastatin. ",negative,pravastatin,lovastatin
"HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, simvastatin, DRUG1, lovastatin, or DRUG2. ",negative,pravastatin,fluvastatin
"HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, simvastatin, pravastatin, DRUG1, or DRUG2. ",negative,lovastatin,fluvastatin
"DRUG1: The total DRUG2 level increased 12-fold in one renal transplant patient receiving multiple medications, including DRUG1. ",negative,Cyclosporine,ezetimibe
"DRUG1: The total ezetimibe level increased 12-fold in one renal transplant patient receiving multiple medications, including DRUG1. ",negative,Cyclosporine,cyclosporine
"DRUG2: The total DRUG1 level increased 12-fold in one renal transplant patient receiving multiple medications, including DRUG2. ",mechanism,ezetimibe,cyclosporine
Patients who take both DRUG1 and DRUG2 should be carefully monitored. ,advise,ezetimibe,cyclosporine
"Carcinogenesis, Mutagenesis, Impairment of Fertility A 104-week dietary carcinogenicity study with DRUG1 was conducted in rats at doses up to 1500 mg/kg/day (males) and 500 mg/kg/day (females) (~20 times the human exposure at 10 mg daily based on AUC0-24hr for total DRUG1). ",negative,ezetimibe,ezetimibe
A 104-week dietary carcinogenicity study with DRUG1 was also conducted in mice at doses up to 500 mg/kg/day (>150 times the human exposure at 10 mg daily based on AUC0-24hr for total DRUG1). ,negative,ezetimibe,ezetimibe
"In oral (gavage) fertility studies of DRUG1 conducted in rats, there was no evidence of reproductive toxicity at doses up to 1000 mg/kg/day in male or female rats (~7 times the human exposure at 10 mg daily based on AUC0-24hr for total DRUG1). ",negative,ezetimibe,ezetimibe
"In rabbits treated with DRUG1, an increased incidence of extra thoracic ribs was observed at 1000 mg/kg/day (150 times the human exposure at 10 mg daily based on AUC0-24hr for total DRUG1). ",negative,ezetimibe,ezetimibe
Multiple dose studies of DRUG1 given in combination with DRUG2 (statins) in rats and rabbits during organogenesis result in higher DRUG1 and statin exposures. ,negative,ezetimibe,HMG-CoA reductase inhibitors
Multiple dose studies of DRUG1 given in combination with HMG-CoA reductase inhibitors (DRUG2) in rats and rabbits during organogenesis result in higher DRUG1 and statin exposures. ,negative,ezetimibe,statins
Multiple dose studies of DRUG1 given in combination with HMG-CoA reductase inhibitors (statins) in rats and rabbits during organogenesis result in higher DRUG1 and statin exposures. ,negative,ezetimibe,ezetimibe
Multiple dose studies of ezetimibe given in combination with DRUG1 (DRUG2) in rats and rabbits during organogenesis result in higher ezetimibe and statin exposures. ,negative,HMG-CoA reductase inhibitors,statins
Multiple dose studies of DRUG2 given in combination with DRUG1 (statins) in rats and rabbits during organogenesis result in higher DRUG2 and statin exposures. ,negative,HMG-CoA reductase inhibitors,ezetimibe
Multiple dose studies of DRUG2 given in combination with HMG-CoA reductase inhibitors (DRUG1) in rats and rabbits during organogenesis result in higher DRUG2 and statin exposures. ,negative,statins,ezetimibe
"When DRUG1 is administered with an DRUG2 in a woman of childbearing potential, refer to the pregnancy category and package labeling for the DRUG2. ",negative,ZETIA,HMG-CoA reductase inhibitor
"When DRUG1 is administered with an DRUG2 in a woman of childbearing potential, refer to the pregnancy category and package labeling for the DRUG2. ",negative,ZETIA,HMG-CoA reductase inhibitor
"When ZETIA is administered with an DRUG1 in a woman of childbearing potential, refer to the pregnancy category and package labeling for the DRUG1. ",negative,HMG-CoA reductase inhibitor,HMG-CoA reductase inhibitor
"However, DRUG1, a potent inhibitor of cytochrome P450 3A4, may increase plasma levels of DRUG2 during concomitant dosing.",mechanism,ketoconazole,mometasone furoate
"DRUG1 may enhance the effects of DRUG2, barbiturates and other CNS depressants.",effect,SKELAXIN,alcohol
"DRUG1 may enhance the effects of alcohol, DRUG2 and other CNS depressants.",effect,SKELAXIN,barbiturates
"DRUG1 may enhance the effects of alcohol, barbiturates and other DRUG2.",effect,SKELAXIN,CNS depressants
"SKELAXIN may enhance the effects of DRUG1, DRUG2 and other CNS depressants.",negative,alcohol,barbiturates
"SKELAXIN may enhance the effects of DRUG1, barbiturates and other DRUG2.",negative,alcohol,CNS depressants
"SKELAXIN may enhance the effects of alcohol, DRUG1 and other DRUG2.",negative,barbiturates,CNS depressants
"The DRUG1 (DRUG2), one of S-adenosylhomocysteine (AdoHcy) hydrolase inhibitors, has shown antitumor activities in a broad range of solid tumors and acute myeloid leukemia. ",negative,3-Deazaneplanocin A,DZNep
"We also found that Bcl-2 was overexpressed in DRUG1 insensitive cells, and cotreatment with DRUG1 and ABT-737, a Bcl-2 family inhibitor, synergistically inhibited growth and induced apoptosis of DRUG1 insensitive MM cells. ",negative,DZNep,DZNep
"We also found that Bcl-2 was overexpressed in DRUG1 insensitive cells, and cotreatment with DRUG1 and DRUG2, a Bcl-2 family inhibitor, synergistically inhibited growth and induced apoptosis of DRUG1 insensitive MM cells. ",negative,DZNep,ABT-737
"We also found that Bcl-2 was overexpressed in DRUG1 insensitive cells, and cotreatment with DRUG1 and ABT-737, a Bcl-2 family inhibitor, synergistically inhibited growth and induced apoptosis of DRUG1 insensitive MM cells. ",negative,DZNep,DZNep
"We also found that Bcl-2 was overexpressed in DRUG1 insensitive cells, and cotreatment with DRUG1 and DRUG2, a Bcl-2 family inhibitor, synergistically inhibited growth and induced apoptosis of DRUG1 insensitive MM cells. ",effect,DZNep,ABT-737
"We also found that Bcl-2 was overexpressed in DRUG1 insensitive cells, and cotreatment with DRUG1 and ABT-737, a Bcl-2 family inhibitor, synergistically inhibited growth and induced apoptosis of DRUG1 insensitive MM cells. ",negative,DZNep,DZNep
"We also found that Bcl-2 was overexpressed in DRUG2 insensitive cells, and cotreatment with DRUG2 and DRUG1, a Bcl-2 family inhibitor, synergistically inhibited growth and induced apoptosis of DRUG2 insensitive MM cells. ",negative,ABT-737,DZNep
"In addition, DRUG1 insensitivity might be associated with overexpression of Bcl-2, and the combination of DRUG2 and DRUG1 could synergistically induced apoptosis. ",negative,DZNep,ABT-737
"In addition, DRUG1 insensitivity might be associated with overexpression of Bcl-2, and the combination of ABT-737 and DRUG1 could synergistically induced apoptosis. ",negative,DZNep,DZNep
"In addition, DRUG2 insensitivity might be associated with overexpression of Bcl-2, and the combination of DRUG1 and DRUG2 could synergistically induced apoptosis. ",effect,ABT-737,DZNep
"DRUG1 enhances the antinociceptive effect of DRUG2 in mice.
",effect,Ephedrine,dexmedetomidine
The purpose of this study was to evaluate whether the psychostimulant drug DRUG1 has any effect on DRUG2-induced antinociception and locomotor inhibitor activity in mice in acute application.,negative,ephedrine,dexmedetomidine
"saline + saline, DRUG1 (10   mg/kg) + saline, saline + DRUG2 (15     g/kg) and DRUG1 (10   mg/kg) + DRUG2 (15     g/kg), intraperitoneally, 30 min before hot plate or holed open field tests. ",negative,ephedrine,dexmedetomidine
"saline + saline, DRUG1 (10   mg/kg) + saline, saline + dexmedetomidine (15     g/kg) and DRUG1 (10   mg/kg) + dexmedetomidine (15     g/kg), intraperitoneally, 30 min before hot plate or holed open field tests. ",negative,ephedrine,ephedrine
"saline + saline, DRUG1 (10   mg/kg) + saline, saline + DRUG2 (15     g/kg) and DRUG1 (10   mg/kg) + DRUG2 (15     g/kg), intraperitoneally, 30 min before hot plate or holed open field tests. ",negative,ephedrine,dexmedetomidine
"saline + saline, DRUG2 (10   mg/kg) + saline, saline + DRUG1 (15     g/kg) and DRUG2 (10   mg/kg) + DRUG1 (15     g/kg), intraperitoneally, 30 min before hot plate or holed open field tests. ",negative,dexmedetomidine,ephedrine
"saline + saline, ephedrine (10   mg/kg) + saline, saline + DRUG1 (15     g/kg) and ephedrine (10   mg/kg) + DRUG1 (15     g/kg), intraperitoneally, 30 min before hot plate or holed open field tests. ",negative,dexmedetomidine,dexmedetomidine
"saline + saline, DRUG1 (10   mg/kg) + saline, saline + DRUG2 (15     g/kg) and DRUG1 (10   mg/kg) + DRUG2 (15     g/kg), intraperitoneally, 30 min before hot plate or holed open field tests. ",negative,ephedrine,dexmedetomidine
"In the hot plate test in mice, co-administration of 15     g/kg DRUG1 with 10   mg/kg DRUG2 intraperitoneally not only enhanced, but also prolonged the duration of antinociception induced by DRUG1. ",effect,dexmedetomidine,ephedrine
"In the hot plate test in mice, co-administration of 15     g/kg DRUG1 with 10   mg/kg ephedrine intraperitoneally not only enhanced, but also prolonged the duration of antinociception induced by DRUG1. ",negative,dexmedetomidine,dexmedetomidine
"In the hot plate test in mice, co-administration of 15     g/kg DRUG2 with 10   mg/kg DRUG1 intraperitoneally not only enhanced, but also prolonged the duration of antinociception induced by DRUG2. ",negative,ephedrine,dexmedetomidine
"At the same time, the locomotor inhibitory effect of DRUG1 was counteracted by DRUG2. ",effect,dexmedetomidine,ephedrine
"We concluded that the combined administration of DRUG1 with DRUG2 may have beneficial effects in the treatment of pain without causing sedation, which limits the use of DRUG1 as an analgesic in humans.",effect,dexmedetomidine,ephedrine
"We concluded that the combined administration of DRUG1 with ephedrine may have beneficial effects in the treatment of pain without causing sedation, which limits the use of DRUG1 as an analgesic in humans.",negative,dexmedetomidine,dexmedetomidine
"We concluded that the combined administration of DRUG1 with ephedrine may have beneficial effects in the treatment of pain without causing sedation, which limits the use of DRUG1 as an DRUG2 in humans.",negative,dexmedetomidine,analgesic
"We concluded that the combined administration of DRUG2 with DRUG1 may have beneficial effects in the treatment of pain without causing sedation, which limits the use of DRUG2 as an analgesic in humans.",negative,ephedrine,dexmedetomidine
"We concluded that the combined administration of dexmedetomidine with DRUG1 may have beneficial effects in the treatment of pain without causing sedation, which limits the use of dexmedetomidine as an DRUG2 in humans.",negative,ephedrine,analgesic
"We concluded that the combined administration of DRUG1 with ephedrine may have beneficial effects in the treatment of pain without causing sedation, which limits the use of DRUG1 as an DRUG2 in humans.",negative,dexmedetomidine,analgesic
Protective effect of DRUG1 and  DRUG2 against the acute toxicity of diepoxybutane to human lymphocytes.,negative,acetyl-l-carnitine,alpha lipoic acid
"(ii) DRUG1 elicits a significant protective effect on DEB induced toxicity, which was potentiated by  DRUG2.",effect,acetyl-l-carnitine,alpha-lipoic acid
"The role of p27(Kip1) in DRUG1-enhanced DRUG2 cytotoxicity in human ovarian cancer cells.
",effect,dasatinib,paclitaxel
"The effect of DRUG1, an inhibitor of Src and Abl kinases, on DRUG2 sensitivity was measured in ovarian cancer cells and HEY xenografts. ",negative,dasatinib,paclitaxel
"The roles of p27(Kip1), Bcl-2, and Cdk1 in apoptosis induced by DRUG1 and DRUG2 were assessed using a terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) assay, siRNA knockdown of gene expression, transfection with Bcl-2 and Cdk1 expression vectors, and flow cytometry. ",negative,dasatinib,paclitaxel
HEY cells treated with DRUG1 plus DRUG2 formed fewer colonies than did cells treated with either agent alone. ,effect,dasatinib,paclitaxel
"Treatment of HEY xenograft-bearing mice with DRUG1 plus DRUG2 inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, DRUG1 + DRUG2 vs DRUG2: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014); ",effect,dasatinib,paclitaxel
"Treatment of HEY xenograft-bearing mice with DRUG1 plus paclitaxel inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, DRUG1 + paclitaxel vs paclitaxel: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014); ",negative,dasatinib,dasatinib
"Treatment of HEY xenograft-bearing mice with DRUG1 plus DRUG2 inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, DRUG1 + DRUG2 vs DRUG2: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014); ",negative,dasatinib,paclitaxel
"Treatment of HEY xenograft-bearing mice with DRUG1 plus DRUG2 inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, DRUG1 + DRUG2 vs DRUG2: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014); ",negative,dasatinib,paclitaxel
"Treatment of HEY xenograft-bearing mice with DRUG2 plus DRUG1 inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, DRUG2 + DRUG1 vs DRUG1: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014); ",negative,paclitaxel,dasatinib
"Treatment of HEY xenograft-bearing mice with dasatinib plus DRUG1 inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, dasatinib + DRUG1 vs DRUG1: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014); ",negative,paclitaxel,paclitaxel
"Treatment of HEY xenograft-bearing mice with dasatinib plus DRUG1 inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, dasatinib + DRUG1 vs DRUG1: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014); ",negative,paclitaxel,paclitaxel
"Treatment of HEY xenograft-bearing mice with DRUG1 plus DRUG2 inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, DRUG1 + DRUG2 vs DRUG2: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014); ",negative,dasatinib,paclitaxel
"Treatment of HEY xenograft-bearing mice with DRUG1 plus DRUG2 inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, DRUG1 + DRUG2 vs DRUG2: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014); ",negative,dasatinib,paclitaxel
"Treatment of HEY xenograft-bearing mice with dasatinib plus DRUG1 inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, dasatinib + DRUG1 vs DRUG1: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014); ",negative,paclitaxel,paclitaxel
DRUG1 + DRUG2 vs. ,negative,dasatinib,paclitaxel
"The siRNA knockdown of p27(Kip1) decreased DRUG1- and DRUG2-induced apoptosis compared with a negative control siRNA (sub-G1 fraction, control siRNA vs. p27(Kip1) siRNA: 42.5% vs. 20.1%, difference = 22.4%, 95% CI = 20.1% to 24.7%, P = .017). ",negative,dasatinib,paclitaxel
Studies with forced expression and siRNA knockdown of Bcl-2 and Cdk1 suggest that DRUG1-mediated induction of p27(Kip1) enhanced DRUG2-induced apoptosis by negatively regulating Bcl-2 and Cdk1 expression. ,effect,dasatinib,paclitaxel
Inhibition of Src family and Abl kinases with either siRNAs or DRUG1 enhances DRUG2 sensitivity of ovarian cancer cells through p27(Kip1)-mediated suppression of Bcl-2 and Cdk1 expression.,effect,dasatinib,paclitaxel
"Interaction of DRUG1 with different DRUG2 is antagonistic in breast but not in other cancer cells.
",effect,celecoxib,anti-cancer drugs
This study investigates the ability of DRUG1 to sensitize cells from different origins to several DRUG2. ,negative,cyclooxygenase-2 inhibitors,chemotherapeutic agents
"The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to DRUG1, DRUG2, doxorubicin and etoposide   celecoxib following different incubation schedules were analyzed.",negative,5-FU,cisplatin
"The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to DRUG1, cisplatin, DRUG2 and etoposide   celecoxib following different incubation schedules were analyzed.",negative,5-FU,doxorubicin
"The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to DRUG1, cisplatin, doxorubicin and DRUG2   celecoxib following different incubation schedules were analyzed.",negative,5-FU,etoposide
"The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to DRUG1, cisplatin, doxorubicin and etoposide   DRUG2 following different incubation schedules were analyzed.",negative,5-FU,celecoxib
"The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to 5-FU, DRUG1, DRUG2 and etoposide   celecoxib following different incubation schedules were analyzed.",negative,cisplatin,doxorubicin
"The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to 5-FU, DRUG1, doxorubicin and DRUG2   celecoxib following different incubation schedules were analyzed.",negative,cisplatin,etoposide
"The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to 5-FU, DRUG1, doxorubicin and etoposide   DRUG2 following different incubation schedules were analyzed.",negative,cisplatin,celecoxib
"The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to 5-FU, cisplatin, DRUG1 and DRUG2   celecoxib following different incubation schedules were analyzed.",negative,doxorubicin,etoposide
"The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to 5-FU, cisplatin, DRUG1 and etoposide   DRUG2 following different incubation schedules were analyzed.",negative,doxorubicin,celecoxib
"The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to 5-FU, cisplatin, doxorubicin and DRUG1   DRUG2 following different incubation schedules were analyzed.",negative,etoposide,celecoxib
We found antagonism between DRUG1 and the four drugs in the breast cancer cells MCF7 following all incubation schedules and between DRUG1 and doxorubicin in all cell lines except for two combinations in HCT116 cells. ,negative,celecoxib,celecoxib
We found antagonism between DRUG1 and the four drugs in the breast cancer cells MCF7 following all incubation schedules and between DRUG1 and DRUG2 in all cell lines except for two combinations in HCT116 cells. ,negative,celecoxib,doxorubicin
We found antagonism between DRUG1 and the four drugs in the breast cancer cells MCF7 following all incubation schedules and between DRUG1 and DRUG2 in all cell lines except for two combinations in HCT116 cells. ,effect,celecoxib,doxorubicin
"These results, if confirmed in-vivo, indicate that DRUG1 is not a suitable chemosensitizer for breast cancer or with DRUG2 for other cancers. ",negative,celecoxib,doxorubicin
The authors report the case of an infant with confirmed congenital hypothyroidism on DRUG1 who experienced a possible drug interaction with DRUG2. ,int,levothyroxine,simeticone
Questioning revealed the child was taking DRUG1 drops before feeds while on DRUG2. ,negative,Infacol,levothyroxine
Drug interaction of DRUG1 with DRUG2 has not been reported previously and is not listed in the British National Formulary for Children. ,negative,thyroxine,simeticone
"In vivo CYP3A activity is significantly lower in DRUG1-treated as compared with DRUG2-treated renal allograft recipients.
",negative,cyclosporine,tacrolimus
In vitro studies have identified DRUG1 and DRUG2 as CYP3A inhibitors. ,negative,cyclosporine,tacrolimus
"Systemic and apparent oral DRUG1 clearance were 24% (269    73 vs. 354    102  ml/min, P = 0.022) and 31% (479    190 vs. 688    265  ml/min, P = 0.013), respectively, lower in DRUG2-treated patients (n = 20) than in matched tacrolimus-treated patients (n = 20). ",mechanism,midazolam,cyclosporine
"Systemic and apparent oral DRUG1 clearance were 24% (269    73 vs. 354    102  ml/min, P = 0.022) and 31% (479    190 vs. 688    265  ml/min, P = 0.013), respectively, lower in cyclosporine-treated patients (n = 20) than in matched DRUG2-treated patients (n = 20). ",negative,midazolam,tacrolimus
"Systemic and apparent oral midazolam clearance were 24% (269    73 vs. 354    102  ml/min, P = 0.022) and 31% (479    190 vs. 688    265  ml/min, P = 0.013), respectively, lower in DRUG1-treated patients (n = 20) than in matched DRUG2-treated patients (n = 20). ",negative,cyclosporine,tacrolimus
The latter displayed DRUG1 clearances similar to those in two larger cohorts of nonmatched DRUG2-treated patients (n = 58 and n = 80) and to those receiving a calcineurin inhibitor-free regimen (n = 6). ,negative,midazolam,tacrolimus
The latter displayed DRUG1 clearances similar to those in two larger cohorts of nonmatched tacrolimus-treated patients (n = 58 and n = 80) and to those receiving a DRUG2-free regimen (n = 6). ,negative,midazolam,calcineurin inhibitor
The latter displayed midazolam clearances similar to those in two larger cohorts of nonmatched DRUG1-treated patients (n = 58 and n = 80) and to those receiving a DRUG2-free regimen (n = 6). ,negative,tacrolimus,calcineurin inhibitor
"This implies that in vivo hepatic and first-pass CYP3A activities are significantly lower in patients receiving DRUG1 than in those receiving DRUG2, indicating that, at the doses generally used in clinical practice, DRUG1 is the stronger of the two with respect to CYP3A inhibition. ",negative,cyclosporine,tacrolimus
"This implies that in vivo hepatic and first-pass CYP3A activities are significantly lower in patients receiving DRUG1 than in those receiving tacrolimus, indicating that, at the doses generally used in clinical practice, DRUG1 is the stronger of the two with respect to CYP3A inhibition. ",negative,cyclosporine,cyclosporine
"This implies that in vivo hepatic and first-pass CYP3A activities are significantly lower in patients receiving DRUG2 than in those receiving DRUG1, indicating that, at the doses generally used in clinical practice, DRUG2 is the stronger of the two with respect to CYP3A inhibition. ",negative,tacrolimus,cyclosporine
DRUG1   failure in an HIV-positive woman on DRUG2 therapy resulting in two ectopic pregnancies.,effect,Implanon,antiretroviral
We present an interesting case of an HIV-positive woman on DRUG1 therapy having tubal pregnancies on two separate occasions with DRUG2 in place.,effect,antiretroviral,Implanon
Synergistic interaction between DRUG1 and DRUG2 is sequence dependent in human non-small lung cancer with EGFR TKIs-resistant mutation.,int,sunitinib,docetaxel
This study was aimed to investigate the efficacy of single use of DRUG1 and that of concurrent or sequential administration of DRUG1 and docetaxel in NSCLC cell lines that are resistant to EGFR TKIs.,negative,sunitinib,sunitinib
This study was aimed to investigate the efficacy of single use of DRUG1 and that of concurrent or sequential administration of DRUG1 and DRUG2 in NSCLC cell lines that are resistant to EGFR TKIs.,negative,sunitinib,docetaxel
This study was aimed to investigate the efficacy of single use of DRUG1 and that of concurrent or sequential administration of DRUG1 and DRUG2 in NSCLC cell lines that are resistant to EGFR TKIs.,negative,sunitinib,docetaxel
NSCLC cell lines with EGFR T790M mutation and K-ras mutation were exposed to either DRUG1 or DRUG2 or both based on various sequential administrations. ,negative,sunitinib,docetaxel
"DRUG1 exhibited dose-dependent growth inhibition in NSCLC cell lines and arrested cell cycle at G1 phase, whereas DRUG2 arrested at S phase. ",negative,Sunitinib,docetaxel
"Although single or concurrent use of DRUG1 and DRUG2 has some anti-proliferative effects, the sequential administrations of both drugs remarkably enhanced anti-tumor activity. ",effect,sunitinib,docetaxel
"When cells were exposed to DRUG1 followed by DRUG2, synergism was observed. ",effect,docetaxel,sunitinib
The molecular basis of this synergism is that the signaling pathways that were initially activated by DRUG1 exposure were efficiently suppressed by the subsequent exposure to DRUG2. ,effect,docetaxel,sunitinib
DRUG1 as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of DRUG2 followed by DRUG1 is superior to DRUG1 followed by DRUG2 and concurrent administration.,negative,Sunitinib,docetaxel
DRUG1 as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of docetaxel followed by DRUG1 is superior to DRUG1 followed by docetaxel and concurrent administration.,negative,Sunitinib,sunitinib
DRUG1 as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of docetaxel followed by DRUG1 is superior to DRUG1 followed by docetaxel and concurrent administration.,negative,Sunitinib,sunitinib
DRUG1 as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of DRUG2 followed by DRUG1 is superior to DRUG1 followed by DRUG2 and concurrent administration.,negative,Sunitinib,docetaxel
DRUG2 as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of DRUG1 followed by DRUG2 is superior to DRUG2 followed by DRUG1 and concurrent administration.,effect,docetaxel,sunitinib
DRUG2 as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of DRUG1 followed by DRUG2 is superior to DRUG2 followed by DRUG1 and concurrent administration.,negative,docetaxel,sunitinib
Sunitinib as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of DRUG1 followed by sunitinib is superior to sunitinib followed by DRUG1 and concurrent administration.,negative,docetaxel,docetaxel
DRUG1 as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of docetaxel followed by DRUG1 is superior to DRUG1 followed by docetaxel and concurrent administration.,negative,sunitinib,sunitinib
DRUG1 as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of DRUG2 followed by DRUG1 is superior to DRUG1 followed by DRUG2 and concurrent administration.,negative,sunitinib,docetaxel
DRUG1 as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of DRUG2 followed by DRUG1 is superior to DRUG1 followed by DRUG2 and concurrent administration.,negative,sunitinib,docetaxel
"In the present study, we tested whether the highly specific metabotropic glutamate receptor 5 antagonist, DRUG1, reduces dopaminergic and noradrenergic neuronal loss in monkeys rendered parkinsonian by chronic treatment with low doses of DRUG2. ",negative,"3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine","1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine"
"Weekly intramuscular DRUG1 injections (0.2-0.5 mg/kg body weight), in combination with daily administration of DRUG2 or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups (DRUG1/DRUG2 versus DRUG1/vehicle). ",negative,"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine","3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine"
"Weekly intramuscular DRUG1 injections (0.2-0.5 mg/kg body weight), in combination with daily administration of 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups (DRUG1/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine versus DRUG1/vehicle). ",negative,"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine","1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine"
"Weekly intramuscular DRUG1 injections (0.2-0.5 mg/kg body weight), in combination with daily administration of DRUG2 or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups (DRUG1/DRUG2 versus DRUG1/vehicle). ",negative,"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine","3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine"
"Weekly intramuscular DRUG1 injections (0.2-0.5 mg/kg body weight), in combination with daily administration of 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups (DRUG1/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine versus DRUG1/vehicle). ",negative,"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine","1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine"
"Weekly intramuscular DRUG2 injections (0.2-0.5 mg/kg body weight), in combination with daily administration of DRUG1 or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups (DRUG2/DRUG1 versus DRUG2/vehicle). ",negative,"3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine","1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine"
"Weekly intramuscular 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine injections (0.2-0.5 mg/kg body weight), in combination with daily administration of DRUG1 or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/DRUG1 versus 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle). ",negative,"3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine","3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine"
"Weekly intramuscular DRUG2 injections (0.2-0.5 mg/kg body weight), in combination with daily administration of DRUG1 or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups (DRUG2/DRUG1 versus DRUG2/vehicle). ",negative,"3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine","1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine"
"Weekly intramuscular DRUG1 injections (0.2-0.5 mg/kg body weight), in combination with daily administration of DRUG2 or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups (DRUG1/DRUG2 versus DRUG1/vehicle). ",negative,"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine","3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine"
"Weekly intramuscular DRUG1 injections (0.2-0.5 mg/kg body weight), in combination with daily administration of 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups (DRUG1/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine versus DRUG1/vehicle). ",negative,"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine","1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine"
"Weekly intramuscular DRUG2 injections (0.2-0.5 mg/kg body weight), in combination with daily administration of DRUG1 or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups (DRUG2/DRUG1 versus DRUG2/vehicle). ",negative,"3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine","1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine"
"After 21 weeks of DRUG1 treatment, all DRUG1/vehicle-treated animals displayed parkinsonian symptoms, whereas none of the DRUG1/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine-treated monkeys were significantly affected. ",negative,"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine","1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine"
"After 21 weeks of DRUG1 treatment, all DRUG1/vehicle-treated animals displayed parkinsonian symptoms, whereas none of the DRUG1/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine-treated monkeys were significantly affected. ",negative,"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine","1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine"
"After 21 weeks of DRUG1 treatment, all DRUG1/vehicle-treated animals displayed parkinsonian symptoms, whereas none of the DRUG1/DRUG2-treated monkeys were significantly affected. ",negative,"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine","3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine"
"After 21 weeks of DRUG1 treatment, all DRUG1/vehicle-treated animals displayed parkinsonian symptoms, whereas none of the DRUG1/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine-treated monkeys were significantly affected. ",negative,"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine","1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine"
"After 21 weeks of DRUG1 treatment, all DRUG1/vehicle-treated animals displayed parkinsonian symptoms, whereas none of the DRUG1/DRUG2-treated monkeys were significantly affected. ",negative,"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine","3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine"
"After 21 weeks of DRUG1 treatment, all DRUG1/vehicle-treated animals displayed parkinsonian symptoms, whereas none of the DRUG1/DRUG2-treated monkeys were significantly affected. ",effect,"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine","3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine"
"These behavioural observations were consistent with in vivo positron emission tomography dopamine transporter imaging data, and with post-mortem stereological counts of midbrain dopaminergic neurons, as well as striatal intensity measurements of dopamine transporter and tyrosine hydroxylase immunoreactivity, which were all significantly higher in DRUG1/DRUG2-treated animals than in DRUG1/vehicle-treated monkeys. ",effect,"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine","3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine"
"These behavioural observations were consistent with in vivo positron emission tomography dopamine transporter imaging data, and with post-mortem stereological counts of midbrain dopaminergic neurons, as well as striatal intensity measurements of dopamine transporter and tyrosine hydroxylase immunoreactivity, which were all significantly higher in DRUG1/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine-treated animals than in DRUG1/vehicle-treated monkeys. ",negative,"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine","1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine"
"These behavioural observations were consistent with in vivo positron emission tomography dopamine transporter imaging data, and with post-mortem stereological counts of midbrain dopaminergic neurons, as well as striatal intensity measurements of dopamine transporter and tyrosine hydroxylase immunoreactivity, which were all significantly higher in DRUG2/DRUG1-treated animals than in DRUG2/vehicle-treated monkeys. ",negative,"3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine","1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine"
The DRUG1 treatment also had a significant effect on the DRUG2-induced loss of norepinephrine neurons in the locus coeruleus and adjoining A5 and A7 noradrenaline cell groups. ,effect,"3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine","1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine"
"In DRUG1/vehicle-treated animals, almost 40% loss of tyrosine hydroxylase-positive norepinephrine neurons was found in locus coeruleus/A5/A7 noradrenaline cell groups, whereas the extent of neuronal loss was lower than 15% of control values in DRUG1/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine-treated monkeys. ",negative,"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine","1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine"
"In DRUG1/vehicle-treated animals, almost 40% loss of tyrosine hydroxylase-positive norepinephrine neurons was found in locus coeruleus/A5/A7 noradrenaline cell groups, whereas the extent of neuronal loss was lower than 15% of control values in DRUG1/DRUG2-treated monkeys. ",negative,"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine","3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine"
"In DRUG1/vehicle-treated animals, almost 40% loss of tyrosine hydroxylase-positive norepinephrine neurons was found in locus coeruleus/A5/A7 noradrenaline cell groups, whereas the extent of neuronal loss was lower than 15% of control values in DRUG1/DRUG2-treated monkeys. ",effect,"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine","3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine"
"Our data demonstrate that chronic treatment with the metabotropic glutamate receptor 5 antagonist, DRUG1, significantly reduces DRUG2 toxicity towards dopaminergic and noradrenergic cell groups in non-human primates. ",effect,"3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine","1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine"
"[Interaction between DRUG1 and DRUG2].
",negative,clopidogrel,proton pump inhibitors
The drug interaction between DRUG1 and DRUG2 has been the subject of much study in recent years. ,negative,proton pump inhibitors,clopidogrel
Contradictory results regarding the effect of DRUG1 on platelet reactivity and on clinical outcome in DRUG2-treated patients have been reported in literature. ,negative,proton pump inhibitors,clopidogrel
"Concomitant use of DRUG1 and DRUG2 was found to decrease the exposure (AUC) to DRUG2's active metabolite by 50% and to sharply increase platelet reactivity, as a result of inhibition by DRUG1 of CYP2C19, a cytochrome P450 (CYP) enzyme. ",mechanism,omeprazole,clopidogrel
"Concomitant use of DRUG1 and clopidogrel was found to decrease the exposure (AUC) to clopidogrel's active metabolite by 50% and to sharply increase platelet reactivity, as a result of inhibition by DRUG1 of CYP2C19, a cytochrome P450 (CYP) enzyme. ",negative,omeprazole,omeprazole
"Concomitant use of DRUG2 and DRUG1 was found to decrease the exposure (AUC) to DRUG1's active metabolite by 50% and to sharply increase platelet reactivity, as a result of inhibition by DRUG2 of CYP2C19, a cytochrome P450 (CYP) enzyme. ",negative,clopidogrel,omeprazole
DRUG1 has a much weaker effect on DRUG2's pharmacokinetics and on platelet reactivity during concomitant use. ,mechanism,Pantoprazole,clopidogrel
The influence of the other DRUG1 when used simultaneously with DRUG2 has not yet been investigated in adequately randomized studies. ,negative,proton pump inhibitors,clopidogrel
Regulatory agencies state that the combination of DRUG1 and the CYP2C19 inhibitors DRUG2 and esomeprazole should be avoided. ,advise,clopidogrel,omeprazole
Regulatory agencies state that the combination of DRUG1 and the CYP2C19 inhibitors omeprazole and DRUG2 should be avoided. ,advise,clopidogrel,esomeprazole
Regulatory agencies state that the combination of clopidogrel and the CYP2C19 inhibitors DRUG1 and DRUG2 should be avoided. ,negative,omeprazole,esomeprazole
"To date, there is no conclusive evidence of a clinically-relevant interaction between any of the DRUG1 and DRUG2.",negative,proton pump inhibitors,clopidogrel
"Effect of DRUG1-mediated CYP3A4 inhibition on clinical pharmacokinetics of DRUG2 (LBH589), an orally active histone deacetylase inhibitor.
",negative,ketoconazole,panobinostat
"Effect of DRUG1-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (DRUG2), an orally active histone deacetylase inhibitor.
",negative,ketoconazole,LBH589
"Effect of DRUG1-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active DRUG2.
",negative,ketoconazole,histone deacetylase inhibitor
"Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of DRUG1 (DRUG2), an orally active histone deacetylase inhibitor.
",negative,panobinostat,LBH589
"Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of DRUG1 (LBH589), an orally active DRUG2.
",negative,panobinostat,histone deacetylase inhibitor
"Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (DRUG1), an orally active DRUG2.
",negative,LBH589,histone deacetylase inhibitor
"This study evaluated the effect of a potent CYP3A inhibitor, DRUG1, on the pharmacokinetics and safety of DRUG2.",negative,ketoconazole,panobinostat
"On day 8, a single DRUG1 dose was co-administered with DRUG2. ",negative,panobinostat,ketoconazole
"In the presence of DRUG1, there was 1.6- and 1.8-fold increase in C (max) and AUC of DRUG2, respectively. ",mechanism,ketoconazole,panobinostat
Co-administration of DRUG1 with CYP3A inhibitors is feasible as the observed increase in DRUG1 PK parameters was not considered clinically relevant. ,negative,panobinostat,panobinostat
"Considering the variability in exposure following enzyme inhibition and the fact that chronic dosing of DRUG1 was not studied with CYP3A inhibitors, close monitoring of DRUG1-related adverse events is necessary.",negative,panobinostat,panobinostat
"Phase I trial of DRUG1 and DRUG2 in patients with relapsed multiple myeloma: evidence for DRUG1-DRUG2 interaction via P-glycoprotein.
",negative,lenalidomide,CCI-779
"Phase I trial of DRUG1 and CCI-779 in patients with relapsed multiple myeloma: evidence for DRUG1-CCI-779 interaction via P-glycoprotein.
",negative,lenalidomide,lenalidomide
"Phase I trial of DRUG1 and DRUG2 in patients with relapsed multiple myeloma: evidence for DRUG1-DRUG2 interaction via P-glycoprotein.
",negative,lenalidomide,CCI-779
"Phase I trial of DRUG2 and DRUG1 in patients with relapsed multiple myeloma: evidence for DRUG2-DRUG1 interaction via P-glycoprotein.
",negative,CCI-779,lenalidomide
"Phase I trial of lenalidomide and DRUG1 in patients with relapsed multiple myeloma: evidence for lenalidomide-DRUG1 interaction via P-glycoprotein.
",negative,CCI-779,CCI-779
"Phase I trial of DRUG1 and DRUG2 in patients with relapsed multiple myeloma: evidence for DRUG1-DRUG2 interaction via P-glycoprotein.
",negative,lenalidomide,CCI-779
The preclinical combination of DRUG1 with the mTOR inhibitor DRUG2 has displayed synergy in vitro and represents a novel combination in MM.,effect,lenalidomide,CCI-779
DRUG1 (DRUG2)--better than clopidogrel (Plavix),negative,Ticagrelor,Brilinta
DRUG1 (Brilinta)--better than DRUG2 (Plavix),negative,Ticagrelor,clopidogrel
DRUG1 (Brilinta)--better than clopidogrel (DRUG2),negative,Ticagrelor,Plavix
Ticagrelor (DRUG1)--better than DRUG2 (Plavix),negative,Brilinta,clopidogrel
Ticagrelor (DRUG1)--better than clopidogrel (DRUG2),negative,Brilinta,Plavix
Ticagrelor (Brilinta)--better than DRUG1 (DRUG2),negative,clopidogrel,Plavix
"The FDA has approved DRUG1 (DRUG2-AstraZeneca), an oral antiplatelet drug, for use with low-dose aspirin to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS). ",negative,ticagrelor,Brilinta
"The FDA has approved DRUG1 (Brilinta-AstraZeneca), an oral DRUG2, for use with low-dose aspirin to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS). ",negative,ticagrelor,antiplatelet drug
"The FDA has approved DRUG1 (Brilinta-AstraZeneca), an oral antiplatelet drug, for use with low-dose DRUG2 to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS). ",effect,ticagrelor,aspirin
"The FDA has approved ticagrelor (DRUG1-AstraZeneca), an oral DRUG2, for use with low-dose aspirin to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS). ",negative,Brilinta,antiplatelet drug
"The FDA has approved ticagrelor (DRUG1-AstraZeneca), an oral antiplatelet drug, for use with low-dose DRUG2 to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS). ",effect,Brilinta,aspirin
"The FDA has approved ticagrelor (Brilinta-AstraZeneca), an oral DRUG1, for use with low-dose DRUG2 to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS). ",negative,antiplatelet drug,aspirin
It will compete with DRUG1 (DRUG2) and prasugrel (Effient) for such use. ,negative,clopidogrel,Plavix
It will compete with DRUG1 (Plavix) and DRUG2 (Effient) for such use. ,negative,clopidogrel,prasugrel
It will compete with DRUG1 (Plavix) and prasugrel (DRUG2) for such use. ,negative,clopidogrel,Effient
It will compete with clopidogrel (DRUG1) and DRUG2 (Effient) for such use. ,negative,Plavix,prasugrel
It will compete with clopidogrel (DRUG1) and prasugrel (DRUG2) for such use. ,negative,Plavix,Effient
It will compete with clopidogrel (Plavix) and DRUG1 (DRUG2) for such use. ,negative,prasugrel,Effient
"Exposure to oral DRUG1 is unaffected by DRUG2 but greatly increased by ticlopidine.
",negative,S-ketamine,itraconazole
"Exposure to oral DRUG1 is unaffected by itraconazole but greatly increased by DRUG2.
",effect,S-ketamine,ticlopidine
"Exposure to oral S-ketamine is unaffected by DRUG1 but greatly increased by DRUG2.
",negative,itraconazole,ticlopidine
This study examined drug-drug interactions of oral DRUG1 with the cytochrome P450 (CYP) 2B6 inhibitor DRUG2 and the CYP3A inhibitor itraconazole. ,negative,S-ketamine,ticlopidine
This study examined drug-drug interactions of oral DRUG1 with the cytochrome P450 (CYP) 2B6 inhibitor ticlopidine and the CYP3A inhibitor DRUG2. ,negative,S-ketamine,itraconazole
This study examined drug-drug interactions of oral S-ketamine with the cytochrome P450 (CYP) 2B6 inhibitor DRUG1 and the CYP3A inhibitor DRUG2. ,negative,ticlopidine,itraconazole
"In this randomized, blinded, crossover study, 11 healthy volunteers ingested 0.2 mg/kg DRUG1 after pretreatments with oral DRUG2 (250 mg twice daily), itraconazole (200 mg once daily), or placebo in 6-day treatment periods at intervals of 4 weeks. ",negative,S-ketamine,ticlopidine
"In this randomized, blinded, crossover study, 11 healthy volunteers ingested 0.2 mg/kg DRUG1 after pretreatments with oral ticlopidine (250 mg twice daily), DRUG2 (200 mg once daily), or placebo in 6-day treatment periods at intervals of 4 weeks. ",negative,S-ketamine,itraconazole
"In this randomized, blinded, crossover study, 11 healthy volunteers ingested 0.2 mg/kg S-ketamine after pretreatments with oral DRUG1 (250 mg twice daily), DRUG2 (200 mg once daily), or placebo in 6-day treatment periods at intervals of 4 weeks. ",negative,ticlopidine,itraconazole
"DRUG1 treatment increased the mean area under the plasma concentration-time curve extrapolated to infinity (AUC(0-   )) of oral DRUG2 by 2.4-fold, whereas itraconazole treatment did not increase the exposure to S-DRUG2. ",mechanism,Ticlopidine,ketamine
"DRUG1 treatment increased the mean area under the plasma concentration-time curve extrapolated to infinity (AUC(0-   )) of oral ketamine by 2.4-fold, whereas DRUG2 treatment did not increase the exposure to S-ketamine. ",negative,Ticlopidine,itraconazole
"DRUG1 treatment increased the mean area under the plasma concentration-time curve extrapolated to infinity (AUC(0-   )) of oral ketamine by 2.4-fold, whereas itraconazole treatment did not increase the exposure to DRUG2. ",negative,Ticlopidine,S-ketamine
"Ticlopidine treatment increased the mean area under the plasma concentration-time curve extrapolated to infinity (AUC(0-   )) of oral DRUG1 by 2.4-fold, whereas DRUG2 treatment did not increase the exposure to S-DRUG1. ",negative,ketamine,itraconazole
"Ticlopidine treatment increased the mean area under the plasma concentration-time curve extrapolated to infinity (AUC(0-   )) of oral DRUG1 by 2.4-fold, whereas itraconazole treatment did not increase the exposure to S-DRUG1. ",negative,ketamine,S-ketamine
"Ticlopidine treatment increased the mean area under the plasma concentration-time curve extrapolated to infinity (AUC(0-   )) of oral ketamine by 2.4-fold, whereas DRUG1 treatment did not increase the exposure to DRUG2. ",negative,itraconazole,S-ketamine
The ratio of DRUG1 AUC(0-   ) to DRUG2 AUC(0-   ) was significantly decreased in the ticlopidine (P &lt; 0.001) and itraconazole phases (P = 0.006) as compared to placebo. ,negative,norketamine,ketamine
The ratio of DRUG1 AUC(0-   ) to ketamine AUC(0-   ) was significantly decreased in the DRUG2 (P &lt; 0.001) and itraconazole phases (P = 0.006) as compared to placebo. ,negative,norketamine,ticlopidine
The ratio of DRUG1 AUC(0-   ) to ketamine AUC(0-   ) was significantly decreased in the ticlopidine (P &lt; 0.001) and DRUG2 phases (P = 0.006) as compared to placebo. ,negative,norketamine,itraconazole
The ratio of norketamine AUC(0-   ) to DRUG1 AUC(0-   ) was significantly decreased in the DRUG2 (P &lt; 0.001) and itraconazole phases (P = 0.006) as compared to placebo. ,negative,ketamine,ticlopidine
The ratio of norketamine AUC(0-   ) to DRUG1 AUC(0-   ) was significantly decreased in the ticlopidine (P &lt; 0.001) and DRUG2 phases (P = 0.006) as compared to placebo. ,negative,ketamine,itraconazole
The ratio of norketamine AUC(0-   ) to ketamine AUC(0-   ) was significantly decreased in the DRUG1 (P &lt; 0.001) and DRUG2 phases (P = 0.006) as compared to placebo. ,negative,ticlopidine,itraconazole
"In the DRUG1 and DRUG2 phases, the areas under the effect-time curves (self-reported drowsiness and performance) were significantly higher than those in the placebo phase (P < 0.05). ",negative,ticlopidine,itraconazole
The findings suggest that the dosage of DRUG1 should be reduced in patients receiving DRUG2.,advise,S-ketamine,ticlopidine
"Improved parathyroid hormone control by DRUG1 is associated with reduction in DRUG2 requirement in patients with end-stage renal disease.
",negative,cinacalcet,darbepoetin
"Uncontrolled hy-per-parathyroidism causes bone marrow fibrosis, leading to DRUG1 (DRUG2) resistance. ",negative,erythropoietin,EPO
"Medical treatment with DRUG1 is effective in reducing plasma parathyroid hormone (PTH) levels, but its effect on DRUG2 dosing is unknown. ",negative,cinacalcet,darbepoetin
The primary objective of the study was to ascertain the difference in DRUG1 responsiveness before and after 12 months of DRUG2 therapy. ,negative,darbepoetin,cinacalcet
Reduction of PTH by DRUG1 is associated with a decrease in DRUG2 requirement. ,effect,cinacalcet,darbepoetin
"DRUG1-DRUG2 interaction and associated gastrointestinal bleeding risk in a case-control study.
",negative,Antidepressant,warfarin
We sought to evaluate whether initiation of an DRUG1 increases the risk of hospitalization for gastrointestinal bleeding in DRUG2 users.,negative,antidepressant,warfarin
"In total, 430,455 DRUG1 users contributed 407,370 person-years of DRUG1 use. ",negative,warfarin,warfarin
"DRUG1 users had an increased odds ratio of gastrointestinal bleeding upon initiation of DRUG2 (OR   =   1.73 [95% CI, 1.25-2.38]), fluoxetine (OR   =   1.63 [95% CI, 1.11-2.38]), paroxetine (OR   =   1.64 [95% CI, 1.27-2.12]), amitriptyline (OR   =   1.47 [95% CI, 1.02-2.11]). ",effect,Warfarin,citalopram
"DRUG1 users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram (OR   =   1.73 [95% CI, 1.25-2.38]), DRUG2 (OR   =   1.63 [95% CI, 1.11-2.38]), paroxetine (OR   =   1.64 [95% CI, 1.27-2.12]), amitriptyline (OR   =   1.47 [95% CI, 1.02-2.11]). ",effect,Warfarin,fluoxetine
"DRUG1 users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram (OR   =   1.73 [95% CI, 1.25-2.38]), fluoxetine (OR   =   1.63 [95% CI, 1.11-2.38]), DRUG2 (OR   =   1.64 [95% CI, 1.27-2.12]), amitriptyline (OR   =   1.47 [95% CI, 1.02-2.11]). ",effect,Warfarin,paroxetine
"DRUG1 users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram (OR   =   1.73 [95% CI, 1.25-2.38]), fluoxetine (OR   =   1.63 [95% CI, 1.11-2.38]), paroxetine (OR   =   1.64 [95% CI, 1.27-2.12]), DRUG2 (OR   =   1.47 [95% CI, 1.02-2.11]). ",effect,Warfarin,amitriptyline
"Warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of DRUG1 (OR   =   1.73 [95% CI, 1.25-2.38]), DRUG2 (OR   =   1.63 [95% CI, 1.11-2.38]), paroxetine (OR   =   1.64 [95% CI, 1.27-2.12]), amitriptyline (OR   =   1.47 [95% CI, 1.02-2.11]). ",negative,citalopram,fluoxetine
"Warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of DRUG1 (OR   =   1.73 [95% CI, 1.25-2.38]), fluoxetine (OR   =   1.63 [95% CI, 1.11-2.38]), DRUG2 (OR   =   1.64 [95% CI, 1.27-2.12]), amitriptyline (OR   =   1.47 [95% CI, 1.02-2.11]). ",negative,citalopram,paroxetine
"Warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of DRUG1 (OR   =   1.73 [95% CI, 1.25-2.38]), fluoxetine (OR   =   1.63 [95% CI, 1.11-2.38]), paroxetine (OR   =   1.64 [95% CI, 1.27-2.12]), DRUG2 (OR   =   1.47 [95% CI, 1.02-2.11]). ",negative,citalopram,amitriptyline
"Warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram (OR   =   1.73 [95% CI, 1.25-2.38]), DRUG1 (OR   =   1.63 [95% CI, 1.11-2.38]), DRUG2 (OR   =   1.64 [95% CI, 1.27-2.12]), amitriptyline (OR   =   1.47 [95% CI, 1.02-2.11]). ",negative,fluoxetine,paroxetine
"Warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram (OR   =   1.73 [95% CI, 1.25-2.38]), DRUG1 (OR   =   1.63 [95% CI, 1.11-2.38]), paroxetine (OR   =   1.64 [95% CI, 1.27-2.12]), DRUG2 (OR   =   1.47 [95% CI, 1.02-2.11]). ",negative,fluoxetine,amitriptyline
"Warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram (OR   =   1.73 [95% CI, 1.25-2.38]), fluoxetine (OR   =   1.63 [95% CI, 1.11-2.38]), DRUG1 (OR   =   1.64 [95% CI, 1.27-2.12]), DRUG2 (OR   =   1.47 [95% CI, 1.02-2.11]). ",negative,paroxetine,amitriptyline
"Also DRUG1, which is not believed to interact with DRUG2, increased the risk of GI bleeding (OR   =   1.75 [95% CI, 1.30-2.35]). ",effect,mirtazapine,warfarin
"DRUG1 users who initiated DRUG2, fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. ",effect,Warfarin,citalopram
"DRUG1 users who initiated citalopram, DRUG2, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. ",effect,Warfarin,fluoxetine
"DRUG1 users who initiated citalopram, fluoxetine, DRUG2, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. ",effect,Warfarin,paroxetine
"DRUG1 users who initiated citalopram, fluoxetine, paroxetine, DRUG2, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. ",effect,Warfarin,amitriptyline
"DRUG1 users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or DRUG2 had an increased risk of hospitalization for gastrointestinal bleeding. ",effect,Warfarin,mirtazapine
"Warfarin users who initiated DRUG1, DRUG2, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. ",negative,citalopram,fluoxetine
"Warfarin users who initiated DRUG1, fluoxetine, DRUG2, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. ",negative,citalopram,paroxetine
"Warfarin users who initiated DRUG1, fluoxetine, paroxetine, DRUG2, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. ",negative,citalopram,amitriptyline
"Warfarin users who initiated DRUG1, fluoxetine, paroxetine, amitriptyline, or DRUG2 had an increased risk of hospitalization for gastrointestinal bleeding. ",negative,citalopram,mirtazapine
"Warfarin users who initiated citalopram, DRUG1, DRUG2, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. ",negative,fluoxetine,paroxetine
"Warfarin users who initiated citalopram, DRUG1, paroxetine, DRUG2, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. ",negative,fluoxetine,amitriptyline
"Warfarin users who initiated citalopram, DRUG1, paroxetine, amitriptyline, or DRUG2 had an increased risk of hospitalization for gastrointestinal bleeding. ",negative,fluoxetine,mirtazapine
"Warfarin users who initiated citalopram, fluoxetine, DRUG1, DRUG2, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. ",negative,paroxetine,amitriptyline
"Warfarin users who initiated citalopram, fluoxetine, DRUG1, amitriptyline, or DRUG2 had an increased risk of hospitalization for gastrointestinal bleeding. ",negative,paroxetine,mirtazapine
"Warfarin users who initiated citalopram, fluoxetine, paroxetine, DRUG1, or DRUG2 had an increased risk of hospitalization for gastrointestinal bleeding. ",negative,amitriptyline,mirtazapine
"Enhancement of humoral immune responses to inactivated Newcastle disease and DRUG1 by oral administration of DRUG2 in chickens.
",negative,avian influenza vaccines,ginseng stem-and-leaf saponins
The objective of this study was to evaluate the effect of oral administration of DRUG1 (DRUG2) on the humoral immune responses of chickens to inactivated ND and AI vaccines. ,negative,ginseng stem-and-leaf saponins,GSLS
The objective of this study was to evaluate the effect of oral administration of DRUG1 (GSLS) on the humoral immune responses of chickens to inactivated ND and AI vaccines. ,negative,ginseng stem-and-leaf saponins,inactivated ND vaccines
The objective of this study was to evaluate the effect of oral administration of DRUG1 (GSLS) on the humoral immune responses of chickens to inactivated ND and AI vaccines. ,negative,ginseng stem-and-leaf saponins,inactivated AI vaccines
The objective of this study was to evaluate the effect of oral administration of ginseng stem-and-leaf saponins (DRUG1) on the humoral immune responses of chickens to inactivated ND and AI vaccines. ,negative,GSLS,inactivated ND vaccines
The objective of this study was to evaluate the effect of oral administration of ginseng stem-and-leaf saponins (DRUG1) on the humoral immune responses of chickens to inactivated ND and AI vaccines. ,negative,GSLS,inactivated AI vaccines
The objective of this study was to evaluate the effect of oral administration of ginseng stem-and-leaf saponins (GSLS) on the humoral immune responses of chickens to inactivated ND and AI vaccines. ,negative,inactivated ND vaccines,inactivated AI vaccines
"In experiment 1, oral administration of DRUG1 at a dose of 5 mg/kg of BW for 7 d on the immune response in chickens intramuscularly injected with DRUG2 was evaluated. ",negative,GSLS,inactivated ND vaccine
"In experiment 2, the same regimen of DRUG1 was administered to chickens inoculated with DRUG2, and an enhanced serum antibody response to AI vaccination was also observed. ",effect,GSLS,inactivated AI vaccines
"Considering the safety of DRUG1, because no adverse effect was found throughout the experiments, DRUG1 may be a promising oral adjuvant to improve immunization in poultry.",negative,GSLS,GSLS
DRUG1 does not inhibit the absorption of 5 milligrams of nonheme or heme iron at doses less than 800 milligrams in nonpregnant women.,negative,Calcium,nonheme iron
DRUG1 does not inhibit the absorption of 5 milligrams of nonheme or DRUG2 at doses less than 800 milligrams in nonpregnant women.,negative,Calcium,heme iron
Calcium does not inhibit the absorption of 5 milligrams of nonheme or DRUG2 at doses less than 800 milligrams in nonpregnant women.,negative,nonheme iron,heme iron
DRUG1 is the only known component in the diet that may affect absorption of both nonheme and heme iron. ,mechanism,Calcium,nonheme iron
DRUG1 is the only known component in the diet that may affect absorption of both nonheme and DRUG2. ,mechanism,Calcium,heme iron
Calcium is the only known component in the diet that may affect absorption of both nonheme and DRUG2. ,negative,nonheme iron,heme iron
"However, the evidence for a DRUG1 effect on DRUG2 absorption mainly comes from studies that did not isolate the effect of DRUG1 from that of other dietary components, because it was detected in single-meal studies. ",mechanism,calcium,iron
"However, the evidence for a DRUG1 effect on iron absorption mainly comes from studies that did not isolate the effect of DRUG1 from that of other dietary components, because it was detected in single-meal studies. ",negative,calcium,calcium
"However, the evidence for a DRUG2 effect on DRUG1 absorption mainly comes from studies that did not isolate the effect of DRUG2 from that of other dietary components, because it was detected in single-meal studies. ",negative,iron,calcium
Our objective was to establish potential effects of DRUG1 on absorption of nonheme and heme iron and the dose response for this effect in the absence of a meal. ,negative,calcium,nonheme iron
Our objective was to establish potential effects of DRUG1 on absorption of nonheme and DRUG2 and the dose response for this effect in the absence of a meal. ,negative,calcium,heme iron
Our objective was to establish potential effects of calcium on absorption of nonheme and DRUG2 and the dose response for this effect in the absence of a meal. ,negative,nonheme iron,heme iron
We evaluated the effects of DRUG1 doses between 200 and 1500 mg on absorption of 5 mg DRUG2 (as ferrous sulfate). ,negative,calcium,nonheme iron
We evaluated the effects of DRUG1 doses between 200 and 1500 mg on absorption of 5 mg nonheme iron (as DRUG2). ,negative,calcium,ferrous sulfate
We evaluated the effects of calcium doses between 200 and 1500 mg on absorption of 5 mg DRUG1 (as DRUG2). ,negative,nonheme iron,ferrous sulfate
We also evaluated the effects of DRUG1 doses between 200 and 800 mg on absorption of 5 mg DRUG2 [as concentrated RBC (CRBC)]. ,negative,calcium,heme iron
DRUG1 was administered as DRUG1 chloride in all studies and minerals were ingested on an empty stomach. ,negative,Calcium,calcium chloride
DRUG1 was administered as DRUG1 chloride in all studies and DRUG2 were ingested on an empty stomach. ,negative,Calcium,minerals
Calcium was administered as DRUG1 in all studies and DRUG2 were ingested on an empty stomach. ,negative,calcium chloride,minerals
DRUG1 doses   1000 mg diminished DRUG2 absorption by an average of 49.6%.,mechanism,Calcium,nonheme iron
A DRUG1 dose of 800 mg diminished absorption of 5 mg DRUG2 by 37.7%. ,mechanism,calcium,heme iron
"In conclusion, we demonstrated an isolated effect of DRUG1 (as chloride) on absorption of 5 mg of iron provided as nonheme (as sulfate) and heme (as CRBC) iron. ",mechanism,calcium,nonheme iron
"In conclusion, we demonstrated an isolated effect of DRUG1 (as chloride) on absorption of 5 mg of iron provided as nonheme (as sulfate) and heme (as CRBC) iron. ",mechanism,calcium,heme iron
"In conclusion, we demonstrated an isolated effect of calcium (as chloride) on absorption of 5 mg of iron provided as nonheme (as sulfate) and heme (as CRBC) iron. ",negative,nonheme iron,heme iron
"DRUG1 locomotor sensitization and conditioned place preference in adolescent male and female rats neonatally treated with DRUG2.
",negative,Amphetamine,quinpirole
The objective was to analyze the effects of neonatal DRUG1 treatment on effects of DRUG2 in adolescent rats using locomotor sensitization and conditioned place preference procedures. ,negative,quinpirole,amphetamine
"In female rats, neonatal DRUG1 treatment enhanced DRUG2 locomotor sensitization compared with DRUG1-free controls sensitized to DRUG2. ",effect,quinpirole,amphetamine
"In female rats, neonatal DRUG1 treatment enhanced amphetamine locomotor sensitization compared with DRUG1-free controls sensitized to amphetamine. ",negative,quinpirole,quinpirole
"In female rats, neonatal DRUG1 treatment enhanced DRUG2 locomotor sensitization compared with DRUG1-free controls sensitized to DRUG2. ",negative,quinpirole,amphetamine
"In female rats, neonatal DRUG2 treatment enhanced DRUG1 locomotor sensitization compared with DRUG2-free controls sensitized to DRUG1. ",negative,amphetamine,quinpirole
"In female rats, neonatal quinpirole treatment enhanced DRUG1 locomotor sensitization compared with quinpirole-free controls sensitized to DRUG1. ",negative,amphetamine,amphetamine
"In female rats, neonatal DRUG1 treatment enhanced DRUG2 locomotor sensitization compared with DRUG1-free controls sensitized to DRUG2. ",negative,quinpirole,amphetamine
"Male rats demonstrated sensitization to DRUG1, although this was muted compared with female rats, and were unaffected by neonatal DRUG2. ",negative,amphetamine,quinpirole
"Rats treated with neonatal DRUG1 enhanced time spent in the DRUG2-paired context compared with DRUG1-free controls conditioned with DRUG2, but only female controls conditioned with DRUG2 spent more time in the drug-paired context compared with saline-treated controls. ",negative,quinpirole,amphetamine
"Rats treated with neonatal DRUG1 enhanced time spent in the amphetamine-paired context compared with DRUG1-free controls conditioned with amphetamine, but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls. ",negative,quinpirole,quinpirole
"Rats treated with neonatal DRUG1 enhanced time spent in the DRUG2-paired context compared with DRUG1-free controls conditioned with DRUG2, but only female controls conditioned with DRUG2 spent more time in the drug-paired context compared with saline-treated controls. ",negative,quinpirole,amphetamine
"Rats treated with neonatal DRUG1 enhanced time spent in the DRUG2-paired context compared with DRUG1-free controls conditioned with DRUG2, but only female controls conditioned with DRUG2 spent more time in the drug-paired context compared with saline-treated controls. ",negative,quinpirole,amphetamine
"Rats treated with neonatal DRUG2 enhanced time spent in the DRUG1-paired context compared with DRUG2-free controls conditioned with DRUG1, but only female controls conditioned with DRUG1 spent more time in the drug-paired context compared with saline-treated controls. ",negative,amphetamine,quinpirole
"Rats treated with neonatal quinpirole enhanced time spent in the DRUG1-paired context compared with quinpirole-free controls conditioned with DRUG1, but only female controls conditioned with DRUG1 spent more time in the drug-paired context compared with saline-treated controls. ",negative,amphetamine,amphetamine
"Rats treated with neonatal quinpirole enhanced time spent in the DRUG1-paired context compared with quinpirole-free controls conditioned with DRUG1, but only female controls conditioned with DRUG1 spent more time in the drug-paired context compared with saline-treated controls. ",negative,amphetamine,amphetamine
"Rats treated with neonatal DRUG1 enhanced time spent in the DRUG2-paired context compared with DRUG1-free controls conditioned with DRUG2, but only female controls conditioned with DRUG2 spent more time in the drug-paired context compared with saline-treated controls. ",negative,quinpirole,amphetamine
"Rats treated with neonatal DRUG1 enhanced time spent in the DRUG2-paired context compared with DRUG1-free controls conditioned with DRUG2, but only female controls conditioned with DRUG2 spent more time in the drug-paired context compared with saline-treated controls. ",negative,quinpirole,amphetamine
"Rats treated with neonatal quinpirole enhanced time spent in the DRUG1-paired context compared with quinpirole-free controls conditioned with DRUG1, but only female controls conditioned with DRUG1 spent more time in the drug-paired context compared with saline-treated controls. ",negative,amphetamine,amphetamine
"In vitro activity of DRUG1 combined with DRUG2 against clinical isolates of methicillin-resistant Staphylococcus aureus.
",negative,minocycline,fosfomycin
"In vitro activity of DRUG1 combined with fosfomycin against clinical isolates of DRUG2-resistant Staphylococcus aureus.
",negative,minocycline,methicillin
"In vitro activity of minocycline combined with DRUG1 against clinical isolates of DRUG2-resistant Staphylococcus aureus.
",negative,fosfomycin,methicillin
This study aimed to evaluate the in vitro activity of DRUG1 combined with DRUG2 against isolates of methicillin-resistant Staphylococcus aureus (MRSA). ,negative,minocycline,fosfomycin
This study aimed to evaluate the in vitro activity of DRUG1 combined with fosfomycin against isolates of DRUG2-resistant Staphylococcus aureus (MRSA). ,negative,minocycline,methicillin
This study aimed to evaluate the in vitro activity of minocycline combined with DRUG1 against isolates of DRUG2-resistant Staphylococcus aureus (MRSA). ,negative,fosfomycin,methicillin
The susceptibility results for DRUG1 and DRUG2 were interpreted according to the most relevant criteria. ,negative,minocycline,fosfomycin
The combination of DRUG1 and DRUG2 can be synergistic against MRSA. ,effect,minocycline,fosfomycin
"DRUG1 enhances DRUG2-mediated antibody-dependent cellular cytotoxicity by up-regulation of cell surface HER2 expression.
",effect,Lapatinib,herceptin
"Although it was previously reported that DRUG1 combined with DRUG2 improved the progression-free survival rate compared with DRUG1 alone for patients with DRUG2-refractory HER2-positive metastatic breast cancer, the mechanism is purported to be an antiproliferative effect relating to the synergism of these two agents.",effect,lapatinib,Herceptin
"Although it was previously reported that DRUG1 combined with Herceptin improved the progression-free survival rate compared with DRUG1 alone for patients with Herceptin-refractory HER2-positive metastatic breast cancer, the mechanism is purported to be an antiproliferative effect relating to the synergism of these two agents.",negative,lapatinib,lapatinib
"Although it was previously reported that DRUG1 combined with DRUG2 improved the progression-free survival rate compared with DRUG1 alone for patients with DRUG2-refractory HER2-positive metastatic breast cancer, the mechanism is purported to be an antiproliferative effect relating to the synergism of these two agents.",negative,lapatinib,Herceptin
"Although it was previously reported that DRUG2 combined with DRUG1 improved the progression-free survival rate compared with DRUG2 alone for patients with DRUG1-refractory HER2-positive metastatic breast cancer, the mechanism is purported to be an antiproliferative effect relating to the synergism of these two agents.",negative,Herceptin,lapatinib
"Although it was previously reported that lapatinib combined with DRUG1 improved the progression-free survival rate compared with lapatinib alone for patients with DRUG1-refractory HER2-positive metastatic breast cancer, the mechanism is purported to be an antiproliferative effect relating to the synergism of these two agents.",negative,Herceptin,Herceptin
"Although it was previously reported that DRUG1 combined with DRUG2 improved the progression-free survival rate compared with DRUG1 alone for patients with DRUG2-refractory HER2-positive metastatic breast cancer, the mechanism is purported to be an antiproliferative effect relating to the synergism of these two agents.",negative,lapatinib,Herceptin
"We evaluated how DRUG1 interacts with DRUG2 in HER2-positive breast cancer, with a particular focus on DRUG2-mediated antibody-dependent cellular cytotoxicity (ADCC). ",negative,lapatinib,Herceptin
"We evaluated how DRUG1 interacts with DRUG2 in HER2-positive breast cancer, with a particular focus on DRUG2-mediated antibody-dependent cellular cytotoxicity (ADCC). ",negative,lapatinib,Herceptin
"We evaluated how lapatinib interacts with DRUG1 in HER2-positive breast cancer, with a particular focus on DRUG1-mediated antibody-dependent cellular cytotoxicity (ADCC). ",negative,Herceptin,Herceptin
"In an in vitro assay, DRUG1 induced HER2 expression at the cell surface of HER2-positive breast cancer cell lines, leading to the enhancement of DRUG2-mediated ADCC. ",effect,lapatinib,Herceptin
"Furthermore, we present a case report in which a second DRUG1 treatment following DRUG2 resulted in the marked shrinkage of multiple metastatic tumors in HER2-positive breast cancer. ",effect,Herceptin,lapatinib
DRUG1 may have the potential to convert DRUG2-refractory to DRUG2-sensitive tumors in HER2-positive breast cancer by up-regulation of the cell surface expression of HER2.,negative,Lapatinib,Herceptin
DRUG1 may have the potential to convert DRUG2-refractory to DRUG2-sensitive tumors in HER2-positive breast cancer by up-regulation of the cell surface expression of HER2.,negative,Lapatinib,Herceptin
Lapatinib may have the potential to convert DRUG1-refractory to DRUG1-sensitive tumors in HER2-positive breast cancer by up-regulation of the cell surface expression of HER2.,negative,Herceptin,Herceptin
"Influence of DRUG1 on DRUG2 induced antinociception and its pharmacokinetics.
",negative,piperine,ibuprofen
"In the present study DRUG1 (10 mg/kg) significantly increased the dose-dependent antinociceptive activity of DRUG2 evaluated by both acetic acid writhing and formalin test, when it was administered with DRUG2. ",effect,piperine,ibuprofen
"In the present study DRUG1 (10 mg/kg) significantly increased the dose-dependent antinociceptive activity of ibuprofen evaluated by both DRUG2 writhing and formalin test, when it was administered with ibuprofen. ",negative,piperine,acetic acid
"In the present study DRUG1 (10 mg/kg) significantly increased the dose-dependent antinociceptive activity of DRUG2 evaluated by both acetic acid writhing and formalin test, when it was administered with DRUG2. ",negative,piperine,ibuprofen
"In the present study piperine (10 mg/kg) significantly increased the dose-dependent antinociceptive activity of DRUG1 evaluated by both DRUG2 writhing and formalin test, when it was administered with DRUG1. ",negative,ibuprofen,acetic acid
"In the present study piperine (10 mg/kg) significantly increased the dose-dependent antinociceptive activity of DRUG1 evaluated by both acetic acid writhing and formalin test, when it was administered with DRUG1. ",negative,ibuprofen,ibuprofen
"In the present study piperine (10 mg/kg) significantly increased the dose-dependent antinociceptive activity of DRUG2 evaluated by both DRUG1 writhing and formalin test, when it was administered with DRUG2. ",negative,acetic acid,ibuprofen
DRUG1 plasma concentration was also increased when it was administered with DRUG2. ,mechanism,Ibuprofen,piperine
The synergistic antinociception activity of DRUG1 when administered with DRUG2 can be attributed to increased plasma concentration of DRUG1. ,mechanism,ibuprofen,piperine
The synergistic antinociception activity of DRUG1 when administered with piperine can be attributed to increased plasma concentration of DRUG1. ,negative,ibuprofen,ibuprofen
The synergistic antinociception activity of DRUG2 when administered with DRUG1 can be attributed to increased plasma concentration of DRUG2. ,negative,piperine,ibuprofen
From this study it can be concluded that DRUG1 can be used as a bioenhancer along with DRUG2.,effect,piperine,ibuprofen
To determine whether the co-injection of extracellular matrix degrading enzymes improves retinal transduction following intravitreal delivery of DRUG1 (DRUG2).,negative,adeno-associated virus-2,AAV2
"DRUG1 containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including DRUG2, hyaluronan lyase, heparinase III, or chondroitin ABC lyase. ",negative,AAV2,collagenase
"DRUG1 containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including collagenase, DRUG2, heparinase III, or chondroitin ABC lyase. ",negative,AAV2,hyaluronan lyase
"DRUG1 containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including collagenase, hyaluronan lyase, DRUG2, or chondroitin ABC lyase. ",negative,AAV2,heparinase III
"DRUG1 containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including collagenase, hyaluronan lyase, heparinase III, or DRUG2. ",negative,AAV2,chondroitin ABC lyase
"AAV2 containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including DRUG1, DRUG2, heparinase III, or chondroitin ABC lyase. ",negative,collagenase,hyaluronan lyase
"AAV2 containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including DRUG1, hyaluronan lyase, DRUG2, or chondroitin ABC lyase. ",negative,collagenase,heparinase III
"AAV2 containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including DRUG1, hyaluronan lyase, heparinase III, or DRUG2. ",negative,collagenase,chondroitin ABC lyase
"AAV2 containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including collagenase, DRUG1, DRUG2, or chondroitin ABC lyase. ",negative,hyaluronan lyase,heparinase III
"AAV2 containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including collagenase, DRUG1, heparinase III, or DRUG2. ",negative,hyaluronan lyase,chondroitin ABC lyase
"AAV2 containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including collagenase, hyaluronan lyase, DRUG1, or DRUG2. ",negative,heparinase III,chondroitin ABC lyase
The addition of DRUG1 or DRUG2 greatly enhanced transduction of the retinal ganglion cell layer and increased the depth of transduction into the outer retina. ,negative,heparinase III,chondroitin ABC lyase
DRUG1 had a limited effect and DRUG2 was ineffective. ,negative,Hyaluronan lyase,collagenase
Electroretinograms survived with higher concentrations of DRUG1 and DRUG2 than were required for optimal retinal transduction. ,negative,heparinase III,chondroitin ABC lyase
DRUG1-mediated retinal transduction is improved by co-injection of DRUG2 or chondroitin ABC lyase. ,effect,AAV2,heparinase III
DRUG1-mediated retinal transduction is improved by co-injection of heparinase III or DRUG2. ,effect,AAV2,chondroitin ABC lyase
AAV2-mediated retinal transduction is improved by co-injection of DRUG1 or DRUG2. ,negative,heparinase III,chondroitin ABC lyase
"The aim of the present study was to investigate whether HB-EGF is a therapeutic target for T-ALL, and to further elucidate the antitumor effects of a specific inhibitor of HB-EGF, DRUG1 (DRUG2). ",negative,cross-reacting material 197,CRM197
"We elucidated the expression of HB-EGF in T-ALL cell lines, and evaluated the effect of DRUG1 on these cells alone or in combination with DRUG2. ",negative,CRM197,anticancer agent
"DRUG1 induced apoptosis, and furthermore, the combination of DRUG1 plus doxorubicin enhanced cytotoxicity in a T-ALL cell line. ",negative,CRM197,CRM197
"DRUG1 induced apoptosis, and furthermore, the combination of DRUG1 plus DRUG2 enhanced cytotoxicity in a T-ALL cell line. ",negative,CRM197,doxorubicin
"DRUG1 induced apoptosis, and furthermore, the combination of DRUG1 plus DRUG2 enhanced cytotoxicity in a T-ALL cell line. ",effect,CRM197,doxorubicin
"Prevention of emergence agitation in seven children receiving low-dose DRUG1 and DRUG2 total intravenous anesthesia.
",negative,ketamine,propofol
We retrospectively reviewed the records of 7 pediatric oncology patients who received low-dose DRUG1 in conjunction with DRUG2 for total intravenous anesthesia (TIVA) repeatedly for radiation therapy. ,negative,ketamine,propofol
EA signs were observed in all 7 patients in association with DRUG1 TIVA but did not recur in any of 123 subsequent anesthetics sessions during which low-dose DRUG2 was added to DRUG1. ,negative,propofol,ketamine
EA signs were observed in all 7 patients in association with DRUG1 TIVA but did not recur in any of 123 subsequent anesthetics sessions during which low-dose ketamine was added to DRUG1. ,negative,propofol,propofol
EA signs were observed in all 7 patients in association with DRUG2 TIVA but did not recur in any of 123 subsequent anesthetics sessions during which low-dose DRUG1 was added to DRUG2. ,negative,ketamine,propofol
"Based on this experience, we suggest that low-dose DRUG1 added to DRUG2 may be associated with prevention of EA in children with a history of EA with DRUG2 TIVA.",effect,ketamine,propofol
"Based on this experience, we suggest that low-dose DRUG1 added to DRUG2 may be associated with prevention of EA in children with a history of EA with DRUG2 TIVA.",negative,ketamine,propofol
"Based on this experience, we suggest that low-dose ketamine added to DRUG1 may be associated with prevention of EA in children with a history of EA with DRUG1 TIVA.",negative,propofol,propofol
"Distinct synergistic action of DRUG1 and DRUG2 against Pseudomonas aeruginosa.
",negative,piperacillin,methylglyoxal
"Results revealed that the strains were resistant to many drugs at high levels, only DRUG1, DRUG2, amikacin and ciprofloxacin showed resistances at comparatively lower levels. ",negative,piperacillin,carbenicillin
"Results revealed that the strains were resistant to many drugs at high levels, only DRUG1, carbenicillin, DRUG2 and ciprofloxacin showed resistances at comparatively lower levels. ",negative,piperacillin,amikacin
"Results revealed that the strains were resistant to many drugs at high levels, only DRUG1, carbenicillin, amikacin and DRUG2 showed resistances at comparatively lower levels. ",negative,piperacillin,ciprofloxacin
"Results revealed that the strains were resistant to many drugs at high levels, only piperacillin, DRUG1, DRUG2 and ciprofloxacin showed resistances at comparatively lower levels. ",negative,carbenicillin,amikacin
"Results revealed that the strains were resistant to many drugs at high levels, only piperacillin, DRUG1, amikacin and DRUG2 showed resistances at comparatively lower levels. ",negative,carbenicillin,ciprofloxacin
"Results revealed that the strains were resistant to many drugs at high levels, only piperacillin, carbenicillin, DRUG1 and DRUG2 showed resistances at comparatively lower levels. ",negative,amikacin,ciprofloxacin
Distinct and statistically significant synergism was observed between DRUG1 and DRUG2 by disc diffusion tests when compared with their individual effects. ,effect,methylglyoxal,piperacillin
Synergism was also noted when DRUG1 was combined with DRUG2 and amikacin.,effect,methylglyoxal,carbenicillin
Synergism was also noted when DRUG1 was combined with carbenicillin and DRUG2.,effect,methylglyoxal,amikacin
Synergism was also noted when methylglyoxal was combined with DRUG1 and DRUG2.,negative,carbenicillin,amikacin
"Interaction study of DRUG1 and DRUG2 with co-administered drugs.
",negative,moxifloxacin,lomefloxacin
DRUG1 and DRUG2 are fluoroquinolone antibiotics used in treating urinary and respiratory tract infections. ,negative,Moxifloxacin,lomefloxacin
DRUG1 and lomefloxacin are DRUG2 used in treating urinary and respiratory tract infections. ,negative,Moxifloxacin,fluoroquinolone antibiotics
Moxifloxacin and DRUG1 are DRUG2 used in treating urinary and respiratory tract infections. ,negative,lomefloxacin,fluoroquinolone antibiotics
"Being DRUG1 and lomefloxacin DRUG2 the interaction study of was carried out with sucralfate, gelusil, erythromycin and multi minerals. ",negative,moxifloxacin,fluoroquinolones
"Being DRUG1 and lomefloxacin fluoroquinolones the interaction study of was carried out with DRUG2, gelusil, erythromycin and multi minerals. ",negative,moxifloxacin,sucralfate
"Being DRUG1 and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate, DRUG2, erythromycin and multi minerals. ",negative,moxifloxacin,gelusil
"Being DRUG1 and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate, gelusil, DRUG2 and multi minerals. ",negative,moxifloxacin,erythromycin
"Being DRUG1 and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate, gelusil, erythromycin and DRUG2. ",negative,moxifloxacin,multi minerals
"Being moxifloxacin and lomefloxacin DRUG1 the interaction study of was carried out with DRUG2, gelusil, erythromycin and multi minerals. ",negative,fluoroquinolones,sucralfate
"Being moxifloxacin and lomefloxacin DRUG1 the interaction study of was carried out with sucralfate, DRUG2, erythromycin and multi minerals. ",negative,fluoroquinolones,gelusil
"Being moxifloxacin and lomefloxacin DRUG1 the interaction study of was carried out with sucralfate, gelusil, DRUG2 and multi minerals. ",negative,fluoroquinolones,erythromycin
"Being moxifloxacin and lomefloxacin DRUG1 the interaction study of was carried out with sucralfate, gelusil, erythromycin and DRUG2. ",negative,fluoroquinolones,multi minerals
"Being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with DRUG1, DRUG2, erythromycin and multi minerals. ",negative,sucralfate,gelusil
"Being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with DRUG1, gelusil, DRUG2 and multi minerals. ",negative,sucralfate,erythromycin
"Being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with DRUG1, gelusil, erythromycin and DRUG2. ",negative,sucralfate,multi minerals
"Being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate, DRUG1, DRUG2 and multi minerals. ",negative,gelusil,erythromycin
"Being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate, DRUG1, erythromycin and DRUG2. ",negative,gelusil,multi minerals
"Being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate, gelusil, DRUG1 and DRUG2. ",negative,erythromycin,multi minerals
The response of DRUG1 and DRUG2 after interaction with co-administered drugs at different conditions and temperature were noted using a Shimadzu HPLC system with PDA detector. ,negative,moxifloxacin,lomefloxacin
DRUG1 and DRUG2 reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. ,negative,Moxifloxacin,Lomefloxacin
DRUG1 and Lomefloxacin reacts faster with DRUG2 and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. ,mechanism,Moxifloxacin,sucralfate
DRUG1 and Lomefloxacin reacts faster with sucralfate and DRUG2 in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. ,mechanism,Moxifloxacin,gelusil
DRUG1 and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with DRUG2 in basic media and multi-minerals in neutral media. ,mechanism,Moxifloxacin,erythromycin
DRUG1 and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and DRUG2 in neutral media. ,mechanism,Moxifloxacin,multi-minerals
Moxifloxacin and DRUG1 reacts faster with DRUG2 and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. ,mechanism,Lomefloxacin,sucralfate
Moxifloxacin and DRUG1 reacts faster with sucralfate and DRUG2 in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. ,mechanism,Lomefloxacin,gelusil
Moxifloxacin and DRUG1 reacts faster with sucralfate and gelusil in acidic media whereas with DRUG2 in basic media and multi-minerals in neutral media. ,mechanism,Lomefloxacin,erythromycin
Moxifloxacin and DRUG1 reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and DRUG2 in neutral media. ,mechanism,Lomefloxacin,multi-minerals
Moxifloxacin and Lomefloxacin reacts faster with DRUG1 and DRUG2 in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. ,negative,sucralfate,gelusil
Moxifloxacin and Lomefloxacin reacts faster with DRUG1 and gelusil in acidic media whereas with DRUG2 in basic media and multi-minerals in neutral media. ,negative,sucralfate,erythromycin
Moxifloxacin and Lomefloxacin reacts faster with DRUG1 and gelusil in acidic media whereas with erythromycin in basic media and DRUG2 in neutral media. ,negative,sucralfate,multi-minerals
Moxifloxacin and Lomefloxacin reacts faster with sucralfate and DRUG1 in acidic media whereas with DRUG2 in basic media and multi-minerals in neutral media. ,negative,gelusil,erythromycin
Moxifloxacin and Lomefloxacin reacts faster with sucralfate and DRUG1 in acidic media whereas with erythromycin in basic media and DRUG2 in neutral media. ,negative,gelusil,multi-minerals
Moxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with DRUG1 in basic media and DRUG2 in neutral media. ,negative,erythromycin,multi-minerals
"DRUG1, an DRUG2, is the standard hormone treatment for breast cancer. ",negative,Tamoxifen,estrogen antagonist
DRUG1 and DRUG2 reduce the plasma concentration of endoxifen by about 50%. ,negative,Paroxetine,fluoxetine
DRUG1 and fluoxetine reduce the plasma concentration of DRUG2 by about 50%. ,mechanism,Paroxetine,endoxifen
Paroxetine and DRUG1 reduce the plasma concentration of DRUG2 by about 50%. ,mechanism,fluoxetine,endoxifen
"It is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with DRUG1 for breast cancer, especially DRUG2 such as paroxetine and fluoxetine. ",advise,tamoxifen,SSRI antidepressants
"It is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with DRUG1 for breast cancer, especially SSRI antidepressants such as DRUG2 and fluoxetine. ",advise,tamoxifen,paroxetine
"It is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with DRUG1 for breast cancer, especially SSRI antidepressants such as paroxetine and DRUG2. ",advise,tamoxifen,fluoxetine
"It is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with tamoxifen for breast cancer, especially DRUG1 such as DRUG2 and fluoxetine. ",negative,SSRI antidepressants,paroxetine
"It is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with tamoxifen for breast cancer, especially DRUG1 such as paroxetine and DRUG2. ",negative,SSRI antidepressants,fluoxetine
"It is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with tamoxifen for breast cancer, especially SSRI antidepressants such as DRUG1 and DRUG2. ",negative,paroxetine,fluoxetine
"Depression does not always require DRUG1 therapy, and DRUG2 have no proven preventive impact on hot flushes linked to the menopause. ",negative,antidepressant drug,antidepressants
"If in certain cases, an DRUG1 is considered necessary, it may be advisable to replace DRUG2 with anastrozole.",advise,antidepressant,tamoxifen
"If in certain cases, an DRUG1 is considered necessary, it may be advisable to replace tamoxifen with DRUG2.",negative,antidepressant,anastrozole
"If in certain cases, an antidepressant is considered necessary, it may be advisable to replace DRUG1 with DRUG2.",negative,tamoxifen,anastrozole
[Efficacy of fixed combination DRUG1/DRUG2 in hospitalized patients with hypertensive disease],negative,amlodipine,valsartan
Efficacy and tolerability of fixed DRUG1/DRUG2 combination was studied in 86 patients with hypertensive disease hospitalized in departments of general internal medicine or cardiology. ,negative,amlodipine,valsartan
All patients had indications for antihypertensive therapy and were randomized either to fixed combination DRUG1/DRUG2 (n=43) or to therapy which corresponded to the hospital formulary (n=43). ,negative,amlodipine,valsartan
Rate of achievement of target BP with fixed combination DRUG1/DRUG2 (93%) was comparable with that on traditional therapy (90%). ,negative,amlodipine,valsartan
"But the use of fixed combination DRUG1/DRUG2 compared with traditional therapy was associated with lower clinical and self measured BP, quicker achievement of target BP (5.8+/-2.3 and 9.2+/-1.8 days, respectively, 0.05), lesser number of antihypertensive drugs (2.5+/-0.6 and 3.0+/-0.9 days, respectively), lower rate of concealed inefficacy of treatment (12 and 31%, respectively, 0.05). ",effect,amlodipine,valsartan
"But the use of fixed combination DRUG1/valsartan compared with traditional therapy was associated with lower clinical and self measured BP, quicker achievement of target BP (5.8+/-2.3 and 9.2+/-1.8 days, respectively, 0.05), lesser number of DRUG2 (2.5+/-0.6 and 3.0+/-0.9 days, respectively), lower rate of concealed inefficacy of treatment (12 and 31%, respectively, 0.05). ",negative,amlodipine,antihypertensive drugs
"But the use of fixed combination amlodipine/DRUG1 compared with traditional therapy was associated with lower clinical and self measured BP, quicker achievement of target BP (5.8+/-2.3 and 9.2+/-1.8 days, respectively, 0.05), lesser number of DRUG2 (2.5+/-0.6 and 3.0+/-0.9 days, respectively), lower rate of concealed inefficacy of treatment (12 and 31%, respectively, 0.05). ",negative,valsartan,antihypertensive drugs
"We have demonstrated appropriateness of inhospital administration of fixed DRUG1/DRUG2 combination as an approach allowing to achieve target BP in shorter time, with the use of fewer antihypertensive drugs, and diminishing concealed inefficacy of treatment.",effect,amlodipine,valsartan
"We have demonstrated appropriateness of inhospital administration of fixed DRUG1/valsartan combination as an approach allowing to achieve target BP in shorter time, with the use of fewer DRUG2, and diminishing concealed inefficacy of treatment.",negative,amlodipine,antihypertensive drugs
"We have demonstrated appropriateness of inhospital administration of fixed amlodipine/DRUG1 combination as an approach allowing to achieve target BP in shorter time, with the use of fewer DRUG2, and diminishing concealed inefficacy of treatment.",negative,valsartan,antihypertensive drugs
"Interaction of DRUG1 and DRUG2, in vitro and in vivo, in human A375 melanoma cells.
",negative,dacarbazine,imexon
"We evaluated mechanisms of interaction between the alkyating agent DRUG1 (DRUG2) and the pro-oxidant, imexon, in the human A375 melanoma cell line.",negative,dacarbazine,DTIC
"We evaluated mechanisms of interaction between the alkyating agent DRUG1 (DTIC) and the pro-oxidant, DRUG2, in the human A375 melanoma cell line.",negative,dacarbazine,imexon
"We evaluated mechanisms of interaction between the alkyating agent dacarbazine (DRUG1) and the pro-oxidant, DRUG2, in the human A375 melanoma cell line.",negative,DTIC,imexon
"The effect of DRUG1 and DRUG2, alone and in combination, was evaluated for growth inhibition (MTT), radiolabeled drug uptake, cellular thiol content (HPLC), and DNA strand breaks (Comet assay). ",negative,DTIC,imexon
There was a >75% reduction in cellular glutathione and cysteine with DRUG1 but not DRUG2. ,negative,imexon,DTIC
DRUG1 and DRUG2 show additive effects in vitro but not in vivo in human A375 melanoma cells.,effect,Imexon,dacarbazine
"[Influence of DRUG1 and DRUG2 on MPTP-evoked behavior violations in C57BL/6 mice].
",negative,hemantane,doxycycline
"The effects of DRUG1 DRUG2 [(2-adamantyl)hexamethylenimine] (10 mg/kg, p. o.) ",negative,anti-parkinsonian drug,hemantane
"The effects of DRUG1 hemantane [(2-adamantyl)hexamethylenimine] (10 mg/kg, p. o.) ",negative,anti-parkinsonian drug,(2-adamantyl)hexamethylenimine
"The effects of anti-parkinsonian drug DRUG1 [(2-adamantyl)hexamethylenimine] (10 mg/kg, p. o.) ",negative,hemantane,(2-adamantyl)hexamethylenimine
"and/or DRUG1 DRUG2 (100 mg/kg, p. o.), as well as that of neurotoxin 1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine (MPTP) (4 x 20 mg/kg, i. p.) ",negative,antibiotic drug,doxycycline
"and/or DRUG1 doxycycline (100 mg/kg, p. o.), as well as that of neurotoxin DRUG2 (MPTP) (4 x 20 mg/kg, i. p.) ",negative,antibiotic drug,"1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine"
"and/or DRUG1 doxycycline (100 mg/kg, p. o.), as well as that of neurotoxin 1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine (DRUG2) (4 x 20 mg/kg, i. p.) ",negative,antibiotic drug,MPTP
"and/or antibiotic drug DRUG1 (100 mg/kg, p. o.), as well as that of neurotoxin DRUG2 (MPTP) (4 x 20 mg/kg, i. p.) ",negative,doxycycline,"1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine"
"and/or antibiotic drug DRUG1 (100 mg/kg, p. o.), as well as that of neurotoxin 1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine (DRUG2) (4 x 20 mg/kg, i. p.) ",negative,doxycycline,MPTP
"and/or antibiotic drug doxycycline (100 mg/kg, p. o.), as well as that of neurotoxin DRUG1 (DRUG2) (4 x 20 mg/kg, i. p.) ",negative,"1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine",MPTP
"Acute administration of DRUG1 or DRUG2 failed to influence locomotion in mice, while their combination normalized motor activity. ",effect,hemantane,doxycycline
"The incubations were performed in the absence and presence of the non-specific CYP inhibitor, DRUG1 (DRUG2) and isoform-specific inhibitors. ",negative,1-aminobenzotriazole,ABT
"DRUG1 decreased the toxicity of DRUG2, increased exposure to parent compound, and decreased metabolite levels in a dose-dependent manner. ",effect,ABT,precocene I
"Of the isoform-specific CYP inhibitors tested for an effect on the DRUG1 metabolite profile, only DRUG2 was noticeably effective, indicating a role of CYPs 2A6, 2C9, 2Cl9, and 2E1. ",negative,precocene I,tranylcypromine
"With respect to toxicity, the order of CYP inhibitor effectiveness was DRUG1>DRUG2~tranylcypromine>ketoconazole. ",negative,ABT,diethyldithiocarbamate
"With respect to toxicity, the order of CYP inhibitor effectiveness was DRUG1>diethyldithiocarbamate~DRUG2>ketoconazole. ",negative,ABT,tranylcypromine
"With respect to toxicity, the order of CYP inhibitor effectiveness was DRUG1>diethyldithiocarbamate~tranylcypromine>DRUG2. ",negative,ABT,ketoconazole
"With respect to toxicity, the order of CYP inhibitor effectiveness was ABT>DRUG1~DRUG2>ketoconazole. ",negative,diethyldithiocarbamate,tranylcypromine
"With respect to toxicity, the order of CYP inhibitor effectiveness was ABT>DRUG1~tranylcypromine>DRUG2. ",negative,diethyldithiocarbamate,ketoconazole
"With respect to toxicity, the order of CYP inhibitor effectiveness was ABT>diethyldithiocarbamate~DRUG1>DRUG2. ",negative,tranylcypromine,ketoconazole
"DRUG1 and DRUG2 had no effect, while quinidine appeared to augment precocene I toxicity. ",negative,Furafylline,sulfaphenazole
"DRUG1 and sulfaphenazole had no effect, while DRUG2 appeared to augment precocene I toxicity. ",negative,Furafylline,quinidine
"DRUG1 and sulfaphenazole had no effect, while quinidine appeared to augment DRUG2 toxicity. ",negative,Furafylline,precocene I
"Furafylline and DRUG1 had no effect, while DRUG2 appeared to augment precocene I toxicity. ",negative,sulfaphenazole,quinidine
"Furafylline and DRUG1 had no effect, while quinidine appeared to augment DRUG2 toxicity. ",negative,sulfaphenazole,precocene I
"Furafylline and sulfaphenazole had no effect, while DRUG1 appeared to augment DRUG2 toxicity. ",effect,quinidine,precocene I
These results suggest that rat liver slices do not reproduce the reported in vivo biotransformation of DRUG1 and therefore may not be an appropriate model for DRUG1 metabolism. ,negative,precocene I,precocene I
